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Background: Early cancer detection and early diagnosis have a key role in multilevel 
policy initiatives aiming to improve cancer outcomes. In Scotland, the Detect Cancer 
Early (DCE) Programme was launched in 2012 with the aim to increase the proportion 
of lung, breast and bowel cancers diagnosed at Stage I by 25%. Initiatives such as 
DCE are complex, with many interacting components, and influenced by the context. 
It is important to investigate such initiatives to ensure accountability, to learn from their 
experience, and inform other strategies. This PhD aimed to investigate the role of 
multilevel policy initiatives in promoting the earlier diagnosis of cancer, using the DCE 
Programme as a case study. Objectives were: 1) to understand the international 
landscape of multilevel policy initiatives promoting earlier cancer diagnosis; 2) to 
evaluate DCE’s first three years (2012-2015); 3) to compare DCE with other initiatives; 
and 4) to provide recommendations for policy.  
Methods: Three studies were carried out: 1) a systematic review (Study 1) 
synthesising characteristics of multilevel policy initiatives promoting the earlier 
diagnosis of cancer, their target populations, outcomes and stakeholder views; 2) 
development and refinement of a mixed-methods, theory-based evaluation (Study 2), 
carried out through documentary analysis and stakeholder interviews, guided by the 
Medical Research Council Framework for Process Evaluation of Complex 
Interventions, complexity theory/systems thinking, and theory-based evaluation in 
order to elicit programme theory, implementation assumptions and mechanisms of 
impact; 3) an evaluation of the DCE programme (Study 3); its outcomes (through 
secondary analyses of data) and processes (whether assumptions and mechanisms 
were confirmed by stakeholders, barriers and facilitators, and unanticipated 
outcomes) through stakeholder interviews and an online questionnaire.  
Results: Study 1: eighteen initiatives from 10 countries were included and grouped 
as strategies to improve public cancer awareness and/or knowledge, professional 
education, referral pathways based on cancer symptoms or combinations of these 
strategies. Most of them targeted patients suspected of having cancer based on high-
risk symptom criteria. Very few of them reported on high-level outcomes such as 
survival (inconclusive results), mortality (one study; higher mortality associated with 
low use of urgent referral pathways) and tumour staging (some positive results). Other 
outcomes included positive changes in knowledge/awareness (but limited impact on 
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behaviour) and reduced diagnostic intervals. Views on initiatives were often positive. 
Study 2: 160 documents were analysed and a logic model was developed; nine 
stakeholders were interviewed – this resulted in a refined logic model, development 
of a textual programme theory and outcomes chains, and elicited assumptions and 
mechanisms to be examined in the evaluation. Study 3: a) outcome evaluation: DCE 
objectives were often aspirational, with limited outcome measures and data 
availability – DCE’s key aim was not met, although there were improvements in 
tumour staging; there was increase in awareness of cancer symptoms and signs, in 
consultations due to breast symptoms and in requests for bowel screening kits, but 
barriers to help-seeking persisted; b) process evaluation: 25 stakeholders were 
interviewed and 53 completed the questionnaire. There was support for an early 
detection initiative, and most agreed that DCE was part of their role. Increasing 
diagnostic resources was challenging when there was no staff available to recruit. 
Communication challenges influenced engagement and sense of ownership. Demand 
drove action but resulted in frustration, especially when strategies attracted the 
worried well seeking reassurance. Targets negatively influenced engagement when 
they were perceived to be unachievable and to have limited clinical relevance. Several 
barriers and facilitators were described, in addition to unanticipated outcomes. By 
being a government initiative, DCE brought early cancer detection to the centre of 
attention, but also generated conflict due to short timescales (not conducive to long-
term changes).  
Discussion: Multilevel policy initiatives give prominence to earlier diagnosis of 
cancer. There are mixed findings on their benefits, and the ability to measure impact 
is affected by variation in outcome measures, data availability, and the short-term 
aspect of government initiatives. In Scotland, the aspirational nature of objectives and 
limited definition of outcome measures hindered outcome assessment, while the 
process evaluation highlighted support for DCE, provided that communication is 
efficient, efforts are acknowledged, structural barriers are recognised and 
stakeholders are able to see that they can make a difference. Recommendations for 
policy refer to data quality, relevance and availability; setting measurable objectives; 
targeting populations at risk; communication and dissemination; and considering 
contextual influencers. Results show that much can be learned from available 
initiatives promoting the earlier diagnosis of cancer. 
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Lay Summary 
Cancer affects us all in different ways. In Scotland, it is estimated that one in two 
people will have cancer sometime in their lives. However, more people are now 
surviving cancer than in the past. This is mostly because of better treatment and 
because cancers are being found earlier. Cancer found earlier is more likely to be 
successfully treated. In different countries, governments have developed 
programmes to promote earlier cancer diagnosis. It is important that these 
programmes are well understood and evaluated, so we know what works and who is 
benefitting from them. 
This project aimed to understand these government initiatives worldwide, evaluate a 
specific programme in Scotland (the Detect Cancer Early Programme or DCE), 
compare these initiatives, and prepare recommendations for future programmes. This 
was done by identifying and summarising the findings of programmes in the UK and 
elsewhere and developing and carrying out an evaluation of the DCE Programme. 
I found eighteen government programmes in ten countries, all of which aimed to find 
cancer early. Commonly used approaches were to 1) increase public 
knowledge/awareness of cancer, of cancer screening, cancer symptoms and signs; 
2) educate health care professionals; and/or 3) create faster care routes so patients 
with certain symptoms do not need to wait too long for a diagnosis. It was difficult to 
summarise the impact of these eighteen programmes as they were describing 
different types of results. Positive results included increase in public awareness of 
cancer symptoms and signs (although it was harder to see change in attitudes), and 
patients waiting less to receive a cancer diagnosis after being in contact with a health 
care professional. 
Before I evaluated DCE, I had to spend some time learning more about it. I read and 
analysed 160 government documents and interviewed nine people who were deeply 
involved in the programme. Then, I created a description of the programme in text 
and figures, often called “programme theory”: it includes assumptions about how the 
programme is expected to work and descriptions of how programme activities will end 
up with an early cancer diagnosis (these descriptions are called “mechanisms”). The 
DCE evaluation then checked if the programme’s official objectives were met 
(checking published and unpublished reports describing impact), if the programme 
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activities were carried out as planned, and if the assumptions and mechanisms 
identified previously were confirmed (through interviews and an online questionnaire). 
I found that most of DCE objectives were aspirational and hard to measure. The 
programme’s main aim was to have more cancers diagnosed in earlier stages: this 
was only partially met. There was increase in awareness of cancer symptoms and 
signs, in consultations with GPs because of breast symptoms, and in requests for 
bowel screening test kits. From the interviews and online survey, I learned that most 
professionals were in favour of having an early diagnosis programme, and believed it 
was part of their jobs to be involved. However, the programme increased the amount 
of work they had to do, and often it was hard to cope because NHS resources were 
limited. The increase in workload caused frustration when professionals could not see 
that they were making a difference/finding cancer early. Professionals said that 
sometimes communication between them and DCE could have been better, and that 
they not always had time to prepare for programme activities. DCE created some 
targets that were not approved by some professionals as it was not possible to 
achieve them. Although the programme helped to bring early cancer detection to the 
centre of attention, professionals believed that the government was expecting 
changes to happen too quickly. 
Overall, my studies found that government initiatives have an important role in 
promoting early cancer diagnosis, but it is hard to calculate exactly how much 
difference they can make. Using my findings and discussing them with other 
professionals, I developed recommendations for the government about collecting 
better data, using objectives that can be measured, focusing on groups that are more 
likely to develop cancer, improving communication with professionals, and 
understanding external issues that may affect the programme’s ability to make a 
difference (for example, having enough NHS staff or equipment). The results from this 
project show that a lot can be learned from early diagnosis initiatives. I hope that my 
recommendations are useful not only for the Scottish Government, but also for other 
governments and policy makers working on similar programmes. 
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Chapter 1 Introduction 
1.1 Overview 
This chapter describes the background to this PhD project, its overall aims and 
objectives. Furthermore, it outlines the thesis structure and the contents of each thesis 
chapter. 
1.2 Background to the study 
This PhD project was developed in late 2014 when I was working as a Research 
Fellow at the University of Edinburgh (UoE). Dr Christine Campbell and Prof David 
Weller were my supervisors in a study aiming to improve bowel screening uptake in 
Scotland (1, 2). I was interested in undertaking a PhD, and they asked me to prepare 
brief research proposals for discussion. The evaluation of the Detect Cancer Early 
(DCE) Programme was one of these proposals. With their guidance, I refined the 
proposal to share with DCE management at the Scottish Government, which 
approved and funded it in 2015. Although this PhD is broader than the evaluation, it 
includes components outlined in the funded proposal. 
1.3 Overall study aims and objectives 
This PhD project aimed to investigate the role of multilevel policy initiatives in 
promoting the earlier diagnosis of cancer, using the DCE Programme in Scotland as 
a case study. It had four objectives: 
1. To understand the international landscape of multilevel policy initiatives 
promoting earlier cancer diagnosis 
2. To evaluate the first three years of the DCE programme (2012-2015 – the 
initially planned duration), assessing its processes and outcomes 
3. To compare DCE with other initiatives promoting earlier cancer diagnosis  
4. To provide recommendations to inform policy in this area 
Objective 1 was addressed through a systematic review of initiatives promoting the 
earlier diagnosis of cancer (Study 1). Objective 2 was addressed through a theory-
based evaluation of the DCE programme comprising: evaluation development and 
refinement (Study 2); and process and outcome evaluations (Study 3). All three 
studies addressed Objectives 3 and 4 (Figure 1.1). 
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Figure 1.1 Studies and objectives 
 
1.4 How this thesis is structured 
This thesis comprised a cyclical process of understanding the literature to inform 
methods, acquiring data, reassessing and refining methods for other studies, and 
continuing with data collection. Hence, fieldwork did not have a fully linear strategy. 
The thesis structure is illustrated in Figure 1.2. 
Figure 1.2. The thesis structure 
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Chapter 1 (this Chapter) describes how this study originated, introduces its objectives 
and overall structure.  
Chapter 2 focuses on describing why multilevel policy initiatives promoting early 
diagnosis of cancer are important; this is done by describing the cancer burden 
worldwide and in Scotland, and the role of early cancer detection in cancer survival. 
The DCE programme and the policy context in Scotland are also outlined.  
Chapter 3 gives an overview of the methods adopted in this PhD research project (i.e. 
use of a theory-based evaluation and mixed-methods research). It also provides the 
rationale for carrying out a systematic review and evaluating the DCE programme, 
and outlines the relationships between the three studies in this PhD project. 
Chapter 4 comprises the methods and the results of the systematic review 
investigating the landscape of multilevel policy initiatives promoting the earlier 
diagnosis of cancer (Study 1).  
Chapter 5 describes the methods and results of the development and refinement of 
the DCE evaluation (Study 2) and outlines how Study 2 outputs informed the DCE 
evaluation.  
Chapter 6 describes the methods adopted for the evaluation of DCE outcomes and 
process (Study 3).  
Chapter 7 comprises the results of the outcome evaluation of the DCE programme.  
Chapter 8 describes the results of a questionnaire survey carried out as part of the 
process evaluation, while Chapter 9 focuses on the second component of the process 
evaluation: semi-structured interviews with stakeholders. 
Finally, Chapter 10 integrates data from the three studies, provides recommendations 
for policy and research, and concludes this thesis. 
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Chapter 2 Cancer burden and policies 
2.1 Overview 
In order to understand the need for initiatives promoting the earlier diagnosis of 
cancer, it is necessary to recognise the burden of cancer, and the role of early 
detection in cancer survival (including its benefits and limitations). The way the 
population perceives symptoms and acts upon them also provides opportunities and 
challenges when aiming for early detection. Finally, we need to acknowledge the role 
of context in cancer outcomes. This Chapter approaches these issues, then 
introduces the cancer policy landscape in the United Kingdom (UK) (focusing on 
Scotland) and the DCE programme. A brief description of the Scottish health system 
is also provided. 
2.2 Cancer and early detection 
2.2.1 Cancer burden and aetiology 
Cancer is one of the leading causes of morbidity and mortality worldwide. In 2018, 
there were over 18 million new cancer cases and over 9.5 million cancer deaths (3). 
Cancer is the second leading cause of death, with lung, breast and colorectal cancers 
being the most common cancer sites (4). 
Cancer causes are diverse and include several genetic loci (i.e. fixed locations of 
genes or markers), chronic infections, reproductive and hormonal factors, 
occupational/environmental factors (such as exposure to ultraviolet radiation), 
naturally occurring chemical carcinogens and lifestyle factors (such as tobacco 
consumption, alcohol drinking, diet, obesity, and lack of exercise) (5). It has been 
estimated that four in ten cancers can be attributed to modifiable risk factors (6, 7), 
and therefore could be prevented through lifestyle changes.  
Cancer will remain an important public health problem in the upcoming decades due 
to population growth, population ageing (as cancer is more common at an older age, 
mainly due to accumulation of cancer risk factors), and increased prevalence in 
lifestyle behaviours that increase cancer risk (4, 5, 8). This is also the case for 




Box 2.1. Cancer burden in Scotland 
It is estimated that more than two out of five people in Scotland will get cancer in their lifetime 
(9). In 2017, there were 32,234 cancer diagnoses (10) and 16,105 deaths due to cancer (not 
including non-melanoma skin cancers) – NMSC) (11).  
 
Summary statistics for all cancers in Scotland Males Females Persons 
Number of new cases diagnosed in 2017 15,867 16,367 32,234 
Number of deaths recorded in 2017 8,327 7,778 16,105 
Source: adapted from ISD Scotland (12) 
Most cancer cases are diagnosed among those aged 60 and older (76% of cases in 2017) 
(10).  If all cancers were combined (malignant neoplasms (ICD-10 C00-C97)), cancer would 
have been the main cause of death in Scotland in 2018 (13). Lung cancer was the lead 
cause of cancer death among males and females, followed by breast and prostate (the 
second leading causes for women and men respectively) and colorectal cancer (14). 
 
Lung cancer rates in Scotland (both incidence and prevalence) are amongst the highest in 
the world and are higher in Scotland compared to other UK countries. This may be due to 
higher smoking prevalence (15). Scotland also has the highest age-standardised cancer 
mortality rates in the UK. Cancer mortality rates in Scotland are 15% higher than the UK 
average (16, 17). 
 
From the perspective of public health and government policy, it is important to 
consider different strategies to minimise the increasing cancer burden. The World 
Health Organization (WHO) recommends the implementation of national cancer 
control programmes with defined strategies for the “prevention, early detection, 
diagnosis, treatment and palliation of cancer” (18, 19). In 2015, 87% of all its 177 
member states reported having national cancer control policies, strategies or action 
plans (68% reported that these plans were operational) (20). 
2.2.2 Improvements in cancer survival 
Due to improvements in early detection and treatment, more people are surviving 
cancer worldwide (21). In 2018, 43.8 million people were estimated to be living with 
cancer within 5 years of diagnosis (3). Official statistics show that survival has also 
improved in Scotland. Five-year standardised relative cancer survival has increased 
when comparing the periods of diagnosis 1987-1991 and 2007-2011 (22). Cancer 
survival is better for cancers detected through screening and cancers for which 
treatment has improved over time. Survival is lower for patients with cancers often 
presented at later stages (i.e. pancreas, lung and stomach) and higher for cancers 
often presented at earlier stages (e.g. malignant melanoma) (22). Lung cancer has 
an estimated five-year age standardised relative survival of 9.5% for men and 12.0% 
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for women. Breast cancer relative survival is 82.8% for women, while colorectal 
cancer survival is similar for men (59.9%) and women (59.8%) (22). 
Nonetheless, the improvements in survival are not evenly distributed worldwide. This 
is partly due to inequalities in access to diagnostics and treatment within and between 
countries (23). In Europe, the EUROCARE research programme reported that 
England and Denmark have poorer survival rates compared to other Western 
European countries (24-30). Scotland was reported to have the worse age-
standardised relative survival and age and case mix-standardised relative survival 
across all the UK countries for all cancers combined at 5 years after diagnosis (31).  
There are recognised challenges regarding cross-national comparisons such as 
methodological limitations and variations in data collected (32-34), but these do not 
explain the observed variations in survival outcomes, especially when it comes to the 
UK. Issues such as longer diagnostic intervals, access to treatment, limited 
investment in healthcare and suboptimal care are likely to be better explanatory 
factors (35, 36). EUROCARE results describing poorer 1-year survival outcomes (37), 
and studies showing higher number of deaths close to diagnosis (38) also help to 
explain worse survival in England and Denmark. 
The International Cancer Benchmarking Partnership (ICBP) was established in 2009 
to better understand international variation in cancer survival to inform policymaking 
(39, 40). Led by the UK Department of Health, it involves collaborations with Australia, 
Canada, Denmark, Norway, Sweden, and the UK (39). ICBP has compared 
population-based data and has also reported that Denmark and the UK (England, 
Northern Ireland and Wales) have poorer survival rates, especially regarding 1-year 
survival and for patients aged 65 or older (26). 
2.3 The role of early detection in cancer survival 
There are many opportunities to optimise cancer care throughout a cancer trajectory 
(i.e. the cancer care continuum). According to Taplin and Rodgers, there are seven 
types of care in the cancer continuum: risk assessment, primary prevention, detection, 
diagnosis, primary treatment, survivorship and surveillance, and end-of-life-care (41). 
Among these, (early) detection and diagnosis have a prominent role in policies and 
initiatives aiming to improve cancer outcomes (42). They are also key components in 
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evidence-based models investigating pathways to diagnosis and cancer survival 
(described later in this Chapter).  
The focus on early detection can be explained by the relationship between tumour 
staging and prognosis (43). There is evidence of the impact of tumour staging on 
survival for breast (29, 44), lung (30) and colorectal cancers (45). Furthermore, 
successful treatments, less invasive/aggressive treatments and low treatment costs 
are more likely when cancers are detected in earlier stages (46).  
The WHO defines early detection as diagnosing cancer at an earlier stage (e.g. in a 
specific organ and not yet invading any surrounding tissue) (19). There are many 
different classification systems for staging; the TNM system is widely used and refers 
to the extent of the primary tumour (T), the extent of involvement of lymph nodes (N), 
and metastasis (M). Numbers are added after each letter to give more details about 
the cancer. TNM combinations can be grouped into different stages, from Stage I (the 
least advanced) to Stage IV (the most advanced) (47). 
The WHO describes two early detection strategies: 1) systematic screening of 
asymptomatic individuals that identify precancerous lesions or cancer in its earlier 
stages; and 2) early diagnosis of symptomatic patients (19) (Figure 2.1). Throughout 
this thesis, “earlier diagnosis of cancer” and “early detection” are used as synonyms; 
and both terms can refer to either symptomatic or asymptomatic patients.  
Figure 2.1. Early detection according to the WHO 
 
Source: adapted from the World Health Organization 2017 (19) 
9 
Both screening and early diagnosis have limitations; these are discussed below. 
2.3.1 Cancer screening: benefits and limitations 
Screening has been shown to reduce mortality for breast, cervical and colorectal 
cancers in randomised controlled trials and/or observational studies (46, 48-52). 
Evidence for prostate cancer is less strong, with some evidence in reduction in 
disease-specific mortality in a recent systematic review (53) and a less recent trial 
(54), and no significant differences on other trials (55-57). Screening for lung cancer 
has been shown to have benefits in trials (58-60), and the European Union has 
recently developed recommendations for implementation of lung cancer screening, 
suggesting the use of a risk stratification approach (61).  
It is worth noting that screening can cause physical and psychological harm (48, 50) 
(Box 2.2). Several criteria need to be met before a screening programme is 
implemented; seminal screening principles developed in the late 1960s (62) have 
been updated over the years by others (46, 63-65). Implicit in these principles is the 
need to avoid overdiagnosis and overtreatment. 
Box 2.2. Screening risks 
• Physical Risks: Improvements in mortality are considered at a population level. At an 
individual level, most people being screened will not have cancer. Hence, everyone is 
exposed to the same risks (such as x-ray exposure or invasive procedures), but only a 
few will benefit. Furthermore, those who receive a false positive result may undergo 
unnecessary investigations (48). 
• Risk of Psychological Harm: These refer to anxiety prior to/after tests and distress 
after receiving results. False positive results can cause psychological harm. Evidence 
quantifying psychological costs of screening is limited. It is worth noting that screening 
can also have psychological benefits such as reducing worry (48). 
• Overdiagnosis: Not all diagnosed cancers will progress, and it is not always easy to 
know when this is the case. Invasive treatment of a non-progressive abnormality is 
described as overtreatment, and it can have a detrimental impact on the patient’s health 
and quality of life (48, 50, 66). 
 
Since cancers can be identified before symptoms are present, screening can be 
beneficial to early detection. Scotland and other UK countries have organised 
screening programmes for breast, bowel and cervical cancers, with some variations 
regarding eligibility criteria. In Scotland, over three out of five cancers (62.5%) 
diagnosed through bowel screening were diagnosed at the earliest stages (Duke’s A 
and B, the staging system used for colorectal cancer in Scotland) (67). More than half 
(55.5%) of invasive breast cancers found through screening in 2015/2016 in Scotland 
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were smaller than 15mm in size and were therefore unlikely to be detected during 
physical examination (68). 
Increased screening participation is required for benefits to be accrued (69). 
Screening will miss some cancers, and interval cancers (i.e. diagnosed between 
screening rounds) are possible (70, 71). In England, 6% of cancers were diagnosed 
through screening in 2012-2013 (72). The first National Cancer Diagnosis Audit in 
Scotland showed a similar proportion for a sample of the Scottish population in 2014 
(73). Hence, early diagnosis of symptomatic patients is very important. 
2.3.2 Early diagnosis: benefits and limitations 
According to the WHO, early diagnosis has three steps: 1) awareness of cancer 
symptoms and accessing care; 2) clinical evaluation, diagnosis and staging; and 3) 
access to treatment (19). Hence, early diagnosis is dependent on patient, health 
system (such as infrastructure and resources) (46) and professional factors. 
In the UK, where primary care is the first point of contact for patients, most cancers 
are diagnosed after a patient presents to primary care and undergoes diagnostic 
investigations (74). This is also the case for other countries with similar health systems 
such as Denmark (75). Hence, the role of primary care in early diagnosis has been 
increasingly recognised (37, 76-79). In Scotland, the most recent data on routes to 
diagnosis report that less than half of patients diagnosed with cancer (38%) were 
referred without having primary care-led investigations. Almost two out of three 
patients (62.9%) who were diagnosed with cancer first presented in the GP surgery 
with symptoms related to the diagnosis (73). 
Cancer symptomatology is a core issue when trying to understand early diagnosis 
challenges. Cancer is a heterogeneous disease, with diverse symptomatology 
according to tumour type and location (74). Red flag or alarm symptoms have been 
identified for some cancers and urgent referral pathways have been implemented in 
different countries, including Denmark, England and Scotland (80-82). However, 
alarm symptoms typically have low positive predictive values (PPVs) in primary care; 
and most people presenting with them will not have cancer (74, 83). Importantly, alarm 
symptoms may only be present when the disease is advanced. If the “window of 
opportunity” for a successful treatment occurs before symptomatic presentation, then 
early diagnosis of patients presenting with symptoms may provide little benefit (84). 
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Furthermore, not all cancers have alarm symptoms. Cancers may have non-specific 
or vague symptoms common to other health conditions (77, 85). However, symptoms 
may still suggest cancer and may need to be investigated further. Patients without 
alarm symptoms may miss the opportunity to access potentially beneficial rapid 
diagnostic pathways (77).  
General practitioners (GPs) only see a few cancer cases in a year among thousands 
of consultations (74, 79). More than one consultation may be necessary before 
proceeding with exams or referring for more complex diagnostic investigations (74). 
There is also the need to balance the risks of missing cancers against using potentially 
unnecessary, invasive and harmful examinations, over diagnosing or overtreating 
patients. Additionally, diagnostic resources may be urgently needed by other patients 
(and unnecessary use can potentially delay care to those who need it the most) (86). 
Recognising these challenges, a variety of diagnostic pathways for patients 
presenting with symptoms have been pioneered in Denmark and are being tested in 
England. These include the development of diagnostic centres and GPs having direct 
access to diagnostics (85, 87, 88). Furthermore, Cancer Decision Support (CDS) tools 
for professionals have been developed in the UK (89-92). Safety netting is also being 
adopted to help avoid missing cancer in patients with vague symptoms (93). This 
refers to a strategy to deal with uncertainty regarding diagnosis; information is shared 
with patients so they know what to expect, feel empowered, know what to look for and 
how to seek help (94).  
2.3.2.1 The role of longer intervals in the diagnostic pathway 
While early detection can improve cancer survival, longer time intervals in presenting 
to a health care professional, diagnosing and/or treating cancer may result in cancer 
being detected in its later stages (which is detrimental to cancer survival). Shorter 
time to diagnosis (and treatment) has been associated with better outcomes for 
patients with breast, bowel, head and neck, testicular cancers and melanoma, while 
evidence is insufficient (or equivocal) for several other tumour types (95). More high-
quality studies are recommended to better elucidate the role of time to diagnosis in 
cancer outcomes (95). 
Acknowledging the potential impact of longer intervals, Olesen and colleagues 
developed an evidence-based model approaching “delays” in the diagnostic pathway 
(80). The model was developed for a context in which the GP is a gatekeeper of 
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services/referral to specialists and has limited access to diagnostics. The model 
describes the pathway from first symptom to treatment and three types of delay to 
diagnosis: patient delay, doctor delay and system delay. Patient delay is influenced 
by how long it takes for the patient to interpret their symptoms/signs and see the 
doctor; doctor delay will depend on whether s/he considers the likelihood of a cancer 
diagnosis, and system delay is dependent on the speed and efficiency of the pathway 
after investigations commence or the patient is referred, until treatment begins (or a 
cancer diagnosis is rejected) (80) (Figure 2.2). 
Figure 2.2. Model emphasising delays in diagnosis and treatment 
 
Source: Adapted from Olesen et al 2009 (80) 
Walter and colleagues also developed a model after reviewing the use of the 
Andersen Model of total patient delay (96) in studies assessing cancer diagnosis (97, 
98). Their “model of pathways to treatment” incorporates psychological theories and 
the role of decision-making processes and symptom appraisal in patient intervals. 
Walter and colleagues used the term “intervals” instead of “delay” as they believed 
the latter was value laden. The model describes events, processes, outline intervals 
and their contributing factors (97) (Figure 2.3). 
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Figure 2.3. Model of pathways to treatment 
 
Source: adapted from Walter et al 2012 (97) 
Both models are frequently used/referred to in early diagnosis research, and have 
informed the development of international consensus on ways to improve design and 
reporting in the field, including the Aarhus Statement (99). Inconsistencies when 
defining and measuring time points and intervals prior to diagnosis; limited guidance 
on how to measure these; limited evidence on adopted theoretical frameworks 
underpinning definitions and measurements; and no transparency nor precision when 
adopting methods and instruments were some of the issues approached by the 
Aarhus Statement (99). 
2.3.3 Factors influencing early detection 
Evidence shows that many conditions/contextual factors need to be in place to allow 
for early cancer detection. These include health system characteristics, and 
population behaviour and society. Social deprivation also has an important role in 
cancer outcomes. These factors are described below. 
2.3.3.1 Health system characteristics 
Early detection strategies are dependent on resource availability (such as finance, 
equipment and specialist staff). Furthermore, they are influenced by access to care 
and available information about screening programmes, cancer symptoms and signs 
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(19, 46). Not all countries have sufficient resources to have systematic, organised 
screening programmes, and community strategies may be implemented instead (18). 
Furthermore, provision of information is needed so people know what to look for and 
can make an informed choice about what they wish to do (100, 101), considering both 
potential benefits and harms. 
Although health system characteristics can influence early diagnosis, evidence is 
limited on which factors are most important (102). Brown and colleagues investigated 
the role of a range of healthcare system factors in cancer outcomes, including 
financing, the GP gatekeeping role, and direct access to secondary care. They found 
that it was not possible to show a causal relationship between system factors and 
cancer outcomes, although issues such as centralisation of services, free movement 
of patients between different providers and access to secondary care were found to 
influence patient and professional behaviour (and potentially early detection) (102). 
Other studies have found mixed evidence on the role of gatekeeping referrals to 
specialists in longer diagnostic intervals (103-105). 
2.3.3.2 Help-seeking behaviour and society 
The fields of Health Psychology, Sociology and Medical Anthropology are important 
contributors to early diagnosis research, and provide useful evidence on how 
symptoms are perceived, and how/why patients seek help. 
Health Psychology 
Health Psychology explores and explains issues regarding bodily sensations, 
symptom appraisal and health seeking behaviour. A range of theories, models and 
frameworks have been developed over time. These include the Health Belief Model 
(developed to explain why people did not take part in screening, then expanded to 
cover how people respond to symptoms and diagnoses), the Theory of Planned 
Behaviour (developed to explain the relationships between attitudes, intentions and 
resulting behaviours), the Transtheoretical Model and Stages of Change (integrated 
theories of psychotherapy and behaviour change associated with preventive 
behaviours), Social Cognitive Theory (postulates that the individual and the 
environment influence and interact with each other and result in both individual and 
societal changes), and the Health Behaviour Framework (a synthesis of several of the 
models above, while also considering contextual issues) (106).  
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Furthermore, psychological constructs such as fatalism and cancer fear are widely 
used in early diagnosis research. Fatalism refers not only to the perception that events 
are beyond individual control, but also to the assumption that the outcome will be 
negative (e.g. if it is cancer, it will be fatal). Fatalism can be a barrier to receiving 
information about cancer, to early detection and to treatment (107, 108). Cancer fear, 
on the other hand, can be a motivator as screening/test results can provide 
reassurance (48), but can also hinder help-seeking behaviour due to fears about a 
positive result, or about having to undergo unpleasant tests (109). 
Sociology and Medical Anthropology 
Sociology and Medical Anthropology explore how experience, cultural and social 
contexts influence and shape the way people interpret bodily sensations, configurate 
them into symptoms and act upon them. Sensations are described as embodied 
experiences that are transformed into symptoms. While sensations are felt, symptoms 
are socially and historically constructed and require cognitive interpretation (110). 
These acts of recognising socially, cultural and cognitively constructed cancer 
symptoms (and seeking help) are described as being much more complex than what 
is believed by biomedical approaches (111). 
Furthermore, facing illness may be perceived as a threat to one’s sense of self, social 
identity and relationships, a barrier to fulfilling obligations, potential risk of 
marginalisation, and social exclusion. Power relations between the doctor and the 
patient and the way the health system is structured may also influence the patient’s 
decision to seek help (111). 
For people dealing with multimorbidities and a range of challenging social 
circumstances, it can be more difficult to be sensitive to sensations and symptoms 
that may indicate cancer among so many “noises” that require their attention on a 
daily basis (112). Moreover, studies report on the challenges of deciding to seek help 
when trying to be a “good citizen” as this means not only taking care of one’s health, 
but also not wasting public resources nor the doctor’s time (113). 
Similar to issues raised by Walter and colleagues (97) the term “delay” is not seen 
favourably as it is seen as normative and not necessarily corresponding to how 
patients understand their own behaviour (111).  
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2.3.3.3 Social and health inequalities 
Health inequalities are a result of a “toxic combination of poor social policies and 
programmes, unfair economic arrangements, and bad politics” (114, 115). Inequalities 
in health are not the same as variations in health as the former are systematic, socially 
produced (which means that they are not natural nor biological and can be modified) 
and, importantly, unfair (116).  
The reduction of health inequalities can have social and economic benefits such as 
reduction of years of life lost, of productivity losses, of years of illness and disability, 
and of costs for treating poor health (117). The WHO’s Commission on Social 
Determinants of Health argues that different actors in a system need to be involved 
(i.e. governments, communities, businesses and international organisations) in order 
to reduce inequalities (114, 115).  
Social deprivation has a strong and persistent impact on health inequalities in 
Scotland, although age, ethnicity and gender also play an important role (15). 
Deprivation refers to a combination of domains (income, employment, health, 
education, housing, access to services and crime) that cover multiple dimensions. An 
Index (SIMD or Scottish Index of Multiple Deprivation) identifies geographical areas 
of poverty and inequality (118). Deprivation levels vary widely across Scotland, even 
within small local areas. The West of Scotland is more deprived than other regions, 
especially in Glasgow and its surrounding areas (15). 
In Scotland, populations living in less deprived areas have both better life expectancy 
and heathy life expectancy than those living in more deprived areas (15). 
Furthermore, those living in the most deprived areas are more likely to have poorer 
access to primary care and poorer health outcomes and have higher levels of multi-
morbidity (119).  
Available evidence also describes the role of deprivation on cancer outcomes (120, 
121). In Scotland, both cancer incidence and overall cancer death rates are higher 
amongst the most deprived (although effects vary by cancer type) (15, 122). Those 
living in more deprived areas are a third more likely to have a cancer diagnosed 
(compared to those in less deprived areas), with some variations across tumour types 
(10). The three main cancer types (breast, bowel and lung combined) are most often 
diagnosed at advanced stages (30.3% of cases at Stage IV) among the most 
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deprived, while the highest proportion of these cancers (29.5%) are diagnosed at 
Stage II, closely followed by Stage I (28.1%) among the least deprived (123).  
The increased prevalence of risk factors in deprived populations may help to explain 
this discrepancy. Smoking rates, obesity rates (especially among women) and type 2 
diabetes rates are much higher in the most deprived areas. Furthermore, uptake for 
breast and bowel screening is lower amongst the most deprived (15, 124). 
2.3.4 Other factors influencing cancer survival 
Detecting cancer in its earlier stages does not guarantee improved survival. Cancer 
survival is influenced by other factors such as tumour biology, tumour location, and 
patient characteristics. Some tumours are more aggressive than others, and 
aggressive tumours are associated with poorer prognosis. Very short diagnostic 
intervals can be associated with poorer outcomes if a tumour develops very 
aggressively (125). This has been described as the “waiting time paradox”; i.e. 
patients with quicker presentation, diagnosis and treatment having worse outcomes 
than patients with longer diagnostic intervals because of aggressive tumours (95).  
Tumour location can also influence survival; for example, studies have shown that 
patients with right-sided metastatic colorectal tumours have worse prognosis (126) 
and pancreatic cancers of the body and tail have poorer survival compared to head 
lesions (127). Tumour location also influences survival outcomes for primary brain 
tumours such as glioma (128).  
Patient characteristics also influence cancer mortality and survival; these include co-
morbidities (which are associated with poorer prognosis), general health, health 
related behaviours (such as smoking tobacco, drinking alcohol and sedentarism), and 
age (as older people often have poorer survival) (120). Poorer general health and 
limited social support are both associated with poorer cancer survival (129). As 
described above, socioeconomic deprivation (which is an area-level as opposed to an 
individual-level indicator) is another important factor. 
Cognisant of the multiple factors influencing cancer survival, a multilevel early 
detection initiative in England (the National Awareness and Early Diagnosis Initiative 
or NAEDI) developed and updated a comprehensive evidence-based hypothesis of 
factors influencing cancer survival and premature mortality (130). Patient 
characteristics such as sex, age and socio-economic status are described as having 
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an impact on awareness of cancer symptoms and signs, help-seeking behaviours and 
cancer beliefs. Difficulties in accessing primary care may interact with these factors 
and influence late presentation in primary care or poor screening uptake. Challenges 
in accessing diagnostics and problems in the primary and secondary care interface 
can lead to late presentation in hospital, and patients with advanced cancer may be 
unnecessarily diagnosed in emergency hospital departments. Further delays in 
secondary care may lead to cancer being diagnosed at later stages. In these 
scenarios, treatment is likely to provide worse chances of survival. Outcomes may 
deteriorate further if there are additional delays in treatment. Excess cancer deaths in 
these scenarios are described as avoidable deaths (130) (Figure 2.4). From a public 
health perspective, it is important that these deaths are avoided. 
Figure 2.4. Updated NAEDI model: factors influencing cancer survival 
 




2.4 The policy context 
2.4.1 Cancer policies prior to the DCE programme 
The first comprehensive cancer report in the UK (covering England and Wales) was 
published in 1995 (131). Known as the Calman-Hine Report, it provided a policy 
framework for commissioning cancer care and service delivery (132), and was 
followed by Cancer Plans in England (133, 134) and developments in Scotland. These 
included the creation of the Scottish Cancer Group (SCG) in 1998 to provide 
“leadership, direction, advice and guidance for cancer services” (135) (Figure 2.5). 
Figure 2.5. Policy developments in cancer in Scotland until 2012 
Abbreviations: ISD: Information Services Division; SCG: Scottish Cancer Group; QOF: 
Quality and Outcomes Framework; FOBt: Faecal Occult Blood Test; SCT: Scottish 
Cancer Taskforce; HPV: Human Papillomavirus; CWT: Cancer Waiting Times; QPIs: 
Quality Performance Indicators; HEAT: Health Improvement, Efficiency; Access to 
treatment and Treatment. Source: DCE policy documents  
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In 2001 the Scottish Government published: "Cancer in Scotland: Action for Change". 
The SCG was involved in developing and implementing this Cancer Strategy, which 
focused on prevention, diagnosis and treatment (135). It addressed developments in 
screening (including a colorectal screening pilot); proposed to eliminate delays in 
investigation, diagnosis and treatment; and committed to creating urgent referrals for 
breast cancer and establishing a maximum waiting time of two months for urgent 
referral to treatment for all cancers. There was also a plan to develop referral 
guidelines for urgent referrals. The strategy acknowledged the increase in workload 
for radiology and pathology, and issues with shortage of staff, delays in imaging and 
the need to ensure sufficient diagnostic capacity. It proposed the establishment of 
regional cancer networks to oversee the patient journey (135). 
In 2008 “Better Cancer Care: An action Plan” was published. Similar to the previous 
strategy, it focused on prevention, early diagnosis, genetic/molecular testing for 
cancer, referral and diagnosis, and treatment. A Scottish Cancer Taskforce was 
established to oversee the implementation of this plan. The strategy supported the 
roll-out of the Scottish Bowel Screening Programme and looked at ways to encourage 
bowel and cervical screening uptake. It proposed to work with different stakeholders 
to promote public awareness of cancer symptoms and encourage patients to seek 
help early. There were plans to work with different Health Boards in Scotland to 
redesign referrals and investigation pathways. Furthermore, a primary care cancer 
lead would be nominated within each Board (136). This strategy paved the way for 
the development of a national early detection initiative; i.e. the DCE Programme. 
2.4.2 The DCE Programme 
In March 2011, it was announced that the Scottish Government would invest £30 
million in a 3-year “Detect Cancer Early Initiative”; and the commitment was reiterated 
in a political manifesto (137). A draft Implementation Plan was finalised in June 2011 
and circulated to territorial Health Boards, different departments at the Scottish 
Government, cancer charities and other non-governmental organisations (138). A 
refined implementation plan was finalised in December 2011. 
Preparatory work was carried out before DCE launch. Different groups were created 
to coordinate and ensure the management of the programme. The already 
established National Cancer Waiting Times Delivery Group was “refreshed” into the 
“Detect Cancer Early Programme Board” (138). Desk research and insight gathering 
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via focus groups were carried out in order to inform social marketing campaigns 
(Diane Primrose, personal communication).  
DCE was officially launched in February 2012 by the Cabinet Secretary for Health and 
Wellbeing (139). The programme aimed to improve overall 5-year survival for people 
in Scotland diagnosed with cancer, and created a new HEAT (Health, Efficiency, 
Access and Treatment) target to measure this. The target used tumour staging as a 
proxy for cancer survival and referred to an increase in the proportion of cancers 
diagnosed at Stage I by 25%. The DCE implementation plan outlined eight official 
programme objectives (Figure 2.6). 
Figure 2.6. DCE’s aim and objectives 
1. To increase the proportion of 
people with Stage I disease at 
diagnosis by 25% (as a proxy 
indicator of survival outcome) 
and to use performance 
against a HEAT target as a 
lever for whole systems 
approach to improvement 
2. To improve informed 
consent and participation in 
national screening 
programmes to help detect 
cancer earlier and improve 
survival rates 
3. To raise the public’s 
awareness of the national 
cancer screening programmes 
and also the early signs and 
symptoms of cancer to 
encourage them to seek help 
earlier 
4. To work with GPs to 
promote referral or 
investigation at the earliest 
reasonable opportunity for 
patients who may be showing 
a suspicion of cancer whilst 
making the most efficient use 
of NHS resources and avoiding 
adverse impact on access 
DCE’s main aim: 
Improve overall 5-year survival 
for people in Scotland 
diagnosed with cancer 
5. To ensure there is sufficient 
capacity in the screening 
programmes to meet the 
expected increase in those 
choosing to take part 
6. To ensure that imaging, 
diagnostic departments and 
treatment centres are prepared 
for an increase in the number 
of patients with early disease 
requiring treatment 
7. To strengthen data 
collection and performance 
reporting within NHSScotland 
to ensure progress continues 
to be made on improving 
cancer diagnosis, treatment, 
referral, and survival 
8. To facilitate further 
evaluation of the impact of 
public awareness campaigns 
on the stage of cancer at 
presentation and to contribute 
to research that establishes 
evidence for the link between 
late presentation and survival 
deficit 
Source: created with data from the DCE Implementation Plan 2011 (138) 
 
In its first three years, DCE focused on lung, breast and colorectal cancers as these 
were the three main causes of cancer death in Scotland (138). The implementation 
plan emphasised that DCE was “a fundamental shift” in the way that the Scottish 
Government engaged with the National Health Service (NHS) regarding a new cancer 
target; as a “whole systems level of support” was introduced instead of the traditional 
focus on secondary care (138). 
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DCE required collaboration with primary and secondary care professionals, directors 
of Public Health, cancer charities and official providers of health intelligence data. It 
had four main strategies (Figure 2.7). 
Figure 2.7. DCE’s main strategies 
 
Source: created with data from the DCE Implementation Plan 2011 (138). Abbreviations: 
HEAT; Health, Efficiency, Access and Treatment; sGMS: Scottish General Medical 
Services; QOF: Quality and Outcomes Framework; CWT: Cancer Waiting Times 
Additionally, small projects in collaboration with cancer charities, Health Boards and 
Scottish universities were fully or partly funded by DCE (Nicola Barnstaple, personal 
communication). A thorough description of each DCE strategy is available in the final 
report prepared for the Scottish Government (see Chapter 10 for reference to report). 
2.4.3 The Scottish health system: an overview 
In the UK, universal health coverage is provided through the NHS. Services are free 
at the point of use according to need, and funding is obtained from general taxation 
(140). Health was devolved to the Scottish Parliament in 1999. There are differences 
in service provision compared to England such as choices regarding the level of 
funding and other benefits such as free prescriptions (available in Scotland but not in 
England) (140, 141). 
Scotland (NHSScotland) has 14 territorial Health Boards to deliver care services 
through public health, primary, secondary and tertiary care (140). Population, cancer 
incidence and mortality vary across these Boards (Box 2.3). There are seven special 
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Health Boards to cover other services (e.g. ambulances, health improvement and 
health education) and one Public Health body (141). NHS Boards are accountable to 
the Scottish Parliament and subject to frequent reviews, in addition to specific targets 
and standards they should aim for. About 75% of the annual budget for health and 
wellbeing (which corresponds to over a third of the Scottish Government budget) is 
allocated to Health Boards. A specific formula (NHSScotland Resource Allocation 
Committee (NRAC)) determines these allocations based on population characteristics 
(140). Managed Clinical Networks (MCN) have been set up to coordinate work in 
primary, secondary and tertiary care across Health Boards (140); these include three 
Cancer Networks for the North (NOSCAN), South East  (SCAN) and West of Scotland 
(WOSCAN). 
Box 2.3. Territorial Health Boards and population estimates (absolute numbers) 
  
  
   
 











Ayrshire & Arran 369,670 2,433 1,220  
Borders 115,270 894 406  
Dumfries and Galloway 148,790 983 515  
Fife 371,910 2,213 1,181  
Forth Valley 306,070 1,893 861  
Grampian 584,550 3,271 1,575  
Greater Glasgow & Clyde 1,174,980 6,835 3,511  
Highland 321,800 2,002 1,019  
Lanarkshire 659,200 3,951 2,000  
Lothian 897,770 4,654 2,183  
Orkney 22,190 115 81  
Shetland 22,990 137 62  
Tayside 416,080 2,672 1,395  
Western Isles 26,830 181 96  
Total 5,438,100 32,234 16,105  
     
 Ayrshire & Arran  Borders  Dumfries & Galloway  Fife 
   
  
   
 Forth Valley  Grampian  Greater Glasgow & Clyde  Highland 
        
 Lanarkshire  Lothian  Orkney  Shetland 
        
 Tayside  Western Isles     
        
 
Notes: Mortality includes all persons, all ages, exclude NMSC. Highland include Argyll. 
Cancer incidence refers to absolute numbers. Sources: (10, 11, 142, 143) 
Current challenges include integration of health and social care (which require 
involvement from 32 local authorities or councils in Scotland), alongside demanding 
issues from an ageing population, limited resources, and limited workforce (140).  
Furthermore, a new General Medical Services (GMS) contract was implemented in 
April 2018 (144). The new contract refocuses the GP role as expert medical 
generalists and emphasises holistic, person-centred care. It also introduced a new 
funding formula that aimed to better reflect practice workload. Other system changes 
included embedding GP clusters (professional groupings of general practices) in 
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order to improve quality of care and abolishing the Quality and Outcomes Framework 
(QOF) (due to concerns such as its effectiveness over time and its non-holistic, 
disease-specific approach) (144). 
2.5 Summary of Chapter 2 
This Chapter describes how cancer represents an important public health problem 
worldwide. In Scotland, if all cancers were combined, cancer would be the main cause 
of death. Cancer survival has been improving, mainly due to developments in early 
detection and treatment. Indeed, early cancer detection is a key component of cancer 
control initiatives, as recommended by the World Health Organization. 
Early cancer detection comprises systematic screening of asymptomatic individuals 
and early diagnosis of symptomatic patients. Tumours identified in earlier stages are 
more likely to be successfully treated; shorter diagnostic intervals have also been 
found to be beneficial for some tumour types.  
Most patients are still diagnosed with cancer through symptomatic presentation; 
primary care has a key role in promoting early diagnosis. Early diagnosis challenges 
include heterogeneous symptomatology (not all cancers have red flag symptoms – 
even if they do, the positive predictive values are often low, and symptoms may 
indicate late stage disease), risk of overdiagnosis and overtreatment, and limited 
diagnostic resources. Other factors influencing early diagnosis include health system 
characteristics, population behaviour and society, and socioeconomic inequalities. In 
Scotland, socioeconomic deprivation has a key role in cancer incidence, mortality and 
survival. Importantly, early diagnosis does not guarantee improved cancer survival; 
characteristics such as tumour biology, tumour location, patient characteristics (such 
as co-morbidities, age and health-related behaviour), and social deprivation also play 
an important role.  
Recognising the multiple factors influencing early detection and cancer survival, 
multilevel policy initiatives aiming to promote early detection have been implemented 
in a range of countries, including Scotland. The DCE Programme was launched in 
2012 with the aim to increase the proportion of cancers diagnosed at Stage I by 25% 
(a proxy for cancer survival). The Programme had four strategies (public awareness 
and behaviour influencing; primary care symptom management and referral; 
secondary care and diagnostic capacity; and performance management and 
monitoring) and eight official objectives.  
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Despite the importance of such multi-level policy initiatives, no attempts had been 
made to synthesise their components, target populations and outcomes worldwide. 
Furthermore, no system-level evaluation of the DCE Programme had been carried 
out. This PhD research project investigated the role of these initiatives further, 
carrying out a systematic review and evaluating the DCE Programme. The next 
Chapter gives an overview of the methods adopted to do so. 

27 
Chapter 3 Methods overview 
3.1 Overview 
This Chapter describes the rationale for each of the studies in this PhD project, the 
theoretical underpinnings for the DCE evaluation (Study 2 and Study 3) and how 
studies connect to each other. From the outset, I was aware that DCE was a system-
level, government programme with multiple components, stakeholders and outcomes, 
and that I should investigate appropriate ways to evaluate it, while bearing in mind its 
political nature. These thoughts led to investigating evaluation theories and 
complexity theory, and evaluation guidance. Furthermore, I was aware that a PhD 
with multiple components and objectives was likely to require the adoption of mixed 
methods. Therefore, this Chapter also describes key issues I had to consider when 
adopting this approach. Finally, this Chapter gives an overview of methods adopted 
in this PhD project, and of how Studies 1-3 connect with each other. 
3.2 Justification for the studies in this PhD 
3.2.1 Why carry out a systematic review? 
At the time of this study, to my knowledge no other reviews had comprehensively 
synthesised multilevel policy initiatives promoting the earlier diagnosis of cancer 
worldwide; outlining their characteristics, components, target populations and overall 
outcomes. González-Robledo et al analysed databases and documents to describe 
breast cancer early detection initiatives in Latin America; and outlined that such 
initiatives operated through regulation, design and implementation of early diagnosis 
programmes, care provided by public and private services, and the development of 
guidelines for early detection (145). Palmer described a range of UK policies and 
government initiatives promoting early cancer diagnosis (146). Brown et al explored 
how healthcare system characteristics in six different countries contributed towards 
cancer outcomes (not focusing specifically on early diagnosis); approached the issue 
of complexity; and the importance of understanding the context (102). Hence, this 
review had the potential to bridge an important gap in the early diagnosis literature, in 
addition to being necessary in order to answer the PhD research questions. 
3.2.2 Why evaluate DCE? 
Government initiatives are publicly funded; and as such should be evaluated to check 
if they benefit the population they plan to benefit, and for the purposes of transparency 
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and accountability (147). Furthermore, considering the burden of cancer worldwide, 
understanding early detection initiatives worldwide is particularly important. A 
thorough understanding of a national initiative, alongside synthesised evidence from 
several initiatives worldwide can provide a more nuanced understanding of the role of 
multilevel policy initiatives in promoting the earlier diagnosis of cancer. 
No system-level evaluation of the DCE programme had been planned prior to this 
PhD project. Reports on HEAT targets and screening participation were published by 
ISD Scotland, and DCE had internal documents/grey literature with discrete reports 
on different programme components. There was an unmet need to synthesise the 
evidence and develop a comprehensive evaluation of the DCE programme. In order 
to choose the best way to do so, it was important to immerse myself in the field of 
evaluation research. The next section discusses the theoretical underpinnings for the 
DCE evaluation. 
3.2.3 Theoretical underpinnings for the DCE evaluation 
3.2.3.1 Theory-based evaluation 
I was particularly interested in theory-driven or theory-based evaluation; this approach 
had already been outlined in the funded evaluation proposal as it had successfully 
been adopted to evaluate other health policy initiatives (148-150). As opposed to a 
“black box evaluation” that only focuses on inputs and outputs in a programme (i.e. a 
simple outcome evaluation), a theory-based evaluation seeks information about the 
underlying mechanism/conditions that help to generate changes (i.e. the processes 
happening between inputs and outputs) (151). A theory-based evaluation is based on 
the premise that programmes are “theory incarnate”, with implicit or explicit 
assumptions on how they are supposed to work (152). It seeks information on whether 
an intervention is effective and also why it is effective (153), investigating assumptions 
underlying a programme in terms of activities and expected outcomes (154, 155). It 
is method-neutral and open to different research designs (156), and often needs a 
combination of qualitative and quantitative methods as it encompasses several 
different elements (154).  
The term “theory-driven evaluation” was made popular by Chen and Rossi (152) in 
their seminal paper (157), although in the early 1970s, Carol Weiss had already 
emphasised that “there is some kind of theory implicit in almost every program” (158). 
Weiss proposed the term “theory-based evaluation”. Its aim is to examine whether, 
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and to which extent, assumptions about a programme will hold, where they break 
down and which theories underlying a programme are supported by evidence (159). 
Realistic evaluation is also a type of theory-based evaluation; it investigates “what 
works, for whom and in what circumstances”. A programme is described as having 
three key ingredients: context (C), mechanism (M) and outcome (O) – known as the 
CMO configuration. The evaluator identifies, articulates, tests and refines CMO 
configurations (152). Realistic evaluation has been adopted to evaluate public health 
programmes (148, 149, 160). 
A theory-based evaluation is informed by programme theory. Definitions of what 
comprises programme theory vary between authors and overlap with each other.  
Rossi describes programme theory as having three interrelated components: 
programme impact theory, service utilisation plan, and the programme’s 
organisational plan. Programme impact theory refers to assumptions about the 
changes caused by the programme and the expected improvements. The service 
utilisation plan describes how and why the target population will engage with the 
programme until the receipt of services is sufficient to generate the changes described 
by the programme impact theory. Finally, the organisational plan outlines the roles 
and activities of a programme and the resources needed for service provision (161).  
Weiss’ definition of a programme theory was adopted in the DCE evaluation, i.e. 
implicit or explicit assumptions about why planned activities would lead to desirable 
outcomes (155). Weiss also proposed the separation between implementation theory 
and programme theory. While implementation theory concentrates on how a 
programme is carried out, programme theory focuses on the mechanisms intervening 
between service delivery and outcomes (162). Mechanisms are not the programme 
activities, but the response generated by activities. One example would be increased 
knowledge (mechanism) generated by contraceptive counselling (activity) which 
results in reduced pregnancy rates (outcomes) (162). Weiss states that most 
evaluations describing themselves as theory-based only assess implementation 
theory. She developed the term “theories of change evaluation” for evaluations 
assessing both implementation theory and programme theory (162). Theories of 
change are widely used to evaluate public health interventions (163, 164). 
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Representing programme theory 
Programme theory is usually demonstrated in graphic representations, with one of the 
most prominent being the logic model (161). Rossi et al described the logic model as 
having four components: inputs (i.e. resources and constraints; this is where his 
proposed organisation plan is shown); activities (services provided); outputs (where 
components of his proposed service utilisation plan are shown); and outcomes (which 
can be initial, intermediate or long-term) (161).  
A logic model was chosen to describe the DCE programme in order to facilitate the 
identification of evaluation questions, help to recognise important programme issues 
and avoid overlooking critical issues (158, 161, 165). Furthermore, logic model 
development has been found to be useful to highlight weak links, conflicts and 
contradictions, identify different understandings regarding a programme, and shed 
light on possible unanticipated outcomes (166). Finally, the use of logic models has 
been advocated by governmental and non-governmental agencies in the United 
States (US) and the UK (167-169), and evaluation frameworks published by the 
Medical Research Council in the UK (166). 
Theory-based evaluation components 
When adopting a theory-based evaluation, it is important to understand both 
programme processes and outcomes. Therefore, it was necessary to design both a 
process and an outcome evaluation. While the process evaluation investigated what 
happened and how it happened (i.e. the “how and what” in an evaluation) (170), the 
outcome evaluation assessed whether the DCE programme met its 
objectives/generated its intended results. An outcome evaluation can also be called 
an impact evaluation (161), or as seen before in this chapter, a “black box” evaluation 
when carried out on its own (151). 
A process evaluation alongside an assessment of programme outcomes can help to 
distinguish between programme failure or theory failure (155, 158). In other words, a 
programme may have been unsuccessful due to poor implementation or poor theory. 
Even if implementation was successful, an inadequate theory will not result in the 
desired changes/outcomes. Edward Suchman gave a simple example to illustrate this 
almost 50 years ago: “the operation was a success, but the patient died" (171). 
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Process evaluation 
Specific guidance on process evaluation published by the UK Medical Research 
Council (MRC) (166) was used to inform the DCE evaluation. The MRC guidance 
recommends that process evaluation should focus on investigating implementation 
(how intervention is delivered, and the quality and quantity of what was carried out), 
mechanisms of impact (how the intervention generates change) and contextual issues 
(how they influence both implementation and outcomes) (166).  
The MRC guidance was a good fit with theory-based evaluation, in addition to 
providing a comprehensive description of different components of a process 
evaluation (and the bidirectional relationships between them) in a clear framework 
(Figure 3.1). Furthermore, it provided advice when planning, designing, analysing and 
reporting data from a process evaluation; described a range of theories, models and 
frameworks suitable to guide each evaluation component; and provided a checklist 
for reviewers appraising a process evaluation which was used to inform the DCE 
evaluation (completed checklist is available in Appendix 1) (166). Finally, the MRC is 
a well-established, recognised UK organisation that funds high quality research, 
disseminates best practice, and produces widely adopted guidance (172). 
Figure 3.1. The MRC Framework for process evaluation of complex interventions 
 
Source: adapted from Moore et al 2014 (166)  
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In addition to being necessary in a theory-based evaluation, there were other reasons 
for carrying out a process evaluation. My supervisors and I wished to generate new, 
helpful evidence to inform policy and to contribute to new knowledge in early detection 
and evaluation research. Hence, it was important to understand not only whether DCE 
objectives were met, but also to what extent, and why this was the case; while also 
adopting robust theories and frameworks. We were particularly interested in lessons 
that could be learned from the programme to inform DCE and other early detection 
initiatives. Furthermore, analysis of cancer survival needs a long timeframe (173); 
DCE was rolled out nationally as a policy as opposed to a scientific experiment, and 
we were aware that demonstrating causal relationships would be challenging (see 
next section). Hence, an outcome evaluation on its own was not perceived to be as 
useful as a more comprehensive evaluation. 
We also expected that a system-level evaluation assessing both processes and 
outcomes would shed light on outcomes which could be beneficial or even harmful 
and were not part of official programme outcomes (i.e. “unanticipated outcomes”). 
Finally, we expected that a process evaluation would generate useful implementation 
data for those wishing to successfully adopt similar programmes elsewhere (166).  
Outcome evaluation 
Randomised designs (in which outcomes are compared across randomised groups 
that either received or did not receive an intervention) are considered the “gold 
standard” in research as the potential for selection bias is reduced, there is control for 
unmeasured confounding (168, 172), and it is possible to make direct inferences 
regarding causality (174). However, experimental designs are often not feasible, 
practical or cost-effective (168). It may not be possible to have a control group when 
an intervention is delivered to everyone (168, 172, 175). If it takes a long time for 
outcomes to be observed, adequate follow-up may not be possible (168, 172, 175).  
The ability to make reliable estimates when evaluating public health interventions is 
limited (172) as studies without a random allocation do not control for unmeasured or 
poorly measured confounders (175). Nonetheless, quasi-experimental (comparisons 
between groups without random assignments such as case-control studies) and 
observational designs (such as before-and-after studies, time-series analysis, cross-
sectional surveys and case studies) are often adopted in public health interventions 
(168) and to evaluate nationwide programmes, including in early diagnosis research 
in the UK (150, 176-178). Natural experiments are also common (179). Natural 
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experiments refer to programmes, interventions or policies which are not carried out 
for the purposes of research, but whose outcomes are evaluated (by assessing 
exposure and outcomes) in order to make causal inferences (180).  
Before deciding on which design to adopt in the DCE outcome evaluation, it was 
important to consider issues such as appropriateness, feasibility, the study aims and 
how evaluation results would be used (168). MRC guidance on developing and 
evaluating complex interventions recommended caution on selecting outcome 
measures (highlighting that subjective measures were less reliable), on deciding on 
length of follow-up (to ensure that time was sufficient to observe changes), and on 
using proxy outcomes (172). Prioritisation of outcomes according to their importance 
and investigating unanticipated outcomes were described as important requirements 
(166, 172). In order to make such decisions, it was important to better understand the 
DCE programme, and a study was designed to do so (Study 2). 
3.2.3.2 The role of complexity theory 
The adopted MRC Framework for process evaluation of complex interventions 
highlights the importance of the context when carrying out an evaluation. The role of 
contextual issues and the challenges in promoting early cancer diagnosis were 
highlighted in Chapter 2. In this Chapter, challenges in demonstrating causality when 
evaluating public health programmes were outlined. Complexity theory is helpful to 
understand these issues.  
Complexity theory does not have a single origin nor a single definition (181). It has 
been used to describe interventions (172), but also to describe social systems (181, 
182). The MRC describes five characteristics that make an intervention complex: the 
number of interacting components within each group, the number and difficulty of 
required behaviours (in terms of intervention receipt and delivery), number of groups 
or levels targeted, number and variability of outcomes, and how much flexibility or 
tailoring is allowed (172). Funnell and Rogers, building upon a range of authors, 
describe not only complex, but also simple and complicated interventions, with 
different characteristics regarding what they look like and how they work. 
Furthermore, they highlighted that “few, if any” interventions can be characterised as 
simple. The most likely scenario is that some intervention components are simple, 
others complicated, and others complex (165) (Table 3.1). 
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Table 3.1. Simple, complex and complicated aspects of an intervention 
Categories What interventions look like How interventions work 
Simple 
aspects 
• Standardised activities 
• Implemented by one organisation • The same way everywhere 
Complicated 
aspects 
• Multiple components 
• Implemented by multiple 
organisations in ways that can be 
predicted 
• Variation according to different 




• Not standardised and changing, 
adaptive and emergent 
• Implemented by multiple 
organisations with emergent and 
unpredictable roles 
• Generalisations decay quickly 
• Results sensitive to both initial 
conditions and the context 
Source: Adapted from Funnell and Rogers 2011 (165) 
Other authors have criticised the term “complex interventions” due to the likelihood 
that the complexity lies in the context in which the intervention was introduced and 
with which it interacts (183). Hawe recommends that interventions are seen as “events 
in systems”, and that the focus should be in understanding the context, settings, 
strategies and relationships (183). Understanding complexity as a system implies that 
different programmes, even if not complex, may benefit from being evaluated from a 
complexity standpoint (181).  
The terms complexity theory (181), complex adaptive systems (182), complex 
systems, systems science (184), systems thinking (183, 185) or complexity science 
(183) have been used to describe this broad, multidisciplinary area. A widely accepted 
definition of complex systems refers to systems with many heterogeneous 
components that interact with each other, producing an emergent effect which is 
distinct from the effect of each component on its own. This effect persists and adapts 
according to different circumstances (184). An important implication is that the system 
needs to be understood as a whole instead of its separate components (181).  
Peters defines systems thinking as an approach aiming to understand connections 
between “the whole, its parts, and the interactions within and between levels”, all 
“within some notion of a whole entity”. Explicit theories, models and tools developed 
to address complex problems are used (185). These include system archetypes 
(patterns of behaviour in a system that help to understand interactions in a story) and 
causal diagrams (description of how elements of a problem relate to each other) (185). 
Box 3.1 summarises key characteristics of complex systems highlighted by a range 
of authors. 
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Box 3.1. Characteristics of complex systems 
• Interactions in a complex system are non-linear; changes in one component may have a 
minor or a large impact overall (181, 183). There is uncertainty regarding the type/timing 
of impact (181). Longer time frames are needed to be able to investigate changes (183) 
• Different actors may have different views about whether something worked or not, and 
may value different outcomes (181) 
• Interventions/programmes interact with other interventions/programmes in a complex 
system (181) as it has “fuzzy boundaries” (182). Hence, it is difficult to identify the specific 
effects of a single intervention (181). It is also difficult to understand agents and systems 
without understanding the agents and systems with which they interact (182) 
• The agents and the system are adaptive, and changes of behaviour occur over time (182) 
• Complex systems have heterogeneous actors, are usually multilevel, dynamic, and full of 
interactions between actors within the system. Hence, holistic methods are recommended 
in order to examine the whole system and identify underlying mechanisms (184) 
 
Complex systems are common in public health (184), and I believed that the adoption 
of a complexity lens/perspective would be beneficial for the DCE evaluation. Hence, 
I sought to better understand how to adopt this perspective. 
In practical terms, there was limited consensus on how to incorporate complexity 
theory in an evaluation (181), although several general recommendations were 
available. These were synthesised in order to inform the DCE evaluation (Box 3.2). 
Box 3.2. Recommendations for using complexity theory/systems thinking in an evaluation 
• Develop a view of the system and its interactions over time; try to see the big picture and 
the pre-intervention context in order to identify emergent changing processes (181, 186) 
• Adopt mixed methods (181, 186) 
• Adopt approaches that allow for the investigation of interactions (e.g. theory-based 
evaluation approaches such as theories of change and pragmatism) and consider 
different levels; also allow for multiple theories to be used in multiple levels (181). Sole 
reliance on individual level-theories is not deemed appropriate as changes should not be 
understood as an aggregation of individual level results (186) 
• Investigate multiple levels (181, 186), but bear in mind the practicalities of doing so. Case 
studies and other approaches may be an alternative (181) 
• Bear in mind that it is not the form, but the function of an intervention that needs to be 
standardised (183) 
 
Adopting longer timeframes and starting evaluation during programme development 
and implementation were also recommended (181). The latter was also 
recommended by MRC guidance on developing and evaluation complex interventions 
(172). This was not possible for the DCE programme, and implications are 
approached in Chapter 10. 
3.2.3.3 Evaluation as a political activity 
As DCE was a government programme, it was important to understand the 
implications of this for the evaluation. 
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Carol Weiss is one of the key evaluation theorists emphasising that evaluation 
research is a political activity. According to her, a programme is brought by political 
procedures, evaluations inform decision-making processes, and have an inherent 
political stance. They indicate that a programme is important, suggest that it had a 
chance to be successful, and give it legitimacy (187). Furthermore, the acceptance of 
programme goals indicate that these goals are desirable and may imply that other 
elements are not as important. As key goals may not highlight concerns from other 
stakeholders or programme recipients, Weiss argues that “evaluation tends to accept 
the world as it is” (187). Evidence from evaluation can serve as a warning if conditions 
are not improving, can become ammunition (in a positive or negative way) and can 
occasionally provide evidence for action. Furthermore, sometimes it can generate 
enlightenment, i.e. a cumulative effect of new ideas and data becoming part of 
organisational and policymaking discourse (187, 188). 
Pawson and Tilley argue that the very act of engaging in an evaluation constitutes a 
political statement. Social problems are “politically coloured” (i.e. views on what a 
problem is can vary). Evaluations are “petty political” as relevant social/historical or 
political structures are treated as given. Similar to Weiss’ views, they state that 
evaluation often aims to reduce a problem instead of a generating a more radical, 
fundamental structural change (152). Pawson adds that outcome measurement (or 
its “crueller term” performance measurement) is deeply politicised (189). Furthermore, 
he highlights that policymaking is complex, and that programmes do not “stand in 
pristine purity” waiting to be evaluated. Programme theories are borrowed from other 
programmes, adaptations and changes are likely to occur over time, and it is difficult 
to know where one government programme begins and another one ends (189). 
These considerations made me reflect upon challenges in evaluating DCE and its 
components, and upon the need to ensure the evaluation was carried out 
independently.  Furthermore, they indicated the likelihood of facing challenges when 
trying to disseminate results or using them to inform policy. 
Available evidence indicates that well-designed evaluations provide no guarantee that 
results will be used by policymakers. Results may be suppressed, ignored or 
discredited. Policymakers may have beliefs regarding what works that do not match 
the results described by an evaluation (190).  
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Weiss argues that policymakers are faced with “four I’s” any time new research data 
arrives: ideology, interests, institutional norms and practices, and prior information 
(191). Ideology is defined as basic values; it is difficult for good evidence to be 
supported if it goes against the values of policymakers (e.g. supporting abortion 
policy). Interests refer to self-interest (individual or organisational), due to 
opportunities such as career advancement, votes or larger budgets. Institutional 
norms and practices influence how policymakers receive and absorb information. 
They also influence decision-making, and drastic changes in organisational 
processes and rules may not be seen favourably. Finally, information refers to the 
amount of information the policymakers already receive from several sources, how 
they deal with it, and how they add new information to what they already know. If the 
new information challenges previous beliefs, it needs to be very strong to have any 
effect (191).  
I took these considerations into account when designing the evaluation and engaged 
with stakeholders from the earlier stages of the DCE evaluation. The issue is further 
approached in Chapters 5 and 6.  
Furthermore, an independent steering group with specialists in evaluation, public 
policy, primary care and research, and a lay representative was formed in 2016 (full 
names are available in the Acknowledgements page). In addition to helping to ensure 
transparency, the steering group also provided expert advice to the DCE evaluation 
in a range of areas. Having a steering group/advisory team was recommended by the 
adopted MRC guidance (166) and CDC evaluation guidance (168). Furthermore, the 
MRC guidance highlighted that junior researchers often lead complex evaluations and 
emphasised the importance of having an expert advisory team to provide support. 
This was also the case in the DCE evaluation. 
3.3 Research paradigms and mixed-methods 
3.3.1 Research paradigms 
As this project included diverse studies, it was important to investigate the use of 
mixed methods in research. When doing so, I became aware of discussions about 
research paradigms. A paradigm refers to suppositions about the world that give a 
“philosophical and conceptual framework” for studying that world (192). Guba and 
Lincoln state that paradigms are defined by beliefs related to ontology, epistemology 
and methodology. Ontology refers to the “form and nature of reality”, i.e. whether the 
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world exists independently of the way it is perceived or whether reality is a human 
construction (193). Epistemology refers to knowledge, and the relationship between 
the researcher and the research participant (i.e. whether it is possible or not to 
maintain an objective separation between both) (194). Finally, methodology refers to 
how the researcher carries out an investigation (i.e. using qualitative or quantitative 
methods) and is influenced by both ontology and epistemology (193). 
Thomas Kuhn pioneered the use of the term paradigm in science (195, 196). Kuhn 
argued that through scientific revolutions, assumptions and prevailing paradigms that 
are used to guide research are replaced with new ones (197, 198), but there is often 
a misunderstanding between the new and old (or “competing”) paradigms as their 
proponents view the world and do research differently (196). As proponents of 
different paradigms often disagree with the problems that must be solved, or on the 
standards of what constitutes science, communication is challenging (196). Kuhn’s 
views on paradigms have had a strong influence on social research (197), especially 
on discussions regarding the benefits of one paradigm over another. Discussions 
were particularly salient between positivism (the dominant paradigm in scientific 
enquiry – it assumes that human behaviour can be observed and measured, and that 
an existing single objective reality can be tested) (199) and constructivism (that 
postulates that reality is a social construct, and systems and classifications are a 
result of “historical, social and political processes”) (200).  
Closely associated with discussions about competing paradigms were heated 
debates about “the merits and assumptions of quantitative and qualitative research”, 
often described as the “paradigm wars” (201). While quantitative research methods 
are typically used in studies adopting a positivistic/post-positivistic approach, 
qualitative methods have been typically based upon constructive or other interpretive 
paradigms. A crucial implication of linking methods with paradigms is that mixing them 
in research is deemed inappropriate by some theorists (201). Nonetheless, this view 
is disputed by others, who believe that there is a confusion between paradigm and 
method (192, 202), and that focusing on differences is counterproductive in terms of 
advancing science (202, 203). Others argue that such discussions wrongly imply that 
methodological challenges in research can be solved by making a choice between 
different paradigms (197).  
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Onwuegbuzie and Leech state that the conflict between the use of qualitative and 
quantitative methods is often present between methodological purists, who not only 
advocate the use of a single method, but also the superiority of one over the other 
(202). They advocate the adoption of pragmatism, as methods are then not 
necessarily linked to a paradigm (202). Michael Patton, a key name in evaluation, 
believes that “paradigmatic blindness” locks researchers into unconscious biases and 
may affect their ability to be flexible and adaptable (which he describes as crucial in 
evaluation research). He favours “methodological appropriateness” over 
“methodological orthodoxy”, or pragmatism over choosing a side in the paradigmatic 
debate (204).  
Over time, pragmatism became the preferred choice for many researchers because 
it helped to avoid a “forced choice” between paradigms (205), and allowed answering 
questions beyond discussions about ontology, epistemology and methodology (206, 
207).  
As I became aware of these discussions, I investigated pragmatism further. 
Pragmatism has been proposed as a research paradigm (195, 198, 207), but also as 
a useful philosophical or practical approach to research (201, 202, 208, 209). As a 
philosophical tradition (210), pragmatism originated in the late 1800s in the US with 
the philosopher and logician Charles Peirce. Other prominent classic pragmatists 
include William James and John Dewey (211). Deweyan pragmatism is the most often 
approach described in evaluation research. For pragmatists, human inquiry requires 
both “imagination and interpretation, intentions and values” and empirical experience 
(208). Knowledge is relative, and causal relationships are transient and difficult to 
identify (205). Individuals engage with the environment and transform it; these 
experiences produce knowledge and reconstruct reality, which is both constructed 
and real. The environment is always changing, and this requires adaptations from 
individuals. While inquiry helps to deal with uncertainty, it does not result in absolute 
truths as these are transient, and generated through experience with the world (210).  
These definitions reinforced the compatibility of pragmatism with mixed methods 
research; they also showed that pragmatism was a good fit for an evaluation study 
incorporating complexity and systems thinking. Pragmatism’s ability to accommodate 
different perspectives was particularly appealing in order to investigate both 
processes and outcomes in the DCE evaluation. Even before investigating research 
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paradigms, my research questions already guided me towards using mixed methods. 
In other words, pragmatism was underpinning this PhD project even before I realised 
this was the case. Furthermore, pragmatism is well established in both mixed-
methods and evaluation research (170, 202, 205, 207, 210, 212).  
Importantly, irrespective of divergences regarding paradigmatic choices, there is 
consensus regarding the need to be aware of one’s theoretical views and 
assumptions and to report these, as they may influence how research is conducted 
and data are interpreted (193, 195, 199, 208). The concern is also shared in the field 
of evaluation research, (204, 213) as evaluation is often “laden with values”(213). 
3.3.2 Mixed methods research  
Mixed methods research (MMR) can be broadly defined as rigorously collecting and 
analysing both qualitative and quantitative data, mixing or integrating them, prioritising 
either both or one type of data, carrying out these steps either in a single study or in 
multiple components in a study, describing underpinning philosophical worldviews 
and theories, and combining procedures into research designs that will guide a study 
(195). This definition highlights the importance of valuing the benefits of both types of 
data, and the need to combine or integrate these, as “something unique and creative 
will occur” (214). There is growing consensus that integration is a key requirement 
when doing MMR (215, 216).  
Well-established evaluation guidance, core evaluation books and peer-reviewed 
publications have confirmed the usefulness of using mixed methods in evaluation. 
MMR has been recommended in the field of evaluation for over 40 years (195). 
Furthermore, it is suggested by key names in evaluation research (161, 165, 170), 
and endorsed by the MRC guidance adopted for the DCE evaluation (166). MMR was 
also consistent with the questions I was trying to address (i.e. seeking to understand 
not only “what happened”, but also “how” and “why” it happened). The DCE evaluation 
(Studies 2 and 3) required both exploring perspectives and testing hypotheses, 
adopting both deductive and inductive approaches, obtaining both in-depth insights 
and broader views regarding processes and outcomes. Likewise, the systematic 
review (Study 1) required assessing both qualitative and quantitative data in order to 
understand the characteristics of earlier diagnosis initiatives worldwide, allow for 
comparisons with the DCE evaluation and provide recommendations for policy. 
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Hence, a single method would not have been enough for answering my PhD research 
questions. 
After compatibility with mixed methods was confirmed, there was the need to 
understand how to appropriately carry out MMR. Key issues to consider were benefits 
and limitations of using MMR, purpose of using MMR, design, sampling, data 
collection, data validity and quality. These issues are described next. 
3.3.2.1 Benefits and limitations of using MMR 
The available literature highlighted a range of benefits and limitations of using MMR 
(192, 195, 206, 216-218); these were synthesised in Box 3.3. I considered that the 
benefits outweighed the limitations, and that it was still worthwhile (and necessary) to 
use MMR. 
Box 3.3. Benefits and limitations of using MMR 
Benefits 
• Qualitative and quantitative methods help to overcome each other’s weaknesses (e.g. 
bias) and can increase robustness of results; they add meaning to each other, and provide 
new insights; and encourage both inductive and deductive thinking 
• Results from MMR can generate more complex and contextual understanding of 
phenomena; reveal new relationships and patterns; and help to answer questions that a 
single method would not be able to answer, and provide stronger evidence for conclusions 
• MMR can help to produce more complete knowledge to inform theory and practice 
• In evaluation research, MMR can shed light on processes and help with a detailed 
contextual analysis; and help to give meaning to complex constructs (e.g. engagement) 
Limitations 
• Requires skills and knowledge in each method, and in MMR 
• Requires time and resources 
• There may be the need to convince others about its usefulness 
• It is an evolving area, many issues are yet to be solved in terms of paradigms, data 
analysis and interpretation of conflicting results 
• In evaluation research, there is the risk of choosing MMR because it is popular, without 
considering whether the approach best responds the evaluation questions; and research 
findings can be confusing if the evaluator mixes different paradigms uncritically 
Source: synthesised from a range of authors (192, 195, 206, 216-218) 
3.3.2.2 Purpose of using MMR 
In addition to the need to justify the usefulness of adopting MMR, the literature also 
highlights the need for a methodological purpose of doing so. Greene et al developed 
a framework on the rationale for conducting MMR, highlighting five purposes: 
triangulation (to seek convergence/corroboration of results – this can increase validity 
and reduce bias), complementarity (to elaborate, illustrate or clarify results – this can 
enhance interpretations, meanings and validity), development (using results from one 
method to inform the other – this can increase validity), initiation (looking for 
paradoxes, contradictions and new ways of organising results – this can enhance 
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inquiry as different views are considered), and expansion (to extend breadth of 
research) (219).  
The purposes of development, complementarity and triangulation were relevant to 
this PhD project. Study 1 (systematic review) aimed to use MRR for complementarity. 
Study 2 (evaluation development and refinement) was designed mainly for the 
purpose of development (i.e. to inform the DCE evaluation), although it was expected 
that results from initial interviews would also complement those from final interviews. 
The purposes of adopting a theory-based evaluation investigating processes and 
outcomes were complementarity and triangulation. Finally, there was the need to 
have both the review and the evaluation for the purposes of complementarity. 
3.3.2.3 Study design 
The next step was to choose the study design for the PhD project. Study design 
typologies for MMR have been proposed by different authors. Johnson and 
Onwuegbuzie describe a mixed-method design matrix which approaches issues of 
paradigm emphasis (i.e. whether qualitative and quantitative methods have equal 
status) and time order decision (i.e. whether methods are used in a concurrent or 
sequential manner) (206). Morse argues that the research design is informed by the 
research question. A deductive research project would have a quantitative theoretical 
drive (which would be indicated by using uppercase letters - QUAN), while an 
inductive, descriptive or interpretative question would have a qualitative theoretical 
drive (i.e. QUAL). In both cases, when using mixed methods, additional strategies to 
answer the question would be shown using a lower-case letter (i.e. either qual or 
quan). If strategies are used concurrently, a + sign is used. If one strategy follows the 
other (i.e. sequentially), an arrow is used (195). 
Creswell and Plano-Clarke describe six designs which could be adopted as 




Figure 3.2. Frameworks described by Creswell and Plano-Clark 
 
Source: created by synthesising data from Creswell & Plano-Clark 2011 (195) 
After obtaining a better understanding of all possible options and discussing them with 
my supervisors, I have adopted a variant of a multiphase design, using both parallel 
(concurrent) and sequential designs. My supervisors and I agreed that a multiphase 
design was the most appropriate option in order to address the PhD project 
overarching aim (i.e. to understand the role of multilevel policy initiatives in promoting 
the earlier diagnosis of cancer). Furthermore, the approach also allowed for each 
phase to address specific research questions (important in a project with multiple 
study components). A multiphase design is often used in programme evaluation, and 
pragmatism is recommended when methods are used concurrently (195). 
3.3.2.4 Sampling 
In MMR, decisions about sampling designs can affect the researcher’s ability to 
interpret overall results, make inferences, generalise or transfer findings to different 
populations and contexts (220, 221). Furthermore, inadequate sample size in one 
component may lead to limited analysis of another component (especially when these 
are connected/inform one another) (220). 
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The first step for this PhD project regarding sampling was to acknowledge core 
differences in sampling procedures between qualitative and quantitative research 
(195) (Box 3.4).  
Box 3.4. Sampling in qualitative and quantitative research 
Qualitative research: Purposive sampling is used to obtain in-depth, rich insights about 
social phenomena (199, 204, 220). There is no unique rule for defining sample size (222). 
Due to the complexity of the data, costs and the time it takes to obtain them, samples sizes 
are often small (199). Grounded theory recommends the use of theoretical sampling; i.e. 
participants continue to be sampled and data are analysed until saturation. Green and 
Thorogood state that sample size should be defined based on the study aims, and add that 
little new information is expected after 20 interviews within a group with similar 
characteristics (200). Patton recommends answering several questions to define sample 
size (regarding research purpose, what is useful and what is feasible) (204).  
Quantitative research: Probabilistic samples are often used with the aim to obtain a 
representative sample of the population of interest. However, non-probabilistic samples are 
used for practical reasons, or when the researcher is interested in certain characteristics 
which are not common in a larger population (195). Random selection helps to ensure that 
everyone from a specific population has the same chances of being selected, reducing 
selection bias and helping to generalise results (195, 220). Sample sizes are often (but not 
always) large so statistical tests can be carried out (195). 
 
The second step was to acknowledge that in MMR, sampling designs are dependent 
on the purpose and time orientation of the study (220, 223) (Table 3.2). Therefore, 
before deciding on sampling design, I checked whether my chosen purpose and time 
orientation were compatible. 
Table 3.2. Matrix crossing purpose and time orientation 
Purpose of MMR 
Time orientation 
Concurrent design Sequential design 
Triangulation Yes No 
Complementarity Yes Yes 
Development No Yes 
Initiation Yes Yes 
Expansion No Yes 
Source: Adapted from Collins 2010 and Onwuegbuzie & Collins 2007 (220, 223) 
For example, sequential designs are not appropriate for triangulation (as findings from 
the first approach are likely to influence and bias findings from the second approach) 
and concurrent designs are not appropriate for development (as studies occurring at 
the same time cannot inform each other appropriately) (220, 223). These checks were 
made for the PhD in order to ensure compatibility between designs and purposes.  
Then, it was necessary to select a sampling design based on time orientation and 
relationship between the qualitative and quantitative samples. Four types of 
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relationship were described: identical (same sample members in the qualitative and 
quantitative components); parallel (different samples are drawn from the same 
population of interest); nested (sample for one component is a subset of the sample 
from another component); and multilevel (one or more samples extracted from 
different populations) (223). For triangulation purposes, identical or parallel samples 
are acceptable. For development purposes, parallel, nested, and multilevel 
combinations are accepted (223). I was interested in parallel samples for the 
evaluation, in order to reach different groups within DCE stakeholders, while also 
allowing for triangulation and complementarity. 
Finally, I decided to prioritise purposive sampling for qualitative data collection (to 
obtain important insights into a phenomenon), and probabilistic sampling for 
quantitative data collection in order to allow for generalisation of results (unless this 
was not feasible and alternative arrangements had to be made). 
3.3.2.5 Data collection 
It is recommended that data collection procedures are reported in detail when carrying 
out MMR. If adopting a multiphase design, it is important to identify the single objective 
that binds all the study phases together (195). This was clear for the DCE study, as 
all studies were required to understand the role of multilevel policy initiatives in 
promoting the earlier diagnosis of cancer. There are several references to binding 
aims in this thesis; these refer to aims connecting different PhD studies/components. 
3.3.2.6 Data integration 
In MMR, data integration refers to relating different components to the extent that 
findings are then “greater than the sum of parts” (224). Data integration has been 
described as being understudied in MMR (224, 225).  
Creswell and Plano-Clark’s recommendations for integration are dependent on the 
study design. Those adopting a multiphase design should analyse data for each 
component separately, then merge and connect findings in order to meet the key 
research question (195). They suggest the adoption of merged data analysis (using 
side by side comparison, joint displays or data transformation merged analysis) for 
those using concurrent designs, and give advice on connected data analysis for those 
using sequential designs (195). These recommendations were adopted for this PhD 
project; independent data analysis was followed by merged data analysis using joint 
displays of data. Furthermore, informed by a recent book focusing on data integration 
(226), descriptive and narrative accounts merging results were also prepared.  
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3.3.2.7 Data validity and quality 
The final issues to consider when adopting MMR refer to credibility, trustworthiness 
or validity (227). As in most discussions in MMR, this area is still in its early stages of 
development (195). There are debates over whether it is appropriate to apply 
quantitative criteria to qualitative data and vice versa, and criticisms over attempts to 
“impose” validity concepts which some believe only make sense for quantitative 
research (228, 229). Some argue that a “pervasive post-positivism” is prevalent in 
MMR, with qualitative analysis becoming subordinate to quantitative studies (230).  
Creswell and Plano-Clark list several potential threats to validity (such as giving more 
weight to one type of data, not relating different study phases to each other, 
developing instruments without sound psychometric properties, not discussing the 
mixed methods research questions, among many others) and suggest strategies to 
deal with these threats (195). O’Cathain and colleagues developed quality criteria to 
be used as guidelines for those using MMR (GRAMMS) (231). These comprised 
describing why MMR is being used in relation to the research question; outlining the 
adopted design in terms of priority, aim and sequencing; approaching sampling, data 
collection and analysis for each method; explaining where integration occurs, how this 
is done and who has done it; describing limitations of mixing methods; and describing 
new insights obtained with MMR (231). These issues have been addressed in this 
thesis.  
3.4 PhD studies and relationships between them 
In line with guidance, a procedural diagram was developed to communicate the 
complexity of using MMR (195). The diagram describes: 1) the aim that binds study 
components; 2) the purpose of using mixed methods; 3) the adopted designs; and 4) 
data analysis and integration methods (Figure 3.3).  
The systematic review (Study 1) had one component and a qualitative theoretical 
drive. Qualitative and quantitative results were summarised using narrative synthesis. 
Study 1 was carried out independently from, and concurrently with, Study 2 and 3.  
Evaluation development and refinement (Study 2) had a qualitative theoretical drive; 
its two components were linked by a sequential design. Documentary analysis 
informed qualitative interviews (connected data analysis; purpose: development). 
Studies 2 and 3 were linked through a sequential design (connected data analysis; 
purposes: development and complementarity).  
47 
Figure 3.3. Procedural mixed-methods diagram 
 
Abbreviations: QUAL/qual – qualitative; QUAN/quan – quantitative; uppercase 
indicates prioritisation; + indicates a concurrent design; ↑ indicates a sequential design 
DCE evaluation (Study 3) components were organised in a concurrent design. Each 
component was first analysed independently followed by merged data analysis. I was 
the one responsible for data integration. Component 1 (C1) had a quantitative 
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theoretical drive; component 2 (C2) was solely qualitative. Together, they comprised 
the process evaluation (purposes: triangulation and complementarity). Qualitative and 
quantitative methods had equal priorities, and results were merged through a 
synthesis (narrative), joint displays and summary tables. Component 3 (C3) 
comprised the outcome evaluation and was carried out through qualitative (narrative) 
and quantitative synthesis of outcomes. Results were presented prioritising its 
quantitative component. The DCE evaluation had three components for the purposes 
of complementarity and triangulation. Qualitative and quantitative methods had equal 
priority, and results were merged in a narrative description and tables.  
Finally, Study 1 and Study 3 were mixed for the purposes of complementarity in order 
to address the PhD binding aims. I integrated the results using a narrative description. 
Qualitative and quantitative results were equally prioritised.  
3.5 Summary of Chapter 3 
This Chapter described the rationale for the methods adopted in this PhD project. 
Methods for each study are comprehensively described in Chapters 4-6.  
A theory-based evaluation was chosen for the DCE programme. Despite having a 
common premise, different authors described this approach in different ways. I 
expected that with a better understanding of the DCE programme (Study 2 – 
evaluation development and refinement), I would be able to make a more informed 
decision about how to operationalise evaluation components. Choices were made to 
adopt the MRC framework for process evaluation of complex interventions, and to be 
underpinned by complexity theory and systems thinking. 
This PhD project was underpinned by pragmatism (209) and adopted a variant of a 
multiphase mixed-methods design (195), with components adopting sequential and 
concurrent designs. It was informed by overall mixed-methods guidance proposed by 
Creswell and Plano-Clark, and purposes of mixed-methods research and theoretical 
prioritisation requirements described in the literature (195, 219, 232). Guidance on 
sampling (220, 223) and quality in MMR was followed (231). 
This Chapter is the last one of the first part of this thesis (Background and methods 
overview). The next Chapter describes the methods and results of the systematic 
review investigating the characteristics of multilevel policy initiatives promoting the 
earlier diagnosis of cancer.   
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Chapter 4 Systematic review (Study 1) 
4.1 Overview 
This Chapter describes the methods and results for the systematic review 
investigating multilevel policy initiatives promoting the earlier diagnosis of cancer. The 
review aimed to address Objectives, 1, 3 and 4 in this thesis. 
4.2 Review methods 
4.2.1 Aim and objectives 
The systematic review aimed to identify, describe and categorise evidence on 
multilevel policy initiatives aiming to promote the earlier diagnosis of cancer among 
the adult population. It had four research questions: 
1. What are the key components of these initiatives? 
2. Who are the target populations and what are their characteristics?  
3. What are the reported overall outcomes of these initiatives? 
4. Where reported, what are the perspectives of participants (patients, 
professionals and policy makers) on these initiatives? 
If data were available, I also aimed to describe contextual issues that helped to shed 
light on how/why the initiatives’ aims were (or not) met.  
Based on the theories underpinning this PhD, I was aware that the initiatives were 
likely to be complex. Hence, guidance on reviewing complex interventions was 
consulted (233, 234). Furthermore, the review protocol was guided by the PRISMA 
P-checklist (235), registered at PROSPERO (CRD42016047233) and published by 
BMJ Open (236) (Appendix 3). The review was also informed by PRISMA reporting 
guidelines (237), the Cochrane Handbook (238) and the Centre for Reviews and 
Dissemination guidance (239).  
4.2.2 Inclusion and exclusion criteria 
Study selection criteria are summarised in Table 4.1 and described in text. 
Importantly, DCE met inclusion criteria but was already being comprehensively 
evaluated. Hence, for the purposes of the review, only publications found using the 
review search strategy were included. This was to avoid data repetition, and to ensure 
that other strategies could be properly described.
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Table 4.1. Inclusion and exclusion criteria 




• Experimental and non-experimental studies 
o Studies using quantitative, qualitative or mixed methods  
o Protocols, editorials, commentaries, short reports, viewpoints, 
and letters to the editor 
o Reviews/overviews and systematic reviews reporting on a 
number of components from a single national strategy/initiative 
o Conference abstracts when full-text about initiatives is also 
available 
• Reviews and systematic reviews reporting on more than 
one national initiative 
• Conference abstracts when full-text about initiatives is not 
available 
• Published guidelines/recommendations from Professional 
Bodies which are not part of a government initiative 
• Publications without full-text in English 
Population 
and setting 
• Adults (aged 18 or older) 
• Patients/member of the public with or without medical conditions 
• Health care professionals  
• Health institutions/settings 
• High-income countries (World Bank) 
• Children (aged 17 or younger) 
• Professionals working in an administrative capacity (even if 
within a health system) 
• Low- and middle-income countries (World Bank) 
Interventions 
• Initiatives aiming to promote early diagnosis  
AND 
• Initiatives addressing the patient/member of the public and at least 
two more levels of contextual influence (see Taplin et al)  
AND 
• National level initiatives or equivalent (i.e. State or Provincial level 
depending on health system structure and autonomy) 
• Initiatives aiming to support the entire cancer trajectory or 
to reduce cancer disparities (in which early diagnosis is only 
a component) 
• Initiatives focusing on primary prevention, surveillance 
programmes, genetic counselling, cancer recurrence or 
screening programmes 
• Cost-effectiveness studies 
• Initiatives addressing the patient/public only 




• Any comparators (studies without comparators are also eligible for 
inclusion) 
• High-level outcomes (national or equivalent) related to the 
initiatives’ main aims (e.g. improve awareness, diagnose cancer 
earlier) 
• Overall views/experiences about initiatives 
• Local, setting-specific outcomes 
• Outcomes for a single cancer type (when strategies 
targeted more than one type) 
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4.2.2.1 Study designs and publication types 
The review included quantitative (experimental and observational), qualitative and 
mixed-methods studies. Study protocols, editorials, commentaries, short reports, 
viewpoints, letters to the editor, theses, government reports and other policy 
documents were also eligible for inclusion as it was expected that they would have 
relevant information on initiatives. It was important to be inclusive regarding study 
designs and publication types (even including editorials, commentaries and short 
reports) in order to identify background information about initiatives. As the review 
aimed to understand the international landscape (as opposed to being focused on the 
effectiveness of interventions), background information was particularly important. 
From experience (and prior to carrying out the review), my supervisors and I were 
aware that these publication types were often used to introduce initiatives. This was 
the case for at least two well-known initiatives in England, for example (42, 240). 
Furthermore, we also expected that references in these short publications would 
guide us towards government reports and other publications with relevant information 
on eligible initiatives. 
Conference abstracts were only eligible for inclusion if full-text articles were also 
available. Reviews/overviews were eligible if they were about a single initiative; 
otherwise they were excluded, and their references checked in order to identify 
additional relevant initiatives and publications. Published guidelines which were not 
part of a government initiative were not eligible for inclusion. 
4.2.2.2 Study population and setting 
Initiatives aiming to promote earlier cancer diagnosis for the adult population (aged 
18 and over) were included. All cancer types were eligible for inclusion. Early cancer 
diagnosis initiatives aiming at healthy participants or patients with any underlying 
medical conditions were eligible for inclusion. Initiatives targeting health care 
professionals, health care providers, institutions and governments were also eligible 
for inclusion. Initiatives carried out solely with professionals working on an 
administrative capacity were excluded. 
Only initiatives carried out in high-income countries as classified by the World Bank 
(241) were included. Low- and middle-income countries were excluded as it would 
have been challenging (and likely unfeasible) to compare review results with DCE 
activities in Scotland in order to answer the PhD research questions. 
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4.2.2.3 Interventions 
Interventions were defined as any “specified strategy or set of strategies designed to 
change the knowledge, perceptions, skills, and/or behaviour of individuals, groups, or 
organizations, with the aim of improving patients’ health outcomes” (242).  
National initiatives with the explicit aim of promoting earlier cancer diagnosis at a 
health system-level were included. Acknowledging a model of multiple levels of 
contextual influence in the cancer care continuum described in the literature (242), 
initiatives were only included if they addressed the patient (individual level) in addition 
to at least two more levels (Figure 4.1).  
Figure 4.1. Multiple levels of contextual influence 
 
Source: adapted from Taplin and Rodgers 2012 (242) 
Interventions were also required to have involvement from governments (at State or 
National Level). Local research studies within an organisation and purely academic 
research studies were excluded.  
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I expected that initiatives would be about campaigns to increase 
knowledge/awareness of cancer, training for professionals, and development of 
pathways to cancer diagnosis and treatment. Initiatives focusing solely on primary 
cancer prevention, surveillance, genetic susceptibility of cancer, aiming to avoid 
cancer recurrence, or cost effectiveness studies were excluded. Publications solely 
describing cancer screening programmes were excluded as they referred to a 
different, extensive body of literature. 
4.2.2.4 Comparators 
I expected that many included studies would not have comparators, as the review had 
a broader aim and included policy initiatives described in qualitative, quantitative and 
mixed-methods studies. Available comparators were likely to be: 1) indicators before 
(baseline) and after (one or more time points) at an individual and other levels; or 2) 
those in receipt versus those either not in receipt of any initiative or in receipt of a 
different initiative. 
4.2.2.5 Outcomes 
The review aimed to synthesise initiatives and their characteristics rather than assess 
all available outcomes for each initiative, as I was aware that these analyses would 
not be feasible in a single review. Outcome data were reported on overall, high-level 
outcomes. Local outcomes reported for local, small studies were not described. 
Likewise, outcomes from pilot studies, needs assessment and development of 
initiatives were not reported. Finally, if more than one publication reported on the 
same outcomes for the same initiative, data were extracted from the most recently 
published publication (to avoid duplication and inaccuracies). Core publications for 
each initiative were identified (from which data were extracted), and all other relevant, 
additional publications with local outcomes were listed in Appendix 4. 
I expected that high-level quantitative outcomes would include measures of 
knowledge/awareness of cancer, cancer symptoms or cancer screening, mortality, 
cancer survival and proxy measures such as cancer staging. Qualitative outcomes 
would include views or experiences from professionals regarding implementation, 
feasibility and acceptability of initiatives, patient and public views on the impact of the 
initiatives and the importance of outcomes (233). Qualitative findings were also likely 
to describe the context in which initiatives were implemented (233).  
54 
Finally, I was aware that some studies eligible for inclusion would be reporting on 
ongoing initiatives (for which outcome data would not yet be available) or would only 
describe components of eligible initiatives.  
4.2.3 Search strategy  
A search strategy was developed by listing keywords considered to be relevant based 
on my knowledge of available literature on cancer and early diagnosis (complemented 
by my supervisors’ knowledge) and by examining search strategies from publications 
in the area (95, 243). It was then refined after discussions with Marshall Dozier, a 
Senior Academic Liaison Librarian at the UoE. Finally, it was tested to ensure it was 
identifying relevant publications, and not missing any initiatives that I was aware were 
likely to be included (such as 2-week wait in England, and different referral pathways 
in Denmark). It was challenging to define specific keywords based on the exploratory 
research questions as there was the risk of missing relevant studies. Furthermore, I 
expected that national health initiatives would not always be described as such. A 
decision was made to have a broad search strategy and to prioritise sensitivity over 
precision (238). The Medline search strategy is described in Table 4.2. Other search 
strategies are available in Appendix 5. Government, charity websites and data 
repositories for randomised controlled trials and studies funded by the European 
Commission were also checked (Table 4.3). 
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Table 4.2. Medline Search Strategy 
 Search Terms 
1 
government or policy$ or policies or national or regional or multi-level$ or system-level or whole-system$ or NAEDI or "Detect Cancer 
Early" or "National Awareness and Early Diagnosis Initiative" or "Find Cancer Early" or "Be Cancer Aware" or "Be Clear on Cancer" or 
initiative$ or program$ or campaign$ or strateg$ or engagement or awareness.mp 
2 health$ adj2 (care or service$ or system$ or seek$ or provi$).mp 
3 surviv$.mp 
4 delay$ adj4 (diagnos$ or present$ or treat$ or consult$ or patient$ or doctor$ or system$ or refer$ or therap$ or care or detect$).mp 
5 time adj4 (diagnos$ or present$ or treat$ or refer$ or care or detect$).mp 
6 late adj4 (diagnos$ or treat$ or refer$ or present$ or detect$).mp 
7 earl$ adj4 (diagnos$ or present$ or treat$ or refer$ or therap$ or detect$).mp 
8 3 or 4 or 5 or 6 or 7 
9 Cancer$ or neoplas$ or tumour or tumor or malign$ or oncolog$.mp 
10 
Randomi$ or RCT or intervention or trial or cross-sectional or survey$ or questionnaire$ or train$ or "natural experiment" or interview$ 
or "focus group$" or "case study" or observation$ or time-series or "time series" or CBA or "controlled before and after" or "controlled 
before-after" or prospective or retrospective or cohort or case-control or cross-over or "case series" or case-reports or "case reports" or 
feasibility or pilot or narrative or qualitative or quantitative or mixed-methods or "mixed methods" or evaluat$ or assess$ or attitude$ or 
view$ or perception$ or perspective$ or "discourse analysis" or "content analysis" or "thematic analysis" or "narrative analysis" or 
phenomenolog$ or "purposive sampl$" or ethnograph$ or "theoretical sampl$" or "grounded theory".mp 
11 1 and 2 and 8 and 9 and 10 
12 11 not (child$ or pediatric$ or paediatric$ or adolesc$ or teenag$).ti 
13 12 not (palliative or terminal or "end of life" or end-of-life or "advance directive$" or hospice$).ti 
14 13 not (biomarker$ or molecul$).ti. 
15 limit 14 to (english language and humans and yr="2005 -Current") 
a“.mp” searches automatically for subject heading (MeSH) fields
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• Cochrane Database of Systematic Reviews (CDSR) 
• Cochrane Central Register of Controlled Trials (CENTRAL) 
• Database of Abstracts of Reviews of Effects (DARE)  
• Health Technology Assessment 
Database (HTA) 




• Embase Classic + Embase 
• MEDLINE(R) and MEDLINE(R) In-Process & Other Non-Indexed Citations 
• PsycInfo 
• PsycARTICLES full-text 




• Science and Social Sciences 
• Conference Proceedings in Science and Social Science & Humanities 
ProQuest 
(single search) 
• ProQuest Dissertations & Theses Global 
• Applied Social Sciences Index and Abstracts (ASSIA) 
• International Bibliography of the Social 
Sciences (IBSS) 
• PAIS International 
EBSCOhost 
(single search) 
• Cinahl Plus 
SocINDEX with full-text 
Other sources of 
data 
• United Kingdom: UK Department of Health Publications and Statistics; The Knowledge Network (NHS e-library); UK Clinical 
Research Network; Healthcare Management Information Consortium (HMIC) database  
• United States: Centers for Disease Control and Prevention 
• International Agency for Research on Cancer 
• European Commission’s Community Research and Development Information Service (CORDIS) 
• OECD iLibrary 
• Charities worldwide: Cancer Research UK, Marie Curie, Macmillan Cancer Care, The King’s Fund, The Nuffield Trust, National 
Cancer Research Institute, World Cancer Research Fund International, American Lung Association, American Cancer Society, 
Cancer Research Institute, National Cancer Institute, Cancer Council Australia, Canadian Cancer Society, Danish Cancer 
Society, Cancer Society of New Zealand, German Cancer Aid, Irish Cancer Society, Dutch Cancer Society, Norwegian Cancer 
Society, Portuguese Cancer League,, Asociación Española Contra el Cáncer, Swedish Cancer Society, Nordic Cancer Union, 
German Cancer Society 
• Theses: EThOS - Electronic Theses Online Service; Dart-Europe 
• Clinical Trials: U.S. National Institutes of Health’s Clinical Trials Database; WHO International Clinical Trials Registry Platform 
Search Portal; UK Clinical Trials Gateway 
• Grey literature: Open Sigle 
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In addition to electronic sources, I checked the reference lists of all included 
publications. Finally, the list of included studies was checked by me and my 
supervisors to assess whether any relevant studies known to them were missing. 
Studies published prior to 2005 were excluded (as this was when the WHO approved 
its resolution on Cancer Prevention and Control) (244). Only publications in English 
were included.  
4.2.4 Data management, selection and extraction 
Citations and abstracts were exported into EndNote X7 for Windows. After removing 
duplicates, studies were screened through the following procedures: 1) I screened all 
the titles and abstracts against the inclusion criteria, while one of my supervisors 
screened a random selection (30%) of the excluded studies at this step; 2) One of my 
supervisors and I independently screened the full-text of studies included in step 1; 
and 3) One of my supervisors and I carefully independently reassessed the full text of 
all studies included in step 2 (to ensure they had relevant information to be extracted 
– publications without this were excluded from the analysis). The study selection 
process was recorded in SPSS v.23 (245) for Windows and a PRISMA flow diagram 
(237) was developed. Disagreements were solved by consensus.  
Other sources of data and references of included studies were searched by me. A list 
of potentially eligible initiatives was shared with one of my supervisors for discussion 
regarding eligibility. Likewise, disagreements were solved by consensus. 
A data extraction template was created (Appendix 6) to record information on the 
initiatives’ characteristics and key components, target populations and outcomes, in 
addition to study design, setting, location, and participants’ views. Data extraction was 
carried out by me and a postgraduate student at the UoE. The data extraction form 
was piloted with three randomly selected included studies. Forms were compared in 
order to reduce bias and ensure data extraction was being done in a consistent 
manner. Then, I extracted data from 50% of the included initiatives and a Master of 
Public Health (MPH) student extracted data from the remaining 50%. This student 
(Ms Orjola Shahaj) was recruited in order to ensure that quality assessment was 
carried out by independent reviewers and data extraction was completed in a timely 
manner. Orjola had experience working in systematic reviews and had just completed 
a Cochrane review as part of her studies. Initiatives were randomly selected for data 
extraction (initiative names were written in paper, folded, and picked up from a box). 
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All data extraction forms were checked again (by me) against original sources of data 
prior to data synthesis. 
4.2.5 Quality assessment 
As it was expected that the included studies would vary in terms of design, and most 
of them would be observational (125), more than one tool was used to assess quality. 
Study quality was not part of the inclusion criteria; as there were concerns about 
missing relevant studies describing eligible initiatives if doing so. 
Quantitative studies were analysed using the McMaster Critical Review Form for 
Quantitative Studies (246). This tool had multiple choice questions regarding the 
study purpose, literature, design, sample, outcomes, intervention, results, conclusions 
and implications. It also had open-ended questions regarding bias, validity and 
reliability, allowing for the assessment to be carried out for different observational 
designs (246). Initially I had considered using the method of scoring descriptive 
studies developed by Mitchell and colleagues as it had been used in reviews 
investigating factors associated with delays in cancer diagnoses (247, 248). However, 
the McMaster Form was used instead as it allowed for a comprehensive description 
of study limitations, in addition to approaching risk of bias. 
Qualitative studies were assessed using the quality assessment tool from Hawker and 
colleagues (249). The original tool had nine items; one of them was divided into two 
so issues regarding ethics and bias could be assessed separately. I had already 
successfully applied this adaptation in a previous systematic review assessing a 
range of qualitative studies (250). Each item allowed for four possible answer options 
(“good”, “fair”, “poor” and “very poor”). Editorials, commentaries, and viewpoints were 
also assessed using this tool. 
Letters to the editor, conference abstracts, government reports and cancer plans were 
not assessed for quality as I did not identify any appropriate tools to do so. Potential 
methodological issues and implications for the review findings were discussed in a 
narrative format (Chapter 10). Reviews and systematic reviews were assessed using 
the validated Oxman and Guyatt’s 10-item checklist (Overview Quality Assessment 
Questionnaire) (251, 252). Initial considerations to use AMSTAR (253-256) were 
abandoned as it did not perform well with non-systematic reviews during piloting. 
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Mixed-methods studies were assessed using the tools for qualitative and quantitative 
studies. No summed quality scores were calculated due to recognised problems when 
doing so (257, 258). Quality assessment results were prepared for all included studies 
eligible for quality assessment and for each study separately. 
Each study was independently assessed by me and a second reviewer (a visiting 
medical student from the Netherlands or the MPH student who also did 50% of the 
data extraction) with disagreements solved by consensus. Interrater reliability was 
calculated using both percentage agreement and Cohen’s kappa scores in order to 
control for agreement by chance (259, 260). Cohen’s kappa was calculated using 
SPSS v.23 (245). Unweighted Cohen’s kappa was used for nominal data and 
weighted kappa was used for ordinal data (i.e. giving greater emphasis to large 
differences between reviewer ratings compared to small differences) (261). Landis 
and Koch guidelines were used to assess strength of agreement for kappa scores 
(<0.00 poor; 0.00-0.20 slight; 0.21-0.40 fair; 0.41-0.60 moderate; 0.61-0.80 
substantial; and 0.81-1.00 almost perfect agreement) (262). Confidence intervals 
(CIs) for weighted kappa scores were calculated using the formula (k - 1.96 x SEk to 
k + 1.96 x SEk; - with SE representing standard errors and k representing the kappa 
scores) (260).  
4.2.6 Data synthesis 
Narrative synthesis was chosen instead of meta-analysis for several reasons. Firstly, 
heterogeneity was expected in the composition and intensity of initiatives, populations 
and contexts (234, 263). Narrative synthesis is often used when there is heterogeneity 
(239, 263). The method relies on using words and text to “tell a story” of findings (264). 
Secondly, narrative synthesis is useful in reviews that do not focus on the 
effectiveness of interventions (263) and is a good fit for complex interventions (233). 
Finally, narrative synthesis is effective to synthesise both qualitative and quantitative 
evidence (265) and to describe different study contexts and designs (266). Guidelines 
for using narrative synthesis (264) were followed. 
Findings were described in diagrams, text and tables, focusing on key features of 
initiatives (including contextual issues such as drivers and influencers, described 
policies and source of funding); key components (such as referral guidelines); and 
target populations. Findings were categorised according to Taplin et al’s model of 
multi-level influences on the cancer care continuum (242), and the updated NAEDI’s 
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hypothesis of factors influencing cancer survival and premature mortality (shown in 
Figure 2.4) (130). A general overview of included initiatives was prepared, followed 
by findings corresponding to each of the four review questions. For feasibility 
purposes and to ensure reporting of high-level data, any detailed information about 
included initiatives was only provided in Appendices. 
4.3 Review results 
4.3.1 Study selection 
Database searches were carried out on the 13th September 2016, while website 
searches were carried out in April and May 2017. Exact dates and hits in each 
database/website are available (Appendix 8).  
A total of 22,115 records were identified in databases, these were reduced to 14,844 
after removing duplicates and studies which had been published before 2005. A total 
of 13,442 records were excluded in stage 1 (title and abstract screening), and 1,335 
in stage 2 (full-text screening), resulting in 67 records included from the database 
searches.  
Additional searches (websites and other sources and reference lists of included 
records) resulted in further 196 included records. Overall, 263 records corresponding 
to 19 initiatives in ten countries met inclusion criteria (Figure 4.2). Data were extracted 
from 99 core publications describing 18 initiatives; a list of the remaining 164 records 
is available (Appendix 4). There were no core publications for “Be Cancer Aware”, a 
cancer awareness programme in Northern Ireland which met criteria for inclusion 
(267).   
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Figure 4.2. PRISMA flowchart 
 
About a third of core publications (n=32) were peer-reviewed publications; these were 
independently assessed for quality. The remaining core publications consisted of 
reports (n=45), official government correspondence (n=9), official Cancer Plan or 
Cancer Strategy (n=7), theses (n=3), news pieces (n=2) and a power point 
presentation (n=1).  
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4.3.2 Quality assessment 
Fifteen publications were assessed using the McMaster Critical Review Form for 
Quantitative Studies, nine using the tool for qualitative studies; four using both tools 
and four using the OACC tool for reviews. Tables describing quality assessment for 
each publication and results for the interrater reliability assessment are available 
(Appendix 7).  
Percentage agreement across raters varied from 30.8% (question 10 in the tool for 
qualitative studies – importance of findings to policy and practice) to 100% (several 
questions in each tool). There were wide variations in agreement across questions 
and quality assessment tools (especially for tools assessing qualitative and 
quantitative studies). Disagreements between raters were common and solved by 
consensus. This variation was influenced by challenges in using tools for studies with 
a range of designs, even though tools were piloted to assess suitability and reduce 
variability. Low percentage agreement for several items indicated low interrater 
reliability. Similarly, there was wide variation regarding strength of agreement across 
different tools (measured using Cohen’s kappa). Strength of agreement varied from 
slight agreement to almost perfect agreement.  Fair (k=0.21-0.40) strength of 
agreement was often reported for the quantitative tool (strength was often higher for 
other tools); this also indicated low interrater reliability. 
4.3.2.1 Quantitative studies or mixed-methods studies with a quantitative 
component 
Key study limitations referred to the sample not being described in detail (n=10), no 
mention of validity (n=13) or reliability (n=15) for outcome measures, not addressing 
potential contamination (n=8) nor co-interventions (n=13) (Figure 4.3). Key issues in 
terms of bias, validity and reliability referred to study design (i.e. observational studies 
without a control group - there were four case-controls and no trials), limited 
information on the socio-demographic characteristics of cohorts and providing only 
brief descriptions of adopted methods. 
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Figure 4.3. Quality assessment: quantitative studies (n=19) 
When the sample size was not justified, but the whole population of interest was 
included in the study, the question was deemed not applicable. When there was no 
control group, contamination was deemed not applicable. When there was no 
justification for the methods used; the issue was deemed not addressed. The question 
about drop-outs was not applicable depending on the study design. 
4.3.2.2 Qualitative studies or mixed-methods studies with a qualitative 
component 
More than half of the studies (n=7) had either a very poor or poor description of 
methods, nine did not mention sampling, nine had either poor or very poor description 
of data analysis, all but one did not address ethical issues, no studies discussed 
potential biases between researchers and participants, and seven had either poor or 
very poor statements of findings (Figure 4.4). There were challenges in using the tool 
for editorials/commentary papers, and it is likely that the large number of poor/not 
applicable ratings was influenced by this. 
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good fair poor very poor not applicable
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4.3.2.3 Reviews 
All included reviews referred to the same initiative (2-week wait in England) (268-270); 
two publications were assessed together as they referred to the same review (270). 
In terms of rated scientific quality, one review had “minimal flaws” (score 7/7), while 
two had “mid-range extensive to major flaws” (score 2/7). For the latter two, it was not 
possible to tell if the search for evidence was reasonably comprehensive nor if bias 
in the selection of studies was avoided. Furthermore, there was no reporting of the 
criteria to assess study validity. Finally, both reviews did not mention the methods 
used to combine findings (Figure 4.5). 




4.3.3 Characteristics of included initiatives 
4.3.3.1 Country where initiative was implemented 
Most strategies were based in Europe (n=13) and North America (n=3). The UK had 
the highest number of strategies (n=5). Three initiatives were carried out in Spain, two 
in the United States, two in Denmark and one in each of the remaining countries 
(Australia, Canada, Norway, Qatar, Republic of Ireland and Sweden).  
4.3.3.2 Study designs 
There were no randomised controlled trials; all quantitative studies or studies with a 
quantitative component were observational studies. Before-and-after (BA) or pre-post 
studies and cross-sectional studies (often descriptive studies of a specific population 
or online/paper questionnaire surveys) were the most commonly adopted 
observational designs. When comparators were used in BA studies, they were often 
time-period controls or geographical controls. Most qualitative studies or studies with 
a qualitative component adopted interviews or focus groups to collect data. Other 
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findings combined according to question
validity assessed using appropriate criteria
selection bias avoided
search for evidence comprehensive
yes can't tell no
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Table 4.4. Study designs adopted by included studies 
 Quantitative Qualitative Other 
 Cohort Before-and-after / pre-post 
Cross-sectional Other Interviews Focus groups Other 
2 week-wait (2WW)         
Accelerate, Coordinate, Evaluate (ACE)         
Be Clear on Cancer (BCOC)  *       
Cancer Patient Pathways (CPPs)         
Detect Cancer Early (DCE)         
Diagnostic Assessment Pathways (DAPs)         
Fast-track Catalonia         
Fast-track Valencia         
Inside Knowledge         
Listen out for lung cancer         
National Awareness and Early Diagnosis 
Initiative (NAEDI)  *      
 
Non-specific symptoms and signs (NSS) 
CPPs        
 
Norwegian CPPs         
Oral Cancer Maryland         
Rapid Assessment Clinic (RAC)         
Qatar’s first national Cancer Plan         
Rapid Referral Pathway Madrid         
Standardised care pathways (SCPs)         
* Indicates that geographical or time-defined controls were often (but not always) used. Notes: Other quantitative design includes time series 
analysis (2WW), case-control study (NAEDI) and impact and outcome evaluation studies (NAEDI). Other qualitative design comprised 
theoretical and analytical analysis of online data drawing upon critical discourse analysis (CPPs in Norway). Other design includes PhD theses 
(CPPs and NSS-CPPs), systematic and non-systematic reviews (2WW), review of waiting times standards (which included stakeholder 
engagement) and guideline development (2WW).
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4.3.3.3 Types of strategy 
The 18 included initiatives were categorised into: strategies to improve cancer 
awareness and/or knowledge among the public; professional education strategies; 
referral pathways based on cancer symptoms; or combinations of these strategies 
(Figure 4.6). Half of the initiatives comprised at least two of these strategies. Three 
initiatives not only comprised all three strategies; but also developed other activities. 
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Figure 4.6. Types of strategy 
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Initiatives are not fully independent: BCOC was created under the auspices of NAEDI 
before becoming an independent strategy (271). One of the ACE projects initially 
received NAEDI funding (272). The NSS-CPP was developed to complement the pre-
existing Danish CPPs (273). More recent strategies (such as ACE and Qatar’s first 
national Cancer Plan) often referred to established initiatives in other countries 
(especially in England and Denmark).  
4.3.3.4 Placing initiatives into theoretical and evidence-based 
frameworks/models 
All initiatives addressed the individual level of contextual influence described by Taplin 
and colleagues (242) (part of the inclusion criteria). The least often addressed level 
was family/social supports (n=6). All other levels were consistently addressed, except 
for the National Health Policy Environment as initiatives in Spain, Australia, Canada 
and the United States (except for Inside Knowledge) took place at State/Provincial 
level only. 
When considering NAEDI’s updated hypothesis of factors influencing cancer survival 
and premature mortality (130), most initiatives targeted factors associated with health 
systems such as access to diagnostics (n=14), delays in the secondary care interval 
(n=14), and delays in primary care interval (n=10). Difficulty accessing primary care 
was the least often targeted factor (n=4). Regarding patient factors, low public 
awareness (n=8) and barriers to help-seeking (n=8) were targeted more often than 
negative beliefs about cancer (n=6). (Figure 4.7) 
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Figure 4.7. Initiatives according to the updated NAEDI model 
Source: Adapted from Hiom 2015 (130) 
4.3.3.5 Drivers, rationale and aims of the included initiatives 
Most of the included strategies were driven by the high burden of cancer incidence 
and mortality and the need to improve cancer survival (this could be to improve 
performance either within a country in order to reduce disparities or when compared 
to other countries with better cancer outcomes) (Appendix 9). In contrast, 
Standardised Care Pathways (SCPs) were implemented in Sweden, a country with 
good cancer survival and good quality of cancer services, in order to improve patient 
satisfaction (274). In Qatar, the burden of cancer will be an issue in the future, as the 
country’s population is still considerably young (275). 
There was wide recognition of the role of late diagnosis in cancer survival and poorer 
cancer outcomes (and this was often described as a rationale for the developed 
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strategies); some strategies also acknowledged the role of other factors in cancer 
survival. A few also recognised the psychological impact of longer diagnostic 
intervals. The limitations of screening and the fact that most cancers are diagnosed 
through symptomatic presentation were also reported; and at times used as a 
justification for the need to involve and better support a range of primary care 
professionals in early diagnosis. The need to change a perceived low awareness of 
screening and cancer symptoms and signs (which was reported to vary across 
different population groups) was provided as a rationale for awareness raising 
initiatives. Comprehensive information on drivers and rationale for each initiative is 
available in Appendix 9. 
The initiatives aimed to improve cancer survival and promote early cancer diagnosis 
mainly through promoting/encouraging early presentation and reducing diagnostic 
intervals in the health system. Some initiatives also explicitly aimed to improve patient 
satisfaction and quality of care (through the development of more efficient pathways, 
improvement of communication between health care professionals and between 
professionals and patients). (Table 4.5). 
Table 4.5. Aims and core references for included initiatives 
Initiative and 
country Aims and core references 
2WW 
England, UK 
Improve prompt access to specialist services as part of a larger strategy 
to improve cancer outcomes (81, 268-270, 276-285) 
ACE 
England, UK 
Address the NHS outcome of “preventing people from dying 
prematurely”; improve overall patient experience along the diagnostic 
pathway; and accelerate changes by adding to the knowledge base. 





Support earlier diagnosis of cancer and improve survival rates by: 1) 
highlighting cancer signs and symptoms to increase public awareness; 
and 2) encourage prompt health seeking (176, 177, 292-306) 
CPPs 
Denmark 
Increase cancer survival rates through reducing system delay (reducing 
waiting time and ensuring earlier/faster diagnosis), improving the health 
status of cancer patients and increasing satisfaction (by ensuring fast 
treatment, continuity of care and reducing distress) (80, 179, 307-310) 
DCE 
Scotland, UK 
Key aim: improve overall 5-year cancer survival. Objectives included: 
increase the proportion of cancer diagnosed at Stage I; improve 
informed consent and screening participation; raise public awareness of 
screening, cancer symptoms and signs; promote early referral or 
investigation; ensure there is sufficient screening, diagnostic and 
treatment capacity; strengthen data collection (138, 311-317) 
DAPs 
Ontario, Canada 
Improve care quality and patient experience through shorter waiting 




Reduce the time passed between a well-founded suspicion of cancer 
and the start of initial treatment (320) 
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Initiative and 




Improve communication between primary and specialised care, helping 
primary care to decide which patients should be urgently evaluated by a 




Inform women and healthcare providers about the signs, symptoms, risk 
factors, and prevention strategies related to gynaecological cancers, 
and increase knowledge of HPV and the HPV vaccine. Align care with 
evidence-based recommendations (322-330) 




Assess behaviour and knowledge regarding lung cancer (campaign 




Improve cancer survival and reduce premature mortality by reducing the 
number and proportion of cancers diagnosed and treated at a late stage; 
improve outcomes for patients; provide leadership and support to 
activities and research that promote early diagnosis; and assemble 
existing and new evidence linking awareness, early diagnosis and poor 
survival. NAEDI components had specific aims (42, 130, 150, 332-340) 
NSS-CPPs 
Denmark 
Account for the fact that: 1) patients with cancer in its earlier stages 
present very differently in general practice; and 2) a single focus on 




Provide an organised, coherent and predictable pathway to cancer 
patients without unnecessary, non-medically justified delays in 




Increase public and professional awareness/knowledge of oral cancer 
prevention/early detection; increase examinations; and develop 





1) Accelerate the diagnostic process for patients with highly suspicious 
signs and/or symptoms of lung cancer and improve access to treatment; 
2) Provide rapid access to a consultant opinion, and prostate biopsy if 





Improve cancer outcomes and prepare for population changes (no 




Ensure that patients suspected of having colorectal cancer undergo 
colonoscopy within 15 days. Other targets: under 30 days waiting time 
to surgery/under 90 days overall waiting time to surgery (350) 
SCPs 
Sweden 
Part of a larger Cancer Strategy aiming to speed up cancer treatment. 
Three objectives: 1) to reduce waiting times from cancer suspicion to 
start of first treatment; 2) to increase patient satisfaction with cancer 
care; and 3) to reduce regional inequalities in cancer care. In the long 
term, it is expected that health services other than cancer will benefit 
from new and more streamlined ways of working (274, 351) 
 
4.3.4 Key components of included initiatives 
4.3.4.1 Start dates 
Oral Cancer Maryland is likely to be the earliest identified multilevel policy initiative. 
Although it is not fully clear when it was implemented, publications show that needs 
assessment activities commenced in the mid-1990s, while outcomes were assessed 
from 2000-2005 (343).  
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The 2WW initiative in England was the earliest initiative focusing on pathways for 
patients with symptoms indicating a high risk of cancer (1999-2000), and it was often 
mentioned by other initiatives. The NSS-CPP in Denmark (launched in 2012) was the 
first identified initiative developing different pathways for patients who did not present 
with high-risk symptoms (273). Finally, NAEDI in England (launched in 2008) (42) was 
the first national initiative to adopt multiple early diagnosis strategies. 
4.3.4.2 Key Stakeholders 
As required by the review’s inclusion criteria, all initiatives had key government 
involvement, often through their Department of Health, National Cancer Control 
Programme or equivalent. There was support from a range of other government 
departments, such as official data providers and purposively built, newly created 
bodies (these included intelligence networks, guideline development groups, 
implementation groups and transformation groups). Likewise, even when considering 
that not all countries had universal healthcare, all initiatives were either partially or 
fully funded by the government. Other funding often came from charity partners; only 
one initiative reported having received private donations (343).  
Some initiatives were described as government-led in partnerships with charities or 
other not-for-profit organisations (such as professional bodies) (Table 4.6). All 
initiatives in the UK involved not-for-profit organisations. There was less involvement 
from for-profit stakeholders; these included marketing research companies working 
on awareness campaigns and providers of health care services in countries without 
universal healthcare. Only four initiatives mentioned involvement of patient 
representatives (Table 4.6). A comprehensive list of stakeholders is available 
(Appendix 10). 













2WW      
ACE      
BCOC      
CPPs      
DCE      
DAPs      
Fast-track Catalonia      
Fast-track Valencia      














Listen out for lung cancer      
NAEDI      
NSS-CPPs      
CPPs in Norway      
Oral Cancer Maryland      
RAC      
Qatar’s first national 
Cancer Plan      
Rapid Referral Pathway 
Madrid      
SCPs      
Abbreviations: reps: representatives 
4.3.4.3 Policies 
Initiatives in the UK mentioned cancer strategies published in England (134, 271, 337) 
and Scotland (136). Initiatives in Denmark mentioned the first two national cancer 
plans in this country, reported to be published in 2000 and 2005 (352, 353). Inside 
Knowledge referred to the Gynaecologic Cancer Education and Awareness Act of 
2005, often described as Johanna’s Law (354). Oral Cancer Maryland cited the 
Maryland Comprehensive Control Plan for 2004-2008 (355). The strategies carried 
out in Qatar are all part of the country’s first national cancer strategy (347). The 
Swedish SCPs referred to the 2009 Swedish National Cancer strategy (351). National 
Cancer Control Programmes were also mentioned by the Rapid Access Clinics in 
Ireland (345) and Fast-Track Valencia (356). 
4.3.4.4 Initiatives and their key components 
Initiatives adopting strategies to improve cancer awareness and/or knowledge among 
the public were characterised by initial work assessing population awareness, 
consultation with specialists (and sometimes with the public) to develop campaigns 
and information materials. A wide range of media (such as television, radio, social 
media and printed advertising) was used, and campaign materials were often shared 
online. Community, face-to-face events with the presence of trained staff and/or 
health care professionals were also adopted (Table 4.7). 
Initiatives adopting professional education strategies comprised professional 
development, meetings, educational/training sessions to enable staff to recognise 
cancer symptoms and signs, to ask questions about strategies, to learn about early 
detection examinations and referral processes; to promote different ways to 
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incentivise early detection in community pharmacies; to learn how to use CDS tools 
in primary care; and to hone communication skills with patients (Table 4.7). 
Initiatives that included referral pathways based on cancer symptoms focused on 
high-risk symptoms, serious, non-specific or vague symptoms. Pathways based on 
high-risk symptoms were often characterised by the development of guidelines 
(outlining such symptoms, recommending timelines for diagnosis and treatment, and 
often procedures and care). Guidelines were often evidence-based, developed with 
input from clinical specialists, and relevant organisational bodies. Patients or patient 
organisations were involved less often. Other common features were assigned 
pathway coordinators and defined waiting times targets or performance indicators (not 
only for referral and diagnostic investigations, but also for treatment/surgery). The 
development of pathways based on serious, non-specific and/or vague symptoms and 
the implementation of multidisciplinary diagnostic centres were more recent and less 
common strategies (i.e. NSS-CPP in Denmark and ACE in England); there were no 
references to national targets nor specific guidelines (Table 4.7). 
Tumour types 
Only two initiatives targeted a single tumour type; these were Listen Out for Lung 
Cancer in Australia (331) and Rapid Referral Pathway Madrid in Spain (which targeted 
colorectal cancer) (350). Choice of tumour type was often based on its importance in 
terms of cancer incidence/mortality, but at times it was also due to the recognition of 
associated challenges (e.g. treatment issues) or facilitators (such as the availability of 
clinical guidelines). Lung, colorectal and breast were the tumour types most 
commonly targeted, followed by prostate cancer (Table 4.7).
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Table 4.7. Key components of included initiatives 
Initiative and start 
date Key components 
 2WW 
 
Launched in 1999 
(breast) and 2000 
(all other cancers) 
• Wide range of tumour types 
• Patient to be seen in secondary care within two weeks of the initial referral. Other targets (Cancer Waiting Times) comprised 
31 days (first definitive cancer treatment to begin within one month of being informed of diagnosis and agreeing a care plan) and 
62 days (first definitive cancer treatment to begin within 62 days of being urgently referred by the GP/being referred from an NHS 
Cancer Screening Service). An operational standard of 93% was set and targets were monitored 
• Referral guidelines approached high risk symptoms and recommended processes and care; a 'risk threshold' (3% positive 
predictive value or PPV) underpinned recommendations 
ACE 
 
Wave 1 launched 
in 2015 
Wave 2 pilots live 
in 2017 
• Wide range of tumour types, often lung and colorectal for Wave 1 
• Wave 1: about 60 projects across England, split into eight clusters: 1) new approaches for patients presenting with vague 
but concerning symptoms (e.g. new pathways and audits); 2) effective ways to remove barriers to screening for the vulnerable 
and minorities; 3) training for non-GP primary care professionals and pharmacies on how to promote early diagnosis; 4) pathways 
from lung cancer referral to diagnosis using proactive approaches for people at high risk of lung cancer (offers of CT scans and 
self-referral to CXR) and improving lung cancer pathways for people presenting with concerning symptoms; 5) use of CDS tools 
to identify high risk patients; 6) use of colorectal cancer pathways and referral thresholds; 7) effective strategies to improve bowel 
screening uptake among deprived groups; and 8) cost-effective approaches to find lung cancer early  
• Wave 2: ‘one-stop’ diagnostic pathways for patients with non-specific but concerning symptoms, using 
Multidisciplinary Diagnostic Centres (similar to the NSS-CPP in Denmark). There were five different projects; some looked at 
GP referrals, others considered self-referrals and referrals of patients who present at A&E departments 
BCOC 
 
Launched in 2011 
• Tumour-specific (bowel, lung, kidney, bladder, breast, ovarian, oesophageal, skin, and prostate cancers) and symptomatic 
campaigns: clear and concise information, highlighting the importance of key cancer symptoms and when to act. 
• Use of TV, radio and print advertising. Web pages provided key information, more details on cancer symptoms and signs and 
campaign materials. Local pilots used community engagement strategies so the public could talk face-to-face to trained staff 
• Other pilots held education sessions for primary and secondary care professionals. A community champion was assigned  
CPPs 
 
Launched in 2007 
• Included a wide range of tumour types; pathways were developed for 32 cancer sites 
• Recommended timelines for referral until first appointment with specialist/hospital, first hospital visit until diagnosis, 
diagnosis until start of treatment, and overall referral until time of treatment. There was explicit identification of who was 
responsible for each phase. Timelines varied according to tumour type. For example, a patient with a “reasonable suspicion” 
of colorectal cancer should be seen by a specialist within nine days of referral. Targets were monitored 
• Referral guidelines approached high-risk symptoms, recommended treatment, processes and care 
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Initiative and start 
date Key components 
DCE 
 
Launched in 2012 
• Included a wide range of tumour types overall; campaigns and targets focused on breast, lung and colorectal cancers 
• Public Awareness and behaviour influencing: awareness campaigns for the public (overarching and tumour specific) 
• Primary care symptom management and referral: awareness raising of cancer symptoms and signs among primary care 
professionals; update of referral guidelines for patients with high-risk symptoms. There were no specific targets described 
for referral nor diagnosis, although there were other targets: 31-days from decision to treat until first treatment and 62-days 
from urgent referral with suspicion of cancer until first treatment. An operational standard of 95% was set 
• Cancer screening and diagnostic capacity: funds to expand capacity, redesign services, develop pathways and action plans 
• Performance management: development of a HEAT target: improvement of cancers diagnosed at Stage I (25% increase for 
lung, breast and bowel cancers), and financial rewards for reduction in bowel screening non-participation 
DAP 
 
Date not clear, 
likely 2004/2005 
• Breast, lung, colorectal and prostate cancers 
• DAPs provided a single point of access by concentrating/coordinating referral processes from various points of entry from 
the time from initial abnormal results to the date of diagnosis. Clinical units provided multiple diagnostic services in one place (if 




Launched in 2005 
• Breast, colorectal and lung cancers 
• A fast-track programme synchronised clinical needs of patients with a high risk of cancer by implementing passive 
(e.g., slots in diagnostic tests) or active (e.g., case management) measures. Included cases originated from GP referrals, 
screening and emergencies. Two organisational change components: 1) from suspected cancer detection to confirmation 
of diagnosis; and 2) from diagnosis to first treatment.  
• Guidelines were developed by specialists, with recommendations for implementation (responsibilities and maximum waiting 




Launched in 2009 
• Breast, colorectal, cervical, lung and bladder cancers 
• Six hospital specialists, a Primary Care (PC) physician and the oncology coordinator met regularly to discuss cases and 
develop guidelines to be used by PC physicians to refer patients with suspected cancer. On the same day that the PC physician 
identified a patient with suspected cancer, an index card was sent to the oncology coordinator.  
• Referral guidelines were developed by experts and informed by available evidence. Health guidelines were created for the 
public. No specific targets were described 
Inside Knowledge 
 
Launched in 2008 
• Gynaecological cancers: cervical, ovarian, uterine, vaginal and vulvar  
• Campaign messages about the importance of early detection; the need to pay attention to the body, unexplained signs 
and symptoms or warning signs; to attend cervical cancer and take the HPV vaccine. Materials for the public included: 
cancer fact sheets, brochures, print and broadcast announcements, posters, outdoors, and a cancer symptoms diary. Use of 
media and social media (e.g. magazines, television, Facebook, Twitter, podcasts, CDC TV and YouTube channel) 
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Initiative and start 
date Key components 
• For health care providers, the campaign developed educational modules to increase knowledge of each cancer; of genetic 
causes of gynaecologic cancers; and of HPV and the HPV vaccine. Resources were available at meetings and presented at 
professional gatherings. The campaign worked with key partners to ensure wide dissemination of materials. Free campaign 
materials were given to national and local governmental and nongovernmental partners. 
Listen Out for 
Lung Cancer 
 
Launched in 2013 
• Lung cancer 
• Social marketing campaign developed and evaluated in five stages: formative research (understand the attitudes, knowledge 
& behaviours); concept testing (develop & test campaign concepts with consumers); media strategy (use information to design 
media strategy); implement campaign; evaluation. Only data on campaign development was available 
NAEDI 
 
Launched in 2008 
• Wide range of tumour types, with variation across different initiatives (e.g. CDS tools targeted colorectal, lung, oesophago-
gastric (OG), pancreatic and ovarian cancers; for local initiatives tumour type was chosen based on assessments of local 
populations with most targeting lung, bowel or breast cancer, and others targeting prostate or cancer in general) 
• Cancer Networks Supporting Primary Care programme (centrally coordinated, locally delivered improvement initiatives): 
- Clinical audit (National Audit of Cancer Diagnosis): practices used a standard audit template to collect information on patient 
demographics and assessment processes in primary care, including the time taken from first presentation to referral.  
- Significant event analysis (SEA) template: a quality improvement review by the practice team of what happened in relation 
to a cancer diagnosis, why it happened, what could be learned and what should be changed 
- Practice cancer plans: often carried out after reviewing practice cancer profiles (performance measured against metrics for 
screening/diagnosis). Guidance and a template for plans were available to record data an outline tasks to improve outcomes. 
- CDS tools: RAT or Risk Assessment tool or QCancer were used. Both tools were developed in electronic format and had 
distinct functions: a prompt, a symptom checker and a risk stratification list that presented the GP with a risk score for a patient. 
Practices were encouraged to use the tools. Training materials and training sessions for the GP were developed.  
• Other activities: Development and validation of a Cancer Awareness Measure (CAM) tool; development and implementation 
of BCOC (before it became a standalone project); development of the International Cancer Benchmarking Partnership 
(ICBP) to understand international variation in cancer survival and explore associated factors (became a standalone project) 
• Local initiatives: public-facing activity (e.g., advertising/community events to raise awareness and engage with the public); 2) 
changes to services (e.g., extending opening hours, liaising with hospitals to deal with demand, direct access to diagnostics; 





• Included a wide range of tumour types 
• CPPs became accompanied by two more referral routes: the urgent referral for nonspecific, serious symptoms and the no-
yes-clinics (NYC) for vague symptoms. These routes allowed the GP to refer patients and carry out investigations when there 
was a suspicion of cancer, but the patient did not meet criteria for urgent referrals. GP suspicion was enough for a referral 
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Initiative and start 
date Key components 
• The GP can order standard diagnostic investigations (i.e. blood and urine tests and diagnostic imaging) and results are received 
within four working days. The GP then decides on further steps within eight working days e.g. waiting or referral for further 
investigations. If relevant (e.g. there is no explanation for symptoms; a specific disease or type of cancer is suspected) the patient 
is referred to a diagnostic centre. The NYC for vague, ‘low-risk-but-not- no- risk’, symptoms take place in hospitals or specialist 





• Included a wide range of tumour types 
• Introduction of 28 CPPs and 31 diagnostic guidelines in primary and specialist healthcare. Described as “a logistics reform, 
and not new guidelines for diagnosis”. No specific targets were described 
• Pathway was developed to be predictable at all stages. The patient condition is discussed face-to-face and in iterative 






• Oral cancers 
• Comprised: examination training, educational and awareness programme for health care providers; educational and 
awareness campaign for the public; provision of tobacco settlement funds for initiatives 
• Key activities for the public comprised health education materials, oral cancer education (e.g. need for examinations and 
information about risks, signs and symptoms, and smoking cessation), oral cancer screening examinations and referral 
• Professional education and training programs for dental/non-dental health care providers (to properly examine, diagnose, and 
refer patients). A public relations oral cancer prevention campaign was developed, with training programs for care providers. 





Published in May 
2011 
• Priority given to cancers with the highest incidence in Qatar (breast, urological, gastrointestinal, and haematological), but over 
time a wide range of tumour types was included 
• Three access targets were developed to ensure rapid referral, diagnosis & treatment: appointment with a specialist within 
48 hours of referral for patients with suspected cancer; 14 days from seeing a Specialist to a definitive diagnosis using a 
combination of imaging, pathology and physical examinations; 14 days from diagnosis to commencement of treatment. The latter 
two targets were managed by multi-disciplinary teams. A new Referral Management Office coordinated the process. Tumour 
boards developed, validated and published evidence-based care guidelines (for clinical management, screening and suspected 
cancer), coordinated service audits, and conducted other quality assurance activities. Multidisciplinary teams and a patient 
pathway coordinator were established, a rapid access clinic was opened. 
• Awareness campaigns: awareness and myth refutation campaign with influential Qatari figures as Cancer Champions; use 
of media to fight cancer stigma and start a brave/optimistic conversation about battling cancer; tumour-specific campaigns. A 
cancer awareness survey was designed to assess the public understanding of cancer and their lifestyle habits. Education 
sessions in schools were planned, in addition to plans to create a comprehensive cancer information resource online 
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Initiative and start 
date Key components 
• Courses (communication skills such as timely and sensitive communication about a cancer diagnosis); role in cancer 
treatment and referrals) for health care professionals  
• Development of an early detection indicator: 30% increase in the proportion of cancers diagnosed at Stage I and 2 by 2016 
RAC 
Republic of Ireland 
First clinic opened 
in 2010 
 
• Prostate and Lung cancers initially, then breast and melanoma were added 
• Access to a specialist opinion within four weeks of initial appointment; if cancer is confirmed patients should have 
immediate access to a multidisciplinary care team to arrange appropriate treatment.  
• Clinical guidelines developed by specialists, multidisciplinary teams and the Irish College of General Practitioners, and with 
consultation of all relevant stakeholders. A National Rapid Access Clinical Referral Form was developed. Education meetings 
with GPs were held across the country so they could hear about how the clinics operated 
• Provision of funding for recruiting consultant urologists, consultant respiratory physicians, radiologists, pathologists, 
radiographers, medical laboratory scientists, administrative staff; and for endoscopic ultrasound equipment 
• Performance monitored for a wide range of indicators, including: 20 days from referral to appointment in RAC (prostate 
cancer, 90% standard); 10 days from referral to appointment in RAC (lung cancer, 95% standard);. Other targets referred 





Introduced in 2004 
• Colorectal cancer 
• A rapid referral pathway between primary and specialised care, for patients suspected of having colorectal cancer (meeting 
predefined high-risk criteria). The target was for patients to undergo colonoscopy within 15 days. Other targets were <30 days 
waiting time to surgery and <90 days overall waiting to surgery. The pathway allowed for direct referral without the need for a 
specialist consultation. A referral pathway coordinator was appointed in each primary health care centre (there was 




started in 2015 
• Wide range of tumour types; started with five (acute myeloid leukaemia, head and neck, oesophageal and stomach, prostate, 
and ureteral and bladder cancer); aimed to cover “almost all cancer diagnoses” over time 
• The model was based on a “well-founded suspicion of cancer” for diagnosis; the pathway ended with the start of first 
cancer treatment. The total number of days from well-founded suspicion of cancer to start of first treatment is was defined by the 
total number of days for each step and constitutes the total target time for diagnosis. The patient must be informed about the 
process and timeframes to be expected. 
• Indicators were identified for each cancer diagnosis and a manual was developed by diagnosis specific multi-professional 
expert teams. The manual outlined symptoms that should lead to a suspicion of cancer and require further investigations, what 
the referral must contain, the waiting times for a specialist appointment, each procedure prior to treatment and pathological/other 
analysis. A 12-day target (waiting time to start of treatment) is described in a chart (274) 
Source: Included studies
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4.3.5 Target populations 
Awareness campaigns targeted the general public, but also specific population 
groups for which most impact could be achieved in terms of improving cancer 
outcomes. These groups included all within the eligible age groups for cancer 
screening programmes, patients at higher risk of cancer (.e.g. smokers and ex-
smokers; older patients since cancer is more common at older ages; and those from 
more deprived or remote areas as they were more likely to present late) (Table 4.8). 
Adaptations regarding access, language or other culturally sensitive changes were 
made in order to reach vulnerable populations (such as the hard of hearing or visually 
impaired in England  (292)) and ethnic minority groups (such as Hispanic populations 
in the US (322), Black and Minority Ethnic Groups in the UK (292)  and Aboriginal 
people in Australia (331)). In Qatar, initiatives aiming to increase awareness also 
targeted school students (348), while Oral Cancer Maryland also targeted “high risk 
populations” (343) (Appendix 11). 
Professional education most often targeted GPs, dentists, dental hygienists, family 
nurses, medicine counter assistants, pharmacists and community pharmacists due to 
their current and potential role in promoting early diagnosis. Referral pathways 
targeted patients for which there was a high suspicion of cancer, or for which the 
possibility of cancer was sufficient to warrant further investigations (Table 4.8, 
Appendix 11). 
Overall, patients suspected of having cancer based on high-risk symptom criteria 
were the most often targeted groups (n=12), followed by health care staff (n=8) and 
the general public (n=7) (Table 4.8).
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Table 4.8. Target populations 
Initiative 
Patients suspected 
of having cancer 




















 2WW        
ACE        
BCOC        
CPPs        
DCE        
DAPs        
FT Catalonia        
FT Valencia        
Inside Knowledge        
Listen out for lung cancer        
NAEDI        
NSS-CPPs        
CPPs in Norway        
Oral Cancer Maryland        
RAC        
Qatar’s first national Cancer Plan        
Rapid Referral Pathway Madrid        
SCP        
1Referral guidelines, common tools from strategies based on symptoms, were prepared for health care professionals, even though the 
strategies themselves targeted patients. This is not shown in the table to avoid confusion when making sense of target populations and 
associated outcomes. 2Other refers to key influencers such as friends and family, and celebrities (BCOC, DCE and Qatar’s strategy), the media, 
policy makers and trainers (Oral Cancer Maryland), and students (Qatar’s strategy). One of ACE initiatives also targeted patients who presented 




The wide variation in adopted study designs and components of initiatives was 
accompanied by diversity in data collection methods and outcomes. It was not 
possible to report on all described outcome measures and outcomes within the scope 
of this review. A comprehensive description of study designs and outcome measures 
adopted by each initiative is available in Appendix 12.  
High-level outcomes described in the updated NAEDI’s hypothesis (130) are reported 
here. These refer to a) tumour stage at diagnosis (seven initiatives); b) cancer 
mortality (one initiative); and c) cancer survival (two initiatives; but limited national 
data). This is followed by key outcomes according to the type of strategy: professional 
education; strategies to improve public cancer awareness and/or knowledge; referral 
pathways based on cancer symptoms; and other activities. 
4.3.6.1 High-level outcomes described in NAEDI’s hypothesis 
Tumour stage at diagnosis 
All but two initiatives (out of seven) reporting on cancer staging data stated that 
cancers were often diagnosed at early stages. Cancer staging was mostly 
approached by referral pathway strategies. Statistical significance was seldom 
reported. Furthermore, strategies investigating the use of CDS tools in primary care 
(part of ACE and NAEDI) explicitly stated that staging data were not available for 
analysis (291, 334).  
A review about 2WW stated that national data on staging was not available, although 
it identified two studies that reported no impact on identifying cancers at their earlier 
stages (269). An ACE component focusing on pathways for vague symptoms for lung 
cancer reported that when staging data were available, most cancers were in later 
stages (II-IV). Suitability for palliative care was used as an indication of later stages 
when data were not available (88).  
Assessment of the Rapid Referral Pathway in Madrid reported that most patients 
diagnosed with colorectal cancer through the pathway were diagnosed at earlier 
stages. Authors also found that the referral route significantly influenced stage at 
diagnosis (with more cases being diagnosed in early stages in the rapid referral 
pathway compared to the standard referral pathway) (350). Reports about the Fast-
Track Pathway in Valencia outlined that “most cancers were identified in curative 
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stages” (all cases for gynaecological cancers, about a quarter of thoracic cancer 
cases, 40% of head and neck cancers, and over 90% of bladder cancers) (321). 
Outcomes from DAPs included 90% of breast cancers being diagnosed in stages I-II 
and breast cancers being diagnosed (significantly) more often at later stages in the 
control group (318).  
The DCE Programme in Scotland identified a relative 7.0% increase in the proportion 
of cancer diagnoses at Stage I for breast, colorectal and lung cancers combined (the 
official target was 25%) when comparing the baseline (years 2010 and 2011 
combined) and Year 3 (years 2013 and 2014 combined). Reports also highlighted that 
an observed reduction in the proportion of cancers recorded with unknown stages 
may have contributed to the results (316). 
Finally, an evaluation of the BCOC lung cancer campaign identified a positive stage 
shift for non-small-cell lung carcinoma (NSCLC) after campaign launch. Authors found 
that the proportion of lung cancers diagnosed at Stage I significantly increased during 
the campaign period, and this was accompanied by a significant decrease in the 
proportion diagnosed at Stage IV. Similar to DCE, authors acknowledged that 
significant decreases in stages coded as unknown during the same time period may 
have contributed to this shift (176). 
Cancer mortality 
Only one initiative (about 2WW) reported on cancer mortality at a national level. Møller 
et al found that cancer patients registered at primary care practices with the lowest 
use of the 2WW pathway had excess mortality (hazard ratio 1.07 (95%CI 1.05-1.08)) 
compared to patients registered in practices with intermediate or higher use of the 
2WW (81). Cancer mortality was associated with referral ratio (a single general 
practice use of the 2WW compared to other practices) and detection rate; there were 
no significant associations with conversion rates (81). Mortality results were 
consistent across different tumour types (except for breast cancer) and did not change 
after adjusting for confounders (81). 
Cancer survival 
Cancer survival outcomes were described for the 2WW initiative, with limited, 
inconclusive results. Reviews of the use of the 2WW pathway reported on one study 
describing limited impact on survival for pancreatic cancer patients (268), and higher 
one-year survival rates for patients accessing care through the 2WW pathways 
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compared to other routes (except for screening), but differences were often small 
(269). A review of cancer waiting times standards (2WW) described how stakeholders 
such as clinicians and health managers believed that improvements in survival 
brought by the pathway were “impossible to quantify” (278).  
BCOC calculated one-year survival when investigating the impact of awareness 
campaigns for lung cancer, but calculations were not available at a national level. For 
the pilot campaign, there were increases in age-standardised 1-year crude survival in 
both pilot and control areas (176). 
4.3.6.2 Strategies targeting professional education 
Outcome data were available for five (out of eight) initiatives which adopted these 
strategies. Authors often referred to process measures such as how many 
professionals were trained or attended education sessions. Two initiatives reported 
positive changes in knowledge (one of them also described persisting knowledge 
gaps), with limited assessment of statistical significance. 
Inside Knowledge described a range of process outcomes: publications in peer-
reviewed journals, presentations in professional meetings and conferences, 
partnerships with a range of stakeholders, 57 in-person education sessions with 1,101 
health care providers, an online module for nurses aiming to facilitate discussion and 
use of campaign materials, and a free Gynaecologic Cancer Curriculum for primary 
care professionals (as part of continuing education) (327). 
Oral Cancer Maryland reported that 711 health care staff and 643 trainers were 
educated about oral cancer. Results from a follow-up study (2009; compared with a 
baseline survey in 1995) carried out with general practice dentists indicated persisting 
weaknesses in both knowledge and practices concerning oral cancer prevention and 
early detection, but also identified positive changes. There were no clear changes in 
reported knowledge of oral cancer risk factors and diagnostic procedures, although 
88% of professionals recognised HPV is a risk factor for oral cancer (nonetheless, 
only 50% stated that they assessed their patient’s HPV history, and only about a fifth 
asked patients if they had had the HPV vaccine). There was higher compliance with 
recommended screening examinations and an increase in professionals stating that 
they routinely palpated lymph nodes. Furthermore, the percentage of dentists 
describing that they had taken an oral cancer continuing education course in the past 
12 months increased from 14% to 29% (343). 
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In Qatar, it was reported that 31 doctors (including 8 consultants who were also 
trained to be instructors) and 123 members of the nursing team had completed the 
communication skills training about timely and sensitive communication of a cancer 
diagnosis (346). Only data on process measures were available. 
Outcomes for the ACE programme training community pharmacy workers were also 
available, although they were reported separately for different areas/projects. Over 
three-quarters of (77%) of professionals completing a survey in one of the projects 
(Cumbria) stated that the training increased their understanding of bowel screening 
“a lot”. Four professionals completed a survey for another initiative targeting lung 
cancer. When asked how much the training increased their understanding of the 
subject, all reported to understand lung cancer well or fully (prior to training 75% 
reported some knowledge of lung cancer and 25% reported very little knowledge). 
Limited information on costs was also provided (not shown here) (72, 272). 
Some outcomes for professional training provided as part of the Cancer Networks 
supporting primary care programme (part of NAEDI) were also reported. Interviewed 
stakeholders reported that attendance was higher when it was “incorporated into 
formal protected learning sessions”. Practitioners’ attendance to education and 
training sessions was found to be associated with practice engagement (150).  
No outcomes were identified in included publications for the remaining strategies that 
included a professional education component (RAC, BCOC, and DCE). Nonetheless, 
further outcomes for DCE are available as part of the evaluation (Chapter 7).  
4.3.6.3 Strategies to improve public cancer awareness and/or knowledge 
Outcome data were available for three initiatives out of the seven that had a public 
cancer awareness/knowledge component (Figure 4.6): BCOC (national campaigns 
only), Inside Knowledge and Oral Cancer Maryland. In addition to outcomes, all three 
initiatives described a wide range of process measures (not described here) such as 
campaign reach, dissemination and other social marketing measures (such as 
estimates of how many times campaigns were viewed online, product service 
placements in television and radio, and outdoor advertising). 
The most commonly reported outcome measures (all three initiatives) referred to 
changes in knowledge/awareness (prompted or unprompted) about cancer risk 
factors, cancer symptoms and signs, beliefs about cancer, and barriers to help-
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seeking/presentation.  Two initiatives described positive changes in knowledge and 
awareness, two described positive changes in behaviour, and two described 
persisting misconceptions about cancer and barriers to help-seeking. 
Increase in awareness of cancer symptoms and signs as a result of campaigns was 
reported by BCOC (significant changes) (176, 177) and Inside Knowledge (327). 
Positive changes in help-seeking behaviour such as increase in consultations due to 
cancer symptoms and signs (BCOC; significant changes) (176, 177) or increase in 
screening participation (Oral Cancer Maryland) (343) were also described. Persisting 
misconceptions about cancer and/or barriers to help-seeking were reported by BCOC 
(significant changes) and Inside Knowledge (Table 4.9).  
BCOC was the only initiative that consistently assessed whether changes associated 
with the campaigns were statistically significant. Furthermore, it also investigated and 
reported on campaign impact on system-level outcomes such as GP referrals, urgent 
GP referrals, diagnostic investigations and cancer diagnoses (reporting a statistically 
significant increase in all cases) (Table 4.9). BCOC also investigated tumour staging 
and survival, as previously reported in this Chapter. 
No outcome data were reported for NAEDI as its national awareness initiative (BCOC) 
is shown separately; other relevant NAEDI strategies were only developed and 
implemented locally. There was no outcome data available for ACE, DCE, Listen Out 
for Lung Cancer (although data were available for campaign development) (331) and 
Qatar’s Cancer Strategy at the time of review completion.
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Table 4.9. Outcomes for strategies aiming to improve cancer awareness/knowledge among the public 
Initiative Outcomes 
BCOC 
• Significant increase in unprompted and prompted awareness of several lung and bowel cancer symptoms and warning signs, 
including target symptoms, although there were no significant changes to the proportion saying ‘blood in your poo for 3 weeks or longer’ 
is a definite warning sign of bowel cancer (prompted). There were no significant changes for being ‘worried about wasting the 
doctor’s time’ or believing that the ‘doctor would be difficult to talk to’ 
National bowel cancer campaigns 
• Increase in attendances amongst patients over 50 reporting key campaign-related symptoms (significance not clear) 
• Increase in the number of GP visits during the campaign and three weeks after the campaign period 
• Statistically significant increase in 2WW referrals for suspected lower GI cancer and in colonoscopies and flexible sigmoidoscopies 
• Non-significant increase in lower GI cancers diagnosed following a 2WW referral; statistically significant decrease in conversion 
rates (although the same happened for the control groups) and small increase in detection rates (no mention to significance) 
National lung cancer campaigns 
• Significant increase in presentations of patients aged 50+ with a cough 
• Significant increase in urgent GP referrals for suspected lung cancer, the number of CXRs following a GP referral (and from all 
referrals), and the number of GP-referred CTs 
• Significant increase in lung cancers diagnosed; significant increase in the proportion of patients diagnosed with lung cancer via GP 
referral; significant decrease in the proportion diagnosed after an emergency admission or A&E attendance.  
• Significant increase in lung cancer patients receiving surgical resection as a first definitive treatment 
• Non-significant reduction in conversion rates 
• Both campaigns were reported to have reached the broad target audience, but also reached younger and more affluent audiences  
Inside 
Knowledge 
• Ads were reported to be effective in increasing awareness of cancer symptoms (no significance was reported), and in prompting 
women to seek additional information about gynaecological cancer.  Women in the intervention communities had greater 
knowledge of the gynaecological symptoms compared to women not in these communities (no significance reported). 
• However, there was no observable impact on intention to seek help; and misperceptions about the purpose of the Pap test (i.e. 




• Increase in the % of those aged 40+ reporting that they have had an oral cancer exam in the past year (no significance reported) 
• 5,352 individuals screened for oral cancer (81 with cancer findings or possible cancer, 4 cancers detected) 
• Other outcomes:  Improvement in national rankings in terms of oral cancer incidence and mortality; new Oral Cancer Legislation 
implemented; inclusion of oral cancer in the Maryland Cancer Control Plan; creation of an annual Oral Cancer Awareness week 
Source: included studies
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4.3.6.4 Referral pathways based on cancer symptoms 
Initiatives in this category reported on an extensive range of outcomes. These 
included measures of healthcare utilisation and symptom presentation; estimated risk 
of cancer at referral; use of referral guidelines/criteria (i.e. whether this was met for 
referred patients or whether patients were accurately selected for pathway; GP 
compliance; whether guidelines identified correct referrals; whether GPs saw referrals 
as appropriate); number, type and results of investigations; impact of referral 
pathways on waiting times, intervals and outcomes; urgent and non-urgent referrals; 
cancer diagnoses and diagnoses other than cancer; cancer conversion and detection 
rates; and whether targets/indicators were met. 
Data were available for 12 out of 14 initiatives that included referral pathways. There 
were no outcomes available for the SCPs in Sweden nor the CPPs in Norway, 
although a qualitative assessment of how information on the pathways was provided 
online was available (342). 
The most commonly described outcomes were reductions in diagnostic intervals 
(other intervals such as diagnosis to treatment were also reported), performance 
against predefined targets, number and proportion of cancers diagnosed through the 
pathways, and detection and conversion rates. These are further described below.  
Diagnostic intervals and other intervals 
A reduction in diagnostic intervals (days, mean/median days) was found in six 
initiatives: 2WW and their guidelines (281), pathways for patients with vague 
symptoms (ACE) (88), CPPs in Denmark (179), DAPs (318), Fast Track-Catalonia 
(breast cancer only) (320) and Rapid Referral Pathway Madrid (350). Significance 
was reported in half of the cases. Variations by tumour type, symptom presentation, 
GP symptom interpretation (i.e. alarm or vague symptoms), GP cancer suspicion and 
adherence to guidelines were described. Reduction in other intervals was also 
reported, including time to ultrasound and CT scan (pathways for patients with vague 
symptoms – ACE) (88); chest x-ray to CT/outpatient appointment, referral to MDT; 
and quicker access to CT scans compared to the “normal CT referral route” (proactive 
approaches for patients with lung cancer – ACE) (286); abnormal mammography to 
case “resolution” (DAPs) (318); and overall waiting time (Rapid Referral Pathway 
Madrid) (350). Definitions for intervals varied across studies. 
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Performance against predefined targets 
Four strategies focused on reporting whether referral targets/standard were met, with 
most describing positive results and an increase in referrals over time. In the case of 
2WW, targets were consistently met (although the proportion of patients referred and 
seen by a specialist within two weeks reduced over time) (276, 277, 282, 283, 285). 
In the case of RAC, targets were not met overall (with poorer performance for prostate 
compared to lung RACs), although six out of eight designated centres met targets 
(345). In Qatar, there was an improvement over time for most targets, although there 
was a decrease in the proportion of patients receiving specialist treatment within two 
weeks in 2015 (346). DAP results indicated that patients going through the 
programme were more likely to have an abnormal mammography resolved in seven 
weeks compared to those going through other routes (318).  
Cancers diagnosed through the pathways, detection and conversion rates 
Detection rates can be defined as the proportion of all cancers referred through the 
pathway being investigated while conversion rates can be defined as the proportion 
of all referrals through the pathway being investigated that resulted in a cancer 
diagnosis (357). Exact terms used in included publications were used to ensure 
accuracy in reporting. There was wide variation in results, with some initiatives 
focusing on descriptive reporting of rates/proportions, and others comparing these 
with other routes/time periods. 
FT Catalonia reported that at least half of new cancer diagnoses (colorectal, breast 
or lung) were diagnosed through the pathway, with variations by tumour type. There 
was a statistically significant decreasing trend in cancer detection rates (320). 
Similarly, in Ontario (Canada), 51% of breast cancer patients were found to have 
attended a DAP for a diagnostic assessment (318).  
Over one in ten (12%) of all colorectal cancers were identified through the Rapid 
Referral Pathway in Madrid (18% if considering only the final study year – a potential 
indicator of an increase over time). Furthermore, about a fifth (20.6%) of the rapid 
referral patients were diagnosed with colorectal cancer (350). 
2WW reported that the proportion of patients referred who were found to have cancer 
has decreased over time, and most referred patients were found not to have cancer 
(most cancers were diagnosed via other routes) (278). Comparisons between 
practices with higher, intermediate and lower 2WW referral rates found that those with 
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higher referral rates had significantly lower conversion rates and significantly higher 
detection rates. Practices with smaller list sizes had lower detection rates. 
Furthermore, cancer diagnoses from 2WW referrals corresponded to 43% of all first 
cancer treatments (81, 279). 
One pathway providing CT scan after a normal chest x-ray but persisting symptoms 
(ACE) reported that 2.5% of direct access scans resulted in a lung cancer diagnosis. 
Conversion rates were found to be higher for patients who were more seriously ill and 
lower for patients who had non-specific, vague symptoms (88).  
FT Valencia reported that 205 out of 705 (29%) patients who were referred (and went 
for consultation) had a cancer diagnosis (details were also provided for different 
tumour types) (321). The NSS-CPP reported that 16.2% patients referred through the 
pathway were diagnosed with cancer (341).  
Finally, results for RAC in Ireland showed that over a third of newly referred patients 
were diagnosed with either prostate or lung cancer (345) (Table 4.10).
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Table 4.10. Key outcomes for strategies adopting referral pathways based on cancer symptoms 
Strategy Key outcomes 
2WW 
• Annual government reports on waiting times targets reported that the proportion of patients urgently referred for suspected cancer 
(any) by their GP who were seen by a specialist within two weeks of referral was above 95% across most years for which 
evidence was available (2011-2012, 2012-2013, 2013-2014) , except for the latest two years available (proportion was 94.2% for 2014-
2015 and 94.1% for 2015-2016). The operational standard of 93% was met for all types of suspected cancer over the years, with 
variations across tumour types. The number of patients included in the 2WW increased at a constant rate over time 
• The latest systematic review (120) found several studies reporting that delays further along the cancer pathway can offset the 
gains from fast-track referral. It also found that the proportion of 2WW patients with cancer had fallen from 2006/7 to 2009/10, 
that only a minority of cancer patients were referred through 2WW, that while GP selection has improved over the years, not all were 
aware of guidelines or used them. The low PPV of guidelines and the fact that most referred patients would not have cancer was 
also approached. Evidence pointed to wide variation in the use of 2WW in different parts of the country 
• Assessment of diagnostic intervals before and after implementation of the 2005 guidelines for urgent referral (281): First presentation 
of any cancer-related symptom to diagnosis: significant reduction in mean diagnostic intervals from 2001–2002 (before guideline 
implementation) to 2007–2008 (after guideline implementation) for first presentation of any cancer symptom, and for six cancers: 
kidney, head and neck, bladder, colorectal, oesophageal, and pancreatic. After guideline implementation the cancers with the shortest 
intervals were breast, testicular, oesophageal and the ones with the longest were myeloma, lung and lymphoma. For most cancer 
types (except for gastric, cervical and kidney cancers), before  and after guideline implementation, patients presenting with 
symptoms outlined in the guidelines had shorter diagnostic intervals compared to those who did not 
• Practices with higher referral rates had significantly lower conversion rates and significantly higher detection rates. 
Diagnoses from 2WW referrals accounted for 43% of all first cancer treatments. Practices with low referral ratios and smaller list sizes 
had lower detection rates. Median detection rate increased from 17% for practices in the lowest decile of conversion rate to 45–46% 
for practices in the highest four deciles of conversion rate (significant). 11% of referrals resulted in a cancer diagnosis. Practices 
with higher conversion rates generally had higher detection rates and vice versa (significant) overall and for all practice and 
patient subgroups. The median conversion rate increased from 4% to 14%, for practices in the lowest to highest deciles of detection 
rate (statistically significant) (81, 279) 
ACE 
• Pathways for patients with vague symptoms (88): Outcomes reported for four projects (one in Manchester, one in Airedale and two in 
London). Time from referral to diagnosis varied, with most patients having a diagnosis within 2 (Manchester), 3 (Airedale), and 4 
(London multidisciplinary clinic) weeks. In the other London clinic, where patients were too ill to wait for a 2WW, the time from GP 
referral to diagnosis was reduced (mean -7 days). One project (patients too ill for 2WW referral in London) reported a mean of 16.4 
days from referral to treatment, while another (Manchester) reported that time from ultrasound and CT scan to surgery decreased 
both pre-pathway and post-pathway (no significance reported). Projects picked up a significant number of patients with other 
non-malignant diseases (incidental findings or related to presenting symptoms).  
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Strategy Key outcomes 
• Proactive approaches for patients at high risk of lung cancer (289): four different projects (straight-to-CT pathways) and an audit. All 
reported improvements, but not always for the same intervals. Two reported reduction in the CXR to CT interval (one reported 
increase in the proportion of 2WW referrals with CT prior to outpatient appointment (OPA) and improvement in 62 day performance 
(Crawley), reduction in the CXR to chest OPA interval (even with the addition of a diagnostic MDT discussion) (Horsham and Mid 
Sussex), reduction in the time interval from referral to MDT (South Staffordshire). One pathway providing CT after a normal x-ray but 
persisting symptoms reported “quicker access to CT than the normal CT referral route” in addition to reporting that 2.4% of over 150 
direct access CT scans resulted in a lung cancer diagnosis (one other incidental cancer was also found) . An audit in Somerset reported 
that Trusts with poorer performance in relation to waiting times standards for lung cancer had longer intervals between CXR test to 
diagnosis and between CT request and diagnosis compared to top performers. Furthermore, they had a lower proportion of patients 
diagnosed via 2WW and a higher proportion of patients diagnosed via ‘other outpatient’ routes 
• Conversion rates (88): Pathways for patients who were more seriously ill had higher conversion rates. Pathways for patients 
with non-specific vague symptoms had lower conversion rates 
CPPs 
• The GP used CPPs in 1,426 (37.3%) of all cases, also with variations across tumour types. GPs interpretation of a symptom as alarm, 
serious or vague varied according to tumour type. Overall, GPs interpreted symptoms as an alarm symptom (48.2%), serious symptom 
(19.5%) or vague symptom (32.3%) 
• Referral to a CPP was significantly less likely among patients who had symptoms interpreted to be serious or vague 
• Diagnostic interval varied significantly across tumour types (lowest for breast and highest for prostate), between GP symptom 
interpretation (lowest for alarm symptoms and highest for vague symptoms), and GP referral modes (lowest for CPPs and highest for 
“other”). Adjusted diagnostic interval was longer when the GP did not suspect cancer and when the GP did not refer to a CPP. 
Vague symptoms had the strongest association with the diagnostic interval compared to patients with alarm symptoms. 
• The median diagnostic interval was statistically significantly lower over time for all cancers combined; it also reduced over time 
across all investigated tumour types. Overall results remained after adjusting for differences between populations 
• The median diagnostic interval was 14 days shorter during the transition stage than before CPP implementation and 17 days shorter 
after CPP implementation. Compared to the period before CPPs, the diagnostic intervals were shorter both during and after CPP 
implementation for all tumour types (but not statistically significant at all percentiles) 
• The unadjusted median diagnostic interval was (significantly) lower for both the after-CPP group and the after-no CPP group compared 
to before CPP implementation. The diagnostic interval was (significantly) longer for the after-no CPP group compared to the after-CPP 
group). The adjusted median for the after-CPP group was 23 days shorter than before CPP implementation. The adjusted 
median for the after-no CPP group was 9 days shorter than before the CPP implementation. The 90th percentile for the after-
CPP group was 110 days shorter than before, while similar for the after-no CPP group than before. This trend was noted for all cancer 
types (not significant) 
• Diagnostic interval by referral route compared to during CPP implementation: The adjusted median diagnostic interval was 15 (95% 
CI 12-17) days shorter than during implementation for the after-CPP group, while it was  4 (95% CI 1-7) days longer than 
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during implementation for the after-no CPP group. Similarly, at the 90th percentile, the diagnostic interval 80 (95% CI: 34-126) 
days shorter than during the implementation for the after-CPP group compared to (non-significant) 48 (95% CI: −49-145) days longer 
than during the implementation for the after-no CPP group. This was the case for all tumour groups (although not significant for all 
percentiles). Sensitivity analysis did not alter the overall results 
DAPs 
• 51% of the breast cancer patients (organised or opportunistic screening) attended a DAP for diagnostic assessment. Median time to 
diagnosis was 29 days (IQR: 17–50), to diagnostic resolution was 9 days; reduced to 8.3 days (P< 0.001) after adjustments 
• Breast cancer patients diagnosed at a DAP were more likely to have an abnormal screening resolved within 7 weeks than 
those in usual care (79.1% vs 70.2%, P= 0.001). Those in the pathway were significantly more likely to meet the 7-week 
screening target (90% of abnormal screens should be resolved within seven weeks if a tissue biopsy is required) 
FT Catalonia 
• 56,020 patients included in the pathway during 2006-2009. 
• At least half of all new patients with colorectal, breast or lung cancer were diagnosed through the pathway (about 60% for 
colorectal and 40–50% for breast and lung cancer). When there was adherence to clinical criteria for inclusion in the pathway the 
proportions were higher (over 70% for all tumour types) 
• There was a statistically significant decreasing trend for the cancer detection rate (P<0.001).  
• Mean time from cancer detection in primary care to start of first treatment was 32 days for breast, 30 for colorectal and 37 for lung 
cancer (year 2009) 
• Breast cancer was the only tumour type showing a clear positive trend regarding reduction in waiting times (proportions 
divided into ‘under 30 days’; ‘30 to 45 days’ and ‘over 45 days’). For lung cancer, about 50% of cases were in the shortest wait category 
(‘under 30 days’) and about 50% in the two other categories (‘30 to 45 days’ and ‘over 45 days’ in the final year). 
• Cancer detection rates were “around 30%” 
• The number of patients included in the programme increased over time for all three tumour types (colorectal, breast and lung).  
FT Valencia 
• 897 suspected patients were referred to the pathway, 753 met criteria and 705 went for consultation 
• The 144 who did not meet criteria were returned to the primary care professional (n=54; 2 cancers detected); referred to specialised 
departments (n=43; 10 cancers detected); cited in Oncology Department (n=46, 21 cancers detected) 
• 205/705 patients had a confirmed cancer diagnosis (29%); 166 cases (82%) received a potentially curative treatment 
• Breast: 85/367 referred cases resulted in a breast cancer diagnosis; 56 of the diagnosed women were in an age range for which 
screening with mammography was not recommended.  There were 29 interval cancers 
• Colorectal:  43/168 referred cases resulted in a colorectal cancer diagnosis. 
• Gynaecological cancer: 6/20 referred cases resulted in a gynaecological cancer diagnosis 
• Thoracic cancer: 34/71 referred cases resulted in a cancer diagnosis (33 lung cancers and 1 mesothelioma) 
• Head and neck cancer:  5/31 referred cases resulted in cancer diagnoses (1 non-Hodgkin’s lymphoma, 1 chronic lymphocytic 
leukaemia, 2 lung cancers, 1 palatal cancer) 
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• Urological cancer: 30/48 referred cases resulted in a cancer diagnosis (25 bladder carcinoma, 1 renal pelvic carcinoma, 2 localised 
germinal testicular tumours, 2 renal cancers) 
• Waiting times (median days) from primary care to first specialist consultation: 15 for breast, 22 for CRC, 20 for gynaecological, 5 for 
lung, 11 for cervical lymph nodes and 10 for bladder 
• Waiting times (median days) from specialist consultation to histopathological diagnosis: 9 for breast, 18 for gynaecological, 19 for lung, 
19 for cervical, 57 for bladder, no data for CRC as colonoscopy and biopsy are performed on the same day 
• Waiting times (median days) from histopathological diagnosis to start of treatment: 23.82 for breast, 34 for CRC, 1 for gynaecological, 
20 for lung, 34 for cervical and 10 for bladder 
• The median time from submission of a proposal to specialist assessment was 13 days, to histopathological diagnosis 23 days, to 
treatment 46 days 
• Median time to confirm absence of cancer in 498 patients with an initial cancer suspicion: 22 days 
• Almost three-fold increase in the number of referrals between the first and last year (164 cases were referred between 2009 
and 2010, 305 between 2010 and 2011, and 428 between 2011 and 2012) 
NSS-CPPs 
• 82 different symptoms and 51 clinical findings were identified from the 1278 GP questionnaires. Non- specific symptoms (especially 
weight loss and fatigue) were the most common symptoms. Symptoms associated with the highest probability of cancer were jaundice 
(42.9%), dysphagia (36.7%), neurological dysfunction (35.3%) and lump/tumour (26.9%) 
• Three most common clinical findings: affected general condition (35.8%), GPs’ gut feeling (22.5%) and abdominal findings (13.0 %) 
• The highest probability of cancer was found for enlarged lymph nodes (27.3%), neurological findings (26.7%), the GPs’ gut feeling 
(24.0%) and abdominal findings (21.1%) 
• Abnormal diagnostic test results were often related to blood samples and diagnostic imaging; no specific diagnostic test result was 
associated with a particularly high probability of cancer. 
• After six months, 16.2% of all patients were diagnosed with cancer. The most common tumour types were lung (17.9%), CRC 
(12.6%), hematopoietic tissue cancer (10.1%) and pancreatic (9.2%). 
• The median primary care interval for patients diagnosed with cancer was 15 days (75th percentile 72 days and the 90th percentiles 130 
days). Primary care intervals were shorter than average for breast, liver and biliary cancer patients, while they were longer 
for patients with metastases or cancer of the prostate, hematopoietic tissue, oesophagus, stomach or small intestine (it was 
not possible to provide statistical estimates as the population was small)  
• Patients referred with five symptoms were (significantly) more likely to have cancer than patients referred with one symptom. 
Having had one or more clinical/diagnostic test results was associated (significantly) with a higher probability of finding cancer 
• A higher probability of cancer was found among patients who had not been referred to further examination compared to patients who 
had been referred (only significant for patients from one investigated hospital) 
• Cancer probability was not associated with the number of chronic diseases and the length of the primary care interval, but it was 
strongly associated with the GP’s assessments of estimated cancer risk at referral.  The GPs’ estimations were often higher than the 
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cancer probability. GP gut feeling was associated with the four most common clinical findings (weight loss, fatigue, affected 
general condition and abnormal blood sample) for patients diagnosed with cancer (prevalence ratio: 1.50 (95 % CI: 0.82-2.75)) 
RAC 
• Prostate cancer: In 2013, 1591/2870 (55%) attended or received an appointment to attend RAC within 20 working days of receipt 
of referral in the cancer centre. 36% of new patients were diagnosed with a primary prostate cancer. Access “deteriorated” in 
in the first half of 2014 (Jan-May), with 479/1000 (44%) of patients being offered an appointment within 20 days and 39% of new 
patients diagnosed with a primary prostate cancer. 
• Lung cancer: In 2013, 91% were assessed in a RAC by a respiratory physician within 2 weeks of receipt of request from GP or 
Emergency Department for assessment. There were 1,920 attendances to Lung RAC clinics (733 primary lung cancer diagnoses or 
38%) in 2011, 2,751 (909 diagnoses or 33%) in 2012 and 2,980 (868 diagnoses or 30%) in 2013 (provisional data). 40% of patients 
with lung cancer were referred to a Rapid Access Clinic. In 2014 (Jan – May), 1184/1320 (90%) were offered an appointment 
within 10 working days of receipt of referral. 36% (n=473) of new patients were diagnosed with primary lung cancer 
• Proportion of patients attending who were diagnosed with primary lung cancer fell from 38% to 30% between 2011 and 2013 
• Six of the eight designated centres see over 95% of patients within two weeks of referral 




• Cancer patient response times: 3% seen within 48 hours in 2012, 24% in 2013 and 73% in 2014 and 2015.  
• 2015: 61% of patients were diagnosed within 14 days of being seen at a specialist clinic 
• Cancer patient treatment times: 94% received specialist treatment within 2 weeks (2012), 73% (2013), 88% (2014) and 69% (2015) 





• 272 patients were referred via the rapid referral pathway during the study period. 252 (92.6%) underwent colonoscopy. 200/252 
(79.4%) fulfilled at least one high-risk criterion for rapid referral.  
• Fifty-two (20.6%) of the rapid referral patients were diagnosed with CRC. 
• The most common eligible symptom(s) for rapid referral was a change in bowel habits (49.8%), followed by rectal bleeding (23.9%), 
rectal bleeding plus a change in bowel habits (7.7%) and iron deficiency anaemia (10.1%). 
• The waiting time to colonoscopy and overall waiting time were significantly shorter for patients in the rapid referral pathway compared 
to the standard pathway. There were no significant differences for waiting time to surgery.  
• Overall compliance with the referral criteria was 80% (or 100% if only patients diagnosed with CRC are included). Patients who did 
not meet any criteria for rapid referral corresponded to 4% of all inappropriate referrals; patients who did not meet criteria but had 
symptoms and family history of CRC corresponded to 16% of inappropriate referrals.  
• During the study period, 447 new cases of CRC were diagnosed: 12% via the rapid referral pathway, 69% via the standard 
pathway and 19% via emergency presentation. If only considering the study final year (out of three years), the proportions were 
18%, 59% and 22% respectively 
Source: Included studies
96 
4.3.6.5 Other activities (not part of three main strategies) 
Outcomes were also available for additional activities carried out by NAEDI and ACE, 
although not all of them met criteria for inclusion in the review. The International 
Cancer Benchmark Partnership (39) (created under the auspices of NAEDI) did not 
meet inclusion criteria for the review, but a comprehensive list of its publications is 
available at the CRUK website (358). Publications describing the development of a 
Cancer Awareness Measure (CAM) Tool (relevant to both BCOC and NAEDI) can be 
found in the list of additional references for this review (Appendix 4). 
Evaluation of the Cancer Networks Supporting Primary Care Programme (part of 
NAEDI) reported that general practices engaging in any of the four programme 
activities had a significantly greater increase in 2-week referral rates compared to 
practices that did not engage in any activities (although there were no significant 
differences in conversion, detection or emergency presentation rates) (150). General 
practices adopting the CDS tools had a significantly greater increase in referral rates 
for colorectal cancer, but no significance differences for conversions and detection 
rates (150). 
Other outcomes for those using CDS tools (adopted by NAEDI and ACE) referred to 
how the tool influenced patient management, GP decision making and awareness of 
cancer; whether cancer risk scores provided by the tools were shared with the patient; 
whether the reason for the appointment was explained to the patient; the decision 
made by the GP (such as referral, reassurance, safety-netting, or no action); range of 
provided scores and variation by tumour type; perceived GP cancer risk compared 
with the calculated risk; whether GP decision would have been the same if tool had 
not been used; access to, and use of the tool (Table 4.11).  
There was variation in patient management decisions, type of 
investigations/diagnostic tests carried out, choices of when to use the tool (i.e. during 
or after consultation) and in how tools influenced decision-making. Missing data or 
data unavailability were reported for both studies; this often precluded analysis of 
several cancer outcomes. Data on available quantitative outcomes is available (Table 
4.11). Qualitative evaluation of the use of CDS tools provided richer information on 
tool usage and outcomes and is described in the next section. 
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Table 4.11. Key outcomes for the use of CDS tools 
Strategy Key outcomes 
ACE 
Project 1 (London) 
• GP decisions were fast-track (n=210), diagnostic tests (n=131), safety netting (n=69), 
reassurance (n=45), referral for further care (n=42) and active surveillance / review 
appointment (n=34). 
• Most commonly ordered diagnostic tests were (in this order): blood test, referrals for 
chest x-ray; ultrasound scan; colonoscopy; endoscopy; and flexible sigmoidoscopy 
• The symptom checker influenced patient management more often during 
consultation compared to after consultation. However, the tool was used more often 
after consultation. Missing data were an issue. 68% (40/59) of the cases in which the 
tool influenced management were when the tool was used during a consultation. 
• Risk scores had an impact on GPs’ views on whether patient management was 
influenced by the tool: risk <3 (15 yes, 117 no), risk 3-9.99 (35 yes, 122 no), risk 10-
19.9 (6 yes, 50 no), risk 20+ (27 yes, 73 no); comments indicated that scores helped 
the GP to consider the next steps, reinforced the gut feeling and legitimised decisions. 
• Risk scores were shared with the patient in about a fifth of cases  
Project 2 (Tower Hamlets, London) 
• Substantial amount of missing data resulted in analysis of cumulative scores: <3 
(n=232) and ≥3 (n=335).  
• Most commonly ordered diagnostic tests were (in this order): ultrasound, x-ray, 
endoscopy, MRI, and sigmoidoscopy 
• Patient management decisions were fast track cancer referral pathway (34.0%), referral 
to further care (31.0%), active surveillance (21.5%), and patient reassurance (13.5%). 
The proportion of patients reassured by GPs decreased as the risk score 
increased while the proportion of overall referrals increased in line with the risk 
score.  
• Cancer diagnoses: 16 patients received a cancer diagnosis. In all cases where the tool 
was used and a cancer diagnosis was made, the GP took positive action (instead of 
only reassuring the patient) 
Project 3 (Gateshead) 
• The data profiled patients mostly on the lung cancer smoker list, colorectal smoker list 
and oesophago-gastric smoker list. Most patients attended and received a CXR or were 
referred to lower GI for 2WW investigations. No one was diagnosed with the cancer 
being investigated (one unrelated cancer was diagnosed) 
NAEDI 
• Overall, on more than half of recorded uses, GPs stated that their perceived risk 
was about the same as the risk calculated by the tool (perceived risk was lower for 
31% and higher for 15% of uses)  
• Patient management decisions: referral (20%), further investigations (23%), no action 
taken (47%). When a decision for referral was made, GPs reported that they would 
not have referred or investigated further for 19% of patients if they had not used 
the tool. The tool was more likely to have influenced the GP’s decision to further 
investigate than to refer, with variations across cancer types. If considering only 
patients that required further investigation, GPs reported they would not have done so 
without the tool on 28% of cases (10% for those who were referred). 
• Impact ranged from no impact at all, to increasing/shifting knowledge, to 
influencing patient management 
• There was no evidence of impact of the tools on urgent GP referrals, conversion 
or detection rates. It was not feasible to assess impact of access to, or use of the tools 
on cancer outcomes (such as cancer diagnoses) 
Source: Included studies 
4.3.7 Participant views 
Views from the public, patients and/or health care professionals were available for 
several initiatives. These were often obtained from interviews, focus groups or 
questionnaires. Most data were available from assessments and reviews of 2WW 
(278), evaluations of the Cancer Networks Supporting Primary Care Programme 
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(NAEDI) (150), CDS tools (NAEDI and ACE) (291, 334) and a process evaluation of 
ACE that included four different clusters (287). Additionally, data were also available 
from RAC (professional views) (345), BCOC (professional and public views) (177) 
and Fast-Track Catalonia (professional views) (320). 
4.3.7.1 Views on professional education strategies 
There was limited evidence on professionals’ views regarding education strategies (2 
initiatives); when available views were often positive. Community pharmacy workers 
training as part of ACE often believed (75% respondents) that the training was very 
relevant to their role (72, 272). Stakeholders taking part in the evaluation of Cancer 
Networks Supporting Primary Care Programme (NAEDI) reported that the use of 
different approaches helped to keep training interesting. Both education and 
discussions generated from it were considered to be important (150).  
Information on whether education strategies influenced knowledge/behaviour was 
also obtained from professionals (data were reported in the outcomes section).  
4.3.7.2 Views on strategies to improve public cancer awareness/knowledge 
Views on strategies to improve public cancer awareness/knowledge were often 
positive (two initiatives). Inside Knowledge surveyed care providers (gynaecologists, 
primary care physicians, and nurse practitioners) on education materials for the public 
and reported that “most” professionals were positive towards them (328). 
BCOC carried out qualitative research with the public and GPs, and in general both 
groups had positive or neutral views towards the campaigns. The public believed that 
the campaigns were targeted, sensible and easy to understand, drove action, helped 
with decision-making and with normalisation of help-seeking behaviour (177). About 
half of surveyed participants also believed that the campaigns showed them 
something new (51% for bowel campaign and 46% for the lung campaign), while more 
than half believed that the campaigns were relevant to them (67% bowel campaign 
and 55% lung campaign). GPs were also generally positive about the campaigns, and 
most agreed that it was important that such messages were shown to the public (177). 
4.3.7.3 Views on referral pathways based on cancer symptoms 
Views on referral pathways were available for four initiatives. Views were mostly 
positive, although concerns were also raised by health care professionals. 
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A review of the 2WW initiative carried out with patient groups, cancer charities, 
clinicians and NHS managers reported that almost all unanimously agree that the 
strategy helped to improve services and resulted in benefits for patients (including 
reduction in patient anxiety). There was also support for the strategy to continue. 
There was recognition that the strategy was more straightforward (and targets more 
likely to be met) for some types of cancer (such as breast and skin) compared to other 
cancer types with more complex pathways. There were also discussions about how 
to improve referral processes (such as taking into account patients who wanted more 
time to think about treatment or considering different approaches for patients who are 
not meeting targets due to the need to be transferred between different areas) (278). 
As part of Fast-Track Catalonia, semi-structured interviews with programme 
stakeholders indicated initial fears from hospital staff that the pathway would be 
overused by GPs, it would be used inappropriately, and guidelines would not be used 
accurately. However, this was not confirmed after implementation (320). 
A GP survey carried out in the Republic of Ireland showed that 95.5% of GPs who 
had access to a RAC believed they had a ‘very good’ or ‘good’ experience (344). 
Different ACE components carried out a range of surveys and interviews with patients 
and health care professionals. A patient experience survey carried out as part of the 
vague symptoms cluster found that patients were mostly positive about care, waiting 
times, information received and likelihood to recommend the service to others (88). 
Feedback on pharmacy training included a range of perceived benefits by 
professionals such as good communication between primary and secondary care and 
good local stakeholder engagement. However, concerns were raised by GPs about 
pharmacists making appropriate referrals; challenges identifying eligible patients, 
concerns about limited capacity and limited information (2015, 2017). One ACE 
pathway providing CT after a normal x-ray but persisting symptoms surveyed GPs 
and reported that GP satisfaction with the new pathway was rated 8.1 out of 10 (289).  
Finally, stakeholder interviews covering four ACE clusters (287) identified a range of 
issues. Findings included: being part of ACE brought funds and credibility; some 
organisations were more able to change and develop services compared to others; 
diagnostic capacity was described as a potential or real pressure, with many 
concerned about whether they would be able to meet demand or would have enough 
time to deal with additional activity; belief that without a dedicated project manager 
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implementation would have been challenging; belief that efficient stakeholder 
communication about the project and specific roles, and identifying and engaging with 
the right people were fundamental to programme success; belief that the vague 
symptoms project prevented patients being subjected to unnecessary or inappropriate 
investigations and provided a faster route to diagnosis (although there were 
sustainability concerns due to pressures on endoscopy services). There was also 
anecdotal evidence that patients were positive towards ACE projects (287). 
4.3.7.4 Views on other activities 
Stakeholder perspectives were also available regarding the Cancer Networks 
Supporting Primary Care Programme (NAEDI) and the CDS tools (ACE and NAEDI).  
Stakeholders interviewed as part of the Cancer Networks Supporting Primary Care 
Programme reported challenges in maintaining engagement while there were 
structural changes happening to Cancer Networks in England. Concerns about 
information overload to GPs were also reported (150). 
Both in the case of ACE and NAEDI, the use of CDS tools was reported to have 
helped to raise GP awareness of a possible cancer diagnosis during a consultation. 
Tools also helped with decisions regarding patient management. However, there was 
the acknowledgement that the tools were supporting the GP and were not a 
replacement for their own clinical judgement, and that not all GPs would wish to work 
with them (291, 334)  (Table 4.12). 
Table 4.12. Professional and patient views on the use of CDS tools 
Initiative Professional and patient views 
ACE 
• Criticisms/suggestions for improvements from professionals included comments 
on how the tool did not take into account previous tests done or medical history, lack of 
symptoms for some types of cancer, failure to pick up on breast pain, cumbersome or 
confusing design, concerns about the tool’s scientific validity (which could be due to 
limited awareness about the fact that tools had already been validated) 
• GPs reported that tools helped them to formulate their clinical decisions, to 
reinforce (or legitimise) decisions they had made and helped them explain clinical 
decisions to patients (including providing reassurance in case of low cancer risk). 
They helped to raise awareness of cancer during a patient consultation and were 
(potentially) particularly useful in more complex cases (e.g. comorbidities), but less 
useful in the case of clear, red flag symptoms 
• Tools worked as support to the GPs’ own clinical judgement 
• Patient experience questionnaire in one town (Gateshead in England) showed that 90% 
thought the reason for the appointment was clearly explained to them and 70% felt that 
being asked to come in made them feel nervous, anxious or on edge (although nine out 
of ten stated that the doctor made them feel less nervous, anxious or on edge). 80% 
thought telephoning them was the best way to contact them (nobody preferred a letter). 
Appointment times were considered to be suitable by 100% of patients  
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Initiative Professional and patient views 
NAEDI 
• GP Interview data revealed mixed preferences for use of the tool within the 
consultation, and with the patient. There were concerns about taking the focus 
away from patients and the potential for raising anxiety. Similar concerns about 
loss of focus were raised by patients. However, when asked about the tools 
themselves, patient responses were generally positive. There were also concerns 
from GPs about how referrals made based on the tools would be received by 
secondary care, and about prompt overload (i.e. pop ups frequently flashing). Time 
pressures in a GP consultation were reported to be barriers. There were also 
uncertainties about how to interpret the information provided by the tools. 
• Participants thought it unlikely that GPs would adapt their coding style in order to 
enhance the validity of tools and the scores presented.  
• There was consensus that the tools would not suit all GPs, and that they were not 
necessarily the best support for early recognition of cancer symptoms 
Source: Included studies 
4.4 Summary of Chapter 4 
This Chapter describes the methods and results for a systematic review investigating 
the landscape of multilevel policy initiatives promoting the earlier diagnosis of cancer.  
The review described 18 initiatives in 10 countries. The most often adopted early 
diagnosis strategies were referral pathways based on cancer symptoms, followed by 
strategies focused on improving cancer awareness/knowledge amongst the public 
and professional education. In addition to governments, health care professionals, 
charities and to a lesser extent for-profit organisations had an important role. 
Initiatives most often covered breast, lung and colorectal cancers.  
As most initiatives were about referral pathways, the most commonly targeted groups 
were patients suspected of having cancer based on high-risk, alarm symptoms. More 
recent initiatives focused on patients at risk of cancer, or those with either vague, or 
serious, non-specific symptoms. However, other groups such as health care 
professionals, the general public, and minority ethnic groups were also targeted. 
Few initiatives reported on high-level outcomes such as tumour staging, cancer 
mortality and survival, and significance was not always assessed. Outcome data on 
tumour staging was often positive (although improvements in recording were reported 
to contribute to this) (176, 316). Only one study (81) assessed mortality and found 
that practices with lowest use of the 2WW had excess mortality compared to practices 
with intermediate or high use. Limited available data on survival was inconclusive.  
When assessing outcomes by type of strategy, results were mixed for professional 
education, with reports of both positive and no changes. Reports on awareness 
campaigns described positive changes in knowledge/awareness, but also persisting 
102 
misconceptions about cancer and barriers to help-seeking. BCOC was the only 
initiative reporting on statistical significance, including for health system outcomes 
such as GP referrals, diagnostic investigations and cancer diagnoses (176, 177).  
In terms of referral pathways, there were several reports of reduction in diagnostic 
intervals (significance was reported in half of these cases), and mostly positive results 
on whether targets were met. There was mixed data on referral and conversion rates, 
and synthesis was complicated by heterogeneity (especially the use of different 
terminologies and comparisons). There were reports of more referrals to urgent 
pathways being made over time (277, 282, 283, 285, 320, 321, 345, 349), and for 
2WW this resulted in a reduced yield of cancer diagnoses with many cancers being 
diagnosed through other routes (269, 278). Similar trends in increase in activity, but 
not in conversion nor detection rates were reported by those involved in NAEDI 
activities, including those using CDS tools in primary care (150, 334). 
There were positive views on professional training (from professionals) and 
campaigns (from professionals and the public) in terms of their importance and 
relevance. For referral pathways, there were positive views from the public, patients 
and professionals, but also recognition that pathways worked better for some tumour 
types than others, and that referral processes could be improved (278). Across 
different initiatives, there were reported fears about the inappropriate use of pathways 
or referral guidelines and concerns about meeting demand due to limited capacity 
(72, 272, 287, 291, 320). Views on the CDS tools indicated that they helped to raise 
awareness of cancer but did not replace clinical judgement (291, 334).  
This review described the landscape of multilevel policy initiatives promoting the 
earlier diagnosis of cancer. As such, it is not a review of each initiative, although more 
detailed information is available in appendices. This is a dynamic area, and since the 
review was carried out other publications have been made available for Inside 
Knowledge (359-361), ACE (362-368), CPPs in Denmark (369, 370), Sweden (86, 
371, 372) and Norway (373). The review is currently being updated and these recent 
publications will be incorporated. Nonetheless, the current review provides crucial 
information to address the objectives 1, 3 and 4 of this PhD research project. 
The next Chapters will focus on addressing Objective 2, i.e. to evaluate the Detect 
Cancer Early Programme, describing evaluation development (Chapter 5), methods 
(Chapter 6), and full evaluation results (Chapters 7 to 9).  
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Chapter 5 Evaluation development and 
refinement (Study 2) 
5.1 Overview 
This Chapter describes the methods and results from evaluation development and 
refinement (Study 2). Furthermore, it outlines how Study 2 informed the methods 
adopted for the DCE evaluation (Study 3). When explaining how Study 2 outputs 
informed the evaluation, it was important to describe theories and frameworks that 
had not been described previously in this thesis. As a result, this is a complex Chapter, 
but it is hoped that it can show the processes and reflections required to develop the 
DCE evaluation. 
5.2 Binding aims and components 
Study 2’s binding aims were to 1) elicit DCE programme theory; and 2) inform 
evaluation design and methods.  
A robust evaluation needs a thorough, explicit description of the programme being 
investigated (154, 161). An explicit description of programme theory facilitates 
communication between researchers and stakeholders (154), and helps to inform 
evaluation design (154, 155). In Carol Weiss’ words, “if the evaluator has no idea of 
what the program really is, he may fail to ask the right questions” (158). 
A systematic description of DCE was not available; this is common in evaluation 
research (154, 161). Available evidence, stakeholder input and policy documents are 
often used to elicit programme theory (154, 158, 161, 165, 374). These sources were 
also used to elicit DCE programme theory. Therefore, Study 2 had two components: 
1) analysis of policy documents; and 2) interviews with key DCE stakeholders.  
5.2.1 Analysis of policy documents (Component 1) 
5.2.1.1 Aims and rationale 
Documentary analysis is a systematic approach for reviewing documents often used 
alongside other methods (375). It aimed to 1) have a comprehensive description of 
the DCE programme; 2) inform the development of a logic model; and 3) facilitate the 
identification of stakeholders to be interviewed during evaluation development.  
Documents are useful to inform the choice of questions to be asked in research (375) 
and the creation of data collection tools (376). They allow the researcher to capitalise 
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on existing evidence and can reduce research costs (377). Documents help to 
indicate chronology of events, to understand processes and official programme goals 
(204, 378), to identify stakeholders to be interviewed (378), and to show private 
interactions and decisions (204). Finally, documentary analysis has been adopted in 
evaluations assessing early diagnosis initiatives in the UK (150, 335). 
5.2.1.2 Methods: data collection and analysis 
Although documentary analysis has benefits, it also has limitations. Documents are 
created with a purpose in mind, and are embedded in a specific context (379). They 
comprise assumptions and ideas that reflect those who produced the documents and 
intended audiences (380). Knowledge and power define what is to be included (380). 
Documents can be “selective” and report only on positive outcomes; details can be 
given for some components but not for others (158, 204). Moreover, documents can 
legitimise or justify actions (380).  
Having a critical eye is required when doing documentary analysis (375, 379). Hence, 
prior to extracting data about DCE, it was important to interrogate the available 
documents. I developed a framework for analysis, informed by documentary analysis 
steps described by O’Leary (377); and other available guidance (375, 376, 379, 380) 
(Figure 5.1). Importantly, reviewing and interpreting documents should be always 
seen as a “tentative and provisional judgement” (381). 
Figure 5.1. Developed framework for documentary analysis 
 
Source: adapted from (375-377, 379, 380) 
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The first step comprised independent searches of DCE documents; this was followed 
by considering which documents would be relevant to explore, planning what to 
extract and seeking ethical approvals (second step). The third step comprised data 
gathering and organising; unique IDs were created for each document; they were then 
organised in folders based on document sources. Then, documents were reviewed 
and interrogated based on several criteria (Table 5.1). Definitions for the adopted 
criteria were retrieved from the relevant literature (377, 380, 381) and are available in 
Appendix 13. Importantly, even though I used predefined criteria and was transparent 
in adopted procedures, a certain level of interpretation and subjective decision-
making was required when interrogating documents. The adopted criteria were not 
always sufficiently precise when making a decision. SPSS v.23 (245) was used to 
facilitate interrogation and data analysis. Charts were developed in Microsoft Excel 
2016 for Windows (382). 




Source (who provided me with the document) 
Batch (when document was received) 
Publication year 
Document type (classified based on data; e.g. reports, minutes) 
Style (classified based on data; e.g. medical terms, lay terms) 
Function (persuade the reader, validate or justify something) 
Intended audience (classified based on data; e.g. DCE stakeholders) 
Readership (whether it is actual or implied) 
Relevance Whether document helped to address study aims (and if so, which aims) Whether documents had relevant data on process, outcomes or context 
Authenticity Version (draft or final) Soundness (whether document is sound, partially sound or unsound) 
Authorship Source (personal or official) Type of author (individual, group or anonymous) 
Credibility 
Sincerity (sincere or not sincere) 
Possible interests (personal interest, financial gain, political advantage) 
Type of source: first-hand (primary) or second-hand (secondary) 
Type of evidence (document represents facts, opinions or both) 
Survivability Whether document is published, filed, or just stored somewhere 
Availability Whether access to documents is closed, restricted or open access 
Source: Adapted from (377, 380, 381) 
Therefore, when developing the evaluation, documentary analysis was not only about 
the content, but also about how documents looked like, what was their purpose and 
function, who the authors where and who was the intended readership (379). Issues 
such as authenticity and credibility were important, alongside other background 
information (377, 381). 
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A comprehensive qualitative thematic analysis (375) was considered for analysing 
policy documents, but not deemed necessary nor feasible to obtain the data to inform 
the evaluation within the study’s timescales. Similarly, discourse analysis (380) was 
relevant, but not feasible. Instead, after reviewing and interrogating documents, all 
information that was useful to meet the study aims was extracted. A summary was 
developed for each document. Emerging questions/comments to aid evaluation 
design were added in italics to these summaries.  
Summaries were used to create a narrative about DCE development and its four 
strategies (shown in Chapter 2 and the final report produced for the Scottish 
Government). Then, they informed the development of a service utilisation plan and 
a programme impact theory (Appendices 18 and 19). As described by Rossi (161), 
these diagrams helped to synthesise programme data in a way that was useful for 
logic model development.  
5.2.1.3 Results: Documentary analysis 
Independent searches were carried out in late 2015; they resulted in six core DCE 
documents to be included in the documentary analysis: the DCE implementation plan, 
two social marketing newsletters and three documents with action notes and minutes 
from DCE Programme Board meetings. Searches also resulted in several references 
about cancer burden and cancer policies in the UK which informed Chapter 2. 
I received 159 different policy documents by email, in four batches. The first batch 
(n=66) consisted of core documents sent by DCE managers in October 2015. 
Additional requests were made over time reduce the likelihood of only receiving 
documents focusing on a few components or with similar points of view. Requesting 
further documents was particularly important as I needed to obtain sufficient and 
adequate background information about the programme. Requests were made during 
informal meetings with DCE in late 2015 and early 2016. The second batch of 
documents was sent by DCE managers in February 2016 (n=62).  
The market research company evaluating DCE campaigns (TNS) sent the third batch 
(n=14) in February 2016. Finally, the media agency coordinating the social marketing 
campaigns (the Leith Agency) sent the fourth and final batch (n=17) in April 2016.  
Five documents were duplicates; the remaining 160 (six documents found by me plus 
154 received documents after removing duplicates) were analysed.  
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Reviewing and interrogating 
A list of documents reviewed and interrogated is available in Appendix 14. Most 
documents were provided by the Scottish Government. Evaluation reports (often 
prepared by TNS and the Leith Agency to report on campaigns) and reports about 
use of DCE funding comprised 42% of all documents (Figure 5.2).  
Figure 5.2. Background information: source, publication year and type 










     
1Annual reports sent by territorial Health Boards, DCE summaries of how funding was 
used, and allocation of DCE funding across different programme components. 2Include 
the DCE Implementation plan, circulars, and social marketing campaign information 
packs. 3Reports about HEAT targets, the bowel screening initiative and cancer waiting 
times.4Refer to a stakeholder report providing a clinical perspective about DCE and a 
report about Deep End Practices in Glasgow 
All documents were in a digital form, all were unsolicited (i.e. existed irrespective of 
requests). All were classified as copies. Most used general health terms (such as 
mortality and screening uptake), while 21% used social marketing jargon (such as 
“impressions” and “cost-per-click”). Less than half of documents explicitly attempted 
to persuade the intended audience, while over 80% of them used facts or opinions to 
try and validate or justify investment, decisions or further developments. The most 
common audiences were the DCE Programme Board (28%) and the Scottish 
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Figure 5.3. Style, function and intended audience 










     
Other style refers to documents that did not fit in any of the other three styles (n=2; a 
terms of reference document and a table with DCE funding allocation). Other audience 
refers to a document about campaigns prepared for a competition (further information 
not provided). 
 
All documents had information that helped to obtain a comprehensive description of 
the DCE programme; half of them were useful to identify stakeholders to be 
interviewed. More than half of them had information on processes, outcomes or 
context. Most documents were partially sound due to issues such as missing 
appendices and missing references. Most documents did not specify whether the 
author was a group or an individual. There was the possibility of political and financial 
interest/gain in over half of documents. Most documents appeared to be sincere. Most 
documents reported both primary and secondary data sources and described both 
facts and opinions. Half of documents were both stored and published, and most of 










































Figure 5.4. Document interrogation 
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5.2.1.4 Component 1 outputs 
Description of the DCE programme and development of a logic model 
The service utilisation plan, programme impact theory diagrams (Appendix 15) and 
draft logic model (Appendix 16) were developed in December and January 2015, 
using the first batch of 66 documents. All remaining documents were analysed 
between March 2016 and November 2017; they were used to refine the logic model 
and to inform the textual summary of DCE and its components (described in Chapter 
2 and the final report for the Scottish Government). 
In addition to evidence from documentary analysis, the logic model was informed by 
guidance in the literature (154, 161, 167). The DCE logic model described inputs, 
activities, outputs and outcomes (161), and included possible contextual factors that 
could have influenced the programme (154). Furthermore, a box on preliminary, 
potential assumptions regarding the programme based on policy documents was 
added to the model.  
The draft logic model was shared with PhD supervisors and DCE managers in 
February 2016. It was amended after their feedback in order to focus on broader 
outcomes; minor corrections were also made to the described activities and outputs. 
The draft logic model is only available in Appendix 16 as the font was too small for 
the main thesis. It was printed in a larger size (A3 format) to ensure readability. 
Identification of stakeholders to be interviewed 
Potential stakeholders to be approached for interviews were identified in policy 
documents. Names mentioned by DCE management during initial meetings to 
discuss the evaluation were also added to the list, which had 11 names.  
After I had a better understanding of the DCE programme and had prepared a list of 
stakeholders, the next step was to carry out the stakeholder interviews. 
5.2.2 Interviews with key stakeholders (Component 2) 
5.2.2.1 Aims and rationale 
The key stakeholder interviews aimed to: 1) refine DCE’s programme theory (166), 
eliciting assumptions, mechanisms of impact, contextual influencers and 
unanticipated outcomes; 2) confirm the suitability of complexity theory and theory-
based evaluation; 3) inform the choice of implementation and behaviour change 
theories for the evaluation; 4) help to prioritise aspects to be evaluated (162, 166); 
and 5) identify stakeholders to be interviewed in the process evaluation. 
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A small number of “carefully selected stakeholders” can help to identify key issues to 
be taken into account in an evaluation (161). By consulting stakeholders, evaluators 
may identify variations in how a programme is understood, in which components are 
more often emphasised, and regarding who is likely to benefit the most from 
programme. These different views help evaluators to anticipate challenges when 
carrying out a process evaluation (166). Furthermore, stakeholders can help to ensure 
that the right evaluation questions are identified (168). Finally, if stakeholders are 
involved, they are more likely to be supportive and to consider the recommendations 
from the evaluation. Poor stakeholder involvement, on the other hand, may lead to 
resistance, stark criticisms, or sabotage (168). For all these reasons, it was important 
to interview stakeholders during evaluation development.  
5.2.2.2 Methods 
Inclusion and exclusion criteria 
In order to be eligible to be interviewed, stakeholders needed to be directly involved 
in the development or in the running of the DCE programme (as a member of the DCE 
Programme Board or a frequent attender at the DCE Programme Board meetings). 
Stakeholders were excluded if they were unwilling to provide informed consent. 
Data collection 
Sampling and recruitment 
I used the list prepared during documentary analysis to select stakeholders who could 
provide substantial information about the programme, while also ensuring there was 
variation in their geographic location, roles and experience. Characteristics such as 
gender and age were not deemed to be critical for selecting participants. Criterion 
sampling and maximum variation sampling (two different types of purposeful 
sampling) (Patton, 1990) were used to ensure that different groups of stakeholders 
(e.g. clinical, strategic or supportive backgrounds) from the South East, West and 
North of Scotland could provide their views about DCE. Eight potential participants 
were sampled from the list; all of them were invited for an interview by email. 
Interview topic guide and setting 
The interview topic guide (Appendix 17) was informed by the logic model and study 
aims. I also consulted guidance on designing interview guides (161, 166, 168); 
published evaluations (148, 150); and PhD theses reporting on evaluations (149, 160, 
383-385). 
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Participants were asked questions about DCE development; its rationale, aims and 
objectives. Other questions focused on the participants’ views on DCE 
implementation and expected outcomes, and perceived challenges when undertaking 
the DCE evaluation. All participants received the logic model prior to the interview and 
were asked for their views on how well the programme was described. Each interview 
was estimated to last 40-60 minutes. 
Face-to-face interviews were preferred as interviewees were asked to review the logic 
model, which was a complex document (386). Furthermore, as these were initial 
interviews a face-to-face encounter would facilitate the development of rapport (386). 
Nonetheless, an option of a telephone interview was also given in case the 
interviewees found this a more practical alternative. Telephone interviews also have 
benefits such as being more cost-effective (386).  
Transcription 
A well-established company, which regularly provides transcripts for the University of 
Edinburgh, transcribed all the interviews. I checked all transcripts for inaccuracies and 
made corrections as needed. 
Data analysis 
I read each transcript as soon as it was delivered in order to inform future interviews 
and to get acquainted with the data. Continuous analysis in qualitative research is 
“almost inevitable” as fieldwork makes the researcher think of what is being said (387). 
Furthermore, it helps to refine research questions, to pursue different avenues of 
enquiry, and to identify cases that may go against current hypotheses (387). 
In line with the adoption of mixed methods and being underpinned by pragmatism, 
data analysis methods were chosen based on the study aims and what the findings 
were supposed to do (200). I had predefined aims and objectives; and the interview 
topic guide directed the participants towards describing the programme, its activities 
and outcomes. Due to my aims and methods, I did not wish to reach the grounded 
theory definition of “data saturation” (200) as I focused on very specific topics and a 
selective group of participants (described by Patton as “information rich cases”) (204). 
Furthermore, I had a limited amount of time to analyse data. I considered using a 
simple thematic content analysis. However, I was concerned that simply reporting 
these themes would not do justice to the richness of data (200) and its policy context. 
Therefore, I chose to adopt the framework approach (388). 
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The framework approach is a systematic procedure developed by Ritchie and 
Spencer for the analysis of applied policy research (388). It is not aligned with a 
specific paradigm and can be used with different qualitative approaches aiming to 
generate themes (389). Framework analysis allows for the adoption of both inductive 
and deductive approaches. Themes can be generated from research questions, 
available literature or existing theories in addition to the participants’ narratives (387, 
389). The approach goes beyond a simple thematic content analysis as it also looks 
at relationships between codes (200). Framework analysis is commonly used when 
doing thematic analysis of interviews with data about similar topics/issues (389), and 
has been used to evaluate an early detection initiative in England (287). 
Framework analysis approach comprised five stages: familiarisation; identifying a 
thematic framework; indexing; charting; mapping and interpretation (Table 5.2). The 
structured steps allowed for the analysis to be made explicit and accessible (388). 
Table 5.2. Stages and associated steps when doing framework analysis 
Stage Steps 
Familiarisation 
• Check, correct, clean and anonymise transcripts 
• Read field notes and transcripts, listen to recordings 




• Discuss a sample of transcripts (n=2) with another researcher and 
agree on emerging themes. Solve disagreements by consensus 
• Develop a thematic framework informed by key recurrent themes 
and issues, notes, research aims and interview questions 
• Apply the framework to a few transcripts (n=4) using NVIVO 11(390); 
write notes about amendments, additional themes and issues to 
consider when coding data. Make amendments to the original 
framework 
Indexing 
• Apply the amended framework to remaining transcripts. Continue 
writing notes, refining the framework and recoding transcripts 
• Number all themes/sub-themes in a Word document, convert the text 
into a table and describe each theme 
Charting • Rearrange data (participant’s views according to themes) in NVIVO 
Mapping and 
interpretation 
• Create a diagram representing the themes and subthemes 
• Review transcripts and comments, field notes and the framework 
and look for patterns and linkages 
• Refine definitions for each theme and describe associations 
between them; write a summary of findings 
• Write about how findings addressed my research aims, and consider 
what to focus on when doing the evaluation 




Recording reflexive notes and thoughts about data analysis is recommended from the 
earlier stages of data collection (389). I made brief notes during each interview (in 
order not to lose rapport), focusing on key aspects to be considered in future 
interviews. I also wrote field notes at the end of each interview and shared these with 
my principal supervisor. Key reflections are described in Chapter 10. 
5.2.2.4 Results 
All eight sampled stakeholders were invited for an interview and accepted to take part. 
Interviews were carried out between April and June 2016. All stakeholders suggested 
I spoke to a ninth stakeholder whom I had aimed to interview during the full evaluation. 
This additional stakeholder was interviewed in August 2016 as part of evaluation 
development. All nine interviews were recorded, transcribed and checked. Eight were 
face-to-face and one was carried out over the telephone. Face-to-face interviews took 
place either at the interviewees’ current or former workplaces (as some participants 
had retired or changed jobs since DCE had been implemented) or at another place 
suggested by them. The interviews ranged from 32 to 77 minutes (mean 53 minutes). 
In order to avoid participant identification, information is limited on their 
characteristics. Five were men and four were women. Job roles included senior 
management in ISD Scotland; at DCE; in national screening programmes and in each 
of the Scottish Cancer Networks; GPs; and secondary care doctors. These roles are 
not mutually exclusive as some participants had more than one of them. Most 
stakeholders wore “many hats”, giving their input and expertise to several initiatives 
in Scotland. Some had experience working in the private sector, others led or were 
core member of advisory groups at the Scottish Government. Participants 
represented five territorial Health Boards in Scotland: NHS Lothian, NHS Forth Valley, 
NHS Greater Glasgow & Clyde, NHS Tayside and NHS Grampian.  
Feedback from stakeholders was organised according to the adopted MRC 
framework (166) and approached six areas: development and implementation; views 
on DCE and its components; logic model; contextual issues; what to evaluate; and 
outcome evaluation challenges (Figure 5.5). Theme definitions and relationships 
between themes are available (Appendix 18). The terms “participants” and 
“stakeholders” were used interchangeably. 
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Figure 5.5. Themes from key stakeholder interviews 
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Theme 1: DCE development and implementation 
A political decision with a political imperative 
DCE was described as a government programme with a political agenda and a strong 
political imperative, specific targets and investment. Government involvement was 
overall seen as positive as it allowed for the programme to be developed and 
implemented; and facilitated a national concerted effort to promote early detection. 
However, the political imperative meant that DCE “had to work” and resulted in 
pressure to achieve targets/complete tasks within a specific timescale. 
Stakeholders highlighted that DCE was different from other government programmes, 
as it required primary and secondary care to work together with public health and 
gave a prominent role to social marketing campaigns. DCE’s approach to health 
campaigns was also seen as different from everything that had been attempted before 
by the Scottish Government. DCE campaigns were different in terms of quality 
(considered to be more “professional”), vocabulary (with the use of humour) and “bold” 
messages (such as showing real breast cancers in national television). Another 
different characteristic was the choice given to Health Boards to invest DCE funding 
where they thought it would be most useful (see “Resource allocation”).  
Aims, drivers and influencers 
Views on what DCE’s key aims were varied across participants. While some 
emphasised the programme’s aim to diagnose cancer at earlier stages in order to 
improve survival, others focused on the importance of improving population 
awareness, or of promoting system-level changes. Some acknowledged that wide 
changes would be difficult without generating a bit of “chaos” in the system. 
“This programme, as I saw it, was to try and pull a number of strands 
of work together to try and make a concerted effort to raise 
awareness, to influence primary care, to improve diagnostic capacity 
and to promote screening or promote the benefits of screening, make 
people aware what the benefits and risks are.” (ID 7) 
NAEDI in England was considered to have a strong influence in DCE. Contacts with 
key NAEDI implementers working for the charity Cancer Research UK (CRUK) and 
the UK Department of Health helped to inform the programme, with adaptations made 
for the Scottish context. Furthermore, the fact that bowel screening in Scotland had a 
leading role in early detection in the UK was described to positively influence how the 
clinical community embraced early detection initiatives.  
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An evidence-based initiative 
In addition to being strongly influenced by NAEDI, participants emphasised that the 
core tenets of the programme were based on evidence that cancer diagnosed in its 
earlier stages is more likely to be successfully treated. At the same time, emerging 
evidence from an independent review (50) on the benefits and harms of breast 
screening influenced DCE’s strategy to initially target breast symptoms. 
Resource allocation 
Stakeholders reported that Health Boards varied in their approach to use DCE 
funding, described uncertainties regarding how money was invested, and added that 
varying levels of engagement made it difficult to gather information. 
“Primary care's quite defined, marketing's quite defined, then we 
come to secondary care and it's like what did you do?  Well I 
suppose we invested in that and we gave boards money and then 
kinda left them to get on with it” (ID 2) 
Stakeholder involvement 
Participants described how expert advice was sought from a range of stakeholders, 
such as representatives from the Scottish Primary Care Cancer Group, from all 
regional cancer networks, and from cancer charities. Clinical leads at the bowel and 
breast screening programmes also gave input. In general, stakeholders believed that 
their opinions were listened to when DCE was developed. Nonetheless, not all agreed 
on whether clinical views were well represented.  
DCE’s attempts to engage with stakeholders were seen as helpful to provide them 
with a “sense of ownership” over a government-led programme. 
“I think it was great and I think that everybody who was involved 
was enthusiastic, I think, you know, people came from different 
offices, everything, you had clinical input, you had patient input, 
you had the bureaucratic input and it was melding it in and it's 
good and it shows that you can move forward, you can achieve 
goals – we initially didn't agree on all the goals.” (ID 6) 
Voiced concerns and barriers 
Participants described their concerns and shed light on other stakeholders’ 
apprehensions regarding the programme. A recurrent theme referred to worries about 
DCE impact on primary and secondary care, especially regarding diagnostic capacity. 
“There was a concern that we might just increase demand for 
services without actually detecting more people who had cancer 
[…] that GP practices would become even busier with people 
being concerned about symptoms that were unlikely to be cancer, 
[…] that imaging services such as x-ray, ultrasound, CT scanning 
would not be able to cope with the increased number of referrals 
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for imaging, and there were also concerns in other areas such as 
within endoscopy which they might not be able to manage 
increased numbers who come through for colonoscopy.” (ID 3) 
Developing new relationships, systems and roles 
Participants involved in DCE implementation described the development of new 
processes and relationships in order to get the programme running. A Programme 
Board with wide stakeholder representation was created. New IT systems were 
developed in collaboration with ISD Scotland and a point of contact was established 
between them and the programme. Proxy outcomes for survival were discussed and 
agreed upon. Circulars were sent to territorial Health Boards. While in the initial stages 
of the programme stakeholders were mainly contacted through formal mechanisms, 
over time this became a more informal contact over the phone. Furthermore, levels of 
engagement were reported to vary according to Health Boards and Cancer Networks. 
Delays and adaptations 
Implementation delays happened for some DCE components. This was the case for 
the provision of bowel screening non-responder data to general practices and creation 
of general practice profiles. These were perceived as missed opportunities to contact 
patients, and to compare performance. 
Each territorial Health Board could have their own aims, in addition to the ones 
specified by the programme. Participants acknowledged that different Boards had 
different challenges to tackle and described how they also had different approaches 
to different programme strategies. 
Theme 2: Views on DCE and its components 
A driver of change and other long-term aspirations 
DCE was described as a driver of change in many ways. The programme was seen 
by some as a mechanism for improving confidence for primary and secondary care. 
Stakeholders believed that DCE could help to modify the way the population 
perceived cancer, without seeing it with fear or as a death sentence. They hoped that 
increased knowledge and awareness would instil a sense of confidence and empower 
patients to go see their GPs when they noticed symptoms. By improving knowledge 
among young people and other influencers (such as family and employers), 
stakeholders hoped that changes would be sustained “generation after generation”. 
Overall, stakeholders wished that DCE could lead to cultural changes in the long term, 
with early presentation and screening “becoming commonplace”. Stakeholders were 
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aware that these changes were “complex” and challenging, but hoped that DCE would 
leave a legacy, with early detection becoming “business as usual”. 
Belief in the programme and feedback on its activities 
Overall, participants “believed” in DCE, in its importance and in what it proposed to 
do, and often reported being proud of being part of it. Views were particularly positive 
about the quality of the social marketing campaigns. Nonetheless, challenges such 
as having difficult objectives were recognised. Furthermore, there were suggestions 
on issues that could have been done differently. These included targeting advanced 
disease (as survival is poorer; screening already targets early stages; and early 
diagnosis of lung cancer is challenging); updating the referral guidelines prior to 
starting the campaigns; and having more clinical input early on. 
Perceived impact of activities 
Stakeholders were aware that there had been an increase in cancers diagnosed at 
Stage I over time, even though DCE’s key aim (i.e. 25% increase in cancers 
diagnosed at Stage I) had not been met. From their perspective, the increase was still 
positive. The observed impact that the symptomatic breast campaign had on capacity 
(increase in consultations but no more cancers were diagnosed) was noted. 
Conversely, the campaign was also perceived to be successful as the public 
remembered its messages. 
Participants also provided views on other programme impact. They believed that DCE 
helped to drive attention towards cancer screening and prevention. Territorial Health 
Boards had to invest in audit teams, and this was perceived to have a long-term 
positive impact on better tracking patients. Education sessions were seen positively 
as they informed clinicians about the programme and became opportunities to discuss 
referrals. 
Sustainability concerns 
Participants raised several concerns about DCE’s sustainability. Some highlighted the 
need to sustain public interest and acknowledged that campaigns with short bursts of 
activity might not have been the best approach (although limited funding did not allow 
for other alternatives).  
“The problem is that public facing campaigns are very transient 
[…], we always see an increase in uptake, but it comes back down 
to the baseline fairly shortly afterwards. […] You either need 
sustained activity in that area or you need something more 
concrete around the way that services are provided.” (ID 9) 
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Stakeholders were aware of the importance of ensuring payment for GP practices so 
work promoting bowel screening uptake could continue. Other sustainability issues 
included having sufficient resources for diagnostics and treatment over time and 
ensuring continued stakeholder engagement. 
The role of targets 
Participants had mixed views regarding performance targets. For some, they were a 
way to “focus the mind” and drive activity. Stakeholders believed that targets were 
useful for the politicians and the media, as they were quantifiable and easy to report. 
Other stakeholders believed that targets were unhelpful as they diverted attention 
from professionals; led to using scarce diagnostic resources on patients with a very 
low cancer risk; and measured changes in a short period of time. Some questioned 
whether the targets were the best way to estimate the success of a programme aiming 
to drive system-level changes.  
 “If you put a target on it you drive activity, you drive the way they 
focus, the way they work, the way they do things around meeting 
that target. Now they might not meet it but what difference does it 
make whether they meet it or not, if they're doing everything to get 
there you've given them something to work towards, so… but 
that's maybe another thing, you know, were we right to have a 
target?” (ID 7) 
Theme 3: Logic model 
Comprehensiveness and usefulness 
Participants stated that the logic model was comprehensive and mostly accurate; and 
was useful to summarise the programme. However, some believed that the logic 
model displayed too much information, making it difficult to find specific issues. 
Nonetheless, there were requests for adding more information (such as on other 
funded DCE projects, and activities related to diagnostic capacity). 
Scope, importance, links and trajectories 
Participants thought that at times there was an artificial separation between primary 
and secondary care activities. For example, performance management activities and 
symptom management and referral involved both areas. 
“I'd maybe put this QOF [bowel screening initiative] in there just 
because it was such a huge part of primary care engaging with 
secondary care I think, although it does come under performance 
management as well doesn't it” (ID 2) 
Stakeholders also stated that the logic model did not show the relative size/scope and 
importance of each DCE component. Some believed that “more important” 
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components should have been more prominent. Others argued that the model did not 
show the order in which activities happened, although it seemed to imply that the 
initiatives shown first also happened first. Finally, it was suggested that the DCE 
strategies were named exactly as described in the initial DCE implementation plan. 
Proposed outputs and outcomes 
Increased number of bowel consultations due to signs and symptoms (shown as an 
outcome in the draft logic model) was described as inaccurate as DCE focused on 
bowel screening. Increase in participation and improvements in data capture were 
perceived as happening much sooner than what was described in the logic model. 
The practice profiles, on the other hand, were expected to be a longer-term outcome. 
Some stakeholders suggested moving some of the middle-term outcomes into short-
term instead. Others discussed whether the logic model should report what was 
expected to happen or what had happened. These stakeholders gave examples of 
initiatives which had not initially been planned but became an important DCE 
component. Finally, there were requests to add less quantifiable outcomes; such as 
cultural changes regarding cancer. 
“These are quite specific long-term outcomes and I wondered 
about something about that cultural change about, recognising, 
you know, understanding that it's not something to be feared, that 
treatment's changing all the time and that survival's better and the 
earlier you're presenting the better the chance of a healthy… a 
long term outcome.” (ID 7) 
Underlying assumptions 
The assumption that increase in demand would be managed with increase in capacity 
in screening, diagnosis and treatment was questioned. In certain cases, Health 
Boards were not aware of how much they could handle in terms of capacity. 
Stakeholders also discussed the (causal) relationships between described activities, 
outputs and outcomes, and questioned whether some of the proposed outcomes were 
positive. Increase in consultations, more diagnostic tests, and reduction in emergency 
presentation were not seen as successful outcomes, unless they also led to 
improvement in early detection and reduction in mortality. Emergency presentations 
were not always seen as a negative outcome as at times they are unavoidable. 
“Increasing the number of patients consulting due to cancer 
related symptoms, yeah, I mean, I think... […] I don't think that's 
right, it's not a successful outcome unless you can demonstrate 
that it's associated with an increase in early diagnosis and 
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subsequently in mortality.  So, I think one of my problems with that 
is this is not necessarily an index of success.” (ID 9) 
Theme 4: Contextual factors 
Deprivation, age and gender 
Participants described how social deprivation could influence cancer awareness, 
incidence, presentation, screening, diagnosis and mortality. Wide regional variations 
in Scotland according to social deprivation were acknowledged. Participants stated 
that reducing health disparities was paramount in order to improve outcomes for all 
but acknowledged that achieving this aim was beyond the remits of DCE. 
“Yeah, I think the main challenge in Scotland is around equity and 
there's no doubt, you know, Scotland's got a very sort of wide 
socioeconomic gap across its society” (ID 9) 
Population behaviour towards campaigns was described to vary according to social 
deprivation, with the most deprived taking longer to process information from the 
campaigns, or to act upon them. Population age and gender were described as 
interacting with deprivation and providing a more complex picture in terms or response 
to the awareness campaigns. 
Individual behaviour and change 
Stakeholders discussed population’s beliefs about cancer, the general population’s 
concerns about wasting the doctors’ time, cancer fear and fatalism, and how this 
influenced programme development and its expected outcomes. They acknowledged 
that behaviour change was challenging; increased knowledge did not necessarily 
translate into action; and that substantial behaviour changes would take a long time. 
Government characteristics 
Stakeholders commented on how the nature of the campaigns could be in potential 
conflict with other messages coming from the government (i.e. DCE could be 
interpreted as an attempt to save money as opposed to a strategy to improve quality 
of life and promote early detection). Stakeholders also stated that since governments 
change over time, their priorities (and perceived DCE importance) may also change.  
NHS constraints and regional variations 
Participants consistently reported challenges related to NHS capacity, especially 
regarding diagnostics, although surgery and primary care were also mentioned. 
Participants highlighted that the problems were pre-existing of DCE and influenced 
DCE’s strategic decisions.  
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Reported primary care constraints referred to staff shortages and resource limitations. 
In fact, the need to have additional resources was described as a reason why some 
territorial Health Boards engaged with the programme.  
“On the ground I get a sense, but I've got nothing, no evidence to 
support, I get a sense that some people were challenged for lots of 
different reasons way beyond DCE and they used DCE as a route 
to try and access monies […] I know of boards that appointed 
individuals to do maybe breast or colorectal work etc., but actually 
a lot of the challenges were pre-existing irrespective of DCE but 
they just used it as a mechanism and I suppose that's what 
happens.” (ID 8) 
Participants described a perceived “disconnect” between primary and secondary care 
and a “silo mentality” which may have had an impact on the programme. 
Cultural change or shifts 
Participants emphasised the need to have an increased focus on health promotion 
and cancer prevention. DCE was seen as part of a bigger picture, where work from 
cancer charities, development of screening programmes and new technologies would 
also make a large impact in cancer outcomes. 
“Here was funds being channelled towards something that was 
happening in the community, but there's always been this kind of 
long term ambition in the wider health economy that we need to 
shift some of the resources away from acute medicine and surgery 
into preventative and early diagnosis and community work, where 
you're going to achieve the most for your money.” (ID 7) 
Stakeholders described a perceived shift (albeit slow and ongoing) in the way the 
population talked about cancer, being more open to discuss the topic with others. 
Although they believed that DCE had helped to bring about this change, they thought 
that the changes were beyond DCE. 
Changes towards a stratified risk approach for screening were mentioned. 
Furthermore, a drive towards realistic medicine was described. Finally, new 
developments such as the Scottish Primary Care Information Resource (SPIRE) in 
Scotland were highlighted.  
Scottish personality 
The “Scottish personality”, especially a fatalistic and stoical view towards cancer, was 
described as influencing help-seeking behaviour. Nonetheless, the Scottish 




Participants discussed the role of early diagnosis in survival and approached other 
factors which may influence cancer outcomes, including deprivation, standards of 
care, multimorbidity, lifestyle factors, tumour biology, and more aggressive disease. 
Finally, stakeholders stated that a more “targeted” and “efficient” way to diagnose 
patients with cancer was needed to reduce the number of unnecessary diagnostic 
investigations. Focusing on patients at risk was suggested. Some argued that GPs 
should be able to have direct access to diagnostics to expedite referrals. 
The role of the media 
The media was described as a public influencer in several ways. Cancer deaths from 
celebrities could help to initiate conversation about the topic. On the other hand, the 
media was also seen as prone to “sensationalising things” and to focusing on negative 
stories. Their messages were perceived to affect the impact of the DCE campaigns. 
Furthermore, it was reported that the media, similar to the government, was more 
interested in short-term targets and more tangible outcomes, as opposed to wider, 
system-level, long-term changes. 
Theme 5: What to evaluate 
Early diagnosis, survival, mortality or surrogates 
Participants described the importance of analysing clinical data, especially tumour 
staging. Assessing screening uptake, mortality and waiting times was also 
recommended. Looking at one-year survival was suggested, preferably in 
combination with other variables. Additional clinical data included surgery, radical 
radiotherapy for lung cancer and readmissions to hospital. Investigating unanticipated 
outcomes was also suggested. 
“I think the main thing is to look for adverse effects as well as the 
benefits […] particularly if you change your thresholds for referral 
and presentation referral, you're likely to... well almost certain to 
increase the numbers who don't have disease as well as those 
who do.” (ID 1) 
Impact on primary and secondary care 
Stakeholders wished to understand the impact that the programme had on primary 
and secondary care, such as changes in capacity, systems and ways of working. 
Assessing impact on workload and variations in access to primary care were also 
suggested. They also wished to know whether (and if so, how) territorial Health 
Boards were using data from new IT systems, how funding was allocated and used. 
Views varied in terms of which components should be prioritised in an evaluation. 
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“[W]hat's happening in secondary care, what changes have been 
put in place, how are they doing things differently, how are they 
working across the system better, how are they engaging with 
primary care better?” (ID 2) 
“I know that there was an element of money for diagnostics and I 
know that boards put in bids and it would be, I don't know if we 
could ever do it, but it would be quite good to see the outcome of 
what happened to the money.” (ID 8) 
Improvements in knowledge and awareness 
Participants suggested assessing whether there had been an increase in public 
knowledge/awareness of cancer symptoms and signs since the programme had been 
implemented; and whether there had been an increase in screening uptake. 
Seeing the bigger picture 
Stakeholders suggested investigating whether people’s attitudes had changed, 
assessing the extent of the improvement in data collection and any other wider impact 
in addition to hard data on survival.  
“Target aside, I think it's the improvement in data, it's an 
improvement in public awareness, it's improvement in professional 
awareness and it's, you know, this cultural shift that I've been talking 
about, it's all these things so it's not just the numbers”. (ID 7) 
Theme 6: Outcome evaluation challenges 
Bias and confounding 
Stakeholders described sources of bias and confounding which would make it 
challenging to evaluate DCE’s impact. These included separating DCE from other 
early detection activities taking place at the same time and the fact that DCE was not 
a research project. Stakeholders described how survival analyses are affected by lead 
time bias, and mortality is affected by improvements in treatment. 
“[T]his is a government funded high profile, you know, 'let's cure 
cancer' push and I think it's got a lot of merit but it's not... you will 
never be able to tell at the end of the day what the cause and effect 
were because it wasn’t set up like a research project.  It's not like 
you could’ve randomised half of the population to have the DCE 
Programme and the other half not” (ID 9) 
 
Unmeasurable outcomes, unclear definitions and unavailable data 
Stakeholders acknowledged that it would be challenging to investigate improvements 
in awareness and changes in attitudes, wider cultural changes, or changes in primary 
and secondary care. They reported challenges obtaining data on additional funding 
provided by the programme, and in assessing the impact of DCE strategies such as 
the education sessions. 
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Some suggestions were followed by statements about data not being available in 
time, the need to have data for longer timeframes to observe impact (the case of 
survival data), and about data no longer being collected. Examples of unavailable 
data included data on lung resections, and on reasons for consultations in primary 
care (only collected by ISD Scotland until 2012). 
5.3 Using interview findings to inform the DCE 
evaluation 
This section describes how interview findings were used to inform the DCE evaluation. 
Study 2 outputs are presented according to the key interview aims: refinement of 
programme theory and logic model representation (including elicited assumptions and 
mechanisms); adoption of complexity theory; adoption of a theory-based evaluation; 
choosing implementation and behaviour change theories to operationalise 
assumptions and mechanisms; prioritising what to evaluate (processes and 
outcomes); and identifying stakeholders to be interviewed. 
5.3.1 Refinement of programme theory and logic model 
representation 
DCE programme theory and logic model were amended after the interviews. Strategy 
names were replaced with the same ones from the DCE Implementation Plan, 
outcomes were refined and detailed information about activities and outputs was 
removed to facilitate reading (Figure 5.6). Assumptions and contextual issues were 
amended based on interviews, policy documents and relevant literature, removed 
from the logic model and kept aside as a separate output (also to ease reading).  
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Figure 5.6. Refined DCE logic model 
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5.3.2 Adopting complexity theory 
5.3.2.1 DCE and complexity 
Stakeholder descriptions of DCE were consistent with how the literature depicts 
complex programmes implemented into a complex system. Different Health Boards 
were reported to have diverse aims and needs, and different approaches to 
programme activities. DCE was described as part of a system with heterogeneous 
components that interacted at different levels in order to meet aims. These 
descriptions are in line with how complex systems are described in the literature (184). 
Furthermore, the context was a prominent theme emerging from interviews. 
Understanding the context is also expected when investigating complex systems 
(165, 391) and highlighted by the MRC Framework adopted in the evaluation (166). 
DCE’s description was also in line with simple, complex and complicated aspects of 
interventions (165). There were official objectives (simple), but stakeholders 
mentioned different objectives (complicated), and reported on additional objectives 
over time (complex). Some DCE activities were standardised (simple), and others 
such as targeting groups were adaptive (complex). DCE was one of the possible ways 
to achieve outcomes and not essential to achieve them; factors beyond the 
programme were needed for success (complicated). Some outcomes could be easily 
anticipated (e.g. increase in demand) and addressed (simple), but others were only 
likely in some situations, hard to predict and address, e.g. overdiagnosis 
(complicated). Thus, Study 2 (evaluation development) reinforced the need to 
incorporate complexity theory (within interventions and systems) into the evaluation.  
5.3.2.2 Complexity and programme theory representation 
In line with the literature stating that a logic model’s somewhat rigid structure does not 
allow to show multiple interactions and causal relationships (165), participants 
highlighted the limitations of a linear logic model for describing DCE. In order to 
overcome this limitation, I prepared a textual description of DCE’s programme theory 
(Figure 5.7), and followed available guidance to incorporate complex 
systems/systems thinking when describing the DCE programme (165).  
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Figure 5.7. DCE textual programme theory: how DCE was expected to work 
 
Funnel and Rogers propose a different way to represent programme theory using 
outcomes chains, feedback loops and describing potential events that may break the 
chains and influence outcomes. Outcomes chains show assumed relationships 
between initial, intermediate and final outcomes in a programme (165). Feedback 
loops occur when an outcome further up the chain can lead to an earlier outcome 
(165). For example, someone who changed behaviour after watching a TV campaign 
may engage in a conversation and influence other people who may or may not have 
seen the campaign. Breaks in the chain refer to any event which may break the 
outcome chain, with the potential to influence the final outcome. Following Funnell 
and Rogers guidance, I developed outcomes chains and feedback loops for each 
DCE strategy (Appendix 19) and for the whole programme (Figure 5.8). I have also 
considered possible breaks in the chain of events that could influence the 
programme’s intermediate and final outcomes (165). The authors’ definitions for 
assumptions (factors directly related to the programme or outside its scope that can 
also influence the success of achieving aims or outcomes) and mechanisms (“ways 
in which an outcome will occur”) (165) were adopted for consistency purposes. 
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Figure 5.8. New representation of programme theory: outcomes chains 
 
Funnell and Rogers describe an outcomes chain as an “if..then..story”. Mechanisms 
are the “because” underlying the “if…then…story”, while assumptions are the “as long 
as” addition to the “if… then… because…story”. These relationships seem 
complicated but can be easily illustrated for the DCE programme (Figure 5.9). 
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Figure 5.9. Illustrated “if…then…story” for the DCE programme 
 
In addition to findings from Study 2, evidence from the literature was used to inform 
these new depictions of DCE programme theory. Systems archetypes described by 
Funnell and Rogers were particularly helpful to inform the outcome chains (165). The 
authors define archetypes as interventions used to activate mechanisms that bring 
change. They outline five common programme archetypes and provide generic 
outcome chains for each of them (165). Two archetypes were found to be relevant for 
the DCE Programme: information; and carrots and sticks (Figure 5.10). 
Figure 5.10. System archetypes found to be a good fit with the DCE programme 
 
Source: adapted from Funnell and Rogers 2011 (165) 
The final step in the new representation of programme theory was to list relevant 
contextual issues, and elicited assumptions and mechanisms of impact that were 
relevant to the programme overall (strategy-specific assumptions and mechanisms 
are available in Appendix 19 for information but were not investigated). Potential 
unanticipated outcomes were also added, as required to develop a sound programme 
theory (165) (Figures 5.11 and 5.12).   
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Figure 5.11. Assumptions and mechanisms relevant to the DCE programme 
1Informed by interview findings; 2Informed by system archetypes and corresponding 
outcome chains described by Funnell and Rogers 
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Figure 5.12. Contextual issues/external influencers and unanticipated outcomes 
 
1Informed by interview findings; 2Informed by early diagnosis literature 
Importantly, these representations of programme theory developed to guide the 
evaluation should not be seen as the absolute truth. Programme theories can be 
refined indefinitely, and it is reported that a lot of time is wasted by doing so when a 
simpler program theory could suffice (165). Discrepancy between programme theory 
and reality is normal; the nature and magnitude of the discrepancy is explored during 
the evaluation (161). Therefore, evidence-based, elicited assumptions and 
mechanisms may not hold true after further investigations. Multiple programme 
theories may also be appropriate for a single programme (165). 
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5.3.3 Adopting a theory-based evaluation 
Study 2 interviews resulted in better understanding the DCE programme, its 
underlying assumptions and mechanisms. Theory-based evaluation was confirmed 
as a good fit as it worked well with complexity and the adopted MRC framework.  
When I wrote the evaluation proposal for the funder, I was inclined towards using 
realistic evaluation as their approach to investigate “what worked, for whom and in 
what circumstances” seemed relevant (152). After better understanding the DCE 
programme, I changed my mind as I could not see how to operationalise realistic 
evaluation when assessing such a complex and complicated programme, with so 
many interrelated components. Realistic evaluation seemed to be compartmentalising 
DCE initiatives into separate boxes without too many connections between them. 
Hence, it did not seem ideal for what I was proposing to do. I appreciate Pawson and 
Tilley’s emphasis on the context, but the MRC framework (166, 172) and systems 
thinking (186) also postulate their importance, and both work well with broader 
definitions of theory-based evaluation. 
As described in Chapter 3, I have chosen to follow Carol Weiss’s definition of theory-
based evaluation, aiming to achieve what she describes as “theories of change 
evaluation” by assessing both implementation and mechanisms of impact (159, 162, 
187). Weiss also suggested limiting programme theory to a few central assumptions 
in a programme when it is not possible to investigate too many of them (162), which 
seemed very relevant for the DCE evaluation. Another reason for being informed by 
Weiss’ approach was her focus on the political aspect of evaluation research, as DCE 
was a Scottish Government programme. 
As Weiss provided little guidance on how to carry out a theory-based evaluation; I 
followed Funnell and Rogers’ comprehensive guidance and definitions instead. These 
authors incorporated both systems thinking and theories of change in their 
approaches (165).  
5.3.4 Choosing implementation and behaviour change 
theories to guide the evaluation  
Implementation theories, models and frameworks can help to provide context, build 
knowledge, and outline issues to be examined when assessing implementation (392). 
They also help to investigate mechanisms bringing change (393, 394), and the role of 
contextual influencers (394, 395).  
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Therefore, it was important to investigate approaches described in the literature that 
would be suitable for the DCE evaluation. A table was prepared describing a range of 
theories, models and frameworks commonly adopted in evaluation research 
(Appendix 20). Some of the identified approaches focused on the individual and 
incorporated psychological theories, others focused on systems and incorporated 
sociological theory, and a few tried to incorporate both issues. These variations can 
be beneficial: as universal explanations of phenomena are unlikely in complex fields 
such as evaluation, it is expected that the need for different approaches investigating 
different issues will persist over time (392). 
Irrespective of the choices made for the DCE evaluation, I was aware that there was 
a strong call for conceptual clarity, clear description of adopted concepts, and the 
need for better reporting in implementation and evaluation research (396). 
Instrumentation issues described by Martinez and colleagues (397) (Figure 5.13) also 
helped me to make an informed choice on the tools to be used in the evaluation. 
Figure 5.13. Instrumentation issues to be considered in implementation research 
 
Source: created based on guidance from Martinez et al 2014 (397) 
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5.3.4.1 Operationalising mechanisms 
The main challenge was to identify theories or frameworks that would fit well with such 
a broad and complex programme. After discussing  available options (described in 
Appendix 20) with my supervisors, including their strengths and limitations regarding 
ease of use and applicability to the PhD project, we agreed that the Behaviour Change 
Wheel (BCW) was the best option to guide the DCE evaluation. The BCW was 
developed to aid intervention design, improve evaluations and develop theory (394, 
398). It provides evidence-based guidance for identifying interventions and policies 
expected to work for a given behaviour, context and target individual or population 
(394). 
The BCW is a result of a systematic review of frameworks of behaviour change 
interventions which identified 19 frameworks comprising nine intervention functions 
and seven policy categories (394) (Figure 5.14). Intervention functions refer to means 
by which interventions can change a target behaviour. Policy categories help to 
support and enable interventions (394).  
Figure 5.14. The Behaviour Change Wheel 
 
Source: adapted from Michie et al 2014 (394) 
The starting point for understanding the BCW is the COM-B (Capability, Opportunity, 
Motivation – Behaviour) model. This model postulates that, in order for any behaviour 
to occur, there must be: 1) Capability to do it; 2) Opportunity for the behaviour to 
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occur; and 3) Motivation (motivation to do the behaviour must be stronger than 
motivation not to do the behaviour) (394). Furthermore, each COM-B component can 
be further divided into two types (Figure 5.15). 
Figure 5.15. The COM-B model 
 
Source: adapted and informed by Michie et al 2014 (394) 
COM-B components can be further detailed into 14 domains, which are organised into 
the Theoretical Domains Framework (TDF). The TDF synthesises constructs from 
different behaviour change theories and was developed by psychologists and 
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implementation researchers (394). TDF domains, intervention functions and policies 
are comprehensively described in Appendix 21, alongside examples applied to DCE.  
The BCW, and particularly the COM-B model, seemed relevant to inform mechanisms 
in the DCE evaluation. As an example, training health care professionals can increase 
their capability, providing diagnostic capacity resources can increase the opportunity 
to provide services, and financial rewards can increase motivation to meet targets. In 
order to assess the COM-B and the BCW suitability, I followed detailed guidance from 
those who developed the model and mapped DCE into the BCW components (394), 
checking for compatibility (as defined by experts who developed the model). The 
mapping exercise is available in Appendix 22. Furthermore, the BCW was described 
as having a range of features that applied to the DCE Programme: 1) it is well suited 
for “real world” settings; 2) it allows for the systematic characterisation of interventions 
and linkage of mechanisms of action to outcomes; 3) is helpful to assess why an 
intervention did not meet its goal; and 4) it is applicable to different levels (e.g. 
individuals, populations and organisations) (394, 398). 
COM-B provided a better fit to the elicited mechanisms compared to well-known 
theories such as Diffusions of Innovations and the Normalisation Process Theory 
(399-401). These theories focused on innovations being adopted or new 
practices/systems becoming normalised; which are different from what DCE proposed 
to do (even though some of their constructs were relevant). DCE was a multilevel 
programme which incorporated existing initiatives alongside new ones (for example, 
screening programmes and cancer waiting times were pre-existing strategies, and 
referral guidelines were updated as opposed to being created by the programme). 
After suitability was confirmed, guidance was followed to apply the COM-B model to 
elicited mechanisms (394, 398). Three COM-B constructs were applicable to elicited 
mechanisms: reflective motivation, physical opportunity, and automatic motivation. 
5.3.4.2 Operationalising implementation assumptions 
Although the BCW is also an implementation framework, I have used specific 
implementation outcomes to investigate implementation as the BCW was chosen to 
suit a different purpose (i.e. conceptualise mechanisms). Furthermore, the approach 
allowed me to use outcomes widely investigated that the BCW did not cover.  
As before, most theories/general guidance on implementation did not seem 
appropriate for the DCE programme. They focused on randomised controlled trials 
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(402), systematic review reporting (403), diffusing innovation (399) or normalising 
processes (400, 401). There were two promising alternatives: the Consolidated 
Framework For Implementation Research (CFIR) (404), and the Context and 
Implementation of Complex Interventions (CICI) framework (395) (Appendix 20). 
However, both of them were very broad frameworks with which I had no familiarity 
and it was unfeasible to use them considering the timescales. Therefore, I decided to 
follow guidance (as opposed to theory) on assessing implementation. I focused on 
key issues described as relevant by stakeholders in interviews, and then mapped 
these against operationalised implementation components described in the literature. 
I prioritised relevant implementation outcomes from the adopted MRC Guidance (166) 
and their recommended readings (405), followed by others that had a good fit with the 
issues I wished to investigate (393). The MRC guidance recommended assessing 
reach, dose and fidelity (166); these components were also approached by Steckler 
and Linnan, alongside context and recruitment (405). Proctor and colleagues 
described a taxonomy of implementation outcomes which included items such as 
acceptability, adoption, feasibility and sustainability (393).  
Not all these implementation outcomes seemed appropriate for a system-level 
evaluation of the DCE programme. There are also recognised limitations in assessing 
programme fidelity when evaluating complex interventions (166, 172). Furthermore, 
interviews indicated variation in contextual challenges, aims and implementation – 
indicating that fidelity was not appropriate. Assessing dose was also challenging as 
quantitative measures for this were not available for the DCE programme. The 
selected components for the evaluation were feasibility, acceptability, sustainability, 
appropriateness, sufficiency, reach and communication, and adaptability (Table 5.3). 
The aim was not to thoroughly investigate each of these implementation outcomes, 
but to explore them in order to clarify whether a selected number of assumptions 
about programme implementation held true.  
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Table 5.3. Chosen implementation components and definitions 
Components Definitions 
Feasibility Refers to practicability/achievability. Related to “appropriateness”, but 
different as something may be feasible, but not appropriate (and vice-
versa) (393). It covers issues such as impact on workload 
Acceptability Whether DCE is acceptable/agreeable. It is different from “satisfaction” 
which refers to service experience (393) 
Sustainability DCE’s ability to be sustained over time (393) 
Appropriateness Appropriateness refers to programme fit according to stakeholders. It 
is similar to ‘‘acceptability’’, but not equivalent as something may be 
appropriate but not acceptable (and vice-versa) (393) 
Sufficiency Whether resources were sufficient to meet demand brought by DCE, 
and strategies were enough to achieve intermediate outcomes. It was 
chosen instead of “dose delivered” and “dose received” (405) 
Reach and 
communication 
Refers to issues such as quality of information, access to it and quality 
of communication about strategies. Similar to “Penetration” (393) and 
“Reach” (405), but with a stronger focus on the role of communication 
Adaptability Adaptations to adjust to DCE/meet its aims, and how possible it was to 
make changes and be flexible. It was chosen instead of “fidelity” (393, 
405) due to the challenges in defining fidelity for a non-experimental 
programme where adaptations were the rule rather than the exception 
 
The use of validated tools is recommended whenever possible when assessing 
implementation (166). However, it was also necessary to be practical and pragmatic 
(397). In the case of DCE, I concluded that it was more appropriate to identify 
implementation outcomes with a close match to my research questions and interview 
findings, so I could obtain results which were relevant to stakeholders and could 
inform policy recommendations. I trusted that by describing and defining the 
outcomes used, comparisons across different studies could still be made (397). 
5.3.5 Prioritising what to evaluate in the process evaluation 
Elicited assumptions and mechanisms were prioritised according to feasibility of data 
collection/analysis and likely impact on DCE outcomes (166). It was important to 
prioritise what to investigate as it was not possible to assess everything (162). 
Furthermore, robust measurement of fewer implementation outcomes is more likely 
to generate meaningful results than trying to measure all possible outcomes (405).  
Four assumptions and four mechanisms were chosen to be investigated (Table 5.4). 
Assumptions focused on implementation issues from the perspective of health care 
professionals; no assumptions involving the public were investigated. Likewise, no 
elicited mechanisms involving the public were investigated (due to challenges in 
identifying those who were reached by the programme). 
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Assumptions Outcomes Rationale for prioritisation 
1. Different stakeholders bought into 
DCE, its components and what it 





Interviews showed that views about DCE and its different strategies varied 
across stakeholders. It was important to understand this variation and likely 
implications. Stakeholders reported that DCE generated a bit of “chaos” to 
drive changes, and this may have influenced stakeholder buy-in 
2. There was enough targeting and 
communication about DCE aims and its 




Interviews indicated that more clinical input would have been welcomed, that 
communication became more informal over time, and there was often a 
disconnect between primary and secondary care. Communication is also a 
key component in archetypes adopted in the DCE evaluation (165) 
3. Available resources (equipment, 
workforce, general practices, hospitals, 
laboratories, diagnostic and screening 




Stakeholders described how resource constraints existed prior to DCE. It 
was possible that, even with extra funding, resources were not sufficient to 
meet demand. As this has important implications for programme 
implementation and outcomes, the issue was further investigated 




Flexibility is required in complex interventions (166). Interviews described 
variations in context and activities. Hence the need to understand what was 







Mechanisms COM-B constructs Rationale for prioritisation 
1. DCE strategies were in line with what 
professionals perceived as their role, 
identity, organisational commitment and 
professional boundaries 
Reflective motivation It was important to understand how DCE varied from usual work as some 
activities were inherited by the programme and others were added to the 
professionals’ roles. The wording was changed after incorporating BCW 
guidance (394) 
2. Additional DCE funding resulted in in 




Information was limited on how DCE funding was used. Since diagnostic 
resources were limited regardless of DCE, and there were concerns about 
the impact of DCE on capacity, it was important to explore this further 
3. Increased demand brought by DCE 
was a driver for action and created 
pressure to act 
Automatic motivation Stakeholders reported concerns on DCE’s negative impact on workload and 
wished to know more about what happened. Wording was informed by 
evidence on archetypes (165) and adapted after incorporating BCW 
guidance (394) 
4. Targets helped to focus the mind, 
showed where resources were needed 
and increased pressure to act 
Automatic motivation 
Reflective motivation 
There were conflicting views on targets. They were described as not only 
driving activity but also as being unhelpful and in contrast with DCE’s wider 
aims. As DCE’s main objective was measured with the new HEAT target, it 
was important to investigate this further 
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Contextual issues and possible unanticipated outcomes were identified in Study 2, 
and a decision was made to investigate these further as part of the process 
evaluation. Due to time and resource limitations, unanticipated outcomes were only 
planned to be explored as part of the process evaluation. This was also in line with 
the adopted MRC Framework (166). 
5.3.6 Prioritising what to evaluate in the outcome evaluation 
Study 2 results showed how DCE had simple, complex and complicated aspects. 
Complicated aspects included activities taking place at different levels; and the fact 
that different strategies needed to work to achieve the final outcome (i.e. improvement 
in staging). In these cases, it is recommended that several programme components 
are investigated, as focusing on only one or some of them is “dysfunctional” (165). 
Importantly, complicated programmes are often not enough to generate changes, 
although they may still be necessary in order to achieve outcomes (165). 
Furthermore, Study 2 results reiterated the challenges of trying to evaluate a 
government programme which was not set up as a controlled experiment. Therefore, 
it was likely that the outcome evaluation would lead to conclusions about DCE’s 
potential contribution to the final outcome instead of reporting on causality.  
The evaluation proposal funded by DCE planned to use customised datasets to 
explore the impact of DCE on survival, considering variables such as referral patterns, 
diagnoses, emergency presentations, cancer waiting times, and screening uptake. 
Nested case studies were planned to investigate awareness, cancer screening and 
early diagnosis in primary care. Advice from the PhD review panel members (Prof 
Amanda Amos and Prof John Frank) with experience in evaluating tobacco control 
programmes and a range of other public health initiatives, and from the DCE 
Programme Board indicated that the scope of the outcome evaluation was too 
ambitious. My supervisors and I agreed that it was important to reconsider the 
feasibility of the proposed evaluation. The evaluation steering group also 
recommended caution when committing to a broader evaluation, especially after 
hearing about the challenges in obtaining data (highlighted when I presented to them 
results from key stakeholder interviews). Furthermore, the literature indicated that 
some of the variables initially proposed to be investigated (i.e. variation in referral 
patterns and emergency presentations) were more complex than expected, and not 
necessarily an indication of late diagnosis (357, 406-408).  
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Interviewed stakeholders suggested a wide range of outcomes to be investigated, 
including quantifiable outcomes (such as screening uptake, stage at diagnosis, lung 
x-rays, CT scans, and radical radiotherapy) and less tangible outcomes such as 
cultural changes. It was difficult to decide and prioritise what to investigate, and it was 
clear that assessing all outcomes deemed important by stakeholders was impossible.  
After discussing evaluation development results with my supervisors and considering 
feedback from the PhD review panel and the evaluation steering group, we made the 
decision to focus on assessing if, and to what extent, each of the eight DCE official 
objectives were met. By doing so, it was expected that the evaluation would cover the 
whole programme and would not be “dysfunctional”. Importantly, several 
investigations proposed by stakeholders fitted well with the objectives, hence their 
perspectives were still heard. Moreover, the process evaluation would shed light on 
other issues described as important, such as impact on workload. 
For feasibility reasons, outcome evaluation plans changed to reporting available 
outcome data from policy documents; and complementing this with a time-trends 
analysis of bowel screening outcomes (bowel screening data is systematically 
collected in Scotland). Other early diagnosis programmes in England (150, 176-178) 
adopted before-and-after analyses in their evaluations. Initially, I had proposed to  my 
supervisors to do a time-series analysis as this is considered to be a more robust 
strategy when investigating government initiatives and changes over time (409, 410). 
However, limited data availability precluded this. Furthermore, two evaluation experts 
(the PhD review panel) and a statistician at the UoE were consulted and raised 
concerns about the approach. They described challenges of carrying out a complex 
analysis without having discrete timing of exposure (and no clear exposure for DCE 
strategies), the fact that there was no control group and that there were too many 
known and unknown confounding factors. Questions were raised over whether such 
analyses could achieve anything other than what would be achieved by analysing 
data from policy documents. It was suggested that a descriptive analysis of activities 
and outcomes would be less speculative and more informative. Trends shown over 
time (in time flow diagrams and graphs) would describe DCE’s trajectory, highlighting 
specific time points and outcomes. These issues were discussed further in a 
supervision meeting after my second annual PhD review, and we agreed that the 
suggestions to carry out a time-trends analysis were appropriate. Further information 
on the approach is available in Chapter 6. 
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5.3.7 Identifying stakeholders to be interviewed in the 
evaluation 
Study 2 indicated different views on DCE’s aims; evaluation priorities, and on what 
constituted programme success. Hence, it was critical that different stakeholder 
groups were included in the evaluation (165). 
Stakeholders provided several suggestions of whom to interview and at times also 
gave reasons for their suggestions (Table 5.5). Reasons often focused on the 
professionals’ role in DCE, its potential impact on their work, or on whether 
participants could provide different or contrasting views (often implying that these 
views would be less positive). Stakeholders acknowledged that views would vary 
depending on who was contacted, and that not everyone would be available to take 
part. 
Table 5.5. Suggested professionals and reasons for suggestions 
Job role/Institution Why they are appropriate 
Charities: CRUK; Roy Castle Lung Foundation; 
Bowel Cancer UK; British Lung Foundation; 
Scottish Cancer Coalition 
• Due to their involvement in DCE – 
there were no mentions to smaller 
charities due to their “niche” remit 
Partners in social marketing campaigns: 
Leith Agency; TNS  
• They were personally invested, and 
were vital to campaigns 
Scottish Government (DCE or not): Chief 
Operating Officer, Director for Performance; 
social marketing staff; Chief Medical Officer; ISD 
Scotland and NHS Health Scotland staff; DCE 
director and predecessors; Chairs of the Scottish 
Cancer Taskforce and the DCE Programme 
Board; former and current chairman of the 
Scottish Primary Care Cancer Group; Scottish 
Cancer Registry Director 
• Different views, with a role managing 
performance across boards (COO) 
• “They put the data together” and have 
“oversight of primary care”(ISD) 
• They were “at the heart of it” (DCE 
director and predecessors) 
• Have views on the programme since 
its development (Chair) 
Members of the public and tumour-specific 
patient representative groups 
• Were influenced by the programme 
Range of health care professionals: 
colonoscopy provider/scoper; breast surgeon; 
radiologist (chest); someone involved in lung 
cancer imaging, chest x-ray; gastro surgeon; 
those involved in cancer networks; GPs; other 
primary care staff (practice nurses, health 
visitors); specialist doctors; pharmacists; 
specialist breast, lung and bowel nurses; “people 
involved in different cancer groups”; radiation 
oncologist; gynae specialist; “the margin of staff” 
in secondary care; Public Health practitioner; 
clinicians managing tumour types included in 
DCE; melanoma specialist 
• “Key people” 
• They are facing difficulties due to 
pressure in capacity; will have 
something to say 
• GPs  will provide views from primary 
care 
• Can provide views on investigations in 
areas less accessible compared to 
bowel/breast (chest radiologist) 
• May have different views, may not 
have been aware of DCE 
• Were affected by DCE 
NHS management: lead bowel and breast 
screening specialists; Cancer Network leads or 
Chief Executives; director of screening 
programmes; diagnostic service managers and 
• “At the coalface, separate from 
decision making, may have different 
views” (clinical director of radiology) 
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Job role/Institution Why they are appropriate 
directors of diagnostics in NHS Boards; 
executive Leads in NHS Boards; clinical leads for 
tumour types included in DCE; clinical director of 
radiology; Cancer Leads; cancer managers in 
cancer centres; “managers, not clinicians” 
• May have different views as they can 
see impact on diagnostics 
• NHS Management see the 
impact/pressure on services, seek 
resources and have data on targets; 
their job includes managing “all this” 
Other: Administrative teams; prevention 
specialist; those updating the referral guidelines 
• To provide views on the impact of 
targets and atmosphere 
 
Based on stakeholder recommendations and policy documents, a comprehensive list 
of 47 potential stakeholders to be interviewed in the process evaluation was prepared. 
5.4 Ethics 
Study 2 documentation was submitted to the Centre for Population Health Sciences’ 
Ethics Review Group on the 15th February 2016. Ethical approval was granted on the 
4th April 2016 (Appendix 23). Before commencing each interview, I asked participants 
if they had any questions. Two copies of the consent form were signed (one for me 
and another for the participant). All participants consented to having their interviews 
recorded. 
5.5 Summary of Chapter 5 
This chapter described Study 2 methods and results, and how these helped to 
develop the DCE evaluation. Study 2 had two components: analysis of policy 
documents and interviews with key DCE stakeholders.  
Policy documents were useful to understand the DCE programme, develop the logic 
model and identify stakeholders to be interviewed. However, they also reiterated 
limitations described in the literature (204, 380). Documents often referred to opinions 
in addition to facts. When documents were not created for the government, they were 
often prepared for the Government, and the possibility of political and/or financial gain 
was common. Bias in publication and reporting was likely, but it was impossible to 
ascertain the extent to which this happened. Nonetheless, data were invaluable to 
describe the programme and inform the DCE evaluation. 
The stakeholder interviews provided rich information on DCE development, on the 
context, helped to refine the logic model, showed which outcomes were considered 
to be important by stakeholders, and provided evidence on assumptions and 
mechanisms to be investigated in the DCE evaluation. Interview findings confirmed 
the usefulness of adopting complexity theory and systems thinking, and these 
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theories informed the development of a textual programme theory and DCE outcomes 
chains. Finally, interview findings helped me to choose theories/frameworks to 
underpin the DCE evaluation. 
A process of prioritisation was required for the evaluation, and four assumptions and 
mechanisms were chosen to be investigated further. Furthermore, as it was not 
possible to investigate all outcomes described by stakeholders, a decision was made 
to focus on DCE’s key objectives.  
As expected, Study 2 was paramount to inform the DCE evaluation (Study 3). The 
next Chapter describes the methods used to evaluate DCE processes and outcomes.
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Chapter 6 DCE evaluation methods (Study 3) 
6.1 Overview 
This Chapter outlines the methods adopted for the DCE evaluation (Study 3). First, it 
describes the evaluation binding aims and depicts the full evaluation in the adopted 
MRC framework for process evaluation of complex interventions. Then, it outlines the 
methods adopted for the outcome evaluation. Finally, it describes the two components 
of the process evaluation: a purpose-built online questionnaire and semi-structured 
interviews with DCE stakeholders. 
6.2 Binding aim 
The evaluation binding aim was to understand what happened, how and why it 
happened in the DCE programme. The DCE evaluation is described below, according 
to the MRC framework adopted in this PhD. (Figure 6.1). A comprehensive description 
of the DCE programme is illustrated in the first box shown in grey (data were obtained 
from Study 2). The process evaluation (shown in orange boxes in the diagram) 
investigates implementation, mechanisms of impact and context. Finally, the outcome 
evaluation is represented by the blue box in the diagram.
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Figure 6.1. The DCE evaluation situated within the MRC Framework for process evaluation of complex interventions 
 
 
Source: adapted from the original MRC framework for process evaluation of complex interventions (166)
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6.3 Outcome Evaluation 
6.3.1 Aim and rationale 
The outcome evaluation aimed to investigate if, and to what extent, DCE official 
objectives were met. By including all eight official objectives, the outcome evaluation 
expected to have a system-level, broader view of DCE outcomes.  
As described in Chapter 2, DCE developed a HEAT target (25% increase in cancers 
diagnosed at Stage I) which was used as a proxy for cancer survival. The HEAT target 
was assessed as part of DCE’s first objective. 
6.3.2 Data sources and analysis 
6.3.2.1 Data sources 
The outcome evaluation comprised secondary analysis of published and unpublished 
reports, and a descriptive time-trends analysis of requests for bowel screening kits 
using a customised dataset provided by the Scottish Bowel Screening Centre.  
Published reports comprised official health intelligence data from ISD Scotland on 
tumour staging (HEAT target reporting); on bowel and breast screening uptake; on 
consultations due to breast symptoms; purpose-built annual reports prepared by the 
Scottish Bowel Screening Centre reporting on DCE impact; and one published paper 
reporting on the use of symptomatic qFIT in primary care (411). Unpublished reports 
referred to before-and-after evaluation reports prepared by TNS (market research 
company responsible for carrying out social marketing campaign evaluations); DCE 
policy documents (such as reports, minutes, circulars and newsletters) reporting on 
data collected by TNS, Carat (Digital Media Agency), and Consolidated PR (Public 
Relations Agency); evaluation reports of education sessions prepared by Bowel 
Cancer UK and the Roy Castle Lung Cancer Foundation; and annual reports prepared 
by Health Boards describing how DCE funding was used. The level of detail in 
evaluation reports varied. Both ISD Scotland and TNS reports clearly explained their 
methodology and rationale for their decisions. TNS reports also described their efforts 
to ensure data were representative of their populations of interest (such as weighting 
samples), their internal validation and quality assurance procedures. Source 
questionnaires were also provided. Reports from other organisations were less clear 
regarding their adopted methods. Consequently, there was also less certainty 
regarding the quality and representativeness of their data. 
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The dataset (an Excel spreadsheet) provided by the Scottish Bowel Screening Centre 
had anonymised data on issued replacement test kits by territorial Health Board, from 
September 2010 to April 2017. The date the replacement kit was issued was 
considered as a proxy for the date in which the kit was requested (as the latter was 
not available). The dataset did not include requested kits which were not returned to 
the Bowel Screening Centre, nor test kits which were returned but not accurately 
completed (numbers are therefore an underestimation of all requests). No 
sociodemographic information was available for patients who had made the requests. 
6.3.2.2 Outcome measures 
Outcomes referred to cancers diagnosed at Stage I; bowel and breast screening 
uptake; knowledge/motivation before and after campaigns; consultations due to 
breast symptoms; calls to the bowel screening helpline; reminder letters sent to bowel 
screening non-responders; request for bowel screening kits; investment in imaging, 
diagnosis and treatment (soft outcomes); perceived usefulness of education sessions 
(soft outcomes); perceived benefits of DCE funding (soft outcomes); cancers 
diagnosed with unknown staging; and impact on workload (soft outcomes). 
When available, data were reported according to patient sociodemographic 
characteristics, Cancer Networks or territorial Health Boards. Data on Health Boards 
were only made available in Appendices for information; this was done to avoid unfair 
comparisons due to wide regional variations in population size, deprivation, 
performance at baseline, screening uptake, and cancer incidence. 
Even though Cancer Waiting Times targets became part of DCE, these were not 
reported as part of DCE outcomes as data were not available on intervals to 
diagnosis. Similarly, no data on the Primary Care Facilitator Programme were 
reported (in this case, because the strategy was led by CRUK). Nonetheless, an 
evaluation report (prepared by a third-party) is available for information (412).  
6.3.2.3 Data analysis and reporting 
Data analysis comprised the development of new summaries, tables and charts using 
aggregated level data from source documents. When data allowed, descriptive 
statistics N(%) were reported. Percentage changes over time were calculated 
whenever possible. Changes over time referred to relative changes; i.e. the final 
number/proportion at year/month of interest minus initial number/proportion at 
baseline, divided by the initial number/proportion at baseline and multiplied by 100. 
When original data sources did not pre-specify the baseline, I chose this based on the 
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data available (often the year prior to DCE launch); in these cases, I have used the 
term “proxy baseline” and this was specified when presenting results (Chapter 7). 
When the use of descriptive statistics was not possible nor appropriate (i.e. reports 
describing outcomes in a narrative form), textual summaries were prepared with key 
outcomes from source documents. In two cases (data on breast screening uptake and 
consultations due to breast symptoms), data were already available in a suitable 
format and diagrams were adapted and reproduced. In all other cases, additional data 
analyses, synthesis or graphical representations were required. 
Time-trends analysis of requests for bowel screening kits was restricted to descriptive 
statistics due to lack of patient sociodemographic data; the only available independent 
variable was territorial Health Board. Data analysis steps are described in Box 6.1. 
The analysis aimed to summarise trends over time and show whether there was an 
increase in request for bowel screening test kits when the bowel screening campaign 
phases were launched and during the bowel screening initiative. 
Box 6.1. Time trends analysis 
• Data from the Scottish Bowel Screening Centre was converted to SPSS v.23 (245) 
• Data were checked for completeness and inconsistencies. No problems were identified, 
but recoding was required 
• Automatic recode was used to convert string variables into date variables. The variable 
describing the date (day, month and year) in which the kit was issued was used to 
automatically create 1) one variable for issue_month; 2) one variable for issue_year; and 
3) a variable describing kits issued one year prior to DCE (Feb 2011- Jan 2012), Year 1 
(Feb 2012 – Jan 2013); Year 2 (Feb 2013 – Jan 2014), Year 3 (Feb 2014-Jan 2015), Year 
4 (Feb 2015 – Jan 2016) and Year 5 (Feb 2016 – Jan 2017). Data for Year 6 was only 
available up to October 2017. 
• I ran frequencies and annual means and medians in order to identify seasonal effects 
(requests were found to be lower in November and December compared to all other 
months; this was the case in all years) 
• A combination chart was created with columns reporting on number of requests by year 
and a line showing relative percentage increase over time.  
• A time trends chart was created showing the number of requests by month, while also 
outlining when the bowel screening campaign phases and the bowel screening initiative 
took place. Simple smoothing was used to attenuate monthly peaks and troughs in order 
to facilitate visualising long-term trends (413). This was done by calculating a rolling 
average (mean average of the month of interest, the previous and the subsequent month). 
The time trends chart show both the actual number of requests and the rolling average 
• Percentage change of requested kits over time was reported in tables 
 
“Colorectal cancer” and “bowel cancer” were used interchangeably as both terms 
were mentioned by data sources. Objectives 2 and 3 were assessed together as 
outcomes often overlapped. 
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Even though the outcome evaluation focused on DCE’s first three years (its initially 
planned duration), data were also shown for additional years when available. This 
was done for two reasons: 1) due to the recognition that longer timeframes are 
necessary to understand impact on cancer outcomes (especially for screening and 
tumour staging); and 2) to understand if changes were being sustained over time. The 
timeframes corresponding to DCE’s first three years are outlined in each graph. 
Table 6.1 describes the adopted approach for assessing whether DCE official 
objectives were met.
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Table 6.1. DCE objectives, data sources and reporting 
DCE official objectives Item Description 
1. Increase the proportion of 
people with Stage I disease at 
diagnosis and to use 
performance against a HEAT 








• Stage I over time (relative increase in proportion compared to baseline) 
Timeframes • Baseline (2011-2012) 
• Year 1 (2012-2013) 
• Year 2 (2013-2014) 
• Year 3 (2014-2015) 
• Year 4 (2015-2016) 
• Year 5 (2016-2017) 
• Year 6 (2017-2018) 
Analysis • Descriptive statistics: N (%), and % increase in Stage I over time 
Reporting • New textual description, new combined column and line charts, new tables using ISD Scotland data 
– percentage changes were calculated for new tables and checked against official data 
Other 
variables 
• Tumour type (lung, breast and bowel cancers combined and each tumour type separately) 
• Region (nationally, by cancer network and by territorial Health Board) 
• Level of social deprivation (SIMD quintiles – 1 most deprived to 5 least deprived) 
2. Improve informed consent and 
participation in national cancer 
screening programmes 
 
3. Raise public awareness of 
cancer screening programmes 
and the early signs and 
symptoms of cancer 
Data 
sources 
• Screening data (bowel and breast) collected by Screening Centres, reported and published by ISD 
Scotland – aggregated data tables in Microsoft Excel spreadsheets showing trends in uptake over 
time (breast and bowel) and routine appointments, early recall and self/GP referrals (breast) 
• Data on consultations for breast symptoms prepared by ISD Scotland, reporting on estimated 
increase in consultations for breast symptoms (using Practice Team Information) – customised report 
with tables and charts with N of women consulting, N of GP consultations, and 95% CIs 
• Before-and-after tracking surveys (bowel screening, breast screening, breast symptomatic and 
lung campaigns, and 3-year attitudinal tracking) carried out and reported by TNS (market 
research company) – reporting on change in knowledge/motivation, with text, diagrams and tables 
• DCE policy documents (circulars, newsletters and press releases) reporting on reach, business to 
business (B2B), public relations, and field and partnership for all campaigns, using data collected 
by Carat (Digital Media agency) and Consolidated PR (Public Relations agency) 
• DCE policy document reporting on the impact of the breast screening and lung cancer campaigns 
– textual description of campaign impact for breast (calls to the breast screening centres, and 
outcomes for these) and lung (consultations and chest-x-rays) 
• Annual reports prepared by the Scottish Bowel Screening Centre for DCE - textual description of N 
of calls to helpline and N of reminder letters sent to non-responders to screening over time 
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DCE official objectives Item Description 
• Customised Microsoft Excel spreadsheet from the Scottish Bowel Screening Centre) reporting on 
requested replacement bowel screening test kits - prepared for the purposes of this evaluation 
Outcome 
measures 
• Bowel screening uptake over time (relative increase in proportion compared to baseline) 
• Breast screening uptake over time (relative increase in proportion compared to baseline) 
• Knowledge/motivation before and after campaigns 
• Consultations due to breast symptoms over time 
• Calls to the bowel screening helpline over time and reminder letters to bowel screening non-
responders (N(%), relative increase in numbers compared to baseline) 
• Request for bowel screening kits over time (relative increase in numbers compared to baseline) 
Timeframes • Breast screening: uptake from 2005-2008 to 2013-2016 (3-year periods); N screened, routine 
appointments, early recall and self/GP referrals from 2010-2011 to 2015-2016 (1-year periods) 
• Bowel screening: uptake from 2009-2011 to 2015-2017 (2-year periods) 
• Consultations due to breast symptoms: from June-August 2011 to September-November 2012 
(monthly and 3-month periods) 
• Calls to the bowel screening helpline from January 2013 to March 2015 (monthly and annually); 
reminder letters to non-responders from 2012-2013 until 2014-2015 (annually)  
• Requests for bowel screening kits: from February 2011 to January 2016 (daily, recoded into 
monthly, also reported for one year prior to DCE, the first three DCE years and a fourth DCE year) – 
additional data prior to February 2011 and up to April 2017 was not used 
• TNS reports published in 2012, 2013 and 2014; Scottish Bowel Screening reports published in 2014 
and 2015, ISD Scotland on consultations due to breast symptoms published in 2013 
Analysis • Descriptive statistics: N (%), and % increase over time 
• Data synthesis of evaluation reports and DCE policy documents reporting on campaigns 
• Data synthesis of ISD Scotland and the Scottish Bowel Screening Centre reports 
Reporting • Social marketing campaigns: new textual synthesis of findings from each evaluation report 
prepared by TNS and other DCE policy documents, for each campaign, grouped into three areas: 1) 
BA evaluation (changes in knowledge/motivation), 2)campaign reach, and 3) outcomes from 
business to business (B2B), public relations, and field and partnership. New textual synthesis of 
impact of the breast screening and the lung cancer campaigns using data from DCE policy 
documents. New textual synthesis of attitudinal tracking data from the TNS evaluation report, grouped 
into three areas: positive shifts in attitudes, mixed findings, and negative shifts in attitude 
• Breast screening uptake and consultation due to breast symptoms: reproduced charts and 
tables from ISD Scotland, new % change over time 
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DCE official objectives Item Description 
• Bowel screening uptake: new tables and charts using data from aggregated tables published by 
ISD Scotland, showing trends in screening uptake over time (%), and percentage change compared 
to baseline (2009/2011 used as a proxy baseline) 
• New time trends chart plotting calls to bowel screening helpline alongside the bowel screening 
campaign and the bowel screening initiative using data from aggregated tables from the Scottish 
Bowel Screening Centre 
• New tables reporting on reminder letters and calls to the bowel screening helpline by year, new 
calculated % increase using data from aggregated tables from the Scottish Bowel screening centre 
• New tables and time trends chart plotting requests for bowel screening test kits, alongside bowel 
screening campaign phases and the bowel screening initiative, new calculated means and % 
changes over time - using customised dataset provided by the Scottish Bowel Screening Centre 
Other 
variables 
• Bowel screening uptake by sex, by region (nationally, by cancer network and by territorial Health 
Board) and by level of social deprivation (SIMD quintiles – 1 most deprived to 5 least deprived) 
• No information on region and level of social deprivation for breast screening 
4. Promote referral/investigation 
for patients who may be showing 
a suspicion of cancer whilst 
making the most efficient use of 
NHS resources and avoiding 
adverse impact on access 
Data 
sources 
• Evaluation report on education sessions for professionals – data collected, analysed and reported by 
Bowel Cancer UK and the Roy Castle Lung Cancer Foundation 
• Paper published in a peer-reviewed journal 
Outcome 
measures 
• Perceived usefulness of education sessions (soft outcomes) 
• Demand for bowel screening information 
Timeframes • Reports published in 2013; article published in 2016 reporting on data collected from October 2013 
to March 2014 
Analysis • Data synthesis of evaluation reports, textual summary of key results from published paper 
Reporting • New textual synthesis of outcomes from the education sessions, created from reports prepared by 
Bowel Cancer UK and the Roy Castle Lung Cancer Foundation 
Other 
variables 
• Variation in attendance across Health Boards (not reported for confidentiality purposes) 
• Sex and age for qFIT analysis (not reported here) 
5. Ensure sufficient capacity in 
the screening programmes to 




• Annual reports from the Scottish Bowel Screening Centre prepared for the DCE programme – textual 
description of programme impact on laboratory test time and laboratory activity and on time taken for 
patients to receive test results, in addition to strategies adopted to manage demand 
Outcome 
measures 
• Impact on workload (soft outcomes) 
Timeframes • Reports published in 2014 (referring to years 2013-2014) and 2015 (referring to years 2014-2015) 
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DCE official objectives Item Description 
Analysis • Data synthesis of annual reports 
Reporting • New textual synthesis of reported impact on workload and measures adopted to deal with impact, 




6. Ensure imaging, diagnostics 
and treatment are prepared for 
an increase in demand 
Data 
sources 
• DCE policy documents: annual reports submitted to DCE by territorial Health Boards, with a textual 
description of how funding was used, and perceived benefits brought by it 
Outcome 
measures 
• Investment in imaging, diagnosis and treatment (soft outcomes) 
• Benefits of DCE funding (soft outcomes) 
Timeframes • Annual reports submitted for the years 2012-2013, 2013-2014, and 2014-2015 
Analysis • Descriptive synthesis of data described in individual reports 
Reporting • New data table with a textual summary of how DCE funding was invested across Health Boards 
Other 
variables 
• Territorial Health Boards (not all submitted reports every year) 
7. Strengthen data collection and 








• Unknown tumour stages over time (relative increase in proportion compared to baseline) 
Timeframes • Baseline (2011-2012) 
• Year 1 (2012-2013) 
• Year 2 (2013-2014) 
• Year 3 (2014-2015) 
• Year 4 (2015-2016) 
• Year 5 (2016-2017) 
• Year 6 (2017-2018) 
Analysis • Descriptive statistics: N (%), and % decrease in unknown stages over time  
Reporting • New textual description, new combined column and line charts, new tables using ISD Scotland data 
– percentage changes were calculated for new tables and checked against official data 
Other 
variables 
• Tumour staging (unknown) by tumour type (for lung, breast and bowel cancers combined and for 
each tumour type separately), by region (nationally, by cancer network and by territorial Health Board) 
and by level of social deprivation (SIMD quintiles – 1 most deprived to 5 least deprived) 
8. Facilitate further evaluation of 
the impact of public campaigns 
on the stage of cancer at 
presentation and to contribute to 
cancer survival research 
N/A • No secondary data were available for this objective; hence this objective is only approached in the 
Discussion Chapter 
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6.3.3 Ethics 
No ethical approvals were required for the outcome evaluation as it comprised 
secondary analysis of anonymised data that could not be traced back (directly or 
indirectly) to living nor deceased individuals. A completed Usher Research Ethics 
Group (UREG) Level 1 form is available in Appendix 24. 
6.4 Process evaluation 
6.4.1 Aims and rationale 
The process evaluation aimed to investigate what happened and how it happened 
(i.e. the “how and what” in an evaluation) (170) by assessing implementation, 
mechanisms of impact and context (166). This was done by answering the following 
questions (Figure 6.2): 
Figure 6.2. Process evaluation questions 
 
As described in Chapter 5, four assumptions and mechanisms were prioritised to be 
investigated, and mapped against implementation outcomes (assumptions) (Figure 
6.3) and the COM-B (mechanisms) (Figure 6.4). 
Figure 6.3. Investigated assumptions 
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Figure 6.4. Investigated mechanisms 
 
There was a clear relationship between assumptions and mechanisms. For example, 
acceptability (an implementation outcome) could have been influenced by whether 
professionals saw DCE in line with their professional role (a mechanism that may 
have influenced engagement). It was expected that the analysis of both 
implementation outcomes and mechanisms would provide a more complete 
description of what happened, as expected when adopting theories of change (159, 
165).  
The process evaluation had two components: 1) semi-structured interviews 
(qualitative) and 2) a purpose-built online questionnaire (quantitative) with 
stakeholders. While interviews sought to obtain in-depth accounts, the questionnaire 
aimed to analyse quantitative implementation outcomes from a representative sample 
of stakeholders. A self-completion questionnaire was the chosen tool for the 
quantitative component as it is useful to study large groups, participants can respond 
at their own time and costs are low (414). 
Both the interview and questionnaire addressed the same process evaluation 
questions (Figure 6.2). It was expected that the questionnaire would allow for a deeper 
understanding in variations in views according to different stakeholders. 
6.4.2 Inclusion and exclusion criteria 
Inclusion and exclusion criteria for the interviews and questionnaire were the same to 
enable data integration; parallel samples were chosen (221). Stakeholders were 
eligible for inclusion if they were amongst those described in interviews or policy 
documents as being most affected by the programme (i.e. working in diagnostics and 
   
159 
primary/secondary care interface, managing health care services and the DCE 
programme), or having a key role in programme implementation (i.e. preparing health 
intelligence data, or developing partnerships with the Scottish Government). Eligible 
stakeholders were excluded if they were unwilling to provide informed consent or were 
not involved/influenced by DCE from the years 2011-2015 (one year prior to DCE 
launch and DCE’s first three years). Four groups were included: 
A. Professionals working in primary and secondary care: these included GPs, 
nurses, colonoscopy providers, breast screening radiologists, radiographers, 
surgeons, public health practitioners and staff working in administrative roles 
B. Stakeholders managing health care services and DCE strategies: Scottish 
Government managers, DCE managers and programme directors, NHS 
managers; Cancer Leads; Clinical Leads 
C. Providers of Health Intelligence Data: ISD Scotland staff 
D. Charities, creative agencies, and marketing research companies: charities 
include CRUK, the Roy Castle Lung Cancer Foundation and Bowel Cancer 
UK; the Leith Agency (responsible for gathering evidence and developing the 
DCE awareness campaigns with the public); and TNS (the market research 
company responsible for evaluating the DCE campaigns). 
6.4.3 Component 1: Interviews with stakeholders 
6.4.3.1 Data collection and analysis 
Sampling and recruitment 
Similar to Study 2, purposive sampling was adopted for the process evaluation. 
Criterion sampling, maximum variation sampling and snowball sampling were used 
(204). I aimed to speak to participants from all four eligible groups, from different 
Health Boards in Scotland. The list of potential participants prepared in Study 2 was 
used to initially select 20 stakeholders to be invited for an interview; the remaining 
names were kept aside for additional invitations if there were refusals to take part. 
When stakeholders from one particular Health Board refused to take part, attempts 
were made to recruit another stakeholder from the same Health Board. One 
stakeholder interviewed as part of Study 2 (a DCE manager) was interviewed again 
due to his/her in-depth knowledge about the programme. 
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Sample size was decided based on several considerations. I had to reflect upon my 
study aims, while also being pragmatic due to time constraints. I had to consider 
ethical implications of not being able to analyse all data if I interviewed too many 
stakeholders (415). Finally, I also considered that I was collecting process data using 
two different methods. I expected that little new information on each process 
evaluation question would emerge after 20 stakeholders were interviewed (200). 
Participants were contacted directly about the study by email. A face-to-face (at the 
participant’s chosen venue) or telephone interview was then arranged. Interviews 
were expected to last 40-60 minutes.  
Interview topic guide and setting 
The interview topic guide (example in Appendix 25) was informed by elicited 
assumptions and mechanisms. I also consulted other evaluation studies (391, 416, 
417), guidance on implementation (405), on the BCW (394), and on process 
evaluation (166) in order to identify questions used to investigate similar issues. 
Four topic guides (one for each eligible group) were created, with common questions 
to allow for data analysis. Overarching topics included views on the programme; how 
DCE, its components and requirements were communicated; what happened when 
strategies were implemented and whether they were implemented as planned; and 
perceived barriers and facilitators. Topics were mapped to the chosen assumptions 
and mechanisms, unanticipated outcomes and barriers and facilitators. Variations 
across different topic guides are described below (Table 6.2). 
Table 6.2. Eligible groups and topic guides 
Eligible groups Specific areas covered in the topic guide 
Professionals working in 
primary and secondary 
care 
As they were “at the coalface” dealing with targets and the 
impact of the initiatives, they were also asked about how DCE 
influenced their daily work and about any potential impact on 
workload. 
Stakeholders managing 
health care services and 
DCE strategies 
The topic guide adopted a more systems-level, strategic 
approach about estimates of programme impact, available 
resources, views on programme implementation, and perceived 
acceptance across different groups. 
Providers of Health 
Intelligence data 
The topic guide had a stronger focus on the development of 
targets, data preparation, changes in data collection and other 
data-related topics (including feasibility and acceptability of 
adopted outcome measures and targets). 
Charities, creative 
agencies, and marketing 
research companies 
These interviews were seeking views of those whose work was 
influenced in a different way by DCE. The topic guide was 
overarching, but it was hoped that responses would provide a 
different perspective on DCE implementation. 
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Transcription 
All interviews were digitally recorded (with the participants’ consent), anonymised and 
transcribed verbatim for analysis. The same company that provided transcription 
services for Study 2 also transcribed the Study 3 interviews. I checked all transcripts 
for inaccuracies and made corrections when needed. 
Data analysis 
As in Study 2, framework analysis was used to analyse data from interviews, NVivo 
11 aided analysis (390). In Study 3, a preliminary thematic framework was developed 
after reading and analysing all interviews. It was then applied to eight transcripts and 
refined. Further refinements took place until all interviews had been coded. One of my 
supervisors also analysed eight transcripts, and changes to the thematic framework 
were made after discussions. Framework analysis was used as the process 
evaluation had pre-specified questions, and the topic guide was prepared according 
to mechanisms and assumptions being investigated. Findings were organised into 
themes derived from the research questions and themes emerging from interviews. 
Reflexivity 
I have continued to make field notes; key issues are presented in Chapter 10. 
6.4.4 Component 2: Online questionnaire 
6.4.4.1 Data collection and analysis 
Sampling 
I aimed to reach relevant stakeholders while also not approaching too many ineligible 
professionals (such as those whose work was not influenced by the programme, or 
health care professionals who did not have contact with cancer patients). In order to 
do so, my lead supervisor and I asked the Scottish Cancer Networks (NOSCAN, 
SCAN and WOSCAN – reaching health care professionals and other specialists 
working with cancer patients), the Scottish Cancer Coalition (i.e. a coalition of Cancer 
charities with representation in DCE Programme Board) and the Scottish Primary 
Care Cancer Group (comprising professionals from all territorial Health Boards, 
including primary and secondary care professionals) if they would be willing to send 
an invitation to all stakeholders in their mailing lists. The proposed recruitment 
strategy was raised during a Detect Cancer Early Programme Board meeting in early 
2018; emails were also sent to each organisation. All agreed to send invitations. I was 
advised by NOSCAN and the Scottish Primary Care Cancer Group not to expect high 
   
162 
response rates, as these were uncommon when targeting busy health care 
professionals, even if the topic interested them.  
Stakeholders were contacted via an email (prepared by me and sent to contacts at 
each of the organisations) describing the study and inviting them to take part in a 
questionnaire survey. The email provided them with a link to the questionnaire. 
Recognising the importance of sending reminders to increase response rates (418), 
two reminders (15 and 30 days after sending the initial invitation email) were planned. 
However, two Cancer Networks raised concerns about the procedure (i.e. they did 
not wish to commit to sending three waves of emails but were happy to send two). 
Therefore, only one reminder was sent 15 days after the initial email. Bearing in mind 
stakeholders’ busyness and challenges with non-response, questionnaires were 
designed to take 15-20 minutes to be completed. 
All potential participants received the same anonymised link to access the 
questionnaire. No names were asked, and data could not be traced back to the 
participants. An optional question asked for an email address if participants wished to 
receive a summary of the study results. 
Sample size 
Two options were considered for calculating sample size: power-based or precision-
based (419). In power-based calculations, estimates are made of how many 
participants are needed to answer a specific research question in order to accept a 
null or an alternative hypothesis and avoid a type 1 (false positive) or type 2 (false 
negative) error (420). Two issues are particularly important: effect size and power 
analysis. The effect size refers to the magnitude of differences between two groups. 
A power analysis assesses how many participants are required so this effect is 
significant, i.e. generalisable to the population of interest (419, 421). Power-based 
calculations are often informed by similar studies in the literature, or a pilot study 
(422). It was not possible to identify studies similar to the DCE questionnaire to help 
estimate sample size. Furthermore, it was not feasible to pilot the questionnaire in 
advance, and there was uncertainty regarding how many stakeholders would agree 
to participate in the questionnaire survey. Hence, with advice from a statistician at the 
UoE, I opted for a precision-based sample size calculation instead (423). A precision-
based calculation stipulates the ideal width of the study confidence interval (i.e. the 
ideal precision/acceptable margin of error) and then explores how this width varies 
according to study size (419). In other words, a precision-based calculation estimates 
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what precision can be achieved with the responses obtained in a study. Better 
precision requires larger sample sizes (424). 
Question 6.2.a in the questionnaire was chosen to estimate sample size (“The 
benefits brought by DCE outweighed the time and effort required to work towards its 
aims”). This question was chosen as I expected that all eligible groups would be able 
to answer it, and it investigated overall DCE acceptance. A Likert scale of 1-7 (strongly 
disagree to strongly agree) was used for this question; it was recoded into binary (1-
3 and 5-7) to calculate the proportion of responses of those who either strongly 
disagreed or disagreed (1-3) versus those who either agreed or strongly agreed with 
the statement (5-7). A neutral response (4) was excluded from calculations.  
Then, I used a table provided by the National Audit Office (423) to investigate what 
sample size would be needed to achieve 5% precision in confidence intervals (at a 
95% confidence level) according to different population proportions agreeing/strongly 
agreeing with the above statement (Table 6.3). The next paragraph explains how to 
interpret Table 6.3. 
More heterogeneous populations require larger sample sizes in order to obtain a 
higher level of precision (425). Therefore, a 50/50 split (highest possible variability 
when answering question 6.2.a) would require 384 stakeholders in order to achieve  
the planned 5% precision (i.e. for me to be confident that, if I had asked the entire 
relevant population, 45 to 55% of them would also have chosen this answer) (Table 
6.3). This narrow confidence interval indicates better confidence that results are 
representative of the population of interest. On the other hand, if only 66 participants 
took part in the study (also with the 50/50 split in response patterns), then precision 
would be 12%, confidence intervals would be wider (38 to 62%), and I would be less 
confident about representativeness. In other words, better precision not only requires 
larger sample sizes, but samples also need to be larger when there is heterogeneity 
in responses  (424, 425).  
Reassessment was made after data collection to ascertain what precision was 
achieved based on the number of obtained responses. An online sample calculator 
(426) was used to calculate the obtained level of precision after data collection as 
Table 6.3 was not sufficiently comprehensive to do so. 
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Required sample size according to 
different levels of precision 





50% 66 96 150 384 
45% or 55% 66 95 148 380 
40% or 60% 64 92 144 369 
35% or 65% 60 87 136 349 
30% or 70% 56 81 126 323 
25% or 75% 50 72 112 288 
20% or 80% 42 61 96 246 
15% or 85% 34 48 76 195 
10% or 90% 24 35 54 138 
5% or 95% 12 18 28 72 
Source: adapted from the National Audit Office 2001 (423). Precision was estimated at 
a 95% confidence level. 
Questionnaire design 
As there was no suitable existing instrument that could answer the evaluation 
questions, a purpose-built questionnaire was developed. Relevant guidance on 
questionnaire design was followed; this is summarised in Box 6.2. 
Box 6.2. Guidance on questionnaire design informing the study 
General guidance 
• Add estimates on how long it should take to complete the survey (414) 
• Provide guidance and directions throughout the questionnaire (414, 427), use 
transitional phrases (414) 
• Have questions in a logical sequence and use filter questions (414) 
• Start with general questions that most people can answer, and then add more 
specific/sensitive questions (414, 427). Demographic data is sensitive information (428) 
• Consider factors shown to improve response rates such as reminders (418, 427), clear 
layout, clear study aims, keeping the participant interested (427), short questionnaires, 
offering results, simple headers (418), relevance, institutional logos (414)  
Specific guidance when developing questions  
• Free-text boxes help participants can explain their answers (427) 
• Avoid ambiguous, double-barrelled questions (414, 427), technical words or jargon, 
leading/presuming questions, vague questions, double negatives, loaded words and 
hypothetical questions (414); be as specific as possible; add all possible response 
alternatives (including “don’t know”) (414) 
• Present both negative and positive statements on attitudinal scales to deal with “yeah 
sayers”/acquiescence bias (427, 429) 
• “Questions should be short and to the point”, except for sensitive/personal questions as 
then they may be seen as abrupt or threatening (427) 
• Use Likert scales to assess attitudes and values but avoid terms such as “always” or 
“better”. Include a middle response category to avoid forced choices (414, 429) 
• Start response categories with “the least desirable option”, use numbers if there are too 
many answer options (414) 
• Response categories should be “mutually exclusive and “collectively exhaustive” (414) 
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Questions were derived from publications using different BCW components (COM-B 
and TDF) that either evaluated programmes or validated questionnaires (394, 430-
436). Questions about implementation outcomes were also aided by examples 
provided in the literature (394, 405). An audit trail showing the source for the adopted 
questions is available (Appendix 26). Mix of positive and negative statements was 
used to avoid participant fatigue; this was accounted for in data analysis. 
The questionnaire had 50 questions and two parts. Part 1 had five sections (one for 
DCE overall and one for each of the four DCE strategies), with multiple-choice 
(mandatory) and open-ended (all optional) questions. Part 2 comprised socio-
demographic questions and three optional open-ended questions (so participants 
could give their views on what worked and did not work in the programme, outline any 
barriers/facilitators and provide their views on anything else that the questionnaire did 
not approach). The questionnaire is available in Appendix 27; questions were mapped 
to investigated assumptions/mechanisms for information. 
Online provider 
An online questionnaire was chosen instead of a postal of face-to-face questionnaire 
as it was more cost-effective considering the number of professionals I was trying to 
reach (427). Furthermore, obtaining addresses for all potentially eligible participants 
would have been unfeasible. A postal or face-to-face approach would have required 
access to personal data. No need to do data entry reduced the workload (427) and 
the potential for human error when inputting data manually. 
The Bristol Online Survey (BOS) Tool was chosen to host the questionnaire survey. 
BOS is fully compliant with UK Data Protection Laws and is used by approximately 
130 Universities in the UK (437). The system allowed for skip functions, multiple 
choice questions, ranking questions and comments boxes. It indicated on each page 
the proportion of the survey that had been completed. Furthermore, it provided each 
participant with a unique receipt completion number that allowed them to request the 
research team for their data to be withdrawn (if this was their wish). BOS has a user-
friendly layout and I was responsible for adding the questionnaire to the system. I 
tested it with four Usher Institute colleagues to identify any progression errors or 
inconsistencies. None were found. 
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Questionnaire pre-testing 
In order to ensure that the questionnaire was fit for purpose among the target 
population, it was also pre-tested in November and December 2017. Pre-testing 
aimed to: 1) assess whether the instructions were easy to understand (199); 2) 
explore the meaning of specific questions and whether they were difficult, confusing, 
and/or misunderstood (438, 439); 3) assess whether there were appropriate response 
options available for all questions and all reasonable alternatives were included (199); 
4) assess the flow and order of sections, including the skip patterns (439); 5) 
investigate the time taken to answer each section and the whole questionnaire (438, 
439); 6) investigate respondent interest and attention overall (438, 439); and 7) 
explore participants’ overall views about the questionnaire (199). 
The pre-testing was carried out by professionals who would also have been eligible 
to take part in the process evaluation. They had experience working in primary or 
secondary care (for the latter, they had to work in any area related to oncology) or in 
relevant cancer charities in Scotland. Professionals were invited for pre-testing via an 
email to the PhD students’ mailing list and another to DCE contacts. My principal 
supervisor also sent emails to a GP and an oncologist working in secondary care.  
The literature recommends that data are reported on general characteristics of those 
involved in the pre-testing, on how pre-testing was carried out (setting, duration, 
number of actual recruited participants), and on changes made to the instrument as 
a result of the pre-testing (438). Four professionals were invited, and all agreed to 
pre-test the questionnaire: two GPs, one oncologist working in secondary care, and a 
senior manager in a cancer charity who also had prior experience as a health care 
professional. Pre-testing was carried out at the University of Edinburgh (n=2), at a 
general practice (n=1), and at a cancer charity (n=1). Meeting duration ranged from 
20 to 40 minutes. Time taken to read the questionnaire is available below, alongside 
a summary of issues raised and resulting changes to the questionnaire (Table 6.4). 
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Table 6.4. Recommendations from pre-testing and resulting changes to the questionnaire 
Sections Recommendations Changes 
Instructions • The introductory section should briefly state what DCE is about as professionals may 
not know about its activities (or that activities they know about were part of DCE) 
• The term “involved” should be replaced with a statement about whether DCE 
influenced the participants’ work or whether they helped with implementation. This is 
to avoid non-response from eligible stakeholders who may misinterpret the term 
These issues were amended as suggested 
Specific 
questions 
• Recommendations to clarify statements, change one statement to a yes/no question, 
check consistency of verb tenses and the logic flow between questions referring to 
different implementation periods, and between expectations and facts 
• Some questions/statements should be removed from the broad DCE section and 
placed in a section about a specific DCE activity 
Statements were clarified (one of them was 
changed to a question); verb tenses were 
made consistent; questions about 
expectations were moved before the ones 
about facts; a logic flow was respected; 
questions were removed 
Response 
options 
• More comment boxes should be added after questions that may bring back memories 
as these can clarify important issues not covered by the questionnaire 
• Views may vary for different cancer types, and this is not currently captured 
Boxes and a “please specify” probe were 
added to different questions; a question 
was added to capture variation across 
cancer types 
Sections As the sections are not really connected to each other, there may be issues regarding 
relevance. Sections not relevant to a target group may be relevant to other groups, and 
professionals may get frustrated if questions are not relevant to them 






• Introduction: 00:01:20 to 00:03:00 
• Part 1: DCE overall 00:02:00 to 00:06:00; awareness campaigns: 00:00:25 to 
00:02:00; education sessions 00:00:40 to 00:04:00; funding 00:01:00 to 00:03:00; 
targets 00:01:00 to 00:02:00 
• Part 2 (demographic information): 00:00:25 to 00:04:00 
• All sections: median 00:13:08; range 00:07:25 to 00:21:36 
Questionnaire should take less time to 
complete than expected 
Interest and 
attention 
Questionnaire may not be as relevant to oncologists working further down the cancer 
journey - because of the very clear referral patterns for several types of cancer, 
perceptions of the impact of DCE on the oncologists’ work may be watered down – those 
working with diagnostics may find the questionnaire more relevant. 
DCE activities are now described, the term 
“involved” was clarified and filter questions 
were added to help potential participants to 
assess relevance. 
Overall Questionnaire was described as useful, but there are issues regarding clarity and 
relevance to specific groups 
Amendments were made (as above) to 
deal with these issues 
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Data analysis and reporting 
All questionnaire responses were downloaded from the online system and converted 
into a *.sav format to be analysed in SPSS v.23 (245). An unedited, raw data file was 
kept aside. Standardised codes for missing data were added. Frequencies were run 
to assess completeness of information, and to identify any inaccuracies. I then 
checked for out of range/unexpected values. Recoding was necessary for all Likert-
type questions and other questions that had more than two answer options as BOS 
created a single variable for each possible answer. I also recoded questions that had 
reverse scores, open-ended questions clarifying closed-ended questions and 
questions which allowed for “other” issues to be mentioned. Month and day of birth 
were defined as the 1st June in order to estimate age based on year of birth provided 
by participants. Changes to the original dataset were recorded in a diary. After checks 
were made, descriptive, one-way tables for all numeric variables in the dataset were 
created.  
Summary tables, descriptive statistics and inferential statistics were used for 
quantitative data. Syntaxes were saved whenever applicable (recoding and bivariate 
analyses). A table describing sample characteristics was created; summary tables 
and graphs were used for 1) questions about assumptions; and 2) questions about 
mechanisms. N(%) was reported alongside means, standard deviations, medians and 
interquartile ranges (IQR) for ordinal data (in the main thesis and in Appendices). Bar 
and pie charts were created in Microsoft Excel 2016 (382). Inferential statistics were 
used to investigate variations in views across different groups of professionals, based 
on their job role, involvement in DCE, and the tumour type they worked with. Non-
parametric tests were used for ordinal scales in order to investigate differences in 
rating distributions between two groups (Mann Whitney U test) and more than two 
groups (Kruskal-Wallis H test, followed by pairwise comparisons with Bonferroni 
correction for multiple testing). Chi-squared tests (or Fisher’s Exact test when counts 
were less than five) were used for nominal (categorical data) to check for differences 
in proportions. 
Content analysis was used for open-ended questions; this is a structured approach 
for coding qualitative data (199). Content analysis helps to avoid cherry-picking 
quotes that seem relevant to multiple choice questions (427). Comments were coded 
by themes/categories (assumptions, mechanisms, barriers and facilitators, 
unanticipated outcomes and additional themes), and counts of the frequencies with 
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which themes occurred were produced (199). All open-ended comments and a 
preliminary list of themes/categories were shared with my lead supervisor; we then 
agreed on the final list of themes. 
6.4.5 Ethics 
In August 2017, both an NHS Ethics Scientific Officer and the Head of Research 
Governance at the Academic and Clinical Central Office for Research and 
Development were consulted about the need for ethical approvals for the process 
evaluation. They confirmed that the study was a service evaluation and that no ethical 
approval was needed from an NHS Research Ethics Committee nor Research & 
Development. 
Documentation for the process evaluation interviews was submitted to Usher 
Research Ethics Group (UREG) on the 13th October 2017. Unconditional approval 
was granted on the 11th January 2018 (Appendix 29). As in Study 2; study participants 
signed a consent form before taking part. Both the study participants and the 
researcher kept a copy of the signed consent form. 
I was informed by UREG that ethical approval was not required for pre-testing the 
questionnaire as 1) I was not going to record participants’ answers to the 
questionnaire (i.e. I would not be collecting research data); 2) the questionnaire was 
not likely to cause harm; and 3) I was only going to report on overall changes made 
to the questionnaire. The full questionnaire survey required UREG approval; 
documentation was submitted on the 5th March 2018 and approval was granted on 
the 9th April 2018 (Appendix 30). 
Potential questionnaire participants were provided with the research team’s contact 
details so they could ask questions before agreeing to take part in the study. 
Participants consented to take part online after reading an information page (which 
also had a link to a comprehensive downloadable information sheet). Invited 
stakeholders only had access to the questionnaire if they ticked the appropriate 
consent box. 
6.5 Feedback from the evaluation steering group 
Results from Study 2 were presented to the evaluation steering group in December 
2016. The evaluation protocol and topic guide for the Study 3 interviews were shared 
with the steering group in September 2017 and amended based on their feedback. 
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Comments referred to emphasising barriers and facilitators further and asking 
whether stakeholder views about the programme changed over time. 
The questionnaire was sent to the steering group in October 2017 for comments and 
was also amended after their feedback. Comments were overall positive, and minor 
issues were raised regarding clarity and avoiding the use of ambiguous terms (i.e. 
“such as”, efficiency” and “sustainability”). It was also suggested I replaced the socio-
demographic question about urbanisation level (which had been adapted from an 
European Social Survey questionnaire (440)) with the official Urban/Rural 
Classification from the Scottish Government (441) to allow for comparisons between 
studies in Scotland. All suggested changes were made. 
6.6 Summary of Chapter 6 
This Chapter described the methods adopted for Study 3 (the DCE evaluation). The 
outcome evaluation comprised secondary analysis of data from policy documents, 
and a time-trends analysis of bowel screening outcomes. The process evaluation had 
two components: qualitative interviews with DCE stakeholders and a purpose-built, 
online questionnaire for stakeholders. The next three Chapters describe the results 
for these three Study 3 components.  
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Chapter 7 Results: Outcome evaluation 
7.1 Overview 
This Chapter describes the results from the outcome evaluation of the DCE 
programme, which aimed to assess if, and to which extent, each of the eight official 
DCE objectives were met. This was done by secondary analyses of published and 
unpublished reports, and a descriptive time-trends analysis of requests for bowel 
screening kits. As described in Chapter 6, quality and representativeness of the data 
varied across data sources. Descriptive statistics (N, %) were reported and relative 
percentage changes over time were calculated whenever possible. Textual 
summaries/syntheses were also adopted. The outcome evaluation was carried out 
between May and December 2018. 
7.2 Objective 1 
To increase the proportion of breast, colorectal and lung cancers diagnosed at Stage 
I by 25% and use performance as a lever for whole systems improvement 
The first part of this objective was equivalent to the HEAT target, the official proxy for 
improvement in cancer survival (DCE’s key aim). Data produced and published by 
ISD Scotland was analysed to report on this objective. 
There was a 7.0% relative increase in the proportion of breast, colorectal and lung 
cancers (combined) diagnosed at Stage I at Year 3 (2014-2015) compared to baseline 
(years 2011-2012) (442). When analysing each tumour type separately (i.e., not as a 
HEAT target), there were relative increases in the proportion of breast (5.1%) and 
lung cancers (25.0%), and a decrease in the proportion of bowel cancers (4.3%) 
diagnosed at Stage I (442) (Figure 7.1).  
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Source: created using ISD Scotland data and aggregated tables (442). 










Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Breast, colorectal and lung cancers combined
% cancers diagnosed at stage 1 % increase compared to baseline
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Lung cancers
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Increases were noted across all levels of social deprivation (1 most deprived to 5 least 
deprived) for the three tumour types combined, for breast and lung. Considering the 
three tumour types combined, the highest increase was among the most deprived 
(11.6%) (Figure 7.2; Table 7.1) (442).  






Source: created using ISD Scotland data and aggregated tables (442) 
 
  








Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Level 1 - most deprived
% cancers diagnosed at stage 1 % increase compared to baseline
21.7% 23.2% 22.6% 22.5% 23.5% 23.7% 23.6%




Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Level 2
% cancers diagnosed at stage 1 % increase compared to baseline
24.2% 24.3% 24.9% 25.3% 24.7% 25.4% 25.7%





Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Level 3
% cancers diagnosed at stage 1 % increase compared to baseline
25.4% 26.1% 26.4% 27.3% 26.6% 26.7% 27.2%





Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Level 4
% cancers diagnosed at stage 1 % increase compared to baseline
26.7% 27.4% 28.2% 28.3% 29.3% 28.4% 28.1%




Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Level 5 - least deprived
% cancers diagnosed at stage 1 % increase compared to baseline
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Source: created using ISD Scotland aggregated tables (442) 
There were also increases for all three tumour types (combined) in the three Cancer 
Networks in Scotland. SCAN had the highest % change in Year 3 compared to 
baseline (11.8% increase), while NOSCAN had the lowest (3.4%) (442) (Figure 7.3; 
Table 7.2). There were wide variations across territorial Health Boards, with the 
highest percentage change for NHS Lothian (15.8% increase in all three tumour types 
combined at Year 3) and the lowest for NHS Highland (a 6.7% decrease) (442) 
(Appendix 31). 




Source: created using ISD Scotland data and aggregated tables from: (442) 
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Source: created using ISD Scotland aggregated tables (442) 
While the first part of Objective 1 was measurable, it was not possible to ascertain 
whether performance was used as a lever for system-level improvement. 
7.3 Objectives 2 and 3 
Objective 2: To improve informed consent and participation in national cancer 
screening programmes to help detect cancer earlier and improve survival rates 
Objective 3: To raise the public’s awareness of the national cancer screening 
programmes and also the early signs and symptoms of cancer to encourage them to 
seek help earlier. 
Outcomes for both objectives are shown together as they overlapped. Outcome data 
are shown by tumour type. The tumour-specific sections are followed by synthesis of 
a TNS evaluation that covered awareness campaigns across all tumour types (443).  
There was limited information on whether informed consent improved, although one 
of the campaign evaluations shed light on whether this was the case for breast 
screening (see below and summary of Chapter).  
7.3.1 Breast cancer 
7.3.1.1 Measuring changes in knowledge/awareness and motivation 
TNS carried out before-and-after evaluations of the breast symptomatic (444, 445) 
and the breast screening campaigns (446). Carat and Consolidated PR collected data 
on campaign reach and other process measures; these data were then disseminated 
through DCE documents. Data from these sources are synthesised here. 
Data from the symptomatic breast campaign evaluation show that the campaign had 
high level of awareness and recognition among women, especially among the target 
groups (lower socioeconomic status) (Figure 7.4). There was a significant increase in 
awareness of cancer symptoms and signs other than lumps highlighted by the 
campaign. Furthermore, there was an increase in the proportion of women checking 
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their breasts and an increase in the proportion of women stating they would see the 
GP straightaway if noticing symptoms (444, 445).  
Figure 7.4. Synthesis of key findings: symptomatic breast cancer campaign 
 
Sources: data synthesised from TNS and DCE documents (444, 445). Note: TNS does 
not report on social deprivation. Instead, they refer to six social grades which are based 
on the current or former occupation of the main income earner in a household (ABC1 
refers to “professional, managerial and non-manual occupations”, while C2DE refers to 
“manual and unskilled occupations and the long-term unemployed”) (source ID 43).  
 
As for the breast screening campaign, the evaluation reported that those who 
recognised it had higher levels of awareness and understanding of breast screening 
that those who did not recognise it. TNS also found that those who had never been 
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invited or had never attended screening recognised adverts less often than those who 
had experience attending screening (446, 447) (Figure 7.5). Conversely, those who 
recognised the campaign more often strongly agreed that breast screening did not 
carry any risks compared to those who did not recognise it. 
Figure 7.5. Synthesis of key findings: breast screening campaign 
 
Source: data synthesised from TNS and DCE documents (446, 447) 
 
7.3.1.2 Breast screening uptake (routine and self/GP referrals) 
ISD Scotland reports on both routine (screening invitations every three years to all 
eligible asymptomatic women) and non-routine (recall, self-referral and GP referral) 
appointments (9).  
Routine breast screening uptake has been slowly declining for over a decade (9, 448). 
As results were available for a three-year rolling period, it was not possible to assess 
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whether there was an increase in breast screening uptake during the DCE campaign 
(which took place in 2014).  
During 2012-2015 (DCE’s first three years), breast screening uptake (72.5%) was 
lower than in any of the available previous periods. Uptake continued to decrease in 
the 2013-2016 period (71.9%) (Figure 7.6).There was an increase in the number of 
women screened in 2013-2014 (in this case, information was only available on a two-
year rolling period) compared to the previous periods, but it was not possible to 
attribute this change to DCE (449). When considering non-routine breast screening 
appointments (also a two-year rolling period), there were increases in self/GP 
referrals in 2011-2012, 2013-2014 and 2014-2015 compared to baseline (9). The 
symptomatic breast campaign took place in 2012; due to limited data granularity it 
was not possible to estimate the extent to which it may have contributed to these 
increases (Figure 7.6). 


















appointments       
Number screened 170,664 167,486 164,472 172,929 158,405 154,641 
% change from 
baseline - -1.9% -3.6% +1.3% -7.2% -9.4% 
Early Recall       
Number screened 27 26 22 17 5 12 
% change from 
baseline - -3.7% -18.5% -37.0% -81.5% -55.6% 
Self / GP Referral       
Number screened 11,195 12,151 10,439 11,972 13,311 11,251 
% change from 
baseline - +8.5% -6.8% +6.9% +18.9 +0.5% 
 
 
Source: Adapted from ISD Scotland 2018 (9) 
7.3.1.3 Consultations due to breast symptoms 
ISD Scotland prepared a customised report for DCE estimating the number of 
consultations due to breast symptoms in order to help assess the impact of the 
symptomatic breast campaign (450). Data were derived from a sample of general 
practices, and included symptoms (lumps, pain and infection) which may not 
75.2% 74.9% 74.9% 74.9% 74.5% 73.5% 72.9% 72.5% 71.9%
0.0%
100.0%
2005-08 2006-09 2007-10 2008-11 2009-12 2010-13 2011-14 2012-15 2013-16
Trends in breast screening uptake (2005-2008 to 2013-2016)
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necessarily indicate breast cancer (450). There was a 51% increase in the number of 
women seeking a GP consultation due to breast symptoms during September-
November 2012 (the campaign was carried out in September and October in that 
year) compared to the same period in the previous year (Figure 7.7).  
Figure 7.7. Estimated consultations in primary care due to breast symptoms 
Estimated N of women consulting in primary care due to breast symptoms 
 
Estimated N of GP consultations for breast symptoms 
 
 
Consultations for breast symptoms (females) 
2011 Estimate 2012 Estimate 
Jan - Jan 5,270 
Feb - Feb 4,650 
Mar - Mar 5,540 
Apr - Apr 5,550 
May - May 6,940 
Jun 5,550 Jun 4,440 
Jul 3,950 Jul 6,270 
Aug 4,960 Aug 5,220 
Sep 4,930 Sep 7,310 
Oct 5,050 Oct 9,130 
Nov 5,600 Nov 8,040 
Dec 3,830 Dec - 
 
 
Source: adapted from ISD Scotland 2013 (450) 
When checking the estimated number of GP consultations for breast symptoms, there 
was a 48% increase in September 2012 (compared to September 2011), and an 81% 
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7.3.1.4 Other outcomes: responses to call to action from breast screening 
campaign 
The breast screening campaign prompted women to text SCREEN and their postcode 
to a purposively assigned number in order to book a screening appointment. The 
telephone number of their regional screening centre was then provided. The Breast 
Screening Centres collected data on how many women texted them as a result of the 
campaign (which had two phases), and how many of those resulted in a booked 
appointment (451).  
In the first phase of the campaign, 372 women left text messages and were sent the 
telephone number of their regional Breast Screening Centre. However, these text 
messages did not translate into many booked/rescheduled appointments at the 
Breast Screening Centres (no actual numbers were provided) (451). In the second 
phase of the campaign, 500 women left text messages and were called back by the 
Screening Centres so an appointment could be booked. However, several women did 
not answer the calls and there were some IT issues when trying to record data in the 
South East of Scotland. Furthermore, women who left text messages were often not 
the target population (i.e. deprived women eligible for screening) (451).  
When women called the Breast Screening Programme, about 10% of them (94 out of 
932) stated that they were prompted by DCE campaigns. More than a third of them 
(n=35) called to change or cancel an appointment, 41 were not eligible for screening, 
11 had general enquiries and 7 declined an appointment (451). 
7.3.2 Colorectal cancer 
7.3.2.1 Measuring changes in knowledge/awareness and motivation 
TNS evaluations assessing awareness and understanding of bowel screening after 
six phases of the bowel campaign showed persisting high spontaneous awareness of 
campaigns (although with a decrease over time). There was persisting agreement 
with several key campaign messages, but also weakening of agreement with others. 
Furthermore, there was a decline in those claiming that they had returned their test 
kit, a decline in motivation, and in wanting to see the campaign again (452) (Figure 
7.8). 
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Figure 7.8. Synthesis of key findings: bowel screening campaign  
Sources: data synthesised from TNS and DCE documents (452, 453) 
7.3.2.2 Colorectal cancer screening uptake 
Official ISD Scotland data show that bowel screening uptake had been slowly, but 
steadily increasing over time. This trend continued during DCE’s first three years. 
Screening uptake increased for both males and females, with a higher % increase 
among males (Figure 7.9; 2009-2011 as proxy baseline), and across all deprivation 
levels (124). Despite improvements over time, uptake remained lower in more 
deprived areas (Figure 7.10) (124). It was challenging to ascertain the extent to which 
the bowel screening campaigns, and the bowel screening initiative contributed to 
these improvements.  
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Source: created using ISD Scotland data and aggregated tables (124) 
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screening uptake % change compared to baseline
51.3% 52.0% 53.5% 54.9% 54.6% 53.5% 52.5%
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7.3.2.3 Calls to the bowel screening helpline 
Annual reports from the Scottish Bowel Screening Centre indicate an increase in calls 
when campaign phases were launched. The highest number of monthly calls was in 
October 2014 (during the sixth phase of the campaign) (454) (Figure 7.11). 
Figure 7.11. Calls to the bowel screening helpline 
 
Number of monthly calls 
 
2013  
(Campaign phases 1 & 2; bowel 
screening initiative launched) 
2014 
(Campaign phases 3-6; bowel 
screening initiative ongoing) 
2015  
(Final three months of 
the bowel screening 
initiative) 
Months N Months N Months N 
Jan-13 5521 Jan-14 3659 Jan-15 6534 
Feb-13 5007 Feb-14 5112 Feb-15 5649 
Mar-13 6092 Mar-14 6112 Mar-15 5550 







May-13 5456 May-14 6587 
Jun-13 4096 Jun-14 5739 
Jul-13 4045 Jul-14 6762 
Aug-13 5528 Aug-14 5789 
Sep-13 4958 Sep-14 6552 
Oct-13 5043 Oct-14 7018 
Nov-13 5947 Nov-14 5994 
Dec-13 3442 Dec-14 4591 
 
 
Source: created using data from the Scottish Bowel Screening annual reports (454, 455) 
 
When comparing 2012-2013 (proxy baseline) with 2014-2015, there was a 37.6% 
increase in the number of calls (from 52,342 to 72,028 calls) (Figure 7.12). 
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screening (a 26.3% increase from 2012-2013 to 2014-2015) (454, 455). Reminder 
letters were sent as part of the Bowel Screening Initiative. 
 
Figure 7.12. Reminder letters and calls to helpline by year (N and % change) 
 
 
Source: created using data from the Scottish Bowel Screening Centre (454, 455) 
 
7.3.2.4 Requests for bowel screening kits 
Anonymised data from the Scottish Bowel Screening Centre on requested and 
returned replacement kits were used for this analysis (456). 
During DCE’s first year (Feb 2012-Jan 2013) the number of requested replacement 
kits was fairly similar to the previous year (Feb 2011-Jan 2012 – used as proxy 
baseline). This changed in DCE’s second year (Feb 2013 – Jan 2014) when social 
marketing campaigns targeting bowel screening commenced and the bowel 
screening initiative was launched. There was a 10.4%, 10.6% and 13.6% increase in 
the number of requested kits in Year 2, Year 3 and Year 4 respectively. The number 




























Reminder letters sent to non-responders to screening
N % increase
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The increase in requested kits occurred across all territorial Health Boards (with 
variations), except for NHS Tayside and NHS Orkney in DCE’s third year (bearing in 
mind small numbers for the latter) (Appendix 32). 
Figure 7.13. Requests for bowel screening kits and % change 
Source: created using data from a customised dataset provided by the Scottish Bowel 
Screening Programme  
When checking monthly data, the highest percentage increases in Year 2 and Year 3 
compared to proxy baseline occurred during campaign periods (April and October 
2013, a 21.4% and 15.9% increase respectively; and February and October 2014, 
with a 19.2% and a 27.0% increase respectively) (Figure 7.14, Table 7.3). Importantly, 
there were also substantial increases in requests in months when there were no 
campaigns. There were no data available to ascertain whether the bowel screening 
initiative contributed to these increases. 
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Table 7.3. Requested kits over time and % change compared to proxy baseline 
 
Year prior to 
DCE (proxy 
baseline) 
Year 1  (prior to bowel 
specific strategies) 
Year 2 
(Campaign phases 1 




3-6; bowel screening 
initiative) 
Year 4 
(Campaign phase 7; 
end of bowel 
screening initiative) 
Year 5 









Feb 3674 4045 10.1% 4205 14.5% 4381 19.2% 4460 21.4% 4332 15.2% 
Mar 4270 4435 3.9% 4857 13.7% 4640 8.7% 4932 15.5% 4599 7.2% 
Apr 3973 4289 8.0% 4825 21.4% 4641 16.8% 4795 20.7% 4391 9.5% 
May 4311 4263 -1.1% 4732 9.8% 4715 9.4% 4809 11.6% 4315 0.1% 
Jun 4273 4113 -3.7% 4418 3.4% 4585 7.3% 5043 18.0% 4429 3.5% 
Jul 4215 4221 0.1% 4744 12.6% 4519 7.2% 5111 21.3% 4278 1.5% 
Aug 4479 4152 -7.3% 4741 5.8% 4368 -2.5% 4905 9.5% 4614 2.9% 
Sep 4460 4121 -7.6% 4856 8.9% 4581 2.7% 4959 11.2% 4197 -6.3% 
Oct 3919 4008 2.3% 4542 15.9% 4979 27.0% 4710 20.2% 3995 1.9% 
Nov 3893 3732 -4.1% 3994 2.6% 4440 14.1% 3964 1.8% 4139 5.9% 
Dec 3766 3602 -4.4% 3940 4.6% 4088 8.6% 4076 8.2% 3845 2.1% 
Jan 4295 4322 0.6% 4814 12.1% 4830 12.5% 4498 4.7% 4494 4.4% 
Total 49528 49303 -0.5% 54668 10.4% 54767 10.6% 56262 13.6% 51628 4.2% 
Mean 
(monthly) 4127 4109 - 4556 - 4564 - 4689 - 4302 - 
Percentage change always refers to proxy baseline. For annual calculations, the year prior to DCE (Feb 2011-Jan 2012) was used as the proxy 
baseline. For monthly calculations, the corresponding month in that year was used as the proxy baseline
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7.3.3 Lung cancer 
7.3.3.1 Measuring changes in knowledge/awareness and motivation 
As there is no organised lung screening programme in Scotland, the lung cancer 
campaign (with three phases) only focused on signs and symptoms, and on changing 
the perception that nothing could be done after a lung cancer diagnosis. Campaign 
evaluations reported a significant increase in spontaneous awareness of lung cancer 
activities, persisting high campaign recognition and increase in motivation over time. 
There was also a significant increase in spontaneous awareness about the “three-
week cough” message. Although many felt more comfortable to see the doctor in three 
weeks if they noticed small changes, there was also an increase in those saying they 
would not see the GP at all (Figure 7.15). 
Figure 7.15. Synthesis of key findings: lung cancer campaign 
 
Sources: data synthesised from TNS and DCE documents (457-461) 
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7.3.3.2 Consultations due to lung symptoms and associated examinations 
There was limited data on impact on consultations and associated examinations. A 
DCE Newsletter sent to GPs reported that more patients were referred for a chest x-
ray by a GP during the first month of the campaign (compared to the previous month). 
There was also a 3% increase in chest x-rays during the campaign (compared to the 
same time in the year prior to the campaign) (460).  
7.3.4 Attitudinal tracking before and after DCE campaigns 
TNS compared people’s attitudes before all the social marketing campaigns (2011) 
and after DCE’s first three years (early 2015) regarding 11 statements (443). Several 
positive, significant changes in attitudes were reported over time (Figure 7.16) but 
there were also mixed and negative shifts (Figure 7.17). 
Figure 7.16. Synthesis of key findings: 3-year attitudinal tracking (positive shifts) 
Source: data synthesised from TNS (443) 
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Figure 7.17. Synthesis of key findings: 3-year attitudinal tracking (mixed and negative 
shifts) 
Source: data synthesised from TNS (443) 
 
7.4 Objective 4 
To work with GPs to promote referral or investigation at the earliest reasonable 
opportunity for patients who may be showing a suspicion of cancer whilst making the 
most efficient use of NHS resources and avoiding adverse impact on access 
The Primary Care Symptom Management and Referral Strategy addressed this 
objective through the updated referral guidelines and the education sessions for 
professionals. The development of practice profiles is also relevant, but this activity 
was not implemented (personal communication, DCE Programme Board meetings).  
Local activities carried out by different Health Boards also addressed this objective in 
different ways (such as developing different referral pathways or implementing one-
stop breast clinics), but outcome data were not available for these activities. A pilot 
study in NHS Tayside using qFIT with symptomatic patients is also relevant (see 
below), although outcome information is limited. It was not possible to assess whether 
resources were used efficiently or whether there was an adverse impact on access. 
7.4.1 Referral guidelines 
With funding from DCE, the existing Scottish referral guidelines for suspected cancer 
were updated and published in 2014 (462). Quick guides were printed and 
disseminated across Scotland. A third-party evaluation about the use of the guidelines 
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was being carried out while this study was ongoing (personal communication, Dr 
Douglas Rigg), but results were not available when this Chapter was written. 
7.4.1.1 Education sessions 
Education sessions were led and evaluated by Bowel Cancer UK and the Roy Castle 
Lung Cancer Foundation (463, 464). Seven engagement sessions and one Webcast 
were delivered to 424 health care professionals between September and October 
2013. GP Sessions covered both colorectal and lung cancers. Key outcomes 
synthesised from evaluation reports prepared by the charities are available (463) 
(Figure 7.18). 
Figure 7.18. Synthesis of key findings from the education sessions 
Sources: Synthesised from Roy Castle Lung Cancer Foundation and Bowel Cancer UK 
documents (463, 464) 
 
7.4.2 Symptomatic qFIT 
Initial results from using qFIT with symptomatic patients in NHS Tayside have been 
published (411). Authors concluded that it was a good “rule-out test”, with negative 
predictive values of 100% for colorectal cancer, 97.8% for higher-risk adenoma and 
98.4% for inflammatory bowel disease. There was no available data on roll out in other 
Health Boards (411). 
7.5 Objective 5  
To ensure there is sufficient capacity in the screening programmes to meet the 
expected increase in those choosing to take part 
Data were limited on investment or plans to ensure that screening capacity was 
sufficient. Data describing increase in consultations due to breast symptoms and 
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increase in self-referrals (shown when reporting outcomes for Objectives 2 and 3) 
indicated increase in workload for the breast screening programme (as its resources 
were required for examinations of patients with symptoms). 
Two annual reports from the Scottish Bowel Screening Centre described increase in 
activity during DCE awareness campaigns and the bowel screening initiative (as 
described for Objectives 2 and 3)(454, 455). The increase in activity was also reported 
to have influenced laboratory test time and the Centre’s ability to meet the NHS 
Quality Improvement Scotland desirable standard (95% of participants receiving their 
results within 7 days of receipt by the Screening Centre). Nonetheless, all screening 
participants received their results within 12 days (2013-2014) and 14 days (2014-
2015). Reports also stated that there was a seasonal peak in laboratory activity during 
February and March 2014 (phase 3 of the bowel screening campaign); this was then 
reduced in April and returned to pre-campaign levels (454, 455).  
Several strategies were adopted to manage impact; these included an automated 
telephone option so those calling could order a replacement kit by leaving a recorded 
message (added in February 2014). About one third of callers used this option, with 
90% accuracy (i.e. without the need to call back) (454). 
7.6 Objective 6 
To ensure that imaging, diagnostic departments and treatment centres are prepared 
for an increase in the number of patients with early disease requiring treatment 
Revenue funding was allocated to Health Boards via NRAC share, taking into account 
population projections, age/sex distribution, needs due to morbidity, deprivation and 
remoteness (465). Health Boards submitted brief annual reports to DCE describing 
how funding was used and perceived benefits. Use of funding varied widely across 
Health Boards (Table 7.4), although many used it to support improvements in 
diagnostics, data capture and reporting; and local awareness initiatives/support for 
national campaigns. There was limited information about resources for treatment and 
no consistent data on whether capacity was sufficient. 
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Table 7.4. How DCE funding was used and reported outcomes 
Territorial 
Health Board How additional funding was used Reported outcomes 
NHS Ayrshire 
& Arran 
• Investment in diagnostics (Radiography, Pathology, Endoscopy, 
Laboratory, local EBUS services) and purchase of 
videoconferencing equipment for MDT meetings 
• Baseline assessment and ongoing measurement (cancer tracking 
and audit staff) 
• Awareness raising activities, engagement with men and other hard-
to-reach bowel screening non-responders 
• Recruitment of locum staff to deal with demand; increase in breast 
surgery capacity 
• Support for GPs to increase bowel screening uptake 
• Better communication with GPs, improved GP engagement 
to increase bowel screening uptake 
• Better communication and engagement with patients, 
volunteers and the public 
• Increase in breast screening/mammography capacity (with 
reduction in waiting times); increase in diagnostic capacity 
(bowel screening, imaging and pathology) 
• Improved audit of cancers diagnosed (A&E admission and 
routine referral); more accurate/complete staging data 
• Improved efficiency of MDTs; additional CT capacity 
NHS Borders 
• Assignment of managers to coordinate work on awareness and 
communication with deprived populations 
• Funding for a clinical nurse specialist in lung cancer; additional 
colonoscopy/CT scan capacity; additional breast clinics and a 
consultant radiologist 
• Development of local material to support staff; staff survey on 
awareness of bowel screening 
• Training and support for practices in order to meet bowel screening 
targets 
• Use of local radio for early detection messages 
• New network of contacts to reach deprived and vulnerable 
populations; work with local initiatives and companies 
• Dedicated staff to work on DCE helped to increase bowel 
screening uptake 
• A multidisciplinary team was established 
• Plans developed to support gaps in service provision with 
new resources brought by funding 
• Events held with GP practices to provide support 
• Messages on risk factor and early detection were embedded 
in staff conversations with patients 
NHS Dumfries 
& Galloway 
• Development of new cross-cancer site MDT data recording system; 
employment and training of new audit staff  
• Display of advertising/marketing from national campaigns in local 
NHS and regional publication; increase in communication activity 
• Increase in capacity in Head and Neck Clinical Nurse Specialist role; 
building capacity in endoscopy (including equipment) and Pathology 
• Better planning for future services and audit of practice 
(developments were incorporated in services provided) 
• Increased engagement with Community Health Teams and 
Educational Institutes  
• Improved reporting in cancer staging data 
NHS Fife • Investment in diagnostics (Endoscopy, Radiology and Pathology); 
recruitment of a respiratory physician; appointment of a lead Cancer 
GP 
• Reduction in the capacity deficit 
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Territorial 
Health Board How additional funding was used Reported outcomes 
• Funding for additional clinical sessions to tackle delays 
NHS Forth 
Valley 
• Funding for additional diagnostics (Radiology and Pathology 
consultants, technical staff for breast services and fast-track x-ray 
for lung) and training 
• Support and redesign the Outpatient Department breast service; 
funding for a breast surgeon, nursing and administrative staff; pilot 
using breast physician to support one-stop clinics 
• Purchase of an additional ultrasound machine; additional 
endoscopy capacity for surveillance 
• Funding for Health Promotion and to train volunteers to work with 
hard to reach groups 
• Cancer prevention activities and awareness raising events, local 
case studies, work in the community, distribution of campaign 
packs; use of websites, social media and community newsletters 
• Additional endoscopy capacity eased the pressure on the 
endoscopy unit 
• Reduced pathway delays, improved patient centred breast 
service  
• Bowel screening awareness training indicated lack of 
awareness of the screening test, of knowledge about the 
importance of symptoms and signs, body and practical 
issues of doing the test. A short weekly briefing session 
implemented for breast has continued and has been rolled 
out to other pathways 
NHS Grampian • Support for endoscopy, radiology, cancer audit team and Managed 
Clinical Network 
• Funding for cancer nurse specialists, cancer pathways team and 
MDT support 
• Complementary early detection initiatives carried out in partnership 
with voluntary and partners 
• Increased diagnostic capacity 
• Network approach to funding allocation taken by consulting 
widely and identifying priorities (this also resulted in better 
engagement of different professionals) 
• Ability to undertake systematic review of pathways; 
establishment of a Cancer Care Network 




• Additional breast and radiology sessions (including evenings and 
weekends); additional imaging capacity, scanning and reporting 
capacity for CT scanning; infrastructure for developing a Sentinel 
Lymph Node Biopsy in Breast Cancer service 
• Targeted marketing for the breast campaign; increase in lung 
capacity ahead of campaigns; additional endoscopy capacity 
• Increase in medical and diagnostic sessions (respiratory medicine) 
• Improved “real time” audit in terms of staging data 
• Improved understanding of residual consequences of 
campaigns 
• Audit system put in place to enable continuous improvement 
and understanding of trends in presentation 
NHS Highland • Procurement of a mammography unit, of an ultrasound machine 
(lung) and a prostate biopsy probe for urology 
• Reduced waiting times for the diagnosis and treatment of 
breast patients; reduced waiting time for TRUS biopsies with 
greater flexibility for treatment. 
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Territorial 
Health Board How additional funding was used Reported outcomes 
NHS 
Lanarkshire 
• Production of teaser letters for breast screening and bowel diaries; 
joint work with partners to raise awareness of bowel and breast 
cancers; health improvement (training, screening toolkits, work in 
prisons and leisure centres) 
• Investment in digital mammography, recruitment of a breast surgeon 
and support for the appointment of a breast clinical assistant 
• Purchase of EBUS services and an introduction of a wide screen 
monitor; purchase of rigid thoracoscopy equipment 
• Investment in specialist Radiology and CT Colonography; piloting a 
one-stop breast clinic; training for nurse endoscopists 
• Support for clinical audit and data gathering; radiology, care 
pathways, and local campaigns 
• Cemented relationships with local authority partners 
• Improved clinical audit data and key performance indicators; 
reduced backlog in data collection; quality assurance 
timescales were met and a rolling programme of quality 
assurance for all tumours was facilitated 
• Development of local reporting and better collection of 
staging data 
• Improved access and local treatment (lung); more efficient 
approaches that reduce the risk and need of anaesthetics 
• Continuous review of pathways to ensure a robust and 
streamlined approach, and to improve services 
• Improvement in data capture and integration of CT 
colonography into Colorectal Services as standard 
NHS Lothian • Increase in diagnostic, screening capacity and treatment costs to 
maintain cancer waiting times targets 
• Baseline assessment and ongoing measurement (audit staffing, 
programme management, analytical capacity, e-health developer 
time and others)  
• To assess, profile and influence primary care referral behaviour 
• Investment in breast symptomatic and screening services, radiology 
for breast, lung and bowel, respiratory medicine (staff, nursing and 
administrative support), breast imaging, biopsy and Magnetic 
Resonance Imaging, support to EBUS/imaging 
• Investment in a pilot study to improve screening uptake 
• Funded additional sessions to increase GP Cancer Lead time 
• Increased understanding of the system while using cancer 
intelligence - changing service provision and delivering 
pathways that support early detection; improved cancer 
analytical capacity and audit 
• Development of a governance and leadership structure 
through the DCE Board 
• 10 pilots on primary care engagement and innovation, with 
improved engagement with general practice and screening 
• Increase in breast service (including one additional one-stop 
clinic) and radiology capacity 
• Improved referral guidance 
• Early diagnosis became central to the Board’s Strategy 
NHS Orkney • Funding for new scopes; endoscopy redesign to support screening 
campaigns; establishment of a CT service; new multifunction room 
• Support for Health Promotion 
• Development of the “Bin your Bra” campaign 
• Support for DCE campaigns locally - giving away keyrings, doing 
radio interviews with local women, having articles in local 
magazines, distributing resources to local businesses and public 
• Increase in the number of scopes 
• Awareness raised for breast cancer and enhanced 
engagement with staff) 
• Increased scrutiny on performance at practice level 
• Rolling programme of replacement scopes to maintain 
scope numbers; adoption of protocols to order scans and 
help to deal with having no radiologist 
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Territorial 
Health Board How additional funding was used Reported outcomes 
venues, and sharing information and links on local pages and 
websites (including social media).  
• Promotion of educational programmes; knowledge and skills 
to be maintained and mainstreamed 
• Revised networked approach through the Isles Network of 
Care to the delivery of care 
NHS Shetland • Investment in DCE leads, data capture, and diagnostic equipment 
• Purchase of video conferencing equipment and use of funding to 
assist with modernising scopes; additional colonoscopy capacity 
• Pump priming for initiatives to support DCE 
• Support of Health Promotion activities (alongside work with 
pharmacists funded by Macmillan); funding allocation alongside 
Urological Cancer Charity (UCAN) and Prostate UK 
• DCE embedded in core business; became a recurring item 
in Cancer Lead Team meetings 
• Increased opportunities for patients to be referred via the 
pharmacist; links with services improved 
• Increased awareness of trigger symptoms and pathways 
across primary care services and improved links between 
specialists and health services – resulting in increased 
capacity and reduction of waiting times for patients requiring 
ongoing surveillance after cancer treatment 
NHS Tayside • Investment in breast capacity though additional staff, and lung and 
colorectal capacity through staff and equipment 
• Investment in capacity for Pathology, Radiology, IT, Primary Care, 
and Medical Records through staff and equipment  
• Pilot development of a cancer decision support tool in primary care 
• Support for national marketing activities 
• Sustained and embedded social marketing. 
• Increased understanding of the importance of systematic 
data collection and analysis, of having an effective and 
influential clinical engagement with DCE, having effective 
senior leadership, good management and administration  




• Funding used towards cancer awareness (breast, bowel, lung, 
prostate, testicular and general cancer awareness) - contacting 
existing cancer support groups, setting up stalls at community 
events, disseminating information in community halls, GP practices 
and workplaces; using survival stories in different media channels 
to engage with the public; targeting men using local media channels 
and women through ladies’ film night 
• Use of out of hours helpline and set up of a dedicated website 
• Breast screening uptake increased 
• Learning built into Health Promotion approaches to enhance 
awareness and screening uptake 
• Increased vigilance for early detection; continued input and 
support for local cancer groups 
Sources: Data synthesised from annual reports sent to DCE by territorial Health Boards (466-499). Abbreviations: EBUS: Endobronchial 
Ultrasound; MDT: multidisciplinary team; CT: computed tomography; GPs: general practitioners; A&E: accident and emergency; IT: 
information technology; NHS: National Health Service 
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7.7 Objective 7 
To strengthen data collection and performance reporting within NHSScotland to 
ensure progress continues to be made on improving cancer diagnosis, treatment, 
referral, and survival 
As part of HEAT target reporting, ISD Scotland reported not only on cancer staging 
for breast, bowel and lung cancers, but also on changes in the proportion of cancers 
diagnosed with unknown stages over time. This was the only available measure to 
assess whether Objective 7 was met. 
There was a 44.2% reduction in cancers diagnosed with unknown stages when 
checking breast, bowel and lung cancer combined, comparing Year 3 (2014-2015) to 
baseline (2011-2012). The highest reduction happened for breast cancer (65.2% in 
Year 3), while the reduction for colorectal and lung cancers in Year 3 was similar 
(36.7% and 38.7% respectively). (Figure 7.19) (442). Reductions occurred across all 
deprivation levels, with the most deprived having the highest reduction in Year 3 
(52.7%) (442) (Figure 7.20, Table 7.5). 
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Source: created using ISD Scotland data and aggregated tables (442) 
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Breast, colorectal and lung cancers combined
% cancers diagnosed with unknown stages % change compared to baseline
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200 






Source: created using ISD Scotland data and aggregated tables (442) 
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Source: created using ISD Scotland data and aggregated tables (442) 
There were reductions in the proportion of cancers diagnosed with unknown stages 
across all Cancer Networks (the highest reduction happened for WOSCAN) (Figure 
7.21; Table 7.6) (442). Reductions did not occur across all territorial Health Boards 
(Appendix 34) (442). 




Source: created using ISD Scotland data and aggregated tables (442) 
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Source: created using ISD Scotland aggregated tables (442) 
7.8 Objective 8 
To facilitate further evaluation of the impact of public awareness campaigns on the 
stage of cancer at presentation and to contribute to research that establishes 
evidence for the link between late presentation and survival deficit  
There were no available outcome measures to assess this objective. Challenges in 
assessing DCE objectives are discussed below and in Chapter 10. 
7.9 Summary of Chapter 7 
This Chapter outlines the results from the outcome evaluation, which investigated 
DCE official objectives using secondary data sources. Several objectives were 
aspirational, referred to soft outcomes or did not have specific key performance 
indicators/outcome measures, and there was limited outcome data available. 
Therefore, it was not always possible to assess whether objectives had been met. 
Objective 1 was not met, although a positive increase in the proportion of cancers 
diagnosed at Stage I was noted overall, for breast and lung cancers, and across all 
deprivation levels. Conversely, there was a decrease for bowel cancer. Reasons for 
this are hard to interpret in the absence of relevant data (i.e. staging for cancers 
diagnosed through screening and through symptomatic presentation; and profile of 
screening participants). Possible explanations include removal of precancerous 
polyps through screening, long-term non-responders becoming responders but 
presenting with late-stage disease, or more patients presenting with symptoms (which 
often indicate more advanced bowel cancer) (500, 501). These possibilities would 
need to be checked in further studies. Analyses of other shifts in staging (such as 
shifts from Stages III and IV to stage II) may be helpful, but these were beyond the 
scope of this evaluation. Importantly, results show that having a composite 
performance target can mask variations that may be important when trying to promote 
early detection for different tumour groups.  
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Several data sources were used to assess Objectives 2 and 3. It was not possible to 
note any positive impact on breast screening uptake. In terms of symptomatic breast 
presentation, results from campaigns showed positive impact on knowledge, 
awareness of symptoms and intention to act, and likely increase in help-seeking 
behaviour. ISD Scotland data (450) showed increase in consultations for breast 
symptoms during the campaign periods. A recent systematic review found that 
awareness interventions in the UK had a positive impact in both breast screening and 
self-examinations; this was only partially confirmed for DCE (502). Two important 
issues would deserve further investigation (beyond the scope of this evaluation). The 
first is the finding that women more aware of campaigns more often agreed that breast 
screening carried no risks; the second is the risk of overdiagnosing and overtreating 
the increasing number of worried well consulting with symptoms.  
For colorectal cancer, it is possible that the bowel screening campaigns and the bowel 
screening initiative have contributed towards the (existing) trends in increase in 
uptake. There were positive increases for males (who take part in bowel screening 
less often) and amongst the most deprived (who also have lower participation and 
present more often with late stage disease) (124). Both groups were specifically 
targeted by DCE activities. Data showed an increase in requested and returned test 
kits when different phases of the campaign were launched. The impact of the bowel 
screening initiative could not be ascertained.  
For lung, there were high levels of awareness of the campaign message about the 3-
week cough, but also an increase in the proportion of people not wanting to see the 
GP at all if they noticed small changes. There were very limited outcome data as data 
on consultations/examinations were not routinely collected for the purposes of the 
programme. Finally, the 3-year attitudinal tracking showed positive changes in 
population knowledge/awareness and intention to act, but also persisting challenges 
regarding prompt help-seeking. 
It was not possible to assess the extent to which Objective 4 was met due to limited 
data on referrals/investigations and the use of NHS resources. Professionals taking 
part in the education sessions found them useful and planned to share information 
with work colleagues, but engagement varied across Health Boards. Symptomatic 
qFIT was found to be a good rule out test for bowel diseases. 
Similarly, it was not possible to ascertain to which extent Objective 5 was met. There 
were (limited) data on increase in workload for the Breast and Bowel Screening 
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Centres, but there was no information on whether capacity was sufficient (nor on how 
this could have been measured).  
Funding was provided to Health Boards in order to ensure that Objective 6 was met. 
Data from Health Boards described a wide variety of (positive) soft outcomes, 
including better communication and more efficient diagnostic processes. However, 
data were lacking on whether capacity was sufficient to meet demand. 
There were clear improvements in data collection, for different tumour types and 
among the most deprived. These results indicated that Objective 7 was partially met. 
ISD Scotland acknowledged that increases in the proportion of cancers diagnosed at 
Stage I were partly due to improvements in data recording (316). 
Finally, due to the aspirational, long-term nature of Objective 8, no outcome data were 
available to assess whether it had been met. 
In summary, outcome evaluation results showed that DCE’s key aim was not met, 
and in most cases DCE objectives were partially met. Results should be interpreted 
with caution due to limited data availability, lack of outcome measures, the descriptive 
nature of the analysis, and the use of aspirational objectives.  
The next two Chapters describe the results from the process evaluation of the DCE 
programme, in order to shed light how and why objectives were met, not met, or were 
only partially met.
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Chapter 8 Results: Process evaluation 
(Questionnaire survey) 
8.1 Overview 
This Chapter describes the results from the questionnaire survey, carried out as part 
of the process evaluation of the DCE Programme. Interview results are described in 
Chapter 9. The process evaluation aimed to investigate implementation, mechanisms 
of impact, barriers and facilitators and unanticipated outcomes. Questionnaire results 
are organised according to the process evaluation questions, followed by additional 
issues/themes highlighted by stakeholders.  
8.1.1 Recruitment 
The process evaluation questionnaire is available (Appendix 27). Initial invitations to 
complete it were sent on the 8th May 2018, except for invitations sent by SCAN (sent 
on the 11th May 2018 due to operational issues). A reminder email was sent on the 
22nd May 2018. The questionnaire was available for completion until the 6th July 2018 
(inclusive).  
The first page of the online questionnaire was viewed 189 times; 79 of these were 
first-page views only, before eligibility could be checked and before reaching the 
informed consent page.  
Fifty-six potential participants were screened out of the study; i.e. they either did not 
consent to take part (n=13) or they ticked the box stating that DCE did not influence 
their daily work during 2011-2015 and they did not help develop/implement one or 
more of its activities (n=43). 
Fifty-four eligible participants consented to complete the questionnaire, and 53 of 
them submitted it after completion. All 53 submissions were used for data analysis 
(Figure 8.1).  
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Figure 8.1. Questionnaire recruitment flowchart 
 
Abbreviations: NOSCAN, North of Scotland Cancer Network; SCAN, South East 
Scotland Cancer Network; WOSCAN, West of Scotland Cancer Network 
8.1.2 Questionnaire survey results 
8.1.2.1 Response rates 
Response rates were only estimated as it was not possible to accurately determine 
the denominators; i.e. how many stakeholders were invited, and among these, how 
many were eligible to take part. The organisations sending the invitation emails 
provided me with an estimated number of emails sent by them (shown in Figure 8.1). 
All of them highlighted that some email addresses referred to different organisations 
or tumour-specific groups, and it was not possible to estimate how many times the 
invitations were forwarded to others. Based on these estimates, the emails were sent 
to about 1,532 potentially eligible stakeholders; an estimated 12% (n=189) viewed the 
questionnaire first page, and 53 completed it (28% of those who viewed the first page 
and 4% of those who received the email). Therefore, estimates indicate a low 
response rate. Low response rates can result in non-response bias when there are 
systematic differences between those who take part and those who choose not to 
take part in a survey (503). Implications of the low response rate are approached in 
Chapter 10 (Discussion). 
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Furthermore, I had aimed for 5% precision (95% confidence level). Across all 
participants, 40.5% either agreed or strongly agreed that “benefits brought by DCE 
outweighed the time and effort required to work towards its aims” (after removing 
those who neither agreed nor disagreed with the statement). Therefore, I would have 
needed 369 participants (Table 6.3) to reach 5% precision. With 53 participants, the 
achieved precision was 13.2% instead. Hence, I could be confident that, if I had asked 
the entire relevant population, 27.3% to 53.7% of them would have chosen this 
answer. The small sample size and wide confidence intervals indicate larger margins 
of error/less precision of results obtained from the survey compared to the relevant 
population. As the planned level of precision was not reached, there is more 
uncertainty regarding external validity and generalisability. Precision was even lower 
when considering answers to different questionnaire sections, as participants could 
skip commenting on a DCE strategy if it was not relevant to them. 
8.1.2.2 Questionnaire completion over time 
Almost half (45.3%, n=24) of the 53 responses were returned on the invitation and 
reminder dates (8th May, 11th May and 22nd May). Most questionnaires (90.6%; n=48) 
were returned in May 2018.  
8.1.2.3 Characteristics of questionnaire participants 
Most participants were women (59.2%). Mean age was 50.8 (normal distribution; 
Shapiro-Wilk Test, p=0.481). Most common job roles were secondary (62.7%) and 
primary care doctors (13.7%). Over three-quarters (75.8%) were involved in/had their 
work influenced by DCE for at least three years. Most worked in urban areas (73.6%) 
and hospitals (73.1%) (Table 8.1). 
Table 8.1. Characteristics of questionnaire participants 
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Characteristics N (%) 
Profession 
Medical – secondary care 













Bowel, anal and/or upper GI 
Lung 
One tumour type, but not specified 










Period programme influenced work 
from pre-implementation to at least the first three years 
from programme launch to at least the first three years 
at least 2 years 








Territorial Health Board 
NHS Ayrshire and Arran 
NHS Dumfries and Galloway 
NHS Fife 
NHS Forth Valley 


















Large urban areas 
Other urban areas 
Accessible small towns 
Remote rural areas 













Primary Care Practice 











Sums may not add up to 100% due to rounding. Missing data: sex (n=4); age (n=19); 
profession (n=2); tumour type (n=1); period programme influenced work (n=20); Health 
Board (n=2); workplace (n=1); other workplace (n=1). Other medical professions 
included one consultant and one endoscopy lead; 14 participants chose medical as a 
profession but did not specify any further. Other professions correspond to two audit 
staff and four respondents who ticked “other” but did not specify. Other urbanisation 
level (n=1) was not specified; other workplace (n=1) refers to “Board wide” 
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All questionnaire responses are available in Appendix 35 (including for recoded 
variables used in the analysis); all bivariate analyses are available in Appendix 36. 
Results are described below according to the process evaluation research questions. 
8.1.3 Assumptions about programme implementation 
8.1.3.1 Assumption 1. Different stakeholders bought into DCE, its components 
and what it proposed to do 
Stakeholder views were mixed over whether DCE’s benefits outweighed the time and 
effort required to work towards its aim. Almost a fifth (17.6%, n=9) neither agreed nor 
disagreed with the statement. About half (49.0%) disagreed to a certain extent 
(somewhat disagree, disagree or strongly disagree), while 33.3% agreed to a certain 
extent with the statement (somewhat agree, agree or strongly agree) (Figure 8.2).  
Figure 8.2. DCE overall acceptability – benefits and costs 
 
The higher the median scores, the higher the agreement with the statement (range 1 
strongly disagree to 7 strongly agree). Missing data: 2 (don’t know) 
Median scores were significantly differently depending on tumour type (H(4)=14.445, 
p=0.006). Post-hoc tests showed that significant differences were between 
professionals working with breast cancer compared to those who worked with bowel, 
anal and/or upper GI cancers (adjusted p=0.017). Those working with breast cancer 
had lower median scores (indicating lower agreement with the statement). 
While 22 participants (43.1%) agreed to a certain extent that DCE was appropriate to 
promote early detection, 21 (41.1%) disagreed to a certain extent. Perceived 
appropriateness varied according to DCE strategies (85.7% agreement for the bowel 
screening initiative, and 40.7% for the HEAT targets) (Figure 8.3).  
About half of participants (49.0%) agreed to a certain extent that they supported DCE 
continuation; the proportion was slightly higher for whether they believed that their 
team supported DCE continuation (55.3%), although there was considerable missing 
data for the latter (n=14) (Figure 8.3). 
90% 70% 50% 30% 10% 10% 30% 50% 70% 90%
The benefits brought by DCE outweighed
the time and effort required to work
towards its aims (n=51)
1 (strongly disagree) 2 3 4 5 6 7 (strongly agree)
median 4
(IQR 2-5)
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Figure 8.3. DCE appropriateness and sustainability 
The higher the median scores, the higher the agreement with the statement. Missing data for appropriateness: DCE overall (n=2; don’t 
know), public awareness campaigns (n=12; 2 don’t know, 10 section not applicable); education sessions (n=30; 10 don’t know, 14 section 
not applicable, 6 question not applicable); guidelines (n=13; 5 don’t know; 7 section not applicable, 1 question not applicable); provision of 
extra funding (n=15; 2 don’t know, 12 section not applicable, 1 question not applicable); HEAT targets (n=26; 7 don’t know, 18 section not 
applicable,1 question not applicable); bowel screening initiative (n=32; 31 section not applicable; 1 question not applicable). Missing data 
for sustainability: individual support (n=2, don’t know); team support (n=15; 14 don’t know, 1 not applicable).
90% 70% 50% 30% 10% 10% 30% 50% 70% 90%
Local team supports continuation of DCE (n=38)
I support continuation of DCE (n=51)
Bowel screening initiative (n=21)
HEAT targets (n=27)
Provision of extra funding (n=38)
Updated guidelines (n=40)
Education sessions (n=23)
Public awareness campaigns (n=41)
DCE overall (n=51)
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There were significant variations in responses according to DCE involvement and job 
role (Box 8.1). 
Box 8.1. Bivariate analysis results: appropriateness 
Median scores for appropriateness of DCE and HEAT targets were significantly differently 
depending on DCE involvement (H(2)=8.191, p=0.017 and H(2)=6.028, p=0.049 
respectively). Post-hoc tests showed significant differences between those who were not 
involved in developing or implementing DCE strategies, but would have liked to have had 
an input compared to 1) those who were involved  (adjusted p=0.047) (DCE 
appropriateness) and 2) those who were not involved, but were happy with that (adjusted 
p=0.042) (appropriateness of HEAT targets). In both cases, those who were not involved 
but wished they had had an input had lower median scores (indicating lower agreement with 
statements). 
Median scores for appropriateness of DCE (H(3)=12.386, p=0.006), of public awareness 
campaigns (H(3)=8.915, p=0.030), of updated guidelines (H(3)=8.827, p=0.032), and 
individual support for DCE continuation (H(3)=10.544, p=0.014)  also varied significantly 
according to job role. Post-hoc tests did not provide evidence to elucidate between which 
pairs of professionals there were significant differences. 
 
8.1.3.2 Assumption 2. There was enough targeting and communication about 
DCE aims and its strategies, and what was expected from everyone 
About a fifth of participants (18.0%) were involved in developing and/or refining DCE 
or its strategies. Among those who were not involved, a similar proportion was either 
happy not to be involved or would have liked to have had an input (Figure 8.4). 
Figure 8.4. DCE involvement and wish to have further input (n=50) 
Missing data: three participants chose “other”: one did not specify further, one stated: 
“not applicable as was still in training”; another wrote “my colleague was involved in 
implementation, so I heard by word of mouth and from tv adverts”. 
In terms of receiving information prior to DCE launch/implementation, most 
participants (72.7%) reported being sufficiently informed about the bowel screening 
initiative. A minority reported having been sufficiently informed about extra funding 
Yes
18%
No, and I was 
happy with that
42%
No, but I 
would have 
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(10.0%). A substantial proportion of participants would have liked to have received 
more information about DCE and its components (38.5%), especially about additional 
funding (37.5%), the public awareness campaigns (35.7%) and the HEAT targets 
(30.3%) (Figure 8.5). 




 Yes, I was sufficiently informed 
 
 Yes, but I would have liked to have 
had more information  
 
 No, I was not informed about 
it/them  
   
   
Missing data: DCE overall (n=1; other); public awareness campaigns (n=11, 1 other, 10 
section not applicable); education sessions (n=17; 3 other, 14 section not applicable); 
work to update guidelines (n=9, 2 other, 7 section not applicable); provision of extra 
funding (n=13, 1 other, 12 section not applicable); HEAT targets (n=20, 2 other, 18 
section not applicable); bowel screening initiative (n=31, section not applicable) 
When asked about communication between primary and secondary care regarding 
how to use DCE funding, over half (55.6%) strongly disagreed that communication 
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Figure 8.6. Communication between primary and secondary care 
 
The higher the median score, the higher the agreement with the statement. Missing 
data: n=26 (10 don’t know; 4 question not applicable, 12 section not applicable) 
There were significant variations in responses according to tumour type and job role 
(Box 8.2). 
Box 8.2. Bivariate analysis results: communication 
Professionals working with more than one tumour type were significantly more likely to 
report being sufficiently informed about DCE campaigns (p=0.004, FET) and the bowel 
screening initiative (p=0.016, FET) compared to professionals working with a single tumour 
type. 
Secondary care doctors were significantly less likely to report being sufficiently informed 
about education sessions (p=0.036, FET), referral guidelines (p=0.001, FET), and additional 
funding (p=0.002, FET) compared to GPs, nurses and other professionals. 
Professionals involved in developing DCE (overall) were significantly more likely to report 
being sufficiently informed about the referral guidelines (p=0.009, FET) compared to those 
not involved in developing the programme. 
Median scores for question about whether communication between primary care and 
secondary care went well varied according to professional roles (H(3)=9.686, p=0.021). 
Post-hoc tests comparisons showed significant differences between secondary care doctors 
and nurses (adjusted p=0.028). Secondary care doctors had lower median scores, 
indicating lower agreement with the statement. 
 
8.1.3.3 Assumption 3. Available resources were sufficient to meet aims 
(focusing on time) 
Most participants (64.5%) disagreed to a certain extent that there was enough time to 
engage with DCE and its strategies (Figure 8.7). 
  
90% 60% 30% 0% 30% 60% 90%
Primary and secondary care
communicated well
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Figure 8.7. Sufficiency (time) 
 
The higher the median scores, the higher the agreement. Missing data: DCE and its 
strategies (n=5, 2 don’t know, 3 question not applicable); education sessions (n=29; 3 
don’t know, 12 question not applicable and 14 section not applicable); funding (n=24; 6 
don’t know, 6 question not applicable and 12 section not applicable); reach non-
responders (n=43; 4 don’t know, 8 section not applicable and 31 section not applicable) 
Median scores for questions regarding time varied significantly by tumour type and 
involvement in DCE (Box 8.3). 
Box 8.3. Bivariate analysis results: sufficiency 
Median scores for the question on whether there was enough time to engage with DCE and 
its activities varied according to tumour type (H(4)=13.051, p=0.011), job role (H(3)=8.484, 
p=0.037) and involvement in DCE development (H(2)=6.925, p=0.031). Post-hoc tests to 
test pairwise comparisons showed: 
• significant differences between those working with breast cancer and those working with 
more than one tumour type (adjusted p=0.031), with lower median scores for the former 
• no significant differences between any pairs of job roles 
• significant differences between those who were not involved in developing DCE but 
wished they had had an input and those who were involved in DCE development 
(adjusted p=0.040), with lower median scores for the former 
 
8.1.3.4 Assumption 4. Flexibility was permitted when allocating resources 
Regarding DCE overall, most participants (65.2%) disagreed to a certain extent that 
they had flexibility to make changes in order to meet DCE aims (Figure 8.8). 
Figure 8.8. Flexibility to make changes in order to meet aims 
 
The higher the median score, the higher the agreement with the statement. Missing: 
n=7; 3 don’t know, 4 question not applicable 
90% 70% 50% 30% 10% 10% 30% 50% 70% 90%
My team had enough time to reach non-
responders to bowel screening (n=10)
We had enough time to plan how to use the
funding (n=29)
I had enough time to attend the education
sessions (n=24)
There was enough time to engage with DCE
and its strategies (n=48)









90% 60% 30% 0% 30% 60% 90%
I had flexibility to make changes in order to
meet DCE aims (n=46)
1 (strongly disagree) 2 3 4 5 6 7 (strongly agree)
median 2
(IQR 1-4)
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Median scores varied significantly according to job role (H(3)=9.795, p=0.020). Post-
hoc tests showed that there were significant differences between secondary care 
doctors and nurses (adjusted p=0.026), with lower median scores for the former 
(indicating lower agreement with the statement).  
8.1.4 Mechanisms of impact 
8.1.4.1 Mechanism 1. DCE strategies were in line with what professionals 
perceived as their role, identity, organisational commitment and 
professional boundaries  
Most participants (77.4%) agreed to a certain extent that it was part of their job to be 
involved in the DCE Programme (Figure 8.9). There were no statistically significant 
variations across groups. 
Figure 8.9. DCE and the professionals’ role 
 
The higher the median scores, the higher the agreement with the statement. Missing 
data: n=2 (1 don’t know, 1 not applicable) 
When asked about integrating DCE components into their usual work, most 
participants (86.8%) stated that it was difficult to do so to a certain extent. Challenges 
were particularly evident for the education sessions (71.4%), and less so for the bowel 
screening initiative (44.0%) (Figure 8.10). There were no statistically significant 
relationships. 
Figure 8.10. Challenges integrating DCE components into usual work 
Low median scores indicate stronger agreement that it was difficult to integrate DCE 
components into usual work. Missing data: education sessions (n=32; 5 don’t know, 13 
question not applicable, 14 section not applicable); HEAT targets (n=29; 8 don’t know, 
3 question not applicable, 18 section not applicable); bowel screening initiative (n=35; 
4 question not applicable, 31 section not applicable) 
90% 60% 30% 0% 30% 60% 90%
It was part of my job to be involved in DCE
(n=51)
1 (strongly disagree) 2 3 4 5 6 7 (strongly agree)
median 6
(IQR 5-7)
90% 60% 30% 0% 30% 60% 90%
It was difficult to integrate the bowel
screening initiative with my usual work (n=18)
It was difficult to integrate meeting HEAT
targets with my usual work (n=24)
It was difficult to integrate the education
sessions with my usual work (n=21)
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8.1.4.2 Mechanism 2. Additional DCE funding resulted in more diagnostic 
equipment and/or workforce 
Most participants disagreed to a certain extent that additional funding resulted in more 
diagnostic equipment (83.4%) and workforce (73.4%) (Figure 8.11). 
Figure 8.11. Additional funding 
 
The higher the median scores, the higher the agreement with the statement. Missing 
data: n=23 for each; 9 don’t know, 2 question not applicable, 12 section not applicable 
Most (66.6%) also disagreed to a certain extent that they were confident about their 
ability to manage demand when informed about additional funding (Figure 8.12).  
Figure 8.12. Confidence about being able to manage demand 
 
The higher the median scores, the higher the agreement with the statement. Missing 
data: (n=20; 4 don’t know, 4 question not applicable, 12 section not applicable). 
There were significant variations depending on job role and tumour type (Box 8.4) 
Box 8.4. Bivariate analysis results: funding 
Median scores for the question about additional funding resulting in more equipment for 
diagnosis varied across job role (H(3)=9.942, p=0.019) and tumour type (H(4)=10.096, 
p=0.039). Post-hoc tests showed: 
- significant differences between secondary care doctor and nurse (adjusted p=0.024), with 
lower median scores for the former 
- no significant differences between any pairs of tumour types 
Median scores for the question on whether stakeholder was confident about the team being 
able to manage demand varied according to job role (H(3)=8.875, p=0.031) – post-hoc tests 
did not find significant differences between any pairs of job roles 
90% 70% 50% 30% 10% 10% 30% 50% 70% 90%
Resulted in more equipment for
diagnosis (n=30)
Resulted in more workforce for
diagnosis (n=30)





90% 70% 50% 30% 10% 10% 30% 50% 70% 90%
Confidence about team being able to manage demand for screening 
and diagnostics when informed about the funding (n=33)
1 (strongly disagree) 2 3 4 5 6 7 (strongly agree)
median 2
(IQR 1-4)
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8.1.4.3 Mechanism 3. Increased demand brought by DCE was a driver for 
action and created pressure to act 
When asked about the programme overall, most participants (92.6%) stated that DCE 
increased demand for services. The majority of them also reported that the increased 
demand did not drive the development of early detection strategies (Figure 8.13) 
Figure 8.13. Whether DCE increased demand for services 
 
ED: early detection. Missing data: whether DCE increased demand (n=3, 1 don’t known, 
2 question not applicable), whether increased demand led to development of strategies 
(n=17; 1 other, 1 don’t know, 6 question not applicable, 1 no response). 
Similarly, most participants stated that the awareness campaigns (94.9%), the 
updated referral guidelines (80.6%) and the bowel screening initiative (81.3%) 
increased demand for services (Figure 8.14). There were no statistically significant 
relationships. 
Figure 8.14. Whether DCE activities increased demand for services 
   
Missing data: awareness campaigns (n=14; 1 don’t know, 3 question not applicable, 10 
section not applicable); updated referral guidelines (n=17; 8 don’t know, 2 question not 
applicable, 7 section not applicable); and bowel screening initiative (n=37; 3 don’t know, 









Did the increased demand drive the 
development of ED strategies? (n=36)






Did the public awareness 






Did the updated referral 






Did the bowel screening 
initiative increase demand for 
services? (n=16)
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8.1.4.4 Mechanism 4. Targets helped to focus the mind, showed where 
resources were needed and increased pressure to act 
Most participants (63.7%) agreed to a certain extent that they were confident in their 
ability to meet QOF targets. The situation was different for the HEAT targets (53.8% 
disagreed to a certain extent) (Figure 8.15). 
Figure 8.15. Confidence in the ability to meet targets 
 
The higher the median scores, the higher the agreement with the statement. Missing 
data: confidence in the ability to be awarded QOF points (n=42; 4 don’t know, 7 question 
not applicable, 31 section not applicable); confidence in the ability to meet HEAT targets 
(n=27; 7 don’t know, 2 question not applicable, 18 section not applicable) 
Views were less contrasting for whether targets pressured the team to act, with the 
same median scores for the HEAT targets and the bowel screening initiative (Figure 
8.16) 
Figure 8.16. Pressure to act 
 
The higher the median scores, the higher the agreement with the statement. Missing 
data: HEAT targets pressured team to act (n=28; 8 don’t know, 2 question not 
applicable, 18 section not applicable); bowel screening initiative pressured team to act 
(n=35; 1 don’t know, 3 question not applicable, 31 section not applicable) 
Finally, most participants (62.9%) disagreed to a certain extent with the statement that 
HEAT targets worked as a reminder for where efforts should be focused. The 
90% 70% 50% 30% 10% 10% 30% 50% 70% 90%
Confidence in the ability to meet HEAT targets
(n=26)
Confidence in the ability to be awarded QOF
points (n=11)





90% 70% 50% 30% 10% 10% 30% 50% 70% 90%
Bowel screening initiative pressured our team
to act (n=18)
HEAT targets pressured our team to act
(n=25)
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proportion was much lower (36.8%) for the bowel screening initiative, with 41.3% of 
participants agreeing with the statement to a certain extent (Figure 8.17). 
Figure 8.17. Reminder on where to focus efforts 
 
The higher the median scores, the higher the agreement with the statement. Missing 
data: HEAT targets worked as a reminder (n=26; 6 don’t know, 2 question not applicable, 
18 section not applicable), bowel screening initiative worked as a reminder (n=34; 1 
don’t know, 2 question not applicable, 31 section not applicable) 
8.1.5 Content analysis 
Over two-thirds of questionnaire participants (n=37) completed one or more open-
ended questions (median 4 comments per participant; range 1-16 comments per 
participant). There were 175 comments, and all were included in the content analysis 
(Table 8.2). 
Table 8.2. Themes derived from content analysis 







A1: Stakeholder buy-in 
Confirmed by stakeholders 




A2. Enough targeting and communication 
Confirmed by stakeholders 




A3. Available resources were sufficient to meet aims 
Not confirmed by stakeholders 
 
17 
A4. Flexibility when using resources 
Confirmed by stakeholders 










M1. DCE in line with the professionals’ role and organisational commitment 
Not confirmed by stakeholders 
 
2 
M2. Additional DCE funding resulted in more diagnostic equipment/workforce 
Confirmed by stakeholders 




M3. Increased demand was a driver for action and created pressure to act 
Confirmed by stakeholders 
 
7 
M4. Targets helped to focus the mind and increased pressure to act 
Not confirmed by stakeholders 
 
5 
90% 70% 50% 30% 10% 10% 30% 50% 70% 90%
The bowel screening initiative worked as a
reminder for where efforts should be focused
(n=19)
HEAT targets worked as a reminder for where
efforts should be focused (n=27)
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NHS challenges (recruitment challenges, stretched resources) 
Early detection challenges (overdiagnosis, overtreatment, fear, poor awareness) 






Consistency in data recording, good quality data, digital data for bowel screening 
Good leadership, management and teamwork 
Ability to plan for changes and demand 
Having an open, transparent process and ‘attempt’ to share learning 














Negative impact for other patients in need of care and for other performance 
targets 
Inappropriate referrals 
Negative impact for professionals (stress, burn-out and anxiety) 
Fears of over diagnosing the worried well 
















References to DCE official outcomes 
Comments on official DCE objectives perceived to be met 
Comments on positive service changes brought by DCE 
Comments on how DCE did not lead to positive service changes 






Views on other DCE processes not covered by assumptions and mechanisms 
Impact on service provision and workload 
Increasing numbers of worried well seeking reassurance 







Better planning, more time to plan and better communication 
Target different tumour types or population groups 
Focus on breast screening as it is effective; symptoms indicate late disease 
Consider the whole cancer pathway, have diagnostic clinics and direct GP access 
to diagnostics 
Review the HEAT targets (e.g. use a QI approach instead) 
Have ongoing campaigns instead of short bursts of activity 











References to previous questions, statements about questions not being 
applicable, feedback to the researcher 
12 
As one comment may refer to more than one theme, sums add up to more than 175. 
Open-ended comments provided further evidence on investigated assumptions and 
mechanisms. Furthermore, they provided evidence on barriers and facilitators, 
unanticipated outcomes and other process issues. 
8.1.5.1 Content analysis: implementation assumptions 
Elicited implementation assumptions were more often not confirmed by stakeholders. 
Comments shed light on the reasons why views on DCE appropriateness and 
sustainability were mixed. Stakeholders stated that although they agreed with DCE’s 
premise of promoting early detection, raising public awareness and educating 
professionals, there were several DCE approaches perceived not to be appropriate 
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(such as the focus on breast symptoms or the targeted tumour types). Other criticisms 
referred to campaigns with timings coinciding with other awareness events and 
reaching populations with a very low cancer risk. In terms of sustainability, one 
participant stated that DCE remained in their cancer strategy, another argued that 
non-recurring funding was “fairly pointless” as a long-term strategy, and others 
believed that changes needed to be made so the programme was accepted in the 
long-term. 
Closed-ended questions highlighted that a substantial proportion of stakeholders 
would have liked to have had more input about the programme, and levels of 
information varied according to different DCE strategies. Comments also referred to 
the ability to give input. Participants appreciated when experts were heard and 
complained about not being asked for their views, and about giving their input and not 
having it considered. Others complained about not being fully informed about DCE, 
the scale of the campaigns and their likely impact, or about delays in receiving 
information. Some were not aware of the education sessions for GPs, the HEAT 
targets, nor the additional funding provided. Three participants did not know that DCE 
had continued after 2015. Concerns about now knowing about DCE outcomes were 
also common. Those who started working when DCE was already ongoing 
complained about challenges regarding handover. 
There was only one closed-ended question about assumption 3 (DCE resources 
being sufficient to meet aims), and it focused on the professional’s time (with most 
disagreeing that time was sufficient). Comments, on the other hand, focused on 
workforce and physical resources. Stakeholders emphasised that existing resources 
were limited and stated that DCE stretched resources to maximum or unsustainable 
levels (with the service “near to collapse”). Some areas ran evening and weekend 
clinics to “get things back under control”, with perceived impact on services and staff’s 
wellbeing, often without extra resources to deal with demand. 
Finally, closed-ended questions showed that most stakeholders disagreed that they 
had flexibility to make changes in order to meet DCE aims. Comments highlighted 
several complaints from areas reported to having received no funding in different 
Health Boards (including endoscopy, pathology, staff at the “shop floor”, symptomatic 
breast screening, primary care and other clinical teams). One stakeholder reported to 
be pleased that funding could be used in line with their local work. Illustrative quotes 
for implementation assumptions are shown in Figure 8.18. 
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Figure 8.18. Illustrative quotes: implementation assumptions 
 
8.1.5.2 Content analysis: mechanisms 
Elicited mechanisms were often not confirmed by stakeholders in open-ended 
comments.  
Results from closed-ended questions showed how professionals often agreed to a 
certain extent that it was part of their job to be involved in the DCE Programme, but 
there were issues when integrating DCE components into usual work. Comments 
highlighted the role of competing responsibilities, and the fact that the HEAT target 
was not a clinical measure. 
In closed-ended questions stakeholders reported disagreement with the statement 
that funding resulted in more equipment and workforce and were often not confident 
about their ability to manage demand. Most comments referred to not being aware of 
funding, or to funding not being sufficient (especially in a scenario where qualified 
professionals were not available). However, two stakeholders reported cases in which 
funding provided benefits; one of them stated that the “funding rightly ensured that 
diagnostics were sufficient”. 
Similar to closed-ended questions, stakeholder comments highlighted that DCE 
increased demand for services. Comments also highlighted how DCE drove action. 
Increase in demand led to recruitment of specialist staff and training of non-medical 
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staff to perform colonoscopies; and stimulated focus on diagnostic capacity. However, 
demand also led to increased waiting times and stress, although at times the 
experience was used to make changes to improve services. 
Finally, comments reiterated disagreement with the role of targets. Stakeholders 
argued that external targets were not needed as they already knew where “efforts 
should be focussed”. HEAT targets were described as “unhelpful”, “unrealistic”, and 
requiring review, and different approaches were suggested. Illustrative quotes for 
mechanisms of impact are available (Figure 8.19). 
Figure 8.19. Illustrative quotes: mechanisms of impact 
 
8.1.5.3 Barriers and facilitators 
Barriers and facilitators were only approached in open-ended questions. Stakeholders 
acknowledged that stretched diagnostic capacity and limited workforce pre-dated 
DCE. Persisting early detection challenges such as cancer fear, lack of knowledge 
and/or awareness among more deprived communities, over investigations and 
overdiagnosis were also mentioned. Some recognised that “there is NOT a one size 
fits all for cancer”. 
Having good quality data, being consistent when recording cancer staging data and 
having electronic results for bowel screening were some of the facilitators described 
by participants. Having a designated lead and receiving advice about the programme 
early on, good teamwork, and being able to plan and share learning were also 
highlighted. One participant referred to the fact that bowel screening was an evidence-
based early detection method (Figure 8.20). 
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Figure 8.20. Illustrative quotes: barriers and facilitators 
 
8.1.5.4 Unanticipated outcomes 
Participants referred to increasing numbers of “inappropriate referrals” attributed to 
reasons driven by DCE: both following/not following referral guidelines; the worried 
well seeking reassurance from professionals; and GPs’ attempts to get patients seen 
quickly. Consequences described included delays for patients requiring surveillance 
or patients with cancer, and impact on other performance targets. There were also 
reports on negative impact on staff well-being (including stress and burn-out). Some 
participants raised concerns about overdiagnosing the worried well. Finally, some 
stated that the symptomatic approach for breast cancer led to patients presenting at 
later instead of earlier stages (Figure 8.21). 
Figure 8.21. Illustrative quotes: unanticipated outcomes 
 
8.1.5.5 Other issues raised by questionnaire participants 
Open-ended comments also referred to issues not covered by the investigated 
assumptions and mechanisms. Stakeholders highlighted not being aware of changes 
brought by DCE and wished to know more about its outcomes. Many stated that DCE 
did not result in more cancers being diagnosed earlier; some reported that they did 
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not see any changes in practice. Some stated that planning on how to deal with DCE 
impact was limited or underestimated and complained about DCE’s impact on 
workload (Figure 8.22).  
Figure 8.22. Illustrative quotes: views on DCE outcomes and other process issues 
 
Finally, stakeholders provided a range of recommendations. These included more 
planning (with better communication and multidisciplinary discussions), early advice 
about DCE initiatives and more time to prepare bids for funding. Some recommended 
focusing on breast screening, others suggested DCE focused on tumour types for 
which there were no screening programmes or for which there was a “greater chance 
of influencing behaviour” (no examples were given). Some suggested targeting 
patients at risk of lung cancer (e.g. “annual low dose CT of the chest for smokers” or 
having “direct access for GP to CTs”). Others recommended targeting more deprived 
populations through education and information. Two participants recommended that 
a QI approach replaced the HEAT targets. One participant recommended the 
establishment of a clinic for patients with vague symptoms, while others commented 
on the importance of looking at the whole cancer pathway (Figure 8.23).  
Figure 8.23. Illustrative quotes: recommendations 
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8.2 Summary of Chapter 8 
This chapter described the results from the questionnaire survey, one of the 
components of the DCE profess evaluation. Key findings are summarised below. 
8.2.1 Implementation assumptions 
Stakeholder buy-in varied according to DCE strategies, with the bowel screening 
initiative seen more positively compared to other DCE strategies. Support for DCE 
continuation was limited. Involvement in programme development was associated 
with stakeholder buy-in. Nonetheless, a substantial proportion of stakeholders was 
happy not to be involved.  
Perceived sufficiency of information varied according to DCE strategies. There was 
often disagreement with the statement that communication went well between primary 
and secondary care when using funding, with secondary care doctors showing higher 
levels of disagreement. Those working in secondary care also more often reported 
not being sufficiently informed about DCE strategies.  
Stakeholders often disagreed that time was sufficient to engage with the programme. 
Those who wished they had had further input in DCE had higher levels of 
disagreement about time being sufficient. Comments highlighted that there were also 
issues regarding limited resources and workforce. 
Most stakeholders disagreed about having flexibility on how to use funding, with 
secondary care doctors having higher levels of disagreement compared to nurses.  
8.2.2 Mechanisms of impact 
Stakeholders often agreed that it was part of their role to be involved in the 
programme. However, they also often disagreed that it was easy to integrate DCE 
components into their usual work and reported on competing responsibilities.  
There was often disagreement that additional funding resulted in more diagnostic 
capacity. Comments indicated that funding did not reach all relevant areas or 
departments. Secondary care doctors had higher levels of disagreement with the 
statement that funding was sufficient (compared to nurses). A substantial proportion 
of stakeholders disagreed they were confident about being able to manage demand. 
There was agreement that DCE increased demand for services, but this did not 
necessarily drive the development of early detection strategies. Impact on workload 
was often described as a negative experience. 
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Stakeholders were more confident about their ability to meet targets for the bowel 
screening initiative compared to HEAT targets. Views were mixed over whether 
targets pressured the team to act. There was often disagreement that HEAT targets 
reminded professionals of where efforts should be focused. 
8.2.3 Barriers and facilitators, and unanticipated outcomes 
Shortage of professionals, competing responsibilities and persisting early detection 
challenges were some of the barriers mentioned. Facilitators included good quality 
data, good IT resources, good management and early planning. 
Unanticipated outcomes included delays for other patients, impact on performance 
targets, risk of overdiagnosis, patients presenting late instead of early, and stress and 
anxiety for professionals. 
8.2.4 Other issues raised by stakeholders 
Stakeholders reported wanting to know more about DCE outcomes. They also 
described additional process issues (such as planning not being appropriate). Finally, 
stakeholders provided a series of recommendations for the programme. These 
included targeting other tumour types and population groups, focusing on the whole 
cancer pathway and better planning. 
In sum, questionnaire results indicated that stakeholders agreed with being involved 
in promoting early detection but buy-in varied according to involvement in the 
programme and different DCE strategies. There were issues regarding 
communication, and time to engage with strategies was limited. Funding did not reach 
all required areas and was often not sufficient to result in more diagnostic resources. 
Demand had a negative impact on workload, and at times on professional well-being. 
The increase in worried well seeking help was a reason for concern. Targets did not 
necessarily drive action nor showed where efforts should be focused. 
The next Chapter describes the results from the second component of the process 
evaluation, i.e. stakeholder interviews. 
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Chapter 9 Results: Process evaluation 
(Interviews) 
9.1 Overview 
This Chapter describes the results from stakeholder interviews carried out as part of 
the process evaluation of the DCE programme. The process evaluation aimed to 
investigate assumptions regarding implementation, mechanisms of impact, barriers 
and facilitators, and unanticipated outcomes.  
9.2 Recruitment 
Interview recruitment was carried out in two waves; in the first wave 20 potential 
participants were invited and 12 interviews were carried out. In the second wave, 27 
potential participants were invited and 11 took part. Interview participants also 
recommended three additional stakeholders, and all were interviewed (Figure 9.1).  
Figure 9.1. Interview recruitment flowchart 
 
In total, 26 interviews were carried out between January and July 2018. One of them 
was excluded from analysis as during the interview it became clear that the participant 
did not meet eligibility criteria (i.e. s/he had been involved in DCE only after 2015). 
Nonetheless, the interview provided relevant background information that was useful 
in subsequent interviews; it also helped to inform discussions in Chapter 10.  
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Sixteen stakeholders were interviewed face-to-face and nine over the telephone. Two 
stakeholders were interviewed in a single telephone call; the other stakeholders were 
interviewed individually. Face-to-face interviews were carried out at the stakeholders’ 
workplaces (offices, meeting rooms, cafeterias or empty hospital rooms), coffee 
shops, and a meeting room at the University of Edinburgh. Interview duration ranged 
from 17 to 79 minutes (mean 48 minutes). 
9.3 Characteristics of interview participants 
No individual-level stakeholder characteristics are described in order to avoid direct 
or indirect identification. Most stakeholders managed health care services or DCE 
strategies; 10 territorial Health Boards were represented (Figure 9.2).  
Figure 9.2. Interview participants 
1Charities targeted bowel cancer, lung cancer and all tumour types. 2All primary care 
professionals were GPs, some were also GP leads or Clinical leads. Secondary care 
professionals worked in respiratory care and urology. 3Included DCE managers and 
those managing NHS services (i.e. Access; Imaging, Public Health, Policy, Screening, 
and Strategy). 
9.4 Interview results 
Data analysis was done iteratively, revisiting and refining emerging themes, in 
discussion with my lead supervisor (Dr Christine Campbell). Interview findings were 
categorised according to 1) process (stakeholder buy-in, communication, DCE and 
the professionals’ roles, using DCE funding, impact on workload, and partnerships 
and collaborations); 2) outcomes (official DCE outcomes and soft outcomes and other 
benefits); 3) overlapped processes and outcomes (flexibility as a two-edged sword, 
unanticipated outcomes, and recommendations); and 4) contextual issues (barriers, 
facilitators, a government initiative, cultural shifts, regional variation, and DCE beyond 
three years) (Figure 9.3). Definitions for themes are available in Appendix 37. 
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Figure 9.3. Interview themes 
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9.4.1 Theme: Stakeholder buy-in 
9.4.1.1 Support for core aim 
Overall, stakeholders supported DCE’s premise to promote early detection and 
believed it was a worthwhile initiative. They recognised that early detection was 
important, and that Scotland’s cancer outcomes could be improved. Some openly 
acknowledged that reasons for disagreement were about how to promote early 
diagnosis, but not about the programme’s overall aim. 
“I think the focus as well, everyone agrees that we want to try and 
diagnose people at an earlier stage, you know, where differences 
of opinion lay was perhaps how best to go about doing that […] 
but I think the actual underlying ethos people supported. So, I 
think that was having a focus on trying to up our game around 
early detection I think was helpful, I think most people bought into 
that” (ID 34) 
Nonetheless, there were reports that the “enthusiasm” about the programme and its 
activities varied according to specialist interest in cancer diagnosis or level of 
engagement of lead primary care clinician/lead cancer GP in each Health Board.  
Buy-in was also described as being influenced by the perception over whether DCE 
would result in improvements in service provision. 
“In the broader picture, you know, early intervention means people 
live longer and better and have more effective treatment, you 
know, so in principle obviously there's sign up to that but I'm not 
sure if there was that sense 'well this will help us do our jobs 
better, this will improve the system'”.(ID 31) 
9.4.1.2 Early detection approaches and chosen tumour types  
Stakeholder views were mixed over whether the programme should have focused on 
screening or early diagnosis of symptomatic patients, and similarly on which tumour 
types should have been targeted.  
Focusing on screening was viewed favourably as evidence shows it is effective to 
identify cancer at earlier stages. If there was a screening programme in Scotland (i.e. 
for bowel or breast cancer), concerns were raised when campaigns focused on 
symptoms, either because of fears that the health system would not be able to cope, 
or because symptoms in these cases often indicated late stage disease. Similarly, 
there were concerns about highlighting lung cancer symptoms (there is no screening 
programme for lung cancer in Scotland) as lung cancer is often asymptomatic in its 
early stages.  
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Conversely, other stakeholders believed that the programme should have focused on 
tumour types for which there were no screening programmes in order to improve 
outcomes for them.  Informing the population about cancer signs and symptoms was 
also considered to be important to increase awareness and potentially reduce 
inequalities. 
 “The clinicians and managers were unhappy with the focus on 
signs and symptoms, but I think that we’re doing our population a 
disservice if we don’t make sure that the population understands 
the signs and symptoms. Those people who are well educated it’s 
a no brainer to them, but there’s a lot of people […] So I think that 
part is really important, and it tackles inequalities (ID 30) 
Prostate cancer was often mentioned as a tumour type that should have been 
included in the programme (stakeholders did not specify how they believed this should 
have been done). However, professionals working in urology disagreed with including 
prostate cancer for many reasons, including the fact that urology services were 
already struggling to cope with demand, and issues with overdiagnosing and 
overtreating patients. 
While some stakeholders believed that the DCE’s tumour choices (breast, bowel and 
lung) were “sensible and pragmatic” as they were the most prevalent in Scotland, 
others were frustrated that their tumours of choice were not included (despite 
perceived promises that this would happen over time). 
9.4.1.3 Feedback on different strategies 
The process of updating the Scottish referral guidelines for suspected cancer was 
widely accepted by stakeholders, as there was an Independent Chair, consensus 
from experts (described as very “labour intensive”) and use of evidence. The process 
was also described as a less complex procedure than the one carried out by the 
equivalent NICE guidelines in England. However, some were concerned about the 
guidelines’ low yield, the fact that they did not identify early stages for some tumour 
types, and that too many patients met referral criteria. There was recognition that not 
all professionals used the guidelines (or used them in the same way), and that buy-in 
was lower among secondary care professionals. 
“Cancer guidelines are quite helpful but the yield from cancer 
guidelines is not incredibly... it's not as good as you get from 
screening programmes, and the other problem is that the stage at 
which you might identify them through symptoms is obviously 
going to be later.” (ID 30) 
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Views on the bowel screening initiative were always positive. It was considered to be 
a good use of primary care and DCE money. Reasons for buy-in were also described. 
The incentive for improvement was clear, general practices developed their own plans 
on how to improve bowel screening uptake (influencing their sense of ownership 
about the initiative) and often could see the result of their activities (such as change 
in uptake or local cases of bowel cancers being diagnosed). 
“I think it just seemed to catch their imagination, their enthusiasm 
actually, the fact that a lot of enhanced services that they do, I 
think they often think 'I'm actually not really very sure why we're 
doing this and how this is going to help' but for a lot of practices 
they're looking at it and thinking 'actually, d'you know, you can see 
why we're doing this' and practices would be feeding back to us 
about 'actually we had somebody who wasn’t going to do their 
bowel screening and they did and they did have cancer'” (ID 17) 
However, there was also disappointment when the initiative ended after two years, 
especially since the first year was dedicated to planning and implementation, and 
there were delays for practices in terms of receiving data on non-responders. In most 
cases, activities related to the strategy also ended after two years. 
“QOF was very much to be encouraged, I was very disappointed to 
see after it being there for basically the two years, the year for planning 
and the year for delivery, for then the money just disappeared again. 
[…] There's a timing involved in that for a member of staff and 
practices have to make a business decision at that point, you know, if 
we are going to encourage two or three people or four people or five 
people to screen but it's taken us 52 weeks to do it” (ID 13) 
Stakeholders often shared their views on the social marketing campaigns. They were 
generally liked, described as “clever”, “well made”, and (more often than not) 
necessary in order to increase population knowledge and awareness. However, there 
were reports of disagreements between health care professionals and the social 
marketing team. Some wished that the marketing team had spent more time getting 
clinical buy-in as this could have had a positive impact on stakeholder engagement 
and sense of ownership and could potentially have resulted in more effective 
strategies. Others believed that DCE money could have been invested in other areas 
instead of campaigns (such as other early detection initiatives in primary care). 
“I think where things were perhaps not so successful was the kind 
of... I'm using management guru nonsense terminology but a 
whole systems approach, so the kind of responsibility and 
ownership for the campaign sat with DCE and I think there was an 
element where, if you like, both the primary care but also the 
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diagnostic services didn't really engage with it as an opportunity to 
look at 'right how can we get more of the most likely people 
through our doors and into early diagnosis and what do we need 
to do to the service to make that easier?' so I think there was more 
focus on trying to get the right people through the same front door, 
rather than going 'is this the best shape, size, location for the front 
door'. (ID 31) 
The bowel cancer campaign was described as having “the right level of humour” and 
was praised for targeting more deprived populations. The symptomatic breast 
campaign had lower clinical support due to concerns over its impact on workload. The 
breast screening campaigns had limited acceptance from clinicians who did not 
perceive breast screening to be an appropriate early detection method.  
The lung cancer campaign was described as “powerful”, with a respected, non-
judgemental public figure. However, there were concerns about using the term “3-
week cough” (as it is common for patients with chronic obstructive pulmonary disease) 
and having campaigns during wintertime (when the flu and colds are more prevalent 
resulting in persistent cough for many patients).  
“There was certainly sometimes where we launched lung cancer 
campaign or had lung cancer pushes, kind of in the winter months 
when you'd expect an increase in people presenting with coughs 
and colds, and coughs was the kind of symptoms that the 
campaign was highlighting.  So, I think people understood the 
nature of the campaign and the rationale for it, but the timing 
perhaps was a bit of an issue coinciding with winter months and 
upper respiratory tract infections” (ID 34) 
9.4.1.4 Performance targets 
In principle, stakeholders were not averse to having targets, as they served the 
purpose of focusing minds, indicated what to measure, set a level/standard and 
helped to show what stakeholders should aim for. However, several limitations of 
using targets were described: the need for sustained funding so they could continue 
working (as professionals have other jobs to do); the need to carefully choose the 
target to ensure that the right things are being measured; the fact that targets become 
repetitive and over time require a lot of work for very small returns; and the risk of 
missing important outcomes by focusing on a very specific target. 
Stakeholders referred to both DCE performance targets: QOF and HEAT. QOF was 
described as a clear incentive for improvement that provided GPs with a sense of 
ownership and facilitated engagement. As for the HEAT targets, stakeholders widely 
acknowledged that they were unlikely to be achieved. Some believed that the 
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“unrealistic” targets resulted in limited engagement and sense of ownership, caused 
frustration and perplexity. Others were unsure if the targets were the right measure, 
and whether they were clinically relevant. Finally, some wished the targets had been 
designed using data that were already available (as new data had to be collected in 
order to assess performance). 
“Right away it seemed like a figure that would not be achievable.  
So, for some people it was then well 'we'll just keep on doing what 
we're doing anyway because we're not going to be able to have 
that big an influence'” (ID 15) 
“Well the 25%, I think a number of boards have been challenged 
around that figure, hugely challenged around that figure, and that 
maybe [it] wasn’t the right measure? So where's the learning 
around all of that as well and how do people think that the next 
time there's possibly an initiative that is hugely well intentioned 
and based on lots of really good and sound principles, but how do 
we make sure that we do that in a better way that gets the right 
support and is seen as a clinically important and meaningful thing 
as opposed to something that we're never going to achieve and 
therefore we didn't hit 25% so what does that mean?” (ID 20) 
Other stakeholders believed that the ambitious target was needed to generate 
change. For them, the target was inspiring, aspirational, in order to push boundaries. 
Stakeholders from charities reported being comfortable with such targets as they were 
used to having them. Those managing DCE strategies emphasised that there was 
much more to DCE than the aspirational targets. 
“That was always an over ambitious aim in my mind but 
sometimes you need to be over ambitious to actually pull the curve 
to the left” (ID 13) 
Some stakeholders highlighted that, on a daily basis, healthcare professionals most 
likely did not worry about the HEAT targets, as they were likely “quite focused on the 
specific job at hand”. 
9.4.2 Theme: Communication 
9.4.2.1 Source of information 
Several stakeholders reported that they had had formal contact with DCE and were 
involved in developing some of its strategies, especially the referral guidelines, initial 
training sessions and the bowel screening initiative. Communication took a number of 
forms including emails, discussions in Cancer Boards and hospitals, letters, 
government circulars and meetings, in addition to government documentation. The 
DCE team visited Health Boards to meet stakeholders, and representatives from 
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different Boards were nominated to take part in specific DCE groups (often the 
Communications Group or the DCE Programme Board). There were bowel screening 
groups with representatives from primary and secondary care. Meetings/workshops 
about the referral guidelines were carried out in several locations across Scotland. 
Decisions from the DCE Programme Board were filtered to Health Boards, which then 
took different approaches on how to disseminate information (although Cancer Leads 
and Executive Leads were often involved).  
A stakeholder acknowledged that it was hard for GPs to find time to read everything 
in their Inbox, and unless they had a specific reason to search for DCE documents, it 
was likely that any communication “got lost among hundreds of circulars”.  
Stakeholders recognised that involvement in specific meetings and groups, or 
involvement in policymaking made a difference over whether they were aware of DCE 
strategies and the rationale for them. However, there was reported uncertainty 
regarding some DCE components even when stakeholders were more involved. 
9.4.2.2 Ongoing communication and timeliness 
Stakeholders reported that over time it became more difficult to follow information 
about the programme and act upon it, especially regarding the social marketing 
campaigns.  
“[W]e always got information as a Board but it got a little bit more 
difficult to follow I guess as the social marketing programme 
matured and started to try different things […] I guess at the end of 
whatever it would've been going into year three we kind of ended 
up shrugging our shoulders saying, you know, I was pressing 
forward saying more radio adverts are going, more... but because 
they were stretched out over time it was something that we simply 
acknowledged rather than specifically planned for in all occasions” 
(ID 11) 
While groups more involved with DCE often believed that they had received “plenty 
of notice” about DCE and its strategies, others acknowledged that the same may not 
have been true for front line staff and primary and secondary care professionals. 
Several stakeholders complained about limited notice before campaigns and short 
campaign timelines. A “strict embargo” was reported for campaign materials, and this 
resulted in delays sending them.  As a result, it was difficult to support the activities 
and engage with the community. Gaps in information that resulted in “periods of 
guesswork” were also reported. 
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“Then I'd be saying 'right okay, so I've been to the communications 
group meeting, they've said they're going to do something about 
breast signs and symptoms so I'll be getting all the stuff out to 
you', and then it was just so badly organised that the campaign 
had suddenly hit the TV and somebody phoned me up and said 'I 
just seen it on TV' and I was like 'I don't have any resources for 
that'.  And then I looked stupid, then people thought that I was the 
one that hadn't done anything and you'd be getting posters a week 
later coming from the Scottish Government, the marketing team, 
and then some various things to put on websites and different 
things, all the images and stuff and, you know, email signature 
things you could do, but it was always after the fact” (ID 15) 
9.4.2.3 Rationale for strategies  
Stakeholders reported uncertainty over DCE’s rationale for a range of strategies. This 
was particularly salient for information on the groundwork informing the social 
marketing campaigns, and further explanations about the HEAT targets (such as how 
they were decided upon, and what they meant).  
 “That 25% figure, we sort of banged ourselves over the head with 
it for years and I probably shouldn’t say this, but it did feel like it 
had slightly been plucked from nowhere at the start.” (ID 24) 
9.4.2.4 Input from the healthcare community and charities 
Stakeholders gave examples of good communication between DCE and primary care 
professionals. Nonetheless, stakeholders often commented on the fact that decisions 
had often already been made when they were consulted (even in the case of early 
involvement). As a result, some stakeholders reported frustration and limited 
engagement from specialists, charities and health care professionals.  
“I think the other thing might have been better engagement with 
the clinical... and I'm sure people think they did do that and there's 
a level of how much you can but, you know, engagement with 
clinical teams about what did they think actually is important to do 
here, what actually if you had something and wanted to try and 
improve your detection rates around cancer, how do you do that in 
a way that's meaningful and is the way that we did it, was that the 
right way that we did it?” (ID 20) 
Those managing the DCE programme acknowledged the importance of having 
effective communication with stakeholders and keeping an open dialogue as this 
facilitated buy-in and engagement. However, they also discussed the challenges of 
balancing communication with getting the work done in a timely manner.  
“So we were always wanting that dialogue between the Boards and 
ourselves at a national perspective to be seamless […] you know, 
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getting them on board from very early, not too early mind you 
because it's a difficult balance I suppose cause you want stakeholder 
buy in, but at the same time it's realising that we're the experts in this 
area. Otherwise nothing will get done” (ID 25) 
9.4.2.5 Dissemination of DCE activities and outcomes 
There were suggestions from both DCE managers and other stakeholders that 
dissemination of activities could have been better managed, especially regarding 
sharing information from local activities, successful stories and best practice; and 
disseminating referral guidelines more widely to secondary care professionals.  
“I don't think that's necessarily always been as well communicated 
in terms of sharing good practice, so you know, if an area has 
done pilot projects for service redesign to make the front door 
bigger or wider or easier to access, the potential is that has benefit 
for services in other areas but I'm not sure how widely that has 
been shared”. (ID 31) 
DCE organised a Conference in 2016 to disseminate local and national activities, but 
stakeholders acknowledged that a single conference was not sufficient to disseminate 
all DCE activities to different audiences. 
9.4.3 Theme: DCE and the professionals’ roles 
9.4.3.1 Business as usual 
The DCE programme was often described as “business as usual” by stakeholders for 
several reasons. GPs could see their role in engaging with patients regarding bowel 
screening participation; lead Cancer GPs saw DCE activities as part of their core 
work; and screening coordinators were involved due to the nature of their jobs. Some 
participants described DCE as “just more work”. In a particular Board, DCE was seen 
as something to be embedded into core activities (in order to acknowledge the work 
of those already carrying out similar work and ensure sustainability). For those 
working at ISD Scotland, DCE activities related to health intelligence data were 
incorporated into their jobs.  
“In my lead cancer GP role, it was core work, it wasn’t extra work, it 
was what I was there to do, it was core work and it was positive and 
well-focused work.  I thought the project from a primary care 
perspective it was a useful project that helped my role as a lead 
cancer GP, gave some real focus that could have an impact”. (ID 23) 
9.4.3.2 Competing responsibilities and new tasks 
For other stakeholders, many other issues were also important, and time and 
resources were needed so they could be involved in DCE activities.  
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“So for example we run a local road show in our area and they 
wanted to provide some staff and we're happy to do that and staff are 
happy to support these things but if we don't get enough notice it's 
extremely difficult, we don't have people who are ready and waiting to 
down tools and go and run off and do a roadshow, we need to kind of 
free them up, so that presented difficulties” (ID 34) 
Furthermore, DCE also resulted in the need to have professionals assigned to new 
tasks/responsibilities; i.e. there was nobody “in the NHS whose job is to go to the 
bingo and engage with women”. 
9.4.4 Theme: Using DCE funding 
9.4.4.1 Allocation and variation 
In general, DCE funding was reported to being mostly allocated to secondary care, in 
order to deal with an expected increase in demand brought by the programme. 
Funding was invested in diagnostics (including colonoscopy, thoracoscopy, radiology, 
other machine and equipment, one-stop breast clinics); hiring professionals; treating 
patients; health intelligence and informatics; increasing GP sessions; surveying health 
care professionals and the public; and developing local community initiatives to 
increase population awareness of cancer signs and symptoms. Stakeholders 
acknowledged that without funding, many DCE-related activities would not have 
happened. Additional resources were needed and welcomed and helped to ease 
concerns about the programme impact on diagnostic capacity.  
Although funding was used for new activities and to deal with resource implications 
from the programme, there were also reports of money being used to fill already 
existing gaps, and to fund services that were under-resourced.  
“Other difficulties, problems... getting people to see the DCE 
actually as money that needed to be focused on changing the way 
things were dealt with in detecting early cancers rather than just 
being used as an extra pot of money to shore up a grossly under 
resourced service in total, and I think there were times when I was 
at meetings, both national level and board level, where secondary 
care were saying 'oh excellent here's £100,000 that's just what we 
need just to keep the ordinary service running” (ID 23) 
Some primary care professionals accepted that it was difficult to be allocated funding 
and recognised that it made sense to invest mostly in diagnostics. Others could not 
understand how allocation was decided in their Health Boards and wished there had 
been more transparency.  
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“Actually when it came to it there was this big round table 
discussion with all the clinicians and of course our bids, mine and 
the nurses' bids, were the bids that were put last on the list cause 
they were felt to be least relevant to be preferred to the money by 
the people who wouldn't really know anyway because their job 
isn't to do that bit of it!” (ID 27) 
While some stakeholders openly stated that funding was sufficient for what they 
wished to do, others stated that funding was less than what they expected and not 
enough to make all required changes. 
“Clinicians would still say that it wasn’t quite enough money to do 
the sort of changes that they would've wanted to have done and 
some of it still felt like sticking plaster”. (ID 19) 
A stakeholder commented on the fact that funding was diluted across different areas, 
and some areas (such as laboratories) ended up getting very little. Some stakeholders 
were frustrated as they believed that some Health Boards managed to benefit more 
from funding than others, which allowed them to develop novel initiatives (such as 
testing the qFIT with symptomatic patients). 
9.4.4.2 Funding is not necessarily the solution 
Stakeholders often highlighted that although funding was important, it did not 
necessarily solve diagnostic problems faced by Health Boards, such as shortage of 
radiologists or pathologists. For similar reasons, it was not always possible to use 
funding as initially intended. If there were no professionals available to be recruited, 
funding was used to pay for overtime work instead. 
 “I suppose many of our problems then and especially now are as 
a result of vacancies, long term vacancies where we haven't been 
able to recruit to established posts. So, we've probably had to use 
the money available in a less efficient way by having to pay 
members of staff overtime rates to cover posts that we might have 
filled in a different way and more efficient way”  (ID 34) 
Hiring professionals while also knowing that funding would not be available in the 
long-term was described as a challenge. There were reports of professionals only 
being able to stay for a couple of years, and more permanent staff having to absorb 
their roles when funding ended. 
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9.4.5 Theme: Impact on workload 
9.4.5.1 Impact of different strategies 
Stakeholders reported on the impact that DCE activities had on workload; these were 
particularly associated with social marketing campaigns (especially the symptomatic 
breast campaign). 
“To cut a long story short the outstanding additional activity 
pressure that we actually felt was in the breast pathway after the 
first Elaine C Smith campaign [breast symptomatic]” (ID 11) 
The impact of the symptomatic breast campaign was reported to have happened 
quickly, requiring drawing on resources from both symptomatic services and breast 
screening in order to get the required radiological support. Demand in breast clinics 
was reported to increase considerably. Stakeholders often stated that the campaign 
resulted in the system being flooded with the worried well, and this caused frustration 
among health care professionals. A stakeholder highlighted that the frustration was 
more due to the limited impact on cancer outcomes than due to the impact on 
workload. 
“I think the reward was not there for the work and that was for me 
the major difference. So, there was an enormous amount of 
activity, a lot of pressure on the service and the cancers didn't turn 
up.  I think if the cancers turned up then there wouldn't have been 
unhappiness […] We don't mind working hard and having a lot of 
activity if you see why” (ID 22) 
The bowel campaign was reported to result in an increase in demand for endoscopies 
(and a knock-on impact on pathology), with spikes during each campaign wave. Work 
was carried out with the Bowel Screening Centre to make sure they would be able to 
cope with increase in calls and returned bowel screening kits to their laboratory. 
Weekend working and overtime were also required. The bowel screening initiative 
also required extra work in order to provide information on non-responders to 
screening to each primary care practice. 
There were reports of increased anxiety among professionals when young people 
started to show up with post-viral cough after the lung cancer campaigns, and 
concerns over whether the right groups were being targeted.  
9.4.5.2 Unexpected impact 
While some stakeholders believed that the impact on workload was “entirely 
predictable” and short-lived, there was reported surprise from others when demand 
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increased during the campaigns. Some wished they had been better warned about 
the potential impact on workload. Those who had planned for the increase in demand 
often reported that the impact was higher than expected. 
Some Health Boards were able to put in additional resources for appointments, using 
resources they already had in place or obtained with additional funding provided by 
DCE. Others faced challenges as there was no funding left to deal with the demand. 
9.4.6 Theme: Partnerships and collaborations 
9.4.6.1 The role of charities 
Cancer charities were described not only as important collaborators/stakeholders, but 
also as leads in early detection strategies that were supported by DCE. For example, 
CRUK approached DCE regarding implementing the primary care facilitator 
programme in Scotland (it had already been implemented by the charity in England). 
CRUK worked directly with practices, and DCE supported the programme expansion 
into five other Health Boards.  
Relationships were reported to be driven by common aims (such as promoting early 
cancer detection, or even targeting cancer prevention) and the opportunity to share 
knowledge and expertise. Charities were able to gather outcome information on their 
own and prepare evaluation reports, although at times they had to rely on official 
health intelligence data.  
Charities could have a different relationship with health care professionals compared 
to the government (as they were able to have a more customised approach). 
Furthermore, charities had a different relationship with the public as they were a non-
governmental agency. 
“Is it more powerful if it seems as though it's coming from Cancer 
Research UK or a charity, there's a charity affiliation compared to 
the government speaking to you” (ID 25) 
As a result, charities were reported to facilitate the development and implementation 
of initiatives, and at times also ensured sustainability when DCE funding ended. 
Stakeholders (especially the ones at the government) were cognisant of the 
importance of having charity support and aimed to ensure that their input was 
obtained regarding DCE initiatives (thorough ongoing consultation, participation at 
Programme Board meetings and the Scottish Cancer Coalition). Those working in 
charities agreed that consultation took place at times, but some wished they had had 
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the opportunity to give more input (including expert advice on how to engage with 
communities in more deprived areas). 
 “The social marketing stuff and the coming with a done deal to 
people and saying 'this is what we're going to do' rather than 
letting the experts in the room have some sort of opinion and 
contribution to that as well.  So that was the one thing I really did 
want to get across and something that has been a continual 
problem” (ID 15) 
9.4.6.2 The role of creative and market research agencies 
Different agencies contributed with expert knowledge that the Scottish Government 
often lacked. This included insight gathering among the public, developing, testing 
and refining creative campaigns, evaluating and interpreting them. Different agencies 
had different roles, although they worked in coordination, with the Leith Agency 
working as the lead. 
Although agencies collected their own data and triangulated different data sources, 
they were also dependent on the government to provide them with data to help them 
understand the impact of social marketing activities. Data were not always available. 
While the Scottish Government and agencies worked in partnership, views on what 
constituted programme success varied. This was particularly evident regarding the 
symptomatic breast campaign, as from a social marketing perspective the outcomes 
were very positive (persistent results for increase in awareness and change in help-
seeking behaviour with more women presenting in primary care).  
“If it was the case that actually they just got a lot of worried well 
and they didn't find any more cases then that's fine, you know, 
that's a valid learning and reason not to do it, but it sounds terribly 
unacademic to say but intuitively it always felt like it didn't quite 
add up, and also had anecdotal stories of people from GPs and 
people we all know who'd been diagnosed as a result, and we 
used PR case studies of people who'd been diagnosed as a result, 
and yet all the feedback coming back was 'it's not working, it's not 
working, we'll never do it again'” (ID 24) 
Furthermore, there was reported frustration when calculations made by agencies 
showed that it would be virtually impossible to meet performance targets. 
9.4.6.3 The role of the media 
There were reports of both positive and negative interactions with the media. Although 
it helped to disseminate early detection messages, issues arose when the media and 
DCE had different interests. There were reports of the media criticising a DCE 
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campaign showing a GP at a “coughing” bus stop (to highlight lung cancer symptoms). 
Instead of encouraging readers with a cough to go see their GP, the emphasis was 
on the fact that “highly paid GPs” do not take the bus. 
Negative messages (e.g. reporting bad cancer experiences) were commonly reported 
by the media, and mixed messages were described to cause confusion among the 
public: while DCE campaigns focused on encouraging the public to seek help and 
attend screening, the media constantly reported that the NHS was struggling to cope. 
9.4.7 Theme: Official DCE outcomes 
9.4.7.1 Joining the dots 
Stakeholders widely acknowledged that it was complex and challenging to understand 
DCE impact on cancer outcomes. They reported uncertainty over attributing positive 
cancer outcomes to the programme, as other relevant activities were happening at 
the same time, and often it was not possible to determine exposure to DCE strategies. 
 “Okay you've got numbers yes, but we don't know whether these 
people who turned up and be staged even had any idea of the 
DCE programme” (ID 29) 
Understanding which DCE components contributed to changes was also described 
as a challenge, and so was the ability to evaluate all different activities. The 
challenges were not only due to their large number, but also due to their 
characteristics. For example, it was reportedly difficult to measure change in practice 
as a result of the new referral guidelines or change in behaviour after digital social 
marketing activities. Other reported limitations included challenges when trying to link 
intermediate and final outcomes (such as how increase in knowledge resulted in an 
early stage diagnosis). 
“It's very difficult to distil out what was the contract [bowel 
screening initiative], what was the adverts, what was the stuff that 
you were doing, what was the stuff that local NHS boards were 
doing, but I think it's we always talked about DCE being this whole 
systems approach so it's always going to be difficult to evaluate 
individual pieces of work” (ID 33) 
“The holy grail is where you've got a continuation of information, 
so we know that somebody saw the campaign, we know that 
somebody went to the GP, we know that that person was then 
referred on, we know they were diagnosed at an earlier stage and 
I think that... it's very, very hard to do that”  (ID 24)  
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9.4.7.2 Anecdotal evidence 
Stakeholders often referred to local, anecdotal evidence when discussing positive or 
negative programme outcomes. This was due to having limited knowledge of national 
outcome data (whether because it was not collected, had ceased to be collected, or 
because they were not aware of national data). Anecdotal data were commonly 
mentioned when discussing changes in cancers being diagnosed over time or 
specialist referrals. 
“I don't know if it's backed up, but I certainly feel like I do a whole 
load more chest x-rays now than I would've done previously” (ID 10) 
Stakeholders also believed that even small, local activities could have a long-term 
impact but acknowledged that maybe this would never be measured. 
9.4.7.3 Views on official outcomes 
Stakeholders talked about the positive impact of campaigns on knowledge and 
awareness, on presentation due to symptoms, and referrals for diagnostics. 
Stakeholders also discussed the large numbers of worried well patients seeking 
reassurance, the (often limited) impact on cancers being diagnosed, or cancers being 
diagnosed in earlier stages. Some believed that the limited perceived impact on 
staging was because symptoms are not necessarily associated with early stage 
detection. Others acknowledged that shifts would take a long time to be noticed. 
 “[C]hanging something like stage at diagnosis at population level, 
it's like turning an ocean liner, you know, it's very small increments 
if possible, but hopefully the liner won't suddenly just drift back to 
the original course and will have some lasting benefit in terms of 
people being less fearful of cancer, understanding how screening 
programmes work and taking up the opportunity”. (ID 16) 
There were reported improvements in staging for lung and breast cancers. 
Stakeholders were surprised when national data did not show improvements for 
bowel cancer, and possible explanations for this were discussed (e.g. screening found 
pre-invasive disease or removed polyps).  
The temporary effect of campaigns and the challenges of campaign wear out were 
also mentioned. The breast screening campaign was described as having had limited 
impact on shifts in staging, and this caused frustration. 
“Obviously when you look at the outcomes lung shows the biggest 
one, breast there's been good movement, sort of stage one/two, 
and there is some inequalities ones within those and the screening 
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outputs are frustrating cause you just look at the figures and it 
doesn't look like a huge amount has shifted” (ID 24) 
There were reported positive outcomes associated with the bowel screening initiative, 
such as high participation rates from primary care practices, and increase in 
requested kits. However, data were often anecdotal, increases were often described 
as temporary and did not necessarily translate into increase in uptake. Figures were 
also reported to have dropped after funding ended. There were criticisms towards a 
perceived limited evaluation of this initiative.  
“I don't think we capitalised enough on the learning from the 
contract initiative and we did feed that back, we didn't then bring it 
together and say 'X number of practices participated, X met the 
target and here's what they said in their action plans' cause we got 
detailed action plans from the practices, we never really captured 
that learning and built that into something and looked at it for other 
screening programmes or any of that kinda thing” (ID 12) 
9.4.8 Theme: Soft outcomes and other benefits 
9.4.8.1 A cumulative effect 
Stakeholders believed and expected that DCE would have a long-term impact on 
health-seeking behaviour and would contribute to long-term changes in cancer 
outcomes. Some gave examples of activities introduced as part of DCE that had 
continued after funding had ended. 
9.4.8.2 Changes in service provision 
Stakeholders reported on a range of changes in service provision. These included 
having more telephone consultations, discussing patient cases in meetings and 
reflecting upon diagnoses and referrals, developing new referral pathways and 
referral processes, and implementing one-stop clinics. They acknowledged that these 
changes were not solely due to DCE. 
Other perceived benefits included the development of a good practice guide for bowel 
screening (in collaboration with Cancer Research UK), the opportunity to access 
better data, put research into practice, and focus on inequalities; and new IT 
developments (such as referral guidelines added to computer systems, development 
of tools to access information on bowel screening non-responders, and being able to 
use electronic referrals). 
“In terms of positive things, I think the opportunity to get better 
data, the opportunity to put into place some of the things that 
people had been researching I think was really positive.  The 
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attention to this area was positive.  The focus that we had on 
inequalities was positive.  The ability to eventually get data for 
bowel screening, eventually get data on non-attendance and being 
able to do something about it.  The understanding that where we 
had issues with uptake of screening and different things we could 
do, the opportunity to work with groups of people to understand 
what the barriers were and to try and start to address them, all of 
those things were good.” (ID 19) 
Furthermore, some believed that DCE helped to re-establish communications 
between primary and secondary care; helped to make the linkage between cancer 
prevention, early diagnosis and the health care system; improved conversations 
between secondary care and the government; and united different stakeholders with 
an interest in early cancer detection. 
 “I think overall the campaign has added something, it's making 
that linkage both between prevention, early diagnosis and the 
healthcare system that responds to those people presenting, it's 
the longer term and bigger challenge for all of us” (ID 31) 
9.4.8.3 Opportunity to develop local activities 
Stakeholders described how DCE facilitated the development of a range of small 
activities, standalone projects and ideas that would not have been tested otherwise. 
These included engagement with local businesses/employers, work in deprived 
areas, activities with minority ethnic groups, engagement with pharmacists, surveys 
with health care professionals and the public, and a CPD session with health 
improvement professionals. 
9.4.8.4 Enhanced partnerships 
DCE was also reported to result in long-term projects with charity partners. It allowed 
for the CRUK facilitator programme to be implemented in Scotland, for prevention 
activities to be developed in partnership with the Teenage Cancer Trust, and for new 
partnerships with the media to be developed. 
9.4.8.5 Normalised discussions about cancer 
Stakeholders believed that DCE “got people talking” about early detection; and 
brought the topic to the centre of attention of the public and health care professionals. 
DCE was reported to help normalise discussions about cancer.  
“Yeah.  I think probably the biggest one and I think one that was 
really, really welcome and one of the great successes of the 
programme is the fact that it got people talking about cancer, and I 
think the information that was circulated at the time and 
subsequently in relation to about early diagnosis […] I think that 
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change and shift in public perception is probably really, really 
important” (ID 32) 
9.4.8.6 Measuring soft outcomes 
Stakeholders recognised the challenges of measuring soft outcomes. 
“Would we do a piece of activity, you know, that is a difficult thing 
with the roadshow, how do you measure that impact, you know, 
we get reports through and it's you know 'we handed out X 
number of leaflets and we engage with X many people and here's 
some lovely quotes that people have said'” (ID 25) 
9.4.9 Theme: Flexibility as a two-edged sword 
9.4.9.1 A “chameleon” programme 
Stakeholders managing DCE activities described the programme as a “chameleon” 
due to its flexibility regarding funded local and national activities, and its ability to 
adapt according to contextual changes. The programme targeted not only patients 
eligible for screening, but also the general public and those presenting with cancer 
symptoms and signs. Furthermore, DCE was involved in prevention activities, and 
over time increased its focus on addressing health inequalities. The programme tried 
to be as flexible as possible when providing funding to Health Boards, as it believed 
that different areas knew better about how to invest in capacity. 
“So I suppose it can be seen as a positive and a negative in terms 
of the programme in its flexibility and its... you know, we can put 
out messages tomorrow if we wanted to, depending on what 
happens today, we're like chameleons aren't we really, we're very 
adaptable, and in this current climate we have to be just that I 
suppose” (ID 25) 
Importantly, there were also reports of limited programme flexibility. This was the case 
for requesting to use and adapt campaign materials in local areas, due to copyright 
and embargo issues, and delays in distributing materials. 
9.4.9.2 Challenges brought by flexibility 
DCE flexibility was reported to make it difficult for a Health Board to decide on how to 
incorporate the programme into their work, as it did not fit within a specific structure. 
“I think it's some time it was where that line was about the DCE, is 
it within public health, cause if it's sat with the screening 
coordinators in the first place then it probably would've been a 
clearer route, but because it included different sites and it included 
just not screening population but the whole population, then it 
seemed to have arms and legs” (ID 29) 
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The flexibility when providing funding to Health Boards was also reported to result in 
limited ability to assess the local impact of the programme and ensure accountability 
from different Health Boards. 
“[W]hat we said was 'these are the five areas of work and it's up to 
you to prioritise your funding and where it goes' and we left boards 
to it. And then we went back on an annual basis to try and get an 
evaluation of what they spent the money on and that was hugely 
difficult to do. It was just like, it was almost like so difficult to get 
the accountability for the funding and where they spent it […]So if 
we were to do it again I think you probably would be more 
prescriptive to say 'this is where the funding should be sent to and 
actually give us your proposals of where you're putting that 
money” (ID 33) 
Stakeholders also commented on how the ability to be flexible could result in the 
programme becoming “piecemeal”. Comments focused particularly on the inclusion 
of prevention strategies into the programme. Stakeholders emphasised that DCE was 
an early detection strategy, even though it recognised the increasing importance of 
cancer prevention. They also acknowledged that prevention was a challenging area 
that would most likely need a programme of its own. 
9.4.10 Theme: Unanticipated outcomes 
Some stakeholders were concerned about conditions other than cancer being 
downgraded due to the need to urgently see patients with a suspected cancer, about 
patients who had high-risk cancer symptoms to be moved to the bottom of waiting 
lists due to increasing demand for diagnostics or about potentially slowing down 
cancer treatment for patients. 
Initial concerns about mobilising the worried well or patients with trivial symptoms to 
seek help were confirmed when demand for diagnostics increased, but no more 
cancers were diagnosed. Furthermore, the increase in demand resulted in the need 
to hire more specialist staff, and competition across Health Boards due to professional 
shortage in Scotland. The increase in demand was also reported to increase 
professional anxiety (due to fears that they would not be able to cope) and public 
anxiety (indicated by the large number of patients with a low risk of cancer seeking 
reassurance). 
A range of positive unanticipated outcomes were also reported; these included 
lessons learned from DCE informing other government campaigns; DCE’s strong 
focus on hard to reach groups being reflected on a new Cancer Strategy; the 
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development of a staff survey in a Health Board which showed that reluctance to see 
the doctor and limited knowledge of screening were not only an issue among the 
public; and the purchasing of a thoracoscopy machine that was useful to diagnose 
and treat patients with metastatic cancer and mesothelioma. Stakeholders also 
believed it was likely that the programme resulted in diagnosing conditions other than 
cancer (such as a patient with a persistent cough being diagnosed with COPD) and 
hoped that campaigns encouraging help-seeking resulted in the public seeking help 
for tumour types not included in the programme. 
9.4.11 Theme: Stakeholder recommendations 
9.4.11.1 Consider other early-diagnosis approaches 
Suggestions included implementing one-stop multi-diagnostic centres, piloting 
different strategies with direct access to diagnostics, focusing on tumour types for 
which early detection gives the best results (no examples were given), targeting 
patients at high-risk of lung cancer, involving other professionals (such as dentists) in 
early cancer detection, and focusing more on health improvement strategies.  
Some also believed that changes in the way GPs and the public interpreted early 
cancer symptoms were needed (highlighting the need for follow-up and to continue 
with help-seeking if symptoms persisted). 
9.4.11.2 Broader views: national umbrella and the whole cancer pathway 
Stakeholders believed it was important to keep DCE’s national umbrella (without 
stopping with local initiatives). They also highlighted that it was important to focus on 
the whole cancer pathway instead of only up to cancer diagnosis. 
9.4.11.3 Tackle health inequalities and inequities in access 
Stakeholders acknowledged the need to tackle health inequalities and recognised that 
the issue was beyond DCE. Recommendations included improvements in access, 
better supporting patients in more remote areas, investing on health literacy, and 
considering not only diagnostics but also treatment burden and risk of social isolation. 
Some described social deprivation as the biggest challenge to be tackled in other to 
make a substantial impact on public health. 
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9.4.11.4 Have good local and national data 
Stakeholders acknowledged that better data were needed so the programme could 
be properly evaluated. Having staging data for more tumour types was also 
suggested. 
9.4.11.5 Better planning, evaluation and dissemination 
Stakeholders believed it was important to assess more programme components 
(including how funding was used and any potential unanticipated outcomes) and 
disseminate results to stakeholders. Gathering information on lessons learned from 
the programme was also considered to be important. 
9.4.11.6 Reconsider some adopted strategies  
While some stakeholders suggested DCE continued to focus on screening, others 
believed it was more important to focus on signs and symptoms and on understanding 
help-seeking behaviour.  
Some believed that awareness campaigns should continue as cancer fear and limited 
awareness of cancer symptoms and signs were persisting barriers. Others suggested 
focusing on patients at high risk of cancer using tailored messages (to avoid attracting 
the worried well and overwhelming services).  
While some suggested larger investment in primary care, others believed DCE should 
be investing more in capacity (especially radiologists, scanners, and direct access to 
CT).  
Finally, some believed that DCE should consider more clinically relevant outcomes 
(and reassessed the HEAT target). Others suggested DCE explored further the role 
of influencers, maximised the use of qFIT with symptomatic patients and had IT 
systems in place before starting strategies. 
9.4.11.7 Engage further in prevention 
Some stakeholders also suggested a stronger focus on prevention due to its 
importance for improving cancer outcomes, even though others recognised that this 
was not DCE’s aim. 
9.4.11.8 Improve communication and stakeholder engagement 
Recommendations included better engagement with screening programmes, clinical 
teams, charities and other stakeholders, ensuring they were part of the process rather 
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than just being informed about it. Better dissemination of programme outcomes was 
also recommended. 
9.4.12 Theme: Barriers 
9.4.12.1 Health system barriers 
Several health system barriers were reported by stakeholders. There was recognition 
that diagnostic services were struggling irrespective of DCE, that funding was already 
not sufficient, and that there was overspending across cancer services. Increase in 
demand for services was reported for both primary and secondary care, alongside 
shortage of professionals (GPs and nurses for the former and radiologists, 
endoscopists and pathologists for the latter). Primary care was also reported to 
struggle with more and more responsibilities added to their work, while secondary 
care had to deal with increasing pressures such as waiting times targets. 
“I think everybody's just got so busy and we haven't actually... 
instead of being honest about it and saying, 'here's the capacity 
we've got', particularly in primary care, everything just keeps 
getting added and added and added and there's no way of saying 
stop. We need some space to think things through” (ID 13) 
There were reported difficulties in booking appointments with a GP, long waiting times 
for diagnostics, and delays for GPs in receiving diagnostic information. Challenges 
were described as being compounded by the GP gatekeeping system in the UK and 
their limited ability to access diagnostic services. 
The way the health system was organised was also criticised, especially regarding 
booking systems that did not recognise barriers to access for the most vulnerable 
populations (such as people having to take two or three buses very early in the 
morning for a consultation). 
9.4.12.2 Factors influencing early detection 
Individual variation and help-seeking behaviour 
Stakeholders acknowledged a range of factors that influenced early detection. These 
included individual lifestyle behaviours, barriers to help-seeking (especially cancer 
fear, fatalism, Scottish stoicism, and concerns about wasting the doctor’s time), and 
co-morbidity. Stakeholders recognised that health behaviours were “ingrained” and 
changing them was a long-term endeavour.  
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Social deprivation 
Social deprivation was a salient theme when describing barriers to early detection. 
Stakeholders were widely aware of its association with low screening uptake, late 
presentation and poor cancer survival. Reasons for these differences in outcomes 
were also widely mentioned: different priorities, chaotic lifestyles, lower literacy levels, 
poorer health in general, accumulation of risk behaviours, financial barriers (such as 
fear of losing a job or not having enough money for transportation), lower locus of 
control  and tragic cancer experiences. 
“Their lived experience of cancer is sort of the worst possible, it's 
lots of people dying fast in horrible ways with seemingly no hope 
of treatment working. So, we sort of come into that going 'oh don't 
get scared get checked' you know” (ID 24) 
9.4.12.3 Funding system in Scotland 
Some stakeholders criticised the way funding was provided to health services in 
Scotland. They reported that having different funding streams with different conditions 
attached to them was detrimental to improving the whole patient experience. 
9.4.12.4 Data challenges 
Stakeholders commented on the challenges on getting practice level data, especially 
regarding referrals, and on the implications for service improvement. There were also 
comments about data on consultation due to breast symptoms that ceased to be 
collected over time and limited availability of data on lung cancer examinations in 
secondary care. Some recognised that progress was still to be made before Scotland 
had better data on cancer-related services. 
“[T]o get your practice level data is really, really difficult.  Same 
with breast, it's so difficult to get that and not even the primary 
care facilitators can get that easily for you, it's always behind time, 
behind time, behind time.  It's really frustrating that something that 
you think should be such a high priority that you can't get the data 
that you're looking for at the touch of a button” (ID 10) 
9.4.13 Theme: Facilitators 
9.4.13.1 Country size 
Some stakeholders believed that the relatively small size of the country facilitated 
DCE being seen as a priority, adaptations over time and allowed for scaling up 
activities when needed. 
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9.4.13.2 Cancer prevalence 
The fact that cancer affects everyone’s lives was also described as a motivator and 
facilitator to engagement in DCE and its activities. 
9.4.13.3 Good quality data  
Being able to access and use data to make plans/develop strategies was also 
described as a facilitator. Data were described as important to make good decisions, 
to make national comparisons, for practices to benchmark themselves, to start 
meaningful conversations about what could be changed, and to be able to assess 
programme impact. 
 “One of the things that Be Clear [on Cancer] in terms of results 
and impact addressed that DCE has been slightly less direct about 
is that having done this intervention here are the number of people 
who have had earlier diagnosis, here's the stage shift and I think 
Be Clear on Cancer have been able to have more of that data and 
put more of that data into the public domain […] what it also does 
is it's part of that convincing healthcare professionals that this is 
an issue that's worth engaging with, and I don't think DCE have 
been able to present the data in the same way and been able to 
kinda demonstrate the impact quite as directly” (ID 31) 
9.4.13.4 Funding as a hook 
DCE funding was reported to facilitate engagement. 
“It brought people to the table, so my imaging colleagues if I can 
use them as an example, always up to their eyes in waiting times 
pressures, the demands on imaging are horrific as we lean on 
imaging more and more in the diagnostic and treatment pathway.  
They came to the table because they knew that there was new 
investment” (ID 11) 
Funding provided as part of the bowel screening initiative was described as 
particularly useful as it allowed primary care to focus on it alongside a range of other 
responsibilities. 
“To be honest it wasn’t much funding that was needed, and it's not 
like the practices were making a big profit out of it or anything like 
that, it was more I think I used the term it's financial enablement.  
The money allowed them to do that work because they could pay 
for extra admin time and such like, and a lot of it was admin really 
to be honest rather than it having to be a clinician doing it” (ID 17) 
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Funding was also reported to facilitate the introduction of the CRUK facilitator 
programme to general practices, and their subsequent engagement with the 
programme.  
When funding ended, activities also often ended, although there were exceptions 
across Health Boards. 
“If it's incentivised for a short period of time what happens is if nothing 
else is incentivised they would continue with that, but because then 
something else comes in they have to take the admin and the 
resource off that first project and put it to the next one” (ID 12) 
9.4.13.5 Benefiting from existing activities and relationships 
Stakeholders from territorial Health Boards that could build upon earlier work in cancer 
detection reportedly found it easier to implement the programme and decide where to 
invest additional funding. 
9.4.13.6 Tailoring messages 
Stakeholders often believed that it was important to make initiatives meaningful to 
different groups, tailoring messages to them and linking activities to their current 
needs and demands. 
9.4.14 Theme: A government initiative 
9.4.14.1 Prioritisation of early detection 
Stakeholders described how the policy focus of DCE brought early cancer detection 
to the centre of attention, helping to “bring coherence and forward direction”. As DCE 
was a flagship, high priority government programme, time, effort and resources were 
spent to develop and implement it. The HEAT target was also reported to help drive 
efforts, as it was based on an established framework and included in local delivery 
plans. Hence, early cancer detection was prioritised and DCE gained visibility. 
“What would've happened if there was no policy focus on it, I think 
the programme would've remained in the back corridors of public 
health […] the policy focus on it really pulled it to the top of the 
pyramid in terms of the boards, and I mean the Health Board 
members, executive and non-executive directors, understanding of 
what we were tasked to do” (ID 11) 
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9.4.14.2 A dual purpose: politics and health 
There were also perceived downsides of being a government programme. For 
stakeholders, political involvement also meant not receiving full information about 
where decisions about the programme came from.  
A salient issue was the need to deal with increased time pressures. This was 
particularly true for timing between campaigns (which was reported to affect 
engagement and evaluations), and short intervals between them. 
 “[T]hen there was breast and then there was bowel and then there 
was lung, so in some ways it was good that we had those four 
defined phases […] But then there was also something about... 
you felt that you were being concertinaed, that you were working 
on the bowel and then 'stop that now I've got to do the lung' […] 
you spend a lot of time and effort getting teed up ready to go with 
the bowel cancer and then you were still analysing that when the 
lung cancer one came along and when you didn't have definite 
resources that meant you had to put things to one side” (ID 28) 
Furthermore, time pressures were perceived to be in conflict with being able to change 
cancer outcomes (as they require large timescales). 
“Realising that there was political need to get an impact within a 
matter of a couple of years or a few years, that cancer doesn't do 
that and making big changes in the way things happen, it's very 
difficult to get measurable outcomes in that sort of timescale” (ID 23) 
There were also divergences between government aims and what health care 
professionals believed to be important. These included the use of ambitious targets 
(perceived to be important for politicians, but less so for health care professionals), 
and the need to emphasise benefits and harms of screening (instead of only 
promoting screening participation in government-funded campaigns). 
“[T]here was a lot of discussion about whether or not it [HEAT 
target] was achievable and whether it was an evidence based 
clinically manageable target, or whether it was driven by political 
ambition!  So, I know there was that discussion, you know, 'yeah, 
this is just politicians spouting forth and telling us how it ought to 
be but actually they haven't thought through whether this is 
possible and how this can be achieved in reality'” (ID 31) 
“At the end of the day it is a Scottish Government campaign, but 
initially there was quite a lot of, if you like, educating from the part 
of the NHS, of the marketing team, about the fact that screening is 
a choice and you can't just promote screening because it's going 
to be good for you because there is the potential to do harm to 
otherwise healthy people” (ID 14) 
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Furthermore, stakeholders discussed DCE’s dual purpose of promoting early cancer 
detection while also showing the public that the Scottish Government was fulfilling its 
political role and commitment. 
“I don't mind the government telling people things about cancer, I 
think as I said it's good that the government is consistent in its 
messages, but there is another reason for DCE which isn't actually 
about detecting cancer early, it's about showing the public that the 
government cares about them and that it's doing something about 
cancer, and that isn't pure about actually getting the message across, 
that's pure about showing that they're doing something” (ID 27) 
Finally, as a government initiative using public money, DCE was described as being 
under constant scrutiny. There was the need to justify its activities and impact, and 
the HEAT target had a key role in showing this. Consequently, when reports showed 
that targets had not been met, the programme came under a lot of criticism.  
9.4.14.3 A new type of initiative 
Stakeholders described how DCE was a new policy, not only approaching an 
unexplored area but also trying to implement a whole systems approach. DCE also 
adopted new, bold approaches to social marketing. There was a deliberate attempt to 
engage with people in deprived areas to encourage conversations about cancer in 
their own environment. Stakeholders also commented on how the DCE management 
team was paramount for enabling such innovations. The team was described as 
having sought opportunities for new projects, as being willing to push new boundaries, 
and trying to avoid unnecessary bureaucracy.  
9.4.15 Theme: Cultural shifts 
Realistic/personalised medicine: patient perspective 
Stakeholders often commented on the need to respect patients’ autonomy and 
informed choice, including on decisions to attend screening and choice of treatment 
(including choosing not to have treatment), and on giving time for patients to make 
decisions (irrespective of waiting times targets). Respecting individual differences and 
reaching out to patients (instead of waiting for them or expecting them to reach out) 
were also urged. A more holistic approach towards patients was described, 
approaching not only early detection, but also incorporating cancer prevention advice. 
Image of cancer has changed 
Stakeholders commented on how the image of cancer had changed in the past 
decade, with reduced fear and normalised discussions (irrespective of DCE role). 
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“it feels like it's something people can talk about, it is talked about, 
it's not taboo, it's not that slightly witchcrafty thing that if I say the 
word I'm going to get it” (ID 24) 
9.4.16 Theme: Regional variation 
Stakeholders discussed regional variation when talking about a range of issues. 
There was reported diversity in terms of population and geography, including 
deprivation (and how this was distributed), literacy issues, health status, prevalence 
of cancer risk factors, remoteness and rurality (and corresponding barriers to health 
promotion, disseminating strategies, and access to services). In terms of health 
system characteristics, there were reported differences in how services were 
organised, in available routes to cancer diagnoses, examinations, specialists, and in 
whether GPs had direct access to diagnostic tests. These variations were reported to 
influence DCE implementation, evaluation, sustainability and cancer outcomes. 
“There was quite a lot of work across Scotland, each Board doing 
it their own little way” (ID 23) 
Health Boards had different levels of engagement with DCE activities, assigned 
different staff for specific roles and responsibilities, had diverse partnerships with local 
business and charities, engagement with other health care professionals and other 
government programmes (such as Keep Well or Transforming Care After Treatment 
programmes). Some areas were reported to benefit more from nationally organised 
roadshows than others (due to bigger population sizes or ease of access), and this 
caused frustration at times. 
Where the Lidls and Aldis are situated, certainly in Highland, 
they're situated in more of our […]  deprived areas, you know, so if 
you had the campaign there or a stall you might have more 
chance of actually reaching some of the sort of people that we'd 
like to reach, but it's a smaller store and maybe it's more difficult 
perhaps to make the connections and get things set up. That's an 
example perhaps where convenience perhaps sometimes dictated 
where they went rather than necessarily need. (ID 34) 
Boards received different amounts of funding and invested it in different ways. Some 
already had strategies in place and data that facilitated DCE implementation, or 
capacity to carry out additional early detection activities and evaluate them (using a 
range of tools), others could not do so. While some Boards had the ability to 
supplement national campaigns with local activities and continue with them after 
funding ended, others struggled to do this. 
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Furthermore, Health Boards had different exposure to TV ads (with those close to 
England not always seeing Scottish ads, but being potentially influenced by Be Clear 
on Cancer, and NICE referral guidelines).  
In terms of outcomes, performance also varied widely across Health Boards, and 
stakeholders were aware that interpreting this variation was difficult. From the 
perspective of DCE managers, variations influenced their ability to coordinate the 
programme nationally, and to communicate with different Boards. 
Wide variation in HEAT target outcomes over time (often due to small numbers) was 
reported to cause anxiety across different Health Boards. Having a national target that 
had to be extrapolated back to local populations was also seen as counterintuitive.  
“What we've noticed is that the variation from quarter to quarter 
and then from year to year is difficult in the percentage change 
and that sometimes makes people anxious about why there's so 
much variation, so we can look like we're doing okay one quarter 
and the next time we've gone really down and the non-execs and 
the execs as well in the organisation they get quite upset with this, 
and it's really just because the numbers are small” (ID 30) 
Concerns were also raised by stakeholders from Health Boards that had high bowel 
screening uptake at baseline, as it was more difficult for them to meet targets 
compared with those with poorer performance. 
9.4.17 Theme: DCE beyond three years 
Stakeholders often commented on a range of other activities taking place alongside 
the DCE programme, which either influenced DCE or were influenced by it. Most of 
these happened after DCE’s first three years.  
Scotland adopted FIT for bowel screening in November 2017 (replacing the FOBt). 
This was reported not only to increase uptake across Health Boards and increase the 
demand for diagnostics, but it also influenced the decision not to target bowel 
screening in social marketing campaigns any longer (as increase in uptake was 
already expected). 
Funding for DCE dramatically decreased after three years, and this required a change 
in strategy. Social marketing campaigns on TV ceased to be tumour-specific 
(although tumour-specific campaigns were still targeted using other media) and it was 
no longer possible to allocate funding to Health Boards (although there was still some 
funding available for local, innovative pilots). 
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Although funding was reduced for DCE activities, a new Cancer Fund was developed 
to provide funding to specifically target inequalities in screening. This was welcomed 
by stakeholders. 
Demand for diagnostic services was reported to have increased over the years. This 
was accompanied by added challenges to diagnostic capacity in Scotland, especially 
in terms of limited workforce. A stakeholder believed that it would have been 
impossible for DCE to be launched in these new circumstances. Another described a 
perceived conflict between the current austerity agenda and the perception that a 
range of investigations can happen. 
“The workforce we just don't have enough now, so I think five/six 
years ago when we introduced the programme we'd a very 
different workforce mix in that we'd a lot of people working, a lot of 
clinicians approaching the age of 50 or so who have now since hit 
55 and retired cause it's not worth them staying longer so we've 
got a bit of a workforce crisis, and particularly in terms of 
diagnostics we don't have enough radiologists to read reports, 
we're outsourcing a lot of reports, we don't have enough 
radiographers to actually go through a lot of the diagnostic 
investigations” (ID 33) 
The HEAT target continued to be measured after three years (it became a Local 
Delivery Plan standard), as those managing DCE activities believed it was still 
important to measure staging (although there was reported disagreement on whether 
targets should have been kept). 
“The other thing is I suppose, you know, when they said it [HEAT 
target] was going to finish in 2015 it should finish in 2015.  There's 
so many things that just end up still on as a priority” (ID 30) 
The referral guidelines were updated again in 2018 in order to include new evidence, 
and DCE changed not only the updating process (using a rapid review process) but 
the dissemination strategy, aiming to more closely involve secondary care, and better 
disseminate the use of apps instead of printed materials. There was the recognition 
that some professionals still referred to NICE in England instead of the Scottish 
guidelines, that communication between primary and secondary care did not always 
happen, and that variation regarding direct access to diagnostics was still an issue. 
DCE also implemented different melanoma pilots across Scotland, and qFIT for 
symptomatic patients continued to be piloted across different Health Boards. A new 
ministerial group was developed looking at performance and delivery of CWTs. 
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Professionals involved in DCE were also reported to have changed over the years. A 
stakeholder believed that staff changes, added to the programme’s length, resulted 
in a certain level of accommodation in terms of efforts to ensure stakeholder 
engagement. 
“So that was a very personal approach I suppose, you know, yet 
individuals have changed in certain teams and I think that 
approach probably has maybe been slightly lost, and I don't know, 
maybe it is because the programme's been running for that length 
of time, there's maybe been a bit of a loss of... there's not laziness 
in terms of who's engaged but maybe it is more about 'I'll fire an 
email and that's me, I've done that' as opposed to actively 
engaging and having a communication, as opposed to this is what 
we're doing, here it is and it's based on research”(ID 25) 
9.5 Summary of Chapter 9 
This chapter reported on results from the interview component of the process 
evaluation of the DCE programme. Interview findings showed that there was wide 
support for a national programme promoting early cancer detection, even though 
there were disagreements with some of the approaches adopted by DCE. Importantly, 
sense of ownership and perceived ability to positively change service provision and 
cancer outcomes influenced engagement and buy-in.  
DCE adopted a range of communication channels to keep stakeholders informed and 
consult with them. Over time, communication became patchier, with “gaps” and limited 
notice regarding social marketing campaigns and associated activities (with 
implications for stakeholder engagement). Stakeholders often reported uncertainty 
regarding the rationale for a range of DCE strategies and wished that their 
input/expertise had been sought before decisions about the programme had been 
made. Additional knowledge of, and involvement in, decision-making regarding DCE 
strategies was reported to influence engagement and sense of ownership. 
Stakeholders wished that there had been more dissemination of local activities and 
sharing of best practices, so they could learn from different experiences.  
There was wide variation in resource availability across different Health Boards, but 
in general it was clear that both primary and secondary care were under-resourced 
and understaffed irrespective of DCE. Hence, there were concerns regarding DCE’s 
impact on workload, as many professionals did not think they would be able to cope 
with increase in demand brought by the programme.  
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Stakeholders also reported wide variability in how funding was used. Flexibility was 
not only allowed by DCE but also encouraged. Nonetheless, there was evidence that 
the process of allocating funds was not always transparent (which caused frustration), 
and that some areas benefited more from funding than others. Too much flexibility 
made it difficult to evaluate how DCE funding was used, and any associated 
outcomes. At a national level, flexibility allowed for investing in a range of activities, 
but also resulted in the programme having “arms and legs” and running the risk of 
becoming piecemeal. 
Stakeholders often saw DCE as part of their role, but many also highlighted that DCE 
activities required additional work, resources, and sufficient notice so tasks could be 
properly allocated.  
(Limited) evidence on how funding was used indicated that it was most often used in 
secondary care, although it was also used to keep the normal service running. 
Funding on its own was often not sufficient to increase capacity. 
DCE strategies resulted in increase in demand for diagnostics and corresponding 
increase in workload. This increase drove professionals to act, but caused frustration 
when patients were not the ones they expected to see and there were no 
corresponding improvements in cancer outcomes.  
Targets were reported to focus minds and to help bring DCE and early detection to 
the centre of attention, but different targets generated different reactions. While the 
QOF targets were seen positively, HEAT targets caused frustration and affected buy-
in. Some believed that the HEAT targets were a politically driven measure with limited 
clinical relevance. Others liked the idea of having an ambitious target, as it was 
aspirational and helped to drive improvements. 
A range of barriers were reported by stakeholders; including the ones referring to an 
overstretched health system, other factors influencing early detection, and limited 
availability of data. Likewise, several facilitators were reported; these included having 
good quality data and having funding as an enabler. 
Both positive and negative unanticipated outcomes were reported. Negative 
outcomes included delays diagnosing patients with a higher risk of cancer, delays 
treating cancer patients or increasing professional and patient anxiety. Positive 
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outcomes included lessons learned from DCE being used to inform other government 
initiatives, and new equipment to provide better treatment to cancer patients. 
This was the final Chapter reporting on results from the DCE evaluation. The next 
(and final chapter) in this thesis integrates and discusses evaluation results and 
addresses the two remaining PhD objectives. 
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Chapter 10 Discussion 
10.1 Overview 
This PhD project aimed to investigate the role of multilevel policy initiatives in 
promoting the earlier diagnosis of cancer. It had four objectives: 1) to understand the 
international landscape of such initiatives; 2) to evaluate the DCE programme; 3) to 
compare DCE with other initiatives; and 4) to provide recommendations for policy. 
The systematic review (Study 1, Chapter 4) reported on 18 multilevel policy initiatives 
which often targeted 1) public cancer awareness and/or knowledge; 2) professional 
education; 3) referral pathways based on cancer symptoms; or combinations of these 
strategies. Evidence was limited on high-level outcomes such as survival, mortality 
and tumour staging. There were data for intermediate outcomes such as positive 
changes in knowledge/awareness (and limited data on change in behaviour) and 
reduced diagnostic intervals. Stakeholder views on initiatives were often positive. 
Evaluation development and refinement (Study 2, Chapter 5) resulted in a 
comprehensive description of DCE, development of a logic model, a textual 
programme theory, outcomes chains, and assumptions and mechanisms of impact 
which were then investigated in the DCE evaluation. 
Finally, the DCE evaluation (Study 3, Chapters 6 to 9) outlined that DCE’s key aim 
was not met, although there were improvements in tumour staging. There was 
increase in awareness of cancer symptoms and signs and in help-seeking behaviour, 
but barriers to help-seeking persisted. Process evaluation results showed that there 
was wide support for an early detection initiative but buy-in varied according to 
different programme strategies. Communication challenges influenced buy-in and 
sense of ownership. Increase in demand drove action but had negative implications. 
Views on targets were mixed, especially when they were unachievable or perceived 
to have limited clinical relevance. Stakeholders valued “soft outcomes” which were 
not often assessed and wished that local activities had been better disseminated. 
This final chapter integrates findings from these three studies. Recommendations for 
policy and research are provided. Study strengths and limitations are outlined, 
followed by personal reflections about the PhD journey and overall conclusions. 
References to relevant literature are made throughout the chapter. 
   
266 
10.2 Integrating evaluation findings 
10.2.1 Evaluation development and the DCE evaluation 
Prior to the evaluation, it was necessary to have a clear description of the DCE 
programme, its components, underlying assumptions and mechanisms, and 
contextual issues (154, 158, 161, 165, 374). This was achieved with Study 2, which 
also reinforced the importance of incorporating complexity-theory/systems thinking 
into the evaluation and helped to identify suitable implementation and behaviour 
change theories/frameworks. It would not have been possible to carry out the DCE 
evaluation without the evidence obtained in Study 2. 
Several stakeholder responses from evaluation development were similar to 
responses which came out of the DCE evaluation (Box 10.1). These similarities were 
inevitable as the studies were connected, and issues raised in the initial interviews 
were further investigated in the DCE evaluation. Furthermore, in both cases several 
interview participants had a similar profile (i.e. were involved in the development or in 
the running of the DCE programme). 
Box 10.1. Similar issues identified in Study 2 and Study 3 
• Stakeholder buy-in: overall belief in the programme, despite criticisms. Concerns about 
how demand brought by DCE would be managed 
• Reach and communication: Some reports of limited clinical input and limited clinical 
relevance of measures/strategies, challenges in the primary and secondary care 
interface, comments on how information provision helped with sense of ownership 
• Sustainability: funding needed over time, challenges with communication over time 
• Contextual issues: regional variation (challenges, aims, and use of funding); NHS 
constraints; political imperative and pressure to work; political conflict of interest; 
deprivation; behaviour change challenges (fear, fatalism, Scottish stoicism); cultural shifts 
and changes in the way cancer is perceived (irrespective of DCE, but helped by it) 
• The role of targets: can focus the mind and drive activity at times, but also uncertainty 
regarding their usefulness, and its short-term aspect 
• DCE outcomes: challenges in showing causality, aspiration for long-term changes, 
intermediate outcomes do not equal success, different views on what success means 
• Challenges when interacting with the media 
• Recommendations to target patients at risk and provide direct access to diagnostics 
 
10.2.2 Integrating process evaluation findings 
The process evaluation investigated whether implementation outcomes and 
mechanisms of impact identified during evaluation development were confirmed by 
stakeholders, looked for barriers and facilitators, and unanticipated outcomes. Data 
were collected through semi-structured interviews and a purpose-built online 
questionnaire. 
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The same inclusion/exclusion criteria were applied for interviews and the 
questionnaire in order to obtain parallel samples and carry out a merged data analysis 
(221). There was a different composition of DCE stakeholders between the studies. 
While most interview participants managed health care services or DCE strategies, 
most questionnaire participants were secondary care doctors. There was also 
variation in terms of views, with those answering the questionnaire often having more 
negative views about the programme. This could be due to variations in the 
respondents’ profile, but it could also be due to guaranteed anonymity for those 
answering the questionnaire. There is evidence that anonymised questionnaires can 
increase willingness to report sensitive information and can also result in more 
accurate reporting (504). Interviews, on the other hand, are more prone to social 
desirability bias, although ensuring anonymity and confidentiality (as done in this 
study) can help to avoid this (504).  
Furthermore, the observed low level of precision (and wide confidence intervals) 
obtained with the questionnaire indicates less confidence that the population of 
interest would have answered the questions in a similar way. No power-based 
calculations were carried out, but the very small sample size (n=53) also indicates 
uncertainty over whether the observed effect (i.e. variations in responses across 
groups) would be true to the population of interest. Therefore, even though the use of 
mixed methods aimed to obtain both in-depth accounts and representative responses 
from the population of interest (i.e. DCE stakeholders), the latter may not have been 
achieved in this study. 
Bearing in mind these limitations, Table 10.1 comprises a joint display (195, 226) 
synthesising results from the interviews and questionnaire, while also showing 
process evaluation questions. Results are then integrated using a narrative approach. 
Furthermore, illustrative quotes from interviews and open-ended questions in the 
questionnaire were mapped onto implementation outcomes and COM-B components; 
these are available in Appendix 38. 
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Table 10.1. Joint display of findings: interviews and questionnaire 
Interviews (I) Questionnaire (Q) 
Stakeholders’ profile 
• N=25; women (n=15) 
• Most managed health care services or DCE strategies (n=14) 
• Interview duration 17-79 minutes (mean 48 minutes) 
• N=53; women (59.2%); mean age 50.78 (SD 5.66) 
• Secondary care doctors (62.7%); GPs (13.7%)  
• Worked with a specific tumour type (75.0%; most often breast) 
Assumption 1: Different stakeholders bought into DCE, its components and what it proposed to do 
• Wide support for promoting early detection, but disagreements regarding 
DCE approaches (i.e. appropriateness of focusing on symptoms that did not 
indicate early stages, choice of tumour types and timing of campaigns) 
• Sense of ownership and perceived ability to improve services and cancer 
outcomes influenced engagement and buy-in 
• Wide support for the bowel screening initiative (and frustration when it 
stopped), but less support for the HEAT targets (“unachievable”)  
• DCE not as feasible in the current environment; reduced funding 
• Persisting barriers to help-seeking, campaigns with temporary impact 
• Many activities ended when funding ended (Health Board variations) 
• Stakeholders have different perspectives of what constitutes success 
• Views on other approaches to adopt, such as focusing on the most deprived 
• Themes: stakeholder buy-in, impact on workload, official outcomes, 
recommendations, a government initiative, DCE beyond three years 
• 49.0% disagreed to a certain extent that DCE’s benefits outweighed 
the time and effort required to work towards its aim 
• Mixed views on appropriateness, high agreement for the bowel 
screening initiative (85.7%) and low for HEAT targets (49.0%) 
• Mixed support for DCE continuation (49.0% agreement) 
• Those who wished they had had an input in programme 
development/implementation had lower median scores for the 
appropriateness of DCE (p=0.047) and HEAT targets (p=0.042) 
• Content analysis: assumption often not confirmed (48 counts). 
Comments referred to issues such as the focus on breast symptoms 
(attracting the worried well and not resulting in more cancer 
diagnoses), and timings of campaigns 
• Questions: Q6.1a, Q6.2a,Q11.1.a, Q11.1.b, Q15.1.a, Q20.1.a, 
Q24.1.a, Q29.1.a, Q33.1.a, Q37.1.a., general feedback 
Assumption 2: There was enough targeting and communication about DCE aims and its strategies, and what was expected from everyone 
• Reports of limited information for some components but recognition that 
information may have been provided, but got lost among other information 
• Over time, communication became patchier, with “gaps” and limited notice 
regarding campaigns (with implications for stakeholder engagement) 
• Stakeholder uncertainty regarding the rationale for DCE strategies, and 
frustration when expert views were not heard – knowledge and involvement 
in decision-making influenced engagement and sense of ownership 
• Referral guidelines could have been better disseminated to secondary care 
• Calls for further dissemination of local activities (including soft outcomes), 
national outcome data, and sharing of best practices 
• About half of those not involved in developing/implementing DCE 
would have liked to have had an input 
• Mixed views on whether information was sufficient; highest for the 
bowel screening initiative (72.7%) and lowest for funding (10.0%) 
• 85.2% disagreed that communication between primary and 
secondary care went well on how to use funding, secondary care 
doctors had lower median scores (p=0.028) 
• They were also less informed about guidelines (10.7%, p=0.001), 
education sessions (13.0%; p=0.036) and funding (0%, p=0.002) 
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Interviews (I) Questionnaire (Q) 
• Calls for better stakeholder engagement (including with screening 
programmes), ensuring stakeholders were involved in decision-making 
• Themes: communication, DCE beyond three years, recommendations, soft 
outcomes and other benefits 
• Content analysis: assumption often not confirmed (39 counts), 
comments about not having the opportunity to give input, not being 
aware of DCE strategies, and delays in receiving information 
• Questions: Q3, Q4, Q14, Q19, Q23, Q28, Q29.4.a, Q32, Q36, 
general feedback 
Assumption 3: Available resources were sufficient to meet aims 
• Wide recognition that primary care and diagnostic services were 
understaffed, under-resourced and overstretched irrespective of DCE, and 
concerns about not being able to cope with increase in demand brought by 
the programme 
• Variation in resource availability across Health Boards both facilitated or 
hindered implementation, evaluation and sustainability of early detection 
strategies 
• Themes: impact on workload, barriers, facilitators, regional variation 
• Most disagreed that there was enough time to engage in DCE 
(64.5%). Those working with breast cancer had lower scores 
(p=0.031) compared to more than one tumour type 
• Those who were not involved in developing/refining DCE but wished 
they had had an input on DCE had lower median scores compared 
to those who were involved (p=0.040) 
• Content analysis: assumption often not confirmed (17 counts). 
Comments on limited resources/planning and impact on workload 
• Questions: Q7.3.a, Q20.3.a, Q29.3.a, Q37.4.a, general feedback 
Assumption 4: Flexibility was permitted when allocating resources 
• Wide variability in how funding was used; flexibility was encouraged. 
However, there was frustration when funding allocation was not clear 
• Too much flexibility resulted in challenges when trying to assess how funding 
was used, and evaluate programme impact 
• Flexibility allowed for investing in local strategies, in more innovative 
approaches and in prevention activities 
• DCE had the ability to adapt and change according to need, but flexibility 
resulted in the programme having “arms and legs” 
• Recommendation to be more prescriptive about how to use funding 
• Themes: flexibility as a two-edged sword, using DCE funding, 
recommendations, regional variation 
• Most disagreed that flexibility was permitted (65.2%) with secondary 
care doctors having significantly lower median scores than nurses 
(p=0.026) 
• Content analysis: assumption often not confirmed (10 counts). 
Comments often referred to complaints about areas that did not 
receive funding 
• Questions: Q7.2.a, general feedback 
Mechanism 1: DCE strategies were in line with what professionals perceived as their role, identity, organisational commitment and professional 
boundaries 
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Interviews (I) Questionnaire (Q) 
• DCE strategies were in line with the job carried out by many professionals - 
for others, time and resources were needed so they could be involved in DCE 
activities in addition to their daily jobs (most were happy to participate) 
• Novel aspects of the programme (e.g. engaging with women at the Bingo) 
were not described as being part of the professionals’ roles 
• Theme: DCE and the professionals’ roles 
• Most agreed that it was part of their job to be involved in DCE 
(77.4%). However, most also agreed that it was difficult to integrate 
DCE components into their usual work (86.8%) 
• Content analysis: mechanisms often not confirmed (2 counts). 
Targets not seen as clinical measures, competing responsibilities 
• Questions: Q7.1.a, Q20.2.a, Q33.3.a, Q37.3.a 
Mechanism 2: Additional DCE funding resulted in in more diagnostic equipment and/or workforce 
• Funding often invested in secondary care to increase capacity (with wide 
variations in activities), but also used to keep the service running 
• Funding on its own not enough to increase capacity if there were not enough 
specialists to recruit – at times it paid for overtime or to cover empty posts 
• Funding did not reach all areas that had projects in mind for DCE, and some 
believed it was not enough for what they had proposed to do 
• Calls for transparency on how funding was used 
• Themes: using DCE funding, barriers, regional variation, facilitators, 
stakeholder buy-in, recommendations 
• Most disagreed that additional funding resulted in more equipment 
(83.4%) or workforce (73.4%), secondary care doctors had 
significant lower median scores than nurses (p=0.019) 
• Most disagreed that they were confident about their ability to manage 
demand (66.6%) 
• Content analysis: mechanism often not confirmed (23 counts). 
Comments about funding not being sufficient, being used to deal with 
backlogs, and not being the solution for recruiting specialists 
• Questions: Q29.2.a, Q29.5.a, Q29.6.a, general feedback 
Mechanism 3: Increased demand brought by DCE was a driver for action and created pressure to act 
• DCE strategies resulted in an increase in demand for primary care 
consultations, diagnostics and corresponding increase in workload  
• Impact of the symptomatic breast campaign in primary care (“flooded with 
the worried well”) and in breast screening services; increase in demand at 
the bowel screening centre, for endoscopy and pathology services 
• Primary care practices developed diverse strategies to identify and engage 
with non-responders to bowel screening 
• Mixed views on impact (expected, unexpected, underestimated) 
• Frustration when there were no improvements in cancer outcomes 
• Themes: impact on workload, stakeholder buy-in 
• Most stated that DCE increased demand (92.6%), but often this did 
not drive the development of ED strategies 
• Most stated that campaigns (94.9%), referral guidelines (80.6%) and 
bowel screening initiative (81.3%) increased demand for services 
• Content analysis: mechanism confirmed (7 counts). Comments 
referred to how demand drove the recruitment of professionals, 
stimulated focus on capacity, and increased pressure (this was not 
always seen as a positive outcome) 
• Questions: Q8, Q9, Q16, Q25, Q38, general feedback 
Mechanism 4: Targets helped to focus the mind, showed where resources were needed and increased pressure to act 
• In general, targets were reported to focus minds and to bring early detection 
to the centre of attention. However, while QOF facilitated engagement and 
helped to develop a sense of ownership, HEAT targets affected engagement 
• Recognition that changes in cancer outcomes required longer time frames – 
in contrast with short-term targets 
• Variation in confidence to meet targets; 63.7% agreed (QOF); 53.8% 
disagreed (HEAT) – but same median scores (4) for QOF and HEAT 
on whether targets pressured the team to act 
• Disagreement that HEAT target was a reminder for where efforts 
should be focused (62.9%); lower disagreement for QOF (36.8%) 
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Interviews (I) Questionnaire (Q) 
• For some, HEAT targets were a politically driven measure with limited clinical 
relevance. Others liked the aspirational target to help drive improvements, 
but believed DCE was not about targets 
• Variation in performance (HEAT) caused anxiety across Health Boards 
• Themes: stakeholder buy-in, a government initiative, official DCE outcomes, 
soft outcomes and other benefits 
• Content analysis: mechanism not confirmed (5 counts). Comments 
referred to HEAT targets being unhelpful and unrealistic, and being 
public health measures (instead of clinical) 
• Questions: Q33.2.a, Q33.4.a, Q33.5.a, Q37.2.a, Q37.5.a, Q37.6.a, 
general feedback 
Barriers 
• Overstretched professionals, limited resources, long-term vacancies, 
challenges in accessing care and meeting waiting times targets 
• Lifestyle behaviours, barriers to help-seeking (fear, fatalism, stoicism and 
concerns about wasting the doctor’s time) and social deprivation 
• Limited data availability, especially practice-level data on referrals 
• Themes: barriers, using DCE funding, DCE beyond three years, regional 
variation 
• Content analysis: 22 counts referring to NHS challenges (stretched 
capacity and recruitment issues), early detection challenges 
(barriers to help-seeking) and competing responsibilities 
• Questions: Q49, general feedback 
Facilitators 
• Country size; cancer being an experience most people can relate to; having 
good quality data; funding as a hook to facilitate engagement; benefiting from 
existing activities and relationships (wide variations); and tailoring messages 
to different stakeholders 
• Themes: facilitators, using DCE funding, regional variation 
• Content analysis:  9 counts referring to good quality data, IT 
resources, good leadership, management and teamwork, ability to 
plan and share learning and having an effective screening method 
• Questions: Q49, general feedback 
Unanticipated outcomes 
• Negative unanticipated outcomes: delays diagnosing high risk 
patients/treating cancer patients; competing for professionals across 
different Health Boards; increasing professional and patient anxiety 
• Positive unanticipated outcomes: lessons learned from DCE informing other 
government initiatives; new equipment to provide better treatment to cancer 
patients; identifying knowledge gaps among health care professionals; 
potential diagnoses of conditions other than cancer (such as COPD); 
increase in help-seeking behaviour for other tumour types 
• Theme: unanticipated outcomes 
• Content analysis:29 counts referring to negative impact of the 
worried well seeking reassurance (such as delays for other patients 
who needed care), stress and burn-out for professionals, concerns 
about overdiagnosis and breast campaigns leading to patients 
presenting with symptoms of late stage disease 
• Questions: general feedback (Q5, Q10, Q12, Q14.a, Q17, Q19.a, 
Q21, Q23.a, Q26, Q28.a, Q30, Q32.a, Q34, Q36.a, Q39, Q48, Q50) 
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10.2.2.1 Data integration: implementation assumptions 
Views on DCE appropriateness were more positive across interview participants, 
although there was overall agreement that it was important to promote early detection. 
Reasons for disagreement were similar across both groups; these referred to the 
choice between focusing on screening or symptoms and signs, and timing of 
awareness campaigns. The bowel screening initiative was more widely accepted 
compared to HEAT target (which was perceived to be unachievable) both among 
interview and questionnaire participants. Furthermore, both qualitative and 
quantitative findings showed that buy-in was associated with involvement in the 
programme, and with being able to see positive outcomes. About half of questionnaire 
participants agreed to a certain extent that they supported DCE continuation; 
interview participants wished that the bowel screening initiative had been sustained 
for a longer period and were aware that many activities ended when funding ended. 
Hence, assumption 1 (different stakeholders bought into DCE, its components 
and what it proposed to do) was partially confirmed by stakeholders, with 
variations across different DCE strategies and stakeholder groups. 
Both interview and questionnaire findings indicated that those providing direct 
services to patients (i.e. those at the frontline) knew less about DCE and its activities. 
This was particularly evident among secondary care professionals, especially 
regarding referral guidelines and awareness campaigns. Furthermore, there was 
reported frustration across stakeholders when expert views were not heard, when 
there was not enough notice before campaigns were launched, and when information 
on programme outcomes was not made available. Results indicated that assumption 
2 (there was enough targeting and communication about DCE aims and its 
strategies, and what was expected from everyone) was often not confirmed as 
neither reach nor communication were perceived to be sufficient by a range of 
stakeholders. Nonetheless, it is important to highlight contextual issues mentioned 
by stakeholders that may have affected these results, such as information overload 
or overstretched professionals. 
Both interview and questionnaire participants recognised that the NHS had limited 
resources and was struggling irrespective of DCE, and this resulted in raised concerns 
about resources not being sufficient to cope with demand brought by the programme. 
Furthermore, these concerns were reported to have become a reality for many 
stakeholders and influenced acceptability across questionnaire participants. 
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Assumption 3 (available resources were sufficient to meet aims) was therefore 
not confirmed. 
Interview participants who managed DCE commented on the programme’s ability to 
adapt; other interviewed stakeholders also highlighted DCE’s flexibility (especially 
regarding the use of funding). Questionnaire participants, however, most often 
disagreed that flexibility was permitted when using funding. Results indicated that 
those at the frontline (at least in the case of those answering the questionnaire) may 
have had less influence on how funding was used. Assumption 4 (flexibility was 
permitted when allocating resources) was partially confirmed by stakeholders. 
10.2.2.2 Data integration: mechanisms of impact 
Both questionnaire and interview data indicated agreement with mechanism 1 (DCE 
strategies were in line with what professionals perceived as their role, identity, 
organisational commitment and professional boundaries), with very few 
exceptions. Stakeholders consciously believed that DCE was part of their 
professional role and identify (reflective motivation). Nonetheless, challenges were 
reported in terms of competing responsibilities and engaging in novel activities. 
Compared to interview participants, views were more negative across questionnaire 
participants over whether funding resulted in more diagnostic capacity (equipment or 
workforce), although in both cases there were examples of new equipment/staff 
bought with DCE funding (physical opportunity). Concerns were also raised by both 
groups. There were reports of funding not being sufficient, criticism regarding funding 
being used to deal with pre-existing challenges (i.e., evaluations/beliefs about what is 
good and bad - reflective motivation), and shortage of qualified professionals 
impeding the recruitment of required diagnostics staff. Therefore, mechanism 2 
(additional DCE funding resulted in in more diagnostic equipment and/or 
workforce) was only partially confirmed and was mostly influenced by contextual 
barriers (especially limited resources and workforce challenges). 
Both interview and questionnaire participants reported that DCE increased demand 
for services in primary and secondary care, and this had a direct impact on workload, 
requiring adjustments and changes from health care professionals. In both cases, 
there were reports of services being “flooded” with the worried well (especially due to 
the symptomatic breast campaign), and both short- and long-term impact on services. 
This resulted in “angst” and stress among professionals (automatic motivation). 
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Therefore, mechanism 3 (increased demand brought by DCE was a driver for 
action and created pressure to act) was confirmed by stakeholders. Importantly, 
increase in demand caused frustration when it did not result in more cancers being 
diagnosed or early detection (as described both in questionnaires and interviews). 
Views on targets were more negative across questionnaire participants, although 
concerns about HEAT targets were raised both in interviews and questionnaires. 
Some interview participants were happy for the HEAT targets to be a driver of change 
even though they were not met (reflective motivation); similar views were not shared 
by those answering the questionnaire. In both cases, there were references to targets 
not being clinically relevant (reflective motivation), and mixed views over whether the 
targets pressured the team to act. Wide variations in meeting HEAT targets was 
reported to make stakeholders anxious in different Health Boards (automatic 
motivation). Both for questionnaire and interview participants, QOF targets were seen 
more positively than the HEAT targets. In the case of interviews, this was reportedly 
due to the ability to see impact with the bowel screening initiative (reflective 
motivation). Therefore, mechanism 4 (targets helped to focus the mind, showed 
where resources were needed and increased pressure to act) was partially 
confirmed. Evidence indicated that views differed based on previous experience with 
aspirational targets, and their relevance to the professionals’ work.  
10.2.2.3 Data integration: barriers and facilitators 
Several barriers were reported by stakeholders, with marked similarities between 
interview and questionnaire participants. In both cases, health system barriers 
(namely overstretched capacity, limited resources and scarce workforce) and barriers 
to help-seeking were described. 
Likewise, facilitators were similar. Having good quality data and good IT resources, 
and benefiting from existing relationships, good management and teamwork were 
mentioned both in interviews and questionnaires. 
10.2.2.4 Data integration: unanticipated outcomes 
In both cases, unanticipated outcomes due to increase in demand and workload (often 
resulting from an increase in the worried well seeking reassurance) were mentioned. 
Unanticipated outcomes included increase in professional anxiety and negative 
impact on patients who needed urgent care. Positive unanticipated outcomes were 
only mentioned by interview participants. Importantly, while some unanticipated 
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outcomes were based on actual experience, others referred to concerns and 
expectations (that may or not have become reality). It was not always possible to 
differentiate between these two possibilities due to limited data on patient outcomes. 
10.2.2.5 Summary: integrating process evaluation findings 
In sum, when integrating findings, assumptions and mechanisms were most often 
only partially confirmed (Figure 10.1). Key implementation issues referred to 
challenges regarding reach and communication and having sufficient resources 
(assumptions not confirmed). It was clear that DCE was line with the professionals’ 
roles and that demand was a driver for action (confirmed mechanisms), although the 
latter had a negative impact on professionals. 
Figure 10.1. Were assumptions and mechanisms confirmed by stakeholders? 
 
 
10.2.3 Integrating findings from the full evaluation 
10.2.3.1 Integrating process, context and outcomes 
The purpose of having a process and an outcome evaluation was to understand not 
only what happened, but also how and why it happened. In order to do so, it was 
necessary to integrate process and outcome evaluation findings (166). This was done 
in a joint display table (195, 226) (Table 10.2) and in a textual narrative. Perceived 
benefits of carrying out a process evaluation are also highlighted. 
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Table 10.2. Process and outcomes 
Outcome evaluation Process evaluation 
Objective 1: To increase the proportion of breast, colorectal and lung cancers diagnosed at Stage I by 25% and use performance as a lever for whole 
systems improvement 
• Objective was not met, but improvements in staging were noted 
• 7.0% increase in the proportion of cancers diagnosed at Stage 
I (lung, breast and bowel combined) at Year 3 
• 25.0% increase for lung, 5.1% increase for breast, and 4.3% 
decrease for bowel at Year 3 
• Increase across all five levels of social deprivation (lung, breast 
and bowel combined), with the highest increase for the most 
deprived (11.3%) 
• Increases across all three cancer networks (lung, breast and 
bowel combined) at Year 3 
• Variations across territorial Health Boards 
• HEAT target was ambitious, and some agreed that was useful to drive change – 
most stakeholder did not expect it would be met 
• For some, an unachievable target resulted in frustration, reduced engagement 
and sense of ownership – questions were also raised over what it meant if target 
was not met (i.e. how the programme’s impact would be ascertained) 
• Some were unsure of the rationale for the target and its limited clinical significance 
• Stakeholders believed that soft outcomes were important but not measured 
• Recognition that change in staging would take a long time (although measured 
with a short-term target), and that the target made more sense for politicians 
• Process evaluation measures: Assumption 1, Assumption 2, Mechanism 1, 
Mechanism 4, Barriers and Facilitators 
Objective 2: To improve informed consent and participation in national cancer screening programmes. Objective 3: To raise the public’s awareness 
of the national cancer screening programmes and also the early signs and symptoms of cancer to encourage them to seek help earlier. 
• Objectives were met to a certain extent 
Breast screening 
• No perceived impact; calls to screening centre to book 
appointments did not result in increased screening uptake 
• Campaign recognition, awareness of screening risks, benefits 
and limitations higher for those already invited and screened 
Breast (symptomatic) 
• 51.1% increase in consultation for breast symptoms during the 
campaign periods; potential increase in GP/self-referrals 
• Campaigns showed positive impact on intention to act, 
knowledge and awareness of symptoms 
Bowel screening 
• Increase in uptake overall, for males and the most deprived 
(targeted by campaigns) – but in line with existing trends 
• Increase in workload was not perceived to translate in more cancer diagnoses – 
this resulted in frustration (there were also anecdotal reports of women presenting 
with late stage cancer) 
• Variations in the perception of whether the symptomatic breast campaign was 
successful 
• Acknowledgement that buy-in for breast screening may not have been high 
across some professionals 
• Concerns over whether the right people had been targeted, as there were lots of 
worried well – some recommended a stronger focus on patients at risk and the 
most deprived, or more investment in primary care instead 
• Mixed views on whether the focus should have been on screening or symptomatic 
presentation 
• Reports that outcomes from local awareness initiatives were not disseminated – 
acknowledgement that perhaps results would never be known 
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Outcome evaluation Process evaluation 
• Campaigns well recognised, but decline in motivation, in 
returned kits and in intention to get screened over time 
• Increase in requested and returned kits when different phases 
of the campaign were launched - no outcomes for bowel 
screening initiative other than increase in reminder letters 
Lung cancer 
• Higher levels of awareness of the campaign message about the 
3-week cough, and higher levels of agreement with the 
statement that much could be done to improve symptoms 
• Limited evidence on increase in x-rays during campaigns 
• Increase in the proportion of people not wanting to see the GP 
at all if noticing small changes 
Changes in attitudes (3-year attitudinal tracking) 
• Positive changes in population knowledge/awareness and 
intention to act, but persisting challenges in prompt help-
seeking, and concerns about wasting the doctor’s time 
• Frustration about the bowel screening initiative having been cancelled as they 
believed it worked well - also frustration when outcomes were not measured 
• Considerations over whether the screening programmes should have been more 
involved due to their important role in the programme 
• Frustration with lung campaigns at wintertime 
• Recognition that it was hard to have good data, especially data on referrals, and 
that this was important 
• Recognition that different territorial Health Boards had different abilities to carry 
out, evaluate and sustain local activities 
• Recognition that it was hard to measure programme impact and change in 
behaviour, and that there were challenges in changing behaviour in the long-term 
• Hopes that DCE would be a long-term endeavour facilitating incremental changes 
• Process evaluation measures: Assumption 1, Assumption 2, Barriers and 
Facilitators 
Objective 4: To work with GPs to promote referral or investigation at the earliest reasonable opportunity for patients who may be showing a suspicion 
of cancer whilst making the most efficient use of NHS resources and avoiding adverse impact on access 
• Limited data for assessment; objective met to a certain extent 
• No data on referrals/investigations nor use of NHS resources 
• qFIT with symptomatic patients a good rule out test 
• Referral guidelines were updated; professionals who attended 
associated training found it useful and planned to share 
information, but engagement varied across Health Boards 
• Recognition that referral guidelines could have been better disseminated and that 
secondary care was less involved 
• Recognition that use of guidelines varied across Scotland 
• Frustration about not being able to use qFIT in their local area 
• Frustration over the challenges of getting referral data 
• Process evaluation measures: Assumption 2, Mechanisms 2, Barriers and 
Facilitators 
Objective 5: To ensure there is sufficient capacity in the screening programmes to meet the expected increase in those choosing to take part 
• Not possible to assess whether objective was met – some data 
on increase in workload, no information on funding or on 
whether capacity was enough 
• Limited data on increase in workload for the Breast and Bowel 
Screening Centres - seasonal peaks in laboratory activity in the 
bowel screening centre 
• Stakeholders reported an increase in workload brought by DCE, and explained 
that the breast screening centres were affected by increase in symptomatic 
presentation 
• Evidence showed that screening programmes did not receive additional funding 
• Process evaluation measures: Assumption 2, Mechanism 3 
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Outcome evaluation Process evaluation 
Objective 6: To ensure that imaging, diagnostic departments and treatment centres are prepared for an increase in the number of patients with early 
disease requiring treatment 
• Objective met to a certain extent - no information on treatment 
nor on whether capacity was enough 
• Textual data on a range of investments across Health Boards 
to increase diagnostic capacity and improve service provision 
• Textual data on several soft outcomes, including better 
communication and more efficient diagnostic processes 
• While stakeholders highlighted the importance of soft outcomes, they also 
acknowledged the challenges of measuring them 
• They also wished that there was more transparency in funding allocation, and that 
DCE had been more prescriptive regarding how to use funding 
• Stakeholders highlighted that capacity was often not sufficient before the 
programme started, and that increase in demand was often more than what they 
could cope with, especially for breast cancer - this caused anxiety 
• Some wished they had had more time to plan for increase in demand, others were 
frustrated when planning underestimated capacity needs 
• Funding was not sufficient to increase capacity (no professionals available) 
• Process evaluation measures: Assumption 1, Assumption 2, Assumption 3, 
Assumption 4, Mechanism 2, Mechanism 3, Unanticipated outcomes, Barriers 
Objective 7: To strengthen data collection and performance reporting within NHSScotland to ensure progress continues to be made on improving 
cancer diagnosis, treatment, referral, and survival 
• Objective partially met, with decrease in the proportion of 
breast, lung and bowel cancers recorded with unknown stages  
• No data available on the bowel screening initiative – it was also 
not possible to measure the second part of the objective 
• 44.2% reduction in the proportion of cancers diagnosed with 
unknown stages (lung, breast and bowel combined) at Year 3 
• 38.7% reduction for lung, 65.2% reduction for breast, and 
36.7% reduction for bowel at Year 3 
• Reduction across deprivation levels (lung, breast and bowel 
combined), highest reduction among the most deprived (52.7%) 
• Reductions across all three cancer networks (lung, breast and 
bowel combined) at Year 3 
• Variations across territorial Health Boards 
• Recognition that having better data was one of the benefits brought by DCE, but 
also that improvements were still needed 
• Process evaluation measures: Barriers and facilitators 
Objective 8: To facilitate further evaluation of the impact of public awareness campaigns on the stage of cancer at presentation and to contribute to 
research that establishes evidence for the link between late presentation and survival deficit 
• Not possible to assess whether this objective was met as no 
relevant outcomes were available 
• Acknowledgement that some outcomes would take a long time to appear 
• Process evaluation measures: Barriers 
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Available outcome data showed that, from the eight official programme objectives, 
one was not met (Objective 1 – the one associated with the key programme aim), five 
were met to a certain extent; and for two of them evidence was not sufficient for 
assessment. Without the process evaluation, conclusions would have been that 1) 
most of the programme objectives were difficult to measure; 2) when measurement 
was possible, positive impact of the programme was limited when considering its 
objectives; and 3) the key programme aim was not achieved. Hence, the DCE 
programme failed to meet its key aim and only partially met several of its objectives. 
Although these are reasonable conclusions, they do not tell the whole story about the 
programme. By incorporating a process evaluation, it was possible to have a much 
better understanding of what happened, and possible reasons why (in addition to the 
measurement issues mentioned above) the programme objectives were not/may not 
have been met. Furthermore, the process evaluation shed light on additional 
programme impact that would not have been noticed otherwise. 
Process evaluation results showed that the inability to see programme impact 
(because data were not available, targets were unachievable, or increase in workload 
did not result in tangible improvements) caused frustration and influenced buy-in. 
Stakeholder reports on impact associated with official objectives were often based on 
anecdotal information, except for data on the HEAT targets and screening outcomes 
(which require long timeframes so changes can be observed). These issues are likely 
to have influenced stakeholder engagement in programme activities and 
consequently overall programme impact.  
Furthermore, stakeholders commented on a range of relevant local initiatives and 
potential positive impact (also often referring to anecdotal data), but in these cases 
evaluations were not carried out, data were not collected, or evaluations were not 
disseminated. It is possible that DCE’s actual impact was underestimated; and it is 
likely that additional unanticipated outcomes (either positive or negative) would have 
been identified if more data on activities was made available. Without the process 
evaluation, these possibilities beyond the programme’s official, national strategies 
and the eight official outcomes would not have been known.  
For many stakeholders, the DCE programme was much more than its key aim and 
associated HEAT target. “Soft outcomes”, improvements in services and cumulative 
changes in the way people perceived symptoms and sought help were some of the 
areas that stakeholders also considered to be important when assessing impact 
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(although they recognised the challenges of measuring such outcomes). Perceived 
cultural shifts in the way the population perceived cancer were highlighted during 
evaluation development and the process evaluation. Hence, many saw DCE as a 
contributor towards long-term changes rather than a time-limited programme. These 
views are in line with the aspirational nature of some of DCE objectives but are not in 
line with a programme that was initially planned to last three years (with targets to 
measure changes during this short period). As described by the process evaluation, 
this may be related to the conflict between being a government programme (with the 
need to show results in the short-term) and a programme that makes a difference to 
cancer outcomes in the long-term. Therefore, even though the government can bring 
early detection to the centre of attention and help to drive action, there are also 
possible negative impacts (including the inability to show results). Furthermore, by 
attaching a very specific target (that was also unrealistic), the programme risked being 
assessed only based on this target and having its value underestimated. 
Process evaluation results highlighted limited communication of the rationale for the 
programme and its strategies, gaps in communication and limited notice about 
activities. These were reported to influence buy-in, the ability to engage in different 
programme activities, and to plan for impact on workload. This was also likely to have 
influenced implementation and DCE’s ability to meet its objectives.  
Results also highlighted that local activities were adapted to local needs and 
circumstances and incentivised by DCE’s flexible approach to funding. This flexibility 
also resulted in additional challenges to estimate programme impact. This evidence 
clearly shows that implementation influenced the ability to measure outcomes. 
Finally, process evaluation resulted in a comprehensive understanding of structural 
barriers which influenced the ability to meet objectives, in addition to a range of 
facilitators. Findings also indicated wide regional variation needs, activities and 
implementation, and these are likely to have influenced outcomes (172). 
10.2.3.2 Revisiting programme theory 
After the evaluation, DCE programme theory was revisited (Figures 10.2 and 10.3). 
Many changes were made, as assumptions and mechanisms were often only partially 
or not confirmed and DCE’s key aim was not met. The new representation illustrates 
how achieving intermediate outcomes does not necessarily result in expected final 
outcomes, as outlined by interviews and the literature (165). For example, increase in 
breast consultations did not result in more breast cancer diagnoses, and positive 
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changes in bowel screening outcomes did not result in positive shifts in tumour 
staging. These findings show the importance of having good data that helps to link 
intermediate and final outcomes, with sufficient granularity to show variations across 
populations with different characteristics. For example, it would have been useful to 
know who was consulting with breast symptoms, or the proportion of late tumour 
stages for bowel cancer according to routes to diagnosis (i.e. screening or 
symptomatic presentation). 
Figure 10.2. Revisited textual programme theory: how DCE worked 
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Figure 10.3. Revisited outcomes chain 
 
10.2.3.3 Summary: integrating findings from the full evaluation 
Data integration for the full evaluation shed light on how/why DCE objectives were not 
met. It highlighted issues regarding implementation (such as communication 
challenges and flexibility/adaptability) which are likely to have influenced outcomes 
and the ability to measure them. Furthermore, it showed that for many stakeholders 
DCE was much more that the programme’s targets. The revisited programme theory 
showed that expectations of how the programme was supposed to work (elicited in 
Study 2) did not often become reality. 
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10.3 Comparing systematic review and DCE findings 
One of the thesis objectives was to compare DCE with other multilevel policy 
initiatives. The systematic review reported on 18 of such initiatives (including the DCE 
programme). Both in the case of DCE and other initiatives in the review, evidence was 
often available in government reports and other stakeholder reports/grey publications. 
There was a wealth of information available in lengthy reports, and careful reading 
was required to identify specific information. Comparisons are made below in a 
narrative format; key similarities and differences are then summarised in a table. 
10.3.1 Characteristics of initiatives 
Multilevel policy initiatives were arranged in three specific groups, or a combination of 
them. DCE, NAEDI, ACE and the Cancer Strategy in Qatar crossed all identified 
groups. Most initiatives included at least one type of diagnostic pathway, often for 
patients presenting with alarm symptoms. Awareness campaigns were also a 
common component of initiatives, while professional education was less common. 
Due to wide heterogeneity in populations, measures and outcomes (even beyond 
what was initially expected), comparisons across initiatives were not straightforward.  
Perhaps unsurprisingly, most strategies (including DCE) focused specifically on 
factors directly linked to cancer diagnosis. A minority of initiatives targeted access to 
primary care as part of their initiatives. Considering the important role of general 
practitioners as gatekeepers of services in many of the investigated countries (104, 
505, 506), this limited focus on access may need to be reconsidered. It is worth 
noticing, however, that several initiatives recognised the importance of other steps in 
the cancer care continuum (although the focus was often on interval to treatment). 
Governments either led or co-led initiatives, but charities and not-for-profit 
organisations had an active role in many of them, especially in the UK, US and 
Australia. They were involved in implementation, prepared evaluation reports and 
helped to disseminate information about the initiatives. Furthermore, for-profit 
organisations provided expert knowledge in social marketing, or health care services 
in countries where care was not free at the point of delivery. Academic institutions 
were often involved in the analysis and reporting of outcome data. Therefore, 
multilevel policy initiatives are also multi-actor policy initiatives (although most funding 
still comes from the government). As highlighted by the DCE evaluation, these 
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relationships can be beneficial, but also have implications in terms of expectations 
and communication needs.  
10.3.2 Outcomes and data availability 
As expected, there were challenges in showing how initiatives contributed to improved 
cancer outcomes. This was recognised by initiatives included in the review and by 
stakeholders in the DCE evaluation. Although these challenges are inherent to 
uncontrolled experiments (172, 175), they were managed by adopting a range of 
statistical methods and triangulating different sources of information. Initiatives that 
were able to access relevant data on outcomes, patient sociodemographic 
characteristics and other covariates (such as BCOC (176, 177), some NAEDI 
activities (150, 336), 2WW (81, 279) and both initiatives in Denmark (179, 273, 308, 
309, 341)) were often able to show positive (with statistically significant results) impact 
regarding changes in knowledge/awareness, help-seeking behaviour, diagnostic 
intervals, and (less often) mortality and tumour staging. Different studies recognised 
the challenges in having access to data (particularly DCE, NAEDI and ACE).  
There were only systematic reviews available for a single initiative (2WW in England). 
Hence, in order to report on higher level outcomes, it was necessary to first try and 
synthesise evidence for each initiative. The need to do so in the review and to use 
policy documents to understand DCE impact identified that national (or equivalent) 
policy initiatives do not necessarily translate into national level outcomes. Local 
activities were common and approaches to evaluation varied. It is important that local 
activities, small scale studies are carried out prior to wider implementation (172), but 
it was not always possible to estimate wider impact as a consequence, since local 
results were not always comparable. In the case of DCE, data on local activities was 
often not available, and there were concerns about limited dissemination of best 
practices. Perhaps a better balance is needed in terms of understanding local 
activities and outcomes (as contextual issues are important, and populations and 
needs may be different), and being able to assess overall programme impact. 
Across initiatives, high level outcomes such as cancer survival, mortality and tumour 
staging were seldomly reported. This is not surprising considering recognised 
challenges in accessing data, the recognition that it takes a long time to be able to 
assess impact on survival (173), and that survival analyses on their own (without data 
on mortality and prevalence) can be misleading (507). A recent analysis of cancer 
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policies between 1996 and 2013 showed that these had limited impact on cancer 
survival in England, and that the deprivation gap persisted (508). Hence, other 
outcomes are likely to provide a more appropriate short-term measure of impact, 
although linkages to higher level outcomes would still be expected in the long-term. 
Results from the review and the DCE evaluation indicated limitations in showing 
overall impact and long-term impact; the next subsections discuss impact across 
different strategies. Although these limitations are inherent to the types of initiatives 
being evaluated, evidence showed that more sophisticated analyses are possible 
provided that relevant data are available. 
10.3.3 The role of awareness campaigns 
Initiatives reported on several process measures of reach and dissemination, and on 
changes in knowledge/awareness in the short term. It was more challenging to link 
programme activities to long-term changes, changes in health seeking behaviour or 
improved cancer outcomes, although some evidence on positive changes in 
behaviour was available for BCOC (176), Oral Cancer Maryland (343) and DCE.  
Cancer fear and concerns about wasting the doctor’s time persisted both in England 
and Scotland. There could be many reasons for this, including issues raised in the 
DCE evaluation such as being aware of NHS constraints and stoicism. The 
importance of these issues was also confirmed by an ICBP study, which showed that 
they were also present in other countries (509). 
The DCE process evaluation highlighted concerns about the impact of campaigns in 
demand for services and about them attracting the worried well. Even though 
evidence on this was limited in the review, the literature indicates that these concerns 
are shared at least by health care professionals in England, alongside fears that such 
initiatives may increase health inequalities (510, 511).  
Evidence from Health Psychology indicates that knowledge is necessary, but not 
sufficient to result in target behaviours (48). Different theories highlight the role of 
motivation, relevance and other issues, in addition to barriers such as poor literacy 
(48). Moreover, studies underpinned by Medical Anthropology indicate that the 
decision not to seek help or to delay help seeking is not necessarily due to lack of 
knowledge or limited awareness. In fact, it can be a rational and pragmatic decision 
due to individual and social circumstances (111). 
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A review assessing impact of campaigns promoting cancer awareness and early 
presentation found that campaigns increased awareness in the short-term, but 
evidence was limited on the impact in early presentation and high level outcomes 
such as tumour staging (512). The ABC-Deep Consortium is currently updating this 
review, and it will be important to see if changes were noted since then as a result of 
current initiatives (513). The US National Cancer Institute’s guidance on mass health 
communication campaigns highlights that communication can increase and reinforce 
knowledge and awareness, influence views, refute myths, show benefits of changes 
in behaviour and increase demand for services (514). However, it cannot result in 
sustained change for complex health behaviours without being part of a larger 
programme addressing contextual issues, and it cannot overcome barriers such as 
limited access to care. Furthermore, the guidance recognises that it is often 
impossible to isolate the impact of such communications, because changes often do 
not only occur due to them, and audiences are influenced by a range of 
activities/messages at the same time (514). Similar issues were recognised by DCE 
stakeholders; those evaluating BCOC campaigns also acknowledged that 
determining exposure to campaigns was not straightforward (298). 
10.3.4 The role of diagnostic pathways 
Diagnostic pathways were the most commonly adopted strategies. The mostly 
commonly reported outcomes were diagnostic intervals, but this information was not 
available for DCE as waiting times were only available for decision to treat/referral 
and treatment (515). Therefore, it was challenging to compare DCE with other referral 
strategies. Data on routes to diagnosis are now being collected in Scotland (73), and 
it is hoped that comparisons can be made in the near future. 
DCE process evaluation highlighted challenges in accessing referral data, and the 
detrimental impact this had for benchmarking and service improvements. The 
systematic review described increase in referrals (patients with high-risk symptoms) 
over time across different initiatives; this increase did not necessarily translate into 
more cancers being diagnosed. Increase in demand is likely to continue considering 
the increased cancer burden worldwide, and this will have implications in terms of 
resources, and risks of overdiagnosis and overtreatment of cancers that would not 
have progressed. These implications will need to be balanced against the risk of 
missing cancers.  
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There is increasing recognition that urgent referral pathways are less likely to be 
beneficial for patients without alarm symptoms and that additional pathways are 
needed to ensure earlier diagnosis for a range of tumour types with different 
symptomatic presentation (85, 87, 134). More recently, DCE has shown interest in 
focusing more in such pathways (personal communication, DCE Programme Board). 
Importantly, these different pathways are coexisting, demonstrating their importance 
for different population and tumour groups.  
10.3.5 The role of professional education 
There was little information from either DCE or other initiatives which adopted this 
strategy (eight initiatives had this as a component). There were mixed findings 
regarding change of knowledge/behaviour over time. The DCE evaluation reported 
that professionals found the sessions useful and planned to share information, but 
attendance/engagement varied across territorial Health Boards. Process evaluation 
results indicated that health care professionals can have limited 
knowledge/awareness about cancer, and this may not be particularly obvious. Results 
do not allow for firm conclusions on the usefulness of education sessions for 
professionals, but they do highlight that needs assessments may be beneficial in order 
to identify any potential gaps in knowledge regarding early cancer diagnosis. A 
systematic review has found such gaps (and wide variations) among nurses (516); it 
is possible that this is also the case among other health care professionals. 
10.3.6 Stakeholder views on initiatives 
Most evidence on stakeholder views referred to DCE (obtained through the process 
evaluation), although some initiatives included in the review also had data. 
Educational training was often considered to be important for professionals. Overall, 
most professionals also had positive (or neutral) views on awareness campaigns, and 
GPs often agreed that it was important to show such messages to the public. BCOC 
also sought patient views and these were often positive (with campaigns being 
described as sensible, relevant and showed something new) (177).  
Views on referral pathways were mostly positive from professionals and the public as 
they believed pathways were beneficial to patients, but there was also recognition that 
these pathways had limitations. Professionals raised concerns about primary care 
professionals overusing the pathway, pharmacists making inappropriate referrals, or 
guidelines not being used appropriately (the latter was also raised by DCE 
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stakeholders). A qualitative study assessing challenges in implementing 2WW in 
England (included as an additional file in the review as it only approached colorectal 
cancer) (517) described a range of challenges with the 2WW pathway (such as 
difficulties applying referral criteria and their low predictive value), but also proposed 
a range of strategies to deal with challenges.  
Other findings from ACE and NAEDI also resonated with DCE process evaluation 
findings, although at a much broader scale (i.e. they referred to the programme overall 
instead of only to referral pathways). Indeed, there was substantial overlap between 
ACE (287) and DCE process evaluation findings. Similarities included contextual 
barriers such as limited diagnostic capacity and concerns about not being able to 
meet demand, references to the importance of having good management, good 
communication and engagement. Challenges in maintaining engagement over time 
were also reported (287). Both England and Scotland are struggling with NHS 
workforce and resource challenges (518, 519), so these commonalities across the 
initiatives are not surprising. 
There were no reports about the use of CDS tools as part of DCE, although there 
were plans to implement this over time (personal communication, DCE Programme 
Board). For ACE and NAEDI (291, 334), there were reports of technical difficulties 
and challenges in accessing outcome data. If DCE is planning to use similar tools, it 
is important that these challenges are considered. 
10.3.7 Summary: review and DCE evaluation 
Evidence from initiatives included in the review and data from the DCE evaluation 
showed that initiatives often approach referral pathways, awareness campaigns and 
to a lesser extent professional education. Different initiatives faced similar challenges 
when assessing programme impact, although some managed to carry out more 
robust analyses. DCE adopted strategies which had been implemented by different 
initiatives included in the review, in line with review findings showing that initiatives 
influence each other. DCE did not have the same ability to show impact compared to 
initiatives in Denmark and England (Table 10.3) . This was often due to limited data 
availability, but also due to other issues such as limited dissemination and the chosen 
targets/objectives. Based on lessons learned from the DCE experience and review 
findings, the next section discusses recommendations for policy.  
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Table 10.3. DCE and other initiatives: similarities and differences 
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10.4 Recommendations for policy 
A key objective of this PhD was to provide recommendations to inform DCE and other 
initiatives. Draft recommendations were presented at a Workshop with DCE 
stakeholders (a deliverable to the study funder) on the 18th September 2018 
(Appendix 37). The workshop aimed to ensure that recommendations were fit for 
purpose and realistic. Acknowledging that DCE adopted a whole-systems approach, 
and that contextual barriers and facilitators were important, recommendations were 
given at a provider level, organisational level, local level, and national level. These 
recommendations are available in the final report prepared for the Scottish 
Government (Appendix 37 – formatting was changed to meet thesis requirements). 
In order to inform both DCE and other initiatives, recommendations were further 
refined after integrating review results (Figure 10.4). 
Figure 10.4. Recommendations for policy 
 
Recommendations outline what is needed, why it is needed, and provide a list of 
possible issues to consider (these issues were found to have an impact on 
implementation, outcomes, and the ability to compare data from DCE and other 
initiatives). The levels of contextual influence (242) are also reported. 
The first recommendation refers to careful consideration of data to be collected as 
part of a multilevel initiative, especially regarding quality, relevance and availability. 
This recommendation is meant to facilitate measuring the impact of initiatives, build 
knowledge, facilitate stakeholder buy-in and enhance discussions on how to improve 
early cancer detection (Figure 10.5). As part of this recommendation, it is suggested 
that data on costs are collected so cost-effectiveness analyses can be carried out. It 
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was beyond the scope of this PhD research project to carry a cost-effectiveness 
analysis (hence, the issue was not approached in the review either). Nevertheless, 
these are important and beneficial to decision-makers (172), and there are available 
examples in the field or earlier cancer diagnosis (59, 363, 520). 
Figure 10.5. Consider data quality, relevance and availability 
 
The second recommendation refers to setting measurable objectives (Figure 10.6). 
This was a particular issue with the DCE programme, but it may also apply to other 
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government initiatives. This recommendation also approaches other areas highlighted 
by the WHO’s guidance on cancer control programmes, such as defining SMART 
(specific, measurable, achievable, realistic and timely) objectives (46). As described 
earlier in this Chapter, when investigating intermediate outcomes, it is also important 
to consider how these will result in the final expected outcomes. 
Figure 10.6. Set measurable objectives 
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The third recommendation refers to targeting populations at risk (Figure 10.7). This 
recommendation aims to target groups for whom cancer outcomes are often the 
poorest, to avoid targeting the worried well and to make the most of available 
resources. It is based on the recognition of social determinants of health, and the role 
of social deprivation in cancer outcomes. Importantly, as described in Chapter 2, 
tackling social determinants of health requires coordination from a range of actors in 
a system (115). This recommendation also recognises the role of primary prevention, 
especially among groups with a high prevalence of high-risk lifestyle behaviours (7).  
Figure 10.7. Target populations at risk 
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The fourth recommendation refers to prioritising communication and dissemination 
(Figure 10.8). Communication challenges are a recognised problem in programme 
evaluation (165), and in initiatives promoting the earlier diagnosis of cancer (287, 
372). Furthermore, communication challenges were reported to influence stakeholder 
buy-in (DCE evaluation). The importance of having stakeholder input, and especially 
clinical input has been recognised (287, 521, 522). Furthermore, disseminating 
evidence is paramount in order to learn from previous initiatives. In addition to reports, 
policy briefs, press-releases and peer-reviewed publications, online dissemination 
platforms (such as social media and blogs) should also be considered (523, 524). 
Figure 10.8. Prioritise communication and dissemination 
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The final recommendation refers to the need to acknowledge the context, due to its 
recognised role in complex interventions (166, 172), and the way it can influence both 
processes and outcomes (Figure 10.9). The DCE evaluation and the literature 
described in Chapter 2 indicate that issues to consider include social deprivation, 
population needs, resource availability, access to care, and factors influencing cancer 
survival. 
Figure 10.9. Consider contextual influencers 
 
In addition to these recommendations, it is worth highlighting important prerequisites 
already mentioned in this thesis: full programme evaluations need to be planned as 
part of programme development, and ideally should be preceded by pilot and 
feasibility studies (172). It is recognised that policy initiatives (especially the ones 
deriving from political manifestos) are often implemented before such studies are 
carried out and evaluations can be properly planned, as there is pressure to show 
results quickly (525). As indicated by the DCE evaluation, all these issues influence 
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the ability to demonstrate programme impact. At a minimum, it is important that 
evaluation guidance is followed (168, 172, 180, 526), especially those focusing on 
cancer control (18, 19, 46, 527), and that lessons are learned from previous 
experiences. 
10.5 Recommendations for research 
Further recommendations specifically targeting researchers were developed (Figure 
10.10). The first three discuss issues to consider when carrying out evaluations; the 
fourth refers to areas that could benefit from further research.  
Figure 10.10. Recommendations for research 
 
10.5.1 Acknowledging the benefits and limitations of 
developing a theory-based evaluation 
This thesis used theory-based evaluation in order to better understand the DCE 
programme. Its premises fit well with the adopted theories and frameworks, and it 
helped to prioritise elements in the evaluation. As described in the literature, it was 
also expected that theory-based evaluation would show mechanisms that worked (or 
did not work) (155) and potentially inform other early detection initiatives. Although 
there were many benefits in adopting a theory-based evaluation, there were also 
challenges. Table 10.4 outlines some of these benefits and challenges. By being 
transparent about my experience, I hope to help other researchers to make an 
informed decision about their evaluation approach. 
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Table 10.4. Benefits and limitations of using a theory-based evaluation 
Benefits Limitations/challenges faced 
Theory-based evaluation 
• Allowed me to have a comprehensive 
understanding of the DCE programme, 
identifying its “reality rather than its illusion” 
(158) – this resulted in a much deeper 
understanding of what happened 
(outcomes), how and why it happened 
(process) and how and why implementers 
expected the programme to work (the 
programme theory) 
• Contributed to building knowledge on 
mechanisms of impact in early diagnosis - 
an area for which evidence is scarce 
• Allowed for theory to be applied in practice 
• It took a long time to elicit programme 
theory as there was no clear, 
comprehensive description of the 
programme a priori. This is a recognised 
problem with theory-based evaluation 
(154, 218, 528)  
• DCE evolved over time, and adapted 
according to need – complicating 
programme description 
• Despite available guidance, differentiating 
assumptions and mechanisms was not 
always easy (definitions overlapped 
depending on the source), and results also 
overlapped 
Using a logic model and outcomes chains 
• After refinements, the logic model provided 
a clear description of programme inputs, 
activities, outputs and outcomes – this 
informed the evaluation and was 
welcomed by the funder  
• Outcomes chains were found to be quite 
useful to represent the DCE programme as 
they incorporated complexity (and a range 
of relationships) well 
• Initial model was overcrowded (529) 
• Logic model was not ideal for complex 
studies (530), flexible and adaptable 
programmes 
• Logic model was done retrospectively 
• The distinction between logic model 
outputs and outcomes was clear in text, but 
it was not clear for stakeholders. Many of 
the reported outcomes/impact (both 
reported by authors from initiatives 
included in the review and by stakeholders 
in the DCE evaluation) can be classified as 
outputs or process measures 
 
Based on my experience, the benefits of using theory-based evaluation and the 
underpinning theories and frameworks outweighed the costs, as they provided me 
with an opportunity to build knowledge in different areas and apply theory to a national 
early detection programme. Nonetheless, I believe that important issues and 
preconditions need to be considered before deciding to carry out a theory-based 
evaluation.  
The key consideration is what the theory-based approach is expected to add to the 
evaluation. If there is uncertainty about how programme activities will result in 
expected outcomes, the evaluation aims to build theory and contribute to knowledge, 
then in principle the approach is justifiable. However, if there is no uncertainty 
regarding mechanisms (i.e. evidence is clear on how such interventions are supposed 
to work), and the aim is to assess whether objectives were met (and if not, whether 
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this was due to poor implementation), then a simpler evaluation covering processes 
(addressing implementation) and outcomes would suffice.  
Preconditions refer to: 1) available time, resources and expertise (as a theory-based 
evaluation will require more of each); and 2) access to comprehensive information on 
the programme components, implementation and context – and to stakeholders who 
developed the programme (needed for all evaluations, but I found it to be critical for a 
theory-based evaluation). If preconditions are met, a theory-based evaluation is an 
intensive, but rewarding experience. If not, other approaches may be more 
appropriate. 
10.5.2 The need for collaborations and dissemination 
Evidence showed that initiatives were not fully independent entities. Indeed, they 
often influenced each other. Hence, being able to share information about different 
initiatives, in a way that allows for comparisons is paramount. It has already been 
recognised that sharing best practices and using available knowledge can be widely 
beneficial to early diagnosis research (130). In order to do so, more consistency in 
definitions is needed, but also in evaluation methods and reporting. National and 
International collaborations and coordinated approaches such as the Aarhus 
statement (99), ICBP (39) and CanTest (531) are welcomed. Further collaborations 
of researchers with government initiatives and policymakers are also paramount. 
NAEDI was a good example of such collaborations, and resulted in a wealth of 
publications, including two special supplements in the British Journal of Cancer (532, 
533) and the evidence-based hypothesis of factors influencing cancer survival and 
premature mortality adopted in this PhD project (130).  
There are recognised challenges in engaging with policy (534), but these 
collaborations have a stronger potential to improve cancer outcomes for patients. A 
“middle ground” approach has been proposed as a good compromise so research 
can better inform practice and policy, and more robust initiatives can be developed 
and evaluated (535, 536). Suggested approaches include collaborations between 
researchers and health care providers in programme evaluations; and co-creation of 
complex interventions / models of care (535). This “middle ground” may also be useful 
for multilevel initiatives promoting earlier cancer diagnosis. It incorporates the notion 
of realistic medicine (emphasised by DCE stakeholders), which has gained 
prominence in Scotland since a report was published in 2016 (537). Realistic medicine 
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emphasises shared-decision-making and a personalised approach to care while 
aiming to reduce harm, waste, and unnecessary variation in practices and outcomes 
(537). 
Importantly, research and policy collaborations often result in peer-reviewed 
publications, helping to reduce bias and enhancing transparency. Peer-reviewed 
publications have a unique identifier and are easier to retrieve compared to reports 
(although open access issues need to be considered). During this PhD project, links 
to relevant reports changed, and not all of them could be identified again (I was 
fortunate as I had saved all files when I found them).  
The MRC guidance on process evaluation of complex interventions recommends that 
evaluators publish a report describing all evaluation components, or a protocol paper 
that also refers to all articles reporting on the evaluations (166). This advice may also 
be useful for early detection initiatives, in order to share knowledge and facilitate 
replicability. 
10.5.3 The need to try new approaches to tackle 
recognised challenges 
While reflecting upon the PhD findings alongside the available literature, it was clear 
there was more corroborating than contrasting evidence available. This was 
particularly evident when comparing results from the process evaluation of ACE (287) 
and DCE. The existence of corroborating data is perhaps not surprising considering 
the exploratory, and descriptive (rather than hypothesis testing) nature of this PhD. 
However, the fact that the same issues feature consistently in multiple programmes 
may also indicate the need to better learn from our experiences. Box 10.2 highlights 
some issues which were consistently shown in publications. They are not easy to 
tackle, but it is important that further attempts are made if we wish to continue 
improving cancer outcomes. 
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Box 10.2. Issues consistently shown in publications and in the DCE evaluation 
• Communication challenges, limited clinical input and dissemination are widely 
recognised issues. It is important to consider optimum ways to tackle these. A recent 
publication has highlighted lessons learned in 20 years assisting with implementation of 
communication efforts as part of US cancer control strategies (538). Evidence from other 
fields (such as management and organisational science) may also be helpful 
• The mixed role of performance targets and/or financial incentives: over 20 years 
ago, Smith had highlighted a range of unintended consequences of performance data, 
including issues which were found in the DCE evaluation: tunnel vision (i.e. target does 
not cover everything that is seen as important), myopia (using short-term targets at the 
expense of long-term objectives), measure fixation (emphasis on the measures instead 
of the underlying objective), and ossification (targets leading to stakeholders ignoring 
other opportunities and threats) (539). Reviews focusing on QOF in England (540, 541) 
and Scotland (542) found that positive results in performance associated with QOF did 
not persist over time. This indicates that stakeholder engagement with the bowel 
screening initiative as part of DCE was likely to be short-lived if the strategy had 
continued for longer (and QOF had not been abolished in Scotland in 2016 (535)). 
Furthermore, these reviews showed that the use of targets carry the risk of a crowding 
out effect (i.e. a negative impact on patients that need access to care), concerns which 
were also raised by DCE, and by those using waiting times targets (371). Aspirational 
targets, on the other hand, have the ability to “demoralise and distort” (543). Further 
discussions about the role of performance targets and financial incentives in earlier 
cancer diagnosis are needed, while also recognising that they can be useful and that 
they are not all the same (as outlined in the DCE evaluation). 
• The use of mass awareness campaigns: there is persisting evidence of limited impact 
of mass awareness campaign in changes in behaviour. The impact of campaigns in the 
worried well is a reason for concern. Although it is hard to argue against the need to 
increase knowledge/awareness of cancer symptoms and signs, there is scope for 
reassessing what awareness campaigns can and cannot do. It is paramount to widely 
acknowledge their benefits and limitations in order to optimise awareness raising 
strategies and promote positive changes in behaviour. The risks of overdiagnosing and 
overtreating the worried well also need to be considered. 
• In terms of measuring outcomes, the importance of triangulating data to better show 
impact is recognised by researchers, but challenges in accessing data persist, 
influencing the ability to measure outcomes. Furthermore, despite wide recognition that 
changes in cancer outcomes require long timeframes, there is still the expectation that 
evaluations in the short-term can show impact. Perhaps better clarity is needed on what 
can be expected from evaluations of earlier diagnosis initiatives. The role of contextual 
barriers (such as limited data or short follow-up periods) over which researchers may 
have no control also needs to be better acknowledged. 
• Barriers: a range of health system barriers were reported for the UK (there was wider 
variation across other countries, although there will be resource implications for all as 
the burden of cancer increases). Social inequalities are likely to persist as a key barrier 
to improving cancer outcomes. Sharing best practices and disseminating successful 
stories is helpful, but (as previously discussed) a wider, coordinated approach outwith 
earlier cancer diagnosis is also needed to overcome these challenges. 
 
10.5.4 Looking forward: early diagnosis research 
While carrying out this PhD research project, different opportunities for further 
research were identified: 
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• Carry out more systematic reviews for a single multilevel policy initiative, 
focusing on understanding both variation across different population groups 
and overall impact. Such reviews would have facilitated analysis and reporting 
for Study 1, and would make evidence more accessible to other researchers 
• Carry out systematic reviews about 1) barriers and facilitators to 
implementation and to meeting outcomes; and 2) unanticipated outcomes for 
multilevel policy initiatives promoting the earlier diagnosis of cancer 
• Carry out qualitative reviews seeking to identify causal mechanisms, theories 
and assumptions underlying multilevel policy initiatives promoting the earlier 
diagnosis of cancer 
• Carry out and publish more process evaluations of multilevel policy initiatives, 
as evidence is available but still limited  
• Carry out further early diagnosis research to identify effective ways to reach 
out to populations in deprived areas and vulnerable groups 
Future studies should also try to have a stronger public involvement from evaluation 
development, in order to measure system-level changes from the perspectives of both 
professionals and the public. This was not possible for the DCE evaluation (see 
strengths and limitations), but I recognise the importance of doing so, especially 
considering the current drive towards shared patient/professional decision-making. 
Finally, there is increasing recognition (particularly in the UK) that diagnostic 
resources are finite, and that increasing demand for examinations such as 
colonoscopies is unsustainable (83). These issues have also been raised by DCE 
stakeholders and other initiatives. Therefore, it is important that more research 
continues to look for simpler, preferably non-invasive, cost-effective tests in primary 
care that can be used as rule-out tests (531) including for tumour types for which 
survival is poorest. For colorectal cancer, there is increasing evidence of the benefit 
of using qFIT in primary care (411, 544, 545). Further research into inflammatory 
markers (546, 547) and safety netting for patients presenting with vague symptoms 
(93, 548) is also needed. 
10.6 Methodological considerations 
10.6.1 Managing potential conflicts of interest 
The DCE evaluation was funded by the Scottish Government and DCE had an interest 
in the evaluation results. Although feedback from stakeholders at the Scottish 
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Government was sought, it was only considered if it did not compromise the 
independent nature of the DCE evaluation. In order to ensure independence and 
transparency, key measures were taken: 
1. The funded evaluation proposal was prepared by me and refined with my 
supervisors’ feedback. The Scottish Government knew that the evaluation 
would be carried out independently, as part of a PhD. They were also informed 
that results would be presented in Conferences and published in peer-
reviewed journals. Dissemination was a key study component in order to 
ensure transparency and knowledge sharing. The final evaluation output to 
the funder (available in Appendix 39) will be made available after thesis 
submission.  
2. An independent steering group provided feedback on the DCE evaluation. 
3. Purposive sampling and a snowball technique were used in order to reach 
stakeholders with diverse views on the programme. Confidentiality and 
anonymity were ensured so stakeholders could be open about their views. 
4. All study information sheets, presentations, and reports to the Scottish 
Government stated how the study was funded, while also highlighting that the 
evaluation was being carried out independently. 
5. There was a continuous process of reflexivity regarding the evaluation, 
changes in relationships during the study and potential impact on the 
evaluation (166). 
10.6.2 Strengths and limitations 
This thesis comprised three different studies. It followed respected guidance on 
systematic reviewing and evaluating complex interventions. The complexity lens 
highlighted the dynamic aspect of the health system, the importance of the context 
and the limitations in showing causality in cancer control initiatives. The use of a 
process and outcome evaluation provided a much more informative view of the DCE 
programme, while the use of a theory-based evaluation helped to build knowledge in 
implementation assumptions and mechanisms. The systematic review synthesised 
and discussed a wealth of evidence in order to learn from national and international 
experiences of carrying out multilevel early diagnosis initiatives. Results have 
informed evidence-based recommendations which are expected to be useful not only 
   
303 
for the DCE programme in Scotland, but also for early diagnosis initiatives being 
developed, implemented and evaluated worldwide. 
Nonetheless, this thesis also had limitations. Some of these have already been 
addressed throughout the thesis; additional limitations are described below. 
10.6.2.1 Systematic review (Study 1) 
Challenges when carrying out the review referred mainly to three areas: quality 
assessment, inclusion and exclusion criteria, and data extraction and reporting. 
Quality assessment 
Most included studies could not be assessed for quality. When quality assessment 
was possible, key issues across quantitative studies referred to limited data on 
sampling, validity, reliability, contamination and co-intervention. As for qualitative 
studies, very few of them described methods, sampling, and data analysis. Interrater 
reliability was low, indicating inconsistent use and interpretation of the adopted quality 
assessment tools (likely to having been influenced by the wide range of 
designs/publication types included in the study). Even though disagreements were 
solved by consensus, low reliability raises questions about the soundness/validity of 
the assessments. Furthermore, while assessing quality of publications is important, it 
is important to consider whether it was appropriate to include quality assessment in a 
review including papers for which there were no properly suitable tools. Perhaps a 
scoping review (as opposed to a systematic review) would have been more 
appropriate. While still adopting procedures consistent with a systematic review (such 
as robust search strategies), the approach does not seek to investigate the quality of 
evidence, includes a wide range of study designs, and is deemed more appropriate 
for reviews aiming to map the available literature in a specific area (549). 
Inclusion and exclusion criteria 
Initiatives were required to have a leading role from the government, as this PhD was 
interested in multilevel policy initiatives which were comparable to the DCE 
programme. Consequently, many initiatives led by research groups and charities 
(even if there was government funding) were excluded from the review. These 
included several charity-led initiatives in the US, and a randomised controlled trial in 
Australia that had initially been included (550, 551). A review with broader inclusion 
criteria is likely to generate additional relevant findings to initiatives promoting the 
earlier diagnosis of cancer. 
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Data extraction and reporting 
Wide heterogeneity in terms of chosen outcome measures and their definitions 
complicated data synthesis. The level of detail in which outcomes were reported 
varied, and data were not available for every investigated outcome. A choice was 
made to report on outcomes which were more often described while making additional 
information available in appendices. Heterogeneity not only precluded meta-analysis 
(this was expected), but also made it challenging to use narrative synthesis. As a 
result, evidence was often shown in large tables, with lots of text. 
It was only possible to report on some contextual factors (such as drivers, policies, 
and source of funding). There was a wealth of additional contextual information, 
including implementation challenges. A review focusing on contextual issues would 
provide useful information for those developing multilevel policy initiatives (as 
described in recommendations for research).  
Since the review focused on higher level outcomes, there were important variations 
in outcomes across different population groups, regions and tumour types that it did 
not cover. Nonetheless, amendments had to be made as some national initiatives 
were comprised of local activities distributed across a country. In these cases, data 
were synthesised whenever possible, or reported separately in tables. It is important 
to emphasise that additional publications (Appendix 4) have important evidence about 
outcomes at a local level, or for specific tumour types. 
10.6.2.2 Developing and refining the evaluation (Study 2) 
Even though I carried out independent searches of DCE documents, made requests 
for specific documents over time and gathered documents from different sources, I 
was still mostly dependent on DCE’s decision on which documents would be shared. 
Therefore, in addition to specific limitations of documentary analysis highlighted in 
Chapter 4, it is impossible to ascertain how many more documents had relevant 
information, were available, but were not shared (and the impact that adding these 
would have had to the evaluation). Nonetheless, those managing DCE activities 
openly shared several documents I did not expect to have access to, including drafts 
for internal circulation only, and minutes with tracked changes. Hence, I expect that I 
received most documents they had available. 
DCE programme theory and its graphical representations (i.e. the logic model and the 
outcomes chains) were all developed retrospectively. For the logic model, this meant 
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that some of the outputs and short-term outcomes were informed by actual experience 
and events rather than expectations. On the other hand, the resulting logic model was 
more realistic regarding programme activities, outputs and outcomes.  
Although the Behaviour Change Wheel was found to be a good fit for DCE, mapping 
was done retrospectively. Similarly, implementation outcomes were mapped 
retrospectively. There were no predefined/validated measurement tools to measure 
implementation assumptions nor mechanisms of impact. This resulted in new tools 
being developed. Although this is common in evaluation studies (397), it results in 
uncertainties regarding validity and reliability. In order to minimise this, the 
questionnaire was informed by studies adopting the same implementation 
outcomes/behaviour change theories. Definitions were provided for all outcomes and 
constructs and the questionnaire was pre-tested, but further validations are needed.  
While the questionnaire allowed for developing very specific questions approaching 
implementation assumptions and mechanisms of impact, the same approach was not 
deemed feasible for interviews, where broader questions and prompts were used 
instead in order to avoid leading stakeholders into confirming/rejecting specific 
assumptions and mechanisms. Themes were derived both from the data and the 
investigated assumptions and mechanisms. Mixed methods research has been 
criticised by being prone to subordinating qualitative to quantitative components 
(230), and this was avoided by allowing each method to contribute as much as 
possible to the evaluation results. While it may seem easier to operationalise 
constructs and outcomes in a questionnaire, it was clear from the study results that 
1) open-ended comments in the questionnaire were crucial to understand quantitative 
results, in addition to generating data not approached by closed-ended questions); 2) 
the richness of qualitative interviews was paramount to answer all research questions, 
and to shed light on why DCE objectives were (or not met). Therefore, the evaluation 
confirmed what is recommended in the literature, i.e. the use of mixed methods is 
beneficial in evaluations, especially theory-based evaluations (161, 166, 195). 
10.6.2.3 The DCE evaluation (Study 3) 
Outcome evaluation component 
DCE was a large, complex government programme, with little predefined evaluation 
parameters prior to the study being funded. This had implications in terms of the ability 
to measure programme impact.  
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During a meeting with the evaluation steering group in 2017, after presenting findings 
from Study 2, there was a discussion about how this study had several similarities to 
an evaluability assessment. An evaluability assessment comprises systematic, early 
engagement with stakeholders; development and testing of programme theory/theory 
of change; identification and assessment of available data sources; and development 
of recommendations for and against a full evaluation (552). If the evaluation is 
deemed not feasible nor useful to improve a programme, then it is not recommended 
(552, 553).  As a government programme using publicly funded money, it was agreed 
that it was important to carry out the evaluation regardless of identified limitations in 
terms of data availability. Furthermore, one of the key interests was to learn lessons 
from the programme (to inform DCE and other initiatives). Considering all the 
evaluation challenges, I believe I made the most of the available data and resources 
in order to meet the thesis aims, funder requirements and to develop evidence-based 
recommendations. 
Although I did not expect to demonstrate causality due to the nature of the programme 
(165, 186), being able to triangulate different sources as done by other initiatives (150, 
176, 298, 310, 341) would have helped to ascertain DCE’s potential contribution to 
observed outcomes (165). The alternative was to carry out a descriptive analysis of 
secondary data sources. Data on proxy measures (i.e. tumour staging) and screening 
were only available in aggregated tables. Data on request for bowel screening kits did 
not have any patient sociodemographic information. Variation in outcomes across 
Health Boards and Cancer Networks was difficult to interpret. It was not possible to 
assess exposure to different DCE components, or to other activities that may have 
influenced outcomes. Furthermore, although data on tumour staging and screening 
uptake were routinely reported by ISD Scotland, timelines varied even for the same 
outcomes. 
The Scottish Government was aware of data limitations and welcomed receiving a 
final report which synthesised very significant amounts of evidence into a single 
document (as this had not been done for the programme). The descriptive outcome 
evaluation was necessary to integrate data on processes and outcomes, and indeed 
was a key component of the theory-based evaluation. Furthermore, the analysis was 
needed to generate evidence-based recommendations. Therefore, although the 
outcome evaluation did not happen as planned, it was still a demanding, labour 
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intensive process of data collection, synthesis and analysis that made the most of the 
available published and unpublished evidence. 
Knowledge of programme outcomes 
When the evaluation was carried out, most stakeholders were aware that the HEAT 
targets had not been met. I had also already read policy documents reporting on a 
range of outcomes, although I only synthesised outcome data while carrying out the 
outcome evaluation. It is likely that this prior knowledge influenced design and 
analysis of the process evaluation (166). Interviews were an opportunity to discuss 
what worked and did not work, and the awareness that targets had not been met may 
have driven participants to suggest the assessment of other outcomes or discuss 
potential programme benefits that they would not have discussed otherwise. This 
additional knowledge may have also influenced expectations of what long-term impact 
DCE could be expected to have in the future.  
Process evaluation 
10.6.2.4 Assurance of confidentiality and anonymity 
Evidence indicated that the professionals’ roles can have an impact on their views on 
the programme. However, in order to avoid indirect identification, I did not refer to 
roles when reporting interview findings. This is a limitation as this information would 
have helped the reader to make sense of the results, but it was necessary as Scotland 
is a small country and some job roles are not very common. Several interview 
participants raised concerns about indirect identification, and ensuring anonymity took 
priority. 
Views represented in the process evaluation 
Stakeholders from NHS Orkney, NHS Shetland and NHS Western Isles did not take 
part in the study (despite repeated attempts during interview recruitment, and 
invitation emails to the questionnaire being sent). It may be that their views about the 
programme would be different. There were also no stakeholders from NHS Grampian 
represented in the process evaluation, although one interview was managed during 
evaluation development. 
The evaluation did not seek views from the public as it focused on process issues 
from the perspective of professionals who influenced or were influenced by the 
programme. The evaluation steering group and the workshop to discuss evaluation 
results both included a lay representative to ensure that their views were included in 
evaluation design and recommendations for policy. While recognising the importance 
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of public views for a programme that aimed to improve population cancer outcomes, 
the evaluation focused on understanding service provision according to professionals. 
These views were shared during a DCE Programme Board meeting when I was asked 
about public involvement. It was agreed that it was best not to include the public if 
there was no clear purpose to do so based on the evaluation aims and objectives (for 
both ethical and practical reasons). 
Survey questionnaire 
Key limitations of the questionnaire referred to non-response bias, and issues 
regarding representativeness and generalisability. 
It was not possible to ascertain how many professionals in Scotland were eligible to 
take part in the questionnaire survey as eligibility was dependent on personal 
experience, and professionals’ perception of how DCE influenced their work. It was 
only possible to estimate the denominator in order to calculate response rates.  
Estimated response rates were low (4%). Low response rates are common when 
recruiting health care professionals in the UK (554-557), although there are also 
examples of high response rates in studies recruiting a specific group of professionals 
(558, 559). No data were collected on non-responders, but official estimates on 
NHSScotland and GP workforce in Scotland (560, 561) were used to help shed light 
on non-response bias regarding sex, age and profession. Most of the workforce in 
Scotland is female (560, 561); this was also the case in the questionnaire but there 
was a likely overrepresentation of female secondary care doctors.  
Questionnaire participants were often older compared to official statistics. 
Furthermore, as medical professions represent 9% of the NHSScotland workforce 
and nurses (and midwifery) represent 45%, the former was over- and the latter under-
represented in the survey (560). Statistics for GPs are shown separately and 
representativeness is difficult to ascertain, although GPs are likely to have been 
slightly overrepresented if adding GP numbers to the overall workforce (561). As 
secondary care professionals often showed statistically higher levels of disagreement 
to a range of statements in the questionnaire; it is possible that this overrepresentation 
biased overall results towards more negative experiences. However, this possibility 
would need to be checked further. 
A 2008 systematic review on surveys for physicians and other medical professionals 
reported that studies often found minimal non-response bias. When there was bias, 
   
309 
non-specialist physicians, young physicians and women were more likely to take part 
(562). Only the latter seemed to have been the case in the DCE evaluation. 
Guidance on how to improve response rates was followed. Only one reminder was 
sent instead of the planned two, as requested by Cancer Networks. Most 
questionnaire responses happened on the day of the first invitation and the reminder; 
it is likely that a second reminder would have resulted in more responses.  
Resonance/relevance (414, 504) is another issue that could have influenced 
response rates. Even though DCE was still ongoing, questions were being asked 
about events that happened up to 2015 (while the survey was carried out in 2018). 
Recall bias is also a key issue in questionnaire surveys (504), although in the case of 
DCE the impact is likely to have been small due to the broad nature of questions. 
Despite limitations, the survey questionnaire managed to reach professionals whose 
views were important (as they were at the frontline or services) and not yet known (as 
they were less often approached in stakeholder interviews). Based on the large 
number of open-ended comments, these professionals also had a lot to say about the 
programme. Therefore, although the survey had limitations in terms of 
representativeness, it provided much needed data for an important group of relevant 
professionals. 
10.6.2.5 DCE changes 
The evaluation funded by the Scottish Government referred to the first three years of 
the programme (its original planned duration). However, the programme did not end 
as planned in 2015. In fact, it remained a key component in the most recent Scottish 
Cancer Strategy (563), with a stronger focus on tackling health inequalities. New 
campaigns were also developed, but not described here. These changes had 
implications for the evaluation, as balance was needed between having defined 
evaluation timeframes while also ensuring that evaluation results were still relevant 
and useful. Outcomes available after 2015 were shown to ensure relevance. 
Furthermore, as described in Study 2 and Study 3, DCE constantly adapted to 
contextual changes and needs. A decision had to be made to focus on DCE’s four 
main strategies.  
Despite variation in outcome data, results often showed fewer positive results in terms 
of performance, especially regarding tumour staging (although still better compared 
to baseline) and bowel screening uptake over the years. Process evaluation results 
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showed that DCE funding was drastically reduced after three years. It is possible that 
these constraints limited DCE ability to make a longstanding impact on cancer 
outcomes. 
Finally, it is worth noting that when DCE was implemented, cancer waiting times 
targets were being met in Scotland (138). This is no longer the case, and a clinical 
review was carried out (564) to assess whether targets were still fit for purpose. An 
interview participant highlighted that in such a scenario it would have been impossible 
to implement DCE. It is possible that DCE activities (and the corresponding impact on 
workload) had an impact on these pre-existing targets (it could be an unanticipated 
outcome, for example), but assessing this was beyond the scope of this PhD project. 
10.7 Reflexivity 
10.7.1.1 Research background and scope of this evaluation 
Perhaps due to my previous experience as a researcher, when I started this PhD 
project I planned to consider it as a standard research study; i.e. a research project 
with several milestones to be met, and outputs to be prepared for the research funder. 
After commencing my PhD project, I quickly realised that it was much more than a 
research study and understood why friends and colleagues often called it a PhD 
journey. I also have a background in business administration and I am often quite task 
oriented. Hence, not being able to track progress when working towards “invisible 
milestones” (such as investing time to read and assess theories and frameworks), 
was challenging. 
Connecting all three individual studies of this PhD through a single aim, while ensuring 
that the underpinning methods, theories and frameworks were compatible was a 
challenging experience. Preparing both academic and policy-driven outputs, 
attending DCE meetings and presenting at Conferences was also demanding.  
Synthesising vast amounts of evidence in this thesis, while also aiming to write a 
coherent story outlining my PhD trajectory was also challenging. I believe that 
evaluation development was the most demanding PhD component, although it was 
one of the most rewarding experiences as it allowed me to look for/identify 
connections between theory and evidence.  
In hindsight, this was an ambitious project to be carried out in three years, even with 
constant supervision, support from other researchers in quality assessment and data 
extraction (systematic review), and from an independent evaluation steering group. 
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Nonetheless, all three studies were needed to reach the conclusions outlined in this 
discussion. 
I was not shy from trying different approaches in this PhD, but I was also careful to 
justify all my decisions. If I were to undertake this evaluation again, I would have 
developed a narrower evaluation plan, perhaps focusing on two assumptions and two 
mechanisms (instead of four each). Even though I believe that theory-based 
evaluation was helpful, I also believe I was trying to test too much theory. 
Furthermore, even though it is important to be faithful to the programme when 
choosing frameworks, an already established implementation framework (with 
validated questionnaires) could have facilitated data analysis, data interpretation and 
comparisons with other studies.  
10.7.1.2 Stakeholder interviews 
I am also a Psychologist with prior experience interviewing research participants. 
Although I was aware of the importance of establishing rapport in interviews and 
helping to make participants feel comfortable, I found myself feeling very 
uncomfortable prior to commencing my initial interviews with key stakeholders (Study 
2). I was speaking to busy professionals who were quite knowledgeable about the 
programme (and at times, personally invested in it), while I was an outsider who was 
planning to evaluate it. Furthermore, I was still learning about DCE and became 
worried about professionals questioning my ability to carry out the evaluation. 
Although this never happened during the interviews, I was questioned about the 
usefulness of the evaluation during a government meeting in 2017, and it took me a 
while to regain confidence. The experience taught me some hard lessons on the 
challenges of evaluating a high-profile government initiative which involved 
stakeholders with different interests and expectations. 
I took care to listen to recordings and read interview transcripts not only to inform data 
analysis, but also to identify scope for improvements. This was a difficult experience 
as it required identifying my own shortcomings at a time when I was still gaining 
confidence about the PhD journey. English is not my native language, and it was 
uncomfortable to notice grammatical errors in my speech. I identified some key areas 
for improvement: do more prompting when stakeholders did not elaborate on 
something that seemed relevant to the evaluation or something that was not fully 
clear, be more careful in order not to break the flow of conversation, use the topic 
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guide but not let it constrain me when unexpected (and useful) comments about other 
topics arose. 
I relaxed over time as I was feeling more comfortable with my role as an interviewer 
and evaluator, and with my knowledge about the programme. The interviews then 
became richer conversations, with the participants also feeling more comfortable to 
share their views on what worked well and what did not work so well with the 
programme. When participants could see that I was aware of a certain programme 
component, then they focused on describing their experiences rather than what the 
component was about. Importantly, I believe that the focus on programme processes 
in order to learn lessons about what worked and did not work in the programme 
(instead of being a “pass or fail assessment”) (166) also helped stakeholders to relax. 
Data analysis of interviews also evolved over time. When analysing data from Study 
2, everything seemed novel and important. When analysing data from Study 3, there 
were many more common/overlapping themes, and I am aware that my knowledge of 
the programme facilitated the identification of these. 
Another factor that may have facilitated data collection over time was my attendance 
to DCE programme board meetings and presentations at different meetings and 
Conferences. Some stakeholders knew about the evaluation when I approached them 
for an interview or when they received an invitation to complete the questionnaire. 
Over time, the DCE evaluation became a recurring item in the DCE Programme Board 
Agenda. Meetings became opportunities for stakeholders to ask questions about the 
evaluation, and for me to provide updates. I believe that this increased involvement 
may have influenced my views on the programme. Even though I never stopped being 
an outsider as I was not part of DCE, closer involvement allowed me to better 
understand different roles and interests from different stakeholders. It was also easier 
to see and understand “different truths”, realities and priorities. Having an evaluation 
steering group, carrying out the workshop with professionals to discuss evidence-
based recommendations and receiving constant supervision were helpful for me to 
maintain a balanced view of what happened.  
10.7.1.3 Process evaluation questionnaire 
Developing the questionnaire was a challenging experience not only in terms of 
methods, but also in terms of how to approach the programme. It became clear over 
time that some professionals still wished to give their views about DCE even if they 
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did not think that it had directly influenced their work. Conversely, even when it was 
clear that DCE strategies had influenced the professionals’ work, some stakeholders 
were not aware of this as they did not see the strategy as part of DCE. I found out 
about these issues when pre-testing the questionnaire (when a GP highlighted that 
s/he did not know that the referral guidelines had been updated as part of DCE) and 
when I received an email about the questionnaire (a secondary care professional who 
had been screened out after the eligibility question, but still wanted to give their views 
about the programme). The experience highlighted two issues: 1) I became so 
immersed in the programme that I forgot that the professionals’ lives did not revolve 
around DCE (as mine did because of my PhD), with many carrying out their work as 
usual and incorporating whichever DCE component was introduced in the health 
system; and 2) having a single questionnaire about the whole programme, asking 
about involvement before stakeholders could see the questions (even though DCE 
components were described in the introductory page), may have resulted in missing 
professionals who wished to share their views about the programme (even though in 
principle they were not eligible to do so). If I were to carry out the evaluation again, I 
would probably reconsider the eligibility question in order to be more inclusive, even 
though a broader approach would have likely meant more missing data in the 
questionnaire. 
10.8 Concluding remarks 
This PhD aimed to understand the role of multilevel policy initiatives in promoting the 
earlier diagnosis of cancer. In order to do so, three studies were carried out. These 
studies identified that such initiatives have an important role in promoting the earlier 
diagnosis of cancer. However, they are influenced by the context, and dependent on 
collaborations with several other stakeholders. Importantly, although these initiatives 
are necessary to bring earlier diagnosis to the centre of attention, in isolation they are 
not sufficient to generate long-term changes in cancer outcomes. Furthermore, it is 
challenging to ascertain their contribution due to their nature (uncontrolled 
experiments), limited data availability, and heterogeneity across different initiatives. 
Perhaps we need to be more realistic about what government initiatives can do, while 
also specifying parameters of what is acceptable in terms of incremental changes and 
ensuring that measures are in place so expected long-term changes can be assessed 
in due time. Collaborations between research and policy are necessary to ensure 
initiatives are well designed, implemented, evaluated and disseminated. 
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10.8.1 How this PhD contributes to knowledge 
A key feature of this PhD was the adoption of a range of theories and frameworks in 
the evaluation of a government-led initiative. To my knowledge, this is the first time 
that a multilevel policy initiative promoting the earlier diagnosis of cancer is assessed 
using theory of change and adopting outcomes chains in addition to a logic model. 
Evaluations of NAEDI and ACE adopted realist evaluation, a type of theory-based 
evaluation which was found not to be an ideal fit for the DCE programme. The DCE 
evaluation builds much needed knowledge on mechanisms of impact in early 
diagnosis initiatives, while also incorporating behaviour change theory. There are not 
many available examples of the BCW and COM-B being used in early diagnosis 
research (565, 566), and this thesis helps to build knowledge in the field. 
Another important thesis contribution was the comprehensive description of how to 
design a theory-based evaluation. By being transparent about evaluation 
development, I believe this thesis is a useful (and rare) example for other researchers 
aiming to carry out similar evaluations.  
In terms of implementation research, this thesis reinforces calls for better 
understanding of variation in implementation. Challenges in assessing 
implementation fidelity are already recognised (166, 172), and in this study 
adaptability was used instead. Adaptability and flexibility were key characteristics of 
the DCE programme, although these were not always described as positive 
characteristics. Adaptability has been reported as a core characteristic of other cancer 
control programmes (521). It is important that adaptability is further investigated in 
future evaluations of similar initiatives. 
The MRC framework for process evaluation of complex interventions is fairly recent, 
and the number of studies adopting it has been increasing in the past few years (417, 
567-569). To the best of my knowledge, this PhD is the first to adopt it to evaluate a 
multilevel policy initiative promoting the earlier diagnosis of cancer. Hence, the DCE 
evaluation enhances understanding on how to use the framework in this context. 
Furthermore, the separate data collection and analysis of processes and outcomes 
followed by integration of results generated two important lessons for those planning 
to adopt the MRC framework while using mixed-methods research. First, merging 
results led to a more complex set of relationships between evaluation components, 
creating a “whole” that was more than the sum of its parts (224). Second, not all data 
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could be integrated. Each component on its own provided rich data that would have 
been missed without independent data analyses. I would recommend that data 
integration approaches in mixed-methods evaluation research are carefully 
considered in order not to miss important evidence. The guidance adopted in this PhD 
project (195, 226) was invaluable. 
This thesis also provided a range of evidence-based recommendations for policy and 
research, including about issues that consistently appear in programme evaluation 
and may require further coordinated, collaborative thinking to identify creative 
solutions. 
Finally, it is hoped that the data described in this thesis and the evidence-based report 
prepared for the Scottish Government are helpful to generate ideas and fruitful 
discussions on how to promote earlier cancer diagnosis in Scotland and worldwide. A 
recent ICBP publication has shown that cancer survival has improved over time 
(period 1995-2014) across seven high-income countries (all represented in the review 
except for New Zealand), but that the UK (including Scotland) still has poorer 1- and 
5- year survival (570). Considering the persisting burden of cancer and the challenges 
in ensuring better cancer outcomes for all, helping to generate these discussions on 
how to move forward would be the most important contribution of this PhD project. 
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APPENDICES 
Appendix 1. MRC framework checklist 
1. Working with policy and practice stakeholders 
1.1 Are there any potential conflicts of interest 
arising from the relationship between 
evaluators and policy/practice stakeholders? 
Yes, these issues are addressed and discussed 
in Chapter 10 
1.2 Have the authors described how they will 
address these and ensure that the evaluation 
remains independent? 
Yes, the evaluation steering group I described 
in Chapter 3, issues are discussed in Chapter 
10 
1.3 Does the proposal set out a clear plan for 
communicating findings to policy and 
practice stakeholders during the evaluation?  
Yes, this is discussed in the thesis: 
stakeholders were involved from early stages 
(Chapter 3) and evaluation was disseminated 
as widely as possible (Chapter 10) 
2. Relationships between evaluation components 
2.1 Is the relationship between the process 
evaluation and other evaluation components 
clearly defined and justified? 
Yes, this is presented in Chapter 3, reiterated in  
Chapters 5-9 and discussed in Chapter 10 
2.2 Will process and outcomes evaluation be 
conducted by the same team or by separate 
teams? 
Conducted by one researcher, with advice from 
supervisors, a steering group and evaluation 
courses 
2.3 If the former, how will researchers ensure 
that knowledge of outcomes or process does 
not bias analysis of the other? 
This was addressed by constant reflexivity; the 
issue is discussed in Chapter 10 
2.4 If the latter, is there clear oversight of the 
two components?  
Yes, process and outcome evaluations were 
carried out independently and then integrated 
2.5 Is it clear that the principal investigator 
values all aspects of the evaluation, and will 
provide effective oversight of all aspects of the 
evaluation?  
There was constant supervision, and support 
from an evaluation steering group. I also 
attended several evaluation courses, including 
a course designed by the authors who 
developed the MRC framework adopted in this 
evaluation 
3. Intervention description and theory 
3.1 Is the intended intervention fully 
described? Are standardised terminology and 
definitions of intervention components 
adopted where possible?  
Yes, descriptions are available throughout the 
thesis (especially Chapter 5 and Chapters 5-9), 
in addition to Appendices 
3.2 Are the structures and processes involved 
in intervention delivery fully described? If 
appropriate, will a full intervention manual be 
made publicly available? 
There was no full description available; 
evaluation development and refinement was 
paramount for this. Publications are planned 
with full programme descriptions 
3.3 Is s a clear, plausible, set of causal 
assumptions specified and justified (for 
example, in a logic model)? 
Yes; the logic model was developed after 
analysing policy documents and refined after 
feedback from stakeholders; the outcomes 
chains were revisited after the full evaluation 
3.4 Does this draw upon appropriate theories? Yes; robust and well-recognised theories and 
frameworks were adopted; published guidance 
on how to implement them was followed 
3.5 If not, are there plans to develop a theory 
as part of the research? 
N/A 
3.6 Have the authors planned to review these 
assumptions with policy and practice 
stakeholders to explore agreement and 
divergence on what the intervention is, and 
how it will work? 
Yes, these were investigated during the 
evaluation and revisited afterwards. 
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4. Process evaluation aims and research questions 
4.1 Are the research questions clear, 
important and well justified with reference to 
the theory of the intervention and the status of 
the evidence base? What decisions will they 
inform?  
Yes, the research questions were informed by 
evidence, data collection and adopted theories. 
The aim was not only to generate knowledge 
but to inform policy 
4.2 Have the authors considered whether 
previous process evaluations have been 
conducted of interventions involving similar 
components or theories of change? 
Literature was consulted for similar evaluations. 
Terms and descriptions from the adopted 
frameworks/theories (BCW and theories of 
change, especially archetypes) were adopted in 
the evaluation 
4.3 Have they adopted comparable aims and 
methods, or justified not doing so? 
When it was not possible to use validated tools, 
definitions of adopted constructs were provided 
4.4 Has the theory of the intervention (or logic 
model) been used to identify key areas of 
uncertainty for investigation by process 
evaluation? 
The programme theory was informed by 
evidence and critical issues/uncertainties 
identified during evaluation development 
(documentary analysis and interviews) 
4.5 Have the authors considered which 
components may prove most challenging to 
implement (e.g. which represent more 
fundamental change, or for which there is 
least agreement on what they are and the 
purposes they serve)? 
Areas of disagreement/uncertainty were 
identified during evaluation development and 
investigated further 
4.6 Have the authors considered for which 
causal assumptions evidence is most 
equivocal? 
Several areas of uncertainty were investigated 
as it was not clear which one was most 
equivocal during evaluation development 
4.7 How will unanticipated consequences be 
captured? 
Due to limited data availability, these were 
investigated in the process evaluation only 
4.8 Is there linkage between research aims? Binding aims are described throughout the 
thesis, especially in Chapter 3 and figure 3.3 
4.9 Do they fit together to address the overall 
study aim? 
Yes, described in Chapter 3 and figure 3.3 
4.10 If conducted alongside an outcomes 
evaluation, is the added value of the process 
evaluation explained? Is it clear how the 
research will enhance the interpretation of 
outcomes? 
The rationale for a process evaluation is 
described in Chapter 3, its benefits are 
reiterated in Chapter 10 when integrating 
findings 
4.11 Will process evaluation provide sufficient 
assurances regarding the internal validity of 
the outcomes evaluation? 
There were several limitations when carrying 
out the outcome evaluation, but the process 
evaluation still helped to show why objectives 
were met/not met 
4.12 Will it enable policymakers/practitioners 
to understand how the intervention might be 
applied in different contexts?  
Contextual influencers were often approached, 
regional variation is outlined in Chapter 9, 
impact of variation is also approached in 
Chapter 10 
4.13 Have the authors stated how and when 
they will combine process and outcomes 
data?  
This is described in Chapters 3 and 10 
5. Selection of methods to address research questions 
5.1 Are the quantitative and qualitative 
methods selected appropriate to the research 
questions?  
These issues are comprehensively described 
and justified in Chapters 3-6 
5.2 Will implementation be captured in 
sufficient detail to establish consistency with 
the theory of the intervention?   
I tried to obtain and report on as much detail as 
possible 
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5.3 Are existing validated measures used 
where possible? Are plans to validate new 
measures included?  
These were used whenever possible (e.g. 
COM-B). When this was not possible (e.g. 
questionnaire), justification was provided and 
adopted concept/constructs were defined to 
enable comparisons. Currently, there are no 
plans to validate the evaluation questionnaire 
5.4 How will emerging changes, adaptations 
or additions to the intervention be captured?  
These issues are described in Chapter 9 and 
discussed in Chapter 10, acknowledging 
limitations to evaluate a dynamic programme 
5.5 Are the quantitative methods appropriate? 
(e.g. ‘tick box’ self-report by implementers of 
intervention delivery should be avoided if 
possible).  
It was impossible to avoid self-reporting, but the 
questionnaire reached stakeholders who were 
not involved in implementation. There were 
issues regarding representativeness. 
Limitations are discussed in Chapter 10 
5.6 Are the qualitative methods appropriate?  Purposive sampling and framework approach 
were chosen, justification and rationale are 
provided in Chapters 5 and 6 
5.7 Have the authors considered how change 
in practice as a result of being observed or 
measured will be minimised?  
N/A; the evaluation was carried out 
retrospectively 
5.8 Have the authors considered the timing of 
data collection, and its impact on the data 
collected?  
Yes, challenges and limitations are available in 
Chapter 10 
5.9 Have the authors investigated whether 
any routine programme monitoring data can 
be used? If so, are there plans to check their 
validity and reliability?  
Yes, policy documents were used as much as 
possible, for both evaluation development and 
the outcome evaluation. A framework for 
reviewing and interrogating data was developed 
based on available guidance 
5.10 Have the authors stated how quantitative 
and qualitative methods will be combined?  
Yes, this is approached in Chapters 3 (see 
Figure 3.3) and 10 
5.11 Have the authors considered how they 
will respond if challenges emerge during the 
evaluation - for example, if serious 
implementation failures are identified which 
need deeper investigation?  
This was not planned but was not needed 
6. Resource considerations in collecting/analysing process data 
6.1 Who will lead or conduct the process 
evaluation? Do they have, or have direct 
access to, appropriate expertise and 
experience?  
I was the lead (a PhD student). I am an 
experienced researcher and attended several 
courses on evaluation. I also had two 
supervisors and support from an evaluation 
steering group 
6.2 Does the research team have sufficient 
expertise in quantitative and qualitative 
methods, and relevant social science theory?  
I have a diverse background (business and 
psychology), and experience in qualitative and 
quantitative methods. I immersed myself in 
theory for several months in order to develop 
the DCE evaluation 
6.3 Is sufficient time, funding and staff 
resource included for data collection, analysis 
(including sufficient time to conduct good 
quality analysis of qualitative data, with quality 
checks by a second coder where appropriate) 
and reporting?  
Yes; the evaluation was carried out as part of a 
full-time PhD, with full-time dedication. 
Sampling for interviews considered the time 
resources available to analyse data. One of my 
supervisors also read transcripts and helped to 
refine the thematic framework 
Source: Moore et al 2014. Process evaluation of complex interventions. Available from: 
https://mrc.ukri.org/documents/pdf/mrc-phsrn-process-evaluation-guidance-final/  
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Appendix 3. List of additional publications included in the review 
N   Reference Source Initiative Type of reference 
1 Allgar VL, Neal RD, Ali N, et al. Urgent GP referrals for suspected lung, colorectal, prostate and 
ovarian cancer. Br J Gen Pract. 2006;56(526):355-62. 
website 
or other 
2WW full paper 
2 Barrett J, Jiwa M, Rose P, et al. Pathways to the diagnosis of colorectal cancer: an observational 
study in three UK cities. Fam Pr. 2006;23(1):15-9. 
database 
search 
2WW full paper 
3 Beggs AD, Bhate RD, Irukulla S, et al. Straight to colonoscopy: The ideal patient pathway for the 
2-week suspected cancer referrals? Ann R Coll Surg Engl. 2011;93(2):114-9. 
database 
search 
2WW full paper 
4 Bethell GS, Leftwick P. Views of general practitioners and head and neck surgeons on the referral 
system for suspected cancer: a survey. J Laryngol Otol. 2015;129(9):893-7. 
database 
search 
2WW full paper 
5 Blick C, Bailey D, Haldar N, et al. The impact of the two-week wait rule on the diagnosis and 
management of bladder cancer in a single UK institution. Ann R Coll Surg Engl  2010;92(1):46-50. 
reference 
lists 
2WW full paper 
6 Chohan DPK, Goodwin K, Wilkinson S, et al. How has the ‘two-week wait’ rule affected the 
presentation of colorectal cancer? Colorectal Disease. 2005;7(5):450-3. 
reference 
lists 
2WW full paper 
7 Currie AC, Evans J, Smith NJ, et al. The impact of the two-week wait referral pathway on rectal 
cancer survival. Colorectal Disease. 2012;14(7):848-53. 
database 
search 
2WW full paper 
8 Department of Health. Impact Assessment of the introduction of a right to access services within 




9 Department of Health. Implementation of the right to access services within maximum waiting 




10 Department of Health. Improving Outcomes: A Strategy for Cancer. Department of Health, 2011. website 
or other 
2WW Official Cancer 
Plan or Strategy 
11 Dua RS, Brown VS, Loukogeorgakis SP, et al. The two-week rule in colorectal cancer. Can it 
deliver its promise? Int J Surg. 2009;7(6):521-5. 
reference 
lists 
2WW full paper 
12 Duvvi SK, Thomas L, Vijayanand S, et al. Two-week rule for suspected Head and neck cancer. A 
study of compliance and effectiveness. J Eval Clin Pract. 2006;12(6):591-4. 
reference 
lists 
2WW full paper 
13 Executive S. Scottish Referral Guidelines for Suspected Cancer. Scottish Executive,, 2007. website 
or other 
2WW Report 
14 Hamilton W. Diagnosing symptomatic cancer in the NHS: Fast track referral is one part of an 
improving picture. BMJ. 2015;351 (h5311). 
database 
search 
2WW full paper 
15 Hancox T. National Cancer Waiting Times Monitoring Dataset Specification. Verson 2.1. 
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17 Hobson JC, Malla JV, Sinha J, et al. Outcomes for patients referred urgently with suspected head 
and neck cancer. J Laryngol Otol. 2008;122(11):1241-4. 
database 
search 
2WW full paper 
18 Hodder RJ, Ballal M, Selvachandran SN, et al Variations in the evaluation of colorectal cancer risk. 
Colorectal Dis. 2005;7(3):254-62. 
reference 
lists 
2WW full paper 
19 Humphries A, Clarke J, Bhatnagar G, et al. A new lower gastrointestinal 2-week wait -direct to test' 




20 John SK, Jones OM, Horseman N, et al. Inter general practice variability in use of referral 
guidelines for colorectal cancer. Colorectal Dis. 2007;9(8):731-5. 
reference 
lists 
2WW full paper 




2WW news, blogs, 
correspondence 
22 Leung E, Grainger J, Bandla N, et al. The effectiveness of the '2-week wait' referral service for 
colorectal cancer. Int J Clin Pract. 2010;64(12):1671-4. 
reference 
lists 
2WW full paper 
23 Lim M, Al-Naib S, Fazel M. Do all GP referrals really need to be seen within 2 weeks in the breast 




24 Maruthachalam K, Stoker E, Chaudhri S, et al. Evolution of the two-week rule pathway – direct 
access colonoscopy vs outpatient appointments: one year's experience and patient satisfaction 
survey. Colorectal Dis. 2005;7(5):480-5. 
reference 
lists 
2WW full paper 
25 McKie C, Ahmad UA, Fellows S, et al. The 2-week rule for suspected head and neck cancer in the 




2WW full paper 
26 Miller CC, Hierons RJ. Two audits of the diagnosis of oral cancer and the two-week rule following 
referrals from primary care practitioners in newcastle. Primary Dental Care. 2012;19(2):63-8. 
database 
search 
2WW full paper 
27 Mukherjee S, Fountain G, Stalker M, et al. The 'straight to test' initiative reduces both diagnostic 




2WW full paper 




2WW full paper 
29 National Cancer Intelligence Network. Urgent GP referral rates for suspected cancer. NCIN Data 




30 National Institute for Health and Care Excellence. Referral guidelines for suspected cancer. 
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31 Nicholson BD, Oke JL, Rose PW, et al. Variation in Direct Access to Tests to Investigate Cancer: 
A Survey of English General Practitioners. PloS one. 2016;11(7):e0159725. 
reference 
lists 
2WW full paper 
32 Pacifico MD, Pearl RA, Grover R. The UK government two-week rule and its impact on melanoma 
prognosis: An evidence-based study. Ann R Coll Surg Engl. 2007;89(6):609-15. 
database 
search 
2WW full paper 
33 Patel RK, Sayers AE, Seedat S, et al. The 2-week wait service: a UK tertiary colorectal centre's 




2WW full paper 
34 Pencavel TD, Strauss DC, Thomas GP, et al. Does the two-week rule pathway improve the 
diagnosis of soft tissue sarcoma? A retrospective review of referral patterns and outcomes over 
five years in a regional sarcoma centre. Ann R Coll Surg Engl 2010;92(5):417-21. 
database 
search 
2WW full paper 
35 Potter S, Govindarajulu S, Shere M, et al. Referral patterns, cancer diagnoses, and waiting times 




2WW full paper 
36 Rai S, Kelly MJ. Prioritization of colorectal referrals: a review of the 2-week wait referral system. 
Colorectal Dis. 2007;9(3):195-202. 
reference 
lists 
2WW full paper 
37 Redaniel MT, Ridd M, Martin RM, et al. Rapid diagnostic pathways for suspected colorectal 
cancer: views of primary and secondary care clinicians on challenges and their potential solutions. 
BMJ Open. 2015;5(10):e008577. 
Database 
search 
2WW full paper 
38 Savage SA, Wotherspoon HA, Pentland D, et al. Cancer waiting times: what is the value of a 
lymphoma waiting time? Scott Med J. 2008;53(3):5-7. 
reference 
lists 
2WW full paper 
39 Sharpe D, Williams RN, Ubhi SS, et al. The "two-week wait" referral pathway allows prompt 




2WW full paper 
40 Shaw AG, Simpson J, Tierney G, et al. Referral of patients with iron deficiency anaemia under the 
lower gastrointestinal two-week wait rule. Colorectal Dis. 2008;10(3):294-7. 
reference 
lists 
2WW full paper 
41 Singh P, Warnakulasuriya S. The two-week wait cancer initiative on oral cancer; the predictive 
value of urgent referrals to an oral medicine unit. Br Dent J. 2006;201(11):717-20. 
database 
search 
2WW full paper 
42 Singhal R, Marudanayagam R, Balasubramanian B, Paterson IS. Managing the 2-Week Wait for 
Breast Patients. Ann R Coll Surg Engl. 2008;90(1):69-71. 
reference 
lists 
2WW full paper 
43 Sladden MJ, Mortimer NJ, Chave TA, et al. Melanoma in Leicestershire: effect of the 2-week wait 
system on presentation. Br J  Dermatol. 2006;154(5):1017. 
reference 
lists 
2WW news, blogs, 
correspondence 
44 Smith RA, Oshin O, McCallum J, et al. Outcomes in 2748 patients referred to a colorectal two-
week rule clinic. Colorectal Dis. 2007;9(4):340-3. 
reference 
lists 
2WW full paper 
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2WW full paper 
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database 
search 
2WW full paper 
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Qual Prim Care. 2006;14:185–92. 
website 
or other 
2WW full paper 
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49 Webb JB, Khanna A. Can we rely on a general practitioner's referral letter to a skin lesion clinic to 




2WW full paper 
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Appendix 4. Review search strategies 
Web of Science Core Collection 
17 (#16) AND LANGUAGE: (English)  DocType=All document types; Language=All languages; 
#16 #11 NOT #15 
#15 #14 OR #13 OR #12 
#14 TI=(biomarker* or molecul*) 
#13 TI=(palliative or terminal or "end of life" or end-of-life or "advance directive*" or hospice*) 
#12 TI=(child* or pediatric* or paediatric* or adolesc* or teenag*) 
#11 #10 AND #9 AND #8 AND #2 AND #1 
#10 
TS=(Randomi* or RCT or intervention or trial or cross-sectional or survey* or questionnaire* or 
train* or "natural experiment" or interview* or "focus group*" or "case study" or observation* or 
time-series or "time series" or CBA or "controlled before and after" or "controlled before-after" 
or prospective or retrospective or cohort or case-control or cross-over or "case series" or case-
reports or "case reports" or feasibility or pilot or narrative or qualitative or quantitative or mixed-
methods or "mixed methods" or evaluat* or assess* or attitude* or view* or perception* or 
perspective* or "discourse analysis" or "content analysis" or "thematic analysis" or "narrative 
analysis" or phenomenolog* or "purposive sampl*" or ethnograph* or "theoretical sampl*" or 
"grounded theory") 
#9 TS=(Cancer* or neoplas* or tumour or tumor or malign* or oncolog*) 
#8 #7 OR #6 OR #5 OR #4 OR #3 
#7 TS=(late near/4 diagnos*) OR TS=(late near/4 treat*) OR TS=(late near/4 refer*) OR TS=(late near/4 present*) OR TS=(late near/4 detect*) 
#6 TS=(earl* near/4 diagnos*) OR TS=(earl* near/4 present*) OR TS=(earl* near/4 treat*) OR TS=(earl* near/4 refer*) OR TS=(earl* near/4 therap*) OR TS=(earl* near/4 detect*) 
#5 TS=(time near/4 diagnos*) OR TS=(time near/4 present*) OR TS=(time near/4 treat*) OR TS=(time near/4 refer*) OR TS=(time near/4 care) OR TS=(time near/4 detect*) 
#4 
TS=(delay* near/4 diagnos*) OR TS=(delay* near/4 present*) OR TS=(delay* near/4 treat*) OR 
TS=(delay* near/4 consult*) OR TS=(delay* near/4 patient*) OR TS=(delay* near/4 doctor*) OR 
TS=(delay* near/4 system*) OR TS=(delay* near/4 refer*) OR TS=(delay* near/4 therap*) OR 
TS=(delay* near/4 care) OR TS=(delay* near/4 detect*) 
#3 TS=(surviv*) 
#2 TS=(health* near/2 care) OR TS=(health* near/2 service*) OR TS=(health* near/2 system*) OR TS=(health* near/2 seek*) OR TS=(health* near/2 provi*) 
#1 
TS=(government or policy* or policies or national or regional or multi-level* or system-level or 
whole-system* or NAEDI or "Detect Cancer Early" or "National Awareness and Early Diagnosis 
Initiative" or "Find Cancer Early" or "Be Cancer Aware" or "Be Clear on Cancer" or initiative* or 
program* or campaign* or strateg* or engagement or awareness) 
 
Cochrane library 
Search Name: Cochrane_130916_corrected 
Last Saved: 13/09/2016 14:12:44 
ID Search 
#1 government or policy* or policies or national or regional or multi-level* or system-level or whole-
system* or NAEDI or "Detect Cancer Early" or "National Awareness and Early Diagnosis Initiative" or 
"Find Cancer Early" or "Be Cancer Aware" or "Be Clear on Cancer" or initiative* or program* or 
campaign* or strateg* or engagement or awareness with Publication Year from 2005 to 2016 
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#2 health* near/2 (care or service* or system* or seek* or provi*) with Publication Year from 2005 
to 2016 
#3 surviv* with Publication Year from 2005 to 2016 
#4 delay* near/4 (diagnos* or present* or treat* or consult* or patient* or doctor* or system* or 
refer* or therap* or care or detect*) with Publication Year from 2005 to 2016 
#5 time near/4 (diagnos* or present* or treat* or refer* or care or detect*) with Publication Year 
from 2005 to 2016 
#6 late near/4 (diagnos* or treat* or refer* or present* or detect*) with Publication Year from 2005 
to 2016 
#7 earl* near/4 (diagnos* or present* or treat* or refer* or therap* or detect*) with Publication Year 
from 2005 to 2016 
#8 #3 or #4 or #5 or #6 or #7 
#9 Cancer* or neoplas* or tumour or tumor or malign* or oncolog* with Publication Year from 2005 
to 2016 
#10 Randomi* or RCT or intervention or trial or cross-sectional or survey* or questionnaire* or train* 
or "natural experiment" or interview* or "focus group*" or "case study" or observation* or time-series or 
"time series" or CBA or "controlled before and after" or "controlled before-after" or prospective or 
retrospective or cohort or case-control or cross-over or "case series" or case-reports or "case reports" 
or feasibility or pilot or narrative or qualitative or quantitative or mixed-methods or "mixed methods" or 
evaluat* or assess* or attitude* or view* or perception* or perspective* or "discourse analysis" or 
"content analysis" or "thematic analysis" or "narrative analysis" or phenomenolog* or "purposive sampl*" 
or ethnograph* or "theoretical sampl*" or "grounded theory" with Publication Year from 2005 to 2016 
#11 #1 and #2 and #8 and #9 and #10 
#12 child* or pediatric* or paediatric* or adolesc* or teenag*.ti 
#13 palliative or terminal or "end of life" or end-of-life or "advance directive*" or hospice*:ti 
#14 biomarker* or molecul*:ti 
#15 #12 or #13 or #14 
#16 #11 not #15 
#17 #16 with Publication Year from 2005 to 2016 
 
PROQUEST (Dissertations and Theses Global) 
noft(government OR policy* OR policies OR national OR regional OR healthcare OR multi-level* OR 
system-level OR whole-system* OR NAEDI OR "Detect Cancer Early" OR "National Awareness and 
Early Diagnosis Initiative" OR "Find Cancer Early" OR "Be Cancer Aware" OR "Be Clear on Cancer" 
OR initiative* OR program* OR campaign* OR strateg* OR engagement OR awareness) AND 
noft(health* NEAR/2 (care OR service* OR system* OR seek* OR provi*)) AND (noft(surviv*) OR 
noft(delay* NEAR/4 (diagnos* OR present* OR treat* OR consult* OR patient* OR doctor* OR system* 
OR refer* OR therap* OR care OR detect*)) OR noft(time NEAR/4 (diagnos* OR present* OR treat* OR 
refer* OR care OR detect*)) OR noft(late NEAR/4 (diagnos* OR treat* OR refer* OR present* OR 
detect*)) AND noft(earl* NEAR/4 (diagnos* OR present* OR treat* OR refer* OR therap* OR detect*))) 
AND noft(Cancer* OR neoplas* OR tumour OR tumor OR malign* OR oncolog*) AND noft(Randomi* 
OR RCT OR intervention OR trial OR cross-sectional OR survey* OR questionnaire* OR train* OR 
"natural experiment" OR interview* OR "focus group*" OR "case study" OR observation* OR time-series 
OR "time series" OR CBA OR "controlled before and after" OR "controlled before-after" OR prospective 
OR retrospective OR cohort OR case-control OR cross-over OR "case series" OR case-reports OR 
"case reports" OR feasibility OR pilot OR narrative OR qualitative OR quantitative OR mixed-methods 
OR "mixed methods" OR evaluat* OR assess* OR attitude* OR view* OR perception* OR perspective* 
OR "discourse analysis" OR "content analysis" OR "thematic analysis" OR "narrative analysis" OR 
phenomenolog* OR "purposive sampl*" OR ethnograph* OR "theoretical sampl*" OR "grounded 
theory") NOT ti(child* or pediatric* or paediatric* or adolesc* or teenag*) NOT ti(palliative or terminal or 
"end of life" or end-of-life or "advance directive*" or hospice*) NOT ti(biomarker* or molecul*) 
 
PROQUEST (ASSIA, IBSS, PAIS) 
(government OR policy* OR policies OR national OR regional OR healthcare OR multi-level* OR 
system-level OR whole-system* OR NAEDI OR "Detect Cancer Early" OR "National Awareness and 
Early Diagnosis Initiative" OR "Find Cancer Early" OR "Be Cancer Aware" OR "Be Clear on Cancer" 
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OR initiative* OR program* OR campaign* OR strateg* OR engagement OR awareness) AND (health* 
NEAR/2 (care OR service* OR system* OR seek* OR provi*)) AND ((surviv*) OR (delay* NEAR/4 
(diagnos* OR present* OR treat* OR consult* OR patient* OR doctor* OR system* OR refer* OR therap* 
OR care OR detect*)) OR (time NEAR/4 (diagnos* OR present* OR treat* OR refer* OR care OR 
detect*)) OR (late NEAR/4 (diagnos* OR treat* OR refer* OR present* OR detect*)) AND (earl* NEAR/4 
(diagnos* OR present* OR treat* OR refer* OR therap* OR detect*))) AND (Cancer* OR neoplas* OR 
tumour OR tumor OR malign* OR oncolog*) AND (Randomi* OR RCT OR intervention OR trial OR 
cross-sectional OR survey* OR questionnaire* OR train* OR "natural experiment" OR interview* OR 
"focus group*" OR "case study" OR observation* OR time-series OR "time series" OR CBA OR 
"controlled before and after" OR "controlled before-after" OR prospective OR retrospective OR cohort 
OR case-control OR cross-over OR "case series" OR case-reports OR "case reports" OR feasibility OR 
pilot OR narrative OR qualitative OR quantitative OR mixed-methods OR "mixed methods" OR evaluat* 
OR assess* OR attitude* OR view* OR perception* OR perspective* OR "discourse analysis" OR 
"content analysis" OR "thematic analysis" OR "narrative analysis" OR phenomenolog* OR "purposive 
sampl*" OR ethnograph* OR "theoretical sampl*" OR "grounded theory") NOT ti(child* OR pediatric* 
OR paediatric* OR adolesc* OR teenag*) NOT ti(palliative OR terminal OR "end of life" OR end-of-life 
OR "advance directive*" OR hospice*) NOT ti(biomarker* OR molecul*) 
 
EBSCO 
TX ( government or policy* or policies or national or regional or multi-level* or system-level or whole-
system* or NAEDI or "Detect Cancer Early" or "National Awareness and Early Diagnosis Initiative" or 
"Find Cancer Early" or "Be Cancer Aware" or "Be Clear on Cancer" or initiative* or program* or 
campaign* or strateg* or engagement or awareness ) AND TX ( Health* N2 (care or service* or system* 
or seek* or provi*) AND (TX ( (delay* N4 (diagnos* or present* or treat* or consult* or patient* or doctor* 
or system* or refer* or therap* or care or detect*)) OR (time N4 (diagnos* or present* or treat* or refer* 
or care or detect*)) OR (late N4 (diagnos* or treat* or refer* or present* or detect*)) OR (earl* N4 
(diagnos* or present* or treat* or refer* or therap* or detect*)) OR (surviv*) )) AND TX ( Cancer* or 
neoplas* or tumour or tumor or malign* or oncolog* ) AND TX ( Randomi* or RCT or intervention or trial 
or cross-sectional or survey* or questionnaire* or train* or "natural experiment" or interview* or "focus 
group*" or "case study" or observation* or time-series or "time series" or CBA or "controlled before and 
after" or "controlled before-after" or prospective or retrospective or cohort or case-control or cross-over 
or "case series" or case-reports or "case reports" or feasibility or pilot or narrative or qualitative or 
quantitative or mixed-methods or "mixed methods" or triangulat* or evaluat* or assess* or attitude* or 
view* or perception* or perspective* or "discourse analysis" or "content analysis" or "thematic analysis" 
or "narrative analysis" or phenomenolog* or "purposive sampl*" or ethnograph* or "theoretical sampl*" 
or "grounded theory ) AND TX ( NOT (child* or pediatric* or paediatric* or adolesc* or teenag*) ) AND 
TX ( not (palliative or terminal or "end of life" or end-of-life or "advance directive*" or hospice*) ) AND 
TX ( not (biomarker* or molecul*) )  
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Appendix 5. Data extraction template 
Reviewer’s initials:   
Date of data extraction (completion):  
 
General Information 
Study ID (from EndNote):  
Publication Title:  
Publication year and 
Journal/Publisher 
 
N and Study ID of publications about the same study (or other supporting information 
sources): 
Country and region within country where study took place: 
Language □ English □ other (specify): 
 
Inclusion criteria (final check) 
Is the initiative aiming to promote earlier 
cancer diagnosis or improve cancer 
survival? 
□ Yes □ No □ Unclear 
(discuss with peers) 
Is it aiming to promote earlier cancer 
diagnosis/ improve survival for adults (18 
and older)? 
□ Yes □ No □ Unclear 
(discuss with peers) 
Is it a health system level initiative? □ Yes □ No □ Unclear 
(discuss with peers) 
It is a multi-level initiative (as per Taplin et 
al’s model)? □ Yes □ No □ Unclear 
(discuss with peers) 
Does the publication type meet inclusion 
criteria (reviews, overviews, editorials, 
commentaries and published guidelines are 
to be excluded)? 
□ Yes □ No □ Unclear 
(discuss with peers) 
ONLY PROCEED IF THE STUDY MEETS INCLUSION CRITERIA 
  
Study design 
Study type □ qualitative □ quantitative □ mixed 
methods 
If a qualitative study or with a 
qualitative component, please specify 
design (multiple options possible): 
□ interviews □ focus groups □ observation 
□ other (specify):  
If a quantitative study or with a 
quantitative component, please 




□ observational study (specify): 
□ case-control 
□ ITS 
□ before-after (controlled or 
not)/pre-post 
□ cross-sectional 
□ natural experiment 
□ other (specify): 
RCT: randomised controlled trial; CCT: controlled clinical trial; ITS: interrupted time series 
   
395 
 
Study characteristics (all study designs) 
Study aim(s):  
Is an evidence base 
given for the initiative? □ Yes (specify):  
 
□ No  
□ Unclear 
Is a theoretical 
rationale given for the 
initiative? 
□ Yes (specify):  
 
□ No  
□ Unclear 
Are any relevant health 
policies mentioned? □ Yes (specify):  
 
□ No  
□ Unclear 
Target population:  
Who is carrying out the initiative (key stakeholders)? 
 
Contextual information – (e.g. universal health care provision, cultural, geographical, political 
issues, etc.) 
 
How many levels does the initiative cover and what are they (as per Taplin et al’s model)? 
 
Has the study finished? □ Yes (and results are reported): 
□ Yes (but results are not reported) 
□ No, but preliminary results are reported 
□ No, and no results 
are reported 
□ Unclear 
   
Quantitative studies only OR quantitative components of a mixed-methods study 
Study design (if RCT report if blinding occurred) 
Sampling strategy   
Setting   
Population characteristics (if there is more than one group report these separately) 
 
Intervention components (if there is more than one group report these separately and explain 
what the control group received) 
 
Time duration of the intervention 
 
Outcome measures (including definition of outcomes such as survival, etc.) 
 
According to the NAEDI’s model (Hiom 2015), which factors influencing survival are being 
taken into account? 
 
Measurement tools (including time points investigated) 
 






□ Yes (specify):  
 




Authors’ interpretation of results 
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Any reported barriers/facilitators? (even if only in the discussion section) 
 
Any reported implementation issues? (even if only in the discussion section) 
 
 
Qualitative studies only OR qualitative components of a mixed-methods study 
Study design   
Sampling strategy   
Setting   
Population 
characteristics (if there 




Main components of 
the initiative (if there is 




Time duration of the 
study 
  
Phenomena of interest   
According to the 
NAEDI’s model (Hiom 
2015), are any factors 
influencing survival 
being discussed? 
□ Yes (specify):  
 
□ No  
□ Unclear 
Data collection tools   








□ Yes (specify):  
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Appendix 6. Results from quality assessment 
Quantitative studies and mixed-method studies with a quantitative component (n=19) 
Strategy References Q1 Q2 Q3 Q4A Q4b Q5A Q5B Q6A Q6B Q6C Q7A Q7B Q7C Q7D Q8 
2WW 
Meechan et 




add yes N/A no yes yes yes no yes 
Møller et al 




add yes N/A 
not 
add yes yes yes no yes 
Neal et al 




add yes N/A no yes yes yes no yes 
BCOC 
Ironmonger 




add yes yes yes no yes 
Moffat et al 
2015 yes yes BA and CS no no yes yes yes N/A 
not 
add yes yes no no yes 
Power et al 
2015 yes yes BA yes no 
not 
add yes yes 
not 
add yes yes yes yes N/A yes 
CPPs 
Denmark 
Jensen et al 




add yes N/A 
not 
add yes yes yes no yes 
Jensen et al 
2015 yes yes natural experiment yes N/A 
not 
add yes yes N/A 
not 
add yes yes yes no yes 
Jensen et al 








add yes yes yes N/A yes 
Olesen et al 












add N/A N/A yes 
Probst et al 
2012 yes yes 
not stated 










add N/A yes 
Fast-track 
Catalonia 
Prades et al 
2011 yes yes 
not stated 
























add yes yes yes 
Inside 
knowledge 
Cooper et al 




add yes N/A no yes yes 
not 
add no yes 
Cooper et al 




add yes N/A N/A N/A yes no no yes 
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Strategy References Q1 Q2 Q3 Q4A Q4b Q5A Q5B Q6A Q6B Q6C Q7A Q7B Q7C Q7D Q8 
NAEDI Rubin et al 2015 yes yes BA yes N/A yes yes no no 
not 




al 2015 yes yes cross-sectional yes N/A yes yes yes N/A 
not 





al 2012 yes no 
not stated 















Lopez et al 
2012 
yes yes case control yes N/A not add 
not 




add yes yes yes 
N/A: not applicable: not add: not addressed; BA: before and after; Q: question. Source: included studies 
Qualitative studies and mixed-method studies with a qualitative component (n=13) 
Strategy References Pub Type Q1 Q2 Q3 Q4A Q5 Q6 Q7 Q8 Q9 Q10 








poor poor poor fair 
CPPs 
Denmark 
Olesen et al 
2009 
qualitative 
















poor fair fair fair 
Fast-track 
Catalonia 
Prades et al 
2011 
qualitative 
component (MM) fair good fair good good Fair 
very 
poor fair fair poor 
Inside 
Knowledge 
Rim et al 












































poor poor poor poor 
Richards 








poor poor poor fair 
Rubin et al 
2015 
qualitative 




poor fair fair fair 
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Howitt et al 





























poor poor poor 
Q: question; N/A: not applicable; MM: mixed methods. Source: included studies 
Reviews (n=3) 
References Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 
Hanna et al 2005 yes can't tell no can't tell no can't tell no yes partially mid-range extensive to major flaws 
Harrison & Foot 2012 partially can't tell partially can't tell no can't tell no yes yes mid-range extensive to major flaws 
Lewis et al 2005 
Lewis et al 2005 yes yes yes yes yes yes yes yes yes minimal flaws 
Quality assessment was merged for both of Lewis publications as they refer to the same review. If one of the publications had the required 
information but the other one did not, then the best rating was considered. Source: included studies. 
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Interrater reliability: % agreement, kappa and strength of 
agreement 










Q1 94.7% Not calculated N/A N/A 
Q2 68.4% 0.109 (-0.095 - 0.508) slight 0.554 
Q3 57.9% 0.729 (0.611 - 0.960) substantial <0.001 
Q4A 63.2% 0.232 (0.058 - 0.573) fair 0.216 
Q4B 57.9% 0.244 (0.071 - 0.583) fair 0.142 
Q5A 57.9% 0.24 (0.107 - 0.500) fair 0.107 
Q5B 57.9% 0.283 (0.149 - 0.545) fair 0.077 
Q6A 68.4% 0.288 (0.143 - 0.572) fair 0.029 
Q6B 57.9% 0.228 (0.05 - 0.576) fair 0.216 
Q6C 42.1% 0.114 (-0.02 - 0.376) slight 0.283 
Q7A 89.5% 0.719 (0.554 - 1.04) substantial <0.001 
Q7B 84.2% 0.565 (0.343 - 1.000) Moderate 0.013 
Q7C 73.7% 0.431 (0.262 - 0.762) Moderate 0.006 
Q7D 73.7% 0.585 (0.444 - 0.861) Moderate <0.001 










Q1 61.5% 0.524 (0.155-0.893) Moderate 0.007 
Q2 69.2% 0.639 (0.335-0.943) substantial 0.002 
Q3 53.8% 0.636 (0.321-0.950) substantial 0.002 
Q4 69.2% 0.823 (0.675-0.971) Almost perfect 0.001 
Q5 61.5% 0.776 (0.541-1.010) Substantial 0.003 
Q6 92.3% Not calculated N/A N/A 
Q7 100% Not calculated N/A N/A 
Q8 46.2% 0.366 (0.152-0.580) fair 0.008 
Q9 69.2% 0.656 (0.328-0.985) substantial 0.007 








Q1 75% 0.364 (-0.211-0.939) fair 0.212 
Q2 100% 1.000 (1.000-1.000) Almost perfect 0.008 
Q3 75% 0.851 (0.594-1.108) Almost perfect 0.013 
Q4 50% Not calculated N/A N/A 
Q5 100% 1.000 (1.000-1.000) Almost perfect 0.008 
Q6 75% 0.632 (0.393-0.870) Substantial 0.008 
Q7 100% 1.000 (1.000-1.000) Almost perfect 0.008 
Q8 100% Not calculated N/A N/A 
Q9 75% Not calculated N/A N/A 
Q10 75% 0.881 (0.764-0.999) Almost perfect 0.009 
K: kappa; CI: Confidence intervals. Significant p-values indicate that agreement is 
significantly different from what would be achieved by chance. Kappa was not 
calculated when all ratings were the same for at least one rater; in these cases SPSS 
considers that the variable is a constant as there is no variation, and measures of 
association are not calculated. 
 
   
401 
Appendix 7. Outcomes from review searches 
Database searches – all searched on 13/09/2016 
Search platform Database Hits Duplicates Total without duplicates 
OVID (.mp) 
MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid 
MEDLINE(R) 1946 to Present 4741 327 4414 
Embase Classic+Embase 1947 to 2016 September 13 9698 216 9482 
PsycARTICLES Full Text 1011 6 1005 
PsycINFO 1806 to July Week 4 2016 569 1 568 
Web of Science (topic) 
Core Collection Timespan: 2005-2016. Indexes:SCI-EXPANDED, SSCI, 
CPCI-S, CPCI-SSH 2634 1 2633 
SciELO Citation Index Collection Timespan: 2005-2016 20 0 20 
Cochrane Library 
(search all text) 
Database of Abstracts of Reviews of Effect : Issue 2 of 4, April 2015 35 
24 
11 
Health Technology Assessment Database : Issue 3 of 4, July 2016 22 22 
NHS Economic Evaluation Database : Issue 2 of 4, April 2015 287 287 
Cochrane Central Register of Controlled Trials : Issue 8 of 12, August 2016 461 461 
Cochrane Database of Systematic Reviews : Issue 9 of 12, September 2016 302 302 
EBSCO (all fields) CINAHL Plus 1778 35 1743 SocINDEX with Full Text 
PROQUEST 
(anywhere) 
Applied Social Sciences Index and Abstracts (ASSIA) (1987 - current)  
301 29 272 International Bibliography of the Social Sciences (IBSS) (1951 - current) 
PAIS Index (1914 - current)  
PROQUEST 
(anywhere but full-text) 
ProQuest Dissertations & Theses Global 256 2 254 
Total 22115 641 21474 
Total after merging files and removing papers published before 2005   21331 
Total after merging file and removing dups  6485 14846 
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Searches – Other Digital sources 
Region Website Results Search date 
UK 





• 2923 publications; 139 with the word cancer 
• Several publications on Be Clear on Cancer, ACE 
• Several publications on the 2011 National Cancer Strategy, GP 
databases, Cancer Waiting Times and Guidance and Cancer Referrals, 
Cancer Plans in England 
26/04/2017 
UK 
The Knowledge Network (NHS e-library) 
http://www.knowledge.scot.nhs.uk/home.as
px 
• Looked for Cancer AND (programme or initiative or strategy or 
campaign – title only) AND (early detection or early diagnosis) - 211 hits 
• Changed programme or initiative or strategy or campaign to any field 
instead of title only, then got 1277 results; - several references included 
as part of already identified initiatives (BCOC, NAEDI, 2WW) 
11/06/2017 
UK 




• 13 results when searching for the word cancer 26/04/2017 
UK Healthcare Management Information Consortium (HMIC) database (EBSCO) 
• 97 hits (88 after duplicates), five kept for further examination – two 
eligible but already included, two reviews kept for checking references 11/06/2017 
US 




• Checked the cancer specific page only (https://www.cdc.gov/cancer/). 
Most screening only, or already included (i.e. Inside Knowledge) 
• Searched for “cancer” at the NCCD website (2005-2017), found 704 
publications. Restricted it to “detection OR diagnosis OR pathway OR 
referral” and found 47 hits – all about screening. Searched for 
“awareness” and found two publications for Inside Knowledge 
• References to initiatives across the US carried out as part of 
Comprehensive Cancer Control Programmes, but none met inclusion 
criteria. There were 66 Cancer Plans available for US States and 









• IARC staff publications http://www.iarc.fr/en/publications/scientific-
papers/index.php. Using keywords: referral awareness diagnosis 
detection programme program initiative campaign strategy survival 
delay engage (title searches, 2005-2017) – 265 hits – none eligible 
27/04/2017 
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Region Website Results Search date 
• IARC Databases, publications, page for the IARC Screening Group, 
Cancer Topics page, guidebooks for early detection, and publications 
list for the Early Detection and Prevention Groups – no new initiatives 
• IARC Book and Report Series – checked all sections on early 
detection/prevention for all biannual reports (2015/2015, 2012/2013, 
2010/2011,and 2008/2009) –none eligible. 
Worldwide CORDIS http://cordis.europa.eu/home_en.html 
• Cancer AND early retrieved 2309 hits – research studies and 
collaborative research, but none eligible 27/04/2017 
Worldwide 
OECD iLibrary http://www.oecd-ilibrary.org/  • 198 results for All Fields containing ‘cancer’ AND All Fields containing 
‘early’ OR All Fields containing ‘referral’ - none eligible 
• Cancer Care and improving survival (online access only): 
http://www.oecd-ilibrary.org/social-issues-migration-health/cancer-
care_9789264181052-en  – refers to waiting times for several 
countries, but no new eligible initiatives were identified 
• Specific report focusing on waiting times - no new eligible initiatives 
27/04/2017 
UK 
Cancer Research UK 
https://www.cancerresearchuk.org/ 
• “early diagnosis” retrieved 378 pages of hits - 3,772 results, “detection” 
retrieved 325 hits in 33 pages 
• Range of ED initiatives; references to studies relevant for background 
information, to Be Clear on Cancer, NICE guidance for urgent referrals, 
ACE, DCE, NAEDI – additional references of included initiatives. Small 
research studies that did not meet criteria, links to all UK Cancer plans 
02/05/2017 
UK Marie Curie https://www.mariecurie.org.uk/ • Cancer AND early retrieved 575 results; diagnosis retrieved 102 results – focus on end of life care, no eligible initiatives 01/05/2017 
UK 
Macmillan Cancer Support 
https://www.macmillan.org.uk/ 
• "early diagnosis" OR "early detection" – 25 hits; “routes to diagnosis” – 
35 hits; “diagnostic pathways” – 7 hits 
• Eligible ACE documents, other local initiatives did not meet criteria 
01/05/2017 
UK 
The King’s Fund 
https://www.kingsfund.org.uk/ 
King’s Fund Library 
• “Cancer” retrieved 642 results, no new eligible initiatives. 
• Library Database: searched for 'ti,wrdl: cancer and kw,wrdl: early or 
kw,wrdl: referral' with limit(s): 'yr,st-numeric=2005-2017'  - 837 results, 




UK The Nuffield Trust https://www.nuffieldtrust.org.uk/ 
• Keyword cancer from 2005-2017 retrieved 111 results – none eligible 27/04/2017 
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Region Website Results Search date 
UK 
National Cancer Research Institute 
http://www.ncri.org.uk/ 
• One reference to NAEDI, no new eligible initiatives 
• Searched for word “early” – no total hits shown, but there were seven 
pages of results available. Reference to an International Cancer 
Research Partnership (ICRP) – did not meet inclusion criteria 
27/04/2017 
Worldwide 
World Cancer Research Fund International 
http://www.wcrf.org/ 
• Specific section on policy – no eligible initiatives 
• Looked for “early diagnosis” (2 hits, none relevant), “early detection” (no 
hits), referral (no hits), and pathway (3 hits, none relevant) 
02/05/2017 
US American Lung Association http://www.lung.org/ 
• Several initiatives, none led by the government, focus on prevention 27/06/2017 
US American Cancer Society - Cancer.org https://www.cancer.org/research.html 
• “early diagnosis” OR “early detection” retrieved 6271 hits. No new 
eligible initiatives 01/05/2017 
US  Cancer Research Institute https://www.cancerresearch.org/ 
• Search for detection on diagnosis retrieved several hits (total number 
not shown) – no new initiatives 01/05/2017 
US 
National Cancer Institute (part of National 
Institutes of Health - NIH) 
https://www.cancer.gov/ 
• Section on diagnosis and staging – no eligible initiatives 
• Publications pages – no new initiatives 
• "Division of Cancer Control and Population Sciences (DCCPS) website  
- no eligible initiatives, often focus on screening 
• Press releases were checked from 2012 to 2017 
• Another publications web page: https://publications.nci.nih.gov/ , 
searched for detection, early AND detection, early AND diagnosis, 
awareness, campaign, initiative AND diagnosis, initiative AND 
detection. All were imported to EndNote (1889 in total) – some 





Cancer Council Australia 
http://www.cancer.org.au/ 
• Early Detection Policy focuses on screening – not eligible for inclusion 
• Reference to “Listen out for lung cancer” which met inclusion criteria 
• Improving rural cancer outcomea trial and Find Cancer Early campaign 
- excluded as research study 
• Frequent awareness initiatives for skin cancer – not eligible 
24/04/2017 
Canada 




• Different pages for different provinces/territories; partnerships with the 
government, private organisations and charities. Website sections on 
screening and early diagnosis, but no references to initiatives 24/04/2017 
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Region Website Results Search date 
Denmark 
Danish Cancer Society 
https://www.cancer.dk/om-os/the-danish-
cancer-society/ 
• Annual reports refer to Danish initiatives already included, fundraising 
campaigns and charity-led initiatives did not meet criteria for inclusion 24/04/2017 
New 
Zealand 
Cancer Society of New Zealand 
https://cancernz.org.nz/ 
• Materials on prevention (and reference to SunSmart) and information 
on early diagnosis (but not part of any initiative) 24/04/2017 
Germany German Cancer Aid https://www.krebshilfe.de/ 
• Information not available in English 24/04/2017 
Republic of 
Ireland 
Irish Cancer Society 
https://www.cancer.ie/ 
• Initiatives focusing on prevention did not meet inclusion criteria, other 
initiatives were led by charities 24/04/2017 
The 
Netherlands 
Dutch Cancer Society 
https://www.kwf.nl/english/Pages/The-
organisation.aspx 
• Report on early diagnosis, but not about initiatives 
• Reports on surveillance, primary prevention, screening and treatment 
did not meet inclusion criteria 
24/04/2017 
Norway 
Norwegian Cancer Society 
https://kreftforeningen.no/ 
• Search within site (early diagnosis, campaigns, etc.) – no results  
• Cancer prevention focuses on lifestyle and screening programmes 
• Pathways were introduced in 2015 – met inclusion criteria 
24/04/2017 
Portugal Portuguese Cancer League https://www.ligacontracancro.pt/  
• Website not available in English 24/04/2017 
Spain 
Asociación Española Contra el Cáncer 
https://www.aecc.es/Paginas/PaginaPrincip
al.aspx  
• Website not available in English 
24/04/2017 
Sweden 
Swedish Cancer Society 
http://www.uicc.org/membership/swedish-
cancer-society-cancerfonden 
• Very limited information in English. Reference to Cancer Plans which 
were checked further for initiatives 24/04/2017 
Nordic 
countries 
Nordic Cancer Union (NCU) 
http://www.ncu.nu/Default.aspx?ID=27 
• Reference to Norwegian Diagnostic Pathways and waiting times. 
Annual reports referred to CPPs in Denmark – no new eligible initiatives 24/04/2017 
Germany 
German Cancer Society 
https://www.krebsgesellschaft.de/german-
cancer-society.html 
• Search within website for both English and German ‘early diagnosis / 
detection / delay / initiative – no results 
• Associate partner at the EU-project CanCon and part of EPAAC 
(European Partnership for Action Against Cancer) –  screening only 
• Reference to earlier diagnosis strategies but they were research studies 
24/04/2017 
Worldwide 
EThOS - Electronic Theses Online Service • “early diagnosis” OR “early detection” AND cancer – 97 records; 
“cancer diagnosis” OR “cancer detection” – 163 records; “Cancer 
pathway” – 9 records; “routes to diagnosis” OR “diagnostic pathway” – 
24/04/2017 
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Region Website Results Search date 
14 records; awareness AND cancer – 88 records; referral AND cancer 




• early diagnosis” AND cancer - 61 hits in English; “early detection” AND 
cancer - 126 hits English; “diagnostic pathway” AND cancer - 0 hits; 
awareness AND cancer - 58 hits in English; “routes to diagnosis” and 
cancer – 0 hits; Referral AND cancer – 25 hits – no new initiatives 
24/04/2017 
USA 
U.S. National Institutes of Health’s Clinical 
Trials Database https://clinicaltrials.gov/  
• cancer AND (diagnosis OR detection OR referral OR pathway OR 
awareness) – 12580 hits (11,926 when restricting time period, 11,718 
when restricting to adults only) – exported to EndNote as Tab Delimited 




WHO International Clinical Trials Registry 
Platform Search Portal 
http://apps.who.int/trialsearch/  
• Cancer AND detection OR diagnosis OR pathway OR referral OR 
awareness. 518 records for 271 trials – none eligible 25/04/2017 
UK 
UK Clinical Trials Gateway 
https://www.ukctg.nihr.ac.uk/#popoverSearc
hDivId  
• “early diagnosis” OR “early detection” – 31 trials; cancer AND referral – 
17 trials; cancer AND awareness – 5 trials; cancer AND pathway – 69 
trials; detection AND cancer – 60 trials; diagnosis AND cancer – 468 
trials - none eligible 
24/04/2017 
Worldwide 
Open Sigle http://www.opengrey.eu/  
All searches restricted to English 
• Cancer AND referral – 20 hits, including about already included 
initiatives (2WW); cancer AND pathway, restricted to English – 318 hits, 
none eligible; cancer AND awareness, restricted to English - 15 hits, 
none eligible; cancer AND diagnosis, restricted to English – 238 hits, 
none eligible; cancer AND detection, restricted to English – 204 hits, 
none eligible; cancer AND strategy, restricted to English – 150 hits, 
none eligible; cancer AND initiative, restricted to English -  1 hit, none 
eligible; cancer AND program, restricted to English – 27 hits, none 
eligible; cancer AND programme, restricted to English – 86 hits – none 
eligible; cancer AND plan, restricted to English – 25 hits – retrieved old 
publications for NHS Cancer Plans for background information; cancer 
AND campaign, restricted to English – 23 hits, none eligible; cancer 
AND policy, restricted to English – 30 hits, none eligible; cancer AND 
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Appendix 8. Drivers and rationale for included initiatives 
Strategy Drivers and influencers Evidence/rationale 
2WW 
• National burden of cancer (mortality and survival) 
• Government’s commitment to focus on cancer outcomes 
and prioritise assessment of patients with suspected 
cancer 
• Health policy for achieving early cancer diagnosis 
• Belief that patients in England accessed specialist care 
too late in the progression of their disease.  
• Poorer cancer outcomes compared to European 
countries and others  
• Tumours can progress during the time taken to reach a diagnosis 
and start treatment 
• There is an association between time to diagnosis and mortality 
• There is (limited) evidence that early diagnosis and shorter overall 
time to diagnosis can improve cancer outcomes and avoid cancer 
deaths 
• Diagnostic delay may explain the poor UK performance 
ACE 
• Cancer outcomes in England poorer than in other 
countries in Europe (even when health systems are 
comparable) and late stage diagnosis play a key role 
• Informed in part by developments in cancer diagnostic 
services in other countries, especially the NSS-CPP in 
Denmark 
• Enhancing GP’s ability to identify those in need of a rapid referral 
can help to achieve earlier diagnosis. Cancer decision support tools 
can have a positive impact on their performance 
• Community pharmacies can help with early diagnosis (raising 
awareness or even directly referring patients) due to their 
accessibility (even to more deprived populations), opening hours 
and familiarity with the local population 
• The best way to improve lung cancer survival is to identify lung 
cancers early when treatments are most effective. Approaches 
focusing on finding and ‘checking’ people at high risk before 
symptoms have developed may be useful 
• Some cancers can be more difficult to diagnose, especially for 
patients who present with vague symptoms. Some symptoms or 
combinations of symptoms can have a number of causes and can 
also be symptoms of several types of cancer. This can result in an 
extended diagnostic interval when comparing with easier to suspect 
cancers. The result may be poorer clinical outcomes and a poor 
patient experience 
• A bit more than a quarter of cancers are diagnosed through urgent 
referral routes, but only about half of cancer patients present with 
symptoms that indicate a particular type of cancer .This can result 
in delays for patients with vague symptoms, or patients who present 
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Strategy Drivers and influencers Evidence/rationale 
at earlier stages with less clear symptoms. Referral guidelines 
lowering the referral threshold can help, but the urgent referral 
pathway still requires the GP to identify a specific site pathway. 
Access to diagnostic tests for symptoms that do not meet referral 
criteria can help 
• Survival for lung cancer patients is closely related to stage at 
diagnosis. Later stages are associated with poorer survival. Despite 
improvements in cancer outcomes, there is still scope to save more 
patients through a specific route 
BCOC 
• Cancer burden (incidence and mortality) 
• Poor cancer survival rates compared to other countries, 
particularly 1-year survival (for which late diagnosis is a 
major contributor) 
• High levels of cancers diagnosed through emergency 
routes 
•  Reducing the ‘patient interval’ by encouraging prompt 
presentation after the onset of symptoms was a key 
NAEDI issue 
• Poor cancer awareness, especially among men and 
individuals from lower socioeconomic groups 
• Possibility to reduce avoidable cancer deaths due to late 
diagnosis 
• Broad agreement that late diagnosis is due to low symptom 
awareness, delays in presentation to the GP, practitioner or system 
delay, insufficient use of 2WW and insufficient access to diagnostic 
tests 
• People’s reluctance to visit the GP with what may seem like minor 
symptoms, or concerns about wasting the doctor’s time 
CPPs in 
Denmark 
• Denmark has a higher incidence of cancer and poorer 
cancer survival rates than many other European 
countries 
• Publication of several case stories of cancer patients 
experiencing delayed diagnosis or delayed treatment 
with fatal consequences 
• Politically agreed timeframes 
• In 2007 scientific evidence on the negative impact of waiting time 
for patients with head and neck cancer was presented to Danish 
decision makers - it showed the importance of system delay 
• Double gatekeeping in Denmark (for GP referral to specialist and 
for specialist to refer to investigations) resulting in delays 
DCE 
• Burden of cancer in Scotland (mortality), especially for 
lung, colorectal and breast cancers, with a deprivation 
gradient 
• Evidence that excess in mortality is due to advanced disease at 
presentation, bearing in mind other factors such as co-morbidity, 
tumour biology, stage of disease at treatment, pre-treatment 
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Strategy Drivers and influencers Evidence/rationale 
• Poor cancer survival in the UK compared to the 
European counterparts and its association with late 
stage diagnosis 
• Population ageing and its consequences 
• Influenced by NAEDI in England 
• In line with the Scottish Government’s purpose and five 
strategic objectives, in addition to fitting with the 
Healthcare Quality Strategy 
physical and psychological well-being, and quality of care 
immediately and after treatment 
DAPs 
• Motivation for improving efficiency of diagnostic care 
derived from the work carried out in breast cancer and 
provincial wait times initiative 
• There was also a policy gap as cancer programmes had 
little guidance and support for improving diagnostic 
intervals 
• The interval from suspicion to diagnosis is complex and important in 
cancer care; there is the need for several tests and consultations – 
this often results in considerable anxiety among patients 
• Diagnostic delays may result in a greater likelihood of disease 
progression and this may lead to worse patient outcomes 
• In the usual care route (UC), positive screening mammogram 
results (organised or opportunistic) are sent to the primary care 
doctor who must then order diagnostic tests and refer for specialist 
consultation – this results in a disconnection between screening 
and assessment that can increase the diagnostic interval 
Fast-track 
Catalonia 
• The incidence of breast, colorectal and lung cancer • The reduction in waiting time was assumed to  reduce psychosocial 
impact (patient anxiety and a sensation of vulnerability intervening 




• National burden of cancer 
• Insufficient cooperation between the different healthcare 
professionals involved in cancer diagnosis, treatment, 
and follow-up 
• Early detection increases the chances of an effective treatment and 
better outcomes 
• Warning symptoms and prompt action can lead to early diagnosis - 
symptom detection by professionals may result in a referral to 
specialist and earlier diagnosis 




• Burden of gynaecologic cancers (incidence and 
mortality), even though it is easy to prevent cervical 
cancers with regular screening and follow-up, there have 
been advances in treatment 
• Education and awareness has the potential to benefit patients with 
gynaecological symptoms; and to improve surveillance and 
diagnostic workup. Campaigns informed by gynaecologic cancer 
experts and further refined based on focus group research and 
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Strategy Drivers and influencers Evidence/rationale 
formative research with healthcare providers, national health 
surveys on women’s and healthcare providers’ knowledge, 
attitudes, and practices related to gynaecologic cancer.  
• Educational materials developed in consultation with scientists and 
external gynaecologic cancer experts 
Listen out for 
lung cancer 




• NAEDI was one of the key commitments of the English 
Cancer Reform Strategy due to the recognition that more 
needed to be done to promote early diagnosis in the 
majority of patients who present with symptoms 
• Informed by the EUROCARE studies 
• Poor 1-year survival rates (often a proxy for advanced 
stage of cancer at diagnosis) 
• Delays following referral to specialist services 
• Unacceptable within country variation in diagnosis: some 
groups are more likely to be diagnosed with later stages 
than others 
• Low public awareness of cancer signs and symptoms 
among men, most deprived and ethnic minority groups 
• Burden of cancer (mortality) and the possibility to reduce 
avoidable deaths 
• Primary care professionals have key roles in early detection as 
most cancer patients present first to a GP. More than referral 
guidance and checklists should be available to support them 
• Pharmacists and social workers can also plan an important role 
• Low awareness of cancer and the benefits of early detection lead to 
low screening uptake and late presentation with symptoms. Robust 
data on levels of awareness is needed to highlight groups for whom 
awareness raising initiatives are likely to be of greatest benefit 
• NAEDI’s key underpinning hypothesis: delays result in patients 
being diagnosed with more advanced disease, resulting in poor 1-
year and 5-year survival and potentially avoidable deaths 
• Many factors affect staging at diagnosis, so it is important to raise 
awareness; tackle negative attitudes to cancer and barriers to help-
seeking; support primary care, and ensure optimum and prompt 
access to diagnostics and referral pathways 
• When cancer is diagnosed early, treatment options and chances of 
a full recovery are greater 
• Missed cancer diagnoses are important - it is important to 
understand more about the nature and extent of diagnostic delays 
NSS-CPPs 
• Burden of cancer in Denmark (mortality) and poorer 
cancer survival compared to other Western European 
countries 
• Motivated by poor cancer control, public discontent with 
long waiting times and search for efficiency in 
standardised diagnostic pathways 
• Danish cancer patients’ confidence in their GPs decreases with 
increasing time to diagnosis 
• The way the health system is organised can have adverse effects 
which are associated with longer diagnostic intervals 
• Gatekeeping can result in reluctance to refer early to diagnostic 
investigations 
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Strategy Drivers and influencers Evidence/rationale 
• Relatively long waiting times due to delays in 
presentation, diagnosis and treatment (associated with 
higher mortality and stage progression) 
• Danish CPPs not appropriate to ensure timely diagnosis 
of all cancer patients - only about 40% of cancer patients 
seem to have benefitted, and only half of cancer patients 
initially present symptoms classified as alarm symptoms 
• Despite screening, most cancers are diagnosed through 
symptomatic presentation. It is still the GP’s duty to identify the 
cancer over the whole symptom continuum. Some cancer patients 
do present in general practice, but not with symptoms indicative of 
cancer. If the GP regards the symptom as vague, 50% of cancer 
patients will wait at least one month more and 25% at least 2.5 
months longer until diagnosis, compared with those with alarm 
symptoms 
• General practice use increases significantly several months before 
a patient is diagnosed 
Norwegian CPPs 
• Although eHealth is widely available, there is a cultural 
and social gap between those who use the eHealth 
services and those who do not – this can negatively 
influence health outcomes and needs to be considered 
in the communication and information distributed to 
patients 
• “Politically decided” introduction of CPPs and guidelines 




• Passage of legislation and related funding for a 
statewide Oral Cancer Prevention Initiative 
• Oral cancer identified as one of the seven cancers to be 
targeted, with the receipt of tobacco settlement funds 
• Oral cancer mortality rate was higher than the US 
average 
• Substantial disparities in oral cancer mortality rates 
between blacks and whites 
• Less than a third (28%) of oral cancers are detected at 
the earliest stage 
• Evidence that most oral cancers were diagnosed by physicians, not 
dentists 
• Most dentists and dental hygienists provide oral cancer 
examinations, but do not perform palpation and many do not know 
what to look for 
• Despite awareness that tobacco and alcohol are risk factors for oral 
cancer, the issue was not addressed with patients 
• Adult public not knowledgeable about oral cancer prevention and 
early detection 
RAC Ireland 
• Burden of lung cancer (diagnosis and mortality); survival 
compares poorly with best international outcomes  
• Late diagnosis helps to explain poor cancer survival in 
Ireland, including in cross-national comparisons 
• High smoking prevalence 
• Earlier diagnosis, efficient and correct diagnosis and staging, and 
modern multidisciplinary management lead to improved short and 
long term survival with good quality of life 
• Early diagnosis of lung cancer increases the chance for a cure 
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Strategy Drivers and influencers Evidence/rationale 
• Improvements in the delivery of care are necessary  
• The NCCP prioritised the establishment of the rapid 




• Qatari population is growing and ageing and this 
requires a more comprehensive cancer strategy 
• Changing lifestyles and a unique demographic profile 
have already led to a high burden of non-communicable 
diseases 
• Some elements of the population had misconceptions 
about cancer, e.g. it is always fatal or most cancers are 
hereditary or contagious 
• A National Cancer Program team was established within 
the Ministry of Public Health (MoPH) 
• Reference to the Danish Cancer Plans and experiences 




• Burden of cancer (incidence and mortality) • Stage at diagnosis is the most important factor associated with 
survival 
• Direct referrals for colonoscopy is practical and effective to reduce 
N of specialist consultations and diagnostic delay (although 
evidence is more limited on the impact on survival) 
SCP • Influenced by CPPs in Denmark and their outcomes 
• Perceived unacceptable delays in care pathways 
• N/A 
Source: included studies 
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Appendix 9. Key stakeholders in included initiatives 
Initiative Key Stakeholders 
2-week wait 
• The Department of Health (policy, monitoring, reporting and funding) 
• NICE 
• The National Collaborating Centre for Cancer 
• The Guideline Development Group (guideline development and updates). It comprised healthcare professionals 
(including consultants, GPs and nurses), patients and carers, and technical staff, which reviewed the evidence and 
drafted recommendations which were finalised after public consultation  
• GPs, primary and secondary care professionals were responsible for the urgent referral pathway 
• NHS Trusts monitored performance and gave feedback to GPs. Trusts and Strategic Health Authorities (SHA) were 
expected to submit and collate national waiting times data and encouraged to carry out clinical audits 
Accelerate, Coordinate, 
Evaluate (ACE) 
• NHS England initiative supported by Cancer Research UK and Macmillan Cancer Support, with a team made up of 
staff from the three organisations 
• Support on evaluation provided by the Department of Health’s Policy Research Units (PRUs) 
• Other stakeholders include:: national lung cancer experts, Lung Cancer Clinical Expert Group (LCCEG), CRUK primary 
care facilitators, primary care professionals, secondary care professionals, Clinical Commissioning Groups across 
England, NHS Foundation Trusts across England, University Hospitals, One-step cancer clinics, cancer experts 
Be Clear on Cancer 
(BCOC) 
• Department of Health working with the National Cancer Action Team, COI (pilots), NHS England, NHS Improving 
Quality and Public Health England working in partnership. The Office for National Statistics was also involved 
• The charity Cancer Research UK (CRUK) was appointed in 2011 to help develop the evaluation framework and 
coordinate the data flows for evaluations. CRUK led evaluations of BCOC activities until March 2013, after this date 
evaluation was led by PHE through the National Cancer Intelligence Network. An expert advisory group (academics, 
clinicians, statisticians and epidemiologists) has helped to guide the evaluation 
• For each BCOC campaign a market research agency (TNS BMRB) was commissioned to conduct campaign tracking 
surveys with the target audience and GPs 
• The University of York and University of Sheffield estimated the cost effectiveness of the lung/bowel campaigns 
Cancer Patient Pathways 
(CPPs) 
• The National Board of Health (NBH) was given the task to facilitate the process of developing the national CPPs.  
• Five health regions were responsible for both primary and secondary health services and for CPP implementation 
• CPP development: Administrators contributed with organisational knowledge; Health professionals with health specific 
knowledge; Politicians with the patient’s voice and political power. All stakeholders were able to influence the process 
which could be characterised as a ‘bottom-up and top-down’  
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Initiative Key Stakeholders 
• The Danish Prime Minister announced that cancer should be treated as an acute condition; this led to a political 
agreement between the government and health regions to implement the CPPs 
• Danish Multidisciplinary Cancer Groups (DMCGs); National Cancer Task Force 
Detect Cancer Early 
(DCE) 
• A partnership involving the Scottish Government (including public health, health promotion, health improvement 
services and the Cabinet Secretary), Regional Cancer Networks, Scottish Primary Care Cancer Group, Third Sector, 
NHS Health Boards, primary and secondary care professionals, cancer charities 
• Clinical leadership was required to drive the initiative. Media was also expected to be involved 
Diagnostic Assessment 
Pathways (DAPs) 
• Cancer Care Ontario, regional cancer programmes, nurses, primary and secondary health care providers, radiologists, 
private donors and corporations 
Fast-track Catalonia 
 
• Department of Health and Catalonia Health Service (mix of private- and publicly-owned health facilities) 
• Professionals in primary and secondary care 
Fast-track Valencia 
• Clinico-Malvarrosa Health Department in Valencia 




• Developed and implemented by the Centres for Disease Control and Prevention (CDC), in collaboration with the U.S. 
Department of Health and Human Services’ (HHS) Office on Women’s Health 
• Professionals include gynaecologic oncologists, gynaecologists, paediatricians, nurses, other medical practitioners, 
health and behavioural scientists, and representatives of non-profit and advocacy organisations committed to raising 
awareness of gynaecologic cancers 
• Other stakeholders include Sheryl Silver (instrumental in the creation of Johanna’s Law), the Society of Gynaecologic 
Oncologists, the Foundation for Women’s Cancer, the Allied Support Group of the FWC; the Ovarian Cancer National 
Alliance; the National Cervical Cancer Coalition; Fran Drescher’s Cancer Schmance 
Listen out for lung cancer • New South Wales (NSW) government and Cancer Institute NSW 
National Awareness and 
Early Diagnosis Initiative 
(NAEDI) 
• Public sector/third sector partnership, led by NHS England, Public Health England, Cancer Research UK and the 
Department of Health, co-chaired by the National Cancer Director and Cancer Research UK’s Chief Executive 
• Other stakeholders include other public and voluntary sector organisations (such as Macmillan Cancer Support), the 
National Cancer Action Team (NCAT), the Royal College of General Practitioners (RCGP), the National Patient Safety 
Agenda (NPSA), the National Cancer Research Institute (NCRI), local Authorities, primary care trusts, the research 
community (including included behavioural scientists, experts in social marketing, public health physicians, primary 
care academics and epidemiologists), health care professionals, patient groups and patients. A National Cancer 
Intelligence Network (NCIN) was also established by the initiative 
Non-Specific Symptoms 
CCPs (NSS-CPPs) 
• the National Board of Health and Danish Regions 
• Primary and secondary care including primary care practices, hospitals, diagnostic centres and “yes-no-clinics” 
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Initiative Key Stakeholders 
Norwegian CPPs • Norwegian Government and the Directorate for Health 
• Primary and secondary care 
Oral Cancer Maryland 
• A “small group of stakeholders” developed, implemented and evaluated the programmes. It expanded over time to 
include members/partners from the “Maryland Department of Health and Mental Hygiene (DHMH), Office of Oral 
Health; the National Institute of Dental and Craniofacial Research (NIDCR); the University of Maryland’s schools of 
dentistry and nursing; health care provider associations such as dentists, dental hygienists, and family practice 
physicians; local health departments; and the American Cancer Society” 
Rapid Access Clinic 
(RAC) 
• Department of Health, the National Cancer Registry of Ireland (NCRI), the National Cancer Control Programme, All 
Ireland Cancer Foundation Ltd, the Irish College of General Practitioners, the Irish Thoracic Society 
• Primary and secondary care professionals, designated centres/clinics, national multidisciplinary prostate cancer team 
Qatar’s first national 
cancer strategy 
• “Collaborative effort” led by the Ministry of Public Health, the Supreme Council of Health (SCH) and health care 
providers (Hamad Medical Corporation and Primary Health Care Corporation), in addition to several other stakeholders 
(such as small care providers, care staff, multidisciplinary teams and private surgeons) 
• A National Cancer Committee was established to guide strategy development  
• Other stakeholders included the Supreme Education Council and the Qatar National Cancer Society (awareness 
campaigns), government officials; international health policy experts from the Institute of Global Health Innovation, 
Imperial College London, in the United Kingdom 
• Two key Implementation groups, the Cancer Implementation Group (CIG) and The Cancer Transformation Team (CTT) 
drove the clinical application of the strategy 
Rapid Referral Pathway 
Madrid 
• “Developed and coordinated by a committee consisting of hospital and primary care managers and specialists involved 
in the health care process”. 
• GPs, hospital specialists and a coordinator were involved in each health centre 
Standardized Care 
Pathways  
• The Swedish Central Government (through the Ministry of Health and Social Affairs) initiated it, funds its monitoring 
and evaluation. SALAR (six regional cancer centres), Swedish regions and patient representatives are responsible for 
designing and implementing the programme. There is continuing dialogue between both groups 
• Diagnosis-specific multi-professional teams provide medical knowledge and represent health care professionals - they 
make the reform bottom-up instead of top-down (which they describe as similar to the Danish reform)  
• The Swedish National Board of Health and Welfare monitors and evaluates the SCPs through an expert group with 
different expertise (improvement sciences, quality assessment, clinicians and patient representatives). 
• There is a central agreement with SALAR and the independent Swedish counties that incentivises implementation, but 
the grant is described as “of a more symbolic nature”) 
Source: included studies  
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Appendix 10. Population groups targeted by initiatives 
Initiative Target populations 
2-week wait 
• Patients with a suspicion of cancer (presenting with alarm symptoms) 
• Different studies investigated several subgroups (patients referred through the pathway, often aged 40 or older, patients 
going through other routes (for comparison purposes), patients diagnosed and not diagnosed with cancer, treated and 
followed up after a cancer diagnosis) and targeted health professionals in order to assess their views on the strategy 
• Referral guidelines targeted patients with high-risk symptoms suggesting cancer (covering children, young people and 
adults – although guideline assessment did not include children and young people aged 17 and younger), healthcare 
professionals and people involved in clinical governance in both primary and secondary care 
Accelerate, Coordinate, 
Evaluate (ACE) 
• Primary care professionals (General practitioners, pharmacists and other community pharmacy staff) 
• Patients at high risk of lung cancer 
• Patients that present with non-specific but concerning symptoms that do not indicate a likely primary tumour site, or 
meet the criteria for a site specific urgent referral pathway for cancer 
• Patients that present late to their GP with new suspected cancer, but the GP regards the patient as already too ill to wait 
for a two week wait (2WW) referral or is unsure of the primary cancer site 
• clinicians, managers, commissioners and other key informants in different AE projects (as part of ACE evaluation) 
Be Clear on Cancer 
(BCOC) 
• Varied according to campaigns 
• Most campaigns targeted men and women from lower socioeconomic groups (C2DE) aged 50+ (55 years for the early 
bowel activity) where most improvements could be made, with adaptations according to the type of media used 
• Key influencers, such as friends and family 
• Television campaigns adapted for the hard of hearing; easy versions of leaflets were developed, in addition to versions 
in Braille, audio, and large print on-line for the visually impaired – this aimed to reduce inequalities 
• To counter cultural, religious and language barriers preventing Minority Ethnic Groups from presenting early to their 
GPs, work was carried out with a specialist multicultural marketing consultancy 
Cancer Patient Pathways 
(CPPs) 
• Patient for whom a cancer diagnosis was suspected (based on alarm symptoms).  
• Different studies often assessed subgroups, e.g. focused on specific cancer types, or on patients who attended general 
practice prior to being diagnosed with cancer 
Detect Cancer Early 
(DCE) 
• Anyone at risk of cancer, focusing on patients at high risk, deprived populations and non-responders to screening (e.g. 
men for bowel cancer initiatives as they were more likely to have poorer outcomes.  
• Primary and secondary care professionals 
Diagnostic Assessment 
Pathways (DAPs) 
• Patients suspected of having breast, lung, colorectal or prostate cancers 
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Initiative Target populations 
Fast-track Catalonia • Patients suspected of having a breast, lung or colorectal cancer 
• Study also targeted health professionals who participated in fast-track management as stakeholders or data manager 
Fast-track Valencia • Patients suspected of having breast, colorectal, cervical, lung, or bladder cancers 
• Primary and secondary health care professionals 
Inside Knowledge 
• Women of all ages, races, and ethnic groups, especially those aged 35 years and older; YouTube female users, female 
users actively searching for gynaecologic cancer content online 
• Health care providers 
Listen out for lung cancer 
• General public (campaign development) 
• All adult population, especially the ones at risk of lung cancer: 50 years or older, smokers & ex-smokers, low SES, 
Regional & Remote NSW; aboriginal people (awareness campaigns) 
National Awareness and 
Early Diagnosis Initiative 
(NAEDI) 
• Several different groups depending on the strategy. General public, targeted activities for specific subgroups such as 
older ages (e.g. 50 +), more deprived populations, specific ethnic groups 
• Primary care practices and health care professionals 
Non-Specific Symptoms 
CCPs (NSS-CPPs) 
• Patients for which there was a suspicion of a cancer diagnosis, with alarm symptoms, nonspecific, serious symptoms or 
vague symptoms 
• Different studies focused on specific population subgroups (e.g. focusing on a specific referral pathway) 
Norwegian CPPs • Patient suspected of having cancer 
• Primary and secondary health care professionals 
Oral Cancer Maryland • General public (several settings), focus on underserved, high-risk populations 
• Health care providers (dentists; dental hygienists; family nurses/physicians), trainers, the media and policy makers 
Rapid Access Clinic 
(RAC) 
• Patients with highly suspicious signs and/or symptoms of lung or prostate cancers 
Qatar’s first national 
cancer strategy 
• Target group varied according to the strategy 
• General public, students (schools) 
• Patients suspected of having cancer based on high-risk symptoms 
• Health Care providers 
Rapid Referral Pathway 
Madrid 
• Patients suspected of having colorectal cancer based on high-risk symptom criteria – targeting patients who consulted 
with a GP between Aug/2004 and Oct/2007 and met high risk criteria for CRC cancer 
Standardized Care 
Pathways  
• Patients with a “well-founded suspicion” of cancer (see components) 
Source: included studies  
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Appendix 11. Study designs and outcome measures for included initiatives 
Study designs (including comparators and definitions if 
applicable) Outcome measures 
2WW 
• Quantitative: cohort study (investigating the 
association between the propensity of general 
practices to use the urgent referral pathway and the 
precision of its use, and overall mortality among their 
patients diagnosed with cancer) (1) and cross 
sectional analysis (of data from the Cancer Waiting 
Times database for urgent referrals and patients 
receiving a first definite treatment) (2) 
• Reviews (systematic and non-systematic) (3-6)  
• Audit (annual government reports) (7-11): time-series 
analysis, time-trends analyses and descriptive 
statistics. 
• Review of cancer waiting times standards (12): 
literature review, qualitative and quantitative findings 
from meetings of advisory groups, written 
communication and an engagement event with health 
professionals, patient groups, charities and NHS 
managers 
• Guideline development (13): evidence from primary 
care was used as the basis for the guidelines. 
Recommendations were developed using a 'risk 
threshold', whereby if the risk of symptoms being 
caused by cancer is above a certain level then action 
(investigation or referral) is warranted. 
• Assessment of guidelines (14): cohort study, 
assessing cancer diagnostic intervals before and 
after guideline implementation. 
• Referral metrics (1): practice referral ratio (indirectly standardised number of urgent referrals 
for suspected cancer by general practitioners, standardised according to list size and to the 
age and sex distributions of patients); practice conversion rate (proportion of urgent referrals 
for suspected cancer by general practitioners that result in a diagnosis of cancer; this is the 
PPV for cancer among the patients selected for urgent referral; practice detection rate (% of 
CWT recorded cancers resulting from an urgent referral; this is the sensitivity of the selection 
of patients for urgent referral). 
• Referral metrics (2): age standardised referral ratio (indirectly standardised number of urgent 
referrals relative to list size), conversion rate (% or urgent referrals that result in a cancer 
diagnosis or PPV) and detection rate (% of cancers treated which were urgent referrals – 
sensitivity). 
• Reviews (3-6): outcome measures included: waiting time to first appointment; GP conformity 
to guidelines, cancer detection, appropriateness of type of referral according to the clinician, 
the ability of guidelines to identify correct referrals, process of referral (referrals received by 
the hospital within 24 hours and the mode of referral – fax or post/letter or proforma), 
compliance with the 2WW target); impact on timeliness (whether cancer patients are now 
being seen more quickly than before); accuracy of patient selection (successfully minimising 
both ‘underuse’ and ‘over-use’ of the pathway); impact on clinical outcomes (whether survival 
rates or tumour staging improves); impact on patients accessing care by other routes 
(whether routine referrals or patients diagnosed through other routes have longer waits or 
poorer outcomes). 
• Audit (annual government reports) (7-11): proportion of patients urgently referred for 
suspected cancer by their GP who were seen by a specialist within two weeks of referral and 
changes over time (N and % increase over time); proportion of patients urgently referred with 
an exhibited breast symptom (where cancer was not initially suspected) who were seen by 
a specialist within two weeks of referral (N and % increase over time) 
• Review of cancer waiting times standards (12): Whether 2WW was consistently achieved 
and whether there was regional variation; % of patients reported being seen by a hospital 
doctor within 2 and 4 weeks of referral, whether CWTs helped to drive service improvement 
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Study designs (including comparators and definitions if 
applicable) Outcome measures 
and resulted in benefits for patients, whether targets led to improvements in cancer survival, 
helped to reduce patient anxiety; whether there was support for continuation of standards; 
whether targets continued to be justified and should be retained; whether standards should 
apply to all types of cancer. Qualitative outcomes not predefined. 
• Assessment of guidelines (14): Diagnostic interval (duration from the first occurrence of a 
symptom code in the database to the date of cancer diagnosis); date of diagnosis (first entry 
of the code pertaining to a cancer diagnosis in the primary care record); % of patients who 
had any identifiable symptom code during the year prior to diagnosis  
ACE 
• All references were evaluation reports 
• Qualitative evaluation of four clusters: detailed case 
studies at purposefully selected nine of the 60 ACE 
sites (distributed between four of the eight ACE 
clusters: Colorectal cancer pathways, Proactive 
approach to patients with a high risk of lung cancer, 
cancer screening uptake for vulnerable groups and 
vague symptoms pathway). Data was collected 
through sequential one-to-one interviews, review of 
meeting notes and observation of cluster action 
learning sets. Interviews were recorded, transcribed 
and analysed using a Framework approach. Realistic 
evaluation (investigating context, mechanisms and 
outcomes) and Normalisation Process Theory were 
adopted (15) 
• Vague but concerning symptoms (16): Time to diagnosis (N and means); stage at diagnosis 
(I to IV); other diagnoses (non-cancer); conversion rates; referral rates, patient experience 
(survey): how patients rated their care; the length of time they had to wait for tests and 
appointments; the information they received and whether they were likely to recommend the 
service to friends and family 
• Pharmacy training (17, 18): project costs, feedback on training, knowledge of cancer  
• Pathways from lung cancer referral to diagnosis (19): Attendances to the self-referral CXR 
services; N of invitations to CT scans; N of booked appointments; N of health checks 
undertaken; N of referrals to CT scan; N of CT scans; N of identified lung nodules and non-
cancer significant findings; N of referral to local lung cancer services, imaging follow up and 
surgery; N of patients eligible to attend (RR); N of allocated health assessment slots; N of 
lung health checks completed 
• CDS tools (20) : Project 1: Range of risk scores (more or less than 3%); decision made as a 
result of consultation (e.g. fast-track, diagnostic tests, safety-netting); N and type of 
diagnostic test (e.g. bloods, ultrasound); what prompted use of tool (own clinical judgement, 
CDS tool); whether symptom checker was using during and/or after consultation; whether 
tool influenced management of patient; whether risk score was shared with the patient. 
Project 2: previous cancer diagnosis, co-morbidities, referral to diagnostic imaging 
procedures (e.g. ultrasound, endoscopy, x-ray, patient management decisions (fast-track 
pathway, referral for further care, active surveillance, reassurance, proportion of patients 
where the GP reassured the patient that their risk of cancer was low; proportion of overall 
referrals (fast track and referral for further care); proportion of patients being reassured by a 
GP; % patients who were fast-tracked; proportion of active surveillance,  N receiving a cancer 
diagnosis, tumour type, range of cumulative QCancer risk score. Qualitative methods: GP 
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Study designs (including comparators and definitions if 
applicable) Outcome measures 
survey carried out independently from quantitative data, but aimed at GPs from the same 
area investigating access to, and use of the tool, training on how to use the tool, whether tool 
raised the professional’s awareness of cancer, whether tools helped with decision making. 
Project 3: (acceptability and utility of using a CDS Tool to detect patients at high risk of five 
types of cancer); Patient suitability to attend clinic; Which tumour types had the highest 
scores; Referrals to diagnostic investigation; N of cancers diagnosed after investigations; 
Whether reason for appointment was clearly explained to patients; Emotional/psychological 
impact of being asked to come to the clinic; Patients’ views on the best way to be contacted 
BCOC 
Before-and-after studies: 
• (21): Evaluation of national and regional lung cancer 
campaigns. Data relating to the period during and/or 
immediately after the campaign were compared with 
data from a pre-campaign time period (often the same 
time in the previous year) for several metrics. Before 
and after campaign surveys were carried out by a 
third-party to evaluate campaign impact. 
• (22): Evaluation of the BCOC bowel and lung 
campaigns’ impact across the entire pathway 
comparing estimates of outcome measures of interest 
before and during or after the intervention for the 
sample as a whole and stratified by population 
subgroups. Public awareness was assessed by a 
third-party  
• (23): Analysis of data from awareness surveys using 
the validated CAM measure to test the prediction that 
there would be greater awareness of the symptoms 
highlighted in these national campaigns than non-
targeted symptoms, and the hypothesis that barriers 
associated with the ‘approachability’ of the GP would 
be reduced  
• Evaluation reports: Over 40 complex data sets were 
reviewed. Evaluations waited until as much 
Before-and-after study (21): 
• Public awareness of symptoms of lung cancer  
• GPs’ views on numbers of patients presenting with symptoms of lung cancer, numbers of 
suspected lung cancer referrals made, as well as GPs’ views on the campaign’s 
communications.  
• N of patients presenting to GP practices with symptoms directly linked to the campaign (a 
cough) and selected control symptoms 
• N of visits over the 8 weeks around the campaign compared with the same weeks in the 
previous year 
• N of attendances (‘working days’) 
• Urgent GP referrals for suspected lung cancer (N) 
• N of referrals made during the months of the campaign and month directly following 
compared to a control period 
• Proportion of urgent referrals for suspected lung cancer that resulted in a diagnosis of lung 
cancer (the conversion rate)  
• N of chest X-ray and chest with or without abdomen CT scan (CT) from all referral pathways, 
and those following a GP referral during campaign compared with a control period 
• Clinical impact of the campaign: (a) Number of cases diagnosed; (b) Stage at diagnosis 
(TNM) and changes in proportions of lung cancers diagnosed at each; (c) First definitive 
treatment; (d) Performance status; e) source of referral; (f) One-year survival (only for 
regional campaign) compared with control in previous year (age-standardised 1-year crude 
survival calculated using International Cancer Survival Standard weights). 
Before-and-after study (22)  
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Study designs (including comparators and definitions if 
applicable) Outcome measures 
information as possible has been gathered. They 
focused on shifts in campaign recognition and 
knowledge pre- and post-activity, adding a control 
group whenever possible. 
• Unprompted and prompted awareness of bowel/lung cancer symptoms 
• Public views on whether the advertising had told them something new and whether they 
considered it relevant to them.  
• N of patients presenting with Read codes associated with symptoms directly linked to the 
campaign and a set of control symptoms over a specified time period, compared with  
numbers in the same time in the previous year (‘working days’). 
• Urgent referrals for suspected cancer; diagnostic and treatment activity; stage of disease at 
diagnosis; survival and mortality data 
Analysis of data from awareness surveys (23) 
• Awareness of warning signs and symptoms (prompted and unprompted) 
• Change in recall and recognition of the three symptoms that were closest to those targeted 
in the campaign: ‘cough’ or ‘hoarseness’, ‘change in bowel or bladder habits’; remaining six 
symptoms served as control symptoms 
• Perceived barriers to help-seeking (prompted) 
• Change in the frequency of the two barriers closest to those targeted in the campaign (worry 
about wasting the doctor’s time, the doctor being difficult to talk to). Other cited barriers were 
treated as control items 
• Cancer experience (participants, friends or family) 
• Evaluation reports: Diagnostic imaging data 
CPPs 
• Descriptive paper explaining programme inception 
(24, 25) and PhD thesis (26) 
• Population-based GP survey and registry study (27) 
• Ecological study comparing data from three cohorts 
(28) 
• Comparative cohort study (29) 
• Median waiting times (measured in days) 
• Incident cancer (having a cancer diagnosis as the primary diagnosis, except for non-
melanoma skin cancer; and no prior history of cancer recorded in the Danish Cancer Registry 
- previous non-melanoma skin cancer was allowed).  
• Diagnostic interval (the time interval from the date of the patient’ s first presentation of 
symptoms in primary care until the date of diagnosis in accordance with the Aarhus 
Statement (measured in days)) 
• % of people with alarm symptoms; % of people referred to CPP; Clinical tumour stage TNM 
DCE 
• Official Health Intelligence Reports to assess whether 
HEAT targets were met (30-33) 
• Heat targets assessed by describing N, percentages, and percentage increase; percentage 
of people with unknown cancer stage (breast, lung, colorectal and combined) 
DAPs 
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Study designs (including comparators and definitions if 
applicable) Outcome measures 
• Review of DAPs worldwide(34) 
• Retrospective cohort study (35), comparing the 
diagnostic interval between group. 
• Diagnostic interval (the time from the initial screen to the date of diagnosis). Initial screen 
defined as the earliest abnormal OBSP screening test within 12 months before diagnosis or 
the earliest opportunistic screening mammogram within 6 months before diagnosis 
• Tumour histology (Nottingham/Bloom-Richardson) and staging (TNM) 
• Usual health-care utilisation characteristics between 36 months and 12 months prior to the 
date of diagnosis, including frequency of doctor visits, primary care provider (yes/no), 
continuity of care based on Usual Provider Continuity index (high/low/non-user), preventive 
services index (the proportion of preventive services used out of the total number of 
preventive services for which an individual was eligible) 
Fast-track Catalonia 
• Mixed-methods: Cohort study and semi-structured 
interviews (36) 
• N of patients included in the CFP; N of cancer patients diagnosed through the CFP route 
• Patients referred from general practitioners (GPs); compliance with referral guidelines; 
cancer detection rate; mean time between detection of suspected cancer and start of 
treatment 
Fast-track Valencia 
• Cross-sectional study: all patients that went through 
the pathway (37) 
• % of patients diagnosed with a specific cancer 
• % of patients with suspected cancer diagnosis meeting the guideline criteria 
• Time (in days) from submission to initiation of treatment 
Inside Knowledge 
• Audit data, before-and-after comparisons, overview 
documentation, focus groups . Monitoring website 
hits, publication orders, public inquiries, social media 
and search engines, and PSAs. Evaluation of 
campaign advertising mandated by Congress.(38-
44) 
• Before and after comparisons (without control 
groups); comparisons were analysed using t tests 
(45) 
• Cross-sectional (descriptive metrics on video views 
provided by YouTube) (46) 
• Use of search engine advertisements (45): Impressions (N of times adverts were displayed); 
Clicks (N of times users activated web page links in adverts); Click-through rate (clicks 
divided by impressions); Cost-per-click (cost of placing adverts divided by clicks); N of visits 
to web pages linked to search engine adverts; duration of visits to web pages linked to search 
engine adverts 
• Providing gynaecological cancer information on YouTube (46): Impressions: N of times that 
pre-roll videos played automatically, or N of times that keyword-targeted listings appeared; 
Views: N of times pre-roll videos were viewed for longer than the mandatory 5 s, or N of 
times that users initiated playing videos in keyword-targeted listings.; View-through rate: 
number of views divided by number of impressions; Cost-per-view: sponsorship cost divided 
by number of views; Portion of video viewed: percentage of the video shown before users 
halted play electronic impressions; Amount of USD spent in total; Total cost per click in USD; 
N of partners reached; N of publications 
   
423 
Study designs (including comparators and definitions if 
applicable) Outcome measures 
Listen out for lung cancer 
• Campaign development (47): Before-and-after 
telephone interviews with at risk general population.  
• Qualitative study: focus groups with GPs (n=125); 
general community groups, Aboriginal groups, 
culturally and linguistically diverse community groups; 
and interviews with GPs and lung cancer survivors 
• Knowledge of cancer symptoms 
• Intention to see a GP 
NAEDI 
• Local initiatives: mixed methods; self-reported online 
surveys (interventions). Campaign and cancer 
awareness projects were encouraged to use a “pre-
post” survey using the validated Cancer Awareness 
measure (48) 
• CDS tools: use of quantitative (case-control study, 
online experience tab in CDS tool) and qualitative 
(interviews, online experience tab in CDS tool and 
focus groups) data analysis. Controls referred to 
practices not recruited to the project, or those which 
were recruited but did not have the CDS software 
installed before November 2013, which were in the 
same (former) Cancer Network (CN) areas that the 
participating practices belonged to. The framework 
method was used to analyse qualitative data. 
Evaluation of use of CDS tools in practice, impact on 
practice and the management of patients, and 
considerations and implications for further work (49) 
• Cancer Networks Supporting Primary Care 
programme: mixed-methods; qualitative, realistic 
evaluation of overall implementation and impact using 
interviews (50) and quantitative, before and after 
analysis of cancer outcomes (51) 
• Report on outcomes of the national audit (52) 
• Local initiatives: Centrally collected metrics: two-week-wait referral activity and screening 
uptake (bowel and breast cancers). Locally collected metrics: area(s) and general practices 
where the intervention ran in; detailed description of the interventions;  campaign outcomes 
(prompted and unprompted awareness of cancer signs and symptoms, confidence in 
noticing symptoms, attitudes to cancer, early detection and treatment, barriers to 
presentation); behaviour change (e.g. intention to see the GP about signs and symptoms, 
and how quickly, actual or reported visits to the GP); GP requests for diagnostic tests; 
percentage of cancer cases diagnosed following emergency presentation; number of 
cancers diagnosed; stage of disease at diagnosis; radical treatment rate; duration of time 
prior to presentation to primary care; number of presentations to primary care. Also 
information on % of local activities dedicated to Public-facing activity (e.g., 
advertising/community events); GP engagement; other health professional engagement; 
making changes to services (e.g. direct access to chest x-ray) 
• CDS tools: Quantitative evaluation: Differences in referrals, conversion or detection rates for 
each of the referral routes between participating and control practices, between practices 
allocated to the RAT algorithm compared with those allocated to the QCancer algorithm; 
impact on referral activity by age, gender and deprivation, urgent GP referrals, percent 
changes in number of referrals between the time periods (e.g. quarters) in 2012 compared 
with the same time period in 2013. Other (quantitative) measures were presented in the tool’s 
experience tab and referred to: perceived risk compare with the calculated risk; (lower, about 
the same as, higher); additional patient management (admitted, referred, investigation 
required, other, none); whether investigation or referral would have happened if tool had not 
been used (yes, no), tests ordered (list provided). Qualitative evaluation assessed how the 
tools were used in practice, how they impacted in clinical practice and patient management, 
the associated impact on urgent referrals or diagnostic investigations, impact on the primary 
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Study designs (including comparators and definitions if 
applicable) Outcome measures 
and secondary care interface, suggestions on how to improve tools, barriers to use; 
comparison with other tools, potential for dissemination of tools, among other issues. 
Qualitative evaluation also investigated overall patient views on tools and on knowing their 
potential cancer risk, and about decision-making about one’s own healthcare 
• Clinical audit: stage at diagnosis; number of times patient attended surgery; investigations 
ordered; symptoms at presentation; cancer site; patient interval (date of onset of symptoms 
to the first consultation); primary care interval (date of first presentation to the date of 
referral); referral interval (date of referral to the date the patient first attended for specialist 
assessment in secondary care) 
• Cancer Networks supporting primary care (quantitative evaluation): referral activity before 
the start of the programme compared with during the programme; comparison of practices 
that chose to engage at any point in one or more of the four activities against those that did 
not engage in any of them; N of urgent GP referrals for all suspected cancers; N of cancers 
receiving a first treatment during the same period, based on ‘treatment start date’; referral 
rate; conversion rate (percentage of urgent GP referrals resulting in a cancer diagnosis); 
detection rate (percentage of CWT recorded cancers resulting from an urgent GP referral); 
new cancer cases and mode of presentation; % of Hospital Episode Statistics identified 
cancers first presenting as an emergency (i.e. emergency in-patient admission from an A&E 
department or an outpatient clinic or a GP or Bed Bureau referral, or referral to outpatients 
following A&E attendance or emergency admission) 
NSS-CPPs 
• Cross-sectional study describing the characteristics 
of patients referred to the NSSC-CPP and estimating 
cancer probability and distribution in this population, 
using questionnaires completed by GPs and Danish 
databases (53) 
• Descriptive/commentary paper (54) and PhD thesis 
(55) 
• Patient’s symptoms; known chronic diseases; estimated risk of cancer at referral; clinical 
findings (GP’s abnormal findings during the clinical examination of the patient); abnormal 
diagnostic test results; level of the GP’s ‘gut feeling’ regarding possible serious disease; date 
of the first symptom presentation to the GP/practice; presence or absence of 21 specified 
symptoms at the time of referral (other symptoms could be added); primary care interval 
(time from the patient’s first symptom presentation at the GP/practice until referral to the 
NSSC-CPP); referral date (registered inclusion date); cancer diagnoses; date of diagnosis 
(first date of the hospital admission at which the cancer diagnosis was confirmed in the 
Danish Cancer Registry); cancer probability (% of included patients who were diagnosed 
with a new cancer within six months after the referral date). 
Norwegian CPPs 
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Study designs (including comparators and definitions if 
applicable) Outcome measures 
• No quantitative studies/data yet available 
• Qualitative study 
• Theoretical and analytical analysis of online information about the CPP drawing upon critical 
discourse analysis 
Oral Cancer Maryland 
Qualitative (focus groups) and quantitative components 
(cross-sectional surveys, descriptive statistics). 
Comprised three phases (56):  
• Needs assessment: available funds; review of 
epidemiological data; surveys and focus groups 
• Development and pilot testing of educational 
materials and interventions 
• Programme evaluation (data collected from health 
care professionals and trainers at courses and 
seminars, and from the general public at community 
events, health fairs, and cancer screenings) 
• Needs assessment: knowledge, opinions, and practices related to oral cancer early detection 
and prevention (professionals); knowledge of risk factors/signs and symptoms of oral cancer, 
experience of oral cancer examinations (adults – public) 
• Evaluation: N of individuals educated about oral cancer; N of individuals screened for oral 
cancer; N of people reached through the media and resource materials 
• Follow-up: knowledge of oral cancer risk factors (HPV as a risk factor for oral cancer); use 
of (adjunctive) diagnostic procedures; oral cancer screening practices and compliance with 
recommended screening exams (i.e. palpating lymph nodes) 
• Attendance to an oral cancer CE course 
RAC 
• Audit data(57) 
• Quantitative survey on GP experience on the National 
Cancer Control Programme and their views in relation 
to service priorities (58) 
• Referrals to RACs (N and % change) - all attendances, number of primary cancers 
diagnosed; % of attendances who had a primary cancer diagnosed 
• Patients referred to RAC offered an appointment to attend within 20 working days of receipt 
of referral 
• N of patients that attended a Prostate RAC within a month 
• N of patients that attended or received an appointment to attend RAC within 20 working 
days of receipt of referral in the cancer centre 
• % new patients diagnosed with primary prostate/lung cancers 
• N of primary prostate/lung cancers diagnosed 
• Patients referred to RAC offered an appointment to attend within 10 working days of receipt 
of referral 
• The number of new patients that attended a lung RAC within reporting calendar month; of 
those: the number of new patients that attended or received an appointment to attend RAC 
within 10 working days of receipt of referral in the cancer centre; the number of attendances 
(excluding new DNAs) at lung rapid access clinics during the month 
• GP survey: experience with RACs when referring patients 
Qatar’s first national Cancer Plan 
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Study designs (including comparators and definitions if 
applicable) Outcome measures 
• Descriptive/overview paper (59), Cancer Strategy 
(60) and government publications reporting on 
progress (61-64) 
• N (%) of patients referred to a specialist within 48 hours; N (%) patients diagnosed within 
14 days of being seen with a specialist; N (%) patients treated within 4 days of being 
diagnosed; N of professionals completing communication skills training; Measures of 
population awareness (not described); % of cancers diagnosed at stages I and II; National 
screening coverage (%) 
Rapid Referral Pathway Madrid 
• Case control study (65) 
• Cases: patients referred through the rapid referral 
pathway (prospective data collection) 
• Comparator: patients also diagnosed via colonoscopy 
but referred through the standard referral pathway 
(retrospective data collection) 
• Signs and symptoms of cancer of referred patients; whether referral criteria were met for 
referred patients; cColonoscopy results for referred patients 
• Waiting times for referred patient (days): between the request for colonoscopy made by the 
GP and its performance by a specialist (waiting time to colonoscopy), between firm 
diagnosis and surgery (waiting time to surgery) and the overall delay to surgery (waiting 
time between the request for colonoscopy by GP until surgery including any time required 
for anatomopathological diagnosis). 
• Whether waiting time targets were met  
• N of cancers diagnosed; N of endoscopic polypectomies performed; surgery for CRC; 
cancer staging at surgery 
SCPs 
• Descriptive paper (66) and government report (67) No outcome measures described 
References (please see thesis for full references): 1.Møller et al 2015. 2.Meechan et al 2012. 3.Hanna et al 2005. 4.Harrison & Foot 2012. 5.Lewis 
et al 2005 (DARE). 6.Lewis et al 2005. 7.Abdullah et al 2011. 8.Aveyard et al 2013. 9.Pearson et al 2014. 10.Pearson et al 2015. 11.Samuels et al 
2016. 12.Department of Health (Review of CWT) 2011. 13.National Institute for Health and Care Excellence 2015. 14.Neal et al 2014. 15.Ablett-
Spence et al 2017. 16.Lewis et al 2017. 17.Accelerate, Coordinate, Evaluate 2015. 18.Pharmacy training for early diagnosis of cancer Accelerate, 
Coordinate, Evaluate (ACE) Programme, 2017. 19.Gill 2017. 20.Robinson et al 2017. 21.Ironmonger et al 2015. 22.Moffat et al 2015. 23.Power & 
Wardle 2015. 24.Olesen et al 2009. 25.Probst et al 2012. 26.Jensen 2015 (thesis). 27.Jensen et al 2014. 28.Jensen et al 2015. 29.Jensen et al 
2016. 30.ISD Scotland. Detect Cancer Early Baseline 2013. 31.ISD Scotland. Detect Cancer Early Year 3 2015. 32.ISD Scotland. Detect Cancer 
Early Year 2 2014. 33.ISD Scotland. Detect Cancer Year 1 2014. 34.Cancer Care Ontario 2009. 35.Jiang 2013. 36.Prades et al 2011. 37. Martinez 
et al 2015. 38.Inside Knowledge 2012. 39.Inside Knowledge 2013. 40.Inside Knowledge 2014. 41.Inside Knowledge 2015. 42.Inside Knowledge 
2016 (Campaign Background). 43.Inside Knowledge 2016 (2015 Year End Report). 44.Rim et al 2011. 45.Cooper et al 2015. 46.Cooper et al 2016. 
47. Lyons 2014. 48.Department of Health 2012 (First report 2010/11 local projects. 2012). 49.Moffat et al 2014. 50.Ablett-Spence et al 2012. 
51.Rubin et al 2015. 52.Rubin et al 2011. 53.Ingeman et al 2015. 54.Vedsted & Olesen 2015. 55.Ingeman 2015 (thesis). 56.Maybury et al 2012. 
57.National Cancer Control Programme 2014. 58.O'Shea & Collins 2016. 59.Howitt et al 2014. 60.Supreme Council of Health 2011. 61.Supreme 
Council of Health 2013. 62.Supreme Council of Health 2014. 63.Supreme Council of Health 2015. 64.National Cancer Program 2016. 65.Valentin-
Lopez et al 2012. 66.Wilkens et al 2016. 67.Swedish Government 2009.  
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Appendix 12. Document analysis: definitions for adopted criteria 




originals or copies, 
drafts or final 
versions, sound or 
unsound (1) 
version Whether document is a draft or a final version 
• Draft: document has tracked changes, highlighted terms or 
references to pending issues; or is explicitly defined as a draft 
• Final version: document is clean, without tracked changes or 
pending issues, or is explicitly described as a final version 
soundness 
Whether document is corrupted in any way 
(1); e.g. with contradictions or missing 
information 
• Sound: document without (apparent) contradictions, grammatical 
issues that affect meaning; with references to data; with included 
attachments/data referred to in the text 
• Partially sound: document has some (but not all) issues above 
• Unsound: document has none of the issues mentioned above 
Authorship: refers to 
whether authorship 
is private or from the 
State, from an 
individual or group 
(1) 
source 
Whether document was prepared by the 
Scottish Government or by a private 
institution (1) 
• Government: Prepared by the Scottish Government, territorial 
Health Boards, Cancer Networks, Health Boards or others 
• Private: prepared by stakeholders other than the government 
authors 
Whether document authors are 
anonymous, a single individual or a group 
(irrespective of sources) (1) 
• Anonymous: no reference to who the author is 
• Individual: when a single individual is described as the author 
• Group: when more than one individual is described as authors 
Credibility: appraisal 
of how distorted 
document contents 
are likely to be, 
includes issues of 
interest. Sincerity, 
source and evidence 
(1) 
interest Whether there is the possibility of political or financial interest/gain (1) 
• Political interest: when document can result in political gains  
• Financial interest: when document can result in financial gains 
sincerity 
Extent to which one is sincere in the choice 
of a standpoint and in the attempt to have 
an accurate account from that chosen 
standpoint. Something that is not accurate 
can still be sincere (1) 
• Sincere: When to the researchers’ knowledge, accounts seem 
honest, without any alterations to change meaning or facts 
• Partially sincere: when the researcher can see that changes were 
made to the document, altering accounts (e.g. moderating 
criticism in minutes from programme meetings) 
• Insincere: when it is obvious that the document present lies, or is 
deliberately misleading the intended audience 
source Whether document reports on primary or secondary sources 
• Primary: when document reports on first-hand data 
• Secondary: when document reports on second-hand data 
evidence Whether document describes facts, opinions or both (2) 
• Facts: When document describes facts without discussing what it 
means or any implications 
• Opinions: When document describes views, or suggestions 
• Both: When document describes both facts and opinions 
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Area Term Definition How to classify 
Representativeness: 
whether documents 
are representative of 
all relevant 
documents (1) 
overall Dependent upon being aware of what has been produced and is available (1) • Discussed in text as a narrative 
survivability  
Whether document is deposited in a form 
that allows it to survive (e.g. stored in a 
data repository or published) (1) 
• Stored but not published: not published but was stored in a 
folder/data repository (by those who developed the document) 
• Stored and published: document was shared (e.g. reports for the 
Scottish Government,  newsletters for stakeholders) and reached 
different groups (irrespective of whether this was open access) 
• Stored, but unclear if published: when it is not clear whether 
document was published or widely shared 
availability  
Refers to the ability to access a document 
(1). Closed access is mentioned in the 
literature (1), but not approached here. If a 
document was received, it was never 
considered to be closed access 
• Restricted: not freely available; access would not have been 
possible without actively requesting documents 
• Open access: reported to be available (may need rigorous 
searches) 
• Unclear: even though documents are reported to be open 
access, searches for them to confirm this were not successful 
Background 





document type (2) 
date Year of publication • Descriptive information in chart 
audience Who was the intended audience, i.e. who the document was planning to reach (2) • Categories created based on received documents 
purpose Purpose of publication; i.e. what it aimed to describe (2) 
• Described in supplementary tables (based on document content) 
and briefly summarised in the main thesis 
style Refers to the language used, e.g. lay terms, health in general, among others (2) • Categories created based on received documents 
function 
Document function refers to whether it aim 
to persuade, validate or justify activities, 
decisions, outcomes, among others (2) 
• Persuade: provide reasons (facts or opinions) for the intended 
audience to believe in/do something; try to convince the audience 
• Validate: show the value of doing something/its accuracy 
• Justify: to show that actions/results are reasonable 
document 
type 
Type of document, such as reports or 
others • Categories created based on received documents 
References: 1.Scott J. A Matter of Record: Documentary Sources in Social Research. Scott J, editor. Cambridge: Polity Press; 1990. 2.O'Leary 
Z. Indirect data collection: working with observations and existing text. 2009. In: Essential guide to doing your research project . Sage. 3.
 Prior L. Using documents in social research. Prior L, editor. London: SAGE; 2011
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Appendix 13. List of policy documents reviewed and interrogated 
ID Document type Duplicate Source Pub year Purpose 
1 Publications in Journals and Conferences no DCE team 2015 
Show whether weekly monitoring can contribute towards meeting CWT 
targets 
2 Publications in Journals and Conferences no DCE team 2014 
Show results from bowel screening campaigns in requested bowel 
screening kits and bowel screening uptake, in addition to changes in 
knowledge and awareness of bowel cancer symptoms and signs 
3 Publications in Journals and Conferences no DCE team 2015 
Show results from the symptomatic breast cancer campaigns in increase in 
knowledge/awareness, consultations, cancer diagnoses and staging 
4 Publications in Journals and Conferences no DCE team 2014 
Show whether campaigns had an impact on the reduction of inequalities in 
bowel screening uptake and staging (bowel, lung and breast) 
5 Publications in Journals and Conferences no DCE team 2015 
Assess whether a psychoeducational increased adolescents’ cancer 
awareness and addressed help-seeking barriers 
6 Publications in Journals and Conferences no DCE team 2014 
Describe Scottish adolescents’ sun-related behaviours and tanning 
attitudes and assess associations with skin cancer awareness 
7 Publications in Journals and Conferences no DCE team 2015 
Study the diagnostic accuracies of faecal haemoglobin (FHb) and faecal 
calprotectin (FC) in a cohort of symptomatic patients. 
8 Information documents shared with stakeholders no DCE team unknown 
Describe DCE's terms of reference: remit, governance, core and non-core 
members 
9 Agendas, minutes and action notes no DCE team 2011 Outline minutes and action notes from a DCE Programme Board meeting 
10 Agendas, minutes and action notes no DCE team 2011 Outline minutes and action notes from a DCE Programme Board meeting 
11 Agendas, minutes and action notes no DCE team 2012 Outline minutes and action notes from a DCE Programme Board meeting 
12 Agendas, minutes and action notes no DCE team 2012 Outline minutes and action notes from a DCE Programme Board meeting 
13 Agendas, minutes and action notes no DCE team 2013 Outline minutes and action notes from a DCE Programme Board meeting 
14 Agendas, minutes and action notes no DCE team 2013 Outline minutes and action notes from a DCE Programme Board meeting 
15 Performance management reports no DCE team 2015 Describe Cancer Waiting Times in Scotland from January to March 2015 
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ID Document type Duplicate Source Pub year Purpose 
16 Performance management reports no DCE team 2015 
Describe bowel screening key performance indicators from Nov 2012 until 
Oct 2014 
17 Information documents shared with stakeholders no DCE team 2013 
Detail the rationale for choosing, and calculating the baseline for HEAT, and 
how data will be validated and coded separately by ISD Scotland. 
18 Performance management reports no DCE team 2013 
Present the numbers and percentages of patients diagnosed during 2010 
and 2011 by type of cancer, stage of disease at diagnosis for NHS Board, 
Cancer Network of residence and Scotland. These figures were chosen as 
the baseline for the DCE HEAT target 
19 Performance management reports no DCE team 2014 
Present the numbers and percentages of patients diagnosed during 2011 
and 2012 by stage at diagnosis for NHS Board of residence, Cancer 
Network and Scotland for breast, colorectal and lung cancers combined and 
individually (Year 1 - DCE Target) 
20 Performance management reports no DCE team 2014 
Present the numbers and percentages of patients diagnosed during 2011 
and 2012 by stage at diagnosis for NHS Board of residence, Cancer 
Network and Scotland for breast, colorectal and lung cancers combined and 
individually (Year 1 - DCE Target) 
21 Performance management reports no DCE team 2015 
Present the numbers and percentages of patients diagnosed during 2011 
and 2012 by stage at diagnosis for NHS Board of residence, Cancer 
Network and Scotland for breast, colorectal and lung cancers combined and 
individually (Year 3 - DCE HEAT target) 
22 evaluation and insight gathering reports no DCE team 2013 
Describe the outcomes from engagement sessions to inform primary care 
on DCE's work, lung and bowel cancer symptoms and signs, and bowel 
screening 
23 Cancer referral guidelines documents no DCE team 2014 
Outline evidence (UK and international guidelines) for patients with 
suspected cancer (tables created to inform the update of referral guidelines) 
24 Cancer referral guidelines documents no DCE team 2014 
Present the updated Scottish Cancer Referral Guidelines. The guidelines' 
aim was to facilitate appropriate referral between primary and secondary 
care for patients whom a GP suspects may have cancer. 
25 Cancer referral guidelines documents no DCE team 2015 
Present the updated Scottish Cancer Referral Guidelines in a user friendly, 
quick format for consultation.  
26 Information documents shared with stakeholders no DCE team 2013 
Describe the background for the bowel screening initiative, the rationale for 
it, its aims and provide general guidance to relevant stakeholders 
27 Cancer referral guidelines documents no DCE team 2014 
Described who gave feedback to (suggested) updated guidelines, what the 
feedback was and how comments/concerns were addressed 
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ID Document type Duplicate Source Pub year Purpose 
28 Use of DCE funding no DCE team unknown Describe all DCE related activity carried out by the Roy Castle Lung Cancer foundation in 2013 (processes, outputs and outcomes) 
29 Information documents shared with stakeholders no DCE team 2011 
Seek stakeholder feedback on a draft implementation plan for the DCE 
Programme 
30 Press and news releases no DCE team 2012 Describe DCE launch and the programme's initial developments 
31 Press and news releases no DCE team 2012 Describe the symptomatic breast cancer campaign and other developments 
32 Press and news releases no DCE team 2012 Describe the launch and initial results of the symptomatic breast cancer campaign and other developments 
33 Press and news releases no DCE team 2012 Describe results of the symptomatic breast cancer campaign and other developments 
34 Press and news releases no DCE team 2014 Describe published data on staging, programme activities across different territorial Health Boards and the primary care education programme 
35 Press and news releases no DCE team unknown Describe the updated Scottish referral guidelines and activities taking place across all Cancer Networks in Scotland 
36 Press and news releases no DCE team 2015 Commemorate the first three years of the DCE programme and provide update on activities in some territorial Health Boards 
37 Information documents shared with stakeholders no DCE team 2015 Describe the campaign rationale, resources and outcomes. 
38 Information leaflets for patients no DCE team 2013 
Describe to the general public how and why bowel screening can find 
cancer early and improve survival 
39 Information documents shared with stakeholders no DCE team 2013 Introduce the bowel screening stakeholder pack 
40 Information documents shared with stakeholders no DCE team 2013 
Describe the bowel cancer campaign (and all different types of media used), 
its rationale and information resources available to stakeholders 
41 evaluation and insight gathering reports no DCE team 2014 
Describe attitudinal tracking results for six bursts of the bowel screening 
campaign 
42 Press and news releases no DCE team 2013 Describe the bowel screening campaign, some of its outcomes and outline endorsements from survivors, celebrities and relevant DCE stakeholders 
43 evaluation and insight gathering reports no DCE team 2014 
Describe the methodology for the evaluation of the breast screening 
campaign and outline results (data tabulations) 
44 Information documents shared with stakeholders no DCE team unknown 
Describe the breast screening campaign (background, rationale, 
components and results) 
   
432 
ID Document type Duplicate Source Pub year Purpose 
45 Information leaflets for patients no DCE team 2014 
Describe to the general public how and why breast screening can find 
cancer early and improve survival 
46 Information documents shared with stakeholders no DCE team 2014 
Describe the breast screening  campaign, all types of media used, its 
rationale and the information resources available to stakeholders 
47 Information documents shared with stakeholders no DCE team 2012 
Describe the breast symptomatic campaign, all types of media used, its 
rationale and the information resources available to stakeholders 
48 Information documents shared with stakeholders no DCE team unknown 
Describe the breast symptomatic campaign (background, rationale, 
components and results) 
49 Press and news releases no DCE team 2012 Describe the symptomatic breast campaign and outline endorsements from survivors, celebrities and relevant DCE stakeholders 
50 Information leaflets for patients no DCE team 2012 
Describe to the general public early detection of breast cancer can improve 
survival and highlight and describe breast cancer signs and symptoms other 
than lumps 
51 Information documents shared with stakeholders no DCE team 2012 
Introduce the symptomatic breast campaign to GPs, outlining signs and 
symptoms from referral guidelines and eligibility criteria for breast screening 
52 Information documents shared with stakeholders no DCE team 2013 
Describe the lung campaign, all types of media used, its rationale and the 
information resources available to stakeholders 
53 evaluation and insight gathering reports no DCE team 2015 Describe attitudinal tracking results for four bursts of the lung campaign 
54 Information documents shared with stakeholders no DCE team 2015 
Describe the lung campaign (background, rationale, components and 
results) 
55 Press and news releases no DCE team 2013 Describe the lung campaign and outline endorsements from survivors, celebrities and relevant DCE stakeholders 
56 Information documents shared with stakeholders no DCE team 2014 
Introduce the lung campaign focusing on the 3-week cough, describing the 
rationale for it, the target population, symptoms requiring referral, and 
addressing potential concerns regarding increase in demand 
57 Information leaflets for patients no DCE team 2014 
Describe to the general public how early detection of lung cancer can 
improve survival and highlight that if one is experiencing a three-week 
cough (or other symptoms) it is important to go see the GP 
58 Press and news releases no DCE team 2014 Describe outcomes for the breast screening campaign, the bowel screening campaign and the lung cancer campaign 
59 Press and news releases no DCE team 2014 Describe outcomes for the bowel and lung campaigns, and outline plans for 2015, including the two new initiatives “wee c” and #getchecked 
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ID Document type Duplicate Source Pub year Purpose 
60 Press and news releases no DCE team 2015 Announce a new bowel screening test, DCE's third anniversary, highlight key outcomes and endorsements from key stakeholders 
61 Press and news releases no DCE team 2015 Describe the main findings from the 3-year attitudinal tracking carried out by TNS 
62 Press and news releases no DCE team 2015 Describe DCE achievements in its first three years 
63 Press and news releases no DCE team 2015 Describe DCE achievements in its first three years 
64 Press and news releases no DCE team 2015 Describe #getchecked and the “wee c” campaign, with supporting statements from key stakeholders 
65 Press and news releases no DCE team 2015 Describe #getchecked and the “wee c” campaign, with supporting statements from key stakeholders 
66 Information documents shared with stakeholders no DCE team 2015 
Describe “wee c” and #getchecked to stakeholders, focusing on their 
rationale, key messages and available resources 
67 evaluation and insight gathering reports no DCE team 2015 
Explain the rationale for the bowel campaign and describe results from 
attitudinal tracking 
68 Information documents shared with stakeholders no DCE team 2015 
Describe key areas of DCE activity in the last quarter of 2014 and first 
quarter of 2015 (NHS Dumfries and Galloway) 
69 Information documents shared with stakeholders no DCE team unknown Describe DCE-related activities in NHS Lothian 
70 Information documents shared with stakeholders no DCE team 2015 Describe DCE-related activities in NHS Shetland 
71 Information documents shared with stakeholders no DCE team 2015 
This presentation aimed to discuss Comms plans for 2015/16, talk about 
wee c and #getchecked, answer questions and provide local spotlights 
(NHS Greater Glasgow & Clyde, NHS Grampian and NHS Forth Valley) 
72 Press and news releases no DCE team 2015 Provide an update on the DCE social marketing campaigns 
73 Agendas, minutes and action notes no DCE team 2015 
Provide the DCE Programme Board with an update on recent social 
marketing activity 
74 Press and news releases yes DCE team 2014 
Describe latest news on the bowel cancer campaign, inform about the new 
wave of the lung cancer campaign, describe changes to the programme's 
website and plans for the future 
75 Press and news releases no DCE team 2016 Describe DCE-related activities in NHS Lanarkshire while commemorating the World Cancer Day 
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76 Agendas, minutes and action notes no DCE team 2015 
Provide an update for the Programme Board, reflecting on DCE's 
achievements in its first three years, announce the new bowel screening 
test, and show key programme outputs 
77 evaluation and insight gathering reports no TNS 2014 
Describe the methodology for the evaluation of the symptomatic breast 
campaign and results (data tabulations) 
78 evaluation and insight gathering reports no TNS 2014 
Describe the methodology for the evaluation of the breast screening 
campaign and outline results (data tabulations) 
79 evaluation and insight gathering reports yes TNS 2015 
Describe Scottish adolescents’ sun-related behaviours and tanning 
attitudes and assess associations with skin cancer awareness 
80 evaluation and insight gathering reports yes TNS 2015 
Describe the main findings from the 3-year attitudinal tracking carried out 
by TNS 
81 evaluation and insight gathering reports no TNS 2015 
Describe the methodology for the 3-year attitudinal tracking and outline 
results (data tabulations) 
82 evaluation and insight gathering reports no TNS 2015 
Describe the methodology and results for the evaluation of first wave of 
attitudinal tracking after DCE's first three years (data tabulations) 
83 evaluation and insight gathering reports no TNS 2012 
Describe the background, aims, and methodology for the attitudinal 
tracking, describe sample characteristics, risk behaviours, barriers and 
facilitators to early detection overall, for breast, bowel and lung cancers, 
plus provide a summary of results and present conclusions 
84 evaluation and insight gathering reports no TNS 2015 
Describe evaluation results from the seventh wave of the bowel screening 
campaign 
85 evaluation and insight gathering reports no TNS 2014 
Describe public spontaneous and prompted awareness of cancer 
symptoms and signs prior to the symptomatic breast campaign wave (Aug 
2012), post-wave (Oct 2012) and in Feb 2014 
86 evaluation and insight gathering reports no TNS 2012 
Describe awareness of cancer symptoms and signs before and after the 
priming campaign, in addition to providing information about risky behaviour 
(all part of the HITS survey) 
87 evaluation and insight gathering reports no TNS 2012 
Describe outcomes for the symptomatic breast campaign regarding reach, 
communication and motivation to check signs and symptoms of cancer 
88 evaluation and insight gathering reports no TNS 2013 
Describe the methodology for the evaluation of the breast screening 
campaign (Sep/ Oct 2013) using data tabulations 
89 evaluation and insight gathering reports no TNS 2014 
Describe population views regarding the Big C prior to the development of 
the wee c campaign (to inform it) 
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90 evaluation and insight gathering reports no TNS 2012 
Describe outcomes for the priming campaign regarding reach, 
communication and motivation 
91 Use of DCE funding no DCE team 2015 Describe DCE funding allocation from 2011/2012 to 2015/2016 
92 Others no DCE team 2012 
Present the outcomes of a workshop with GPs at the Deep End in Scotland, 
in which particular problems of early detection in deprived areas and how 
these could (or not) be addressed by the DCE programme 
93 Others no DCE team 2012 Present the concerns raised by clinicians from across NOSCAN in respect of DCE 
94 Agendas, minutes and action notes no DCE team 2012 Outline minutes and action notes from a DCE Programme Board meeting 
95 Information documents shared with stakeholders yes DCE team 2011 
Seek stakeholder feedback on a draft implementation plan for the DCE 
Programme 
96 evaluation and insight gathering reports no DCE team 2014 
Describe the outcomes and learning points from the primary care pilot in 
NHS Lothian (aiming to improve bowel and breast screening uptake) 
97 Others no DCE team unknown Summarise outcomes of visits to territorial Health Boards to introduce the DCE programme 
98 Information documents shared with stakeholders no DCE team 2013 
Detail the rationale for choosing, and calculating the baseline for HEAT, and 
how data will be validated and coded separately by ISD Scotland. 
99 Agendas, minutes and action notes no DCE team 2011 Outline Agenda items for a DCE Operational Subgroup meeting 
100 Agendas, minutes and action notes no DCE team 2012 Outline Agenda items for a DCE Operational Subgroup meeting 
101 Agendas, minutes and action notes no DCE team 2012 
Outline minutes and action notes from a DCE Operational subgroup 
meeting 
102 Agendas, minutes and action notes no DCE team 2012 
Outline minutes and action notes from a DCE Operational subgroup 
meeting 
103 Agendas, minutes and action notes no DCE team 2012 Outline Agenda items for a DCE Operational Subgroup meeting 
104 Agendas, minutes and action notes yes DCE team 2012 
Outline minutes and action notes from a DCE Operational subgroup 
meeting 
105 Agendas, minutes and action notes no DCE team 2012 
Outline minutes and action notes from a DCE Operational subgroup 
meeting 
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ID Document type Duplicate Source Pub year Purpose 
106 Agendas, minutes and action notes no DCE team 2012 
Outline minutes and action notes from a DCE Operational subgroup 
meeting 
107 Agendas, minutes and action notes no DCE team 2013 Outline Agenda items for a DCE Operational Subgroup meeting 
108 Agendas, minutes and action notes no DCE team 2013 Outline Agenda items for a DCE Operational Subgroup meeting 
109 Agendas, minutes and action notes no DCE team 2013 
Outline minutes and action notes from a DCE Operational subgroup 
meeting 
110 Use of DCE funding no DCE team 2013 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Orkney in 2012/2013 
111 Use of DCE funding no DCE team 2013 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Borders in 2012/2013 
112 Use of DCE funding no DCE team 2013 Describe activities, challenges, benefits, achievements and issues regarding sustainability for all territorial Health Boards in 2012/2013 
113 Use of DCE funding no DCE team 2013 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Fife in 2012/2013 
114 Use of DCE funding no DCE team 2013 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Ayrshire and Arran in 2012/2013 
115 Use of DCE funding no DCE team 2013 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Forth Valley in 2012/2013 
116 Use of DCE funding no DCE team 2013 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Grampian in 2012/2013 
117 Use of DCE funding no DCE team 2013 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Greater Glasgow & Clyde in 2012/2013 
118 Use of DCE funding no DCE team 2013 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Highland in 2012/2013 
119 Use of DCE funding no DCE team 2013 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Dumfries and Galloway in 2012/2013 
120 Use of DCE funding no DCE team 2013 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Lanarkshire in 2012/2013 
121 Use of DCE funding no DCE team 2013 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Lothian in 2012/2013 
   
437 
ID Document type Duplicate Source Pub year Purpose 
122 Use of DCE funding no DCE team 2013 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Shetland in 2012/2013 
123 Use of DCE funding no DCE team 2013 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Tayside in 2012/2013 
124 Use of DCE funding no DCE team 2014 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Ayrshire and Arran in 2013/2014 
125 Use of DCE funding no DCE team 2014 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Borders 2013/2014 
126 Use of DCE funding no DCE team 2014 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Shetland in 2013/2014 
127 Use of DCE funding no DCE team 2011 Describe activities, challenges, benefits, achievements and issues regarding sustainability for all territorial Health Boards in 2013/2014 
128 Use of DCE funding no DCE team 2014 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Forth Valley in 2013/2015 
129 Use of DCE funding no DCE team 2014 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Dumfries and Galloway in 2013/2014 
130 Use of DCE funding no DCE team 2014 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Grampian in 2013/2014 
131 Use of DCE funding no DCE team 2014 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Greater Glasgow and Clyde in 2013/2014 
132 Use of DCE funding no DCE team 2014 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Lanarkshire in 2013/2014 
133 Use of DCE funding no DCE team 2014 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Lothian in 2013/2014 
134 Use of DCE funding no DCE team 2014 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Tayside in 2013/2014 
135 Use of DCE funding no DCE team 2014 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Western Isles in 2013/2014 
136 Use of DCE funding no DCE team 2014 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Orkney in 2013/2014 
137 Use of DCE funding no DCE team 2016 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Ayrshire and Arran in 2015/2016 
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138 Use of DCE funding no DCE team 2016 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Lanarkshire in 2015/2016 
139 Use of DCE funding no DCE team 2015 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Grampian in 2014/2015 
140 Use of DCE funding no DCE team 2015 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Orkney in 2014/2015 
141 Use of DCE funding no DCE team 2015 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Forth Valley in 2014/2015 
142 Use of DCE funding no DCE team 2016 Describe activities, challenges, benefits, achievements and issues regarding sustainability for NHS Tayside in 2015/2016 
143 evaluation and insight gathering reports no 
the Leith 
Agency 2012 
Present the qualitative research findings from the creative carried out to 
inform the bowel cancer campaign 
144 evaluation and insight gathering reports no 
the Leith 
Agency 2013 
Present the qualitative research findings from the creative carried out to 
inform the lung cancer campaign 
145 evaluation and insight gathering reports no 
the Leith 
Agency 2012 
Describe awareness of cancer symptoms and signs before and after the 
priming campaign, in addition to providing information about risky behaviour 
(all part of the HITS survey) 
146 evaluation and insight gathering reports no 
the Leith 
Agency 2011 
Present the qualitative research findings from the creative carried out to 
inform the priming campaign 
147 evaluation and insight gathering reports no 
the Leith 
Agency 2012 
Present the qualitative research findings from the creative carried out to 
inform the symptomatic breast campaign 
148 evaluation and insight gathering reports no 
the Leith 
Agency 2012 
Present the qualitative research findings from the creative carried out to 
inform the symptomatic breast campaign (public consultation) 
149 evaluation and insight gathering reports no 
the Leith 
Agency 2015 
Present the qualitative findings from insight and creative development 
research for the bowel screening campaign 
150 evaluation and insight gathering reports no 
the Leith 
Agency 2011 
Describe awareness of cancer symptoms and signs, of bowel and breast 
screening, and of risk behaviour (all part of the HITS survey) 
151 evaluation and insight gathering reports no 
the Leith 
Agency 2013 
Present the qualitative research findings from the consultation with lung 
cancer experts (to inform the lung cancer campaign) 
152 evaluation and insight gathering reports no 
the Leith 
Agency 2015 
Describe results from the lung cancer campaign that focused on the three-
week cough 
153 evaluation and insight gathering reports no 
the Leith 
Agency 2011 
Describe desk research carried out to inform social marketing campaign 
development 
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154 Others no the Leith Agency unknown 
Describe the lung cancer campaign as a case study, its rationale, creative 
testing, implementation and outcomes 
155 evaluation and insight gathering reports no 
the Leith 
Agency 2011 
Present findings from insight gathering carried out with health care 
professionals, breast, lung and bowel cancer patients and survivors in order 
to inform the campaigns 
156 evaluation and insight gathering reports no 
the Leith 
Agency 2013 
Describe results from the priming, breast cancer and bowel cancer 
campaigns 
157 evaluation and insight gathering reports no 
the Leith 
Agency 2011 
Present findings from the professional Audience Creative Consultation 
testing routes for DCE campaigns 
158 Others no the Leith Agency unknown 
Describe the symptomatic breast campaign as a case study, its rationale, 
creative testing, implementation and outcomes 
159 Others no the Leith Agency unknown 
Describe the bowel screening campaign as a case study, its rationale, 
creative testing, implementation and outcomes 
160 Information documents shared with stakeholders no 
Independent 
searches 2011 
Present the final DCE implementation plan (after amendments according to 
the stakeholder consultation) 
161 Agendas, minutes and action notes no 
Independent 
searches 2013 Outline minutes and action notes from a DCE Programme Board meeting 
162 Agendas, minutes and action notes no 
Independent 
searches 2014 Outline minutes and action notes from a DCE Programme Board meeting 
163 Agendas, minutes and action notes no 
Independent 
searches 2014 Outline minutes and action notes from a DCE Programme Board meeting 
164 Press and news releases no Independent searches 2014 
Describe updates in different territorial health boards and the partnership 
with Teenage Cancer Trust 
165 Press and news releases no Independent searches 2015 
Describe updates in different Health Boards, about campaigns and describe 
the partnership with CRUK for the Facilitator Programme 
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Appendix 14. DCE service utilisation plan and 
programme impact theory 
Service utilisation plan – patient journey after campaigns 
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Service utilisation plan – care provision 
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Programme impact theory diagram 
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Appendix 15. Draft logic model 
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The role of government policy initiatives in promoting earlier diagnosis of cancer – what can 
we learn from the Detect Cancer Early (DCE) programme in Scotland? 
 
Interview topic guide 
Key stakeholders 
 
The role of government initiatives in promoting earlier diagnosis of cancer 
Development and refinement of the DCE process evaluation 
 
The guide will be used in a flexible and responsive manner, allowing participants to 
introduce new areas for discussion. Ensure signed consent form has been received. 
 
Introduction: Thank you for agreeing to be interviewed. The aim of this interview is to learn 
more about the DCE programme from the perspective of a key stakeholder, to hear your views 
on its rationale, objectives, activities, outputs and expected outcomes. Questions will be open 
ended and quite broad. Firstly I will ask you some background questions (such as your role in 
DCE), then I will ask you about the programme itself. The logic model describing DCE which 
I sent you via email (I also have a larger copy here) will help to guide the discussion but I will 
also ask for your views on how it can be improved. All information you provide is confidential. 
The interview will be recorded and the transcripts will be anonymised. Please feel free to ask 




1. Firstly could you please tell me a bit about yourself? (ask for job title/role if needed) 
2. How did you become involved in DCE? Could you tell me about your role in it? 
3. In your own words, why is a programme like DCE needed in Scotland? 
4. (Only if involved in the development of DCE)  
a. Could you talk about that time period and your role in DCE’s development? (ask 
about the process of designing the programme) 
b. At the time, were there any concerns about the way DCE was developed? 
5. DCE logic model (go through each section: input, activities, outputs, outcomes, 
assumptions and context; ask about missing issues or inaccuracies)  
a. Does the diagram represent well how DCE was supposed to work? What could 
be changed? 
b. Did some DCE activities work better than others? Why might this be the case? 
c. Which changes could DCE bring? Which of the DCE components would bring 
most change? (ask about individual and system level changes) 
d. What are the main challenges DCE faces regarding its ability to be successful? 
(ask about the contextual challenges and causal assumptions if needed) 
6. If you were to evaluate DCE, what would you focus on, and why?  
7. This is the initial stage of DCE’s process evaluation, and I will be interviewing more 
stakeholders in the future. Would you be willing to be interviewed again? 
8. Do you have any key person to suggest, either because of their role in DCE or their 
views about it? 
9. Would you like to comment further on anything I asked you or comment on anything 
else? 
 
Thank the interviewee for his/her participation.  
Page 1 of 1 
v1.0, 15.02.2016 
   
446 
Appendix 17. Theme definitions and relationships between themes 
Theme Description 
1. DCE development and implementation  
1.1 A political decision with a political 
imperative 
Comments on how DCE was a government funded programme, with a political agenda and a strong 
political imperative, with specific targets and investment. Also includes views on how/why DCE was 
different from other government programmes. This theme is linked with "Resource allocation". 
1.2 Aims, drivers and influencers Views on the purpose of DCE, its aims, drivers, and influencers (with variations across participants). This 
theme is linked with overall contextual themes such as "Deprivation, age and gender". 
1.3 An evidence-based initiative Comments on how the programme was informed both by evidence and preliminary research carried out 
by DCE, especially regarding the social marketing campaigns. It also includes views on whether evidence 
was sufficient. 
1.4 Resource allocation Descriptions of how funding was allocated and perceived challenges in assessing how it was utilised 
across boards. This theme is linked with "Outcome evaluation challenges". 
1.5 Stakeholder involvement Descriptions of the range of stakeholders involved, their roles, input and leadership, and variation in terms 
of influence. This theme is linked with “Voiced Concerns and barriers” and “Belief in DCE and feedback 
on its activities". 
1.6 Voiced concerns and barriers These refer to concerns raised by interviewees or reported by them, and the programme’s response to 
these concerns. This theme is linked with “Perceived impact of activities” and “NHS constraints and 
regional variations”. 
1.7 Developing relationships, systems and 
roles 
References to newly developed IT systems and staff roles (such as the Cancer leads in each Health 
Board). 
1.8. Delays and adaptations Reports of any unexpected delays in implementing programme components and required adaptations 
according to different contextual challenges. This theme is linked with “Overall contextual challenges” 
themes. 
2. Views on DCE and its components  
2.1 A driver of change and other 
aspirations 
Views on how DCE can help to promote change in behaviour and attitudes towards cancer, and potentially 
change service provision (becoming “a legacy”). Theme also includes acknowledgements that changes 
will take a long time and that DCE on its own is not capable of changing everything. This theme is linked 
with "Sustainability concerns" and "Cultural change or shifts". 
2.2 Belief in DCE and feedback on its 
activities 
This refers to positive and negative views about the DCE programme, its aims and each of its components 
(such as their relevance and robustness), with a special focus on the social marketing campaigns. 
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Theme Description 
2.3 Perceived impact of activities Comments about perceived impact of the DCE programme and its individual activities. It also includes 
references to negative impact and/or unanticipated consequences. This theme is linked with “The role of 
targets” and “NHS constraints and regional variations". 
2.4 Sustainability concerns Perspectives on the challenges to sustain DCE activities and any perceived changes brought by the 
programme. This is related to “Government characteristics” and “NHS constraints and regional variations”. 
2.5 The role of targets Views on whether/why targets are needed, and the impact these may have on workload and staff. This is 
related to “A political decision with a political imperative” and “NHS constraints and regional variations". 
3. Logic model  
3.1 Comprehensiveness and usefulness Any views on the usefulness and comprehensiveness of the logic model. 
3.2 Scope, importance, links and 
trajectories 
Remarks on how the logic model does not highlight importance of components, omits processes behind 
any activities, and does not show a temporal flow in terms of activities. Challenges in separating activities 
in boxes are also highlighted. 
3.3 Proposed outputs and outcomes Any views on the applicability or likelihood of proposed outcomes. This theme also includes queries about 
whether proposed outcomes should be short, middle or late and any perspectives on how outcomes may 
vary according to different populations. This theme is linked with “Deprivation and other regional 
variations”. 
3.4 Underlying assumptions This concept includes any remarks about the assumptions shown in the model, but also any comments 
on whether proposed outputs or outcomes could result from activities or whether activities would lead to 
DCE’s main aim to improve survival.  
4. Overarching contextual issues  
4.1 Deprivation, age and gender Comments on how deprivation may affect cancer outcomes and population behaviour. Also includes any 
comments about variation in behaviour and cancer outcomes according to population age and gender. 
The theme is linked with "Individual behaviour and change". 
4.2 Individual behaviour and change Any views on challenges to change behaviour (“not a quick fix”) and how to transform knowledge into 
action. 
4.3 Government characteristics Descriptions on how DCE may be influenced by the fact that it is a government-driven program (such as 
challenges with financing and governance requirements). This theme is linked with “A political decision 
with a political imperative”, “Sustainability concerns”, and “The role of targets”. 
4.4 NHS constraints and regional 
variations 
Any references to NHS constraints such as working under pressure and having limited resources 
(especially regarding diagnostic capacity), busyness, and a “silo mentality” in primary and secondary care. 
The theme also includes references to regional challenges due to remoteness or the way Cancer Networks 
are structured. 
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Theme Description 
4.5 Cultural change or shifts Any references to system changes in terms of focusing more on preventative behaviour and health 
promotion, starting health education at schools and focusing on realistic medicine. 
4.6 Scottish personality Any comments on how Scottish initiatives (including DCE) have not yet been carried out elsewhere. Also 
includes references to the country size (and how it can be beneficial to drive change) and the Scottish 
culture (such as being fatalistic about a cancer diagnosis). 
4.7 Tackling cancer   
4.7.1 Early detection and survival Any views on the role of early diagnosis in improving survival (and other factors which may also influence 
this). 
4.7.2 Screening and survival Any references to screening programmes in Scotland, and the role of primary care in promoting this. 
4.7.3 Variation by cancer type Any comments on how DCE approaches and/or cancer outcomes may vary by cancer type. 
4.7.4. Efficiency and different approaches 
to diagnosis 
Any comments on the need to be efficient when using finite resources; also includes comments on 
approaches such as direct GP access to diagnostics.  
4.8 Role of media Any comments on how the media can influence behaviour, and the challenges in liaising with it. 
5. What to evaluate  
5.1 Early diagnosis, mortality, survival or 
surrogates 
Comments on how the focus should be on “hard data”, such as survival or other surrogates (such as stage 
at diagnosis), or screening uptake. This concept also approaches unanticipated (hard) outcomes. 
5.2 Impact on primary and secondary care Descriptions of how the focus should be on the impact the programme had on secondary care (such as 
how funding was used) or on the primary-secondary care interface. 
5.3 Improvement in knowledge and 
awareness 
Views that the focus should be in improving knowledge/awareness for the overall population. 
5.4 Seeing the bigger picture Views that a cultural change and/or change in attitudes are as important, or more important than the hard 
outcomes.  
6. Outcome evaluation challenges  
6.1 Bias and confounding Any comments on potential biases and confounding (such as having no control group or the influence of 
other initiatives taking place) which may influence the evaluator’s ability to demonstrate cause and effect. 
This theme is linked with “A political decision with a political imperative”. 
6.2 Unmeasurable outcomes, unclear 
definitions and unavailable data 
Any descriptions of possible outcomes that, even when relevant, could not possibly be assessed as 
measurement is not possible, data are “woolly” or there are too many different definitions, or data were 
not collected. This is related to the theme “Seeing the bigger picture” and “Improved in knowledge and 
awareness”. This theme also includes any comments on how results (such as shift in attitudes or change 
in survival outcomes) take a long time and this may affect the ability to measure programme effectiveness. 
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Appendix 18. Outcomes chains and feedback 
loops for each DCE strategy 
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Appendix 19. Key theories, models and frameworks in the literature 
Name Rationale for 
development 
Key constructs Recommended uses 
Behaviour 
Change Wheel 
(BCW) (1, 2) 






Synthesis of 19 frameworks of behaviour change from the literature: 
• It incorporates a model of behaviour called COM-B (capability, 
opportunity, motivation and behaviour). In order to change behaviour 
one or more of these components need to change. 
• Linked to the COM-B is the Theoretical Domains Framework (TDF), 
which synthesises constructs from behaviour change theories into 14 
domains (knowledge, skills, memory, attention and decision 
processes, behavioural regulation, beliefs about capabilities, 
social/professional role and identity, optimism, beliefs about 
consequences, intentions, goals, reinforcement, emotion, 
environmental context and resources, and social influences)  
• The BCW describes nine interventions to change behaviour 
(education, persuasion, incentivisation, coercion, training, restriction, 
environmental restructuring, modelling and enablement) and seven 
policies that can deliver them (regulation, guidelines, fiscal 
measures, environmental/social planning, communication/marketing, 
legislation, and service provision) 
• Suitable for “real world” settings 
• Allows for the systematic 
characterisation of interventions 
and linkage of mechanisms of 
action to outcomes 
• Helpful to assess why an 
intervention did not meet its goal 
• Applicable at different levels; i.e. 
individual, groups and different 
populations, organisational levels  
• Useful so the evaluator does not 

















There are five domains:  
• intervention characteristics (intervention source, evidence strength 
and quality, relative advantage, adaptability, trialability, complexity, 
design quality and packaging, and cost) 
• outer setting (patient needs and resources, cosmopolitanism, peer 
pressure, external policy and incentives) 
• inner setting (structural characteristics, culture, networks and 
communications, implementation climate and readiness) 
• characteristics of individuals (knowledge and beliefs about the 
intervention, self-efficacy, individual stage of change, individual 
identification with the organisation, other personal attributes) 
• process (planning, engaging, executing, reflecting and evaluating) 
• The CFIR can be used during and 
after implementation  
• Evaluators should choose the 
relevant constructs, adapt and 
operationalise them, consider 
levels to be evaluated, time points, 
how to measure them and assess 
them, and also document these 
processes. 
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Name Rationale for 
development 







To fill a gap and be 






Three dimensions interact with one another:  
• context (with geographical, epidemiological, socio-cultural, socio-
economic, ethical, legal and political domains) 
• implementation (with implementation theory, process, strategies, 
agents and outcomes) 
• setting (physical location where the intervention takes place) 
The authors propose the use of the 
framework in conjunction with logic 
models to help undertake both 
reviews and health technological 










Iowa, USA in the 
1950s (5) 
Key attributes of innovations explain variation in rates of adoption 
(bearing in mind they are necessary, but not sufficient for adoption): 
• Relative advantage: more effective/cost-effective innovations are 
more easily adopted and implemented. 
• Compatibility: if innovations are compatible with values, norms and 
needs, they are more easily adopted and assimilated 
• Complexity: simpler innovations are more easily adopted. 
Innovations can be more easily adopted if they can be broken down 
in different components and adopted incrementally 
• Trialability: if users can experiment on an innovation it is more likely 
to be adopted and assimilated 
• Observability: If intended users can see benefits, innovations are 
adopted and assimilated more easily 
• Reinvention: modifiable innovations are more easily adopted 
There are also additional attributes to adoption and assimilation such 
as fuzzy boundaries; risk, task issues, knowledge and support. 
Wide range of fields, areas and 
applications. Since its development, 
the theory has expanded broadly, 
especially in the field of Public 







how new practices 
are implemented, 
embedded and 
sustained in a new 
social context 
Implementation is a result of four generative mechanisms:  
• coherence (practices are held together by a set of meanings and a 
range of competencies) 
• cognitive participation (symbolic and real engagement of actors) 
• collective action (actions that organise/enact a practice) 
reflexive monitoring (constant evaluation of collective action and the 
results of these actions) 
• To guide process evaluations, 
approaching implementation and 
sustainability of complex 
interventions in health care 
• It was not designed to deal with 
diffusion and adoption, nor 
intention and volition 
• A tool (NoMad) was developed (9) 
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development 





the need to 
understand which 
components in an 
intervention led to 
its success 
There are seven key process evaluation components: 
• Context: environmental issues that may affect implementation 
• Reach: proportion of the target group taking part 
• Dose delivered: Amount of the interventio/components delivered 
• Dose received: Extent to which groups engaged with, interacted 
with/and were receptive towards the intervention 
• Fidelity: extent to which the intervention was delivered as intended 
• Implementation: composite score of reach, dose and fidelity 
• Recruitment: processes to approach/attract relevant groups 
• Not stated; process evaluation 
(overall) is useful to understand 





the public health 
significance of an 
intervention 
Five factors influence the impact of an intervention:  
• Reach (individual level of participation – to assess 
representativeness and whether groups in need were reached); 
• Efficacy (both positive and negative outcomes – including 
behavioural and psychological); 
• Adoption (proportion that adopts a programme),  
• Implementation (whether the programme was delivered as intended 
– both at individual and programme-level); 
• Maintenance (long-term) 
• A “public health impact score” is calculated by combining factors 
• Developed to be used with a range 
or designs 
• It is compatible with systems-
based thinking and public health 
interventions 
• Investigation of only a few factors 





Solve the pending 







Based on a review of implementation outcomes from the literature, 
eight implementation outcomes indicate implementation success, 
implementation processes and intermediate outcomes: 
• Acceptability: whether a practice is agreeable 
• Adoption: intention or action to employ a practice 
• Appropriateness: whether the practice is a good fit 
• Feasibility: extent that a certain practice be used 
• Fidelity: degree to which a practice was implemented as planned 
• Implementation cost: cost impact of the implementation 
• Penetration: integration of a practice 
• Sustainability: extent to which a practice is maintained 
• Outcomes should be measured 
and tested to shed light on 
mechanisms and causal 
relationships in implementation 
research 
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Appendix 20. Additional definitions for BCW 
components 
 
Evidence described in this Appendix was obtained from: Michie S, Atkins L, West R. The 
Behaviour Change Wheel. A guide to designing interventions: Silverback Publishing; 2014. 
The Theoretical Domains Framework (TDF) 
COM-B components can be further detailed into 14 domains, which are organised into the 
Theoretical Domains Framework (TDF). The TDF synthesises constructs from different 
behaviour change theories and was developed by psychologists and implementation 
researchers. Its 14 domains are described below, alongside interview questions proposed by 
Michie et al, adapted in line with the DCE programme. 
 
Domain Definition Example of questions 
Knowledge Being aware of the existence of something 
Do you know about the HEAT 
targets? 




Ability to retain information, focus 
selectively on it and choose 
between alternatives 
As a GP, is speaking to patients 
about non-response to bowel 




Managing or changing actions Do you have systems in place 
to monitor whether or not QOF 
targets or the HEAT targets are 
being met? 
Social/professional 
role and identity 
Coherent group of behaviours and 
personal qualities in a social or 
work setting 
Is being involved with DCE 





Acceptance of the reality of an 
ability/talent 
How difficult or easy is it for your 
Health Boards to meet the 
HEAT targets? 
Optimism Confidence that things will work out or that goals will be achieved 
How confident are you that you 
will be able to meet targets? 
Beliefs about 
consequences 
Acceptance of the reality of 
outcomes of a behaviour 
What do you think will happen if 
the targets are not met? 
Intentions 
Conscious decision to carry out a 
behaviour or act in a specific way 
Has the general practice made 
the decision to be involved in 
the bowel screening initiative? 
Goals Mental representations of outcomes that one wants to achieve 
How much do you wish to meet 
the HEAT targets? 
Reinforcement 
Increasing the likelihood of a 
response by establishing a 
contingency between stimuli and 
responses 
Are there incentives to meet 
DCE targets? 
Emotion 
Complex reactions based on 
experiential, behavioural and 
physiological components, by 
which someone tries to deal with a 
personally significant event 
Do the DCE strategies evoke an 
emotional response? 
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Any circumstances that encourage 
or discourage the development of 
skills, abilities, independence, 
social competence and other 
behaviours 
To what extent do physical or 
resource factors facilitate or 
hinder your ability to detect 
cancer early? 
Social influences 
Interpersonal issues that result in 
change of thoughts, feelings or 
behaviours 
To what extent do social 
influences facilitate or hinder 
engagement with the DCE 
programme? 
Source: adapted from Michie et al 2014 
TDF can be used at the individual level, organisational level, community level and to identify 
contextual issues influencing behaviour. If it is not feasible to assess all 14 domains, COM-B 
can give an indication of which domains to select. The TDF can be linked to all COM-B 
domains (Figure A). 
 
Figure A. TDF linked to COM-B domains 
 
 
Source: adapted from Michie et al 2014 
Intervention functions 
These refer to means by which interventions can change behaviour. Authors highlight that one 
particular intervention or behaviour change technique can have more than one function. The 
BCW describes nine intervention functions; these are shown below. 
 




Giving information on how 
to check for breast cancer 
symptoms 
Persuasion 
Use of communication to induce 
positive/negative feelings or 
stimulate action 




Create an expectation of a reward Providing financial rewards 
for reducing bowel 
screening non-response 
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Coercion 
Create an expectation of 
punishment or cost 
Explaining that Health 
Boards not meeting targets 
will be monitored 
Training Teach skills Education sessions about referral guidelines 
Restriction 
Use rules to reduce the 
opportunity to engage in target 
behaviour (or increase behaviour 
by decreasing the opportunity to 
engage in competing behaviours 
Not applicable to DCE 
Environmental 
restructuring 
Change of the physical or social 
context 
Introducing meetings to 
discuss referral pathways 
Modelling 
Give an example for people to 
aspire or copy 
Showing the celebrity 
Elaine C Smith having a 
mammogram on television 
Enablement 
Increase means or reduce barriers 
to increase capability (above 
education and training) or 
opportunity (beyond 
environmental restructuring 
Distribution of desk 
versions of referral 
guidelines 
Source: adapted from Michie et al 2014 
Policies 
When synthesising the 19 frameworks, authors identified seven policy categories that help to 
support and enable interventions (shown below). 
 
Policy category Definition Example applied to DCE 
Communication/marketing Use of media Carrying out social marketing campaigns 
Guidelines Creation of documents that mandate practice 
Updating referral guidelines for 
suspected cancer 
Fiscal measures Use of tax to increase or decrease financial costs Not applicable to DCE 
Regulation Establishing rules or principles of behaviour 
Giving feedback on performance 
according to targets 
Legislation Make/change laws Not applicable to DCE 
Environmental/social 
planning 
Design/control the physical 
or social environment Plans on how to invest DCE funds 
Service provision Service delivery Establish early detection services 
Source: adapted from Michie et al 2014 
Behaviour change techniques 
BCW also identified behaviour change techniques that can deliver each intervention function 
under the relevant policy categories. A BCT can be defined as “an active component of an 
intervention designed to change behaviour”. This component should be “observable, 
replicable an irreducible component, and an active ingredient in an intervention”. The BCT 
taxonomy has 93 items organised into 16 groupings by experts: goals and planning; feedback 
and monitoring; social support; shaping knowledge; natural consequences; comparison of 
behaviour; associations; repetition and substitution; comparison of outcomes; reward and 
threat; regulation; antecedents; identity; scheduled consequences; self-belief; and covert 
learning. These are not described further here as they were not adopted in the DCE evaluation, 
except when mapping DCE components to ensure suitability of the BCW for the programme. 
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Appendix 21. DCE mapped into BCW components 
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Appendix 23. Level 1 Ethics Form (outcome 
evaluation) 
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The role of health system level initiatives in promoting the earlier diagnosis of cancer– what can we 
learn from the Detect Cancer Early (DCE) programme in Scotland? 
 
Interview topic guide 
Professionals working in primary and secondary care 
 
Process evaluation of the DCE Programme 
 
The guide will be used in a flexible and responsive manner, allowing participants to introduce 
new areas for discussion. Ensure signed consent form has been received. 
 
Introduction: Thank you for agreeing to be interviewed. This interview is part of a process evaluation 
of DCE. We are particularly interested in processes and changes from 2011 until 2015. Firstly, I will ask 
you to tell me a bit about yourself and your involvement with DCE, then I will ask you specific questions 
about the programme and about how it may have influenced your work. All information you provide is 
confidential. The interview will be recorded and the transcripts will be anonymised. Please feel free to 
ask me any questions at any time. 
 
Interview questions/topics 
10. Ask the participant to tell you a bit about himself/herself and their level of involvement with DCE 
(ask for job role and experience) 
11. Ask about the first time they heard about DCE, their initial views about it and whether these 
changed over time (prompts: information on communicating requirements/strategies) (A1, A2, M1) 
12. Ask for their views on DCE aims and outcomes (mention them) (prompts: how confident they were 
about meeting aims, and why they think some aims were met/not met; unanticipated outcomes) (A1) 
13. Ask for their views on whether the programme made a difference (e.g. what would have happened if 
there was no DCE?) and on any noticeable barriers/facilitators (such as rural/urban differences) (A1) 
14. Ask (health care professionals only) whether they noticed an increase in patients worried about 
possible cancer (prompt for whether patients mentioned the social marketing campaigns) 
15. Ask about what changed in their daily work because of DCE, and whether any adaptations were 
needed (prompt: whether they though their role in the programme was appropriate) (A4) 
16. Ask whether DCE estimates on impact on workload were accurate (think of each of the strategies; 
prompt: was DCE a driver for action? Ask for their views on who carried the greatest workload) (A1, M3) 
17. Ask whether there were any challenges to meet targets, follow guidelines, attend sessions or meet 
demand after campaigns (prompt: ask for their views on the role of performance targets) (M4) 
18. Ask about the level of resources available for what they were required to do (think about human and 
financial resources, equipment, time, and knowledge – prompt: were resources sufficient?) (A3, M2) 
19. Ask about any other external factors influencing implementation and DCE’s success 
 
 
Thank the interviewee for his/her participation and ask if they would like to comment on 
anything you had asked – or anything else.  
Finally, ask whether they would like to receive a summary of the study results. If so, make a 
note for future reference. 
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Appendix 25. Questionnaire audit trail 
 
Survey questions Source, constructs, theory 
Q1. Please choose ONE option New – informed by interviews and pre-testing 
Q2. Informed consent. Please choose one option N/A 
Q3. Were you informed about the DCE programme before it was 
implemented in 2012? 
Adapted from (1). Implementation outcome: Reach and communication 
Q4. Were you involved in developing or refining DCE or any of its 
strategies? 
New – informed by interviews. Implementation outcome: Reach and 
communication 
Q6.1a. DCE was appropriate to promote early detection New – informed by interviews Implementation outcome: appropriateness 
Q6.2.a The benefits brought by DCE outweighed the time and effort 
required to work towards its aims 
Adapted from (1). Implementation outcome: acceptability 
Q7.1.a It was part of my job to be involved in DCE Adapted from. (2, 3). COM-B Component: Reflective Motivation. TDF 
domain: Social/Professional Role & Identity 
Q7.2.a I had flexibility to make changes in order to meet DCE aims New – informed by interviews. Implementation outcomes: feasibility and 
adaptability 
Q7.3.a There was enough time to engage with DCE and its strategies Adapted from (1). Implementation outcome: appropriateness 
Q8 Did the DCE programme increase demand for the services you 
provided to patients?  
New – informed by interviews. COM-B construct: automatic motivation 
(filter for next question) 
Q9 If you said yes to the question above, did the increased demand drive 
the development of local initiatives to detect cancer early? 
New – informed by interviews. COM-B construct: automatic motivation 
Q11.1.a I support continuation of DCE Adapted from (1). Implementation outcome: sustainability 
Q11.1.b My local team supports continuation of DCE Adapted from (1). Implementation outcome: sustainability 
Q13, Q18, Q22, Q27, Q31, Q35 New – filter questions informed by guidance on questionnaire 
development 
Q14 Were you informed about the DCE campaigns before they were 
launched? 
Adapted from (1). Implementation outcome: Reach and communication 
Q15.1.a Public awareness campaigns were an appropriate strategy to 
promote early detection 
New – informed by interviews. Implementation outcome: appropriateness 
Q16 Did this strategy increase demand for the services you provided to 
patients? 
New – informed by interviews. COM-B construct: automatic motivation 
(filter for open-ended comments) 
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Survey questions Source, constructs, theory 
Q19 Were you informed about the education sessions before they 
commenced? 
Adapted from (1). Implementation outcome: Reach and communication 
Q20.1.a The education sessions were an appropriate strategy to promote 
early detection 
New – informed by interviews. Implementation outcome: appropriateness 
Q20.2.a It was difficult to integrate the education sessions with my usual 
work 
New – informed by interviews. COM-B construct: reflective motivation 
Q20.3.a I had enough time to attend the education sessions Adapted from (1). Implementation outcome: appropriateness 
Q23 Were you informed about the work being carried out to update the 
guidelines before they were published? 
Adapted from (1). Implementation outcome: Reach and communication 
Q24.1.a The updated guidelines were an appropriate strategy to promote 
early detection 
New – informed by interviews. Implementation outcome: appropriateness 
Q25 Did the updated referral guidelines increase demand for the services 
you provided to patients? 
New – informed by interviews. COM-B construct: automatic motivation 
(filter for open-ended comments) 
Q28 Were you informed about the additional funding before it became 
available? 
Adapted from (1). Implementation outcome: Reach and communication 
Q29.1.a Providing extra funding was an appropriate strategy to promote 
early detection 
New – informed by interviews. Implementation outcome: appropriateness 
Q29.2.a I was confident that my team would be able to manage demand 
for screening and diagnostics when I was informed about the funding 
Adapted from (2-4). COM-B construct: Reflective motivation. TDF domain: 
Belief about capabilities 
Q29.3.a We had enough time to plan how to use the funding Adapted from (1). Implementation outcome: appropriateness 
Q29.4.a Primary and secondary care communicated well with each other 
when planning how to use the funding 
New – informed by interviews. Implementation outcome: Reach and 
communication 
Q29.5.a Additional funding resulted in more equipment for diagnosis New: informed by interviews. COM-B construct: Physical opportunity. TDF 
domain: Environmental context and resources 
Q29.6.a Additional funding resulted in more workforce for diagnosis New: informed by interviews. COM-B construct: Physical opportunity. TDF 
domain: Environmental context and resources 
Q32 Were you informed about the HEAT targets before they were 
launched? 
Adapted from (1). Implementation outcome: Reach and communication 
Q33.1.a HEAT targets were an appropriate strategy to promote early 
detection 
New – informed by interviews. Implementation outcome: appropriateness 
Q33.2.a I was confident in my ability to meet HEAT targets Adapted from (2-4). COM-B construct: Reflective motivation. TDF domain: 
Belief about capabilities 
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Survey questions Source, constructs, theory 
Q33.3.a It was difficult to integrate meeting HEAT targets with my usual 
work 
New – informed by interviews. COM-B construct: reflective motivation 
Q33.4.a HEAT targets pressured our team to act New – informed by interviews. COM-B constructs: reflective motivation 
and automatic motivation 
Q33.5.a HEAT targets worked as a reminder for where our efforts should 
be focused 
New – informed by interviews. COM-B constructs: reflective motivation 
and automatic motivation 
Q36 Were you informed about the bowel screening initiative before it was 
launched? 
Adapted from (1). Implementation outcome: Reach and communication 
Q37.1.a The bowel screening initiative was an appropriate strategy to 
promote early detection 
New – informed by interviews. Implementation outcome: appropriateness 
Q37.2.a I was confident in my ability to be awarded the QOF points Adapted from (2-4). COM-B construct: Reflective motivation. TDF domain: 
Belief about capabilities 
Q37.3.a It was difficult to integrate the bowel screening initiative with my 
usual work 
New – informed by interviews. COM-B construct: reflective motivation 
Q37.4.a My team had enough time to reach non- responders to bowel 
screening 
Adapted from (1). Implementation outcome: appropriateness 
Q37.5.a The bowel screening initiative pressured our team to act New – informed by interviews. COM-B constructs: reflective motivation 
and automatic motivation 
Q37.6.a The bowel screening initiative worked as a reminder for where 
our efforts should be focused 
New – informed by interviews. COM-B constructs: reflective motivation 
and automatic motivation 
Q38 Did the bowel screening initiative increase demand for the services 
you provided to patients? 
New – informed by interviews. COM-B construct: automatic motivation 
(filter for open-ended comments) 
Q40 Would you describe yourself as:  Informed by the European Social Survey questionnaire (5) 
Question needed to understand the participants’ profile and estimate 
whether sample is representative 
Q41 In what year were you born? Informed by the European Social Survey questionnaire (5); recoded into 
age groups as per official ISD Scotland publications 
Question needed to understand the participants’ profile and estimate 
whether sample is representative 
Q42 What was your profession from 2011 until 2015? You can tick more 
than one answer or choose “Other” if appropriate. 
Questions on profession informed by interviews and categories from the 
National NHS Staff Survey (6); other questions informed by interviews 
Q43 Does your work focus on a specific cancer type (e.g. breast, lung, 
bowel cancer)? 
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Survey questions Source, constructs, theory 
Q44 Still thinking of the 2011-2015 period, please write down the years 
DCE was relevant to your work. For example, from 2012 to 2014. 
Question needed to allow for group comparisons and understand whether 
views on the programme differ across stakeholders with different 
characteristics 
Q45 In which territorial Health Board do you work? You can tick more than 
one answer or choose “Other” if appropriate. 
Question created by listing all Health Boards in Scotland and adding 
“Whole of Scotland” for those working at a national level 
Question needed to understand the participants’ profile 
Q46 Which best describes the area where you work? Categories the same as used by Official Urban/Rural Classification from 
the Scottish Government (7) 
Question needed to understand the participants’ profile 
Q47 Which best describes your workplace? You can tick more than one 
answer or choose “Other” if appropriate. 
Created with information obtained from interviews 
Question needed to understand the participants’ profile and estimate 
whether sample is representative 
Q48. If you wish, please use this space to write your views about what 
worked well and what did not work so well in the programme. 
General feedback question – informed by interviews 
Q49 If you wish, please let us know your views on barriers/facilitators to 
DCE success. 
Question on barriers and facilitators (one of the process evaluation 
questions) – created with information obtained from interviews 
Q5, Q6.2.a, Q10, Q12, Q14.a, Q17, Q19.a, Q21, Q23.a, Q26, Q28.a, Q30, 
Q32.a, Q34, Q36.a, Q39, Q50 
General feedback questions – informed by guidance on designing 
questionnaires (described on Chapter 6) 
References: 1.Steckler A, Linnan L. Process Evaluation for Public Health Interventions and Research. San Francisco, California: Wiley; 2002. 
2.Huijg JM, Gebhardt WA, Crone MR, et al. Discriminant content validity of a theoretical domains framework questionnaire for use in 
implementation research. Implement Sci. 2014;9(1):11. 3.Huijg JM, Gebhardt WA, Dusseldorp E, et al. Measuring determinants of 
implementation behavior: psychometric properties of a questionnaire based on the theoretical domains framework. Implement Sci. 
2014;9(1):33. 4.Skoien W, Page K, Parsonage W, et al. Use of the Theoretical Domains Framework to evaluate factors driving successful 
implementation of the Accelerated Chest pain Risk Evaluation (ACRE) project. Implement Sci. 2016;11(1):136. 5. ESS. Source questionnaire. 
Round 8. 2016/2017 2016. Available from: 
https://www.europeansocialsurvey.org/docs/round8/fieldwork/source/ESS8_source_questionnaires.pdf [Accessed 9 August 2019]. 6. NHS. 
National NHS Staff Survey Co-ordination Centre 2019. Available from: https://www.nhsstaffsurveys.com/Page/1056/Home/NHS-Staff-Survey-
2019/ [Accessed 9 August 2019]. 7.The Scottish Government. Scottish Government Urban/Rural Classification 2013-2014: Scottish 
Government; 2014. Available from: http://www.gov.scot/Resource/0046/00464780.pdf [Accessed 9 August 2019]
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Appendix 26. The process evaluation 
questionnaire 
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Appendix 27. Ethical approval (Study 3 - 
interviews) 
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Appendix 29. Tumour staging by Health Boards 
 
Source: created with  aggregated tables from ISD Scotland: ISD Scotland. Detect Cancer Early - Year 6 Staging Data. Time Period: 01 January 
2010 - 31 December 2017. In: DCE_Staging_Trends. Microsoft Excel. http://www.isdscotland.org/Health-Topics/Cancer/Publications/data-
tables2017.asp?id=2206#2206  
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Appendix 30. Requests for bowel screening kits by Health Boards 
 
Source: created with customised data provided by the Scottish Bowel Screening Centre
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Appendix 31. Tumour staging coded as unknown by Health Boards 
 
Source: created with  aggregated tables from ISD Scotland: ISD Scotland. Detect Cancer Early - Year 6 Staging Data. Time Period: 01 January 
2010 - 31 December 2017. In: DCE_Staging_Trends. Microsoft Excel. http://www.isdscotland.org/Health-Topics/Cancer/Publications/data-
tables2017.asp?id=2206#2206
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Appendix 32. All questionnaire responses 
Q1 and Q2. Eligibility and informed consent 
 % Valid % Cumulative % 
Detect Cancer Early influenced my daily work 
during 2011-2015 AND/OR I did help 
develop/implement one or more of its activities 
100.0 100.0 100.0 
I have read the information above AND I agree to 
take part in this survey 100.0 100.0 100.0 
 
Q3. Were you informed about the DCE programme before it was implemented in 2012? 
 N % Valid % 
Cumulative 
% 
Yes, I was sufficiently informed about DCE 23 43.4 44.2 44.2 
Yes, but I would have liked to have had more 
information 20 37.7 38.5 82.7 
No, I was not informed about it 9 17.0 17.3 100.0 
Total 52 98.1 100.0  
Missing (Other) 1 1.9   
Total 53 100.0   
 
Q4. Were you involved in developing or refining DCE or any of its strategies? This could 
have happened by taking part in DCE meetings, giving feedback on the implementation 
plan, on the urgent referral guidelines for suspected cancer, etc. 
 N % Valid % Cumulative % 
Yes 9 17.0 18.0 18.0 
No, but I would have liked to have had an input 20 37.7 40.0 58.0 
No, and I was happy with that 21 39.6 42.0 100.0 
Total 50 94.3 100.0   
Missing (Other) 3 5.7     
Total 53 100.0   
 
Q5. If you wish, you can use the box below to comment on your answers to the 
questions above. 
As someone whose practice was impacted by the DCE campaign I would have been very 
interested in commenting on the messages which were used, when they were in draft form, 
as I think several were poorly though through. 
Did survey of Breast Cancer units across Scotland regarding the impact of the first DCE 
campaign for Breast Cancer and it’s effect on referral numbers and cancer numbers. 
I provided information / advice for the lung cancer strategy's approach for the public 
campaign to raise awareness of the disease and when patients should see their GP 
I was given the option to feed in, but it didn't seem to affect the outcome. 
I was involved in early meetings regarding the data which would be required 
Mostly involved in the communications and marketing materials developments. 
my colleague was involved in implementation, so I heard by word of mouth and from tv 
adverts 
No thought was given to available resources. This program has resulted in an enormous 
extra spend and will help bring the NHS to its knees. No program should be launched 
without consideration of workforce available 
not applicable as was still in training 
started post in 2015 now spending most of my time re educating and undoing the harm 
created by poor referral criteria. 
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The initial DCE campaign was targeted at the general population and did not increase the 
cancer detection in target group. 
tv advert for breast cancer was ill thought out 
 
Q6.1.a. DCE was appropriate to promote early detection 
Median 4.0 (IQR 3.0-6.0) 
 N % Valid % Cumulative % 
Strongly disagree 7 13.2 13.7 13.7 
Disagree 5 9.4 9.8 23.5 
Somewhat disagree 9 17.0 17.6 41.2 
Neither agree nor disagree 8 15.1 15.7 56.9 
Somewhat agree 7 13.2 13.7 70.6 
Agree 8 15.1 15.7 86.3 
Strongly agree 7 13.2 13.7 100.0 
Total 51 96.2 100.0   
Missing (Don’t know) 2 3.8   
Total 53 100.0   
 
Q6.2.a. The benefits brought by DCE outweighed the time and effort required to work 
towards its aims 
Median 4.0 (IQR 2.0-5.0) 
 N % Valid % Cumulative % 
Strongly disagree 12 22.6 23.5 23.5 
Disagree 10 18.9 19.6 43.1 
Somewhat disagree 3 5.7 5.9 49.0 
Neither agree nor disagree 9 17.0 17.6 66.7 
Somewhat agree 7 13.2 13.7 80.4 
Agree 4 7.5 7.8 88.2 
Strongly agree 6 11.3 11.8 100.0 
Total 51 96.2 100.0   
Missing (Don’t know) 2 3.8   
Total 53 100.0   
 
Q7.1.a. It was part of my job to be involved in DCE 
Median 6.0 (IQR 5.0-7.0) 
 N % Valid % Cumulative % 
Strongly disagree 4 7.5 7.8 7.8 
Disagree 1 1.9 2.0 9.8 
Somewhat disagree 2 3.8 3.9 13.7 
Neither agree nor disagree 3 5.7 5.9 19.6 
Somewhat agree 8 15.1 15.7 35.3 
Agree 10 18.9 19.6 54.9 
Strongly agree 23 43.4 45.1 100.0 
Total 51 96.2 100.0   
Missing (Don’t know) 1 1.9     
Missing (Question not applicable) 1 1.9     
Total missing 2 3.8   
Total 53 100.0   
 
Q7.2.a. I had flexibility to make changes in order to meet DCE aims 
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Median 2.0 (IQR 1.0-4.0) 
 N % Valid % Cumulative % 
Strongly disagree 19 35.8 41.3 41.3 
Disagree 8 15.1 17.4 58.7 
Somewhat disagree 3 5.7 6.5 65.2 
Neither agree nor disagree 6 11.3 13.0 78.3 
Somewhat agree 4 7.5 8.7 87.0 
Agree 4 7.5 8.7 95.7 
Strongly agree 2 3.8 4.3 100.0 
Total 46 86.8 100.0   
Missing (Don’t know) 3 5.7     
Missing (Question not applicable) 4 7.5     
Total missing 7 13.2     
Total 53 100.0   
 
Q7.3.a. There was enough time to engage with DCE and its strategies 
Median 2.0 (IQR 1.0-4.0) 
 N % Valid % Cumulative % 
Strongly disagree 16 30.2 33.3 33.3 
Disagree 10 18.9 20.8 54.2 
Somewhat disagree 5 9.4 10.4 64.6 
Neither agree nor disagree 8 15.1 16.7 81.3 
Somewhat agree 6 11.3 12.5 93.8 
Agree 2 3.8 4.2 97.9 
Strongly agree 1 1.9 2.1 100.0 
Total 48 90.6 100.0   
Missing (Don’t know) 2 3.8     
Missing (Question not applicable) 3 5.7     
Total missing 5 9.4     
Total 53 100.0   
 
Q8. Did the DCE programme increase demand for the services you provided to 
patients? 
 N % Valid % Cumulative % 
Yes 46 86.8 92.0 92.0 
No 4 7.5 8.0 100.0 
Total 50 94.3 100.0   
Missing (Don’t know) 1 1.9    
Missing (Question not applicable) 2 3.8    
Total missing 3 5.7    
Total 53 100.0   
 
Q9. If you said yes to the question above, did the increased demand drive the 
development of local initiatives to detect cancer early? 
 N % Valid % Cumulative % 
Yes 11 20.8 29.7 29.7 
No 25 47.2 67.6 97.3 
Other 1 1.9 2.7 100.0 
Total 37 69.8 100.0   
Missing (Don’t know) 9 17.0    
Missing (Question not applicable) 6 11.3    
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Missing (no answer given) 1 1.9   
Total missing 16 30.2    
Total 53 100.0   
 
Q10. You can use this space to write comments about any of the questions above. 
As a board we had to focus our attention on ensuring capacity to meet potential increase in 
demand 
Big increase in worried well.  No change in cancer diagnosis but increased delays for all.    
Revision to focus on screening more sensible but less visible. 
Due to anticipated and actual extra demand, help to provide impetus for new consultant 
post (mine) in my department 
Endoscopy and diagnostic services are overwhelmed with the worried well. GPs are 
referring all patients as urgent and urgent cancer in order to have any chance of being seen. 
The waiting list has escalated beyond control. People who should be having colonoscopic 
surveillance who are at high risk are suffering the opportunity cost of sending everyone up 
to hospital. There have been notable cases where patients due for recall have not had 
surveillance and have presented with established cancer. This is because of the increasing 
demand since 2012 and before then. DCE is not the only factor responsible but anything 
that does increase demand depletes ability to prioritise to those in most need. Over-
diagnosis is another major issue with many cancers, breast and prostate being the most 
visible 
From where I was positioned (as a GP) it increased demand and pressure with no extra 
resources. Waiting times went up, and it is not clear anything was gained. 
Higher number of Urgent suspicion of cancer GP referrals than previous years.    Fewer 
new referrals via emergency A&E admission 
I personally don't provide a service to patients. 
Increased colonoscopy lists, increased recruitment & training of non-medical endoscopists 
It drove local initiatives to deal with the flood of "worried well". 
NO increase in staff or resources to deal with large influx of patients. These patients were 
detected with pre-cancerous changes mainly.  This attitude of 'early breast cancer' need to 
change 
not enough planning for impact of DCE and totally inappropriate referrals to Outpatients 
subsequently caused - thereby delaying some true cancer referrals 
patients for instance, got the message about early chest x-rays, and organising the first x-
ray was easy enough but dealing with the unclear results, particularly those with "normal" 
x-rays in those who had risk factors for lung cancer, was and remains difficult. I often have 
email conversations with respiratory consultants regards such patients, many of whom go 
on to have CT chest, sometimes CT CAP, and yet I would struggle to remember any who 
had lung cancer. I come to the conclusion that an annual low dose CT of the chest for 
smokers over 60 would be a far better use of resources. (or direct access for GP to CTs) 
Referral to breast services across Scotland, with, I believe, the exception of Dumfries and 
Galloway, rose by approximately 30-40% - data previously presented by Phillipa Whitford. 
There was no increase in cancers detected. Our symptomatic breast service has never 
really recovered. All of the clinical signs used in the campaign - orange peel skin etc are 
LATE signs of breast cancer. 
The breast screening service was not consulted early enough with the strategy and when 
they were consulted the campaigns were not targeted in line with the programme. 
the drive to detect cancer early has led to inappropriate referrals and investigation of the 
worried well - almost no guidelines or evidence is used by referring clinicians. 
The first DCE Breast Cancer campaign coincided with October which is already Breast 
Cancer Awareness month. It was very intense and resulted in 30% - 50% increases in Clinic 
referrals across Scottish units (except Dumfries as the TV adverts were not shown on 
Border TV) but, while there were individual women who came forward as a direct result of 
the information, there was no significant increase in the cancers detected nor change to 
earlier disease stage. Anecdotally, in our unit, it was more advanced cancers with the other 
symptoms highlighted by the campaign (skin dimpling or colour change or change in breast 
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shape) who came forward.  I fed back the survey results and we proposed less intense 
campaigns but more prolonged throughout the year to increase the chance of a woman 
seeing an advert when she might have symptoms rather than stimulating concerns 
generally. 
The increase in demand caused major impact on the resource that was available at the 
time, this led to increased stress levels for those on the front line leading to burn out for staff 
and consequently poorer service for those requiring care. However, the experience was 
used positively to look at working practice and how staff could be better supported and 
change to meet needs of service. 
There was a massive surge in referrals with no commensurate rise in staffing or resource 
There was no thought re what the current service was able to deliver. No realisation that 
most team(s) who diagnose cancer also provide emergency care and care to planned care 
These responses refer primarily to colonoscopy for bowel cancer 
We did the same amount of work. There were no resources put in to do extra operations or 
see extra patients in clinics.   So, it just did not matter whether you detected cancer early or 
not. Everybody just stayed in the queue.   What would have made a difference was if you 
had predicted a certain number of cancer cases being picked up early and estimated how 
much extra operating spaces or clinic spaces would be required to deal with new cases you 
would be picking up. 
we were swamped with the worried well. we found some incidental cancers but generally 
our service was near to collapse. 
Within the breast service, DCE resulted in very large numbers of women who had nothing 
wrong with them asking to be referred from their GP to specialist breast clinics for 
reassurance. This in fact hindered access to breast services for patients with breast cancer 
as no additional resources were put in place to deal with the increased number of referrals. 
 
Q11.1.a. I support continuation of DCE 
Median 4.0 (IQR 3.0-6.0) 
 N % Valid % Cumulative % 
Strongly disagree 7 13.2 13.7 13.7 
Disagree 4 7.5 7.8 21.6 
Somewhat disagree 6 11.3 11.8 33.3 
Neither agree nor 
disagree 9 17.0 17.6 51.0 
Somewhat agree 6 11.3 11.8 62.7 
Agree 9 17.0 17.6 80.4 
Strongly agree 10 18.9 19.6 100.0 
Total 51 96.2 100.0   
Missing (Don’t know) 2 3.8     
Total 53 100.0   
 
Q11.2.a. My local team supports continuation of DCE 
Median 5.0 (IQR 3.0-6.0) 
 N % Valid % Cumulative % 
Strongly disagree 3 5.7 7.9 7.9 
Disagree 4 7.5 10.5 18.4 
Somewhat disagree 3 5.7 7.9 26.3 
Neither agree nor disagree 7 13.2 18.4 44.7 
Somewhat agree 3 5.7 7.9 52.6 
Agree 10 18.9 26.3 78.9 
Strongly agree 8 15.1 21.1 100.0 
Total 38 71.7 100.0   
Missing (Don’t know) 14 26.4     
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Missing (Question not applicable) 1 1.9   
Total missing 15 28.3   
Total 53 100.0   
 
Q12. You can use this space to write any comments about this section. 
Breast and colorectal cancer have screening programmes already. Lung cancer is largely 
related to smoking and that should be the target for campaigns not DCE. 
breast screening is the best way to detect breast cancer early- this was implemented in the 
1980s 
DCE promotes the worried well not the patients we need to see 
DCE works for some cancers but most definitely has limitations e.g. detection of DCIS, 
CSL/RS, tubular cancers (of little clinical significance) 
Detect Cancer Early remains a standing item as part of cancer strategy group remit 
Everybody supports Detecting Cancer early.  The problem is there is NOT a one size fits all 
for cancer. Colorectal cancer is best detected early using the population screening 
programme. This is not appropriate for other cancers 
I didn't know it was still going? What is different now to if we stopped it? 
I didn't know that DCE had continued beyond 2015. 
I don't see much benefit unless it is focusses on other cancers rather than 2 which are 
already covered by screening programmes. 
I think that a dedicated clinic with sufficient resources, to whom unclear cases are referred, 
would be most useful. I have, too often seen people referred UCS to the one specialty, given 
the all clear and then turn out to have cancer of a different system.  Also, those who cannot 
be referred UCS seem to be waiting a lot longer to be seen urgently than they used to 
important but need to be more targeted 
More patients referred for assessment which has not subsequently reduced. small number 
of additional cancers detected compared to our yearly average 
Not in its current format.  The target, 25% increase in Stage 1, requires review.  Many 
Boards had introduced initiatives prior to the baseline year and therefore struggle to achieve 
this target.  A QI approach to early detection would be more beneficial. 
Not sure how this could be addressed. The harms of investigating the worried well - 
rendering the population worried about cancer is another dysbenefit. Cancer phobia is rife 
and yet there is no grade A evidence that early diagnosis of symptomatic people provides 
any benefit. Screening does for colon cancer, but no other cancers have RCT evidence. 
The balance of risks and benefits is the issue here. As well as opportunity cost that is often 
glossed over. Just because someone is identified with a high-risk condition doesn't mean to 
say they are well looked after when on a waiting list that is swamped with people without 
cancer but requiring investigation precipitated by a desire not to "wait and see".  Ironically, 
the more people come up to hospital for "cancer investigations" the better the figures look 
because of the vagaries of reporting cancer survival figures. The incidence date is the last 
date that any given patient attended secondary care. So, if GPs send everyone up all the 
time for irrelevant reasons, the time from incidence to death will be artificially shortened. 
Hence cancer survival statistics look worse in Britain for spurious reasons 
Now that we can take the funding and target it in line with our programme it can be put to 
good use. 
See above! We are overwhelmed with worried well women and we need no further 
encouragement of women to attend with breast symptoms. If we want to pick up more early 
breast cancers spend the campaign money in encouraging the uptake of breast screening 
See above. 
The current target of 25% increase in stage 1 is unrealistic - a trajectory outlining expected 
year on year increases towards this would be more achievable. 
The overall principle of raising awareness to encourage early presentation is important and 
widely supported but must avoid simply engendering fear. 
we would have to have serious input into the project otherwise the referral criteria set by fife 
will be evidenced based and we will ignore the Scottish or DCE guidelines - for endoscopic 
investigation.  our current level of investigation is at 0.3% RR (NICE is 3%) 
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While the funding from DCE would be welcome, the major resource needed - more 
radiologists to deal with additional workload - is difficult to come by, hence existing 
resources are heavily overloaded and taxed. DCE should happen in conjunction with 
additional resources put in place to deal with surge. 
Whilst supporting clinical early detection of breast cancer and the importance of women 
being aware of signs and symptoms the only way to detect early impalpable disease is 
through mammographic screening and DCE should have emphasised that. The increase in 
patients presenting to already busy One Stop Clinics as a result of DCE did not result in any 
increase in cancer detection. This was a very stressful time for patients and staff struggling 
to cope with referrals. We need to encourage Screening uptake which fails the Screening 
standard in West of Scotland. Money could have been better spent in education of poorer 
socioeconomic areas where screening uptake is low, and patients present late with 
symptoms. I support continuation of DCE in symptomatic and screening settings and not 
the original format. Benefits must justify the cost. 
 
Q13. If this strategy is not relevant to you or your work, you will be able to go to a 
different section. Please choose ONE option: 
 N % Valid % Cumulative % 
This strategy influenced my daily work AND/OR I 
helped to develop/implement it 43 81.1 81.1 81.1 
This strategy did NOT influence my daily work and 
I did NOT help to develop/implement it 10 18.9 18.9 100.0 
Total 53 100.0   
 
Q14. Were you informed about the DCE campaigns before they were launched? 
 N % Valid % Cumulative % 
Yes, I was sufficiently informed about the 
campaigns 16 30.2 38.1 38.1 
Yes, but I would have liked to have had more 
information 15 28.3 35.7 73.8 
No, I was not informed about them 11 20.8 26.2 100.0 
Total 42 79.2 100.0  
Missing (Other) 1 1.9   
Missing (Section not applicable) 10 18.9   
Total missing 11 20.8   
Total 53 100.0   
 
Q14.a. If you wish, you can use the box below to comment on your answer. 
It was forced upon us with no discussion and NO additional resources 
More time between agreement of final content and 'go live' dates would have been helpful 
in affording time to coordinate local reinforcement of key messages during campaigns. 
NA 
See prev 
The exact scale of the campaign was not clear nor the likely impact on referral numbers. 
Our unit was completely swamped (as were many others). 
This is essential - the launch of DCE should be filtered to all teams in advance and additional 
clinics planned for. 
 
Q15.1.a. Public awareness campaigns were an appropriate strategy to promote early 
detection 
Median 5.0 (IQR 3.0-6.0) 
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 N % Valid % Cumulative % 
Strongly disagree 3 5.7 7.3 7.3 
Disagree 5 9.4 12.2 19.5 
Somewhat disagree 4 7.5 9.8 29.3 
Neither agree nor disagree 6 11.3 14.6 43.9 
Somewhat agree 7 13.2 17.1 61.0 
Agree 7 13.2 17.1 78.0 
Strongly agree 9 17.0 22.0 100.0 
Total 41 77.4 100.0  
Missing (Don’t know) 2 3.8   
Missing (Section not applicable) 10 18.9   
Total missing 12 22.6   
Total 53 100.0   
 
Q16. Did this strategy increase demand for the services you provided to patients? 
 N % Valid % Cumulative % 
Yes 37 69.8 94.9 94.9 
No 2 3.8 5.1 100.0 
Total 39 73.6 100.0  
Total 42 79.2 100.0  
Missing (Don't know) 1 1.9   
Missing (Question not applicable) 3 5.7   
Missing (Section not applicable) 10 18.9   
Total missing 14 26.4   
Total 53 100.0   
 
Q17. You can use this space to write any comments about this section. 
Always challenging to meet public expectations and speed of access to diagnostics and 
tests. Difficult to determine the "Harm" associated with the worried well.   Small yield in 
relation to number of new cancers identified against the significant increase in numbers of 
people having to undergo tests is often difficult to argue 
As above. Early diagnosis is not a means in itself. The cost of doing this is substantial 
Breast screening got an increase in funding, but the symptomatic service did not! 
It does not matter if demand increases. We have done the same amount of work (since 
2010). There have been no extra resources put in for extra operating slots or clinic spaces.   
What should really be done is extra operating slots over the weekend, which should be in 
addition to the operating slots we already have during weekdays.   What is the point in 
detecting cancer early, when we do not even provide timely treatment to those whose 
cancers are detected (often late) via conventional routes, like going to the GP when 
symptoms develop? 
Little dedicated health improvement resource for cancer related activity. 
My average working day is now 14 hours! 
Referrals increased, but I haven't seen any evidence that early cancer detection increased.  
Perhaps more should have been done to encourage uptake of screening (re breast cancer). 
see prev 
see previous section 
The campaigns often resulted in patients presenting with longstanding problems e.g. nipple 
inversion for >10 years.  The symptoms that the campaign highlighted were not those of 
early cancer e.g. skin changes are often a sign of cancer presenting late. 
The first DCE Breast Cancer campaign coincided with October which is already Breast 
Cancer Awareness month. It was very intense and resulted in 30% - 50% increases in Clinic 
referrals across Scottish units (except Dumfries as the TV adverts were not shown on 
Border TV) but, while there were individual women who came forward as a direct result of 
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the information, there was no significant increase in the cancers detected nor change to 
earlier disease stage. Anecdotally, in our unit, it was more advanced cancers with the other 
symptoms highlighted by the campaign (skin dimpling or colour change or change in breast 
shape) who came forward.  I fed back the survey results and we proposed less intense 
campaigns but more prolonged throughout the year to increase the chance of a woman 
seeing an advert when she might have symptoms rather than stimulating general concern. 
while cancer detection rates did not significantly increase referrals for assessment 
increased dramatically and have stayed high 
 
Q18. If the education sessions are not relevant to you or your work, you will be able to 
go to a different section. Please choose ONE option: 
 N % Valid % Cumulative % 
This strategy influenced my daily work 
AND/OR I helped to develop/implement it 39 73.6 73.6 73.6 
This strategy did NOT influence my daily work 
and I did NOT help to develop/implement it 14 26.4 26.4 100.0 
Total 53 100.0 100.0  
 
Q19. Were you informed about the education sessions before they commenced? 
 N % Valid % Cumulative % 
Yes, I was sufficiently informed about 
the sessions 11 20.8 30.6 30.6 
Yes, but I would have liked to have had 
more information 8 15.1 22.2 52.8 
No, I was not informed about them 17 32.1 47.2 100.0 
Total 36 67.9 100.0  
Missing (Other) 3 5.7   
Missing (Section not applicable) 14 26.4   
Total missing 17 32.1   
Total 53 100.0   
 
Q19.a. If you wish, you can use the box below to comment on your answer. 
for colorectal cancer it has had an adverse effect on referral criteria we are now trying to 
rescue that by using qFIT 
I don't think there were any for GPs? If there were, change my answer above to "No" 
I think there should have been more sessions 
 
Q21.1.a. The education sessions were an appropriate strategy to promote early 
detection 
Median 5.0 (IQR 4.0-6.0) 
 N % Valid % Cumulative % 
Strongly disagree 3 5.7 13.0 13.0 
Disagree 1 1.9 4.3 17.4 
Somewhat disagree 1 1.9 4.3 21.7 
Neither agree nor disagree 3 5.7 13.0 34.8 
Somewhat agree 5 9.4 21.7 56.5 
Agree 5 9.4 21.7 78.3 
Strongly agree 5 9.4 21.7 100.0 
Total 23 43.4 100.0  
Missing (Don’t know) 10 18.9   
Missing (Question not applicable) 6 11.3   
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Missing (Section not applicable) 14 26.4   
Total 30 56.6   
Total 53 100.0   
 
Q20.2.a. It was difficult to integrate the education sessions with my usual work 
Median 2.0 (IQR 1.0-4.0) – reverse scoring 
 N % Valid % Cumulative % 
Strongly disagree 2 3.8 9.5 9.5 
Disagree 1 1.9 4.8 14.3 
Neither agree nor disagree 3 5.7 14.3 28.6 
Somewhat agree 3 5.7 14.3 42.9 
Agree 3 5.7 14.3 57.1 
Strongly agree 9 17.0 42.9 100.0 
Total 21 39.6 100.0  
Missing (Don’t know) 5 9.4   
Missing (Question not applicable) 13 24.5   
Missing (Section not applicable) 14 26.4   
Total 32 60.4   
Total 53 100.0   
 
Q20.3.a. I had enough time to attend the education sessions 
Median 2.0 (IQR 1.0-4.0) 
 N % Valid % Cumulative % 
Strongly disagree 8 15.1 33.3 33.3 
Disagree 6 11.3 25.0 58.3 
Somewhat disagree 2 3.8 8.3 66.7 
Neither agree nor disagree 6 11.3 25.0 91.7 
Somewhat agree 2 3.8 8.3 100.0 
Total 24 45.3 100.0  
Missing (Don’t know) 3 5.7   
Missing (Question not applicable) 12 22.6   
Missing (Section not applicable) 14 26.4   
Total 29 54.7   
Total 53 100.0   
 
Q21. You can use this space to write comments about any of the questions above. 
If, and I bet this is the case, they offered teaching sessions to GPs without backfill then they 
are plonking buffoons who don't understand how independent contractors work. 
Not aware of sessions or content 
not very apparent that any education has gone on 40% referral are inappropriate and 10% 
of routine referral have to be escalated because GP's have misinterpreted or failed to refer 
as USC 
Unaware of any education sessions 
 
Q22. If the referral guidelines are not relevant to your work, you will be able to go to a 
different section. Please choose ONE option: 
 N % Valid % Cumulative % 
This strategy influenced my daily work 
AND/OR I helped to develop/implement it 46 86.8 86.8 86.8 
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This strategy did NOT influence my daily work 
and I did NOT help to develop/implement it 7 13.2 13.2 100.0 
Total 53 100.0 100.0  
 
Q23. Were you informed about the work being carried out to update the guidelines 
before they were published? 
 N % Valid % 
Cumulative 
% 
Yes, I was sufficiently informed about the work 14 26.4 31.8 31.8 
Yes, but I would have liked to have had more 
information 9 17.0 20.5 52.3 
No, I was not informed about it 21 39.6 47.7 100.0 
Total 44 83.0 100.0  
Missing (Other) 2 3.8   
Missing (Section not applicable) 7 13.2   
Total missing 9 17.0   
Total 53 100.0   
 
Q23.a. If you wish, you can use the box below to comment on your answer. 
Breast and lung seemed stupid and lacking in evidence at the time. I have no idea if I was 
wrong about that. 
I was involved in the updated guideline development 
Impact assessment and workforce to meet demand never considered 
NA 
see last answer 40% inappropriate and 10% routines need escalating to USC. they might 
as well toss a coin. 
 
Q24.1.a. The updated guidelines were an appropriate strategy to promote early 
detection 
Median 5.0 (IQR 4.0-6.0) 
 N % Valid % Cumulative % 
Strongly disagree 4 7.5 10.0 10.0 
Disagree 2 3.8 5.0 15.0 
Somewhat disagree 2 3.8 5.0 20.0 
Neither agree nor disagree 7 13.2 17.5 37.5 
Somewhat agree 10 18.9 25.0 62.5 
Agree 8 15.1 20.0 82.5 
Strongly agree 7 13.2 17.5 100.0 
Total 40 75.5 100.0  
Missing (Don’t know) 5 9.4   
Missing (Question not applicable) 1 1.9   
Missing (Section not applicable) 7 13.2   
Total missing 13 24.5   
Total 53 100.0   
 
Q25. Did the updated referral guidelines increase demand for the services you provided 
to patients? 
 N % Valid % Cumulative % 
Yes 29 54.7 80.6 80.6 
No 7 13.2 19.4 100.0 
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Total 36 67.9 100.0  
Missing (Don’t know) 8 15.1   
Missing (Question not applicable) 2 3.8   
Total missing 7 13.2   
Total 17 32.1   
 
Q26. You can use this space to write any comments about this section. 
Again, they appeared risk averse and to increase work without adequate resources, leading 
to delay in other services. I am not aware of any evidence it helped (except in bowel), but 
happy to be proved wrong 
Don't think I'm aware how these changed things, or indeed that they had been rewritten, 
unless this refers to the vast review of all studies on presenting symptoms of cancer, but 
even this made no detectable difference to practice. 
Due to waiting times from primary to secondary care many GPs mark referrals as urgent 
suspicion even where this is not appropriate e.g. young breast pain. This becomes non-
discriminatory and triage of referrals is required which is time consuming for medical staff. 
Have managed to break service. Well done. 
inappropriately so 
More patients referred from primary care for assessment 
Not sure whether it was guidelines themselves 
Revised guidelines should have reduced demand for services but no obvious change. 
see previous section 
We can only do a certain amount of work. Increasing referrals does not mean our workload 
increases. The patients just have to wait in a queue. Because we do not have the flexibility 
to work more, we certainly are not allowed to work more. (lack of resources). 
 
Q27. If this strategy is not relevant to you or your work, you will be able to go to a 
different section. Please choose ONE option: 
 N % Valid % Cumulative % 
This strategy influenced my daily work AND/OR I 
helped to develop/implement it 41 77.4 77.4 77.4 
This strategy did NOT influence my daily work and 
I did NOT help to develop/implement it 12 22.6 22.6 100.0 
Total 53 100.0 100.0  
 
Q28. Were you informed about the additional funding before it became available? 
 N % Valid % Cumulative % 
Yes, I was sufficiently informed about the 
funding 4 7.5 10.0 10.0 
Yes, but I would have liked to have had more 
information 15 28.3 37.5 47.5 
No, I was not informed about it 21 39.6 52.5 100.0 
Total 40 75.5 100.0  
Missing (Other) 1 1.9   
Missing (Section not applicable) 12 22.6   
Total missing 13 24.5   
Total 53 100.0   
 
Q28.a. If you wish, you can use the box below to comment on your answer. 
funding still a mystery - no one knows and run the service!!  bowel cancer screening gone 
up by 120% with no extra funding. 
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I am totally unaware of ANY addition funding available to staff on the 'shop floor'. I saw NO 
evidence WHATSOEVER of this 
it was not recurring funding, therefore fairly pointless as a long-term strategy 
More time to prepare bids. 
NA 
No funds were made available to help manage demand in my area of practice (Pathology). 
There was insufficient time to have employed additional staff so our clinic like many others 
was overwhelmed and patients were waiting up to 12 weeks to be seen. We had to run 
evening and weekend clinics for a considerable time to get things back under control. As 
we did not detect significantly more breast cancers, patients with cancer actually waited 
longer. All of these issues applied most strongly to the first DCE Breast Cancer Campaign. 
Was there additional funding? It certainly did not reach as far as the clinicians. 
Was used to fund some respiratory consultant posts, but not clear whether they were asked 
to document any increase in workload 
Well, we didn't get any of it in primary care. 
 
Q29.1.a. Providing extra funding was an appropriate strategy to promote early detection 
Median 5.0 (IQR 4.0-7.0) 
 N % Valid % Cumulative % 
Strongly disagree 3 5.7 7.9 7.9 
Disagree 1 1.9 2.6 10.5 
Somewhat disagree 4 7.5 10.5 21.1 
Neither agree nor disagree 8 15.1 21.1 42.1 
Somewhat agree 7 13.2 18.4 60.5 
Agree 4 7.5 10.5 71.1 
Strongly agree 11 20.8 28.9 100.0 
Total 38 71.7 100.0  
Missing (Don’t know) 2 3.8   
Missing (Question not applicable) 1 1.9   
Missing (Section not applicable) 12 22.6   
Total 15 28.3   
Total 53 100.0   
 
Q29.2.a. I was confident that my team would be able to manage demand for screening 
and diagnostics when I was informed about the funding 
Median 2.0 (IQR 1.0-4.0) 
 N % Valid % Cumulative % 
Strongly disagree 11 20.8 33.3 33.3 
Disagree 7 13.2 21.2 54.5 
Somewhat disagree 4 7.5 12.1 66.7 
Neither agree nor disagree 4 7.5 12.1 78.8 
Somewhat agree 1 1.9 3.0 81.8 
Agree 5 9.4 15.2 97.0 
Strongly agree 1 1.9 3.0 100.0 
Total 33 62.3 100.0  
Missing (Don’t know) 4 7.5   
Missing (Question not applicable) 4 7.5   
Missing (Section not applicable) 12 22.6   
Total 20 37.7   
Total 53 100.0   
 
Q29.3.a. We had enough time to plan how to use the funding 
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Median 2.0 (IQR 1.0-3.5) 
 N % Valid % Cumulative % 
Strongly disagree 11 20.8 37.9 37.9 
Disagree 8 15.1 27.6 65.5 
Somewhat disagree 3 5.7 10.3 75.9 
Neither agree nor disagree 3 5.7 10.3 86.2 
Somewhat agree 2 3.8 6.9 93.1 
Agree 2 3.8 6.9 100.0 
Total 29 54.7 100.0  
Missing (Don’t know) 6 11.3   
Missing (Question not applicable) 6 11.3   
Missing (Section not applicable) 12 22.6   
Total 24 45.3   
Total 53 100.0   
 
Q29.4.a. Primary and secondary care communicated well with each other when 
planning how to use the funding 
Median 1.0 (IQR 1.0-3.0) 
 N % Valid % Cumulative % 
Strongly disagree 15 28.3 55.6 55.6 
Disagree 4 7.5 14.8 70.4 
Somewhat disagree 4 7.5 14.8 85.2 
Neither agree nor disagree 2 3.8 7.4 92.6 
Somewhat agree 2 3.8 7.4 100.0 
Total 27 50.9 100.00  
Missing (Don’t know) 10 18.9   
Missing (Question not applicable) 4 7.5   
Missing (Section not applicable) 12 22.6   
Total 26 49.1   
Total 53 100.0   
 
Q29.5.a. Additional funding resulted in more equipment for diagnosis 
Median 1.0 (IQR 1.0-3.0) 
 N % Valid % Cumulative % 
Strongly disagree 17 32.1 56.7 56.7 
Disagree 5 9.4 16.7 73.3 
Somewhat disagree 3 5.7 10.0 83.3 
Neither agree nor disagree 1 1.9 3.3 86.7 
Somewhat agree 1 1.9 3.3 90.0 
Agree 3 5.7 10.0 100.0 
Total 30 56.6 100.0  
Missing (Don’t know) 9 17.0   
Missing (Question not applicable) 2 3.8   
Missing (Section not applicable) 12 22.6   
Total 23 43.4   
Total 53 100.0   
 
Q29.6.a. Additional funding resulted in more workforce for diagnosis 
Median 1.00 (IQR 1.00-4.25) 
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 N % Valid % Cumulative % 
Strongly disagree 17 32.1 56.7 56.7 
Disagree 2 3.8 6.7 63.3 
Somewhat disagree 3 5.7 10.0 73.3 
Neither agree nor disagree 1 1.9 3.3 76.7 
Somewhat agree 2 3.8 6.7 83.3 
Agree 3 5.7 10.0 93.3 
Strongly agree 2 3.8 6.7 100.0 
Total 30 56.6 100.0  
Missing (Don’t know) 9 17.0   
Missing (Question not applicable) 2 3.8   
Missing (Section not applicable) 12 22.6   
Total 23 43.4   
Total 53 100.0   
 
Q30. You can use this space to write any comments about this section. 
Additional consultant post (breast surgery) 
Again, we got squat all, and secondary waiting times went up. So, I'm not impressed that 
resources matched demand. 
How can you get more workforce when there a hundreds of consultant (and other staff 
vacancies)? Completely different planet the DCE group live in 
In the initial round the extra funding was used to provide overtime to catch up with the 
backlog. Future tranches were perhaps better spent. 
No funding came to Pathology. 
Not aware of any funding. That could be due to my lack of being aware. or that it was never 
communicated 
temporary funding caused a lot of problems down the line when there was no more money 
There was as far as I know no increase in funding locally. We were expected to absorb a 
significant increase in demand into already stretched capacity. 
This is news to me that additional funding was available. 
unaware of any funding coming to endoscopy or bowel cancer screening in NHS fife 
while funding was directed at diagnosis there seemed to be no additional planning to 
potential increased in treatment requirements following diagnosis or increased demand for 
support to patients 
Workforce issues in diagnostics are the single largest stumbling block; this cannot happen 
overnight or even in a few months. But existing teams can plan appropriately and use funds 
wisely (e.g. equipment, locums) if advised well in advance of project start. 
 
Q31. If the HEAT targets are not relevant to you or your work, you will be able to go to 
a different section. Please choose ONE option: 
 N % Valid % Cumulative % 
This strategy influenced my daily work AND/OR I 
helped to develop/implement it 35 66.0 66.0 66.0 
This strategy did NOT influence my daily work 
and I did NOT help to develop/implement it 18 34.0 34.0 100.0 
Total 53 100.0 100.0  
 
Q32. Were you informed about the HEAT targets before they were launched? 
 N % Valid % Cumulative % 
Yes, I was sufficiently informed about these 
HEAT targets 9 17.0 27.3 27.3 
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Yes, but I would have liked to have had more 
information 10 18.9 30.3 57.6 
No, I was not informed about them 14 26.4 42.4 100.0 
Total 33 62.3 100.0  
Missing (Other) 2 3.8   
Missing (Section not applicable) 18 34.0   
Total missing 20 37.7   
Total 53 100.0   
 
Q32.a. If you wish, you can use the box below to comment on your answer. 
it’s all smoke and mirrors with no reality of the difference between strategy and operational 
delivery 
The targets & how they were to be evaluated were late in being disseminated. 
what are heat targets 
Would have liked an opportunity to influence the targets. 
 
Q33.1.a. HEAT targets were an appropriate strategy to promote early detection 
Median 4.0 (IQR 2.0-6.0) 
 N % Valid % Cumulative % 
Strongly disagree 5 9.4 18.5 18.5 
Disagree 2 3.8 7.4 25.9 
Somewhat disagree 4 7.5 14.8 40.7 
Neither agree nor disagree 5 9.4 18.5 59.3 
Somewhat agree 2 3.8 7.4 66.7 
Agree 9 17.0 33.3 100.0 
Total 27 50.9 100.0  
Missing (Don’t know) 7 13.2   
Missing (Question not applicable) 1 1.9   
Missing (Section not applicable) 18 34.0   
Total missing 26 49.1   
Total 53 100.0   
 
Q33.2.a. I was confident in my ability to meet HEAT targets 
Median 2.5 (IQR 2.0-5.0) 
 N % Valid % Cumulative % 
Strongly disagree 5 9.4 19.2 19.2 
Disagree 8 15.1 30.8 50.0 
Somewhat disagree 1 1.9 3.8 53.8 
Neither agree nor disagree 5 9.4 19.2 73.1 
Somewhat agree 5 9.4 19.2 92.3 
Agree 2 3.8 7.7 100.0 
Total 26 49.1 100.0  
Missing (Don’t know) 7 13.2   
Missing (Question not applicable) 2 3.8   
Missing (Section not applicable) 18 34.0   
Total missing 27 50.9   
Total 53 100.0   
 
Q33.3.a. It was difficult to integrate meeting HEAT targets with my usual work 
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Median 3.0 (IQR 2.0-5.0) – reverse scoring 
 N % Valid % Cumulative % 
Strongly disagree 1 1.9 4.2 4.2 
Disagree 3 5.7 12.5 16.7 
Somewhat disagree 3 5.7 12.5 29.2 
Neither agree nor disagree 3 5.7 12.5 41.7 
Somewhat agree 3 5.7 12.5 54.2 
Agree 6 11.3 25.0 79.2 
Strongly agree 5 9.4 20.8 100.0 
Total 24 45.3 100.0  
Missing (Don’t know) 8 15.1   
Missing (Question not applicable) 3 5.7   
Missing (Section not applicable) 18 34.0   
Total missing 29 54.7   
Total 53 100.0   
 
Q33.4.a. HEAT targets pressured our team to act 
Median 4.0 (IQR 2.0-5.5) 
 N % Valid % Cumulative % 
Strongly disagree 4 7.5 16.0 16.0 
Disagree 4 7.5 16.0 32.0 
Somewhat disagree 1 1.9 4.0 36.0 
Neither agree nor disagree 5 9.4 20.0 56.0 
Somewhat agree 5 9.4 20.0 76.0 
Agree 2 3.8 8.0 84.0 
Strongly agree 4 7.5 16.0 100.0 
Total 25 47.2 100.0  
Missing (Don’t know) 8 15.1   
Missing (Question not applicable) 2 3.8   
Missing (Section not applicable) 18 34.0   
Total missing 28 52.8   
Total 53 100.0   
 
Q33.5.a. HEAT targets worked as a reminder for where our efforts should be focused 
Median 2.0 (IQR 2.0-5.0) 
 N % Valid % Cumulative % 
Strongly disagree 6 11.3 22.2 22.2 
Disagree 8 15.1 29.6 51.9 
Somewhat disagree 3 5.7 11.1 63.0 
Neither agree nor disagree 2 3.8 7.4 70.4 
Somewhat agree 5 9.4 18.5 88.9 
Agree 2 3.8 7.4 96.3 
Strongly agree 1 1.9 3.7 100.0 
Total 27 50.9 100.0  
Missing (Don’t know) 6 11.3   
Missing (Question not applicable) 2 3.8   
Missing (Section not applicable) 18 34.0   
Total missing 26 49.1   
Total 53 100.0   
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Q34. You can use this space to write comments about any of the questions above. 
I presume you mean QOF points, not HEAT in primary care? I am guessing that whoever 
wrote this survey is secondary care based.... 
Reminder! We have other targets that DCE have never considered and are as important. 
these are strategic public health measures not clinical 
Very unhelpful HEAT target.  Suggest a QI approach 
We know where our efforts should be focussed, without external targets. 
 
Q35. If the Bowel Screening Initiative is not relevant to you or your work, you will be 
able to go to a different section. Please choose ONE option: 
 N % Valid % Cumulative % 
This strategy influenced my daily work AND/OR I 
helped to develop/implement it 22 41.5 41.5 41.5 
This strategy did NOT influence my daily work and 
I did NOT help to develop/implement it 31 58.5 58.5 100.0 
Total 53 100.0 100.0  
 
Q36. Were you informed about the bowel screening initiative before it was launched? 
 N % Valid % Cumulative % 
Yes, I was sufficiently informed about 
the bowel screening initiative 16 30.2 72.7 72.7 
Yes, but I would have liked to have had 
more information 4 7.5 18.2 90.9 
No, I was not informed about it 2 3.8 9.1 100.0 
Total 22 41.5 100.0  
Missing (Section not applicable) 31 58.5   
Total 53 100.0   
 
Q36.a. If you wish, you can use the box below to comment on your answer. 
This seemed sensible! 
 
Q37.1.a. The bowel screening initiative was an appropriate strategy to promote early 
detection 
Median 7.0 (IQR 5.5-7.0) 
 N % Valid % Cumulative % 
Disagree 1 1.9 4.8 4.8 
Neither agree nor disagree 2 3.8 9.5 14.3 
Somewhat agree 2 3.8 9.5 23.8 
Agree 5 9.4 23.8 47.6 
Strongly agree 11 20.8 52.4 100.0 
Total 21 39.6 100.0  
Missing (Question not applicable) 1 1.9   
Missing (Section not applicable) 31 58.5   
Total missing 32 60.4   
Total 53 100.0   
 
Q37.2.a. I was confident in my ability to be awarded the QOF points 
Median 6.0 (IQR 2.0-7.0) 
 N % Valid % Cumulative % 
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Strongly disagree 1 1.9 9.1 9.1 
Disagree 2 3.8 18.2 27.3 
Neither agree nor disagree 1 1.9 9.1 36.4 
Somewhat agree 1 1.9 9.1 45.5 
Agree 2 3.8 18.2 63.6 
Strongly agree 4 7.5 36.4 100.0 
Total 11 20.8 100.0  
Missing (Don’t know) 4 7.5   
Missing (Question not applicable) 7 13.2   
Missing (Section not applicable) 31 58.5   
Total missing 42 79.2   
Total 53 100.0   
 
Q37.3.a. It was difficult to integrate the bowel screening initiative with my usual work 
Median 4.5 (IQR 1.75-7.0) – reverse scoring 
 N % Valid % Cumulative % 
Strongly disagree 6 11.3 33.3 33.3 
Disagree 2 3.8 11.1 44.4 
Somewhat disagree 1 1.9 5.6 50.0 
Neither agree nor disagree 1 1.9 5.6 55.6 
Agree 4 7.5 22.2 77.8 
Strongly agree 4 7.5 22.2 100.0 
Total 18 34.0 100.0  
Missing (Question not applicable) 4 7.5   
Missing (Section not applicable) 31 58.5   
Total missing 35 66.0   
Total 53 100.0   
 
Q37.4.a. My team had enough time to reach non-responders to bowel screening 
Median 2.5 (IQR 2.0-4.5) 
 N % Valid % Cumulative % 
Strongly disagree 1 1.9 10.0 10.0 
Disagree 4 7.5 40.0 50.0 
Somewhat disagree 2 3.8 20.0 70.0 
Neither agree nor disagree 1 1.9 10.0 80.0 
Agree 1 1.9 10.0 90.0 
Strongly agree 1 1.9 10.0 100.0 
Total 10 18.9 100.0  
Missing (Don’t know) 4 7.5   
Missing (Question not applicable) 8 15.1   
Missing (Section not applicable) 31 58.5   
Total missing 43 81.1   
Total 53 100.0   
 
Q37.5.a. The bowel screening initiative pressured our team to act 
Median 4.0 (IQR 1.0-6.0) 
 N % Valid % Cumulative % 
Strongly disagree 6 11.3 33.3 33.3 
Disagree 2 3.8 11.1 44.4 
Neither agree nor disagree 4 7.5 22.2 66.7 
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Agree 4 7.5 22.2 88.9 
Strongly agree 2 3.8 11.1 100.0 
Total 18 34.0 100.0  
Missing (Don’t know) 1 1.9   
Missing (Question not applicable) 3 5.7   
Missing (Section not applicable) 31 58.5   
Total missing 35 66.0   
Total 53 100.0   
 
Q37.6.a. The bowel screening initiative worked as a reminder for where our efforts 
should be focused 
Median 4.0 (IQR 2.0-6.0) 
 N % Valid % Cumulative % 
Strongly disagree 2 3.8 10.5 10.5 
Disagree 5 9.4 26.3 36.8 
Neither agree nor disagree 4 7.5 21.1 57.9 
Somewhat agree 2 3.8 10.5 68.4 
Agree 5 9.4 26.3 94.7 
Strongly agree 1 1.9 5.3 100.0 
Total 19 35.8 100.0  
Missing (Don’t know) 1 1.9   
Missing (Question not applicable) 2 3.8   
Missing (Section not applicable) 31 58.5   
Total missing 34 64.2   
Total 53 100.0   
 
Q38. Did the bowel screening initiative increase demand for the services you provided 
to patients? 
 N % Valid % Cumulative % 
Yes 13 24.5 81.3 81.3 
No 3 5.7 18.8 100.0 
Total 16 30.2 100.0  
Missing (Don’t know) 3 5.7   
Missing (Question not applicable) 3 5.7   
Missing (Section not applicable) 31 58.5   
Total missing 37 69.8   
Total 53 100.0   
 
Q39. You can use this space to write any comments about this section. 
bowel cancer screening now causing serious disruption to clinical routine and surveillance 
work. miscalculation ad communication where responsible. Clinical teams advised of a 10-
15% increase (compliance) they failed to inform us that the positivity rate would increase 
from 2% to 3.4 % (public health aware but did not understand the impact and did not pass 
information on) 
Huge increase in demand for scopes, with subsequent increase in operative activity with no 
increase in funding or other support. 
people would come to discuss the positive result, and sometimes would want referred 
privately for the colonoscopy so that it was done even sooner 
Screening in CRC is effective. Demand is highly sensitive to sensitivity of the test and 
concordance. Demand has increased substantially since qFIT was introduced for both these 
reasons 
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The idea made sense. The approach in primary care was an incoherent mess. No idea if it 
helped, we mostly ignored it. 
well done qFIT 
 
Q40. Would you describe yourself as: 
 N % Valid % Cumulative % 
Male 20 37.7 40.8 40.8 
Female 29 54.7 59.2 100.0 
Total 49 92.5 100.0  
Missing (I prefer not to say) 4 7.5   
Total 53 100.0   
 
Q40.a. Please use this box if you wish to specify any answers: 
How is this relevant? 
 
Q41. In what year were you born? 
 N % Valid % Cumulative % 
1957 1 1.9 2.9 2.9 
1958 1 1.9 2.9 5.9 
1960 1 1.9 2.9 8.8 
1961 2 3.8 5.9 14.7 
1962 4 7.5 11.8 26.5 
1963 1 1.9 2.9 29.4 
1964 2 3.8 5.9 35.3 
1965 2 3.8 5.9 41.2 
1967 4 7.5 11.8 52.9 
1968 3 5.7 8.8 61.8 
1969 3 5.7 8.8 70.6 
1970 3 5.7 8.8 79.4 
1972 2 3.8 5.9 85.3 
1974 1 1.9 2.9 88.2 
1975 1 1.9 2.9 91.2 
1978 2 3.8 5.9 97.1 
1980 1 1.9 2.9 100.0 
Total 34 64.2 100.0  
Missing 19 35.8   
Total 53 53 100.0  
 
Year of birth recoded to have complete date, 01/06 chosen for day and month 
 N % Valid % 
Cumulative 
% 
38 1 1.9 2.9 2.9 
40 2 3.8 5.9 8.8 
43 1 1.9 2.9 11.8 
44 1 1.9 2.9 14.7 
46 2 3.8 5.9 20.6 
48 3 5.7 8.8 29.4 
49 3 5.7 8.8 38.2 
50 3 5.7 8.8 47.1 
51 4 7.5 11.8 58.8 
53 2 3.8 5.9 64.7 
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54 2 3.8 5.9 70.6 
55 1 1.9 2.9 73.5 
56 4 7.5 11.8 85.3 
57 2 3.8 5.9 91.2 
58 1 1.9 2.9 94.1 
60 1 1.9 2.9 97.1 
61 1 1.9 2.9 100.0 
Total 34 64.2 100.0  
Missing 19 35.8   
Total 53 100.0   
 
Age variable recoded into age bands used by ISD Scotland to describe NHS workforce 
 N % Valid % Cumulative % 
35-39 1 1.9 2.9 2.9 
40-44 4 7.5 11.8 14.7 
45-49 8 15.1 23.5 38.2 
50-54 11 20.8 32.4 70.6 
55-59 8 15.1 23.5 94.1 
60-64 2 3.8 5.9 100.0 
Total 34 64.2 100.0  
Missing 19 35.8   
Total 53 100.0   
 
Q42. What was your profession from 2011 until 2015? You can tick more than one 
answer or choose “Other” if appropriate. 
 N % Valid % Cumulative % 
Allied Health Professionals, Healthcare 
Scientists and Scientific & Technical staff 1 1.9 2.0 2.0 
Medical Staff 39 73.6 76.5 78.4 
Registered nurse 6 11.3 11.8 90.2 
Public Health or Health Improvement 1 1.9 2.0 92.2 
General managers 1 1.9 2.0 94.1 
Charity worker 1 1.9 2.0 96.1 
Other 2 3.8 3.9 100.0 
Total 51 96.2 100.0  
Missing (I prefer not to say) 2 3.8   
Total 53 100.0   
 
Q42.a. Please use this box if you wish to specify any answers 
 N % Valid % Cumulative % 
Audit staff/coordination 2 3.8 6.7 6.7 
Consultant 1 1.9 3.3 10.0 
Consultant Nurse and Co-Chair of our Board 
Strategy Group 1 1.9 3.3 13.3 
Endoscopy Lead 1 1.9 3.3 16.7 
GP 5 9.4 16.7 33.3 
GP+ specialty doctor+ hospice on call 1 1.9 3.3 36.7 
Histopathologist 1 1.9 3.3 40.0 
Lung Cancer CNS 1 1.9 3.3 43.3 
nurse endoscopist 1 1.9 3.3 46.7 
Pathologist 2 3.8 6.7 53.3 
Radiologist 3 5.7 10.0 63.3 
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Surgeon 11 20.8 36.7 100.0 
Total 30 56.6 100.0  
Missing data 23 43.4   
Total 53 100.0   
 
Question on profession shortened to have fewer categories, based on answers to Q42 and Q42.a 
 N % Valid % Cumulative % 
Medical 39 73.6 76.5 76.5 
Nursing 6 11.3 11.8 88.2 
Audit 2 3.8 3.9 92.2 
Other 4 7.5 7.8 100.0 
Total 51 96.2 100.0  
Missing data 2 3.8   
Total 53 100.0   
 
Q43. Does your work focus on a specific cancer type (e.g. breast, lung, bowel cancer)? 
 N % Valid % Cumulative % 
Yes (please specify) 39 73.6 75.0 75.0 
No, my work includes more than one 
cancer type 13 24.5 25.0 100.0 
Total 52 98.1 100.0  
Missing (Question not applicable) 1 1.9   
Total 53 100.0   
 
Q43.a. Please use this box if you wish to specify any answers 
 N % Valid % 
Cumulative 
% 
Bowel and upper GI 1 1.9 3.3 3.3 
Bowel, colorectal or anal 7 13.2 23.3 26.7 
Breast 18 34.0 60.0 86.7 
Lung 4 7.5 13.3 100.0 
Total 30 56.6 100.0  
Missing (Question not applicable) 14 26.4   
Missing data 9 17.0   
Total missing 23 43.4   
Total 53 100.0   
 
Q43 recoded to indicate more than one tumour type/specific tumour type in the same variable 
 N % Valid % Cumulative % 
More than one tumour type 13 24.5 25.0 25.0 
Focus on breast 18 34.0 34.6 59.6 
focus on bowel, anal or upper GI 8 15.1 15.4 75.0 
focus on lung 4 7.5 7.7 82.7 
focus on one cancer type, missing info on 
which one 9 17.0 17.3 100.0 
Total 52 98.1 100.0  
Missing (Question not applicable) 1 1.9   
Total 53 100.0   
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Q44. Still thinking of the 2011-2015 period, please write down the years DCE was 
relevant to your work. For example, from 2012 to 2014 
 N % Valid % Cumulative % 
12-15 1 1.9 2.9 2.9 
2011 to present 1 1.9 2.9 5.9 
2011-2015 11 20.8 32.4 38.2 
2011-present 1 1.9 2.9 41.2 
2012 - 2016 1 1.9 2.9 44.1 
2012 on 1 1.9 2.9 47.1 
2012 to present day 1 1.9 2.9 50.0 
2012 until the present 1 1.9 2.9 52.9 
2012-2014 3 5.7 8.8 61.8 
2012-2015 1 1.9 2.9 64.7 
2012-2015 and in fact still influencing our 
referral numbers 1 1.9 2.9 67.6 
2013-2015 1 1.9 2.9 70.6 
2014 2 3.8 5.9 76.5 
2014-2015 1 1.9 2.9 79.4 
2015 1 1.9 2.9 82.4 
All 2 3.8 5.9 88.2 
All 1 1.9 2.9 91.2 
All years. 1 1.9 2.9 94.1 
can' remember 1 1.9 2.9 97.1 
No idea of end-date 1 1.9 2.9 100.0 
Total 34 64.2 100.0  
Missing data 19 35.8   
Total 53 100.0   
 
Q44 recoded into categorical variables 
 N % Valid % Cumulative % 
from pre-implementation to at 
least the first three years 14 26.4 42.4 42.4 
from programme launch to at 
least the first three years 11 20.8 33.3 75.8 
at least 2 years in the programme 4 7.5 12.1 87.9 
at least one year in the 
programme 4 7.5 12.1 100.0 
Total 33 62.3 100.0  
Missing data 20 37.7   
Total 53 100.0   
 
Q44 recoded - at least three years involvement versus 1 or 2 years of involvement – not used 
for analysis 
 N % Valid % Cumulative % 
at least three years of involvement 25 47.2 75.8 75.8 
one to two years of involvement 8 15.1 24.2 100.0 
Total 33 62.3 100.0  
Missing data 20 37.7   
Total 53 100.0   
 
Q45. In which territorial Health Board do you work? You can tick more than one answer 
or choose “Other” if appropriate. 
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 N % Valid % Cumulative % 
Ayrshire and Arran 9 17.0 17.6 17.6 
Dumfries and Galloway 2 3.8 3.9 21.6 
Fife 4 7.5 7.8 29.4 
Forth Valley 2 3.8 3.9 33.3 
Greater Glasgow and Clyde 11 20.8 21.6 54.9 
Lanarkshire 3 5.7 5.9 60.8 
Lothian 17 32.1 33.3 94.1 
Tayside 2 3.8 3.9 98.0 
Whole of Scotland 1 1.9 2.0 100.0 
Total 51 96.2 100.0  
Missing data (I prefer not to say) 2 3.8   
Total 53 100.0   
 
Q46. Which best describes the area where you work? 
 N % Valid % Cumulative % 
Large urban areas (Settlements of over 
125,000 people) 29 54.7 54.7 54.7 
Other urban areas (Settlements of 10,000 to 
125,000 people) 13 24.5 24.5 79.2 
Accessible small towns (Settlements of 
between 3,000 and 10,000 people, and within 
a 30-minute drive time of a Settlement of 
10,000 or more) 
4 7.5 7.5 86.8 
Remote rural areas (Areas with a population of 
less than 3,000 people, and with a drive time 
of over 30 minutes to a Settlement of 10,000 or 
more) 
2 3.8 3.8 90.6 
Other (please specify) 5 9.4 9.4 100.0 
Total 53 100.0   
 
Q46.a. Please use this box if you wish to specify any answers 
 N % Valid % 
Cumulative 
% 
Across the whole of Scotland 1 1.9 14.3 14.3 
additionally:  1. accessible small towns  2. 
accessible rural areas   3. remote rural areas 1 1.9 14.3 28.6 
All of the above 1 1.9 14.3 42.9 
Mix of rural and urban 1 1.9 14.3 57.1 
Mixed urban and rural. Large town (with mixed 
severe deprivation to middle class) plus 
surrounding villages and farms 
1 1.9 14.3 71.4 
Screening covers both urban and rural 
population 1 1.9 14.3 85.7 
work at breast screening and also in that time 
period I worked in Clyde symptomatic breast 
service 
1 1.9 14.3 100.0 
Total 7 13.2   
Missing (Question not applicable) 46 86.8   
Total 53 100.0   
 
Q46 recoded to include both information for Q46 and Q46.a 
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 N % Valid % 
Cumulative 
% 
Large urban areas (Settlements of over 
125,000 people) 28 52.8 52.8 52.8 
Other urban areas (Settlements of 10,000 to 
125,000 people) 11 20.8 20.8 73.6 
Accessible small towns (Settlements of 
between 3,000 and 10,000 people, and 
within a 30-minute drive time of a Settlement 
of 10,000 or more) 
4 7.5 7.5 81.1 
Remote rural areas (Areas with a population 
of less than 3,000 people, and with a drive 
time of over 30 minutes to a Settlement of 
10,000 or more) 
2 3.8 3.8 84.9 
Other (please specify) 1 1.9 1.9 86.8 
Mix of rural and urban 7 13.2 13.2 100.0 
Total 53 100.0   
 
Q47. Which best describes your workplace? You can tick more than one answer or 
choose “Other” if appropriate. 
 N % Valid % 
Cumulative 
% 
Primary Care practice 8 15.1 15.4 15.4 
Hospital 38 71.7 73.1 88.5 
Diagnostic centre, but not in a hospital 4 7.5 7.7 96.2 
Cancer charity 1 1.9 1.9 98.1 
Other 1 1.9 1.9 100.0 
Total 52 98.1 100.0  
Missing (I prefer not to say) 1 1.9   
Total 53 100.0   
 
Q47.a. Please use this box if you wish to specify any answers 
 N % Valid % 
Cumulative 
% 
Acute Services 1 1.9 4.8 4.8 
Board wide 1 1.9 4.8 9.5 
Breast surgery 1 1.9 4.8 14.3 
Breast Surgery 1 1.9 4.8 19.0 
Breast unit 1 1.9 4.8 23.8 
Cancer Research UK 1 1.9 4.8 28.6 
Cardiothoracic Surgery 1 1.9 4.8 33.3 
colorectal surgery and endoscopy 1 1.9 4.8 38.1 
General? Colorectal surgery 1 1.9 4.8 42.9 
Head and Neck Service 1 1.9 4.8 47.6 
oncology 1 1.9 4.8 52.4 
Pathology. 1 1.9 4.8 57.1 
QEUH 1 1.9 4.8 61.9 
Quality Department 1 1.9 4.8 66.7 
Queen Margaret Hospital, Dunfermline 1 1.9 4.8 71.4 
radiology 1 1.9 4.8 76.2 
Radiology 1 1.9 4.8 81.0 
Radiology and Screening 1 1.9 4.8 85.7 
Respiratory 1 1.9 4.8 90.5 
Respiratory dept 1 1.9 4.8 95.2 
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Surgery 1 1.9 4.8 100.0 
Total 21 39.6 100.0  
Missing data 32 60.4   
Total 53 100.0   
 
Variable on profession and workplace created with data from Q42, Q42.a, Q47 and Q47.a. 
 N % Valid % 
Cumulative 
% 
Medical - Surgeon 11 20.8 21.6 21.6 
Medical - GP 7 13.2 13.7 35.3 
Medical - Radiologist 3 5.7 5.9 41.2 
Medical - Pathologist 3 5.7 5.9 47.1 
Medical - Other/not specified 15 28.3 29.4 76.5 
Nurse 6 11.3 11.8 88.2 
other 6 11.3 11.8 100.0 
Total 51 96.2 100.0  
Missing data 2 3.8   
Total 53 100.0   
 
Final recoded variable to be used for profession 
 N % Valid % 
Cumulative 
% 
Medical - Secondary care 32 60.4 62.7 62.7 
Medical - GP 7 13.2 13.7 76.5 
Nurse 6 11.3 11.8 88.2 
other 6 11.3 11.8 100.0 
Total 51 96.2 100.0  
Missing data 2 3.8   
Total 53 100.0   
 
Q48. If you wish, please use this space to write your views about what worked well and 
what did not work so well in the programme. 
3 years later, impossible to detect any impact on practice 
Any programme that improves the knowledge of the general public to be aware of their own 
health and seek medical attention is vital, however within my area of work the sudden 
increase in work at the time caused a great deal of stress on the workforce. We were 
fortunate to have good management that kept us informed of what was happening and 
helped us to reshape the service provision following on from diagnosis. I would comment 
that while the funding rightly ensured the diagnostics were sufficient, further work to look at 
the complete pathway including treatment and follow up should have been included. The 
service was swamped very quickly and due to the good will and hard work of the team the 
service managed the workload, but this was not an easy process. 
At the outset the planners failed to anticipate the need to know the mode of referral i.e. 
screening versus symptomatic, and this had to be added to the required data fields at a later 
date.  It had been suggested at the early meetings but was not taken up by the analysts at 
ISD. 
Breast cancer has a well-publicised screening programme. DCE filled our clinics with the 
"worried well" and resulted in delays to the diagnosis and management of patients with 
cancer. 
DCE is an excellent concept - raising public awareness of early cancer signs is good; 
primary health care worker education is important. However, the downstream effects on 
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diagnostics and treatment centres needs more thought and input - often the extra workload 
stretches already stretched resources. 
DCE was completely unsuited to breast cancer diagnosis where there is already a screening 
programme in place. 
did not diagnose any more cancers during this time. Extra work, no extra cancers 
Electronic results were extremely helpful, it meant that they were filed straight into the 
patient's notes without the need for extra admin processes.  They were readily available to 
the GPs and a member of the admin team who sent reminders to patients who did not attend 
for screening. 
Great for patients. TERRIBLE for staff leading to low morale (overworked, underpaid, health 
deterioration of staff, emotional blackmail) 
I don't have the data to usefully answer this. How much did it cost? How many QALYs did 
we get? Based on my limited exposure and internal bias I'm guessing that bowel made a bit 
of a difference, but I don't know at what cost; and lung and breast were a complete waste 
of time and money with the resulting opportunity cost of impacts on non-DCE targets? 
I thought the bowel screening programme worked very well and the adverts were very good 
at raising public awareness. 
Inadequate staff there huge premiums paid to meet demand - sadly no more staff and 5% 
year on year saving means that something has to give/ Should we stop all care except DCE? 
Needed more clarity and preliminary discussion with clinicians to determine which approach 
would work best for which tumour type.    Need much more intelligence on what are causes 
of delays to diagnosis. how many presentations to GP before referral, what are reasons 
patients do not present? Even how do most cancers present 
None of it worked well from our services point of view 
patient more anxious about minor changes. 
Poorly:  The introduction of the programme.  I attended a national meeting at which 
someone from my Health Board said that staff were fully informed and had developed plans 
to implement DCE - this was completely untrue - we knew nothing until the campaign was 
upon us, and no plans were made to cope with additional referrals.  Please note - in 
radiology, the issue is not necessarily funding, but finding trained staff.  I have never seen 
any assessment of the value of the programme.  The only thing which worked well was that 
we were eventually given some additional funding. 
Public campaign raising lung cancer awareness    DCE team listened to expert advice on 
how to approach this group of patients. 
Significant increase in the worried well attending with non-high-risk symptoms. No increase 
in the detection rate of symptomatic breast cancer. Resources stretched with increase in 
appt times for urgent referrals including those with cancer. 
The basic principle of DCE is good and using Elaine C Smith was excellent as she lightened 
the adverts while also seeming like a familiar face. It is not good to just run a short intense 
campaign that creates a flood of the ‘worried well’ which overwhelms a service a causes 
cancer patients to wait longer for diagnosis and treatment. An ongoing campaign is more 
likely to be seen by someone at the time they have a symptom or are due to take part in 
Screening. 
To be honest none of it, cannot see any improvement prior to me starting in 2015, 
improvements have been local and not driven by this project. In fact, the reason to improve 
might have been as a result of unsustainable service pressures caused by the project. 
we didn't pick up any extra cancers as a result of the programme..... 
What did not work well was the marketing campaigns that were not scheduled in line with 
the breast screening programme. 
Worked well - Having a designated lead, taking the time to find out our priority areas and 
having an open and transparent process for identifying funding priorities. Attempting to 
share the learning.  Being consistent about the recording of staging in proformas and 
databases 
worked well in appropriate age group but generally swamped with young people at low risk 
who were anxious and well .. very time consuming and labour intensive 
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Q49 If you wish, please let us know your views on barriers/facilitators to DCE success. 
These could be specific populations, financial issues, regional characteristics, or 
anything else you find relevant. 
Again, did it work? Assuming it didn't in at least two of the three groups, my guess would be 
that specialists did what specialists ought to do - pushed for resources for their own service. 
I'm also guessing that there was minimal competent health economist involvement. SG went 
along with it because who would argue with stopping people dying from cancer? And, as 
pretty much always, nobody cared what primary care thought. :- ) 
Deprived populations continue to have poorer understanding and uptake. Better education 
in schools and communities is required to remove fear and stigma from the word cancer. 
Certain societies continue to have limited understanding and ignorance in cancer due to 
fear. 
didn't meet anyone!  clearly no follow up - I suspect team may have made contact with fife 
earlier on but not sustained involved and not made aware of any ongoing work when I took 
over service. 
In the initial stages the screening service had meetings with SG DCE colleagues however 
the marketing strategies were not influenced by frontline staff and they went ahead as 
planned. 
Lack of engagement with front line clinical staff 
Lack of finance, especially initially.  Lack of trained personnel.  Lack of planning at Health 
Board level. 
Managers who know little or nothing of a service but make judgements based on paper 
statistics. Speak to staff who know!! 
Our clinics were completely swamped with the "worried well" requesting reassurance. The 
uptake should have been predicted in advance and a strategy set in place for dealing with 
the increased number of referrals. 
Screening with qFIT may work well.  HPV immunisation should be considered for specific 
population groups to reduce risk of anal cancer (and head and neck) 
Short projects - worked when post holders were in place. Difficult to maintain or mainstream 
when the projects come to an end. 
STAFFING - they do not exist to recruit. 2020 vision medical staff went to university c2005 
and choose their specialty in 2013. How does this fit with DCE? 
Was also important to advise patients on benefits of breast screening programme which is 
the best current method of diagnosing cancer at an early stage, this message was 
somewhat overshadowed by DCE info 
waste of time and money but SG would not listen 
Without the availability of good quality data, it would never have got off the ground.  It might 
have been more effective if other cancer sites had been chosen where there was a greater 
chance of influencing behaviour. 
 
Q50. Finally, if we missed any issues you wished to talk about, please let us know 
below. 
I found the earlier "rounds" of questions in this questionnaire odd - do those who didn't utilise 
certain aspects in their work not have a contribution to make?    e.g. I attended a training 
course on DCE at its inception, but it had no impact on my work, so I answered "no" - and 
therefore didn't have the opportunity to comment on the training course, as the 
questionnaire flipped to the next section.    I would like to see results of the impact, and 
additional work associated with, the DCE programme. 
If this project is to continue, then you need to review engagement because people leave 
and do not necessarily handover that projects such as this exist.  Clearly if the endoscopy 
and bowel cancer lead doesn't know you exist you have a problem. 
Would be interesting to known what the plans are/were to assess the impact of DCE on 
patient outcomes (i.e. survival, symptom control). 
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Appendix 33. All bivariate analyses 


































































3 (2-5) 2 (1-4) 3 (2-5) 4 (2-6) 4 (2-5.5) 4 (1-6) 4 (3-5) 4 (3.5-7) 3 (1-4) 7 (4-7) 
Medical – GP 5 (4-6) 5 (4-5) 6 (5-7) 6 (5.5-7) 5.5 (3.75-7) 6 (5.5-7) 6 (5-7) 6 (3-6.5) 5.5 (3.75-6) 7 (6-7) 
Nurse 6 (4.25-7) 5 (3.25-6) 6 (5.5-7) 6 (4.5-6.5) 7 (4-7) 6.5 (4.5-7) 6 (5-7) 6.5 (4.5-7) 6 (3.75-6) 6.5 (6-) 
Other 6 (4-6.25) 5 (2-5.5) 4.5 (3.5-6.25) 
5.5 (3.5-
6.25) 6.5 (5.25-7) 4 (3-) 6 (6-6) 5 (5-) 5 (1-) 6 (6-) 






























More than one 
tumour type 5 (3.5-6) 4 (2.25-5) 6 (4-6.5) 6 (4-7) 5.5 (3.75-7) 6 (5-6.75) 6 (3.5-7) 5 (3-6.5) 4.5 (2.25-6) 6 (5-7) 




4 (2-6) 6 (2.5-7) 5.5 (3.25-6.75) 6 (3.5-6.5) 4.5 (2.25-6) 5 (4-) 
4.5 (1.75-
5.25) 5 (2.5-6.5) 4 (4-5.5) 7 (6.25-7) 













































Yes 5 (3.5-6.5) 4 (2.25-4.75) 6 (4-7) 5 (4-7) 6 (3.5-6.5) 5.5 (5-6.25) 5 (4-6) 5 (4-7) 4 (2.5-5.5) 6 (5.25-6.75) 


































No, and I was 
happy with 
that 
5 (3-6) 4 (2-5.75) 4.5 (2.25-6) 6 (2.5-6) 5 (2.75-6.25) 6 (3.5-7) 5 (4-6) 5 (4-6.75) 6 (4-6) 7 (7-7) 
No, but I 
would have 
liked to have 
had an input 
2.5 (1-4.75) 2 (1-5) 4 (2-6) 4 (3-6) 4 (2-6) 4 (1-6) 4 (3-6) 4.5 (2.75-7) 2.5 (1-4.5) 6 (4.5-6) 
1,4,5,6,8No significant differences found between any pairs in post-hoc tests. 2Post-hoc tests showed that distributions were different between those who said “yes” and those 
who said “no, but I would have liked to have had an input (p=0.047).3Post-hoc tests showed that distributions were different between groups focusing on breast cancer 
and those focusing on bowel, anal or upper GI cancers. 7Post-hoc tests showed that distributions were different between those who said “no, but I would have liked to 
have had an input” and those who said “no, and I was happy with that” (p=0.042). 
Table 2. Assumption 2 (except communication between primary and secondary care) – Fishers’ Exact Test used in all cases 
Participant 
characteristics 




inf Suff. Inf 
More 
inf Suff. Inf 
More 
inf Suff. Inf 
More 
inf Suff. Inf 
More 
inf Suff. Inf 
More 
inf Suff. Inf 
More 
inf 
Profession p=0.272; N=50 p=0.098; n=40 p=0.036; n=35 p=0.001; N=43 p=0.002; n=38 p=0.157; n=33 p=0.265; n=21 
Medical – 
secondary care 
32.3% 48.4% 24.0% 44.0% 13.0% 21.7% 10.7% 28.6% 0.0% 36.0% 15.0% 30.0% 44.4% 33.3% 
Medical – GP 42.9% 28.6% 83.3% 0.0% 60.0% 20.0% 71.4% 0.0% 0.0% 40.0% 42.9% 42.9% 100% 0.0% 
Nurse 66.7% 33.3% 60.0% 40.0% 60.0% 20.0% 66.7% 0.0% 75.0% 25.0% 50.0% 0.0% 100% 0.0% 
Other 83.3% 16.7% 50.0% 25.0% 50.0% 50.0% 100% 0.0% 0.0% 75.0% 50.0% 50.0% 66.7% 33.3% 
Cancer type p=0.756; N=51 p=0.004; N=41 p=0.462; n=35 p=0.422; n=43 p=0.942; n=39 p=0.112; n=32 p=0.016; n=21 
More than one 
tumour type 
53.8% 23.1% 70.0% 10.0% 55.6% 11.1% 54.5% 18.2% 20.0% 30.0% 45.5% 36.4% 91.7% 0.0% 
Breast  33.3% 50.0% 6.3% 56.3% 9.1% 27.3% 14.3% 28.6% 8.3% 41.7% 14.3% 42.9% 0.0% 0.0% 
Bowel, anal 
and/or upper GI 
28.6% 57.1% 25.0% 50.0% 16.7% 33.3% 14.3% 28.6% 0.0% 60.0% 0.0% 28.6% 50.0% 50.0% 




55.6% 22.2% 71.4% 0.0% 50.0% 16.7% 42.9% 0.0% 11.1% 22.2% 20.0% 0.0% 100% 0.0% 
DCE 
involvement p=0.229; n=49 p=0.766; n=40 p=0.159; n=35 p=0.009; n=42 p=0.420; n=38 p=0.458; n=31 p=0.916; n=21 
Yes 77.8% 22.2% 55.6% 33.3% 66.7% 16.7% 85.7% 14.3% 16.7% 66.7% 66.7% 33.3% 75.0% 25.0% 








inf Suff. Inf 
More 
inf Suff. Inf 
More 
inf Suff. Inf 
More 
inf Suff. Inf 
More 
inf Suff. Inf 
More 
inf Suff. Inf 
More 
inf 
No, and I was 
happy with that 33.3% 52.4% 42.9% 35.7% 33.3% 13.3% 33.3% 16.7% 12.5% 31.3% 26.7% 26.7% 61.5% 23.1% 
No, but I would 
have liked to 
have had an 
input 
42.1% 36.8% 29.4% 41.2% 14.3% 35.7% 11.8% 29.4% 6.3% 37.5% 15.4% 38.5% 100% 0.0% 
Abbreviations: Suff Inf: sufficiently informed; More Inf: would have liked more information.  
Table 3. Assumption 2 (communication between primary and secondary care) 
Participant characteristics Q29.4.a Median (IQR) 
Profession H(3)=9.686; p=0.021; 
N=251 
Medical – secondary care 1 (1-1.25) 
Medical – GP 3 (1-3.5) 
Nurse 4 (2-) 
Other 2 (1-) 
Cancer type H(4)=3.823; p=0.430; N=26 
More than one tumour type 3 (1-4.5) 
Breast  1 (1-2.75) 
Bowel, anal and/or upper GI 1 (1-1) 
Lung 1 (1-1) 
One tumour type, unclear which one 1.5 (1-2) 
DCE involvement H(2)=1.272; p=0.529; N=25 
Yes 2 (1-4) 
No, and I was happy with that 2 (1-3) 
No, but I would have liked to have had an input 1 (1-2.5) 
1Post-hoc tests showed that distributions were different between secondary care doctors and nurses (p=0.028) 
Table 4. Assumption 3 
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Medical – secondary care 2 (1-3) 2 (1-3) 1 (1-2) 3 (3-3) 
Medical – GP 3 (2-4) 2 (1.5-3.5) 2 (1-) 2 (2-4) 
Nurse 5 (3.25-5.25) 4 (1-4) 4 (2-) 2 (2-2) 
Other 2.5 (1-5) 3.5 (2-) 3 (2-) 6 (6-6) 








More than one tumour type 3 (2-4.5) 2.5 (1.25-4) 2 (1-6) 2.5 (2-3.75) 
Breast  1 (1-2) 2 (1-4) 1.5 (1-3.25)  (-) 
Bowel, anal and/or upper GI 4 (2-4) 1.5 (1-3.5) 1 (1-) 2 (2-2) 
Lung 3 (1.25-4.75) 1 (1-1) 1.5 (1-)  (-) 
One tumour type, unclear which one 4 (1.25-5) 2.5 (1.25-3.75) 2 (1.75-2.50) 6 (6-6) 








Yes 4 (2.5-5) 3.5 (1-5) 2 (1-4.5) 2 (2-2) 
No, and I was happy with that 3 (2-4) 2 (1-3.25) 2 (1-4) 3 (2-4) 
No, but I would have liked to have 
had an input 1 (1-2.5) 2 (1.25-4) 2 (1-3) 4.5 (2-) 
1No significant differences found between any pairs in post-hoc tests. 2,Post-hoc tests showed that distributions were different between 
groups focusing on breast and those focusing on more than one tumour type (p=0.031). 3Post-hoc tests showed that distributions were 
different between those who said “yes” and those who said “no, but I would have liked to have had an input” (p=0.040). 
 
Table 5. Assumption 4 
Participant characteristics Q7.2.a Median (IQR) 
Profession H=9.795; p=0.020; N=441 
Medical – secondary care 1 (1-3) 
Medical – GP 3.5 (1.75-5.25) 
Nurse 4.5 (3.5-6) 
Other 1 (1-6) 
Cancer type H=5.684;  p=0.224; n=45 
More than one tumour type 3 (1-6) 
Breast  1 (1-3.25) 
Bowel, anal and/or upper GI 1 (1-) 
Lung 3 (1.25-4) 
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Participant characteristics Q7.2.a Median (IQR) 
One tumour type, unclear which one 3 (1-5.5) 
DCE involvement H=4.674; p=0.097; n=43 
Yes 3 (3-6) 
No, and I was happy with that 2 (1-5) 
No, but I would have liked to have 
had an input 1 (1-3) 
1Post-hoc tests showed that distributions were different between secondary care doctors and nurses (p=0.026). 
Table 6. Mechanism 1 















Medical – secondary care 7 (IQR 5-7) 2.5 (1.25-6.25) 4 (2-5.5) 7 (6-7) 
Medical – GP 6 (IQR 5-7) 1 (1-1.5) 2 (1-2.25) 2 (1-4) 
Nurse 6.5 (IQR 5.5-7) 1 (1-4) 3 (3-) 2 (2-2) 
Other 5 (3.25-7) 3 (3-3) 1 (1-1) 4 (2-) 








More than one tumour type 6 (IQR 4.5-7) 1.5 (1-3.5) 2 (1-6) 2 (1-5.5) 
Breast  6.5 (IQR 4.75-7) 1 (1-5.5) 2 (1.25-4.25)  (-) 
Bowel, anal and/or upper GI 6 (IQR 4-7) 2 (1-) 4.5 (2.5-5.75) 7 (4-7) 
Lung 7 (2.5-7) 4 (4-4) 4 (4-4)  (-) 
One tumour type, unclear which one 6(5-7) 3.5 (1.5-6.25) 3 (1-) 4.5 (2-) 








Yes 7 (IQR 5.5-7) 3.5 (2.5-6.25) 5 (2-) 5 (2-) 
No, and I was happy with that 6 (IQR 5-7) 1 (1-2) 2 (1-4) 2 (1-7) 
No, but I would have liked to have had 
an input 7 (IQR 4-7) 2.5 (1-4.75) 3 (1.5-4.5) 4 (1-) 
 
Table 7. Mechanism 2 
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Medical – secondary care 2 (1-2.5) 1 (1-2) 1 (1-3) 
Medical – GP 3 (1.5-6) 2.5 (2-) 4 (2-) 
Nurse 4 (4-) 5 (3-) 5 (4-) 
Other 4 (3-) 1.5 (1-) 1.5 (1-) 
Cancer type H=3.598;  
p=0.463; n=32 
H=10.096; 
 p=0.039; n=303 
H=2.952;  
p=0.566; n=30 
More than one tumour type 3 (1.5-6) 2.5 (2-6) 2.5 (1-6) 
Breast  1.5 (1-4.5) 1 (1-2.75) 1 (1-4.5) 
Bowel, anal and/or upper GI 1.5 (1-3.5) 1 (1-1) 1 (1-) 
Lung 1.5 (1-) 1 (1-1) 1 (1-1) 
One tumour type, unclear which one 3 (2-4) 1 (1-3) 2 (1-5) 






Yes 2 (1.5-4.5) 6 (1-) 3 (1-) 
No, and I was happy with that 3.5 (1-4.5) 1.5 (1-3.25) 1 (1-3.25) 
No, but I would have liked to have had an input 2 (1-4.5) 1 (1-2.25) 1 (1-3.5) 
1,3No significant differences found between any pairs in post-hoc tests. 2,Post-hoc tests showed that distributions were different between secondary 
care doctors and nurses (p=0.024) 
 
Table 8. Mechanism 3 – Fishers’ Exact Test used in all cases 
Participant characteristics 
Q8 














Profession p=0.071; N=48 p=0.105; N=36 p=1.000; N=37 p=0.218; N=36 p=0.079; N=16 
Medical – secondary care 93.5% 13.0% 92.0% 78.3% 100% 
Medical – GP 100% 50.0% 100% 85.7% 66.7% 
Nurse 100% 60.0% 100% 100% 100% 
Other 50.0% 50.0% 100% 0% 0.0% 
Cancer type p=0.104; N=49 p=0.101; N=36 p=0.142; N=39 p=0.125; N=36 p=0.314; N=16 
More than one tumour type 91.7% 66.7% 100% 88.9% 75.0% 
Breast  100% 12.5% 100% 81.8% - 
Bowel, anal and/or upper GI 100% 25.9% 100% 100% 100% 


















Lung 75.0% 0.0% 75% 75.0% - 
One tumour type, unclear which one 77.8% 25.0% 85.7% 40.0% 50.0% 
DCE involvement p=0.359; N=47 p=0.749; N=35 p=0.644; N=36 p=0.72; N=34 p=0.516; N=15 
Yes 100% 33.3% 100.0% 80.0% 100% 
No, and I was happy with that 95.2% 33.3% 100.0% 93.3% 83.3% 
No, but I would have liked to have had an input 84.2% 21.4% 87.5% 61.5% 50.0% 
 
Table 9. Mechanism 4 























Medical – secondary care 2 (1-4) 4 (1-4.5) 2.5 (1-4) 4 (1-) 1.5 (1-4) 3 (1.25-4) 
Medical – GP 5 (2-5.25) 4 (2-6.25) 2 (2-5.5) 5.5 (2-7) 4 (1-6) 5 (2-6) 
Nurse 5 (4-) 5 (5-) 5.5 (2-6) 6 (6-6) 6 (6-6) 6 (6-6) 
Other 2.5 (1-) 6 (5-) 3 (1-) 7 (7-7) 5 (4-) 5.5 (5-) 












More than one tumour type 2 (2-5) 2 (2-6) 2 (2-5) 5 (2-7) 2 (1-6) 3.5 (2-6) 
Breast  3 (1.5-5) 4 (2.5-6) 2 (1-2.5)  (-)  (-)  (-) 
Bowel, anal and/or upper GI 2 (2-3.5) 4 (3-) 4 (2.5-5.5) 6 (4-) 3 (1-4.5) 4 (1.75-4.5) 
Lung 4 (4-4) 4 (4-4) 4.5 (4-)  (-)  (-)  (-) 
One tumour type, unclear which one 1 (1-) 5 (1-) 1 (1-) 7 (7-7) 6.5 (6-) 5 (4-) 












Yes 2 (2-3.5) 3.5 (2-5) 3.5 (2-5) 2 (2-2) 3 (2-) 3.5 (2-) 
No, and I was happy with that 4 (2-5) 4 (2-5.25) 2.5 (2-5) 6 (2-7) 4 (1.25-6) 4 (2.5-6) 
No, but I would have liked to have had an 
input 3.5 (1-4.25) 4.5 (3.25-7) 1.5 (1-4.25) 6 (4-) 1 (1-) 4 (2-6) 
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Appendix 34. Theme definitions and relationships between themes 
Theme Description 
1. Stakeholder buy-in  
1.1 Support for core aim Comments on support for the DCE programme, what influenced this and variations across stakeholders 
1.2 Early detection approaches and 
chosen tumour types 
Comments on the appropriateness of focusing on screening or on cancer symptoms and signs, and on 
the tumour types chosen to be targeted by the programme 
1.3 Feedback on different strategies Views on the referral guidelines, the bowel screening initiative and the social marketing campaigns, with 
information on mixed-buy-in, appropriateness, and engagement 
1.4 Performance targets Comments on performance targets, their benefits and limitations, approaching both SQOF and the HEAT 
targets and issues regarding feasibility, clinical relevance and sense of ownership 
2. Communication  
2.1 Source of information Descriptions of different ways in which DCE shared information about the programme 
2.2 Ongoing communication and 
timeliness 
References to how communication between DCE and stakeholders changed over time and limited notice 
about strategies (especially campaigns). This theme is linked with “Stakeholder buy-in” 
2.3 Rationale for strategies Comments on whether the rationale for DCE and its strategies was known across different stakeholders. 
This theme is linked with “Stakeholder buy-in” 
2.4 Input from the health care community 
and charities 
Views over whether stakeholders were able to give input on the programme before activities were 
implemented. This theme is linked with “Stakeholder buy-in” 
2.5 Dissemination of activities and 
outcomes 
Views on DCE’s approaches to disseminating activities and outcomes 
3. DCE and the professionals’ roles  
3.1 Business as usual Comments on how professionals saw DCE as part of their core role 
3.2 Competing responsibilities and new 
tasks 
Comments on how DCE was additional work, and at times indicated a new role altogether 
4. Using DCE funding  
4.1 Allocation and variation Description of how DCE funding was allocated across Health Boards, whether it was used for additional 
capacity or to fill existing gaps, which areas received funds and whether funding was perceived to be 
adequate. This theme is linked to “Regional variation” 
4.2 Funding is not necessarily the solution Comments on how funding was not enough to solve capacity issues if professionals were not available to 
be recruited, and limitations brought by short-term funding. This theme is linked to “Barriers”. 
5. Impact on workload  
5.1 Impact of different strategies Reports of DCE impact on workload, especially regarding the impact of the symptomatic breast campaign 
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Theme Description 
5.2 Unexpected impact Views on whether DCE impact on workload was expected, happened as planned or plans underestimated 
impact 
6. Partnerships and collaborations  
6.1 The role of charities Comments on how charities were collaborators, partners, and leads in DCE activities, and how they added 
value/expertise to the programme. This theme is linked with “Communication” 
6.2 The role of creative and market 
research agencies 
Comments on how different agencies helped to develop and evaluate DCE activities, and variations in the 
perception of programme success. This theme is linked with “Stakeholder buy-in” 
6.3 The role of the media Comments on how interaction with the media had both positive and negative implications 
7. Official DCE outcomes  
7.1 Joining the dots Reports on the challenges of showing programme impact on cancer outcomes (attribution, which 
components contributed to changes), and linking intermediate and final outcomes 
7.2 Anecdotal evidence References to anecdotal data when describing DCE impact , due to limited knowledge of national data, or 
limited measurement of impact 
7.3 Views on official outcomes Any comments on programme impact associated with DCE’s main strategies and official programme 
objectives. This theme is linked to “Barriers” 
8. Soft outcomes and other benefits  
8.1 A cumulative effect Comments on an expected cumulative, long-term effect on help-seeking behaviour and cancer outcomes 
8.2 Changes in service provision Comments on perceived changes brought by DCE in the way care was provided to patients, services were 
organised, and communication between primary and secondary care, prevention and early diagnosis, 
health care professionals and the Scottish Government 
8.3 Opportunity to develop local activities Comments on how DCE enabled the implementation of local activities and projects which would not have 
happened otherwise 
8.4 Enhanced partnerships Comments on how DCE helped to enhance government-charity partnerships 
8.5 Normalised discussions about cancer Comments on how DCE helped to normalise discussions about cancer 
8.6 Measuring soft outcomes Reports on recognised challenges in measuring soft outcomes 
9. Flexibility as a two-edged sword  
9.1. A “chameleon” programme Comments on DCE’s ability to be flexible in terms of funding different activities, focusing on different areas 
(such as cancer prevention) and allowing Health Boards to use funding as they saw appropriate. 
9.2. Challenges brought by flexibility References to challenges brought by DCE flexibility in terms of implementing strategies, measuring 
outcomes and ensuring accountability. This theme is linked to “Barriers” 
10. Unanticipated outcomes Any comments on unanticipated outcomes (positive or negative) brought by the programme (no sub-
themes) 
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Theme Description 
11. Stakeholder recommendations Any recommendations on how DCE should proceed/change, and what should continue. 
Recommendations were listed in a table 
12. Barriers  
12.1 Health system barriers Any references to current challenges faced by the NHS in Scotland 
12.2 Factors influencing early detection Any reference to individual factors and socio-demographic factors influencing early detection 
12.3 Funding system in Scotland Description of how the way the funding system in Scotland is organised can be detrimental to a holistic 
approach to patient care 
12.4 Data challenges Comments on challenges in accessing data, especially on referrals 
13. Facilitators  
13.1 Country size Comments on how Scotland’s small size was a facilitator 
13.2 Cancer prevalence Reflections upon the fact that cancer affects everyone’s lives in different ways and this can be a motivator 
13.3 Good quality data Any comments on the benefits of having good quality data 
13.4 Funding as a hook Any comments on how funding enabled involvement. This theme is linked with “Stakeholder buy-in” 
13.5 Benefiting from existing activities and 
relationships 
Reports on existing activities and developed relationships that facilitated DCE implementation 
13.6 Tailoring messages Comments on how addressing specific needs worked as a facilitator 
14. A government initiative  
13.1 Prioritisation of early detection Any comments on how DCE, as it was a government programme, heled to bring early cancer detection to 
the centre of attention 
13.2 A dual purpose: politics and health Any comments on the challenges brought by being a government programme, including the inevitable 
conflict between short- and  long-term changes (and the use of performance targets), and the need to 
show that the government was fulfilling its commitment to improve population health 
13.3 A new type of initiative Any comments on how DCE was a new, novel approach for government initiatives 
15. Cultural shifts  
15.1 Realistic/personalised medicine Any comments on a drive towards respecting patient’s autonomy and informed choice, individual 
preferences, and towards a more holistic approach to care 
15.2 Image of cancer has changed Reflections on how discussions about cancer are less often considered to be “taboo” 
16. Regional variation Any comments on regional variation and its impact on programme implementation, engagement, 
evaluation, sustainability and outcomes 
17. DCE beyond three years Any comments on contextual changes that happened after DCE’s first three years, and how these 
influenced and were influenced by the programme 
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Appendix 35. Illustrative quotes mapped into 
implementation outcomes and COM-B 
components 
Implementation assumptions 
Examples from interviews and open-ended comments from questionnaire according to 
implementation outcomes 
Assumption 1: Different stakeholders bought into DCE, its components and what it proposed 
to do 
Feasibility 
“I found it very frustrating and had serious practical implications for us which meant that you 
felt as though you were waiting and waiting and waiting and then you had to rush at 
everything and try and finish” (Interview participant, ID 28) 
Acceptability 
“I think it's just become accepted that this is probably the right thing to do. You'll still get your 
group who will never think it's the right thing to do and we should’ve invested our money in 
prevention or different areas” (Interview participant, ID 33) 
Sustainability 
“[I]t's always the case with any of these type of campaigns, unless you [inaudible] sustainable 
and the pressure and the momentum, you lose those gains that you saw in the early days” 
(Interview participant, ID 28) 
“If this project is to continue then you need to review engagement because people leave and 
do not necessarily handover that projects such as this exist” (Questionnaire participant, 
Secondary Care Doctor, NHS Fife) 
Appropriateness 
“But there are times […] that there might be disagreement between the people that are 
working in the service and the marketing team and the advertising contractor that they use 
about what they think is appropriate” (Interview participant, ID 14) 
Assumption 2: There was enough targeting and communication about DCE aims and its 
strategies, and what was expected from everyone 
Reach and communication 
“[A] lot of the time I would be watching social media and stuff to see what was coming up 
because that would be where you would hear about it first” (Interview participant, ID 15) 
“Needed more clarity and preliminary discussion with clinicians to determine which approach 
would work best for which tumour type” (Questionnaire participant, Colorectal Surgeon, NHS 
Lothian) 
Assumption 3: Available resources were sufficient to meet aims 
Feasibility 
“So the one stop breast clinics are very good in that people will get the process done right 
there and right then and get as close to the diagnosis as possible on the one visit.” (Interview 
participant, ID 13) 
“No thought was given to available resources. This program has resulted in an enormous 
extra spend and will help bring the NHS to its knees. No program should be launched without 
consideration of workforce available” (Questionnaire participant, Secondary  Care Doctor, 
NHS Forth Valley) 
Acceptability 
“[F]or us it wasn’t actually a financial incentive, it was that we had money to pay them to do 
things that we had both agreed there was some evidence of likely benefit, both at a 
population level and at an individual patient level (Interview participant, ID 19) 
Sufficiency 
“The service managers say that there wasn’t enough money [laugh] so money's never 
enough” (Interview participant, ID 22) 
4. Flexibility was permitted when allocating resources 
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Examples from interviews and open-ended comments from questionnaire according to 
implementation outcomes 
Feasibility 
“When you've got all these different things that you're asking these people to do you almost 
have to prioritise those and go well actually smoking would disproportionately, you know, 
beneficial to tackle, actually you're betting putting your money behind that than trying to get 
people to do the eat this and do the 10,000 steps and do this, this and this.  It's always a 
trade off with how much stuff you can do” (Interview participant, ID 24) 
Adaptability 
“We did weigh the funding, so if you had a practice population that had, yeah, so it was 
weighted on practice population over 50 and also deprivation, so a more deprived practice, 
a deep end practice for example, they would in theory get more money when they increased 
participation”. (Interview participant, ID 33) 
“Now that we can take the funding and target it in line with our programme it can be put to 
good use” (Questionnaire participant, Allied Health Professional, NHS Lothian) 
 
Mechanisms of impact 
 
COM-B 
construct Examples from interviews and open-ended comments from questionnaire 
Mechanism 1: DCE strategies were in line with what professionals perceived as their role, 




“So I just took it as part of my job” (Interview participant, ID 11) 
“In my lead cancer GP role it was core work, it wasn’t extra work, it was what 
I was there to do, it was core work and it was positive and well-focused work” 
(Interview participant, ID 23) 





 “I think it was very effective, it certain brought to me, you know, it was a great 
mechanism financially to put some resources into services, into messages, 
into buy in from staff to sell the message” (Interview participant, ID 29) 
“Increased colonoscopy lists, increased recruitment & training of non-medical 
endoscopists” (Questionnaire participant, bowel surgeon, NHS Greater 
Glasgow & Clyde) 
Not confirming mechanism 
 “The only other point I would make around that is that in some areas actually 
the money wasn’t the problem, so being allocated the money was great, don't 
get me wrong, but if you can't recruit pathologists or radiologists then you're 




“It basically went on clinical care and it went on clinical care on the argument, 
two arguments, one was well if you're going to do a lot of social marketing 
nationally or locally we'll have to shore up the local services so that they're 
ready for this vast quantity of people coming through the door, and partly 
because the service has always got difficulty” (Interview participant, ID 27) 
Not confirming mechanism 
How can you get more workforce when there a hundreds of consultant (and 
other staff vacancies). Completely different planet the DCE group live in 
(Questionnaire participant, breast surgeon, NHS Ayrshire & Arran) 
Mechanism 3: Increased demand brought by DCE was a driver for action and created 
pressure to act 
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COM-B 




 “It caused a lot of angst at the time cause we deal with the same breast 
surgeons obviously as those in symptomatic” (Interview participant, ID 14) 
Mechanism 4: Targets helped to focus the mind, showed where resources were needed 
and increased pressure to act 
Automatic 
motivation 
Unclear whether confirming or not confirming mechanism 
“[T]he variation from quarter to quarter and then from year to year is difficult 
in the percentage change and that sometimes makes people anxious about 
why there's so much variation, so we can look like we're doing okay one 
quarter and the next time we've gone really down and the non-execs and the 
execs as well in the organisation they get quite upset with this, and it's really 




“In general, as I said, targets, especially with financial incentives, do focus 
minds and I think they do work in general” (Interview participant, ID 10) 
“So having those targets, those stage one increase targets, saw that reflected 
in our local delivery plan because it's based largely on the HEAT framework, 
so that pulled it straight to the centre of attention at the board” (Interview 
participant, ID 11) 
Not confirming mechanism 
“For some of the tumour groups, you know, I think there was recognition lung 
again that you weren't going to be able to do that cause you weren't changing 
anything” (Interview participant, ID 20) 
Confirming mechanisms for one target, but not for the other 
“And I guess where with both screening and the SQOF points there was an 
incentive, there was a clear incentive for the improvement, I'm not sure if from 
a clinical perspective there was a clear incentive for encouraging stage one 
diagnosis” (Interview participant, ID 31) 
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Appendix 36. The DCE workshop 
One of the deliverables to the Scottish Government was a workshop with DCE 
stakeholders. Although it was not a study component, the workshop was useful to 
engage with stakeholders, generate reflections on how to move forward, and ensure 
recommendations were relevant. The workshop had two aims: 1) to present a) results 
from the academic evaluation of the DCE Programme; and b) recommendations for 
policy; and 2) to discuss and refine recommendations to ensure that they were fit for 
purpose and realistic. 
 
In early August 2018, 56 stakeholders were invited by email to attend the workshop 
(the aim was to have up to 25 participants). Stakeholders’ names were obtained from 
the list prepared during evaluation development and included stakeholders who had 
been invited for an interview. An extended invitation was made to members of the 
Scottish Cancer Coalition. The invitation email encouraged stakeholders to forward 
the invitation to their colleagues. Twenty-three stakeholders contacted me to say that 
they wished to take part. And introductory brief describing the evaluation and an 
Agenda (Figure A) were sent in advance to all participants. 
 
Figure A. Workshop Agenda 
 
The workshop took place at a central Edinburgh location (a University of Edinburgh 
venue) on the 18th September 2018. Twenty stakeholders took part. After I presented 
evaluation findings and six draft recommendations, stakeholders were divided into 
four groups to discuss five questions (Figure B). My supervisors worked as facilitators. 
 
Figure B. Workshop questions 
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Overall, findings resonated with the stakeholders’ experience, although some 
mentioned issues not approached in the evaluation. Stakeholders agreed with the 
recommendations but asked for clarifications and discussions of findings resulted in 
a 7th recommendation. It was reportedly challenging to prioritise three 
recommendations as all seemed important, but changes to the order of 
recommendations were suggested. A more detailed description of stakeholders’ 
feedback on recommendations is available in the final evaluation report prepared for 
the Scottish Government (Appendix 37), but a summary of changes made to 
recommendations is available below (Figure C). 
 
Figure C. Draft and refined recommendations after the DCE workshop 
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Executive summary
Overview
This Report describes key findings from an Evaluation of the Detect Cancer Early 
(DCE) Programme’s processes and outcomes until 2015 (i.e. the initial phase). The 
Report firstly provides background evidence on why early detection initiatives are 
needed, with recognition of the limitations of early detection strategies in improving 
cancer survival. Cancer policies leading to DCE development, DCE components and 
objectives are then outlined. Evaluation methods are described. We then report on 
programme outcomes, followed by findings from the process evaluation. Finally, 
recommendations underpinned by findings and refined in a Workshop with 
stakeholders to ensure relevance and appropriateness are presented. It is hoped that 
the results and recommendations can be useful as a tool to guide future directions for 
DCE and other early cancer detection programmes.
The DCE Programme
• DCE is a multi-level early detection initiative launched in 2012 with the aim to 
improve cancer survival, initially focusing on breast, colorectal and lung cancers 
(the three main causes of cancer death in Scotland at the time)
• DCE’s initiatives involve collaboration with multiple stakeholders, including 
primary care practices, charities and official providers of health intelligence data
• Originally planned to last three years, DCE remains a key component of the 
Scottish Cancer Strategy. In its initial phase (2012-2015), DCE had four main 
strategies: public awareness and behaviour influencing; primary care symptom 
management and referral; secondary care and diagnostic capacity; and 
performance management and monitoring.
• Evaluation design was informed by interviews with nine DCE stakeholders, 
analysis of 159 policy documents, and review of health system evaluation methods
• Theory-based evaluation and the Medical Research Council’s Framework for 
Process Evaluation of Complex Interventions were selected as the most appropriate 
methodology to evaluate DCE outcomes and processes
• Outcome evaluation assessed DCE official objectives, while the process 
evaluation assessed contextual barriers and facilitators; mechanisms of impact 
and assumptions about implementation; and explored unanticipated outcomes
• Outcome evaluation comprised secondary analysis of published and unpublished 
data, and a time-trends analysis of requests for bowel screening kits
Evaluation methods
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• DCE had eight main objectives - not all of them could be assessed through
this Evaluation. Some objectives were broad and aspirational; in other cases
insufficient data meant rigorous assessment was not possible
• Although the main programme’s targets (HEAT) were not met in full, critical
improvements in cancers diagnosed in earlier stages were observed. By Year
3, there was a 7.0% increase in cancers (breast, colorectal and lung combined)
diagnosed at Stage 1. There was a 25.0% increase for lung and a 5.1% increase
for breast cancer; and increases were seen across all levels of social deprivation.
On the other hand, there was a decrease in the proportion of colorectal cancers
diagnosed at Stage 1 (4.3% reduction in Year 3)
• Improvements in recording of staging data have been observed (44.2%
reduction in Year 3 for all three cancers combined), with fewer breast (65.2%
reduction), colorectal (36.7% reduction) and lung cancers (38.7% reduction) being
recorded with unknown tumour stages. Reductions occurred across all levels of
social deprivation; with the most deprived having the highest reduction in Year
3 (54.5%). Early improvements in staging (especially in Year 1) were partially due
to improvements in recording.
• Independent evaluation of awareness campaigns indicate an increase in awareness 
of screening, cancer signs and symptoms among the public, but also highlight
• Process evaluation consisted of in-depth interviews and an anonymised online
questionnaire survey with DCE stakeholders (including primary and secondary
care professionals, public health specialists, and those managing DCE activities)
from across Scotland
• Evidence-based draft recommendations were developed and discussed with DCE
stakeholders at a Workshop in September 2018. Recommendations were  refined
according to their feedback.
Key findings: Outcome Evaluation
2. Are assumptions confirmed by stakeholders?
Process
3. Are mechanisms confirmed by stakeholders?
4. What are the barriers and facilitators to processes and outcomes?
5. Were there any unanticipated outcomes?Unanticipated outcomes
Outcomes
1. Which DCE objectives were met, and for whom?DCE outcomes
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Key findings: Process Evaluation
• Interviews (n = 25) and online questionnaire responses (n =53) provided valuable 
insights on both strengths and weaknesses of DCE processes from the perspectives 
of stakeholders, including front-line clinical and Health Promotion staff
• Although hard to quantify, stakeholders identified enhanced professional 
working across cancer diagnostic pathways, heightened awareness of early 
diagnosis, and ‘normalisation’ of conversations about cancer with patients and 
the public as valuable intangible benefits of DCE that transcend the more formal 
programme objectives
• Short-term, ambitious DCE targets were perceived by some to have impacted 
negatively on stakeholder engagement as the objectives were felt to be 
unachievable; questions were also raised over whether targets were a good 
measure of success
• Short-term plans were seen to be in tension with the ability to improve cancer 
outcomes as these often require long-term strategies; and with establishing and 
sustaining successful early detection strategies
• Campaigns that focused on symptoms had an impact on workload in both 
primary and secondary care, but limited impact on cancer outcomes
• Communication issues consistently emerged from interviews and free-text 
comments within the questionnaire survey: some stakeholders indicated that 
more information about the programme, the rationale for its activities, and its 
outcomes, was required. Limited information was associated with a reported 
reduced sense of ownership and engagement
• Stakeholders emphasised that DCE supported many local, successful campaigns 
and recommended the national dissemination of results and best practice in 
order to share learning
• Contextual barriers such as lack of radiologists, stretched capacity and limited 
GP availability were highlighted as challenges to DCE implementation.
the need to continue with campaigns in the long-term (with refinements to avoid 
message fatigue). Attitudinal changes over time were reported, although barriers 
such as cancer fear and concerns about wasting the doctor’s time persisted
• Increases in requests for bowel screening kits and in breast consultations are further 
indications that the campaigns reached the public, although there is no evidence 
that the increases resulted in more breast cancer diagnoses. Furthermore, the 
increases did not result in a higher proportion of bowel cancers being diagnosed 
at Stage 1. Reasons for these results need to be further discussed and investigated.
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Strike a balance between short- and long-term 
outcomes/objectives and aspirational/achievable targets
Ensure communication channels result in more timely, 
targeted information sharing





Good data availability and improved, timely access to 
data are vital and urgent
Consider other early diagnosis approaches for 
patients presenting with symptoms
Consider different ways to target patients at risk, 
especially deprived populations
Broaden the scope of outcomes to include 




Based on Evaluation results and Workshop discussions, we make the following 
recommendations:
Recommendations
“There’s lots of wee projects that have been funded over 
the years that have not been properly shared nationally, 
so if you sit at the Programme Board you hear about 
things [...] I think there’s a lot more than even I’m aware 
of [...] That kind of sharing and showing all the stuff 
that’s been done with the money could be done a bit 
better and a bit more robustly so that people did see all 
the great things that came out of it and, you know, yeah, 
really get to reflect on all of it”
Interview participant, ID 15
Evidence-based recommendations
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1. Introduction
Researchers at the University of Edinburgh 
contacted the Detect Cancer Early (DCE) 
team in late 2014 to propose an academic 
evaluation of the programme. The study 
started in late 2015. 
Four Progress Reports have been prepared; 
this Final Report describes the Evaluation 
of DCE’s first three years (2012-2015 - 
its originally planned duration), while also 
summarising key changes that happened 
since then.
1.1 Background to the study
This Report seeks to inform cancer policy 
and policy-making. We expect that it will 
be useful to health care professionals, 
providers of health intelligence data, and 
those designing or evaluating early cancer 
detection initiatives.
A Workshop was carried out with DCE 
stakeholders in September 2018 to discuss 
the Evaluation results, to obtain feedback on 
the relevance of the findings and to assess if 
the draft recommendations were applicable 
and realistic in the current context. The 
recommendations presented here have 
been refined based on the stakeholders’ 
feedback. Furthermore, the lead author has 
attended DCE Programme Board meetings 
since 2015 to ensure the Evaluation and 
recommendations were up-to-date and 
appropriate.
1.3 Cancer burden, early 
detection and survival
1.2 Intended use and users
Before describing DCE and the Evaluation, 
it is important to understand why such 
an initiative may be needed. To do so, it 
is necessary to recognise the burden of 
cancer, and the role (and limitations) of early 
detection in cancer survival. 
1.3.1  The burden of cancer
Due to ageing populations and increase 
in lifestyle behaviours such as consuming 
tobacco, alcohol drinking, obesity, and lack 
of exercise, cancer will remain an important 
public health problem for the upcoming 
decades1, 2. This is also the case for Scotland 
(Box 1). Nonetheless, more people are 
surviving cancer due to improvements in 
early detection and treatment3. 
Improvements in survival vary across 
countries. The EUROCARE research 
programme reports that England and 
Denmark have poorer survival rates 
compared to other Western European 
countries4-6. Furthermore, Scotland has the 
worse age-standardised relative survival 
and age and case mix-standardised relative 
survival in the United Kingdom (UK) for 
all cancers combined at five years after 
diagnosis7. 
Delays in diagnosis, limited investment 
in healthcare and poor care can help to 
explain the cross-national variation8,9. 
EUROCARE results describing poor 1-year 
survival outcomes10, and studies showing 
higher number of deaths close to diagnosis11 
also indicate that cancers diagnosed at later 
stages are important explanatory factors.
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Box 1. Cancer burden and survival in Scotland
In Scotland, it is estimated that more than two out of five people will have cancer in their 
lifetime12. In 2016, 31,331 people were diagnosed with cancer13 and 15,814 died from the 
disease14 (excluding non-melanoma skin cancers). Lung cancer was the most common 
cause of cancer death, followed by colorectal and breast cancers14. Lung cancer rates in 
Scotland (both incidence and prevalence) are among the highest in the world and are higher 
in Scotland compared to other UK countries15. Furthermore, cancer mortality rates in 
Scotland are 15% higher than the UK average16, 17. 
Importantly, cancer mortality rates have decreased over time, even though the absolute 
number of cancer deaths have increased (mainly due to population ageing)14. Mortality 
rates decreased partly due to improvements in treatment, screening, and decrease in the 
prevalence of diseases that increase the risk of cancer14, 18. 
Cancer survival has improved in Scotland and is better for cancers detected early through 
screening and cancers for which treatment has improved substantially over time. Survival is 
lower for patients with cancers often presented at later stages (such as pancreas, lung and 
stomach)19. Among the three biggest cancer killers in Scotland, lung cancer has the poorest 
estimated five-year age standardised relative survival (9.5% for men and 12.0% for women), 
while breast cancer has the best (82.8% for women). Colorectal cancer survival is similar 
for men (59.9%) and women (59.8%)19.










Service provided for a target population Service provided only for people with symptoms
Fig 1. The WHO’s distinction between screening and early diagnosis
Adapted from:  World Health Organization. Guide to cancer early diagnosis. Geneva: World Health Organization, 2017. 
1.3.2 Early detection and survival
Detecting cancer early is therefore an 
important way to improve cancer survival. 
Early cancer detection is a key strategy 
recommended by the World Health 
Organization (WHO) when implementing 
national cancer control programmes 
(alongside prevention, diagnosis, treatment 
and palliation)20.The WHO defines early 
detection as diagnosing cancer at an earlier 
stage (e.g. in a specific organ and not yet 
invading any surrounding tissue)21,22 through 
two strategies: 1) organised screening 
of individuals without symptoms (i.e. 
asymptomatic) that can find lesions before 
they become cancer or cancer in its earlier 
stages; and 2) early diagnosis of patients 
with symptoms (i.e. symptomatic)23 (Figure 
1). The WHO defines three steps to early 
diagnosis: awareness of cancer symptoms 
and accessing care; clinical evaluation, 
diagnosis and staging; and access to 
treatment, including pain relief21.
Several policies and initiatives aiming to 
improve cancer outcomes24 focus on 
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Box 2. Screening and early diagnosis: the key facts
Screening is important to early detection as cancers can be found before they are advanced. Benefits 
of screening in reducing cancer mortality have been shown in several high-quality studies23, 30-34. 
Importantly, screening has both benefits and harms (such as physical and psychological risks, and 
overdiagnosis)30, 32, and several requirements need to be met before implementing a screening 
programme30, 35. Moreover, a successful screening programme needs increased participation to 
be effective36. Screening will miss some cancers, and cancers can also develop between screening 
rounds37, 38.
In countries such as the UK and Denmark where primary care is the first point of contact for 
patients, most cancers are diagnosed after a patient has had one or more consultations with a 
primary care professional followed by one or more diagnostic investigations39, 40. It is important that 
patients with cancer symptoms are investigated quickly, but symptoms vary according to tumour 
type and location39. Not all cancers have serious, specific, and alarming symptoms; and they may only 
appear when the disease is advanced28. Cancer may also have non-specific, vague symptoms that are 
common for several conditions (serious or not)41, 42. Most people presenting with vague, non-specific 
symptoms will not have cancer. This is also true for patients presenting with alarm symptoms39, 43. 
Primary care professionals only see a few cancer cases in a year among thousands of consultations39, 
44, and need to constantly balance the risks of missing a cancer against referring for unnecessary 
(and sometimes uncomfortable, invasive and harmful) tests, overdiagnosing or overtreating patients. 
Additionally, there is the risk of wasting limited diagnostic resources that other patients need 
urgently (and delay care to them as a consequence).
Evidence-based cancer referral guidelines highlighting alarm symptoms are used to help professionals 
refer for certain cancers, but other resources are also needed. Cancer risk prediction tools such 
as the Risk Assessment Tool (RAT)45, QCancer46, 47 and combinations such as Macmillan Cancer 
Decision Support (CDS)48 are also helpful. Safety netting can help to diagnose patients with vague 
symptoms49, although there are current discussions on what safety netting actually is and how to 
use it well50. Finally, the professionals’ “gut feeling” (something is not right but it is difficult to figure 
out what it is) can also help51-53. 
early detection. Early detection is also 
well described in evidence-based models 
investigating factors associated with delays 
in diagnosis25, 26 and with cancer survival27. 
There is a recognised relationship between 
tumour staging and prognosis28. Cancers 
detected at earlier stages are more likely to 
benefit from treatment and to be cured23. 
Early detection can result in less aggressive 
treatments and reduced treatment costs23. 
Nonetheless, both screening and early 
diagnosis have limitations (Box 2) and 
several other factors can influence early 
detection and cancer survival (Box 3). 
Approaches that explore human behaviour 
and the role of social influencers are useful 
to understand the challenges when trying to 
promote early detection (Box 4).
The role of health system 
characteristics
Resource availability (such as finance, 
equipment and specialist staff) and access 
to care also influence what can be done in 
terms of early detection21, 23. Health system 
characteristics can influence early diagnosis, 
although there is mixed evidence  on which 
factors are most important29.
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Box 3. Other factors influencing cancer survival
• Tumour biology: aggressive tumours are associated with poorer prognosis. Even if a patient 
is diagnosed early, survival will be poor if the tumour is very aggressive and grows too quickly54. 
This has been described as the “waiting time paradox”55. 
• Tumour location: for example, patients with right-sided metastatic colorectal tumours have 
been found to have worse prognosis56 
• Patient characteristics such as co-morbidities (associated with poorer prognosis), general 
health, lifestyle behaviours (e.g. drinking alcohol and sedentarism), and age (as older people 
often have poorer survival)57
• Lead time and length time bias58-60: analyses of survival from diagnosis of cancers detected 
through screening are affected by length and lead time bias58, and it is important that other 
measures (such as mortality rates) are used to measure the benefits of screening59. Overdiagnosis 
is an extreme case of length time bias58, 60. Screening will be more successful if it finds cancers 
that can kill if they are not treated, cancers for which there are good treatments, and cancers 
for which treatment is more likely to work if administered earlier61.
There is mixed evidence on the role of 
gatekeeping referrals to specialists in delays 
to diagnosis29, 70-72, and some evidence of 
health system factors that may influence 
both the patient and the professional’s 
behaviour (such as centralisation of services, 
free movement of patients between different 
providers and access to secondary care)29. 
The importance of providing 
information
As described by the WHO, the population 
needs to be able to access services, and 
to be aware of screening programmes and 
cancer symptoms and signs. Provision of 
information is needed so people can make 
an informed choice about what they wish 
to do, considering both the benefits and 
potential harms of early detection. 
The role of social deprivation
A key factor influencing both cancer 
Box 4. Behaviour and social theories
Theories from Psychology, Social Sciences and Medical Anthropology describe how people perceive 
symptoms and act upon them62; and shed light on barriers and facilitators to help-seeking and fast 
presentation when noticing symptoms30, 63. These theories discuss concepts such as fear64, fatalism65, 
66 and perception of risk67. They also discuss a range of social issues such as power relations, how 
competing responsibilities and concerns about wasting the doctor’s time influence health care 
decisions, the challenges people may face to configurate bodily sensations into symptoms, and to be 
sensitive to these when dealing with multimorbidities and a range of challenging social circumstances 
they face on a daily basis63, 68, 69.
detection and cancer survival is 
socioeconomic deprivation. Evidence from 
several countries and early detection 
models show the role of socioeconomic 
status on cancer outcomes57, 73. In England 
and Wales, cancer survival is worse for 
more deprived groups74. In Scotland, those 
living in the most deprived areas are more 
likely to have poorer access to primary care 
and poorer health outcomes (while also 
having higher levels of multi-morbidity)15. 
Both cancer incidence and overall cancer 
death rates are higher amongst the most 
deprived (although there are variations 
by cancer type)15. Uptake for breast and 
bowel screening is lower amongst the 
most deprived15, and the three main cancer 
types (breast, colorectal and lung) are most 
often diagnosed at advanced stages among 
the most deprived compared to the least 
deprived populations75. 
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2.1  Cancer policies prior to DCE
The Scottish Government has considered 
cancer to be a clinical priority for many 
years91. In 1998, a Scottish Cancer Group 
(SCG) was established to provide “leadership, 
direction, advice and guidance for cancer 
services in Scotland”91. In 2001, the Scottish 
Government published: “Cancer in Scotland: 
Action for Change”. The strategy focused on 
prevention, diagnosis (including screening 
and urgent referrals) and treatment of 
cancer. It also proposed the establishment 
of regional cancer networks to oversee the 
patient journey91. 
2. The DCE Programme
Acknowledging variations in survival and the 
need to improve cancer outcomes, the UK 
and Denmark were pioneers in developing 
strategies to promote early detection. In 
addition to organised screening programmes 
for asymptomatic individuals, urgent referral 
pathways for suspected cancer based on 
alarm symptoms have been implemented25, 
76-79. 
Launched in 2009, the National Awareness 
and Early Diagnosis Initiative (NAEDI)24, 27, 80, 81 
managed and supported a range of activities 
promoting the earlier diagnosis of cancer 
in England. In line with recommendations 
from the WHO and the Cancer Reform 
Strategy in England82, NAEDI also supported 
strategies focusing on cancer awareness 
such as the development and validation 
of a Cancer Awareness Measure (CAM)83, 
84.  Awareness campaigns were further 
developed at regional and national levels by 
Be Clear on Cancer (BCOC) in England and 
Wales85-87. 
More recently, Denmark has developed 
referral pathways for serious, non-specific 
symptoms and “No-Yes-Clinics” for 
common symptoms that may result in a 
cancer being missed42, 88. The approach is 
now being adopted in England through the 
Accelerate, Coordinate, Evaluate (ACE) 
Programme89, 90. 
In Scotland, where there are screening 
programmes for bowel, breast and cervical 
cancers, and urgent referral pathways for 
patients with alarm symptoms, a national, 
multi-levelled early detection initiative (the 
DCE programme) was introduced in 2012. 
DCE is the focus of this Evaluation and will 
be introduced next.
In 2008, “Better Cancer Care: An action 
Plan” was published. It also focused on 
prevention, early diagnosis,  testing  for 
cancer, referral and treatment. A Scottish 
Cancer Taskforce was established to 
oversee the implementation of this plan. 
The strategy supported the roll-out of the 
bowel screening programme and looked at 
ways to encourage participation, promote 
public awareness of cancer symptoms and 
encourage patients to seek help early in 
primary care. A primary care cancer lead 
would be nominated within each territorial 
Health Board in Scotland92. This strategy 
paved the way for the development of the 
DCE Programme.
1.3.3 Strategies to promote early detection
542
Detect Cancer Early Evaluation 13
2.2 DCE: an overview
In March 2011, the Cabinet Secretary 
for Health and Wellbeing in Scotland 
announced that the Scottish Government 
would commit £30 million to a 3-year 
“Detect Cancer Early Initiative”, raising 
cancer awareness and increasing diagnostic 
capacity in order to increase the number of 
patients diagnosed with cancer in its earlier 
stages. The Scottish National Party (SNP) 
Manifesto published in April 2011 reiterated 
the commitment93. 
A draft Implementation Plan was 
circulated to several stakeholders, to all 
territorial Health Boards, different Scottish 
Government departments and cancer 
charities94. Different groups were created 
to coordinate and ensure the management 
of the programme. The already established 
National Cancer Waiting Times Delivery 
Group became the Detect Cancer Early 
Programme Board94. 
DCE wished to be “a fundamental shift in 
how Scottish Government engages with the 
NHS in delivery of a cancer target”, adopting 
a whole systems-level approach instead of 
only focusing on secondary care94. 
DCE was officially launched in February 
2012 by the Cabinet Secretary for Health 
and Wellbeing95. It had four main strategies 
(Figure 2; Appendix 1)94, in addition to 
several projects in collaboration with 
cancer charities, Health Boards and Scottish 
universities (with or without funding from 
DCE). 
DCE’s main aim was to improve overall 
5-year survival for people in Scotland
diagnosed with cancer, but there were
also several programme objectives (Figure
3). The Programme initially focused on
the three main causes of cancer death
in Scotland (lung, breast and colorectal
cancers)94. Although it was supposed to last
three years, DCE has continued after 2015
and remains a key component in the most
recent Scottish Cancer Strategy “Beating
Cancer: Ambition and Action”96. 
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8. To facilitate further 
evaluation of the impact of 
public awareness campaigns 
on the stage of cancer at 
presentation and to 
contribute to research that 
establishes evidence for the 
link between late 
presentation and survival 
deficit
7. To strengthen data collection 
and performance reporting 
within NHSScotland to ensure 
progress continues to be made 
on improving cancer diagnosis, 
treatment, referral, and survival
6. To ensure that imaging, 
diagnostic departments and 
treatment centres are 
prepared for an increase in the 
number of patients with early 
disease requiring treatment
5. To ensure there is sufficient 
capacity in the screening 
programmes to meet the 
expected increase in those 
choosing to take part
4. To work with GPs to 
promote referral or 
investigation at the earliest 
reasonable opportunity for 
patients who may be showing 
a suspicion of cancer whilst 
making the most efficient use 
of NHS resources and 
avoiding adverse impact on 
access
3. To raise the public’s 
awareness of the national 
cancer screening programmes 
and also the early signs and 
symptoms of cancer to 
encourage them to seek help 
earlier
2. To improve informed 
consent and participation in 
national screening programmes 
to help detect cancer earlier 
and improve survival rates
1. To increase the proportion 
of people with Stage 1 disease 
at diagnosis by 25% (as a proxy 
indicator of survival outcome) 
and to use performance 
against a HEAT target as a 
lever for whole systems 
approach to improvement
DCE’s aim:
Improve overall 5-year 
survival for people in 
Scotland diagnosed with 
cancer
Fig 3. DCE aim and objectives according to the Implementation Plan
52. 
1. 
Public awareness & 
behaviour influencing
2. 
Primary care symptom 
management & referral
Social marketing campaigns; public 
relations; field marketing and 
partnership
Professional training; knowledge 
sharing; updating referral guidelines for 
suspected cancer; developing practice 









Distribution of funds to territorial 
Health Boards to be invested in 
diagnostic capacity
HEAT target (25% increase in 
cancers diagnosed at Stage 1); 
sGMS bowel screening initiative;  
CWT targets
*A fifth strategy focusing on screening (Informed Decision Making Around Screening Programme Participation) was added over 
time; and the other four changed names slightly: Public Awareness (1); Primary Care Recognition and Referral Behaviour (2); 
Increasing Diagnostic Capacity (3); and Data, Evaluation and Outcomes (4).  This Report has kept the original strategy names; 
screening outcomes are discussed as part of Strategies 1 and 4.  Abbreviations: HEAT - Health Improvement (H), Efficiency (E),  
Access to treatment (A), and Treatment (T); sGMS - Scottish General Medical Services contract; CWT - Cancer Waiting Times. 
Fig 2. DCE’s four main strategies according to the Implementation plan*
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3.1 Overall aim and theories
3. Methods
This Evaluation aimed to report on DCE 
processes and outcomes in order to learn 
from the programme’s experience and 
provide recommendations for DCE and 
other early detection initiatives (Box 5).
The Evaluation was guided by the Medical 
Research Council’s (MRC) Framework 
for Process Evaluation of Complex 
Interventions97. This Framework describes 
how a process evaluation should 
investigate programme implementation 
(how intervention was delivered, and 
what was done), mechanisms of impact 
(how the intervention generated change) 
and contextual issues (exploring how 
they influenced both implementation and 
outcomes)97. The Framework also describes 
the relationship between these three 
functions and the programme outcomes 
(Figure 4).
The DCE Evaluation was also a theory-based 
evaluation; which is based on the premise 
that all programmes have implicit or explicit 
assumptions on how they are supposed 
to work98. Theory-based evaluation is 
informed by programme theory, which 
is a description of what should be done 
to achieve programme aims, what other 
outcomes can be anticipated, and how these 
aims and outcomes will be generated99. The 
DCE Evaluation assessed both mechanisms 
of impact and implementation. 
This was a mixed-methods100 Evaluation; 
mixed-methods are often required in a 
theory-based evaluation as it includes many 
different elements101. The approach is also 
recommended by the MRC Framework97.
Before the Evaluation was carried out, it 
was necessary to ensure that DCE and its 
programme theory were well described. 
Therefore, the Evaluation had two steps: 
development and full evaluation.
Box 5. Why is this Evaluation needed?
Government-led programmes such as DCE should be evaluated to check if they benefit the 
population, and to ensure transparency and accountability102. Although DCE and collaborators have 
created documents with analyses of different outcomes, not all are easily available, and no system-
level evaluation of the programme had been carried out. 
Importantly, an evaluation that only describes outcomes gives limited information. Analysis of cancer 
survival needs a long timeframe103; DCE was a national programme as opposed to a scientific 
experiment and there are several limitations in demonstrating causality. Conversely, an evaluation 
checking if the programme was implemented well, was acceptable and appropriate to stakeholders, 
and had positive outcomes97 for professionals, patients and the public is much more informative - it 
shows how a programme worked and sheds light on why it worked. This type of evaluation can also 
describe unanticipated benefits (or harms) that would otherwise have been missed. Therefore, we 
have designed an evaluation of both DCE processes and outcomes.
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3.2 Evaluation development
Evaluation development consisted of 
analysis of policy documents;  key informant 
interviews with DCE stakeholders; and 
literature reviews on the burden of cancer, 
evaluation and implementation theories.
The analysis of policy documents aimed to: 
1) better understand DCE; 2) inform the
development of a logic model (i.e. a graphical
representation of DCE’s programme
theory); and 3) identify several assumptions
regarding implementation; and mechanisms
of impact. Furthermore, documents
facilitated the identification of stakeholders
for interviews. 
Documents were read and summarised, 
with emerging issues to aid evaluation design 
added to the summaries. A list of DCE 
stakeholders was prepared. Guidance was 
followed to draft DCE’s logic model101, 104,
105, assumptions and mechanisms106-108. One 
hundred and fifty-nine policy documents 
were analysed from October 2015 to 
November 2017. These comprised minutes 
and agendas from the DCE Programme 
Board and Operational Subgroup meetings, 
official reports on DCE outcomes from 
ISD Scotland, newsletters, posters, leaflets, 
press releases, social marketing reports and 
evaluations of social marketing campaigns.
The interviews aimed to: 1) improve 
understanding of DCE; 2) ensure 
stakeholder views were included in the 
Evaluation; 3) refine the logic model, 
assumptions and mechanisms; and 4) 
inform on additional theories to guide 
the Evaluation97, 106. Stakeholders who had 
been directly involved in the development 
Description of 
intervention and its 
causal assumptions
•Underpinning theories, 
models and frameworks: 
logic model, programme 
theory, BCW, complex and 
complicated interventions
•Methods: documentary 
analysis and semi-structured 
interviews
Context
•Underpinning theories: complex systems and theory-based evaluation
•Methods: documentary analysis, semi-structured interviews and online questionnaire
Mechanisms of impact
•Underpinning theories: 
implementation outcomes from the 
literature and theory-based evaluation
•Methods: documentary analysis, 
semi-structured interviews and 
online questionnaire
Implementation
•Underpinning theories and 
models: theory-based evaluation 
and COM-B
•Methods: documentary analysis, 





complex and complicated 
interventions, complex systems
•Methods: documentary 
analysis and time trends 
analyses of bowel screening 
outcomes
(Unanticipated outcomes are 
explored in the process 
evaluation)
Fig 4. The DCE evaluation according to the MRC Framework97
Abbreviations: BCW: Behaviour Change Wheel; COM-B: Capability, Opportunity, Motivation and Behav-
iour
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or in the running of the DCE programme 
were interviewed. Purposive sampling was 
used to include professionals with clinical, 
strategic or supportive backgrounds from 
different regions in Scotland. Nine potential 
participants from the list of stakeholders 
were invited by email to an interview (face-
to-face or over the telephone); all agreed to 
take part. Interviews took place between 
April and August 2016. Participants were 
asked about DCE development; its rationale 
and aims; and evaluation challenges. They 
received the logic model before the 
interview and were asked for their views on 
how well DCE was described.
The framework approach109 was adopted 
for data analysis; the software NVivo 10110 
was used to facilitate this. Key themes from 
the interviews are available (Appendix 2).
Evaluation development resulted in a refined 
logic model describing DCE components 
(Figure 5), a new diagram representing 
DCE’s programme theory and describing 
assumptions about the programme and 
potential mechanisms of impact (Appendix 
3) and evidence that informed the choice of 
theories and helped to prioritise issues to 
be investigated.  With this information, the 
full DCE Evaluation was designed.
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3.3 The DCE Evaluation
The DCE Evaluation aimed to understand 
what worked and what did not work in the 
DCE programme in terms of processes and 
outcomes (and why this was the case) in 
order to provide recommendations.   The 
Evaluation research questions are described 
below (Figure 6).
The outcome evaluation focused on official 
DCE objectives. The process evaluation 
assessed whether assumptions and 
mechanisms were confirmed by stakeholders, 
3.3.1 Evaluation aims
examined barriers and facilitators and 
unanticipated outcomes. 
Implementation outcomes from the 
literature were used to operationalise 
assumptions about implementation, while 
concepts from the COM-B (Capability, 
Opportunity, Motivation and Behaviour) 
model and the Theoretical Domains 
Framework (TDF)111, 112 were used for 
mechanisms (further information is available 
in Appendix 4). Four assumptions and four 
mechanisms were investigated. (Figure 7).
Fig 7. Investigated assumptions and mechanisms
Assumptions
Mechanisms
1. Different stakeholders 
bought into DCE, its 
components and what it 
proposed to do
1. DCE strategies were in line 
with what professionals 
perceived as their role, identity, 
organisational commitment 
and professional boundaries
2.  Additional DCE funding 
resulted in increased 
physical opportunity (i.e. 
more equipment, 
workforce, etc.)
3. Increased demand 
brought by DCE was a 
driver for action and 
created pressure to act
2. There was enough 
targeting and communication 
about DCE aims and its 
strategies, and what was 
expected from everyone
3. Available resources (equipment, 
workforce, general practices, 
hospitals, laboratories, diagnostic 
and screening centres, etc.) were 
sufficient to meet aims
4. Flexibility was 
permitted when 
allocating resources
4. Targets helped to 
focus the mind, showed 
where resources were 
needed and increased 
pressure to act
2. Are assumptions confirmed by stakeholders?
Process
3. Are mechanisms confirmed by stakeholders?
4. What are the barriers and facilitators to processes and outcomes?
5. Were there any unanticipated outcomes?Unanticipated outcomes
Outcomes
1. Which DCE objectives were met, and for whom?DCE outcomes
Contextual barriers and facilitators
Mechanisms of impact
Implementation assumptions
Fig 6. Evaluation questions
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3.3.2 Outcome evaluation
DCE aimed to improve overall 5-year 
survival, but there was no specific survival 
measurement. Instead, the HEAT target 
was developed (25% increase in cancers 
diagnosed at Stage 1) and adopted as a 
proxy measure. 
The Evaluation focused on the eight 
objectives from the DCE implementation 
plan (described in Figure 2). Outcome data 
(such as staging, screening participation 
and potential impact on workload) were 
synthesised from policy documents and 
other reports published by Information 
Services Division (ISD) Scotland, and the 
Screening Programmes (Bowel and Breast).
Data on requested replacement bowel 
screening test kits were provided by 
the Scottish Bowel Screening Centre in 
Dundee.  “Colorectal cancer” and “bowel 
cancer” are used interchangeably in the 
Report as both terms were used by data 
sources.
TNS (a Market Research Company)  has 
carried out before-and-after evaluations of 
all DCE campaigns and investigated changes 
in attitudes regarding cancer after DCE’s 
first three years. Key results from these 
evaluations are summarised in this Report. 
Carat, Consolidated PR and Leith Agency 
also evaluated the impact of campaigns 
using a range of metrics (such as number 
of engagement events and presence in the 
media). These results are also summarised.
When data allowed, charts and tables 
were developed to show trends over 
time. Likewise, descriptive statistics (N(%) 
and percentage changes over time) were 
calculated and reported whenever possible. 
Percentage change refers to the difference 
between two numbers being compared (i.e. 
number at year of interest and number at 
baseline), divided by the number at baseline 
and multiplied by 100. Negative numbers 
refer to percentage decrease.  
Only a few charts show data at territorial 
Health Board level; this is to avoid unfair 
comparisons due to wide variations 
in population size and characteristics, 
performance at baseline, screening 
uptake, cancer incidence and other issues. 
Tables showing numbers, percentages and 
percentage change by territorial Health 
Board are available as appendices for 
information, but comparisons should be 
made with caution.
Even though this Evaluation is investigating 
outcomes up to 2015 (Year 3 of DCE); 
data is shown for Years 4-6 to  generate 
discussions regarding DCE’s next steps and 
sustainability.
There were no quantitative outcomes (or 
limited information available) for many DCE 
objectives. Hence, the outcome evaluation 
used descriptive tables and boxes in order 
to report on all types of relevant outcome 
data. Furthermore, the process evaluation 
also sheds light on whether objectives were 
met (and why). 
Appendix 5 describes how each official 
DCE objective was assessed in the outcome 
evaluation.
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questionnaire. The questionnaire is available 
in Appendix 7.
No similar studies were identified to aid 
sample size and power calculations for 
the questionnaire.  Possible impact of non-
response and under-/over-representation 
of stakeholders is approached in the 
Discussion. 
Invitation emails with an anonymised link 
to the survey were sent by the Scottish 
Cancer Networks (SCAN, NOSCAN and 
WOSCAN), the Scottish Cancer Coalition 
and the Scottish Primary Care Cancer 
Group to everyone in their mailing lists. 
One reminder was sent 15 days after the 
initial invitation and the online survey was 
active for two months.
Responses to the questionnaire were 
downloaded from Online Surveys and 
analysed in SPSS v.22.  Variables were 
recoded as needed (e.g. reverse scores, 
questions that allowed for multiple answers, 
and questions which allowed for “other” 
issues to be mentioned).  
Descriptive statistics (N, %, means,  standard 
deviations, medians and interquartile ranges) 
were used to report on stakeholders’ 
characteristics and views about the 
programme. Inferential statistics were used 
to investigate variations in views across 
different groups. Most of the questionnaire 
items were rating scales.  Non-parametric 
tests were used to investigate differences 
in distributions on ratings between two 
groups (Mann Whitney U test) and more 
than two groups (Kruskal-Wallis H test 
with adjusted p-value after pairwise 
comparisons and Bonferroni correction). 
Chi-squared tests (or Fisher’s Exact test 
when counts were less than five) were used 
to check for differences in proportions 
when questions generated categorical data. 
Content analysis was used for open-ended 
questions. 
The process evaluation had two 
components: qualitative interviews and 
a purpose-built, mixed-methods online 
questionnaire. Participant eligibility criteria 
were the same for both components: 
stakeholders who were involved in and/
or were influenced by DCE from the years 
2011-2015 (corresponding to one year 
prior to programme launch and the first 
three years of programme implementation). 
These included any professionals working in 
primary and secondary care; professionals 
managing health care services and DCE 
strategies; providers of Health Intelligence 
(national statistics) data; and staff from 
charities, creative agencies and market 
research companies who were DCE 
partners.
Interviews
A topic guide was developed for different 
stakeholder groups, with common questions 
to allow for data analysis (example in 
Appendix 6). Purposive and snowball 
sampling were used to prepare a list of 
eligible stakeholders113. During evaluation 
development, stakeholders suggested 
names for the full evaluation. The list was 
complemented by names mentioned in 
policy documents. 
Stakeholders were contacted about the 
study by email; interviews were either 
face-to-face or over the telephone. The 
framework approach was used to analyse 
data114, 115. 
Questionnaire
Questionnaire development was informed 
by publications adopting the same 
frameworks 111, 116-122, and implementation 
outcomes111, 123. It was designed to take 15-
20 minutes to be completed. Pre-testing 
was carried out by four professionals (two 
GPs, one oncologist working in secondary 
care, and a senior manager in a cancer 
charity). Online Surveys (former Bristol 
Online Survey (BOS) Tool ©) (https://
www.onlinesurveys.ac.uk/) hosted the 
3.3.3 Process evaluation
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3.4 How results are 
organised
Instead of focusing on academic research 
questions and theories guiding the 
Evaluation, this Report focuses on policy- 
relevant findings.
First, we present available evidence for 
DCE official objectives. Objectives 2 and 
3 are addressed together as it was not 
possible to separate outcomes for them. 
This is followed by reporting on the key 
themes and findings from the process 
evaluation.  The terms “stakeholders” and 
“participants” are used interchangeably 
when reporting findings. Job role 
and territorial Health Board are only 
mentioned for questionnaire participants; 
this is to avoid indirect identification of 
interview participants and to comply with 
their dissemination choices (specified in 
their consent forms).
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4. Results
Objective 1: Increase the proportion of breast, colorectal and lung cancers diagnosed 
at Stage I by 25% and to use performance as a lever for whole systems improvement 
According to the most up-to-date trends 
published by ISD Scotland124, there was 
a 7.0% increase in cancers diagnosed at 
Stage I (breast, colorectal and lung cancers 
combined) by the end of DCE’s third year 
(Year 3).There were wide variations across 
tumour types (Figure 8), deprivation levels 
(Figure 9) and territorial Health Boards 
(Appendix 8)124. By Year 3, there was a 5.1% 
increase in breast cancers diagnosed at 
Stage 1, while there was a 25.0% increase 
for  lung cancers, and a 4.3% decrease for 
colorectal cancers (Figure 8).
There were increases in the proportion 
of Stage I cancers across all different 
levels of deprivation (1 most deprived – 5 
least deprived); for all three tumour types 
combined, for breast cancer and lung 
cancer. On the other hand, there was a 
decrease in the proportion of colorectal 
cases diagnosed at Stage 1 across all five 
deprivation levels. The most deprived 
groups showed the highest percentage 
increase in Year 3 (11.6%) for breast, 
colorectal and lung cancers combined124 
(Figure 9).
Increases in the proportion of breast, bowel 
and lung cancers combined happened 
for all three regional Cancer Networks. 
SCAN showed the highest % increase in 
Year 3 compared to baseline (11.8%), while 
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Fig 8. Stage I cancers (Baseline - Year 6) and % increase over time
Created with data from: ISD Scotland. Detect Cancer Early - Year 6 Staging Data. Available from: http://www.isdscot-









Cancer type N(%) at Stage 1 and % change Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 
3 cancers 
combined 
N (%) at Stage 1 5581 (23.3) 5946 (24.2) 6074 (24.6) 6198 (25.0) 6272 (25.3) 6207 (25.4) 6129 (25.3) 
% change  3.6% 5.3% 7.0% 8.3% 9.1% 8.4% 
Breast N (%) at Stage 1 3184 (38.7) 3341 (39.5) 3378 (39.5) 3477 (40.7) 3538 (41.2) 3530 (41.0) 3502 (40.9) 
% change  1.8% 2.0% 5.1% 6.3% 5.9% 5.4% 
Colorectal 
N (%) at Stage 1 1261 (17.8) 1257 (17.9) 1213 (17.8) 1136 (17.1) 1021 (15.4) 996 (15.1) 1040 (15.9) 
% change  0.3% 0.0% -4.3% -13.8% -15.4% -11.0% 
Lung 
N (%) at Stage 1 1136 (13.2) 1348 (14.8) 1483 (15.8) 1585 (16.4) 1713 (17.9) 1681 (18.3) 1587 (17.4) 
% change  12.4% 20.4% 25.0% 35.8% 39.0% 32.4% 
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Fig 9.  Percentage increase in Stage 1 cancers (Baseline - Year 6) across 
deprivation levels (breast, colorectal and lung combined)
Deprivation 
level 
N(%) at Stage 1 
and % change Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 
Level 1 = 
most deprived 
N (%) at Stage 1 1128 (20.2) 1205 (21.1) 1269 (22.0) 1304 (22.6) 1344 (23.4) 1307 (23.7) 1203 (22.6) 
% change 4.2% 8.8% 11.6% 15.4% 17.3% 11.8% 
Level 2 N (%) at Stage 1 1144 (21.7) 1261 (23.2) 1214 (22.6) 1209 (22.5) 1236 (23.5) 1243 (23.7) 1244 (23.6) 
% change 7.3% 4.3% 3.9% 8.5% 9.5% 8.8% 
Level 3 
N (%) at Stage 1 1132 (24.2) 1162 (24.3) 1198 (24.9) 1231 (25.3) 1217 (24.7) 1237 (25.4) 1229 (25.7) 
% change 0.3% 3.0% 4.7% 1.9% 5.1% 6.3% 
Level 4 
N (%) at Stage 1 1114 (25.4) 1199 (26.1) 1208 (26.4) 1262 (27.3) 1223 (26.6) 1202 (26.7) 1232 (27.2) 
% change 2.9% 4.0% 7.6% 5.0% 5.5% 7.2% 
Level 5 = least 
deprived 
N (%) at Stage 1 1049 (26.7) 1111 (27.4) 1172 (28.2) 1180 (28.3) 1247 (29.3) 1212 (28.4) 1206 (28.1) 
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Created with data from: ISD Scotland. Detect Cancer Early - Year 6 Staging Data. Available from: http://www.isdscotland.org/
Health-Topics/Cancer/Publications/data-tables2017.asp?id=2206#2206: ISD Scotland; 2018.
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N(%) at Stage 1 
and % change Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 
NOSCAN 
N (%) at Stage 1 1328 (22.7) 1344 (22.8) 1399 (23.4) 1393 (23.4) 1389 (22.9) 1478 (23.6) 1461 (23.9) 
% change   0.8%  3.5%  3.4%  1.1%  4.3%  5.4% 
SCAN 
N (%) at Stage 1 1557 (23.6) 1670 (24.7) 1675 (25.1) 1775 (26.4) 1831 (27.3) 1727 (26.8) 1711 (26.2) 
% change   4.5%  6.5% 11.8% 15.7% 13.4% 11.1% 
WOSCAN 
N (%) at Stage 1 2696 (23.5) 2932 (24.5) 3000 (24.8) 3030 (24.9) 3052 (25.3) 3002 (25.7) 2957 (25.5) 
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WOSCAN
% cancers diagnosed at Stage I % increase compared to baseline
Created with data from: ISD Scotland. Detect Cancer Early - Year 6 Staging Data. Available from: http://www.isdscotland.org/
Health-Topics/Cancer/Publications/data-tables2017.asp?id=2206#2206: ISD Scotland; 2018.
Fig 10. Percentage increase in Stage 1 cancers (Baseline - Year 6) across 
Cancer Networks (breast, colorectal and lung combined)
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 Objective 2: To improve informed consent and participation in national cancer 
screening programmes to help detect cancer earlier and improve survival rates 
Objective 3: To raise the public’s awareness of the national cancer screening 
programmes and also the early signs and symptoms of cancer to encourage them 
to seek help earlier
There was no available evidence on whether 
informed consent has improved, although 
the programme expected that this would 
be helped by the Public Awareness and 
Behaviour Influencing Strategy.
DCE had campaigns aiming to reduce cancer 
fear and encourage the public to seek help 
when noticing symptoms (e.g. priming 
campaign).  Campaigns also targeted bowel 
and breast screening participation, and 
breast and lung cancer symptoms and signs. 
Further information about the campaigns, 
Priming campaign
The TNS evaluation investigated reach; 
communication of the key campaign 
messages; and motivation with regards to 
the early detection of cancer before and 
after the priming campaign. Other priming 
activities were evaluated by using metrics 
such as engagement with the public, and 
distribution of campaign materials. Key 
findings are described in Box 6.
their key messages and timelines is available 
in Appendix 1.
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Box 6. Key results from the priming campaign
TNS evaluation
• There was no change in the level of spontaneous awareness about getting checked early after 
the campaign, although there were high levels of prompted recognition, especially among women, 
those who had carried out a self-examination in the past three months and those aged 55-74
• One third of the participants who had seen the TV advert described its aspects. Prompted 
recognition of the TV advert was at least 70% across all groups, except for those aged 75+. 85% 
of participants recognised at least one type of advertising
• While the message about getting checked was communicated well (81% saw this as the 
main message), the message “don’t get scared” was seen as the main message only by 15% 
of participants. Seeing more than one type of media was associated with being more likely to 
pick up on the “don’t get scared” message. Women were significantly more likely than men to 
mention “get checked” (84% vs 77%)
• Very high levels of being both motivated and involved were recorded among C1C2DE* adults 
aged 40+ (72%) and all participants who recognised the campaign (77%)
• 64% motivation was recorded among participants who saw/heard at least one advert, and 87% 
for those who saw/heard more than one advert. There were higher levels of motivation among 
women, those aged 40-54 and those who regularly self-examine
• 72% of participants agreed that the adverts increased their interest in getting checked early
• Those aware of the campaign were more likely to agree that more people are surviving cancer 
and early detection increases chances or survival, but also more likely to worry about seeing a 
doctor (i.e. feeling silly about it or worrying about wasting the doctor’s time)
• Those aware of the campaign were more likely to have increased confidence in approaching 
their GP (51% versus 35% for those who were not aware)
• Over half of the participants (55%) who saw the advert stated that it would make them get 
checked earlier if they had signs and symptoms; the lowest proportion was for those aged 75+ 
(43%)
Field and Partnership, Business to Business (B2B) and Public Relations (PR) Activities
• Early Cancer Detection Roadshow: In 70 days, there were 24,917 topline engagements (contact 
lasting up to a minute) and 2,918 in-depth engagements (lasting 1-5 minutes)
• B2B activity & results: In 35 days, 1176 local businesses were visited. Partners were large 
employers, local newsagents, local leisure and entertainment providers, relevant charities 
and places of worship (examples include Belhaven Brewery, Gala Bingo, M&CO., Caledonian 
MacBraybe, STV, and the Edinburgh Woollen Mill). 
• Media Relations: campaign launch, case studies and creative, support media for roadshows 
resulted in over 50 pieces of coverage. Securing the backing of over 10 different celebrities 
resulted in 34 pieces of coverage
* According to TNS, C1C2DE consists of six social grades based on the current or previous occupation of the chief income 
earner in a household. ABC1 includes professional, managerial and non-manual occupations, while C2DE includes manual and 
unskilled occupations and the long-term unemployed. Sources: Policy documents received during evaluation development. 
These included communications from the DCE team sent to stakeholders and an evaluation presentation prepared by TNS 
(“Detect Cancer Early Campaign Evaluation Presentation of Results 29th May 2012”)
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Box 7. Key results from the symptomatic breast campaign
TNS evaluation
• Before-and-after campaign evaluation showed that 88% of DE women recognised some aspect 
of the campaign, and 49% of them could spontaneously mention the key message  “check 
yourself/be aware of changes”
• Spontaneous awareness of symptoms described in the campaign doubled after the campaign; 
women who had seen the advert were about three times more likely to spontaneously refer to 
a symptom compared to women who had not seen it
• 82% of those who recognised the campaign were motivated by it
• There was significant stronger disagreement with the statement  “I worry about feeling silly if I 
go to my doctor with small changes to my body, thinking they could be cancer”
• There was significantly less confusion about spotting signs and awareness of what to recognise
• Half of women who recognised the campaign reported to having taken action as a result of it 
(such as checking their breasts)
Field and Partnership, B2B an PR activities
• There was broad and persistent media coverage in newspapers such as the Dundee Evening 
Telegraph, the Aberdeen Evening Express, Glasgow Evening Times, Edinburgh Evening News, the 
Daily Record, the Scottish Sun, and Sunday Mail
• 55 days of roadshows (in high footfall areas such as shopping centres and supermarkets) resulted 
in 25,365 topline and 9,015 in-depth engagements with the public. There were 1,411 interactions 
on an iPad presentation that allowed people to explore signs and symptoms privately; 1,563 
interactions with symptom cards; and 97 pictures taken for Facebook
• 16,615 leaflets were given out during roadshows, 181 Posters and 181 Vinyl stickers were 
placed at the roadshow locations
• During 63 days of activity, 1,884 local businesses were visited, with 1,653 A3 posters, 1,423 vinyl 
stickers, and 44,840 leaflets sited 
• 1,700 partners signed up to campaign and received campaign materials; partners included local 
authorities, large employers, retailers, local newsagents, housing associations and entertainment 
providers (examples: Tunnock’s, Vion Food Group, Robert Wiseman Dairies, TKMaxx,  Sodexo, 
Semichem, Mecca Bingo, M&Co. and ASDA)
Breast cancer
Data from social marketing campaigns, 
about consultations for breast symptoms 
and about breast screening are relevant 
to address Objectives 2 and 3. These are 
discussed separately. 
Social marketing campaigns
Social marketing campaigns focused initially 
on breast cancer symptoms and signs, and 
then on breast screening. Key results from 
both campaigns are described in Boxes 7 
and 8. 
Sources: Policy documents received during evaluation development. These included a case study document with campaign 
outcomes prepared by the DCE team and sent to stakeholders, and an evaluation report prepared by Made in Leith, Carat and 
Consolidated PR (“Detect Cancer Early campaign wash-up. Priming, Breast Cancer, Bowel Cancer, June 2013”)
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Box 8. Key results from the breast screening campaign
TNS evaluation
• Women who recognised the campaign (i.e. recognisers) showed higher levels of awareness and 
understanding of breast screening compared to women who did not recognise the campaign 
(i.e. non-recognisers). The percentage of recognition was lower for older age groups, higher for 
the target group, higher for the West of Scotland, and the lowest for the never attended and 
never invited to screening
• 34% of recognisers strongly agreed with the statement “I don’t think breast screening carries 
any risks”, compared to 21% of non-recognisers
• There was high agreement across all groups that breast screening is the best way to detect 
cancer early (a bit lower for those who never attended screening and non-recognisers), and 
that breast screening saves lives
• Over half (54%) of recognisers agreed that “breast screening can find cancers that you couldn’t 
see or feel yourself” (compared to 38% of non-recognisers)
• Almost half (49%) of recognisers agreed that “breast screening can find cancers that your GP 
couldn’t see or feel” (compared to 33% of non-recognisers)
• Over two thirds of recognisers (68%) disagreed with the statement that “if you’ve missed a 
breast screening in the past two  years, you need to wait until you are next invited” (compared 
to 51% of non-recognisers)
• 82% of those recognising the campaign disagreed that “you don’t need to check your breasts 
yourself in between screenings” (compared to 69% of non-recognisers) 
• 22% of the never attended group heard the breast screening radio advert; this was the lowest 
among the different types of screening history. Nonetheless, the highest percentage was 41%
• Regarding the newspaper adverts, the lowest percentage of recognition was amongst the never 
invited (34%), followed by the never attended (44%). Newspaper recognition was higher than 
for radio. Recognition was similar for all age groups, although it decreased with age
Field and Partnership, B2B an PR activities
• Over 500 breast screening resources were downloaded from the DCE website
• There were over 37 pieces of breast screening media coverage, the Elaine C Smith’s Video was 
seen over 2,200 times
• There were over 25 field events and 50,000 keychains (thingymaboob) distributed
• DCE website had over 5,000 hits during the campaign period
Consultations for breast symptoms
ISD Scotland and policy documents show 
that during the symptomatic breast campaign 
there was an increase of 50% in women 
seeing the GP with breast symptoms (Figure 
11)125.
Sources: Policy documents received during evaluation development. These included a case study document with campaign 
outcomes prepared by the DCE team and sent to stakeholders, and an evaluation report prepared by TNS (“Breast Cancer 
Screening October ‘14(All women 50+) Data Tabulations. Date: 11th November 2014”)
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Fig 11.  Consultations for breast symptoms 
Reproduced from: ISD Scotland. GP consultations for breast symptoms  September to November 
2012 Publication date – 26 March 2013 https://isdscotland.scot.nhs.uk/Health-Topics/General-Practice/
Publications/2013-03-26/2013-03-26-GP-Breast-Symptoms-Summary.pdf?44254702330
Estimated number of women consulting a GP with breast symptoms including lumps, pain and infection 
Quarter Estimate 
95% confidence interval 
Lower Upper 
Jun - Aug 2011 12,000 10,600 13,400 
Sep - Nov 2011 13,900 12,300 15,500 
Dec 2011 - Feb 2012 12,000 10,500 13,400 
Mar - May 2012 15,800 13,600 17,900 
Jun - Aug 2012 13,800 12,200 15,400 
Sep - Nov 2012 21,000 18,300 23,700 
 
Estimated number of GP consultations for breast symptoms including lumps, pain and infection 
Consultations for breast 
symptoms (females) 
All consultations 
(males and females) 







Lower Upper (millions) Lower Upper 
2011 Jun 5,550 4,640 6,460 1.35 1.28 1.42 0.41 
Jul 3,950 3,100 4,790 1.22 1.15 1.28 0.32 
Aug 4,960 3,890 6,040 1.39 1.32 1.46 0.36 
Sep 4,930 4,060 5,800 1.37 1.30 1.43 0.36 
Oct 5,050 4,080 6,010 1.45 1.37 1.54 0.35 
Nov 5,600 4,620 6,580 1.47 1.38 1.56 0.38 
Dec 3,830 2,980 4,680 1.28 1.22 1.35 0.30 
2012 Jan 5,270 4,470 6,070 1.44 1.37 1.51 0.37 
Feb 4,650 3,870 5,430 1.42 1.35 1.50 0.33 
Mar 5,540 4,570 6,500 1.53 1.45 1.61 0.36 
Apr 5,550 4,750 6,350 1.39 1.31 1.46 0.40 
May 6,940 5,540 8,330 1.54 1.45 1.64 0.45 
Jun 4,440 3,580 5,300 1.34 1.25 1.43 0.33 
Jul 6,270 5,150 7,380 1.42 1.33 1.51 0.44 
Aug 5,220 4,400 6,040 1.48 1.39 1.57 0.35 
Sep 7,310 5,910 8,700 1.32 1.24 1.40 0.55 
Oct 9,130 7,520 10,740 1.63 1.51 1.74 0.56 
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Fig 12.  Breast screening uptake and appointments 
(routine, early recall and self/GP referrals)
 
 
 2010-11 (proxy baseline) 2011-12 2012-13 2013-14 2014-15 2015-16 
Routine appointments       
Number screened 170,664 167,486 164,472 172,929 158,405 154,641 
% change from baseline - -1.9% -3.6% +1.3% -7.2% -9.4% 
Early Recall       
Number screened 27 26 22 17 5 12 
% change from baseline - -3.7% -18.5% -37.0% -81.5% -55.6% 
Self / GP Referral       
Number screened 11,195 12,151 10,439 11,972 13,311 11,251 










2005-08 2006-09 2007-10 2008-11 2009-12 2010-13 2011-14 2012-15 2013-16






2010-11 2011-12 2012-13 2013-14 2014-15 2015-16
N screened
(all ages, routine and non-routine 2010-2011 to 2015-2016)
Routine appointments Early recall Self/GP referral
Created with data from: 1) ISD Scotland. Scottish Breast Screening Programme Statistics 2015-16. Uptake by NHS Board of 
Residence: Scotland, 1st April 2006 to 31st March 2016. 2) ISD Scotland. Scottish Breast Screening Programme Statistics 2015-
16. Attendance by appointment type: Scotland, 1st April 2006 to 31st March 2016. Both files are available from: http://www.
isdscotland.org/Health-Topics/Cancer/Publications/data-tables2017.asp?id=2206#2206
(data provided for every two years), and 
defining 2010-2011 as a baseline period, 
trends in screening do not follow a linear 
pattern (there are both % increases and % 
decreases up to 2015-2016 for all types of 
appointments). There were increases in self/
GP referrals in 2011-2012, 2013-2014 and 
2014-2015 compared to baseline127 (Figure 
12). The symptomatic breast campaign took 
place in 2012; it is not possible to estimate 
the extent to which it has contributed to 
these increases.
Breast screening appointments and referrals
The Breast Screening Centre reports on 
both routine (screening invitations every 
three years to all eligible asymptomatic 
women) and non-routine (recall, self-
referral and GP referral) appointments. 
Routine breast screening uptake has been 
slowly declining for over a decade126 (Figure 
12), and there was no noticeable increase 
in breast screening uptake during the DCE 
campaigns. 
When considering both routine and non-
routine breast screening appointments 
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Data was also collected on how many women 
texted the Breast Screening Programme as 
a result of the breast screening campaign128.
In the first phase of the campaign, 372 
women left text messages and were sent 
the telephone number of their regional 
Breast Screening Centre. However, these 
text messages did not translate into many 
booked/rescheduled appointments at the 
Breast Screening Centres128. 
In the second phase of the campaign, 500 
women left text messages and were called 
back by the Screening Centres so an 
appointment could be booked. However, 
several women did not answer the call and 
there were some IT issues when trying to 
record data in the South East. Furthermore, 
women who left text messages were often 
not the target population (deprived women 
eligible for screening)128. 
In terms of calls to the Breast Screening 
Programme, one in ten women who 
called stated that they were prompted by 
DCE (94 out of 932). More than a third 
of them (n=35) called to change or cancel 
an appointment, 41 were not eligible for 
screening, 11 had general enquiries and 7 
declined an appointment128.
Colorectal cancer
Colorectal cancer was targeted both 
through social marketing campaigns and 
the bowel screening initiative. We report 
on evaluations of the social marketing 
campaigns, trends in bowel screening 
uptake and in requested replacement bowel 
screening kits.
Note about the bowel screening initiative
There is limited quantitative information 
on the outcomes for the bowel screening 
initiative.  A total of 857 practices took part 
(84%), with most of them being rewarded 
to a certain extent for decreasing bowel 
screening non-participation (personal 
communication, DCE Programme Board). 
No policy documents with further 
information were available. 
Social marketing campaigns
Social marketing campaigns focused on 
bowel screening. Key results from six phases 
of the bowel campaign are available in Box 9. 
Campaigns continued after DCE’s first three 
years (data not shown).
Bowel screening
Differently from breast cancer, bowel 
cancer screening uptake has been slowly, 
but steadily increasing over time. This trend 
has continued during DCE’s first three years 
(Figure 13). Screening uptake increased for 
both males and females, with a higher % 
increase among males129. Uptake remains 
lower in more deprived areas, although 
there have been improvements over time 
(Figure 13).
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Box 9. Key results from the bowel screening campaign
TNS evaluation
• Spontaneous awareness of campaigns remained high (68%) after six phases, but there was a 
significant decline over time (especially among men, those aged 45-64 and C2s)
• Increase in prompted campaign recognition was recorded amongst all groups, with significant 
increases for females and 65-74s. There was a very high level of TV recognition (minimum of 
75%) for all groups. However, there was lower recognition of new radio advert, especially 
among males and DEs. Campaign recognition declined significantly with age
• There was increase in spontaneous awareness of the main message “do the test”, but there 
were no changes for messages about survival/cure, which resonated more with those aged 45-
54. Females were significantly more likely to mention “do the test” than males
• Decline in motivation noticed in evaluations of previous campaign phases continued in most 
groups, with the exception of 65-74s and C1C2s. There was also continued fall in the proportion 
wanting to see or hear the advert again. These issues highlighted potential campaign wear out
• There was slight weakening of agreement with the statements “the best way to detect bowel 
cancer early is to do the home screening kit”; “when detected early, most people survive bowel 
cancer”;  and “as I get older, my risk of getting bowel cancer increases”. On the other hand, 
there was continued strong agreement with the statements: “you could have bowel cancer and 
not even know it, as the early stages often have no symptoms”;  and “if bowel cancer is detected 
early it can often be cured”
• Campaign recognisers continue to exhibit more positive views about screening compared to 
non-recognisers 
• There was a slight decline in those claiming that they had returned the test kit (especially among 
men , C1s and those aged 55-64) although there was an increase in those claiming that they 
had received the kit at home. There was also a slight decrease in the likelihood of doing the test 
next time. Similar to previous evaluations, the most common reason for doing the test was that 
“it is the best way to find bower cancer early”
Field and Partnership, B2B an PR activities
• During the first three phases, the DCE page received 5,379 visits, while the bowel screening 
page received 8,385 visits. Increase in traffic was observed around campaign times.
• As of February 2015, the “poo song” had almost 96,151 views on YouTube; a “how to do the 
bowel cancer test” film had 3,629 views 
• PR activity resulted on at least 274 pieces of media coverage
• Scottish football clubs and celebrities supported the campaigns; and about 20,500 in-depth 
engagements took place
Sources: Policy documents received during evaluation development. These included a case study document with campaign 
outcomes prepared by the DCE team and sent to stakeholders, and an evaluation report prepared by TNS (“Bowel 
Cancer Campaign Evaluation / Tracking December 2014”). The “poo song” is still available at: https://www.youtube.com/
watch?v=UrwA_p8H6WY
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Bowel screening uptake overall, for males and females
males females all persons









Level 1 - most deprived
all persons uptake males uptake females uptake










all persons uptake males uptake females uptake










all persons uptake males uptake females uptake










all persons uptake males uptake females uptake









Level 5 - least deprived
all persons uptake males uptake females uptake
all persons % change males % change females % change
Source: ISD Scotland. Scottish Bowel Screening Programme. Key Performance Indicators Report: May 2018 data submission. 
Invitations between 1st November 2015 and 31st October 2017. Available from: https://www.isdscotland.org/Health-Topics/
Cancer/Publications/2018-08-07/2018-08-07-Bowel-Screening-Publication-Report.pdf: ISD Scotland; 2018.
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Requested replacement bowel screening kits
Annual reports from the Scottish Bowel 
Screening Centre indicated an increase 
in requests for replacement kits (and 
consequent increase in calls to the screening 
centre in Dundee, and in laboratory 
activity)130,131.  The section in this Evaluation 
Report describing outcomes for Objective 
5 has further information regarding impact 
on workload.
During the first 12 months of DCE, there 
was often a decrease in monthly requests 
for bowel replacement test kits compared 
to the same month in the previous year 
(2011 used as proxy baseline). This changed 
in DCE’s second year when social marketing 
campaigns targeting bowel screening 
commenced (Figure 14), and numbers 
remained higher every month compared 
to baseline for the three subsequent years, 
except for August 2014 (2.5% decrease 
compared to August 2011).  There was a 
10.4% (DCE’s second year), 10.6% (DCE’s 
third year) and 13.6% (DCE’s fourth year) 
annual increase in the number of requested 
and returned kits; corresponding to 5140, 
5239 and 6734 additional test kits per year 
respectively compared to baseline (source: 
customised data provided by the Bowel 
Screening Centre in Dundee). 
The increase in requested kits occurred 
across all territorial Health Boards (with 
variations), except for NHS Tayside and NHS 
Orkney in DCE’s third year (bearing in mind 
small numbers for the latter) (Appendix 9). 
As both the size of the eligible screening 
population and bowel screening uptake vary 
across Health Boards, absolute numbers in 
this figure should not be used to compare 
performance.
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Lung cancer
As there is no organised lung screening 
programme in Scotland, the lung cancer 
campaign (with three phases) only focused 
on signs and symptoms. Key outcome data 
from the campaign is shown in Box 10.
A DCE Newsletter sent to GPs reported 
that more patients were referred for a 
chest x-ray by a GP during the first month 
of the campaign (compared to the previous 
month). There was also a 3% increase in 
chest x-rays during the campaign (compared 
to the same time in the year prior to the 
campaign)132. No further information on 
outcomes was available.
Box 10. Key results from the lung campaign
TNS evaluation
• After the campaign phase in November 2014, there was significant increase in spontaneous 
awareness of activity about lung cancer, with a similar pattern found across most groups (with 
the exception of those aged 75+ for whom spontaneous awareness decreased)
• Campaign recognition remained high over different campaign phases, with television being the 
most dominant media. Recognition was significantly higher among C2s when compared to 
C1DEs. Written media (press) showed declined recognition (significantly among DEs)
• The “get checked” message remained strong after campaigns; the “three week cough” message 
was also being more recognised
• Motivation has increased over time, especially for men, DEs and 75+
• There were high levels of agreement that much can be done to treat symptoms, and an increase 
in agreement over time (over 70% agreed)
• There was a significant increase in the proportion taking action as a result of campaign. Those 
not motivated by it were significantly less likely to take action than those who were motivated
• In terms and attitudes and behaviours, target audience stated that they felt more comfortable 
going to the doctor with small changes. While there was a significant increase in those who 
would go to the GP after three weeks, more also said they would not go at all
• There was a significant increase in spontaneous awareness of the three-week cough (over 70% 
awareness) as a symptom and smaller increase in prompted awareness (over 90% awareness)
• Prompted symptom awareness increased over time, more as a result of rise in awareness of 
lesser known symptoms, as awareness of the three-week cough remained similar
Field and Partnership, B2B an PR activities
• During campaign times, the campaign website received over 16,200 visits; Sir Alex Ferguson’s TV 
advert received around 4,500 views on You Tube
• Sir Alex Ferguson’s video saying that “lung cancer isn’t what it used to be” was shared on Get 
Checked Early’s Facebook page and reached 294,656 people
• The events team engaged with over 29,000 members of the public in over 28 events
• PR activity resulted in over 95 pieces of coverage in the media
Sources: 1) Consolidated PR Detect Cancer Early campaign briefing pack. Lung Cancer. 2013. 2) TNS. Lung Cancer Campaign 
Evaluation – 2014/15. Presentation of Results to Scottish Government 26 May 2015. 3) DCE News release; 4) Case study 
document with campaign outcomes prepared by the DCE team; 5) Detect Cancer Early Lung Cancer, GP update; 6) DCE Lung 
Cancer leaflet
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TNS Attitudinal Tracking
TNS compared people’s attitudes before all the 
social marketing campaigns (2011) and after 
DCE’s first three years (early 2015) regarding 11 
Box 11. Key results from the 3-year attitudinal tracking
• Statement: There’s not much doctors can really do for cancer - The proportion who 
disagreed increased significantly from 76% to 83%, with strong disagreement increasing from 
27% to 38%. Significant increases happened for both total disagreement and strong disagreement 
for men, those aged 65+ and DEs
• Statement: You can’t survive cancer so what’s the point in worrying about the early 
signs and symptoms of it - Total disagreement increased significantly from 85% to 91%, 
with strong disagreement increasing from 39% to 55%; there were significant increases in total 
disagreement among men, those aged 65+ and DEs
• Statement: Just the thought of cancer puts me off thinking about checking for the 
signs and symptoms of it - Total disagreement fell significantly from 76% to 65%, without a 
change in strong disagreement.  Agreement with the statement showed no substantial changes
• Statement: I might put off going to see my doctor or GP about possible signs of 
cancer – for fear of what they might tell me - Significant decrease in total disagreement 
among all groups, except for those aged 65+
• Statement: I would go to the doctor or GP straightaway if I suspected any signs or 
symptoms of cancer - Total agreement decreased significantly from 91% to 85%. Reduction 
happened in all groups, and was significant among females, 40-54s and DEs
• Statement: Spotting signs of cancer early improves your chances of survival - 
Total agreement increased significantly from 94% to 97%, with strong agreement increasing 
significantly from 50% to 66%
• Statement: People who take part in screening (when invited) are improving their 
chances of surviving cancer - No change in total agreement, but strong agreement increased 
significantly from 41% to 51%, including among men, those aged 65+ and DEs
• Statement: If you get lung cancer there’s little or no chance of you surviving - Total 
disagreement increased from 48% to 58%, with significant increases among men, those aged 
65+ and DEs.  There was a significant increase in strong disagreement (11% to 15%) overall and 
for C2s
• Statement: I am confused generally about what the early signs and symptoms of 
cancer actually are - There  was no change in agreement with this statement (49%); but total 
disagreement decreased from 39% to 29%
• Statement: I worry about wasting the doctor’s or GP’s time unless my symptoms 
are clearly serious - The proportion who disagreed with this statement decreased from 54% 
to 44% (while 45% agreed compared to 42% previously). The decrease was driven by significant 
decreases for women, those aged 40-54s and CIs
• Statement: Taking part in cancer screening (e.g. bowel / breast) reduces the need 
to look out for signs and symptoms yourself - Total agreement decreased significantly 
from 42% to 32%, while total disagreement increased significantly from 50% to 58%. There were 
significant increases in disagreement among women, those aged 65+, C2s and DEs.
statements (Box 11). Several significant changes 
in attitudes were reported.
Source: TNS. DCE Attitude Tracking – 3 Year Anniversary Comparison. 2015
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 Objective 4: To work with GPs to promote referral or investigation at the earliest 
reasonable opportunity for patients who may be showing a suspicion of cancer whilst 
making the most efficient use of NHS resources and avoiding adverse impact on 
access
In order to meet this objective there 
were three key components: the updated 
referral guidelines for suspected cancer,  the 
educational sessions for professionals and 
the use of qFIT with symptomatic patients. 
Local activities using additional funding 
from DCE (Objective 6) have also resulted 
in relevant activities for this objective 
(although there is limited information on 
outcomes for these). 
The development of practice profiles 
was also aimed to help meet objective 4. 
However, it was not feasible to launch them 
until 2015 (work is currently ongoing - 
personal communication, DCE Programme 
Board). Hence, no outcomes are shown for 
this programme component.
Education sessions
Bowel Cancer UK and the Roy Castle 
Lung Cancer Foundation delivered seven 
engagement sessions and one Webcast to 
over 424  professionals between September 
and October 2013. GP Leads helped 
to develop an Agenda for the sessions, 
which covered both colorectal and lung 
cancers. Developed resources included one 
Marketing flyer, handouts covering cancer 
prevention and treatment, one action 
plan document (for bowel screening), one 
resource document (detailing where to find 
supporting literature) and one evaluation 
form133,134. Key results from the evaluation 
(carried out by the charities) are described 
in Box 12.
Box 12. Key results from the evaluation of the education sessions
• Finding out about the bowel screening initiative, the Bowel Screening Programme and the bowel 
cancer referral guidelines were the priorities for attending the sessions
• Attendees thought that the lung and bowel sessions were useful; symptoms and social marketing 
were the most highly rated sessions
• Overall the attendees agreed that the day met their expectations, the event was relevant and 
they were taking away knowledge that they could use
• A third of attendees answered the question about how they would share information within the 
practice and 68% of these planned to do so at a practice meeting
• Bowel Cancer UK saw an increase in demand for their endoscopy booklet and the Bowel Health 
and Screening resource for people with learning disabilities and their care providers. There 
were also requests for awareness talks to surgeries on bowel cancer symptoms, screening, risk 
factors and prevention messages
• Attendance was reported to be poor from three territorial Health Boards and further 
engagement sessions were planned.
Sources: 1) Roy Castle Lung Cancer Foundation. Report to Scottish Government – Detect Cancer Early Workstream 2013; 2) 
Roy Castle Lung Cancer Foundation and Bowel Cancer UK. Detect Cancer Early Primary Care Engagement Project. 2013. 
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Referral guidelines
The key output to reach this objective 
was the publication of the updated referral 
guidelines for suspected cancer135. After 
reviewing international guidelines and 
assessing them for quality (Appendix 1), 
there was wide consultation with different 
professionals and experts in order to 
develop the Scottish guidelines. Quick 
guides were printed and disseminated 
across Scotland.
The use of the guidelines is being evaluated 
(personal communication, Dr Douglas Rigg), 
and results are expected to be published 
at a later date. Furthermore, the current 
guidelines are being updated again (see 
Discussion).
Symptomatic qFIT
DCE has also funded research assessing 
the use of the Faecal Immunochemical Test 
(FIT) with symptomatic patients (personal 
communication - DCE Programme Board), 
in order to assess if this approach would be 
effective for early diagnosis of bowel cancer. 
More recent developments (beyond this 
Evaluation time frames) included testing the 
approach in one Health Board in Scotland 
(followed by dissemination to other Health 
Boards). Results are also expected to be 
published at a later date.
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 Objective 5:  To ensure there is sufficient capacity in the screening programmes to 
meet the expected increase in those choosing to take part
Breast and Bowel Screening Centres were 
not allocated additional funding (Strategy 
3) alongside Health Boards, although DCE 
funded specific screening initiatives.
Breast screening capacity
There is limited information on breast 
screening capacity. Data describing increase 
in consultations due to breast symptoms and 
increase in self-referrals indicate increase 
in workload for screening programmes 
(as resources were used for screening and 
self/GP referrals). The process evaluation 
also sheds light on whether capacity was 
sufficient. 
Bowel screening capacity
Two annual reports from the Scottish 
Bowel Screening Centre describe increase 
in activity during DCE awareness campaigns 
and the bowel screening initiative. These 
included increases in the number of 
reminder letters, helpline calls and emails 
(accompanied by an increase in requested 
and returned replacement kits - as described 
in the previous section)130,131. 
The increase in activity was also reported to 
have influenced laboratory test time and the 
Centre’s ability to meet the NHS Quality 
Improvement Scotland (QIS) desirable 
standard (95% of participants receiving 
their results within 7 days of receipt by 
the Screening Centre). Nonetheless, all 
screening participants received their results 
within 12 days (2013-2014) and 14 days 
(2014-2015). Reports also stated that there 
was a seasonal peak in laboratory activity 
during February and March 2014; this was 
then reduced in April and returned to pre-
campaign levels130,131. 
 
Several strategies were adopted to manage 
impact; these included an automated 
telephone option so those calling could 
order a replacement kit by leaving a recorded 
message (added in February  2014). About 
one third of callers used this option, with 
90% accuracy (i.e. without the need to call 
back)130,131.  
Replacement kits were also requested by 
email. At the time of the first report (2014), 
there were about 60 email requests per 
month. The second report (2015) stated 
that the number of monthly requests was 
350130,131. Calls from GPs and GP practices 
were also reported to have increased 
(Figure 15).
Initially, additional Medical Laboratory 
Assistants (MLAs) fixed term contracts 
were introduced to increase laboratory 
staff resource. This was followed by a review 
of MLA working hours which resulted in 
adjustments in shifts and better management 
of workload130,131.
Revenue funding was allocated to Health 
Boards via NRAC share (Appendix 1). 
DCE adopted a flexible approach to 
funding; territorial Health Boards could 
use it according to their population and 
health system needs and characteristics 
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(Campaign phases 1 & 2; bowel 
screening initiative launched) 
2014 
 (Campaign phases 3-6; bowel 
screening initiative ongoing)  
2015  
(Final three months of the 
bowel screening initiative)  
Months N Months N Months N 
Jan-13 5521 Jan-14 3659 Jan-15 6534 
Feb-13 5007 Feb-14 5112 Feb-15 5649 
Mar-13 6092 Mar-14 6112 Mar-15 5550 
Apr-13 6754 Apr-14 5673     
May-13 5456 May-14 6587     
Jun-13 4096 Jun-14 5739     
Jul-13 4045 Jul-14 6762     
Aug-13 5528 Aug-14 5789     
Sep-13 4958 Sep-14 6552     
Oct-13 5043 Oct-14 7018     
Nov-13 5947 Nov-14 5994     
Dec-13 3442 Dec-14 4591     
 
Reminder letters and calls to helpline by year 
 
Contacts 2012/2013 (proxy baseline) 2013/2014 2014/2015 
 N N % increase N % increase 
Reminder letters 372,825 469,850 26.0% 470,956 26.3% 


















































































































Calls to the Bowel Screening Centre Helpline (2013-2015)
Campaign
phase 1









Sources: Created from 1) Scottish Bowel Screening Centre. Scottish Bowel Screening Centre Annual Report 2014-2015. 
April 2014 to March 2015 as reported in May 2015. Scottish Bowel Screening Centre; 2015. 2) Scottish Bowel Screening 
Centre. Scottish Bowel Screening Centre Annual Report 2013-2014. April 2013 to March 2014 as reported in May 2014. 
Scottish Bowel Screening Centre; 2014.
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(provided that funding was used to meet 
DCE aims). Consequently, investments 
varied across Scotland. Nonetheless, many 
Health Boards used some of their funding to 
support improvements in diagnostics (such 
as purchasing new equipment or hiring 
more staff), data capture and reporting; 
local awareness initiatives and support 
for national campaigns. Many reported 
challenges in recruiting professionals such 
as radiologists and difficulties when funding 
was reduced. There was little information 
Objective 6: To ensure that imaging, diagnostic departments and treatment centres 
are prepared for an increase in the number of patients with early disease requiring 
treatment
about resources for treatment (personal 
communication, DCE Programme Board).
DCE received brief annual reports from 
Health Boards about how funding was 
used, challenges faced, perceived benefits, 
actions to ensure sustainability and lessons 
learned. Examples of how funding was used 
and perceived benefits are described below 
(Table 1). Evidence on challenges faced 








• Investment in diagnostics (Radiography, Pathology,
Endoscopy, Laboratory, local Endobronchial
Ultrasound (EBUS) services) and purchase of
videoconferencing equipment for multidisciplinary
team (MDT) meetings
• Baseline assessment and ongoing measurement
(cancer tracking and audit staff)
• Awareness raising activities, engagement with men
and other hard-to-reach bowel screening non-
responders
• Recruitment of locum staff to deal with demand;
increase in breast surgery capacity
• Support for GPs to increase bowel screening
uptake
• Better communication with GPs, improved GP 
engagement to increase bowel screening uptake
• Better communication and engagement with patients, 
volunteers and the public
• Increase in breast screening and mammography 
capacity (with subsequent reduction in waiting times); 
increase in diagnostic capacity (bowel screening, 
imaging and pathology)
• Improved audit of cancers diagnosed following A&E 
admission and routine referral; more accurate and 
complete staging data
• Improved efficiency of MDTs; additional CT capacity
• Plans to have continuous evaluation, funding and 
awareness raising, work on health improvement and 
reduce inequalities, develop and strengthen 
partnerships, and review cancer pathways
NHS 
Borders 
• Assignment of managers to coordinate work on 
awareness and communication with deprived 
populations
• Funding for an additional clinical nurse specialist in 
lung cancer; additional colonoscopy/computed 
tomography (CT) scan capacity; additional breast 
clinics and a consultant radiologist
• Development of local material to support staff; 
staff survey on awareness of bowel screening
• Training and support for practices in order to 
meet bowel screening targets
• Use of local radio for early detection messages
• New network of contacts to reach deprived and 
vulnerable populations; work with local initiatives and 
companies
• Dedicated staff to work on DCE helped to increase 
bowel screening uptake
• Establishment of a multidisciplinary team
• Plans developed to support gaps in service provision 
with new resources were brought by funding
• Events were held with GP practices to provide follow-
up support
• Messages on risk factor and early detection were 
embedded in conversations staff have with patients
Table 1. How additional funding was used across Scotland
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Health 
Board 
• Examples of how additional funding was
used 





• Development of new cross-cancer site MDT data
recording system; employment and training of
new audit staff
• Display of advertising/marketing from national
campaigns in local NHS and regional publication;
increase in communications activity
• Increase in capacity in Head and Neck Clinical
Nurse Specialist (CNS) role; building capacity in
endoscopy (including equipment) and Pathology
• Better planning for future service developments and
audit of practice (developments were incorporated in
services provided); plans for updated IT systems to
prevent long term need for Cancer Audit staff and to
improve MDT data; plans to develop universal and
specialist workforce capacity and continue
engagement with hard to reach groups
• Increased engagement with Community Health
Teams and Educational Institutes
• Improved reporting in cancer staging data
NHS Fife • Investment in diagnostics (endoscopy, radiology
and pathology); recruitment of a respiratory
physician; and appointment of a lead Cancer GP
• Funding for additional clinical sessions to tackle
system delays
• Reduction in the capacity deficit
NHS Forth 
Valley 
• Funding for additional diagnostics (Radiology and 
Pathology consultants, technical staff for breast 
services and fast-track x-ray for lung) and training
• Support and redesign the Outpatient Department 
breast service; funding for a breast surgeon, 
nursing and administrative staff; pilot using breast 
physician to support one-stop clinics
• Purchase of an additional ultrasound machine; 
additional endoscopy capacity for surveillance
• Funding for Health Promotion and to train 
volunteers to work with hard-to-reach groups
• Cancer prevention activities through events; 
awareness raising in prisons, locally through case 
studies, work in the local community, distribution 
of campaign packs; use of websites, social media 
and community newsletters
• Networking with other Boards to share scarce 
resources in providing services
• Additional endoscopy capacity eased the pressure on 
the endoscopy unit
• Reduced pathway delays, improved patient centred 
breast service
• Analysis undertaken at the start of DCE to identify 
where additional capacity would be needed
• Bowel screening awareness training indicated lack of 
awareness of the screening test, of knowledge about 
the importance of symptoms and signs, body and 
practical issues of doing the test. A short weekly 
briefing session implemented for breast has continued 
and has been rolled out to other cancer pathways
NHS 
Grampian 
• Support for endoscopy, radiology, cancer audit
team and Managed Clinical Network (MCN)
• Funding for cancer nurse specialists, cancer
pathways team and MDT support
• Increased diagnostic capacity
• Complementary early detection initiatives carried out 
in partnership with voluntary and partners
• Network approach to funding allocation taken by 
consulting widely and identifying priorities (this also 
resulted in better engagement of different 
professionals)
• Ability to undertake systematic review of pathways; 
establishment of a Cancer Care Network and 





• Additional breast and radiology sessions (including 
in the evening and over the weekend); additional 
imaging capacity, scanning and reporting capacity 
for CT scanning; additional infrastructure 
associated with developing a Sentinel Lymph Node 
Biopsy in Breast Cancer service
• Targeted marketing for the breast campaign
• Increase in lung capacity ahead of campaigns; 
additional endoscopy capacity
• Increase in medical and diagnostic sessions within 
respiratory medicine and diagnosis
• Improved “real time” audit in terms of staging data
• Improved understanding of residual consequences of
campaigns
• Audit system put in place to enable continuous




• Procurement of a mammography unit, of an
ultrasound machine (lung) and a prostate biopsy
probe for urology
• Reduced waiting times for diagnosis and treatment 
of breast patients; reduced waiting time for TRUS 
biopsies with greater flexibility for treatment.
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Health 
Board 
Examples of how additional funding was used Reported benefits (including soft outcomes) 
NHS 
Lanarkshire 
• Production of teaser letters for breast screening 
and bowel diaries; joint work with partners to 
raise awareness of bowel and breast cancers; 
health improvement (training, screening toolkits, 
work in prisons and leisure centres)
• Investment in digital mammography, recruitment 
of a breast surgeon and support for the 
appointment of a breast clinical assistant
• Purchase of EBUS services and an introduction of 
a wide screen monitor; purchase of rigid 
thoracoscopy equipment
• Investment in specialist Radiology (x2) and CT 
Colonography; piloting of a one-stop breast clinic
• Training for nurse endoscopists
• Support for clinical audit and data gathering; 
radiology, care pathways, and local campaigns
• Cemented relationships with local authority partners
• Improvement of clinical audit data and KPIs; backlog 
in data collection was reduced; quality assurance 
timescales were met and a rolling programme of 
quality assurance for all tumours was facilitated
• DCE funding allowed for the development of local 
reporting (and for better data collection on staging)
• EBUS can improve diagnosis, staging information for 
lung cancer and can reduce invasive procedures
• Improved access and local treatment (lung); more 
streamlined approaches that reduce the risk and the 
need of anaesthetics
• Continuous review of pathways to ensure a robust 
and streamlined approach, and to improve services
• Improvement in data capture and integration of CT 
colonography into Colorectal Services as standard
NHS 
Lothian 
• Increase in diagnostic, screening capacity and 
treatment costs to maintain CWT targets
• Baseline assessment and ongoing measurement 
(audit staffing, programme management, analytical 
capacity, e-health developer time and others)
• Assessing, profiling and influencing primary care 
referral behaviour
• Investment in breast symptomatic and screening 
services, radiology for breast, lung and bowel, 
respiratory medicine (staff, nursing and 
administrative support), investment in breast 
imaging, biopsy and Magnetic Resonance Imaging 
(MRI) family history, support to EBUS/imaging
• Investment in a pilot study to improve screening 
uptake and additional session funding to increase 
GP Cancer Lead time availability
• Increased understanding of the system while using
cancer intelligence - changing service provision and
delivering pathways that support early detection;
improved cancer analytical capacity and audit
• Development of a governance and leadership
structure through the DCE Board; improved learning
about supporting management and clinical leads
• Awareness activities carried out without DCE budget
• 10 pilots on primary care engagement and innovation,
with improved engagement with general practice and
screening programmes
• Increase in breast service (including one additional
one-stop clinic) and radiology capacity
• Improved referral guidance and plans for updating of
the Lothian Refhelp system for cancer pathways




• Funding for new scopes; endoscopy redesign to 
support screening campaigns; establishment of a 
CT service; new multifunction room
• Support for Health Promotion
• Development of the “Bin your Bra” campaign
• Support for DCE campaigns locally - giving away 
thingymaboob keyrings, doing radio interviews 
with local women, having articles in local 
magazines, distributing resources to local 
businesses and public venues, and sharing 
information and links on local pages and websites 
(including social media)
• Increase in the number of scopes carried out, 
awareness raised through “Bin your Bra” (there was 
also enhanced engagement with staff)
• Increased scrutiny on performance at practice level
• Rolling programme of replacement scopes to maintain 
scope numbers
• Promotion of educational programmes; knowledge 
and skills to be maintained and mainstreamed
• New room allows for reshaping and sustaining work
• Adoption of protocols to order scans and help to 
deal with having no radiologist
• Discussing performance with lead clinicians helped to 
support a revised networked approach through the 
Isles Network of Care to the delivery of care
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Health 
Board 
Examples of how additional funding was used Reported benefits (including soft outcomes) 
NHS 
Shetland 
• Investment in capacity of DCE leads, data capture,
and new diagnostic equipment
• Purchase of video conferencing equipment and
use of funding to assist with modernising scopes;
additional colonoscopy capacity
• Pump priming for initiatives to support DCE;
support of Health Promotion activities (alongside
work with pharmacists funded by Macmillan);
funding allocation alongside Urological Cancer
Charity (UCAN) and Prostate UK
• DCE embedded in core business; ideas are being 
generated for engagement; DCE became a recurring 
item in Cancer Lead Team meetings
• Collaborations with charities led to increased 
opportunities for patients to be referred via the 
pharmacist; links with services improved; there were 
increased awareness of trigger symptoms and 
pathways across primary care services and improved 
links before specialists and health services. These 
resulted in increased capacity and reduction of 
waiting times for patients requiring ongoing 
surveillance after cancer treatment
NHS 
Tayside 
• Investment in breast capacity though additional
staff, and lung and colorectal capacity through staff
and equipment
• Investment in capacity for Pathology, Radiology,
Information Technology, Primary Care, and
Medical Records through staff and equipment
• Pilot development of a cancer decision support
tool in primary care
• National marketing support
• Investment in service improvement methodology (to 
happen irrespective of DCE) and sustained and 
embedded social marketing
• DCE Programme perceived as a whole rather than 
individual silos
• Increased understanding of the importance of 
systematic data collection and analysis, of having an 
effective and influential clinical engagement with the 
DCE Programme, having effective senior leadership, 
good management and administration





• Funding used towards cancer awareness (breast,
bowel, lung, prostate, testicular and general
cancer awareness) - contacting existing cancer
support groups, setting up stalls at community
events, disseminating information in community
halls, GP practices and workplaces; using survival
stories in different media channels to engage with
the public; targeting men using local media
channels and women through ladies’ film night
• Use of out of hours helpline and set up of a
dedicated NHS Western Isles Cancer website
• Breast screening uptake increased
• Learning built into Health Promotion approaches to
enhance awareness and screening uptake
• Increased vigilance for early detection; continued
input and support for local cancer groups
 Objective 7:  To strengthen data collection and performance reporting within 
NHSScotland to ensure progress continues to be made on improving cancer diagnosis, 
treatment, referral, and survival
This was a broad objective, and one way 
to measure it was to assess whether the 
proportion of cancers diagnosed with 
unknown stages decreased over time. 
When looking at all three cancer types 
combined, there was a 44.2% reduction in 
cancers diagnosed with unknown stages 
(Year 3 compared to baseline). The highest 
reduction happened for breast cancer (65.2% 
in Year 3). The reduction for colorectal and 
lung cancers in Year 3 was similar (36.7% 
and 38.7% respectively) (Figure 16)124. 
Reductions occurred across all deprivation 
levels, with the most deprived having the 
highest reduction in Year 3 (52.7%) (Figure 
17)124. 
There were reductions in the proportion 
of cancers diagnosed with unknown stages 
across all Cancer Networks (the highest 
reduction happened for WOSCAN) (Figure 
18).  Reductions did not occur across all 
territorial Health Boards (Appendix 11). 
Sources: Annual reports submitted to DCE by territorial Health Boards (2012/2013; 2013/2014 and 2014/2015), 
and summaries of reports prepared by the DCE team
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Fig 16.  Proportion of cancers diagnosed with unknown stages 
and % changes
Created with data from: ISD Scotland. Detect Cancer Early - Year 6 Staging Data. Time Period: 01 January 
2010 - 31 December 2017. http://www.isdscotland.org/Health-Topics/Cancer/Publications/data-tables2017.








N(%) at Stage 1 
and % change Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 
3 cancers 
combined 
N (%) at Stage 1 2008 (8.4) 1669 (6.8) 1368 (5.5) 1164 (4.7) 1195 (4.8) 1296 (5.3) 1415 (5.8) 
% change  -19.2% -34.1% -44.2% -42.6% -36.7% -30.5% 
Breast 
N (%) at Stage 1 365 (4.4) 279 (3.3) 208 (2.4) 132 (1.5) 99 (1.2) 105 (1.2) 103 (1.2) 
% change  -25.8% -45.2% -65.2% -74.1% -72.5% -72.9% 
Colorectal 
N (%) at Stage 1 1047 (14.8) 905 (12.9) 747 (11.0) 624 (9.4) 630 (9.5) 676 (10.2) 683 (10.4) 
% change  -13.0% -25.9% -36.7% -35.9% -30.8% -29.6% 
Lung 
N (%) at Stage 1 596 (6.9) 485 (5.3) 413 (4.4) 408 (4.2) 466 (4.9) 515 (5.6) 629 (6.9) 
















Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Breast, colorectal and lung cancers combined
% cancers diagnosed with unknown stages % change compared to baseline











Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Breast cancers














Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Colorectal cancers
% cancers diagnosed with unknown stages % change compared to baseline












Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Lung cancers
% cancers diagnosed with unknown stages % change compared to baseline
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Fig 17.  Proportion of breast, colorectal and lung cancers (combined) 











stage and % 
change 
Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 
Level 1 = most deprived 
N (%) unknown 508 (9.1) 424 (7.4) 320 (5.6) 249 (4.3) 258 (4.5) 291 (5.3) 305 (5.7) 
% change  -18.6% -39.1% -52.7% -50.8% -42.0% -37.1% 
Level 2 
N (%) unknown 469 (8.9) 374 (6.9) 307 (5.7) 269 (5.0) 261 (5.0) 290 (5.5) 313 (5.9) 
% change  -22.4% -35.7% -43.6% -44.1% -37.7% -33.2% 
Level 3 
N (%) unknown 407 (8.7) 322 (6.7) 274 (5.7) 246 (5.1) 271 (5.5) 276 (5.7) 277 (5.8) 
% change  -22.7% -34.5% -41.8% -36.9% -34.8% -33.4% 
Level 4 
N (%) unknown 324 (7.4) 284 (6.2) 251 (5.5) 212 (4.6) 216 (4.7) 245 (5.5) 274 (6.0) 
% change  -16.2% -25.7% -37.9% -36.3% -26.1% -18.0% 
Level 5 = least deprived 
N (%) unknown 293 (7.4) 260 (6.4) 212 (5.1) 186 (4.5) 188 (4.4) 192 (4.5) 244 (5.7) 
% change  -13.8% -31.6% -40.1% -40.7% -39.6% -23.8% 
 












Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Level 1 - most deprived
% cancers diagnosed with unknown stages
% change compared to baseline












Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Level 2
% cancers diagnosed with unknown stages
% change compared to baseline












Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Level 3
% cancers diagnosed with unknown stages
% change compared to baseline














Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Level 4
% cancers diagnosed with unknown stages
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Created with data from: ISD Scotland. Detect Cancer Early - Year 6 Staging Data. Time Period: 01 January 2010 - 31 
December 2017. http://www.isdscotland.org/Health-Topics/Cancer/Publications/data-tables2017.asp?id=2206#2206: ISD 
Scotland; 2018. 
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Fig. 18. Proportion of breast, colorectal and lung cancers (combined) with 







Cancer type N(%) unknown stage and % change Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 
NOSCAN 
N (%) unknown 552 (9.4) 504 (8.6) 374 (6.3) 347 (5.8) 361 (6.0) 413 (6.6) 568 (9.3) 
% change  -9.1% -33.4% -38.0% -36.8% -29.9% -1.4% 
SCAN 
N (%) unknown 382 (5.8) 373 (5.5) 378 (5.7) 311 (4.6) 321 (4.8) 344 (5.3) 341 (5.2) 
% change  -4.8% -2.0% -20.1% -17.3% -7.9% -9.8% 
WOSCAN 
N (%) unknown 1074 (9.4) 792 (6.6) 616 (5.1) 506 (4.2) 513 (4.3) 539 (4.6) 506 (4.4) 
% change  -29.3% -45.6% -55.6% -54.6% -50.7% -53.4% 
 












Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
NOSCAN
% cancers diagnosed with unknown stages % change compared to baseline













Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
SCAN
% cancers diagnosed with unknown stages % change compared to baseline












Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
WOSCAN
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Created with data from: ISD Scotland. Detect Cancer Early - Year 6 Staging Data. Time Period: 01 January 
2010 - 31 December 2017. http://www.isdscotland.org/Health-Topics/Cancer/Publications/data-tables2017.
asp?id=2206#2206: ISD Scotland; 2018. 
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 Objective 8: To facilitate further evaluation of the impact of public awareness 
campaigns on the stage of cancer at presentation and to contribute to research 
that establishes evidence for the link between late presentation and survival deficit
from ISD Scotland and this Evaluation will 
help to shed light on whether (or to which 
extent) this objective was met.
This was an aspirational,  long-term objective 
for which there are no known outcomes. 
It is possible that evaluations of the social 
marketing campaigns, reports of outcomes 
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Flexibility as a two-edged sword
The role of targets
Demand as a driver for action
DCE and the professionals’ roles
Funding becoming resources
A dynamic and diverse environment
Data collection for the process evaluation 
(interviews and questionnaire) took place 
between January and July 2018. Twenty-
five stakeholders were interviewed (mean 
interview duration: 48 minutes) and 53 
submitted a completed online questionnaire. 
While questionnaire participants were 
often secondary care doctors (67.7%), 
interview participants often managed health 
services or DCE components (56.0%).  Ten 
territorial Health Boards were represented. 
Appendix 12 has further information on 
the stakeholders who took part in the 
interviews and questionnaire.
Over two-thirds of questionnaire 
participants (n=37) completed one or 
more open-ended questions (range 1-16 
comments per participant). There were 175 
comments; all were included in the content 
analysis. Resulting themes from the content 
analysis are available in Appendix 13.
Key themes and findings from the interviews 
and questionnaire were arranged in three 
areas: context, processes and outcomes 
(Figure 19). 
4.2.1 Context
Fig 19. Key findings from the process evaluation
There were four main themes in this area: 
facilitators, barriers, a government initiative, 
and cultural shifts (public and health system).
Theme: Facilitators
Questionnaire
Having good quality data, being consistent 
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Box 13. Facilitators described by interview participants
•International drive towards early cancer detection (EUROCARE, International Cancer 
Benchmarking Partnership (ICBP), ACE, BCOC and different Danish Pathways were highlighted)
•Cancer being “close to home” i.e. a personal experience many can identify with
•The existence of a proactive Primary Care Cancer Group with good representation 
(Health Boards, lead GPs, lead nurses, third sector, and academics) that allows for useful discussions 
about the primary care aspects of cancer
•Benefiting from established infrastructure and knowledge: these included having similar 
interests to DCE, having relevant activities taking place when DCE was implemented, being able to 
assess bottlenecks in the cancer pathway before deciding where to invest
•Ensuring that the team was motivated and engaged: this involved making initiatives 
meaningful to stakeholders, listening to different groups to allocate resources, tailoring messages 
and addressing different professional needs
•Assigning roles and responsibilities to carry out DCE related activities
•Reaching out: this involved understanding the needs of deprived communities
•Funding as an enabler:  funding was reported to bring coherence and forward direction, and 
to facilitate stakeholder engagement. In Primary Care, funding was described as a requirement to 
implement initiatives (otherwise other issues would need to be prioritised)
•Accessing and using good evidence: this was reported to facilitate DCE acceptance, clarify its 
rationale, and increase professional awareness regarding barriers to help-seeking
•Being able to use digital resources (including digital proformas, electronic referrals, desktop 
guides with referral guidelines, and applications that update at real time).
when recording staging data and having 
electronic results for bowel screening were 
some of the facilitators described. Having 
a designated lead for the Programme and 
receiving advice early on, good teamwork, 
and being able to plan and share learning 
were also highlighted. 
“Electronic results were extremely 
helpful [...] they were filed straight 
into the patient’s notes without the 
need for extra admin processes”
Manager, NHS Lanarkshire
Interviews 
Interview participants also emphasised 
the importance of having good quality 
outcome data. Referral data was described 
as particularly useful to primary care 
as GPs have control over it (differently 
from centralised screening data). Good 
data was also described as an enabler 
for conversations about what can be 
improved. In some territorial Health Boards, 
stakeholders reported that the ability 
to access data helped to evaluate local 
initiatives and plan for future activities. 
Several other facilitators were mentioned 
(Box 13).
“Data is the start of a meaningful 
conversation and it’s not about 
getting into the detail of what the 
data says, it’s what you can do as a 
result of that data”
Interview participant, ID 3
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Theme: Barriers
Questionnaire
Questionnaire participants reported that 
stretched capacity and workforce issues 
pre-dated DCE. Limited workforce was 
highlighted, as some specialties (such as 
radiologists) “do not exist to recruit”. 
Other participants referred to competing 
responsibilities (such as the need to meet 
other targets, or to care for patients in 
different settings) that they perceived as not 
being recognised.
“Workforce issues in diagnostics are 
the single largest stumbling block; 
this cannot happen overnight or 
even in a few months”
Secondary care doctor (breast cancer), 
NHS Fife
Interviews
The overstretched health system, limited 
resources, the shortage of radiologists and 
radiographers, and competing responsibilities 
(such as caring for patients with conditions 
other than cancer) were also highlighted by 
interview participants. Endoscopy services 
and lung pathways were described as being 
“under enormous pressure”. There were 
concerns about GPs having to deal with 
information overload and an increasing 
number of responsibilities and reported 
struggles with waiting times. Because of 
these barriers, fears of DCE impact on 
workload were common. System and staff 
changes over time (including GP retirement 
and no available replacements) were also 
mentioned. Staff changes were reported 
to have had an impact on relationships and 
sustainability of programme activities. 
Several other contextual barriers were 
mentioned (Box 14).
Box 14. Barriers described by interview participants
•Challenges associated with early cancer detection:  acknowledgement that early detection 
does not always mean improved clinical outcomes, and that it is challenging to assess vague, non-
specific symptoms in a context of limited resources. Screening controversies (such as benefits vs. 
harms, unpleasant tests and examinations, and timing of screening invitations) were also described 
as barriers
•Persisting barriers to help seeking: these included stoicism, cancer fear and concerns about 
wasting the doctor’s time. Other barriers included limited access to consultations, treatment, 
specialists and hospitals (due to costs, affordability and distance). Stakeholders acknowledged that 
there are many challenges in changing behaviour and social norms (and that these challenges vary 
across different groups). They were also aware of the need to have constant messages in order 
to influence behaviour. Some noted that behaviour change challenges also applied to  health care 
professionals regarding the way they assess cancer symptoms and refer patients
•Regional variation: Scotland is a relatively small country, but it has 14 territorial Health Boards 
and three Cancer Networks with variations in size, distribution of deprived populations, direct 
access to radiology and investigations and different pathways, levels of remoteness and rurality. 
These variations were reported to have implications for programme coordination, communication, 
implementation and engagement
•Prevalence of lifestyle behaviours in Scotland that increase cancer risk: these referred to 
smoking, drinking, obesity and the prevalence of co-morbidities (which were also reported to have 
a role in symptom appraisal and cancer survival)
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Theme:  A government initiative
Interviews
Stakeholders reported that as DCE involves 
publicly funded money, it was frequently 
scrutinised, and all activities needed to be 
justified. Being a government-led initiative 
was perceived as having both benefits and 
limitations. As DCE is part of a national 
cancer strategy, the programme was 
prioritised and had visibility, and a whole 
systems approach could be adopted. 
Having “an unusual amount of funding” 
(for a government programme) for social 
marketing campaigns, alongside a team 
that wished to have an innovative strategy 
resulted in award-winning campaigns and 
“risky” approaches that had never been 
used before (such as showing real breasts 
on television when describing cancer 
symptoms and signs). 
“What would have happened if there 
was no policy focus on it, I think the 
programme would’ve remained in 
the back corridors of public health 
[...] the policy focus on it really 
pulled it to the top of the pyramid”
Interview participant, ID 2
Nonetheless, stakeholders commented on 
a governmental “dual purpose”. DCE was 
not only about early detection, but also an 
indication that the government cared about 
population health and was doing something 
to tackle cancer.  As a  government initiative, 
DCE may have been seen with cynicism by 
groups who are often targeted by Health 
Promotion initiatives. There was the need 
to show impact, which involved defining 
very specific, short-term targets. These 
resulted in time pressures that did not 
“I suppose one of the biggest challenges we have, and we're 
not unique in this regard, is the pressure on primary care [...] 
there are significant number of practices here that have either 
far fewer or far poorer access to a GP and some practices 
have had to be taken over by the Health Board because there 
aren't GPs [...]. It's not just with general practitioners but all 
of primary care. So the advice given 'if you're worried talk to 
your GP' that's all very well if there's a GP”
Interview participant, ID 22
Box 14. Barriers described by interview participants (continued)
•Social deprivation: stakeholders were aware of the multiple challenges brought by social 
deprivation, such as its association with poorer health outcomes, poor literacy (with implications 
for information materials), suspicions regarding the government, low perceived locus of control, 
competing prioritisations, different needs, among many other issues
•Lack of practice level data and limited IT systems connecting different data: these were 
reported to hinder plans for quality improvement, limit discussions about referral behaviour, cancer 
symptoms and signs, and about whether referrals were appropriate. Lack of data also affected the 
ability to compare outcomes in Scotland and England
•Issues with copyright that did not allow campaign materials to be used over time and embargoes 
which influenced timely communication of campaign information were also mentioned.
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allow for piloting many initiatives  before 
implementing them nationally. There was 
also a perceived tension between having 
short-term targets and trying to improve 
outcomes that require long timescales.
“Realising that there was political 
need to get an impact within a 
matter of a couple of years or a few 
years, that cancer doesn’t do that 
and making big changes in the way 
things happen, it’s very difficult to 
measure outcomes in that sort of 
timescale”
Interview participant, ID 13
As DCE was a new strategy, intensive, 
fast learning from experiences in England 
such as NAEDI and BCOC in England was 
required. Learning from experience, being 
aware of new early diagnosis evidence and 
health system changes were issues often 
mentioned by stakeholders. 
Furthermore, there was the need to develop 
and maintain relationships, build trust from a 
very diverse group of stakeholders, manage 
their different aims and concerns, roles and 
expertise, and match diverse interests in 
order to facilitate implementation. It was 
important to engage with stakeholders 
“soon, but not too soon” to ensure that 
decisions could be made within tight time 
frames. Stakeholders managing DCE and/
or its activities were aware that buy-in and 
engagement would differ across different 
groups, and that it would be impossible for 




Stakeholders talked about cultural shifts 
towards cancer prevention and patient 
empowerment. There were references to 
issues pertinent to both personalised and 
realistic medicine, such as having a patient 
perspective, respecting autonomy and 
informed consent, and individual preferences 
and needs. 
Some stakeholders reported an inevitable 
tension between having an expedited 
diagnosis pathway and adopting the best 
clinical approach (as at times the best 
approach may be to watch and wait) or 
addressing patient needs (these could be 
reassurance, but also requests for more 
time before making a decision about care 
and treatment options). 
Other stakeholders were concerned about 
whether the screening campaigns and the 
bowel screening initiative were balanced 
enough regarding benefits and harms. 
Others reflected upon the challenges when 
trying to introduce informed choice in a 40 
seconds advert with a very specific call to 
action.
“If you don’t want to take part in 
the bowel screening programme or 
the breast screening programme, 
cervical screening programme 
and you understand what you’re 
not wanting to take part in, that is 
completely your choice, nobody is 
going to force you to do that, but if 
you don’t understand what you’re 
refusing that’s not good”
Interview participant, ID 8
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Theme: Stakeholder buy-in
Questionnaire
Questionnaire participants were asked 
whether they agreed with the statement 
that DCE and its strategies were appropriate 
to promote early detection. While 22 of 
them (43.1%) agreed to a certain extent 
(somewhat agree, agree or strongly agree) 
that the programme was appropriate, 21 
(41.1%) disagreed with it to a certain extent 
(somewhat disagree, disagree or strongly 
disagree) (Figure 20). 
Perceived appropriateness varied according 
to DCE strategies. While 85.7% of 
participants agreed to a certain extent 
that the bowel screening initiative was 
appropriate, the proportion was 40.7% for 
the HEAT targets (Figure 20). 
4.2.2 Process
Questionnaire participants who were not 
involved in developing or implementing DCE 
strategies, but would have liked to have had 
an input presented statistically significant 
lower median scores when asked about the 
appropriateness of DCE overall (compared 
to those who were involved in DCE; 
adjusted p=0.047), and the appropriateness 
of the HEAT targets (compared who those 
who were not involved, but were happy with 
that; adjusted p=0.042).
Most questionnaire participants (77.4%) 
agreed to a certain extent that it was part 
of their job to be involved in the DCE 
Programme, with no statistically significant 
variations across groups (Figure 21).
 
90% 70% 50% 30% 10% 10% 30% 50% 70% 90%
Bowel screening initiative (n=21)
HEAT targets (n=27)
Provision of extra funding (n=38)
Updated guidelines (n=40)
Education sessions (n=23)
Public awareness campaigns (n=41)
DCE overall (n=51)















Fig 20. Level of agreement with statements about DCE and its strategies 
being appropriate to promote early detection
The higher the median scores, the higher the agreement. Missing data: DCE overall (n=2; don’t know), public awareness campaigns (n=12; don’t 
know and not applicable); education sessions (n=30; don’t know, section/question not applicable); guidelines (n=13; don’t know; section/question 
not applicable); provision of extra funding (n=15; don’t know, section/question not applicable); HEAT targets (n=26; don’t know, section/question 
not applicable; bowel screening initiative (n=32;  section/question not applicable).
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90% 70% 50% 30% 10% 10% 30% 50% 70% 90%
It was part of my job to be involved in DCE (n=51)
1 (strongly disagree) 2 3 4 5 6 7 (strongly agree)
median 6
(IQR 5-7)
Fig 21. Level of agreement with the statement that it was part of their job 
to be involved in DCE
The higher the median scores, the higher the agreement. Missing data: n=2 (don’t known and not applicable)
Comments in the questionnaire showed 
that stakeholders agreed with the premise 
of raising public awareness and educating 
professionals and shed light on why many 
disagreed on the appropriateness of certain 
DCE strategies. Many were critical of the 
choice to target breast, colorectal and lung 
cancers, of campaigns that coincided with 
other awareness events, and of the breast 
cancer campaign focusing on symptoms. The 
use of short/intense campaigns and reaching 
populations with a very low cancer risk also 
generated concerns. 
There were also criticisms regarding DCE’s 
impact on workload and service provision. 
Some referred to increased stress levels and 
burnout across professionals. Participants 
believed that there should have been 
more planning on how to deal with the 
impact caused by the programme, including 
assessing whether available resources were 
sufficient. For others, additional funding 
should have been provided sooner, and 
temporary funding was perceived not to 
allow for a long-term strategy. 
“DCE is an excellent concept - 
raising public awareness of early 
cancer signs is good; primary health 
care worker education is important. 
However, the downstream effects 
on diagnostics and treatment centres 
needs more thought and input”
Medical doctor (secondary care),
 NHS Fife
Interviews
Across interview participants, there was 
also recognition that early detection was 
part of their jobs, and overwhelming 
support for DCE’s overall aim.  The rationale 
for an early detection programme was well 
understood and accepted. Stakeholders 
also commented on DCE’s impact on 
service provision and workload and how 
this affected relationships, especially after 
the symptomatic breast campaign. While 
some stakeholders believed that increase 
in consultations and demand for diagnostics 
were expected and could be predicted, 
others complained that predictions widely 
underestimated demand for diagnostics. 
Stakeholders had diverse views on focusing 
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on screening or symptoms, or on which 
tumour types to target. While some 
believed it was ideal to focus on cancers 
for which there are screening programmes, 
for others the programme should have 
focused on cancers without screening 
programmes as they often have poorer 
outcomes. Others believed this strategy 
was counterproductive as symptoms often 
indicate late stage disease. 
Several comments referred to the 
appropriateness of DCE strategies. 
Strategies perceived to be appropriate 
included having funding that allowed for 
looking at service improvements, the bowel 
screening initiative (as it had support from 
the clinical community, was perceived to 
work well and helped to transfer ownership 
of screening to primary care), and the 
approach of the social marketing campaigns 
and other awareness initiatives. Accepted 
approaches included the use of humour in 
the campaigns, attaching non-judgemental, 
high public profile individuals who can 
communicate with the target population 
(Sir Alex Ferguson and Elaine C Smith), and 
the thingymaboob strategy (distributing a 
keychain with beads demonstrating the size 
of breast tumours).
“We had really high involvement in 
sQOF [bowel screening initiative], 
about 87% of practices were 
involved and they really liked it and 
I think what was nice about that was 
it sort of put over to them the onus 
on trying to come up with ways of 
engaging with their population”
Interview participant, ID 20
DCE strategies perceived not to be 
appropriate included funding that oscillated 
between years and only allowed to have 
dedicated staff for a short time period, 
delays to accessing digital data on bowel 
screening non-responders, and stopping 
the bowel screening initiative when it was 
structured and functioning well. There were 
also criticisms towards carrying out lung 
cancer campaigns during flu season (as this 
resulted in a large number of patients with 
respiratory tract infections seeking help) 
and focusing on breast symptoms (as this 
resulted in large numbers of worried well 
seeking reassurance). Some participants 
believed that the breast and bowel screening 
programmes should have been considered 
as a special Health Board (with specially 
allocated funding).
“I think the sQOF was very much 
to be encouraged, I was very 
disappointed to see after it being 
there for basically the two years, 
the year for planning and the year 
for delivery, for the money just 
disappeared again”
Interview participant, ID 4
Finally,  there were mixed views on the 
HEAT targets. For some, the “ambitious” 
targets brought early detection to the 
centre of attention and resulted in galvanised 
action from professionals in different 
areas. Aspirational targets were reported 
to be common in different organisations 
(such as charities and the government), 
but acceptance across other stakeholders 
varied. Some argued that the target was 
“borderline impossible” and had “slightly 
been plucked from nowhere”. There was 
reported uncertainty over whether Stage I 
was a good measure of DCE’s  success. 
“If you have a target then you’ll find 
people working towards that target, 
you just need to make sure that the 
target is actually what you want to 
achieve”
Interview participant, ID 16
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Theme: Communication
Questionnaire
Questionnaire participants were asked about 
whether they were involved in developing or 
refining DCE strategies. About a fifth of them 
reported being involved. Among those who 
Fig 22. Whether stakeholders were involved in developing or refining 
DCE strategies
were not involved, a similar proportion was 
either happy not to be involved or would 




No, and I was happy 
with that
42%
No, but I would 
have liked to 




Missing data: three participants chose “other” when asked about involvement: one did not specify any further, other responses 
were: “not applicable as was still in training”; “my colleague was involved in implementation so I heard by word of mouth and 
from TV adverts”.
In terms of receiving information about 
the programme and its components prior 
to their launch/implementation, views 
also varied according to different DCE 
strategies. While most participants (72.7%) 
reported being sufficiently informed about 
the bowel screening initiative, a minority 
reported having been sufficiently informed 
about extra funding (10.0%). A substantial 
proportion of participants would have liked 
to have received more information about 
DCE and its components (38.5%), especially 
regarding the additional funding (37.5%), the 
public awareness campaigns (35.7%) and 
the HEAT targets (30.3%) (Figure 23).
The proportion of professionals working 
with more than one tumour type stating 
that they were sufficiently informed 
about the campaigns (p=0.004) and the 
bowel screening initiative (p=0.016) was 
significantly higher than the proportion 
of professionals working with only breast, 
bowel, anal and/or upper gastrointestinal 
and lung cancers. 
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Fig 23. Level of agreement with the statement that information about DCE 
was sufficient
 
90% 70% 50% 30% 10% 10% 30% 50% 70% 90%
Bowel screening initiative (n=22)
HEAT targets (n=33)
Provision of extra funding (n=40)
Work to update guidelines (n=44)
Education sessions (n=36)
Public awareness campaigns (n=42)
DCE overall (n=52)
Yes, I was sufficiently informed Yes, but I would have liked to have had more information No, I was not informed about it/them
Missing data: DCE overall (n=1; other); public awareness campaigns (n=11, other and section not applicable); education 
sessions (n=17; other and section not applicable); work to update guidelines (n=9, other and section not applicable); provision 
of extra funding (n=13, other and section not applicable); HEAT targets (n=20, other and section not applicable); bowel 
screening initiative (n=31, section not applicable).
The proportion of professionals working in 
hospitals stating that they were sufficiently 
informed about the campaigns  (p=0.037) 
and the updated referral guidelines (p=0.023) 
was significantly lower than the proportion 
of professionals working in other settings 
(primary care practice, diagnostic centre but 
not in hospital, charity, other). Furthermore, 
the proportion of participants who were 
involved in developing DCE or its strategies 
and stated that they were sufficiently 
informed about the work on the referral 
guidelines was significantly higher than the 
proportion of participants who were not 
involved in the programme stating that they 
were sufficiently informed (p=0.009).
When asked about communication between 
primary and secondary care regarding 
how to use additional funding, over half of 
participants (55.6%) strongly disagreed that 
communication went well (85.2% disagreed 
to a certain extent) (Figure 24). Secondary 
care doctors had significantly lower median 
scores when compared to nurses (adjusted 
p=0.028). Their scores were also lower than 
the GPs’ median scores, but the difference 
was not statistically significant.
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90% 70% 50% 30% 10% 10% 30% 50% 70% 90%
Primary and secondary care communicated well
when planning how to use additional funding (n=27)
1 (strongly disagree) 2 3 4 5
Median 1 
(IQR 1-3)
Fig 24. Level of agreement with the statement that communication about 
the use of funding went well 
The higher the median score, the higher the agreement with the statement. Missing data: n=26 (don’t known, question/section 
not applicable
Stakeholders’ comments also highlighted 
issues regarding involvement and 
information. Stakeholders appreciated when 
experts were heard.
“Public campaign raising lung 
cancer awareness - DCE team 
listened to expert advice on how to 
approach this group of patients”
Respiratory Nurse, 
NHS Greater Glasgow & Clyde
Nevertheless, others wished they had 
received more information about DCE, the 
scale of the campaigns and their likely impact. 
Some were not aware of the education 
sessions for GPs, the HEAT targets, the 
additional funding provided, nor of DCE 
outcomes. Three participants did not know 
that DCE had continued after 2015. Some 
wished they had had the opportunity to give 
input, while others complained about giving 
it and not having it considered (clinicians, 
frontline staff, breast screening services), 
or about delays in receiving information. 
Those who started working when DCE 
was already ongoing raised concerns about 
sustained involvement and challenges 
regarding handover.
“I attended a national meeting at 
which someone from my Health 
Board said that staff were fully 
informed and had developed 
plans to implement DCE - this 
was completely untrue - we knew 
nothing until the campaign was 
upon us, and no plans were made to 
cope with additional referrals”
Medical Radiologist, NHS Lanarkshire
Interviews
DCE’s communication team was described 
as friendly, welcoming, accessible and 
enthusiastic. Stakeholders received 
information about the programme through 
word of mouth, colleagues involved in 
DCE, documents, Chief Executive letters, 
meetings with policy makers, visits from the 
DCE team, and team meetings. 
However, some stated that dissemination 
of DCE components and outputs did 
not reach all relevant stakeholders. For 
example, referral guidelines were reported 
to be disseminated well in primary, but 
not in secondary care. Stakeholders often 
reported not understanding the rationale 
for some DCE strategies and were not 
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aware of any preparatory work (such as 
research, insight gathering and reasons 
for strategic decisions). Some believed 
that more information sharing would 
have improved sense of ownership and 
responsibility for campaigns, and could have 
enhanced engagement from primary care 
and diagnostic services.
“Certainly we got all the stuff 
about bowel screening but I was 
thinking in general in terms of the 
programme itself at the outset or at 
yearly updates or that type of thing, I 
don’t know that we actually received 
anything.  [...] I went to some of the 
DCE conferences and all that type of 
thing so I kept pretty up to date [...]
Unless you have a specific reason to 
look out the DCE documents I don’t 
know that they’ve been that obvious 
[...] If you go into any GP’s mailbox 
you’ll find a hundred plus a week 
emails coming through with various 
information, bits and pieces from all 
sorts of different teams and people 
asking this, that and the next thing”
Interview participant, ID 1
Concerns were raised about limited ongoing 
contact and explanations for change in 
direction, with some stating that they had 
to chase information themselves. There 
were also comments about limited warning 
in advance of the start date of campaigns, 
the time allowed to make bids for extra 
funding, and the required speed of response 
for preparing roadshows (as Health Boards 
needed more time to get involved and 
distribute materials, especially in more 
remote and rural areas). Some believed that 
at times their concerns were not listened 
to, and that often there was a one-way 
communication process (i.e. stakeholders 
were informed that something was about 
to happen instead of being asked about 
something that was planned to happen).
“They’ve said they’re going to do 
something about breast signs and 
symptoms so ‘I’ll be getting all the 
stuff out to you’ [...] the campaign 
had suddenly hit the TV and 
somebody phoned me up and said ‘I 
[have] just seen it on TV’ and I was 
like ‘I don’t have any resources for 
that’.  And then I looked stupid, then 
people thought that I was the one 
that hadn’t done anything and you’d 
be getting posters a week later [...] It 
did get better with each campaign...”
Interview participant, ID 6
Finally, there was reported frustration 
and disappointment when there were no 
perceived attempts to share findings in 
order to learn from local strategies/pilots 
and from the bowel screening initiative.
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Partnerships and collaborations
Interviews
Stakeholders commented on a range of 
partnerships and collaborations developed 
as part of the programme. Charities were 
described not only as collaborators, but 
also as leads in initiatives supported by 
DCE (with or without DCE funding). 
The relationships were developed due to 
common interests, and the ability to share 
expertise and knowledge. 
Charities had an established relationship 
with the public and had the ability (and 
benefits) of being a non-governmental 
agency. Charities relied on health 
intelligence from the government, but were 
also able to triangulate data from different 
sources and carry out evaluations on their 
own. Stakeholders reported that charities 
facilitated the implementation of initiatives 
and helped to ensure that relevant activities 
continued when DCE funding ended. 
Stakeholders were aware that support from 
charities was paramount and sought their 
input regarding relevant initiatives (although 
charities wished that they had received 
more information and could have given 
input sooner).
“From our perspective there have 
been good engagement with the 
voluntary sector as a partner [...] 
there’s a recognition that cancer 
organisations have a role to play 
in terms of public perception and 
engagement”
Interview participant, ID 21
Creative and market research agencies 
contributed with expertise that the Scottish 
Government lacked. However, their views 
on what constituted programme success 
varied at times. For example, the evaluation 
of the symptomatic breast campaign showed 
positive results in terms of awareness and 
atittudes, but the campaign was not run again 
due to its impact on workload and limited 
effect on more cancers being diagnosed 
earlier.
Relationships and collaborations with the 
media were reported to be both positive 
and negative.  A good relationship facilitated 
dissemination of important early detection 
messages and helped the government to save 
money on disseminating campaign messages. 
However, the media and DCE interests did 
not always match. Stakeholders reported 
that the media helped to disseminate mixed 
messages to the public: while the government 
and health system were emphasising health 
promotion, prevention and intervention, 
media reports were emphasising the fact 
that the NHS was “at breaking point”. 
Negative messages (such as high-profile 
deaths, experiences of suffering and reports 
of bad care, in addition to criticism towards 
campaign strategies) were also common. 
Stakeholders believed that these messages 
helped to confuse the public and influenced 
help-seeking behaviour.
“You’ve just got to be very careful 
with interaction with the media and 
how that’s controlled” 
Interview participant, ID 4
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Flexibility as a two-edged sword
Interviews
Interview participants often described DCE 
as being flexible and open to innovations. 
This flexibility was reported to enable 
funding for local strategies, allow for the 
programme to evolve and adapt over time 
according to new evidence. 
However, the scope of the programme 
and its many approaches reportedly also 
resulted in mixed messages about which 
activities were part of DCE and which 
ones were not. It was also challenging to 
demonstrate the programme’s impact when 
reporting on spin-off initiatives that were 
not part of DCE’s core components. 
Furthermore, flexibility when providing 
funding resulted in limited evidence on how 
it was used to improve diagnostic capacity. 
Some stakeholders also raised issues 
regarding transparency, and about whether 
funding was used appropriately. While some 
Health Boards tried to ensure that the 
money was used to meet DCE aims, others 
reported that they used it to deal with 
backlogs. Some stakeholders acknowledged 
that funding had to be used in a “less efficient 
way” to pay for overtime or cover posts for 
which there was no staff available to recruit. 
In some areas, stakeholders reported that 
clinicians took most of the funding, and 
nurses and Public Health took very little. 
As funding was diluted into different areas, 
some departments (such as laboratories) 
received very little money (or no money at 
all).
“It’s a bit of a balancing act because 
it was this whole systems approach 
we felt at the time we couldn’t be 
very prescriptive with the boards on 
what they should spend the money 
on, what we said was ‘these are the 
five areas of work and it’s up to you 
to prioritise your funding and where 
it goes’ and we left Boards to it. And 
then we went back on an annual 
basis to try and get an evaluation of 
what they spent the money on and 
that was hugely difficult to do [...] 
we found that those who did come 
back there was varying of where 
they spent it, some was in Public 
Health, some Boards didn’t spend 
any on Public Health, it all went 
into secondary care, some went into 
staffing and funding, a lot went into 
audit and data collection”
Interview participant, ID 23
Importantly, some stakeholders gave 
examples of instances when the programme 
was not flexible. There were issues 
regarding one-way communication (as 
described previously). Furthermore, there 
were reports that it was not often possible 
to adapt social marketing materials to local 
populations due to copyright issues.
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4.2.3 Outcomes
Views on DCE outcomes
Questionnaire
Stakeholders often highlighted not being 
aware of changes brought by DCE and 
demonstrated interest in finding out more 
about programme outcomes. Some added 
that they could not identify the impact 
of DCE initiatives (including impact on 
practice) and reported frustration when 
activities did not result in more cancers 
being diagnosed at earlier stages.
“Big increase in worried well.  No 
change in cancer diagnosis but 
increased delays for all”
Breast Surgeon, NHS Lothian
Interviews
Interview participants also wished to 
know more about DCE impact and were 
disappointed when DCE activities did not 
result in better cancer outcomes. However, 
they acknowledged that there were many 
challenges to show impact. It was difficult 
to measure softer outcomes such as change 
in practice, or longer-term outcomes such 
as change in behaviour over time due to 
increased knowledge and awareness.
“Having a national campaign you 
will not be able to attach causality 
ever [...] unless we have a kind of 
experiment”
Interview participant, ID 12
“Joining the dots” between different chains 
of activities (such as trying to assess 
whether increase in knowledge led to help-
seeking) was often not possible. Several 
DCE initiatives happened at the same time; 
making it difficult to demonstrate the role of 
each of them in outcomes (some recognised 
this as an inherent challenge of adopting a 
whole systems approach). 
“We’ve got a much more educated 
bunch of women now that are aware 
of their symptoms other than lumps 
and I think that is like pinning down 
a bit of jelly at times in terms of from 
a measuring perspective trying to 
figure out the impact that we’ve 
had outwith driving early stage 
diagnoses”
Interview participant, ID 15
As briefly mentioned in Barriers, limited 
data was also reported to hinder the 
ability to show impact. For example, it was 
not possible to evaluate the awareness 
campaigns using the same approaches 
used in England for BCOC because data 
on consultations and referrals were not 
available. Data on reasons for consultation 
ceased to be collected in late 2012. 
“I sometimes got the impression 
that the English campaign, the way 
they reported it in the media and 
the success seemed to have a greater 
connection of data points than we 
did”
Interview participant, ID 14
Challenges when trying to access staging 
data differentiating bowel cancers diagnosed 
through screening from those diagnosed 
through symptomatic presentation were 
also mentioned.  
Stakeholders often referred to local 
initiatives, local evaluations and other 
analyses (as opposed to national level 
evaluations), and referred to anecdotal 
evidence when describing outcomes. While 
some reported not being able to evaluate 
local activities (due to time or resource 
limitations), others carried out evaluations 
frequently but were only able to disseminate 
findings locally.
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Benefits beyond official outcomes
Interviews
As before, some participants raised concerns 
about whether performance targets were a 
good measure of the programme’s success. 
Others highlighted that soft outcomes 
should be better acknowledged.
“You can look at the short term 
benefit and outcomes and you 
can look at the medium and the 
long term, the main benefit is 
regardless of whether your board 
has met the targets or not I think 
that’s very short-sighted to think 
that is a good evaluation of the 
programme because what you’ll 
have is it’s raising awareness of the 
messages and that’s to me the main 
benefit of the DCE programme and 
encouraging people to understand 
that if they’ve got signs and 
symptoms they’ve to go to the GP”
Interview participant, ID 19
Stakeholders stated that DCE helped to 
undermine cultural reticence about cancer; 
and to change the public perception about 
wasting the doctor’s time. It challenged 
the perception that lung cancer was not 
worth talking about nor acting upon, and 
increased overall public awareness about 
screening, and cancer symptoms and 
signs. The programme also encouraged 
conversations and reflections about cancer 
diagnoses between primary and secondary 
care and enhanced both local and national 
partnerships. Acknowledging challenges 
in changing behaviour, many saw DCE as 
a programme with a cumulative effect 
that contributes to long-term changes by 
normalising discussions about cancer.
“My impression is that it has  [...] 
united and galvanised everybody 
who has a stake in cancer policy/
clinicians [...] everybody’s come 
together and genuinely contributed 
into that, whether that’s diagnostic 
services, GPs [...] it feels like a fully 
rounded piece of policy making and 
so whether or not that’s worked as 
much as people hoped at the start, 
I feel that has to be a good thing for 
the cancer community [...] everybody 
is more joined up than they were”
Interview participant, ID 14
DCE was also described as an opportunity to 
get better data, to develop events and share 
learning (although stakeholders wished 
that dissemination and shared learning had 
happened more often).
The programme provided an opportunity to 
develop community events to engage with 
hard to reach communities, to fund different 
approaches to promote early detection 
(such as using the qFIT with symptomatic 
patients) and to enhance collaborations with 
charities (such as piloting Cancer Research 
UK’s Primary Care Facilitator Programme 
in Scotland, and developing a “good practice 
guide” informed by the bowel screening 
initiative).
In some territorial Health Boards, 
stakeholders developed different diagnostic 
pathways. In others, regular team meetings 
to discuss patient cases were implemented 
(in order to be able to do so, there was 
an increase in telephone consultations). In 
some areas, stakeholders continued with 
DCE strategies even after funding ceased to 
be provided.
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Questionnaire participants commented on 
an increasing number of “inappropriate” 
referrals that they perceived to be driven 
by DCE: clinicians either following or not 
following the new referral guidelines, the 
increasing number of worried well in need 
of reassurance, and GPs’ attempts to get 
their patients seen quickly in a context 
of increasing waiting times. Some of the 
described consequences were delays for 
patients requiring surveillance or patients 
with a cancer diagnosis, and impact on 
other performance targets. Some stated 
that the symptomatic approach for breast 
cancer led to patients presenting at later 
instead of earlier stages (in discordance 
with the programme’s targets). Others 
were concerned about overdiagnosing the 
worried well.
Interviews
Interviewed stakeholders commented on the 
need to draw on resources from the breast 
screening programme in order to deal with 
demand brought by the symptomatic breast 
campaign, and on the knock-on impact that 
some initiatives had on services (such as an 
increased demand in Endoscopy generating 
an increase in Pathology). 
For some, DCE resulted in raised anxiety for 
both the public and health care professionals. 
Professionals were anxious about not 
being able to meet patient expectations 
to be seen promptly, and about delays 
happening for other patients. Furthermore, 
stakeholders reported that some patients 
were getting anxious due to delays after 
diagnosis. Stakeholders also described the 
need to compete with other Health Boards 
for specialised staff due to shortages in skills 
and expertise.
“You can’t just knit a pathologist. 
So if every Board’s looking for a 
pathologist and there is a shortage of 
them... [...] Then you might become, 
you know, all competing in a very 
small pool for a very limited amount 
of staff and I think that at times  that 
was actually the reality of what some 
Boards found themselves in”
Interview participant, ID 11
Positive unanticipated outcomes included 
enhanced collaborations with cancer 
charities and better GP engagement 
with patients. There were reports of GPs 
taking the opportunity to help patients 
with long-standing problems while having 
conversations about cancer. In one Health 
Board, DCE influenced the development 
of pathways for gastrointestinal conditions 
other than cancer. Finally, the novel aspect 
of DCE campaigns became an influencer for 
other Scottish Government initiatives. 
598
Detect Cancer Early Evaluation 69
Stakeholder recommendations
Questionnaire
Questionnaire participants recommended 
more planning, improved communication 
and discussions between different teams, 
speaking to “staff who know”, and planning 
handovers. Being advised “well in advance” 
of DCE initiatives (such as when campaigns 
would go live or giving more time for Health 
Boards to prepare bids) was also urged. 
Some recommended focusing on tumour 
types for which there is a “greater chance 
of influencing behaviour” (no examples 
were given). Others suggested targeting 
only patients at risk of lung cancer (with 
an “annual low dose CT of the chest for 
smokers over 60”), allowing GPs to have 
direct access to CTs, setting up diagnostic 
clinics, and targeting smoking prevention. 
Others stated that DCE should focus on 
deprived populations through education 
and provision of information.
Box 15. Stakeholder recommendations
•Target patients at risk using tailored messages to help ensure that the right population benefits, 
and that the system is not overwhelmed with the worried well 
•See the big and the small picture: seeing the importance of both the whole cancer pathway 
and of local initiatives was recommended in order to understand bottlenecks, wide barriers to 
access, and acknowledge local needs and characteristics. Participants believed it was important to 
keep the national early detection umbrella, while also investing in more local initiatives
•The role of prevention and educating younger generations: Some stakeholders 
recommended more initiatives with younger people so they are aware of early detection and can 
develop a more holistic approach to their health. Some acknowledged that prevention was not 
DCE’s main aim, but believed that DCE could still contribute to it
•Tackle health inequalities/inequities in access: recommendations included improving access; 
giving support to those in remote areas, who struggle with costs or competing responsibilities; 
investing on health literacy and welfare rights; working with minority ethnic groups; thinking not only 
about diagnostics but also the burden of treatment and challenges due to social isolation
•Focus on signs and symptoms and in understanding help-seeking behaviour: as signs and 
symptoms represent the “here and now”, they may resonate better with populations who do not 
engage with screening. Stakeholders acknowledged that a change in paradigm was required for this 
to happen (i.e. the patient should be aware that a negative result does not mean one should stop 
seeking help if symptoms persist, and professionals may need to  reconsider the way they assess 
symptoms). Learning from the ACE experience in England for vague, non-specific symptoms was 
described as helpful. There was the acknowledgement that adopting a similar strategy would incur 
costs, but also reflections on the fact that other countries are managing to do it nonetheless
“I think that a dedicated clinic 
with sufficient resources, to whom 
unclear cases are referred, would 
be most useful. I have too often 
seen people referred UCS [urgent 
suspected cancer] to the one 
specialty, given the all clear and then 
turn out to have cancer of a different 
system”
GP and Specialist Doctor
 NHS Ayrshire & Arran
Interviews
Interview participants provided a wide 
range of recommendations; these are shown 
in Box 15.
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Box 15. Stakeholder recommendations (continued)
•Have better local and national data: stakeholders acknowledged that better data was needed 
in order to evaluate the programme, and that data for the whole cancer trajectory was required. 
Being able to see staging for more tumour types was also suggested
•Make the most of opportunities to talk to patients: e.g. if tests show no cancer but there are 
cancer risks, take the opportunity to inform the patient about these risks
•Continue with professional training and awareness raising: stakeholders highlighted that 
there was lack of knowledge and awareness about cancer among NHS staff; and that barriers such as 
fear of wasting the doctor’s time also applied to them.  Adding more information on early detection 
to young doctors’ curriculum was also recommended
•Do not rely on staff who have other jobs to do: have well-assigned roles to ensure that 
required work is done. Often, this recommendation also implied providing additional funding
•Challenge the status quo: focus on innovative strategies that change the way services are provided, 
while also bearing in mind low-cost approaches that have shown to be effective (such as GPs sending 
reminder letters to patients)
•Develop more plans outlining possible impacts of initiatives on workload, and design 
evaluations for all DCE components, while also investigating unanticipated outcomes
•Identify different ways to target breast screening in line with the Breast Screening Centres’ 
recruitment timescales
•Be more prescriptive about how additional funding should be used and ask for more 
information on how it was used
•Continue with campaigns to increase population awareness and knowledge: interview 
participants recognised that the campaigns did not fully tackle the issue of cancer fear or limited 
awareness of signs and symptoms, and that more information was needed as barriers to help-seeking 
persisted
•Enhance engagement and ongoing communication with screening programmes, clinical 
teams, charities and others, aiming to ensure that all feel part of the process
•Be more explicit about the rationale for DCE strategies, and about their importance
•Disseminate DCE outcomes widely and look for further opportunities to share learning
•Incorporate the new referral guidelines into GP systems (this has been done in some 
Health Boards), bearing in mind that “you don’t want the IT to get between you and the patient” 
(for example, having to code during a consultation)
“People from the more deprived communities for a variety of reasons don’t 
engage with screening processes. They don’t engage because they don’t know 
about them or they don’t engage because they don’t think it’s for them. There’s 
something about being more mindful of the best way of getting information 
to people [...] If people are living in outer areas with poor housing and no 
jobs and low income, and you know, basically living in poverty, the relative 
importance they’re going to place on taking up a screening test [...] it’s going to 
be low and so we need to also tackle that by raising people out of poverty”
Interview participant, ID 18
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5. Discussion
5.1 Strengths and limitations
This Evaluation was informed by behaviour, 
implementation and complexity theories. 
It was designed to be methodologically 
robust in order to provide evidence-based 
recommendations. By adopting a range of 
methods and having a multi-step procedure, 
the Evaluation was able to describe a 
complex programme, and synthesise vast 
quantities of data about DCE processes and 
outcomes in a single  document. 
As a dynamic programme, DCE has evolved 
over the years. Even though we aimed to 
evaluate DCE up to 2015, the process 
evaluation allowed for more recent issues 
to emerge. The outcome evaluation also 
described data beyond 2015 to help clarify 
programme evolution and potential issues 
regarding sustainability.  Although this 
Evaluation did not aim to comprehensively 
describe and discuss changes beyond 2015, 
a brief outline of contextual and strategic 
changes is described in Box 16 to facilitate 
further discussions about DCE and our 
recommendations. 
It was not possible to carry out a cost-
effectiveness analysis of DCE components 
due to limited data and the large scope 
of the Evaluation. It is important that 
future initiatives (including pilot studies) 
incorporate a cost-effectiveness analysis 
when feasible.
The outcome evaluation consisted mainly 
of secondary analysis of published data. This 
happened for several reasons. First, there 
was already a wealth of information available. 
It was important to acknowledge the work 
carried out by several DCE stakeholders 
and collaborators. Second, initially planned 
analyses of customised datasets were not 
feasible due to limited data availability, 
delays in accessing data, and challenges to 
demonstrate causality.
No response rates were calculated for 
the questionnaire as it was not possible 
to know how many eligible stakeholders 
were invited to take part. It is likely that 
due to their profile (i.e. busy professionals) 
the response rates were low. Based on 
the participants’ characteristics, there was 
an overrepresentation of secondary care 
doctors, while other relevant groups were 
underrepresented. Therefore, the views 
described here do not necessarily represent 
the experiences and opinions of all DCE 
stakeholders. Nonetheless, secondary care 
doctors are difficult to recruit and their 
views are important.
Perhaps due to the assurance of anonymity, 
questionnaire participants were much more 
critical of DCE than interview participants 
(although this may also have been due to 
having different job roles and different levels 
of DCE involvement).  Hence, it is likely that 
the questionnaire overrepresented those 
who had more negative views about the 
programme and were more motivated to 
take part in the Evaluation. 
Four Health Boards were not represented 
in the process evaluation despite attempts: 
NHS Orkney, NHS Western Isles, NHS 
Shetland and NHS Grampian (the latter was 
represented in evaluation development). It 
is possible that their views on DCE would 
differ.
The MRC136 recommends that evaluations 
are planned as soon as possible, preferably 
during programme design. This helps to 
ensure that baseline data are available, and 
that proposed evaluations are feasible. 
We  strongly recommend that any future 
policy initiatives develop evaluation plans 
of both processes and outcomes before 
implementing new programmes.
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Box 16. Relevant developments after 2015
Since 2015, DCE has continued to develop awareness campaigns and initiatives, including the “wee 
c” (aiming to reduce the fear surrounding cancer) and “#getchecked”.  A DCE Conference in 
September 2016 disseminated programme results to stakeholders.  A new Cancer Plan has been 
published96; and DCE remains a key component. Documents outlining DCE progress according 
to the new Cancer Plan have been made available137. Cancer Research UK has published a report 
indicating the next steps for cancer services in Scotland (and discussing DCE objectives)138, while the 
Scottish Parliament has discussed the role of DCE in Cancer Prevention139.
There has been a review of CWT Standards140 and attempts to reach clinical consensus on optimal 
links between pathways and waiting times. Screening programmes have been allocated funding, and 
DCE has a stronger focus on targeting health inequalities and identifying improvement strategies96. 
Furthermore, DCE’s reduced budget required changes in awareness campaigns (such as not focusing 
on a single tumour type) and Strategy 3 (additional funding for Health Boards) is no longer possible. 
However, there is still scope for funding innovative pilots such as multi-diagnostic centres and studies 
investigating direct access to diagnostics (personal communication, DCE Programme Board).  
An app with referral guidelines was launched in 2016; there is a stronger emphasis in using digital 
resources to optimise the referral process, reduce costs, facilitate usage and sustainability, and ensure 
that the most up-to-date guidelines are being used (personal communication, DCE Programme 
Board). Referral guidelines are being updated again through a rapid review process. There is current 
work on Cancer Decision Support Tools; qFIT for symptomatic patients is being piloted in different 
Health Boards; and pilots to improve the early detection of melanoma have been implemented 
(personal communication – DCE Programme Board). The Faecal Occult Blood Test adopted for 
bowel screening was replaced with the FIT in November 201796. The CRUK Facilitator Programme 
is being implemented in different areas in Scotland, and an evaluation of the initiative in NHS 
Greater Glasgow & Clyde has been published141. There is ongoing work with Teenage Cancer Trust, 
targeting both cancer prevention and young influencers to help promote early detection (personal 
communication, DCE Programme Board).
Quality and Outcomes Framework (QOF) ended in April 2017 and was replaced with a new quality 
framework for GP clusters142, 143. HEAT targets are now part of Local Delivery Plan (LDP) Standards 
alongside other Standards such as Treatment Time Guarantee144.
In terms of data, the practice profiles (part of Strategy 2) will be implemented with fewer data 
variables in order to be feasible (personal communication, DCE Programme Board). The Scottish 
Primary Care Information Resource (SPIRE) is being introduced in Scotland145. Furthermore, the 
first National Cancer Diagnosis Audit in Scotland has been published146.  There have  been promising 
findings in breast cancer treatment147 and an European position statement on lung cancer screening 
has been published148. Innovative work adopting the Danish model for vague, non-specific symptoms42, 
88 is happening in England149, and more reviews of cancer pathways and direct access to diagnostics 
have been published150.151. Relevant discussions on how to make the most of limited diagnostics 
resources are also available43. 
602
Detect Cancer Early Evaluation 73
5.2 Reflecting upon results
This Evaluation aimed to investigate DCE 
processes and outcomes and provide 
recommendations for DCE and future 
initiatives. Evaluation results described a 
complex programme that has a widely 
accepted overall premise, but is accompanied 
by different stakeholder views on how 
it should be implemented and how early 
detection should be promoted. Built into a 
context where health care and workforce 
resources are limited, population need for 
diagnostics are increasing (with inequalities 
across different groups) and tight time 
frames are required to show success, DCE 
was (and remains) a challenging undertaking.
5.2.1 Outcome evaluation
Analysis of DCE objectives indicated that 
these were not always associated with 
measurable outcomes. Not all objectives 
were systematically assessed by the 
programme nor by this Evaluation. This 
was due to lack of data (not yet collected, 
expected but not made available, collected 
only for a short period), or barriers 
to accessing available data, challenges 
in gathering and sharing local data, and 
pressures in order to meet the programme’s 
deadlines and key targets. 
There were also situations in which analyses 
were carried out, but not all stakeholders 
had access to the results. As a consequence, 
stakeholders taking part in the process 
evaluation often referred to anecdotal 
evidence, and wished to know more about 
the programme’s impact.
The HEAT targets were not met, but there 
was an increase in cancers diagnosed at 
Stage I overall, and for breast and lung 
cancers (the latter reached 25% in Year 
3). Improvements  in recording of staging 
data have also been noted (such as 44.2% 
reduction in Year 3 for all three cancers 
combined).  These improvements, especially 
in Year 1, explain some of the improvements 
in the proportion of cancers diagnosed at 
Stage 1. 
Evaluations of DCE social marketing 
campaigns showed increase in knowledge and 
awareness, and indicated attitudinal changes 
over time. However, they also highlighted 
the need to continue with messages. Data 
showing increase in breast consultations 
and in requests for replacement bowel 
screening kits also indicated that campaigns 
have reached the public (although not 
necessarily the target population). Increase 
in consultations for breast symptoms did 
not result in more breast diagnoses (as 
most who consulted were the worried 
well). Increase in requested kits did not 
result in a higher proportion of colorectal 
cancers diagnosed at Stage I. In fact, there 
was a decrease. There are many possible 
explanations for these results. Screening 
identifies precancerous polyps; perhaps 
there were no improvements in staging 
for symptomatic patients; or populations 
that did not attend screening in the past 
started to take part and their cancer was 
advanced (personal communication, DCE 
Programme Board). Reasons need to be 
further investigated. In order to do so, data 
on routes to diagnoses would be useful. 
Furthermore, it was challenging to assess 
objectives when they were associated 
with soft outcomes. From the perspective 
of stakeholders, these objectives were 
equally or even more important than those 
associated with hard outcomes. Table 1 
provided a range of examples of activities 
carried out as a result of DCE funding, but 
benefits are hard to quantify.
Finally, stakeholders often recognised that 
despite having short-term targets, the 
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required behavioural changes and shifts 
in cancer outcomes were a long-term 
endeavour (and that DCE benefits may not 
be seen for many years, or it may not be 
possible to measure all of them).
5.2.2 Process evaluation
Findings showed that there was 
overwhelming support for early cancer 
detection, even when stakeholders 
disagreed with DCE strategies or reported 
that the programme had a negative impact 
on workload. Furthermore, findings 
highlighted how communication and buy-
in were associated with engagement and 
sense of ownership. Results also shed 
light on collaborations that resulted in 
developing and continuing early detection 
initiatives, sharing specialised knowledge, 
and disseminating early detection messages.
Results indicated that there was a direct 
relationship between involvement in 
DCE (and being able to give input) and 
considering the programme and its 
strategies to be appropriate. Furthermore, 
understanding the rationale for programme 
initiatives and being able to see their impact 
positively influenced buy-in and engagement. 
Nonetheless, concerns about not receiving 
sufficient (nor timely) information were 
common among both interview and 
questionnaire participants. Conversely, 
questionnaire findings showed that a 
substantial proportion of stakeholders was 
happy not to be involved. This indicates 
that some professionals may prefer more 
detailed information, while others would 
be satisfied with general, less frequent 
communication. It is important to identify 
ways to differentiate these groups.
Stakeholders had positive views about the 
bowel screening initiative, and some argued 
that this was because it was easier to see its 
impact compared to other DCE strategies, 
and stakeholders believed that they could 
make a difference. It is crucial to identify 
and maintain initiatives which are successful 
and widely accepted if DCE wishes to be 
sustainable over time.
Some stakeholders disapproved of the 
HEAT targets as they were perceived not 
to be achievable (and this was detrimental 
to stakeholder engagement and sense of 
ownership) and caused frustration. When the 
targets were not met, some were uncertain 
of whether the programme was worthwhile. 
Conversely, the ones who saw the target as 
aspirational (often stakeholders who were 
more involved in the programme or were 
used to aspirational targets) celebrated the 
results as they indicated improvements (even 
if confounded by better data recording – as 
this was also an improvement). Furthermore, 
others wondered whether meeting the 
target was an indication of success.
Finally, findings showed that initiatives (local 
or national) that are shown to work and 
then are not disseminated can result in 
frustration, disengagement and potentially 
missed opportunities for sharing knowledge. 
Furthermore, it is likely that this limited 
dissemination helped to drive attention 
only to aspirational targets, minimising 
programme impact and not making the most 
of generated evidence that can potentially 
improve practice.
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6. Recommendations
Evaluation findings informed the 
development of draft recommendations; 
these were then presented at a Workshop 
with DCE stakeholders and a lay 
representative (Edinburgh – 18th September 
2018). They helped to refine and prioritise 
the recommendations shown below. 
Prioritisation was perceived to be dependent 
on personal interests, and a challenging task 
as recommendations were often connected 
and interdependent. 
Acknowledging that DCE adopts a whole-
systems approach, and that contextual 
barriers and facilitators are important, 
recommendations are given at a provider 
level, organisational level, local level, and 
national level (for DCE and beyond DCE)152 
(Figure 25).
Strike a balance between short- and long-term 
outcomes/objectives and aspirational/achievable targets
Ensure communication channels result in more timely, 
targeted information sharing





Good data availability and improved, timely access to 
data are vital and urgent
Consider other early diagnosis approaches for 
patients presenting with symptoms
Consider different ways to target patients at risk, 
especially deprived populations
Broaden the scope of outcomes to include 




Fig 25. Evidence-based recommendations
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Recommendation 1: Good data availability and improved, 
timely access to data are vital and urgent
Evaluation findings showed that data availability influenced the ability to measure outcomes, 
compare results with initiatives in other countries, and influenced stakeholder engagement. 
Good data is paramount to assess programme outcomes and identify ways to improve 
service provision.
•National level (beyond DCE): we urgently need better IT systems and datasets. ISD 
Scotland should be consulted about feasibility and sustainability of data collection, storage 
and retrieval.
•Local level: experienced academics and charities should be consulted further to give 
advice on relevant early detection data to be included in datasets
•Organisational level: general practices have information on feasibility of data collection, 
barriers and facilitators
Workshop participants added that having good data also means fixing recognised IT 
problems in computer systems, including at Breast Screening Centres. Furthermore, 
they highlighted that it is not only about having good data, but also having the 
right kind of data (the National Cancer Diagnosis Audit in England was given as an 
example). Having consistent, established, real-time data was urged.
Recommendation 2: Consider other early diagnosis 
approaches for patients presenting with symptoms
This recommendation is based on process evaluation findings and evidence from the 
literature showing that most cancers are still diagnosed after symptomatic presentation. 
Hence, in order to improve early detection, it is important to improve early diagnosis for 
patients with symptoms.
•National level (beyond DCE): consider funding one-stop clinics and multi-diagnostic 
centres, providing more direct access to diagnostics and adopting successful strategies 
currently taking place elsewhere
•National level (DCE): continue funding pilots with innovative ideas on how to diagnose 
symptomatic patients (such as qFIT) – incorporate a cost-effectiveness analysis when 
doing so
Some workshop participants recommended prioritising this recommendation 
above others, and suggested adopting the Danish approach for vague, non-specific 
symptoms. Others referred to local, successful experiences implementing pathways 
for patients with vague symptoms (such as providing direct access to CT scan).  
One of the described initiatives had to end (despite being successful) due to limited 
resources in Radiology.
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Recommendation 3: Consider different ways to target patients 
at risk (especially deprived populations)
Despite attempts to target deprived populations and other groups at a higher risk of 
cancer, DCE campaigns also attracted a high number of worried well seeking reassurance. 
The deprivation gradients for cancer screening, mortality and survival persist despite 
improvements.  Hence, it is important to consider different ways to target those most in 
need, not only to improve cancer outcomes and reduce inequalities in health, but also to 
use valuable, scarce resources efficiently. 
•National level (beyond DCE): ongoing work to reduce inequalities and increase prevention 
strategies should continue
•National level (DCE): charities have experience working with deprived communities and 
can provide further input
•Local level: charities and the community have expert knowledge; past DCE collaborations 
with local businesses have also been positive
•Provider level: primary care has a key role in engaging with deprived communities – but 
additional funding is required to enable this
Workshop participants mentioned current work trying to tackle inequalities such as the 
Screening Inequalities Fund; and DCE’s current focus on reducing inequalities.
Recommendation 4: Broaden the scope of outcomes to 
include intermediate, soft and process outcomes
Evaluation findings indicated that these outcomes facilitated stakeholder engagement and 
enhanced assessment of programme impact (for stakeholders, patients and the public). In 
order to define intermediate outcomes, it is crucial to understand barriers and facilitators 
in different areas, and for different professionals, and assess the feasibility and acceptability 
of data collection. It is also important to understand stakeholders’ expectations.
•National level (beyond DCE): IT systems and data collection should be in place before an 
initiative begins.
•National level (DCE): 1) consult with clinicians and allied health professionals to decide on 
relevant intermediate outcomes (these may be already available) – while ensuring that these 
are feasible and measurable over time; 2) assess and acknowledge improvements in these 
outcomes; 3) continue focusing on new evidence/new developments in early detection
Workshop participants mentioned a range of intermediate outcomes that were already 
available to be assessed. Some believed that measures other than cancer survival should 
be equally promoted. Recommendations included having outcomes that are measured 
every year or every 18 months, and reporting on numbers instead of percentage change 
(as percentages were reported to give unfair advantage to those with poorer performance, 
and penalising those with good performance at baseline). Some suggested the assessment 
of 1-year lung cancer survival for deprived populations.
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Recommendation 5: Strike a balance between short- and long-
term outcomes/objectives and aspirational/achievable targets
This recommendation was developed after presentations and discussions at the Workshop. 
While there may be tension between political and health service aims, there is the need to 
strike a balance between short- and long-term outcomes and the choice of targets. This is 
important to ensure engagement, ownership, measurement of programme benefits (including 
those that require long-term assessments), and sustainability of effective strategies.
•National level (beyond DCE): It is important to ensure at least mid-term sustainability and 
ongoing support for initiatives (including financial enablers)
•National level (DCE): If stakeholders can see how an objective is relevant to them and result 
in positive benefits, while also having the assurance that successful initiatives will continue, 
engagement (and sense of ownership) will be facilitated – good two-way communication is 
also crucial for this to happen
Workshop participants discussed these issues at length. They believed that successful 
DCE strategies (e.g. bowel screening initiative) should have continued. One-off resources 
and funding announced year to year were described as not being conducive to long-term 
planning. Longer-term financial planning would allow for bigger (and more sustainable) 
changes in service provision. Workshop participants also discussed the benefits and 
limitations of having short-term (avoiding challenges due to high staff turnover and system 
changes but hindering engagement) and long-term objectives (which facilitate sustainability, 
but people change over time). Some argued that the key was to ensure that stakeholders 
had confidence about long-term commitment
Recommendation 6: Ensure communication channels result 
in more timely, targeted information sharing
Communication challenges and requests for more information were often mentioned 
by stakeholders. It is important to ensure that appropriate information systems and 
communication channels are in place, while also avoiding information overload.
•National level (beyond DCE): good IT systems and good data are needed to enable 
communication and dissemination
•National level (DCE): 1) Ensure DCE rationale, findings and best practices are well 
disseminated; 2) Identify further avenues for disseminating results, best practice and peer 
learning; 3) acknowledge local work/efforts to promote early detection; 4) identify local 
“communication champions” to help with information sharing
Workshop participants discussed the challenges of communicating with different groups 
and facilitating engagement. There was the recognition that regional representatives had a 
key role ensuring that information was disseminated, as it was not possible to engage with 
everyone, nor address everyone’s needs and concerns. Others emphasised the importance 
of shared learning not only within Scotland, but also across the UK.
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Recommendation 7: More specialist workforce and diagnostic 
equipment are needed
Evaluation findings described several challenges regarding limited workforce and diagnostic 
capacity. Hence, this final recommendation refers to this broad, complex issue.
•National level (beyond DCE): 1) more training and incentives for several areas of expertise 
are needed, in addition to having the ability to recruit outside the UK when necessary; 2) 
Consider carrying out a national consultation and audit of key issues and bottlenecks 
across the whole cancer pathway – otherwise delays may just happen after diagnosis.
Some workshop participants believed that this recommendation should be a long-
term guiding principle, and that smarter use of workforce was also required.
7. Conclusion
This was a large scale, system-level Programme Evaluation carried out over three years. It 
generated and synthesised a wealth of information on DCE processes and outcomes, in 
addition to highlighting key contextual barriers and facilitators, and providing stakeholder and 
Evaluation recommendations. 
It is hoped that the results will be useful as a tool alongside other early detection evidence 
to guide not only future directions for DCE, but also to inform other early cancer detection 
programmes.
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Appendix 1. Description of the four DCE strategies
The DCE Programme developed several social 
marketing campaigns in order to increase public 
awareness about cancer and generate behaviour 
change. The overall aim of social marketing was 
to raise awareness of the benefits of early 
detection, build belief that one can survive 
cancer (as it is not what it used to be) and to 
drive people to attend screening or seek help if 
they have any concerns. Campaign timelines are 
described below.
Social marketing activity started at the DCE 
launching event in February 2012. Insight 
gathering was carried out before campaigns 
started in order to inform them. 
The campaigns involved collaborations with 
a number of agencies. An Advertising Agency 
(Leith Agency) was responsible for insight 
gathering, campaign development, dealing with 
field and partnership, engaging with commercial 
organisations and working with Health Boards 
on campaigns. It also coordinated work with 
a Media Agency (Carat - which prepared 
television adverts and other press outputs), 
a Market Research Company (TNS - which 
organised focus groups with members of the 
public to inform the social marketing campaigns 
and carried out campaign evaluations), and a 
Public Relations (PR) Agency (Consolidated 
PR – which prepared case studies for the 
campaigns, secured free editorials, opinion 
pieces and magazine features). DCE also liaised 
with a Digital Agency (initially Storey and then 
the Union) which was responsible for website 
development. 
The overall media strategy for campaigns 
1.Public Awareness and Behaviour Influencing Strategy
Feb/12 May/12Apr/12Mar/12 Jun/12 Sep/12Aug/12Jul/12 Oct/12
DCE is launched
Nov/12 Feb/13Jan/13Dec/12 Mar/13 Jun/13May/13Apr/13 Jul/13
Phase1 - Bowel Screening campaign (Feb - Apr)
Aug/13 Nov/13Oct/13Sep/13 Dec/13 Mar/14Feb/14Jan/14 Apr/14




Detect Cancer Early campaigns timeline (Feb 2012 - Jan 2015)
Phase 2 - Bowel Screening 
campaign (Sep-Oct)
Phase 3 - Bowel Screening 
campaign (Feb - Mar)
Phase 4 - Bowel 
Screening 
campaign (Apr - May)
Phase 4 - Bowel 
Screening 
campaign (Apr - May)
Phase 5 - Bowel Screening 
campaign (Jul - Aug)
Phase 6 - Bowel 
Screening 
campaign (Oct)
Priming campaign (Feb-Mar) Breast (symptomatic) campaign 
(Sep-Oct)
Repeat of priming 
campaign (2 weeks)
Phase 1 Breast (screening) 
campaign (Jun-Jul)
Phase 2 Breast (screening) 
campaign (Sep-Oct)
Phase 1 Lung campaign
 (Nov-Dec)
Phase 2 Lung campaign
 (Jan-Feb)
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Priming campaign 
The priming campaign targeted adults aged 40+, 
C1C2DE in Scotland. The first phase of the 
campaign ran between Feb-Mar 2012, with the 
use of TV and radio adverts, posters and leaflets. 
The priming campaign aimed to reduce fear 
associated with cancer and encourage earlier 
detection; both issues were salient during insight 
gathering. It was carried out in February and 
March 2012. Core messages included: “Cancer. 
Don’t’ get scared, get checked”; “the earlier we 
find cancer, the easier it is to treat”; “twice as 
many people survive cancer now compared 
to 30 years ago”. It targeted C2DE Adults 45+ 
in Scotland through television adverts (shown 
for 6 weeks - a GP encouraged people to seek 
help when noticing symptoms), radio (shown 
for four weeks - interviews with real doctors), 
washroom posters, leaflets, 6-sheet, and PPC. 
In both rural and deprived areas, media vinyls 
were placed in washrooms in doctor/dentist 
surgeries, pharmacies, community centres and 
libraries to deliver a personal message. PR 
activity and digital media were also used.
included shared media (television to maximise 
coverage – with defined strategies on what 
programmes to target to ensure the right 
groups would see them), one-to-one media 
(radio delivering more personal messages in 
daytime, with coverage in community radio, 
more rural and hard-to-reach areas). There 
were also activities in rural and deprived areas 
(surgeries, pharmacies, libraries). Outdoor was 
used tactically. Furthermore, campaigns were 
supported by the use of social media and pay-
per-click (PPC). 
DCE also aimed to do additional PR and social 
media activity around the breast (October), 
bowel (April) and lung (November) cancer 
awareness months. All campaigns had a key 
message and specific call to action for the public. 
There were several campaigns over the years, 
this appendix describes the key strategies in 
DCE’s first three years: the priming campaign, 
the breast (symptomatic) campaign, the 
breast (screening) campaign, the bowel cancer 
campaign, and the lung cancer campaign.
Breast (symptomatic) campaign 
The first tumour-specific campaign focused on 
symptomatic breast cancer. It aimed to target 
women aged 45+ (as breast cancer incidence is 
higher for this group) living in the most deprived 
areas of Scotland (as they are less likely to 
attend screening and tumours are more likely 
to be detected at later stages). 
The campaign was informed by insight gathering 
showing that women in Scotland had little 
knowledge about breast cancer symptoms and 
signs beyond lumps. Often, they also believed 
that a negative screening result meant an “all 
clear” and that there was no need to check 
for symptoms between screening rounds. 
The decision to focus initially on symptoms 
instead of screening was also influenced by 
an independent review of breast screening 
(Marmot et al 2012. The benefits and harms 
of breast cancer screening: an independent 
review. Lancet; 380(9855);1778-86). It was not 
considered appropriate to focus on screening 
before the review results were available.
The campaign ‘Let’s talk about breasts’ featured 
Scottish actress Elaine C Smith holding boards 
over her breasts, showing real images of breast 
cancers. Creative testing was carried out before 
launching the campaign; focus group participants 
were overwhelmingly in favour of this new, bold 
approach. 
TV adverts were shown for four weeks in 
September 2012 (other activities continued until 
Breast Cancer Awareness month in October). 
Adverts could only be shown after watershed, 
i.e. time when adult content can be broadcast, 
to avoid children from watching graphic images. 
Magazine inserts were placed in titles often 
read by the target audience (such as Bella, Take 
a Break, and Chat). Radio and press adverts 
were also used; and leaflets and posters were 
distributed to general practices, community 
pharmacies and businesses. Radio and press 
adverts further supported the reach and 
frequency to build awareness across Scotland, 
as well as allowing more secondary messages 
such as the importance of participating in 
screening to be incorporated. PR was adopted 
with the use of real-life case studies, while Field 
and Partnership marketing supported a range of 
local messages across Scotland. 
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Breast (screening) campaign 
This campaign aimed to increase breast screening 
uptake, especially among non-attenders from 
deprived areas, by clarifying myths about the 
breast screening process and highlighting the 
benefits of screening (following principles of 
informed choice).
Differently from other campaigns, it adopted 
a regional roll-out (as opposed to national) in 
order to reach areas with the poorest uptake 
and match areas where breast screening was 
taking place (breast screening invitations are 
based upon primary care practices and patients 
are invited every three years). 
The campaign was divided in two phases; the 
first one took place in June-July 2014 and the 
second phase took place in September-October 
2014. Close work with the Scottish Breast 
Screening Programme was required in order 
to target the correct locations. The West and 
the South East of Scotland were chosen to 
be targeted first, and each Breast Screening 
centre provided data on practices due to send 
invitations for screening (including the location 
of mobile screening units when applicable). 
As Elaine C Smith was well accepted for the 
symptomatic campaign, she was also a key part 
of the screening campaign. Her presence also 
helped to ensure that the same target audience 
made a connection between the different 
campaigns. “Real women” from across Scotland 
also took part and shared why they chose to 
attend screening. Different women were shown 
in local press in order to connect with the 
target audience and give the campaign a sense of 
locality. If this was not possible the overarching 
Elaine C Smith execution was used. 
The campaign used local radio, press advertising, 
PR activity and digital media. Leaflets were 
distributed to Health Boards, primary care 
practices and community pharmacies.
Elaine C Smith voiced a radio advert describing 
the importance of screening in finding cancers 
that cannot be seen or felt, and that are easier 
to treat. A trained team visited locations with 
high footfall (such a shopping centres and local 
supermarkets) in areas due to be invited for 
screening. There were face-to-face interactions, 
time to answer questions, distribution of 
campaign materials and a breast challenge 
(putting their hands in two holes where there 
were two prosthetic breasts and counting the 
lumps they could feel).  A a keyring (nicknamed 
“thingymaboob”) which illustrated how 
screening could detect very small cancers was 
also distributed. 
Households in deprived areas that had just been 
invited for screening received a mail drop (acting 
as a reminder or a primer). PR activity took 
place to address screening myths, share positive 
screening stories and try to normalise screening 
through education about its benefits and harms. 
“Screen Stars” was one of these activities: a 
walk of fame was created recognising women 
who are stars of breast screening. 
The call to action was the same across different 
channels:  “If you’ve missed a screening in the 
last two years, or have recently received an invite 
through your letterbox for a time that doesn’t suit 
you, text SCREEN and your postcode to 61611 
to rearrange”.  The telephone number of their 
regional screening centre was then provided. As 
text responses did not result in many screening 
appointments, a second six-week phase was 
developed with a different message: “Thanks for 
contacting us. Your local centre will soon call you 
from a 0800 number to discuss your next screening 
appointment. No SMS? Reply SCREEN STOP”. The 
relevant regional screening centre then called to 
book an appointment. 
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Bowel (screening) campaign 
The bowel screening campaign had six phases 
up to January 2015 (further phases have 
happened since then). The first phase of the 
bowel campaign was launched in February 
2013 and lasted six weeks. Other five campaign 
phases ran from September 2013 (four weeks), 
March 2014 (four weeks), April 2014 (three 
weeks), July 2014 (three weeks) and October 
2014 (four weeks). 
The campaign’s overall aim was to increase 
bowel screening participation. Behaviour shifts 
were planned by 1) providing information about 
how early detection of bowel cancer (through 
screening) was the best way to survive bowel 
cancer; and 2) empowering the population to 
take part in bowel screening. The population 
of interest was both men and women aged 45-
74 from the C1C2DE demographic (although 
men were more targeted as they take part in 
screening less often than women).
The social marketing team wished to normalise 
bowel screening and tackle the social stigma 
attached to it, while also appealing to the male 
population.  A touch of humour was therefore 
added to the campaigns.
The campaign’s key messages were “bowel 
cancer is the third most common cancer in 
Scotland”, and “bowel screening is the best way 
to detect bowel cancer early”. 
A key initial campaign component was a 
TV advert voiced by a Scottish actor (Ford 
Kiernan). Ford was a hidden voice talking to a 
regular guy on the toilet about facts he didn’t 
know about bowel cancer, such as “the early 
signs are often hidden”. Humour was also used 
in a developed ‘poo song’ (launched in April 
2013 – Bowel Screening Awareness Month) 
that aimed to increase conversations about the 
subject and encourage children of those eligible 
for screening to work as influencers.  
Printed materials had three key messages: “the 
early signs of bowel cancer are often hidden”; 
“9 out of 10 people survive bowel cancer 
when it is detected early”; and “the best way 
to find bowel cancer early is to do your home 
screening test”. The call to action was “Bowel 
Cancer. Don’t Take a Chance. Take the Test” 
accompanied by the Scottish Bowel Screening 
Centre Helpline number and the campaign 
website (bowelscreeningtest.org).
 
Television was used to generate widespread 
awareness and create maximum impact. Press 
advertising supported television in reaching the 
targeted DE male audience, while also reaching 
women. There were radio executions (two 
generic and a third carrying a stronger call to 
action - using Ford Kieran’s voice to ensure the 
link between television and radio campaigns). 
Small outdoor formats were placed in areas 
of high deprivation and low screening uptake; 
these included over 800 lenticular posters in 
washrooms, bars, clubs, and Rangers and Celtic 
football club stadiums; 500 panels in toilet 
cubicles; over 2000 bus headliners in buses 
covering areas in Glasgow, Edinburgh, Forth 
Valley and Lanarkshire. Leaflets and posters 
were distributed to primary care practices 
and community pharmacies. Partnerships were 
developed with football clubs across Scotland in 
order to reach more men.
Different campaign phases used television, radio, 
outdoor, press and digital resources. PPC activity 
underpinned all phases. 
Campaigns were also supported by Field 
and Partnership and PR activity. There were 
engagement events with the public in over 60 
locations across Scotland, Event staff visited 
high attendance football matches to engage 
with large numbers of men. Furthermore, the 
PR team worked with Bowel Cancer UK to 
ensure that there was media coverage during 
and beyond the campaigns.
The sixth phase slighted shifted its focus to have 
a stronger message in terms of cancer survival. 
The message “9 out of 10 people survive bowel 
cancer if found early” evolved to become “when 
bowel cancer is found early, it can often be 
cured”. A range of resources (such as hideaway 
books to store the bowel screening test and 
football cards) were developed.
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Lung (symptomatic) campaign 
The lung campaign was carried out after 
the breast and bowel campaigns, and had 
three phases. The first phase was launched 
in November 2013 (Lung Cancer Awareness 
Month) and lasted four weeks.  A second phase 
was launched in January 2014 and was live 
for a month.  The third phase was launched in 
November 2014 and lasted four weeks.
The first two phases aimed to build belief that 
something can be done for lung cancer when 
it is found earlier and highlight that people can 
have better quality of life if cancer is diagnosed 
earlier. The call to action was ‘Don’t Get Scared, 
Get Checked”, accompanied by “If you’re 
worried about a change to your cough, see your 
GP as soon as possible”. The campaign targeted 
men and women aged 55+ from the most 
deprived areas in Scotland.
Compared to the breast and bowel campaigns, 
the lung campaign was less positive around 
survival and more focused on controlling 
symptoms. There was the acknowledgement 
that early detection of lung cancer is challenging 
as symptoms are not often present until later 
disease stages; diagnosis and treatment are also 
difficult. 
Lung cancer was also the only tumour type 
(included in DCE’s first three years) for which 
there was no organised screening programme 
available. In order not to discourage smokers as 
they were a crucial group to reach, the campaign 
did not approach smoking cessation. 
The use of emotion was perceived to be crucial 
to help with behaviour change. The campaign 
was fronted by Sir Alex Ferguson, someone 
well-trusted and known for his honesty, and 
whose parents died of lung cancer.
The first phase used television for two weeks 
to generate widespread awareness and create 
impact. There was also press advertising in 
national, evening and local press titles for 
eight weeks. Radio was not used as it was 
not considered to be effective for the target 
audience. Signs were placed in bus panels. In 
January, television, press and six-sheets were 
used, and campaign messages were placed in 
pharmacy bags across Scotland. 
Field and Partnership and PR activities also 
took place in both phases, with one-to-one 
engagement across Scotland (especially in more 
deprived areas as deprived populations are 
known to be at a higher risk of lung cancer due 
to higher smoking prevalence). There were PR 
collaborations with The Roy Castle Lung Cancer 
Foundation and The British Lung Foundation to 
ensure that there was media coverage about the 
campaigns.
Change in direction
Attitudinal tracking showed that almost half 
of Scots did not know that a persistent cough 
was a sign of lung cancer.  Furthermore, BCOC 
in England had emphasised coughs in their 
campaign, with perceived benefits. Hence, there 
was engagement with the Roy Castle Lung 
Cancer Foundation, British Lung Foundation and 
lead clinicians in both primary and secondary 
care to decide on whether the approach should 
be taken in Scotland. A decision was made to 
use a more direct call to action for phase 3: ‘If 
you’ve had a cough for three weeks, your GP 
wants to see you.’
The campaign objectives shifted to raising 
awareness that a three-week cough can be a sign 
of lung cancer, and reassuring people that their 
GP wanted to see them. Sir Alex Ferguson’s was 
also involved in the three-week cough message.
  
Radio was used to illustrate how a persistent 
cough can be disruptive (advertising space was 
bought before, during and at the end of advert 
breaks) and targeted influencers (those who 
notice someone close to them coughing too 
often).  Pharmacy bags carrying the three-week 
cough message were circulated throughout 
pharmacies in more deprived areas in Scotland. 
Bus panels were added to bus routes in deprived 
areas; and a “coughing bus stop” was added to 
two locations with a special message after the 
coughing: “don’t hang around waiting for that 
cough to clear up, see your GP”.  
Field and partnership, television, press, and 
PR activity also took place. A doctor from a 
deprived area in Glasgow and representatives 
from Roy Castle Lung Cancer Foundation and 
British Lung Foundation were photographed 
showing lit-up letters spelling “cough”; and GPs 
across Scotland were used to reinforce the 
message that they wished to see patients with a 
three-week cough.
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2.Primary Care Symptom Management and Referral Strategy
This strategy consisted of education sessions 
for health care professionals and review of 
urgent referral guidelines for suspected cancer. 
Before DCE implementation, there were also 
plans to develop practice profiles, describing 
primary care referral behaviour in order to 
facilitate planning, reduce variation in referral 
behaviour and potentially decrease rates of 
emergency presentations. However, the practice 
profiles were not made available before DCE 
completed three years. 
Education sessions 
Seven primary care engagement sessions 
were delivered by experts from Roy Castle 
Lung Cancer Foundation and Bowel Cancer 
UK between September-October 2013.  The 
sessions informed primary care professionals 
of DCE’s strategies (such as bowel and lung 
campaigns, and the bowel screening initiative), 
and the role of primary care in them. Sessions 
also discussed cancer signs and symptoms, and 
presented the new referral guidelines for lung 
and bowel cancer.
There were also four pharmacy education 
sessions in Dundee, Edinburgh, Glasgow and 
Dumfries. 
Data sources for Strategy 1: Policy documents received during evaluation development 
and personal communication at the DCE Programme Board meetings. Documents comprised: 
Consolidated PR Detect Cancer Early campaign briefing packs for breast screening, symptomatic 
breast and lung cancers; breast screening, breast symptomatic, lung and bowel screening case 
study documents prepared by DCE,  evaluation report prepared by TNS (“Bowel Cancer 
Campaign Evaluation / Tracking December 2014), evaluation report prepared by Made in Leith, 
Carat and Consolidated PR (“Detect Cancer Early campaign wash-up. Priming, Breast Cancer, 
Bowel Cancer, June 2013”)
Data sources for Strategy 2: Policy documents received during evaluation development 
and personal communications at the DCE Programme Board meetings. Documents comprised: 
Roy Castle Lung Cancer Foundation. Report to Scottish Government – Detect Cancer Early 
Workstream 2013; Roy Castle Lung Cancer Foundation and Bowel Cancer UK. Detect Cancer 
Early Primary Care Engagement Project. 2013 and the Scottish Referral Guidelines for Sspected 
Cancer May 2014 (available from: http://www.healthcareimprovementscotland.org/our_work/
cancer_care_improvement/programme_resources/scottish_referral_guidelines.aspx).
Referral guidelines for suspected cancer 
In order to update referral guidelines, evidence 
tables with recommendations from UK and 
international guidelines (published in English) 
were prepared. Other guidelines were 
identified from websites for several guideline-
producing organisations in June 2012 (and 
updated in January 2013), and Medline and 
Embase searches.  Recommendations were then 
assessed for methodological quality using the 
validated Appraisal of Guidelines for Research 
and Evaluation II (AGREEII) instrument.  A note 
was added on whether they should be further 
recommended (yes/no).
Stakeholders then systematically analysed 
differences in the available recommendations, 
while also considering their clinical and practical 
experience, knowledge of the literature, and 
the Scottish context.  Stakeholders included 
academics, members of the Royal College of 
General Practitioners, from the Scottish General 
Practitioner Committee (SGPC), the Scottish 
Medical School Committee (SMSC), the British 
Medical Association Scotland, clinical leads from 
Cancer Networks, staff from charities, clinical 
directors, directors of imaging, among many 
others.
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3. Secondary Care & Diagnostic Capacity Strategy
Territorial Health Boards were asked to 
make bids for funding, which was allocated via 
NRAC share (http://www.tagra.scot.nhs.uk/
research/). The NRAC formula was developed 
by the NHSScotland Resource Allocation 
Committee (NRAC). It takes into account 
population projections, while adjusting for age/
sex composition, needs due to morbidity or 
other factors such as deprivation, and costs due 
to remoteness. Territorial Health Boards were 
required to send  brief annual reports to DCE 
describing: 
1. Main activities supported by the funding 
allocation in order to help achieve DCE 
objectives from the implementation plan
2. Main challenges to achieving planned 
objectives and action taken to tackle these
3. Main benefits realised as a result of funding
4. Description of how improvements would 
be sustained beyond DCE
5. Key achievements and lessons learned
Data sources for Strategy 3: Policy documents received during evaluation development. 
These comprised summaries prepared by DCE describing how funding was used and the source 
documents used by DCE to prepare these summaries (i.e. annual reports submitted by territorial 
Health Boards (2012/2013, 2013/2014 and 2014/2015)
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4.  Performance Management & Monitoring Strategy
Developing the target and gathering data
The HEAT target was “to increase the 
proportion of people diagnosed and treated 
in the first stage of breast, colorectal and lung 
cancer by 25% by 2015”. Breast, colorectal and 
lung cancers were chosen as they were the 
most common in Scotland (45% of all cancers 
in 2011).
Cancer Registry Data was initially used for the 
DCE baseline (by adopting an average annual 
performance for 2005 to 2009); this was later 
reviewed due to the large number of unknown 
stages and delay between data collection and 
data publication. Cancer Audit data was chosen 
to be used instead after consultation with 
stakeholders. 
A two-year average for baseline was used 
instead of a single year in order to account for 
variation between years. This was especially 
important in smaller Health Boards which 
show large percentage changes from small 
numbers. Since the DCE priming campaign was 
launched in February 2012, the latest data prior 
to this (2010-2011) was considered to be the 
best choice for the baseline. Rolling two-year 
averages were used to compare performance 
with baseline data over the years.
Audit data were recorded onto Boards’ 
prospective cancer audit systems and submitted 
quarterly to ISD Scotland before being validated 
to ensure code consistency and loaded onto 
The HEAT target
the DCE database. In order to define staging, 
a combination of clinical and pathological 
information was used. 
Unknown cancer stages
Staging data cannot be determined at times, 
or it is not appropriate to try to determine it. 
Hence, it was unlikely that staging data would 
ever reach 100% completion. Unknown values 
were included when reporting the baseline and 
the impact of their inclusion was considered. It 
was expected that including these unknowns 
would encourage Boards to improve their 
performance. The level of variation in the 
proportion of unknowns was considered when 
setting targets.
Since the distribution of stages amongst the 
unknown is uncertain it is often not possible 
to separate increases in Stage 1 due to better 
recording or from a potential shift from more 
advanced stages of disease. Both the number 
and percentage of unknown stages should be 
considered when comparing stage distribution 
figures for individual cancers across geographical 
areas.
Different tumour types
The percentage of patients diagnosed at Stage 
1 can vary due to factors such as the presence 
and uptake of national screening programmes.
When making comparisons for breast cancer 
data it is worth noting that in the Island NHS 
Boards the breast screening mobile unit only 
visits once every three years. Furthermore, 
more rural Health Boards such as NHS Borders 
and NHS Dumfries & Galloway may also not be 
visited by mobile units every year. 
For several Health Boards, the start of the bowel 
screening occurred during baseline. The first 
round of bowel screening can result in a higher 
number of patients diagnosed at Stage 1 than in 
later years (depending on uptake). Hence, some 
boards could see higher than usual proportions 
of diagnosis at stage 1.
Revisions and corrections
The national cancer audit datasets for individual 
cancers have changed since 2010.  Efforts were 
This strategy comprised a newly developed 
HEAT target (25% increase in cancers 
diagnosed at Stage 1) and an sGMS Contract 
Bowel Screening Initiative that awarded up 
to the equivalent of 6 Quality and Outcomes 
Framework (QOF) points for reduction in 
bowel screening non-participation. 
Cancer Waiting Times (CWT) targets were 
also managed by DCE, but this initiative was 
not implemented by the programme and is 
not mentioned here. The other targets are 
described below.
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made to ensure that the data items referring 
to DCE remained stable. NHS Dumfries and 
Galloway resubmitted colorectal data in 2010 
after correcting errors in staging. 
There was a revision in 2014 as some small 
differences were identified in the assignment 
of Board of Residence. An error was also found 
in the implementation of the algorithm used to 
derive breast cancer staging. Finally, on 1 April 
2014 NHS Board Boundaries were changed to 
align with those of local authorities. Reports 
with both the previous and the new Board 
Boundaries were made available. 
The Bowel Screening Initiative
As part of DCE, a new sGMS initiative focusing 
on bowel screening was funded. General 
practices received up to 6 QOF points for 
reducing the proportion of non-responders 
to bowel screening. The initiative lasted two 
years (01/04/13 until 31/03/15). The first year 
involved identifying ways to improve screening 
uptake and developing an action plan. The most 
recent uptake data at the time (2011-2012) was 
proposed as baseline data. In the second year, 
practices implemented the action plan.
Rewards were given to practices that showed 
decrease in non-participation rates of at least 
2% (compared to their previous uptake). Two 
points were given for a relative 2% increase, 4 
for a decrease between 2.1-4% and 6 points for 
a relative decrease over 4.1%. The percentage 
reduction in non-participation was a relative 
reduction (e.g. a relative 4% reduction in a 
practice with 60% non-participation would 
correspond to 57.6% non-participation).
All practices registering for the initiative were 
asked to commit for the two-year programme. 
Full payment was possible when targets were 
not met provided that practices could show 
that the action plan was followed and patients 
were offered evidence-based information to 
enable them to make an informed decision. Full 
payment would also be available if practices 
could provide good written evidence of their 
reasons for not achieving the targets, and 
developed a revised action plan. 
Payment weighting was applied based on the 
size of the eligible practice population and the 
most updated information on uptake (higher 
weighting for practices with poorer uptake). 
Weighting was applied to 50% of the payment 
(3 QOF points). Practices obtained data directly 
from the Bowel Screening Centre in order to 
calculate baseline data; data on non-responders 
was also obtained from the Bowel Screening 
data (there were recognised delays in receiving 
this).  A list of recommended medical READ 
codes was provided so primary care practices 
could keep a record of their activities.
Data sources for Strategy 4: The Scottish Government Circular, Detect Cancer Early - Bowel 
Screening Initiative - July 2013; The Scottish Government, Technical note on the calculation of 
the baseline for the Detect Cancer Early HEAT target, 2013.; and annual reports about Detect 
Cancer Early Staging data (Baseline-Year 6, available here: http://www.isdscotland.org/Health-
Topics/Cancer/Publications/index.asp)
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Nine stakeholders were interviewed during 
evaluation development. Job roles included 
senior management in ISD Scotland; at DCE; in 
national screening programmes and in each of 
the three Scottish Cancer Networks; general 
practitioners; and secondary care doctors. 
Some stakeholders had more than one role. 
They worked in five territorial Health Boards: 
NHS Forth Valley, NHS Grampian, NHS Greater 
Glasgow & Clyde, NHS Lothian and NHS Tayside.
Feedback from stakeholders focused on 
six themes: DCE development and 
implementation; views on DCE and 
its components; logic model; overall 
contextual issues; what to evaluate; and 
outcome evaluation challenges. Participants 
also gave suggestions of whom to contact when 
evaluating DCE (staff at cancer charities, range of 
Scottish Government staff, range of health care 
professionals, NHS managers and those working 
in the NHS in an administrative capacity). 
1. Characteristics of interview
participants
Appendix 2. Key findings from evaluation development interviews
CONTEXTUAL ISSUES
DEVELOPMENT AND IMPLEMENTATION
• A political decision with a political imperative
• Aims, drivers and influencers
• An evidence-based initiative
• Resource allocation
• Stakeholder involvement
• Voiced concerns and barriers
• Developing relationships, systems and roles
• Delays and adaptations
VIEWS ON DCE AND ITS COMPONENTS
• A driver of change and other aspirations
• Belief in DCE and feedback on its activities
• Perceived impact of activities
• Sustainability concerns




• Scope, importance, links 
and trajectories




• Bias and confounding
• Unmeasurable outcomes, unclear definitions
and unavailable data
WHAT TO EVALUATE
• Early diagnosis, mortality, survival or surrogates
• Impact on primary and secondary care
• Improvement in knowledge and awareness
• Seeing the bigger picture
• NHS constraints and regional variations
• Cultural change or shifts
• Scottish personality and pioneering
• Tackling cancer





and its causal 
assumptions
Context
• Deprivation, age and gender
• Individual behaviour and change
• Government characteristics
Themes from stakeholder interviews organised in the MRC 
Framework
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Theme 1: development and implementation
DCE was described as a programme with a 
political agenda, specific targets and investment. 
It was driven by the need to improve cancer 
survival, informed by evidence on early 
detection and influenced by existing initiatives 
in England. It aimed to improve cancer survival, 
and aspired to provide changes in the way the 
population perceived cancer and acted towards 
it, in addition to generating more efficient and 
prompt service provision. 
Stakeholders described how, since the initial 
stages of the programme, advice was sought from 
a wide range of stakeholders. In general, they 
thought that their opinions were listened to, but 
acknowledged that views would differ based on 
the level of involvement with the programme. 
Concerns were raised before and during DCE 
implementation about the programme’s impact 
on diagnostic capacity, about increasing the 
number of “worried well” or causing delays for 
patients who had cancer.
Stakeholders’ views differed in which element 
of DCE they regarded as the programme’s  key 
aim (e.g. earlier cancer diagnosis, improved 
public awareness, or system-level changes). Each 
territorial Health Board was described as having 
specific additional aims, depending on local 
priorities, and different approaches regarding 
programme components (such as how to 
engage with patients and the public or how  to 
use additional DCE funding).
Theme 2: views on DCE and its components
DCE was considered to be  a driver for change 
and a mechanism for reducing inequities in 
screening across deprived communities. In the 
long-term, it could help to modify the way the 
population perceived cancer (reducing fear) and 
could empower patients to go see their doctor 
when they noticed symptoms. DCE was also 
seen as an opportunity to develop more efficient 
ways to investigate patients with symptoms, to 
assess how the health system worked, and make 
changes as appropriate.
In general, stakeholders believed in the 
programme’s importance and in what it 
proposed to do, and often reported being proud 
of being a part of it. Nonetheless, they recognised 
that some of the programme objectives were 
difficult to achieve.
Awareness campaigns were complimented 
for their “bold” and “professional” approach, 
but concerns were raised about whether 
information was retained by the population 
and resulted in change in attitudes. There was 
also recognition that campaigns on their own 
would not be sufficient to completely change 
population behaviour towards cancer.
Participants raised several concerns about the 
programme’s sustainability. They highlighted that 
people may get tired of campaign messages and 
emphasised the need to sustain public interest. 
They also emphasised the importance of ongoing 
investment for primary care, for diagnostics and 
treatment.
Stakeholders had mixed views regarding 
performance targets. For some, they drove 
activity, were useful for politicians and the media, 
and a measurable outcome. However, targets 
were also perceived to be unhelpful and some 
questioned whether they were a good measure 
of the programme’s success.
Theme 3: Contextual issues
Stakeholders described how contextual issues 
such as social deprivation, regional differences, 
political interest, and NHS constraints influenced 
and were influenced by the programme. They 
acknowledged the need to reduce health 
disparities to improve cancer outcomes but 
acknowledged that achieving this aim was 
beyond the remits of DCE. 
Population behaviour towards campaigns was 
described to vary according to different levels 
of social deprivation, with the most deprived 
taking longer to process information, or to act 
upon it. Population age and gender were also 
described as interacting with deprivation and 
providing a more complex picture in terms of 
response to awareness campaigns.
Stakeholders reported challenges related to 
NHS capacity, especially diagnostics (equipment 
2. Key themes
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and staff availability), and acknowledged that 
these problems pre-dated DCE. Resource needs 
were also described as a potential reason why 
Health Boards engaged with the programme, 
i.e. in order to obtain additional funds which 
could help with pre-existing challenges. Finally, 
participants described a perceived disconnect 
between primary and secondary care and a “silo 
mentality” that was likely to have affected DCE 
development and implementation.
Stakeholders described a perceived shift (albeit 
slow and ongoing) in the way the population 
talked about cancer, being more open to discuss 
the topic with others. Although they believed 
that DCE had helped to effect this change, they 
considered many changes were beyond DCE’s 
influence, and that they were part of a current 
drive towards healthier behaviours and cancer 
prevention.
Stakeholders discussed the role of early 
diagnosis in survival, describing several factors 
which influence cancer outcomes. The “Scottish 
personality” was described as an important 
contextual factor, especially a perceived fatalistic 
and stoical view towards cancer. Nonetheless, 
the Scottish population was also described as 
“passionate” and engaged when they believed in 
something.
Theme 4: what to evaluate
Interview participants were specifically asked 
what elements of DCE they considered should 
be included in the evaluation.  In response, while 
they emphasised the importance of assessing 
clearly quantifiable outcomes such as stage at 
diagnosis and screening uptake, they also wished 
to understand the impact that the programme 
had on primary and secondary care. There was 
the recognition that additional investment in 
secondary care would not be sufficient if primary 
and secondary care were not working together 
as a system. Understanding the impact that the 
programme had on capacity, systems and ways 
of working due to additional investment was 
also considered important, as was examining 
whether DCE generated increase in knowledge, 
awareness and attitudinal changes towards 
cancer, assessing (if possible) any broader 
cultural health system changes, and examining 
any adverse (as opposed to only investigating 
positive) effects. 
Theme 5: outcome evaluation challenges
Bias and confounding were cited as important 
challenges when assessing outcomes. Participants 
indicated that separating the programme from 
other early detection activities taking place at 
the same time was difficult. They also emphasised 
that DCE was a national programme and that it 
would not be possible to show causality.
Other described evaluation challenges included 
lack of data and measuring soft outcomes. 
Stakeholders recommended the investigation 
of improvement in awareness and change in 
attitudes, and of wider cultural changes, but 
acknowledged that it would be difficult to 
measure these. 
Theme 6: logic model
The logic model was considered useful to 
describe the programme, and mostly accurate 
in terms of DCE components. However, 
stakeholders believed that it displayed large 
amounts of information, which at times made it 
difficult to find or make sense of data in it. 
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Appendix 3. Diagram representing DCE programme theory, and 
elicited assumptions and mechanisms
DCE textual programme theory
DCE awareness campaigns targeting the public allow for increased knowledge, confidence and motivation to seek
help and get screened. Training for health care professionals leads to increased knowledge and confidence to
assess symptoms, request tests, provide screening recommendations and refer to specialists. The provision and
dissemination of updated referral guidelines also increases confidence, and legitimises referrals. Performance
targets drive activity and help to focus the health professionals’ minds.
All these activities increase demand for diagnostic resources; this is managed with the provision of funding for
Health Boards to invest in capacity while adopting a systems approach. Acceptance, appropriate communication
and resource availability lead to better services alongside more knowledgeable and confident populations and
workforce; this allows for more cancers to be diagnosed earlier. Over time, DCE may also trigger wider cultural
changes in the way the population perceives cancer and the way that it is managed by health services.
Performance Management 
& Monitoring
Final outcome: Improved 
performance (staging and 




Final outcome: Increase in 
diagnostic capacity across 
Health Boards; positive impact 
on workload
Final outcome: Target groups have 
a persistent change in behaviour 
regarding help seeking and screening 
and the way they perceive cancer
Public Awareness & Behaviour 
Influencing
Primary Care Cancer Symptom
Management & Referral
Final outcome: Target groups have a change in 
behaviour (or maintain best practice behaviour) 
when referring patients or requesting diagnostic 





• Target groups have timely access to specialist services
• Appropriate tests are carried out timely
• Increase in bowel and breast screening uptake among target 
groups
Intermediate outcomes:
• Patients are referred and 







• 25% increase in cancers diagnosed 
at Stage 1
Possible breaks in the chain
B1 Patient does not consult (too busy, cannot set an appointment, etc.)
B2 Backlog for tests/referrals; or patient would have been referred anyway (no impact)
B3 Additional capacity fills gaps but it is not enough to meet demand
B4 Patient is diagnosed with another condition; no definite diagnosis; too many unknown stages; 
patient has aggressive tumour; patient presented late; other contextual reasons
Intermediate outcomes:
• Target groups consult when having relevant 
cancer symptoms (lung, breast)
• Target groups have the motivation and 
intention to take part in screening
Target population
• General public within the age range eligible for bowel and breast screening
• Bowel/breast screening non-responders (focusing on deprived men for the former and deprived women for the latter)
• Those at risk of lung cancer
• Key influencers (e.g. children and teenagers)
• GPs and other primary care staff
• Secondary care staff
• Primary and secondary care interface
DCE outcomes chain
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Appendix 4.  Theories adopted for operationalising implementation 
assumptions and mechanisms of impact




Feasibility Refers to the practicability/achievability of an initiative. Related to 
“appropriateness”, but different as something may be feasible, but 
not appropriate (and vice-versa)1. It covers issues such as impact on 
workload 
Acceptability Whether DCE is acceptable/agreeable. It refers to views on a 
specific strategy and is different from “satisfaction” which refers to 
service experience1 
Sustainability DCE’s ability to be sustained over time1 
Appropriateness Appropriateness refers to programme fit according to stakeholders. 
It is similar to ‘‘acceptability’’, but not equivalent as something may 
be appropriate but not acceptable (and vice-versa)1 
Sufficiency Whether resources (physical, staff, or skills) were sufficient to meet 
demand brought by the programme, and strategies (training, 
campaigns) were enough to achieve intermediate outcomes. It was 
chosen instead of “dose delivered” and “dose received”2 as 




Refers to issues such as quality of information, access to it and 
quality of communication about strategies. Similar to “Penetration” 
1 and “Reach”2, but with a stronger focus on the role of 
communication 
Adaptability Adaptations to adjust to the programme/meet its aims, and how 
possible it was to make changes. It was chosen instead of “fidelity” 
1,2 due to the challenges in defining fidelity for a non-experimental 




1. Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, Griffey R, Hensley M. Outcomes for 
implementation research: conceptual distinctions, measurement challenges, and research agenda. 
Administration and policy in mental health 2011; 38:65-76. 
2. Steckler A, Linnan L. Process Evaluation for Public Health Interventions and Research. San Francisco, 
California: Wiley, 2002. 
  






The COM-B model adopted in the evaluation 
The COM-B (Capability, Opportunity and Motivation) postulates that in order to 
change behaviour one or more of these three components need to be changed1,2. For 
example, training health care professionals can increase their capability, providing 
diagnostic capacity resources can increase the opportunity to provide services, and 
financial rewards can increase motivation to meet targets. DCE proposed mechanisms 
were mapped into the COM-B constructs: 
• Reflective motivation: Reflective processes involving plans (i.e. self-conscious 
intentions) and evaluations (related to beliefs about what is good and bad)1; e.g. 
intending to attend screening 
• Physical opportunity: Opportunity provided by the environment; this could be 
time, resources, locations, cues, and “physical affordance” 1; e.g. being able to run 
tests for patients because a chest x-ray machine is available 
• Automatic motivation: Automatic processes relating to emotional reactions, 
desires, impulses, inhibitions, drive states and reflex responses1; e.g. feeling 
anticipated fear and worries about the prospects of not meeting targets 
 
References: 
1. Michie S, Atkins L, West R. The Behaviour Change Wheel. A guide to designing interventions. Silverback 
Publishing, 2014. 
2. Michie S, van Stralen MM, West R. The behaviour change wheel: A new method for characterising and 
designing behaviour change interventions. Implementation Science 2011; 6:1-12. 
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DCE Objective Outcome evaluation 
1. Increase the proportion of
people with stage 1 disease at
diagnosis and to use
performance against a HEAT
target as a lever for whole
systems improvement
• Data from ISD Scotland used to create charts showing % of Stage I over time (baseline,
Years 1-6); for all tumour types combined and breast, colorectal and lung separately; for
Scotland and for each Cancer Network; and for each deprivation quintile (1-most deprived
to 5-least deprived)
• Tables in the Appendix describe trends on Stages II-IV over time and Stage I over time
across territorial Health Boards
2. Improve informed consent
and participation in national
cancer screening programmes
• Data from ISD Scotland used to create charts describing screening uptake:
o Breast: national uptake from 2005-2008 to 2013-2016; N screened from 2010-2011 to 
2015-2016; and table outlining N and percentage change for routine appointments, early 
recall and self-GP referral from 2010-2011 to 2015-2016 (2010-11 used as a proxy 
baseline). Data was reproduced from ISD Scotland reports (graphs and tables)
o Colorectal: National uptake data from 2009-2011 to 2015-2017 reproduced from ISD 
Scotland reports. Uptake by deprivation and % change is also reported for the same time 
period (graphs only)
• Data from ISD Scotland, the Scottish Bowel Screening Centre, TNS, Carat and 
Consolidated PR used to report on evidence of raised public awareness:
o Practice Team Information (PTI) data on consultation for breast cancer signs and 
symptoms (Jun-Aug 2011 – Sep-Nov 2012) reproduced in the report, with estimates and 
confidence intervals. PTI data ceased to be collected after this period
o Customised data from the Bowel Screening Centre was used to develop time trends 
graphs showing requested and returned replacement test kits (and % changes) from Feb 
2011 to Jan 2016 alongside the timing of different DCE initiatives targeting bowel 
screening. Time periods were grouped as one year prior to DCE, the first three DCE 
years and a fourth DCE year). N of request by Health Boards (and percentage changes) 
are shown in graphs and tables
o Results from social marketing campaigns (TNS before and after reports on awareness and 
attitudes; Carat and Consolidated PR data on N of events, media impact, among other 
metrics) are shown in boxes (text only) for the priming campaign, breast, colorectal and 
lung cancer campaigns
3. Raise public awareness of
cancer screening programmes




patients who may be showing a
suspicion of cancer whilst
making the most efficient use
of NHS resources and avoiding
adverse impact on access
• Evidence from personal communications (DCE Programme Board meetings) used to briefly 
report on the use of qFIT for symptomatic patients and on the updated referral guidelines 
for suspected cancer (in text)
• Evidence from evaluation reports of education sessions authored by the Roy Castle Lung 
Cancer Foundation and Bowel Cancer UK
5. Ensure sufficient capacity in
the screening programmes to
meet the expected increase in
demand
• Annual reports from the Bowel Screening Centre used to create 1) time trends graph
showing monthly calls to request replacement kits from January 2013 to March 2015
alongside the timing of different DCE initiatives targeting bowel screening; 3) tables with N
of calls to helpline (by month and year) and issued reminder letters (by year); 3) text
describing increase in laboratory activity, email requests, among other issues
• There was no available information for breast screening, although data shown for
Objectives 2-3 may be relevant
6. Ensure imaging, diagnostics
and treatment are prepared for
an increase in demand
• Policy documents (annual reports submitted to DCE by territorial Health Boards) used to
create descriptive summary tables about how additional funding was used, and perceived
benefits of funding
7. Strengthen data collection
and performance reporting
within NHSScotland
• Data from ISD Scotland used to create charts showing the % of tumour staging recorded 
as “unknown” over time (baseline, Year 1-6) for all tumour types combined and breast, 
colorectal and lung separately; for Scotland and for each Cancer Network; and for each 
deprivation quintile (1-most deprived to 5-least deprived)
• Table in the Appendix shows unknown stages (N(%) over time by territorial Health Board
8. Facilitate further evaluation
of the impact of public
campaigns on the stage of
cancer at presentation and to
contribute to cancer survival
research
• Outcomes not available for this objective
Appendix 5. Methods and data sources to assess DCE objectives
630
Detect Cancer Early Evaluation 101
Appendix 6. Interview topic guide
 
 
Stakeholders managing health care services and DCE strategies 
Process evaluation of the DCE Programme 
The guide will be used in a flexible and responsive manner, allowing participants to 
introduce new areas for discussion. Ensure signed consent form has been received. 
Interview questions/topics 
1. Ask the participant to tell you a bit about himself/herself (ask for job role and experience) 
2. Ask about their involvement in DCE development and overall views about the programme (A1, 
M1) (prompt: information on communicating requirements/strategies; whether targeted groups were the right ones; 
whether staff were ready for the programme) (A1, A2) 
3. Ask for their views on DCE aims and outcomes (mention them) (prompts: whether they thought 
DCE aims would be met, why they think some aims were met/not met; unanticipated outcomes) (A1) 
4. Ask for their views on whether the programme made a difference (e.g. what would have happened if 
there was no DCE; prompt for whether they thought DCE was a success) and on any noticeable 
barriers/facilitators (think of urban/rural differences) (A1) 
5. Ask whether DCE estimates on impact on workload were accurate (think of each of the strategies; 
prompt: was DCE a driver for action?) (A1, M3) 
6. Ask about intermediate outcomes related to implementation (think of improved efficiency; increase in 
capacity; developed strategies to meet targets; patients presenting more often in primary care) (A1-A4) 
7. Ask them to what extent they think DCE was implemented as planned (prompt: staff involvement, 
reaching the target groups as planned, organisational and personnel functions handled well, consistent 
implementation across areas; components difficult to implement) (A1-A4, M2) 
8. Ask about the level of resources available for what they were required to do (think about human 
and financial resources, equipment, time, and knowledge – prompt: were resources sufficient?) (A3, M2) 
9. Ask about any other external factors influencing implementation and the programme’s success 
 
Thank the interviewee for his/her participation and ask if they would like to comment 
on anything you had asked – or anything else. 
 Finally, ask whether they would like to receive a summary of the study results. If so, 
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NHS Argyll & Clyde 4285 3844 -10.3% 4679 9.2% 4485 4.7% 4947 15.4% 
NHS Ayrshire & Arran 4019 4001 -0.4% 4500 12.0% 4335 7.9% 4369 8.7% 
NHS Borders 902 966 7.1% 994 10.2% 1110 23.1% 1057 17.2% 
NHS Dumfries & Galloway 1415 1423 0.6% 1601 13.1% 1529 8.1% 1632 15.3% 
NHS Fife 3476 3882 11.7% 3726 7.2% 4011 15.4% 3806 9.5% 
NHS Forth Valley 2714 3075 13.3% 3063 12.9% 3506 29.2% 3301 21.6% 
NHS Grampian 5154 5076 -1.5% 5499 6.7% 5274 2.3% 5702 10.6% 
NHS Greater Glasgow & Clyde 7971 6991 -12.3% 8891 11.5% 8201 2.9% 8972 12.6% 
NHS Highland 1828 2100 14.9% 2009 9.9% 2209 20.8% 2072 13.3% 
NHS Lanarkshire 5799 5948 2.6% 6548 12.9% 6887 18.8% 6827 17.7% 
NHS Lothian 6848 7244 5.8% 7626 11.4% 8200 19.7% 8120 18.6% 
NHS Orkney 182 170 -6.6% 205 12.6% 181 -0.5% 190 4.4% 
NHS Tayside 4527 4123 -8.9% 4881 7.8% 4367 -3.5% 4835 6.8% 
NHS Western Isles 246 276 12.2% 272 10.6% 274 11.4% 252 2.4% 








Year prior to DCE DCE's first year DCE's second year DCE's third year DCE's fourth year
Source: Customised data provided by the Scottish Bowel Screening Centre in Dundee. Data refers only to requested kits that were 
completed, returned to the Bowel Screening Centre and had a valid result. Hence, data underestimates the number of requested kits 
as not everyone who requests one completes it. NHS Argyll & Clyde was dissolved in 2006 and incorporated by NHS Highland and 
NHS Greater Glasgow & Clyde. To avoid misplacing requested kits, numbers are shown as in the original data source. Cumbria and 
Northumbria Boards were included in the original data source but are not shown here due to small numbers (<5 per year in each 
Board). Numbers for both areas were included in Figure 14 reporting on overall requested and returned kits.
Appendix 9. Requests for replacement bowel screening kits across 
territorial Health Boards and % change over time
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• Challenges: being able to accurately plan for the likely impact of campaigns, engage with hard to reach 
groups, and ensure enough diagnostic capacity (including being able to recruit diagnostic staff such as 
Radiologists). Over time, another challenge referred to shortfall in funding and managing increasing demand 
for urgent referrals. 
• Strategies: assumptions regarding impact were compared with other Health Boards and advice was taken 
from the Government; short-term initiatives were carefully planned to avoid issues with timing of campaigns 
and funding allocation; urgent referrals were prioritised, additional sessions were implemented, clinics and 
endoscopy lists were added, and the booking system for breast patients was changed. Non-recurring funding 




• Challenges: establish baseline data to quantify the impact of campaigns; develop new governance structure 
to oversee DCE areas; agree on a sustainable approach to increase bowel screening uptake amongst the 
most deprived and support GP practices to promote this; embed knowledge and awareness of early 
detection and risk factors into routine processes and team assessments; and learn about DCE impact 
elsewhere. 
• Strategies: a data specification report was produced to be populated by monthly data submissions, a 
project group and a multidisciplinary group were established to do better reporting and better reach the 
most deprived groups; short-term funding was used to hire an advisor to work with hard to reach groups; 
local radio channels were used for early detection messages; collaborations with local initiatives and 
businesses were developed; and a bowel screening survey was carried out with staff. Events were held in GP 





• Challenges: creating a business case for construction of a new hospital while trying to ensure coordinated 
spending and plans for service design; not having the national television campaign aired in the region and not 
being included in the roll out of national communications activity for breast cancer; lack of clarity regarding 
recurring funding; challenges to recruit staff; and dealing with QPIs. 
• Strategies: some of the funding was held; local advertising campaigns were launched and there was close 
communication with DCE in order not to commit funding in areas where it could not be sustained; capacity 
was increased in Head and Neck; plans were developed to build capacity for Endoscopy Nursing; and ongoing 
support was provided to the Cancer Audit Team. 
NHS Fife • Challenges: recruitment, uncertainty about demand for secondary care and increased demand in primary 
care. 
• Strategies: more widespread recruitment and funding allocation to meet demand 
NHS Forth 
Valley 
• Challenges: large increase in referrals to breast services after the campaign that exceeded expectations; 
being unable to appoint a Consultant Breast Surgeon; challenges to provide additional ultrasound, endoscopy, 
radiology, and laboratory capacity; and costs that were higher than the allocated funding.  
• Strategies: additional OPD clinics were set up in the short-to-medium term, a locum Consultant Breast 
Surgeon was hired; a Consultant Breast Surgeon and Consultant Radiologists were shared with another 
Health Board (a Breast Surgeon was appointed later) and there was additional endoscopy capacity. The 




• Challenges: increase in referrals from breast and bowel campaigns, implementation of QPIs, challenges in 
recruiting staff and general workforce capacity issues. 
• Strategies: adopting a MCN approach, reviewing resources and processes before deciding on funding, and 





• Challenges: financial risks of not knowing revenue allocation for the following year; decrease in funds over 
time; lack of early clarification on baseline data (HEAT); fluctuations on early stage presentations after the 
breast campaign; unpredictable increase in demand due to campaigns; and recurring issues with breast 
capacity  
• Strategies: no recurring allocations were deployed; internal estimations were made to define a baseline, 
non-recurring sessional staff was established to accommodate demand peaks in breast and colorectal 
services; the Board’s financial profile was revised; assessments of staging data were made; and surgical and 




• Challenges: having to defer decisions due to uncertainty regarding recurring money and impact upon 
diagnostic services.  
• Strategies: funding was carried forward to allow a more strategic approach in terms of funding allocation 
based on both local and national priorities 
 
646
Detect Cancer Early Evaluation 117
Health 
Board 
• Described challenges and strategies to overcome them (continued)
NHS 
Lanarkshire 
• Challenges: “patchy” early communication that affected ability to plan; not being able to recruit radiologists 
due to national shortages; challenges to implement a CT colonography pathway; and having to deal with 
increasing demand for this and the EBUS service
• Strategies: effective communication was established with DCE to be informed about upcoming campaigns 
and plan for their work; job applicants were actively targeted; the Clinical Director and the Senior 
Management Team developed a plan to increase the number of sessions worked by the existing consultant 
radiologists; discussions took place within Radiology & Colorectal teams to agree on an operational pathway; 
it was agreed to test CT colonography before roll out; and demand was reviewed in order to provide 
additional endoscopic capacity and alternatives to diagnostic tests.
NHS 
Lothian 
• Challenges: establish “an effective programme focus and steering structure”; to respond to the significant
increase in demand due to the breast campaign (also to link it with their ongoing work); to predict impact of
campaigns; delays in receiving information from non-responders to bowel screening; maintaining the 62-day
lung cancer performance
• Strategies: the Board reviewed the cancer inequalities evidence base, used Information services and
obtained input from clinical leads; was involved in the DCE Programme Board and Executive; agreed on an
approach to be adopted in order to meet the programme aims; allocated funding for capacity and redesigned
the breast service; established a service redesign group; did pathways analyses and estimated impact. There
was also close work with national colleagues, the bowel screening centre and the bowel screening
coordinator to support pilot practices.
NHS 
Orkney 
• Challenges: having only one theatre which was also the scoping room; not having all GPs engaged with DCE; 
targeting individual practices where screening uptake was low; engaging with staff to redesign services; staff 
changes in small teams impacting on the ability to prioritise DCE
• Strategies: plans were developed for a separate scoping room, there were conversations with practices that 
were not engaging and additional work was undertaken on profile uptake by practice; a new population 
health governance group was set up to discuss uptake and engage with lead clinicians in primary care; there 
were significant discussions with staff to gain buy-in and work with long standing members of staff to support 
new and relieved staff.
NHS 
Shetland 
• Challenges: capturing data for patients seen in NHS Grampian; engaging with clinicians in Grampian;
completing capital programme to modernise diagnostics; increasing public awareness (as local data showed
that people presented late); creating consistency across primary care services for urgent referrals; and linking
health promotion activities to DCE statistics and outcomes
• Strategies: further engagement with NHS Grampian; purchase of video conferencing equipment; funding
was used to assist with modernising scopes; the Board worked across agencies to ensure that patients had
access to resources and advice; and developed a long-term goal to increase awareness and seek help early.
GPs also received training about urgent referral pathways.
NHS 
Tayside 
• Challenges: obtain data for baseline performance and be able to attribute outcomes to the DCE
programme; delays in appointing staff due to recruitment and workforce issues; achieving consensus on
resource allocation and redesigning the financial plan when funding allocation was reduced.
• Strategies: working with the NHS Tayside Cancer Information Team and DCE to clarify definite resource
allocation; progressing through the Executive Management team and administrative steps as promptly as




• Challenges: engaging with rural communities, tackling low bowel screening uptake among males; and 
challenges in demonstrating changes for breast screening due to the three-year rolling geographic programme
• Strategies: issues were tackled by contacting existing cancer support groups, setting up stalls at community 
events, disseminating information in community halls, GP practices and workplaces; using survival stories to 
engage with the public and targeting men through local networks.
Sources: Annual reports submitted to DCE by territorial Health Boards (2012/2013; 2013/2014 and 2014/2015), 
and summaries of reports prepared by the DCE team
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Appendix 12. Characteristics of stakeholders taking part in the 
process evaluation
Interview participants
In order to avoid indirect identification of 
interview participants, only aggregated data 
is provided. Twenty-five stakeholders were 
interviewed between January and June 2018. 
Fiffteen participants were female and 10 were 
Questionnaire participants
male. Interviews were carried out face-to-face 
at the participant’s chosen venue (n=16) or over 
the telephone (n=9).
Stakeholder groups Job roles Territorial Health Boards 
Charities, creative agencies, and 
marketing research companies 
Managers in cancer charities and 
agencies/marketing research 
Nationwide 
Professionals working in primary 
and secondary care 
GPs and secondary care doctors 
(Respiratory and Urology) 
NHS Ayrshire & Arran 
NHS Dumfries & Galloway 
NHS Fife 
NHS Forth Valley 
NHS Greater Glasgow & Clyde 
NHS Lothian 
Providers of Health Intelligence data Data manager Nationwide 
Stakeholders managing health care 
services and DCE strategies  
Stakeholders managing access, 
Public Health, imaging, strategy, 
breast and bowel screening 
NHS Ayrshire & Arran 
NHS Borders 






Initial invitations to complete the questionnaire 
were sent on the 8th May 2018, except for 
invitations sent by SCAN, which were sent 
on the 11th May 2018 due to operational 
issues. A reminder was sent on the 22nd May 
2018. The questionnaire was available for 
completion until the 6th July 2018 (inclusive). 
Fifty-three stakeholders submitted a completed 
questionnaire.
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Medical – secondary care 












Bowel, anal and/or upper GI 
Lung 
Specific tumour type, but not specified 









Period programme influenced work 
from pre-implementation to at least the first three years 
from programme launch to at least the first three years 
at least 2 years 







Territorial Health Board 
NHS Ayrshire & Arran 
NHS Dumfries & Galloway 
NHS Fife 
NHS Forth Valley 

















Large urban areas 
Other urban areas 
Accessible small towns 
Remote rural areas 












Primary Care Practice 










Sums may not add up to 100 due to rounding. Missing data: sex (n=4); age (n-=19); profession (n=2); tumour type (n=1); period programme 
influenced work (n=20); territorial Health Board (n=2); workplace (n=1); other workplace (n=1). Other medical professions included one 
consultant and one endoscopy lead; fourteen participants chose medical as a profession but did not specify any further. Other professions 
correspond to two audit staff and four respondents who ticked “other” but did not specify any further. Other urbanisation level (n=1) was 
not specified by the respondent; other Workplace (n=1) corresponds to “Board wide”. 
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Themes N 
A1. Different stakeholders bought into DCE and what it proposed to do 53 
A2. There was sufficient targeting/communication about DCE 41 
A3. Available resources were sufficient to meet aims 17 
A4. Flexibility was permitted when allocating resources (no quotes available) 0 
M1. DCE strategies were in line with what the professionals perceived as their role 2 
M2. Additional DCE funding resulted in increased physical opportunity 28 
M3. Increased demand was a driver for action and created pressure to act 7 
M4. Targets helped to focus the mind and increased pressure to act 5 
Barriers 
NHS challenges (recruitment challenges, stretched resources) 






Consistency in data recording, good quality data and electronic data for bowel screening 
Good leadership, management and teamwork 
Ability to plan for changes and demand 
Having an open, transparent process and ‘attempt’ to share learning 







Negative impact for other patients in need of care and for other performance targets 
Inappropriate referrals 
Fears of over diagnosing the worried well 





References to DCE official outcomes 
Increase in demand and investigations not resulting in more cancers being diagnosed 
Not being aware of outcomes, and wishing to know more about them 




What worked well 
DCE components (positives) 
To receive funding and be able to use it according to local plans 
8 
4 
What did not work well 
Impact on service provision and workload (including stress among professionals) 
Increasing numbers of worried well seeking reassurance 
Limited planning (e.g. not estimating impact nor considering delays in the cancer pathway) 
DCE components (negatives) 







Better planning, more time to plan and better communication 
Target: tumour types for which campaigns can be more effective and there is no 
screening; groups at risk (including smokers) and more deprived populations 
Focus on breast screening as it is effective; symptoms indicate late disease 
Consider different steps in the cancer pathway (e.g. surgery and follow up) as they 
influence survival, have diagnostic clinics and direct GP access to diagnostics 
Review the HEAT targets (e.g. use a QI approach instead) 
Have ongoing campaigns instead of short bursts of activity 








As a single comment may refer to more than one theme, sums add up to more than 175. 
A: assumption; M=mechanism 
Appendix 13.  Content analysis of open-ended questions in the 
process evaluation questionnaire
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